Table: q1_q4_2019_prescription_drugs_wac_increases , manufacturer_name like all*

A  B  C  D  E  F  G  H  I  J  K  L  M  N  O  P  Q  R  S  T  U  V  W  X  Y  Z  *

oshpd_id	manufacturer_name	date_reported	ndc_number	drug_product_description	wac_effective_date	wac_increase_amount	wac_after_increase	patent_expiration_date	drug_source_type	unit_sales_volume_in_us	unit_sales_volume_non_public_indicator	cost_increase_factors	cost_increase_factors_non_public_indicator	change_improvement_description	change_improvement_non_public_indicator	acquisition_date	company_acquired_from	acquisition_price	acquisition_price_non_public_indicator	acquisition_price_comment	wac_at_acquisition	wac_year_prior_to_acquisition	year_drug_introduced_to_market	wac_at_intro_to_market	supporting_documents	general_comments
Rx0000018	ACADIA Pharmaceuticals Inc.	12/31/2019	63090034030	NUPLAZID Oral Capsule 34 MG 30	12/30/2019	155.00	3341.00	08/27/2038	Single Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	The information contained in this report is subject to the following limitations and assumptions. (1) Consistent with the relevant statutes and regulations, all information contained in this report is limited to that which ACADIA believes is otherwise in the public domain or publicly available. (2) For the latest the latest patent expiration, please refer to Approved Drug Products with Therapeutic Equivalence Evaluations (the “Orange Book”). (3) This drug was developed by ACADIA , therefore the following fields related to drug acquisition have been left blank: ACQUISITION_DATE, ACQUIRED_FROM_COMPANY, ACQUISITION_PRICE, ACQUISITION_PRICE_NONPUBLIC, ACQUISITION_PRICE_COMMENT, WAC_AT_ACQUISITION, YEAR_INTRODUCED, WAC_AT_INTRODUCTION.
Rx0000018	ACADIA Pharmaceuticals Inc.	12/31/2019	63090010030	NUPLAZID Oral Tablet 10 MG 30	12/30/2019	155.00	3341.00	03/23/2037	Single Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	The information contained in this report is subject to the following limitations and assumptions. (1) Consistent with the relevant statutes and regulations, all information contained in this report is limited to that which ACADIA believes is otherwise in the public domain or publicly available. (2) For the latest the latest patent expiration, please refer to Approved Drug Products with Therapeutic Equivalence Evaluations (the “Orange Book”). (3) This drug was developed by ACADIA , therefore the following fields related to drug acquisition have been left blank: ACQUISITION_DATE, ACQUIRED_FROM_COMPANY, ACQUISITION_PRICE, ACQUISITION_PRICE_NONPUBLIC, ACQUISITION_PRICE_COMMENT, WAC_AT_ACQUISITION, YEAR_INTRODUCED, WAC_AT_INTRODUCTION.
Rx0000021	Acorda Therapeutics, Inc.	12/31/2019	10144042760	AMPYRA (dalfampridine) Extended Release 10mg Tablets / 60 Tablet Bottles	10/01/2019	242.27	2934.14	None	Innovator Multiple Source Drug	98877	None	AMPYRA® has not been reformulated, but AMPYRA® is the manufacturer's primary source of revenue while revenue from a more recently-approved product, INBRIJA™, increases.	None	AMPYRA® has not been reformulated, but AMPYRA® is the manufacturer's primary source of revenue while revenue from a more recently-approved product, INBRIJA™, increases.	None	None	None	None	None	None	None	None	None	None	None	Regarding the inquiry relating to acquisition and patent: Regarding Patent & Patent Expiration: Acorda has filed a request with the FDA to delist the AMPYRA® patents from the Orange Book (Approved Drug Products with Therapeutic Equivalents). There are currently multiple generics on the market. Regarding Acquisition: Acorda did not acquire AMPYRA® within the previous five year period.
Rx0000157	Acrotech Biopharma LLC	06/30/2019	68152010809	BELEODAQ® (belinostat)for Injection - 500mg single-dose vial	04/01/2019	28.28	1913.58	10/27/2027	Single Source Drug	8569	None	None	1	None	1	03/01/2019	Spectrum Pharmaceuticals	160000000	None	Acrotech Biopharma acquired the product as part of a portofolio deal involving multiple assets for $160M in upfront payments and up to $140M in additional royalties, and its acquisition price was incorporated into that deal’s overall purchase price.	1885.30	None	2014	1500.00	None	None
Rx0000157	Acrotech Biopharma LLC	09/30/2019	68152010809	BELEODAQ® (belinostat)for Injection - 500mg single-dose vial	07/15/2019	28.70	1942.28	10/27/2027	Single Source Drug	9394	None	None	1	None	1	03/01/2019	Spectrum Pharmaceuticals	160000000	None	Acrotech Biopharma acquired the product as part of a portofolio deal involving multiple assets for $160M in upfront payments and up to $140M in additional royalties, and its acquisition price was incorporated into that deal’s overall purchase price.	1885.30	None	2014	1500.00	None	None
Rx0000157	Acrotech Biopharma LLC	12/31/2019	68152010809	BELEODAQ® (belinostat)for Injection - 500mg single-dose vial	10/01/2019	29.14	1971.42	10/27/2027	Single Source Drug	8569	None	None	1	None	1	03/01/2019	Spectrum Pharmaceuticals	160000000	None	Acrotech Biopharma acquired the product as part of a portofolio deal involving multiple assets for $160M in upfront payments and up to $140M in additional royalties, and its acquisition price was incorporated into that deal’s overall purchase price.	1885.30	1776.30	2014	1500.00	None	None
Rx0000157	Acrotech Biopharma LLC	06/30/2019	48818000101	FOLOTYN® (pralatrexate injection) 20mg, 20mg/mL, 1ml Vial	04/01/2019	81.64	5524.33	05/31/2025	Single Source Drug	3948	None	None	1	None	1	03/01/2019	Spectrum Pharmaceuticals	160000000	None	Acrotech Biopharma acquired the product as part of a portofolio deal involving multiple assets for $160M in upfront payments and up to $140M in additional royalties, and its acquisition price was incorporated into that deal’s overall purchase price.	5442.69	None	2009	3125.00	None	None
Rx0000157	Acrotech Biopharma LLC	09/30/2019	48818000101	FOLOTYN® (pralatrexate injection) 20mg, 20mg/mL, 1ml Vial	07/15/2019	82.87	5607.20	05/31/2025	Single Source Drug	4273	None	None	1	None	1	03/01/2019	Spectrum Pharmaceuticals	160000000	None	Acrotech Biopharma acquired the product as part of a portofolio deal involving multiple assets for $160M in upfront payments and up to $140M in additional royalties, and its acquisition price was incorporated into that deal’s overall purchase price.	5442.69	None	2009	3125.00	None	None
Rx0000157	Acrotech Biopharma LLC	12/31/2019	48818000101	FOLOTYN® (pralatrexate injection) 20mg, 20mg/mL, 1ml Vial	10/01/2019	106.53	5713.73	05/31/2025	Single Source Drug	3948	None	None	1	None	1	03/01/2019	Spectrum Pharmaceuticals	160000000	None	Acrotech Biopharma acquired the product as part of a portofolio deal involving multiple assets for $160M in upfront payments and up to $140M in additional royalties, and its acquisition price was incorporated into that deal’s overall purchase price.	5442.69	5047.97	2009	3125.00	None	None
Rx0000157	Acrotech Biopharma LLC	06/30/2019	48818000102	FOLOTYN® (pralatrexate injection) 40mg, 20mg/mL, 2ml Vial	04/01/2019	163.28	11048.66	05/31/2025	Single Source Drug	2516	None	None	1	None	1	03/01/2019	Spectrum Pharmaceuticals	160000000	None	Acrotech Biopharma acquired the product as part of a portofolio deal involving multiple assets for $160M in upfront payments and up to $140M in additional royalties, and its acquisition price was incorporated into that deal’s overall purchase price.	10885.38	None	2009	6250.00	None	None
Rx0000157	Acrotech Biopharma LLC	09/30/2019	48818000102	FOLOTYN® (pralatrexate injection) 40mg, 20mg/mL, 2ml Vial	07/15/2019	165.74	11214.40	05/31/2025	Single Source Drug	2667	None	None	1	None	1	03/01/2019	Spectrum Pharmaceuticals	160000000	None	Acrotech Biopharma acquired the product as part of a portofolio deal involving multiple assets for $160M in upfront payments and up to $140M in additional royalties, and its acquisition price was incorporated into that deal’s overall purchase price.	10885.38	None	2009	6250.00	None	None
Rx0000157	Acrotech Biopharma LLC	12/31/2019	48818000102	FOLOTYN® (pralatrexate injection) 40mg, 20mg/mL, 2ml Vial	10/01/2019	213.06	11427.46	05/31/2025	Single Source Drug	2516	None	None	1	None	1	03/01/2019	Spectrum Pharmaceuticals	160000000	None	Acrotech Biopharma acquired the product as part of a portofolio deal involving multiple assets for $160M in upfront payments and up to $140M in additional royalties, and its acquisition price was incorporated into that deal’s overall purchase price.	10885.38	10095.94	2009	6250.00	None	None
Rx0000157	Acrotech Biopharma LLC	06/30/2019	20536032201	MARQIBO® (vinCRIStine sulfate LIPOSOME injection)	04/01/2019	214.41	14508.62	09/25/2020	Single Source Drug	558	None	None	1	None	1	03/01/2019	Spectrum Pharmaceuticals	160000000	None	Acrotech Biopharma acquired the product as part of a portofolio deal involving multiple assets for $160M in upfront payments and up to $140M in additional royalties, and its acquisition price was incorporated into that deal’s overall purchase price.	14294.21	None	2013	9750.00	None	None
Rx0000157	Acrotech Biopharma LLC	12/31/2019	20536032201	MARQIBO® (vinCRIStine sulfate LIPOSOME injection)	10/01/2019	565.84	15074.46	09/25/2020	Single Source Drug	558	None	None	1	None	1	03/01/2019	Spectrum Pharmaceuticals	160000000	None	Acrotech Biopharma acquired the product as part of a portofolio deal involving multiple assets for $160M in upfront payments and up to $140M in additional royalties, and its acquisition price was incorporated into that deal’s overall purchase price.	14294.21	13241.25	2013	9750.00	None	None
Rx0000203	Aegerion Pharmaceuticals, Inc.	03/31/2019	76431011001	JUXTAPID 10 MG CAPS, bottle of 28 capsules	01/01/2019	3678.85	40670.85	08/19/2027	Single Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	The drug was developed by the manufacturer therefore the acquisition related fields are blank.
Rx0000203	Aegerion Pharmaceuticals, Inc.	03/31/2019	76431012001	JUXTAPID 20 MG CAPS, bottle of 28 capsules	01/01/2019	3678.85	40670.85	08/19/2027	Single Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	The drug was developed by the manufacturer therefore the acquisition related fields are blank.
Rx0000203	Aegerion Pharmaceuticals, Inc.	03/31/2019	76431013001	JUXTAPID 30 MG CAPS, bottle of 28 capsules	01/01/2019	3678.85	40670.85	08/19/2027	Single Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	The drug was developed by the manufacturer therefore the acquisition related fields are blank.
Rx0000203	Aegerion Pharmaceuticals, Inc.	03/31/2019	76431014001	JUXTAPID 40 MG CAPS, bottle of 28 capsules	01/01/2019	3678.85	40670.85	08/19/2027	Single Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	The drug was developed by the manufacturer therefore the acquisition related fields are blank.
Rx0000203	Aegerion Pharmaceuticals, Inc.	03/31/2019	76431010501	JUXTAPID 5 MG CAPS - bottle of 28 capsules	01/01/2019	3678.85	40670.85	08/19/2027	Single Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	The drug was developed by the manufacturer therefore the acquisition related fields are blank.
Rx0000203	Aegerion Pharmaceuticals, Inc.	03/31/2019	76431016001	JUXTAPID 60 MG CAPS, bottle of 28 capsules	01/01/2019	3678.85	40670.85	08/19/2027	Single Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	The drug was developed by the manufacturer therefore the acquisition related fields are blank.
Rx0000203	Aegerion Pharmaceuticals, Inc.	03/31/2019	76431021001	MYALEPT 11.3MG VIAL - 1 vial	01/01/2019	419.06	4632.82	07/17/2027	Single Source Drug	None	1	None	1	None	1	01/12/2015	AstraZeneca	325000000	None	None	3493.00	None	2014	3493.00	None	The product was introduced to the market before it was acquired by Aegerion Pharmaceuticals which was later acquired by Amryt in 2019. The information provided in this report is the only information available to Amryt. Amryt has no knowledge of the WAC at introduction. Therefore the WAC Aegerion set after acquisition was used - 3493.00 as reported in MediSpan.
Rx0000151	Aerie Pharmaceuticals Inc.	09/30/2019	07072749725	Netarsudil ophthalmic solution 0.02%, 2.5mL bottle	09/23/2019	22.46	272.07	03/14/2034	Single Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	Aerie Pharmaceuticals, Inc. developed Rhopressa. It is not an acquired product.
Rx0000085	Akorn Inc	03/31/2019	17478021515	Atropine Sulfate Ophth Sol 1% 10mg/mL,15mL, 1 Bottle	03/18/2019	31.09	114.83	None	Single Source Drug	None	1	Cost of improvements in manufacturing process of products.	None	None	1	None	None	None	None	None	None	None	None	None	None	Patent Expiration Dates provided for products under patent as of effective date of applicable WAC increase. Information requested in Columns N-U provided for products acquired within five years of the effective date of applicable WAC increase.
Rx0000085	Akorn Inc	03/31/2019	17478030703	Azithromycin 1% Opth Soln 10mg, 2.5ml, 1 Bottle	03/18/2019	18.58	206.21	03/31/2019	Single Source Drug	None	1	Cost of improvements in manufacturing process of products.	None	None	1	None	None	None	None	None	None	None	None	None	None	Patent Expiration Dates provided for products under patent as of effective date of applicable WAC increase. Information requested in Columns N-U provided for products acquired within five years of the effective date of applicable WAC increase.
Rx0000085	Akorn Inc	03/31/2019	17478050305	Dehydrated Alcohol 0.98mL/mL, 5ml, 10 Vials	03/18/2019	261.94	1295.00	None	Non-innovator Multiple Source Drug	None	1	Cost of improvements in manufacturing process of products.	None	None	1	None	None	None	None	None	None	None	None	None	None	Patent Expiration Dates provided for products under patent as of effective date of applicable WAC increase. Information requested in Columns N-U provided for products acquired within five years of the effective date of applicable WAC increase.
Rx0000085	Akorn Inc	03/31/2019	17478010610	Levofloxacin Ophth Solution 0.5%, 5ml, 1 Bottle/ EA	03/18/2019	52.39	114.89	None	Non-innovator Multiple Source Drug	None	1	Cost of improvements in manufacturing process of products.	None	None	1	None	None	None	None	None	None	None	None	None	None	Patent Expiration Dates provided for products under patent as of effective date of applicable WAC increase. Information requested in Columns N-U provided for products acquired within five years of the effective date of applicable WAC increase.
Rx0000085	Akorn Inc	03/31/2019	17478070102	lndocyanine Green 25mg,10ml / Amp, 6Amp	03/18/2019	111.23	683.59	None	Innovator Multiple Source Drug	None	1	Cost of improvements in manufacturing process of products.	None	None	1	None	None	None	None	None	None	None	None	None	None	Patent Expiration Dates provided for products under patent as of effective date of applicable WAC increase. Information requested in Columns N-U provided for products acquired within five years of the effective date of applicable WAC increase.
Rx0000085	Akorn Inc	03/31/2019	17478060930	Tafluprost Ophth Sol .0015%.3ml/.0045mg, .3mL-30 UD pk	03/18/2019	19.19	213.01	05/28/2029	Single Source Drug	None	1	Cost of improvements in manufacturing process of products.	None	None	1	04/01/2014	Merck	None	1	No comment	103.79	None	2014	103.79	None	Patent Expiration Dates provided for products under patent as of effective date of applicable WAC increase. Information requested in Columns N-U provided for products acquired within five years of the effective date of applicable WAC increase.
Rx0000085	Akorn Inc	03/31/2019	17478004532	Tetracaine HCI Injection 1% lOmg/mL, 2ml, 25 Ampules	03/18/2019	994.47	1898.53	None	Non-innovator Multiple Source Drug	None	1	Cost of improvements in manufacturing process of products.	None	None	1	None	None	None	None	None	None	None	None	None	None	Patent Expiration Dates provided for products under patent as of effective date of applicable WAC increase. Information requested in Columns N-U provided for products acquired within five years of the effective date of applicable WAC increase.
Rx0000085	Akorn Inc	03/31/2019	76478000105	Timolol 0.25% Opth Solution 2.56mg/mL, 5ml, 1 Bottle	03/18/2019	11.51	127.76	None	Single Source Drug	None	1	Cost of improvements in manufacturing process of products.	None	None	1	None	None	None	None	None	None	None	None	None	None	Patent Expiration Dates provided for products under patent as of effective date of applicable WAC increase. Information requested in Columns N-U provided for products acquired within five years of the effective date of applicable WAC increase.
Rx0000085	Akorn Inc	03/31/2019	76478000215	Timolol 0.5% Opth Solution 5.12mg/ml, 15ml, 1 Bottle	03/18/2019	36.74	407.89	None	Single Source Drug	None	1	Cost of improvements in manufacturing process of products.	None	None	1	None	None	None	None	None	None	None	None	None	None	Patent Expiration Dates provided for products under patent as of effective date of applicable WAC increase. Information requested in Columns N-U provided for products acquired within five years of the effective date of applicable WAC increase.
Rx0000085	Akorn Inc	03/31/2019	76478000205	Timolol 0.5% Opth Solution 5.12mg/mL, 5ml, 1 Bottle	03/18/2019	12.71	141.07	None	Single Source Drug	None	1	Cost of improvements in manufacturing process of products.	None	None	1	None	None	None	None	None	None	None	None	None	None	Patent Expiration Dates provided for products under patent as of effective date of applicable WAC increase. Information requested in Columns N-U provided for products acquired within five years of the effective date of applicable WAC increase.
Rx0000085	Akorn Inc	03/31/2019	76478000210	Timolol 0.50% Opth Solution 5.12mg/ml, 10ml, 1 Bottle	03/18/2019	24.41	271.01	None	Single Source Drug	None	1	Cost of improvements in manufacturing process of products.	None	None	1	None	None	None	None	None	None	None	None	None	None	Patent Expiration Dates provided for products under patent as of effective date of applicable WAC increase. Information requested in Columns N-U provided for products acquired within five years of the effective date of applicable WAC increase.
Rx0000235	Alembic Pharmaceuticals, Inc.	06/30/2019	62332004230	Irbesartan 150mg Tablet 30ct	04/17/2019	63.91	75.00	None	Non-innovator Multiple Source Drug	12060	None	1. Additional costs of manufacturing and production incurred by its parent Alembic Pharmaceutical, Ltd. Including a) additional cost of key starting materials used to manufacture active ingredients driven by lack of supply from China; b)costs to change Alembic Pharmaceutical, Ltd.’s manufacturing process to eliminate use of recovered solvents in manufacturing; c) additional capital investment for manufacturing of these Sartan products of approximately $200,000 to $300,000 per year; and d) longer and more stringent quality testing requirements mandated by FDA for Sartan products. 2. Any financial penalties and charges to Alembic Sales associated with a WAC price increase. 3. WAC Price of competing products.	None	High volume of requests received from customers to supply these products as quickly as possible. Prior to this increased volume of customer requests, Alembic Sales’ revenue and volume for all of these products was very small, driven by poor economics, and its goal was to provide sustainable supply to the market to meet the increased demand.	None	None	None	None	None	None	None	None	None	None	None	Product was not acquired. This is Alembic ANDA.
Rx0000235	Alembic Pharmaceuticals, Inc.	06/30/2019	62332004271	Irbesartan 150mg Tablet 500ct	04/17/2019	1068.80	1250.00	None	Non-innovator Multiple Source Drug	0	1	1. Additional costs of manufacturing and production incurred by its parent Alembic Pharmaceutical, Ltd. Including a) additional cost of key starting materials used to manufacture active ingredients driven by lack of supply from China; b)costs to change Alembic Pharmaceutical, Ltd.’s manufacturing process to eliminate use of recovered solvents in manufacturing; c) additional capital investment for manufacturing of these Sartan products of approximately $200,000 to $300,000 per year; and d) longer and more stringent quality testing requirements mandated by FDA for Sartan products. 2. Any financial penalties and charges to Alembic Sales associated with a WAC price increase. 3. WAC Price of competing products.	None	High volume of requests received from customers to supply these products as quickly as possible. Prior to this increased volume of customer requests, Alembic Sales’ revenue and volume for all of these products was very small, driven by poor economics, and its goal was to provide sustainable supply to the market to meet the increased demand.	None	None	None	None	None	None	None	None	None	None	None	Product was not acquired. This is Alembic ANDA.
Rx0000235	Alembic Pharmaceuticals, Inc.	06/30/2019	62332004290	Irbesartan 150mg Tablet 90ct	04/17/2019	191.72	225.00	None	Non-innovator Multiple Source Drug	14040	None	1. Additional costs of manufacturing and production incurred by its parent Alembic Pharmaceutical, Ltd. Including a) additional cost of key starting materials used to manufacture active ingredients driven by lack of supply from China; b)costs to change Alembic Pharmaceutical, Ltd.’s manufacturing process to eliminate use of recovered solvents in manufacturing; c) additional capital investment for manufacturing of these Sartan products of approximately $200,000 to $300,000 per year; and d) longer and more stringent quality testing requirements mandated by FDA for Sartan products. 2. Any financial penalties and charges to Alembic Sales associated with a WAC price increase. 3. WAC Price of competing products.	None	High volume of requests received from customers to supply these products as quickly as possible. Prior to this increased volume of customer requests, Alembic Sales’ revenue and volume for all of these products was very small, driven by poor economics, and its goal was to provide sustainable supply to the market to meet the increased demand.	None	None	None	None	None	None	None	None	None	None	None	Product was not acquired. This is Alembic ANDA.
Rx0000235	Alembic Pharmaceuticals, Inc.	06/30/2019	62332004330	Irbesartan 300mg Tablet 30ct	04/17/2019	76.15	90.00	None	Non-innovator Multiple Source Drug	3828	None	1. Additional costs of manufacturing and production incurred by its parent Alembic Pharmaceutical, Ltd. Including a) additional cost of key starting materials used to manufacture active ingredients driven by lack of supply from China; b)costs to change Alembic Pharmaceutical, Ltd.’s manufacturing process to eliminate use of recovered solvents in manufacturing; c) additional capital investment for manufacturing of these Sartan products of approximately $200,000 to $300,000 per year; and d) longer and more stringent quality testing requirements mandated by FDA for Sartan products. 2. Any financial penalties and charges to Alembic Sales associated with a WAC price increase. 3. WAC Price of competing products.	None	High volume of requests received from customers to supply these products as quickly as possible. Prior to this increased volume of customer requests, Alembic Sales’ revenue and volume for all of these products was very small, driven by poor economics, and its goal was to provide sustainable supply to the market to meet the increased demand.	None	None	None	None	None	None	None	None	None	None	None	Product was not acquired. This is Alembic ANDA.
Rx0000235	Alembic Pharmaceuticals, Inc.	06/30/2019	62332004371	Irbesartan 300mg Tablet 500ct	04/17/2019	1269.20	1500.00	None	Non-innovator Multiple Source Drug	3984	None	1. Additional costs of manufacturing and production incurred by its parent Alembic Pharmaceutical, Ltd. Including a) additional cost of key starting materials used to manufacture active ingredients driven by lack of supply from China; b)costs to change Alembic Pharmaceutical, Ltd.’s manufacturing process to eliminate use of recovered solvents in manufacturing; c) additional capital investment for manufacturing of these Sartan products of approximately $200,000 to $300,000 per year; and d) longer and more stringent quality testing requirements mandated by FDA for Sartan products. 2. Any financial penalties and charges to Alembic Sales associated with a WAC price increase. 3. WAC Price of competing products.	None	High volume of requests received from customers to supply these products as quickly as possible. Prior to this increased volume of customer requests, Alembic Sales’ revenue and volume for all of these products was very small, driven by poor economics, and its goal was to provide sustainable supply to the market to meet the increased demand.	None	None	None	None	None	None	None	None	None	None	None	Product was not acquired. This is Alembic ANDA.
Rx0000235	Alembic Pharmaceuticals, Inc.	06/30/2019	62332004390	Irbesartan 300mg Tablet 90ct	05/01/2019	228.46	270.00	None	Non-innovator Multiple Source Drug	23292	None	1. Additional costs of manufacturing and production incurred by its parent Alembic Pharmaceutical, Ltd. Including a) additional cost of key starting materials used to manufacture active ingredients driven by lack of supply from China; b)costs to change Alembic Pharmaceutical, Ltd.’s manufacturing process to eliminate use of recovered solvents in manufacturing; c) additional capital investment for manufacturing of these Sartan products of approximately $200,000 to $300,000 per year; and d) longer and more stringent quality testing requirements mandated by FDA for Sartan products. 2. Any financial penalties and charges to Alembic Sales associated with a WAC price increase. 3. WAC Price of competing products.	None	High volume of requests received from customers to supply these products as quickly as possible. Prior to this increased volume of customer requests, Alembic Sales’ revenue and volume for all of these products was very small, driven by poor economics, and its goal was to provide sustainable supply to the market to meet the increased demand.	None	None	None	None	None	None	None	None	None	None	None	Product was not acquired. This is Alembic ANDA.
Rx0000235	Alembic Pharmaceuticals, Inc.	06/30/2019	62332004130	Irbesartan 75mg Tablet 30ct	04/17/2019	49.46	60.00	None	Non-innovator Multiple Source Drug	18744	None	1. Additional costs of manufacturing and production incurred by its parent Alembic Pharmaceutical, Ltd. Including a) additional cost of key starting materials used to manufacture active ingredients driven by lack of supply from China; b)costs to change Alembic Pharmaceutical, Ltd.’s manufacturing process to eliminate use of recovered solvents in manufacturing; c) additional capital investment for manufacturing of these Sartan products of approximately $200,000 to $300,000 per year; and d) longer and more stringent quality testing requirements mandated by FDA for Sartan products. 2. Any financial penalties and charges to Alembic Sales associated with a WAC price increase. 3. WAC Price of competing products.	None	High volume of requests received from customers to supply these products as quickly as possible. Prior to this increased volume of customer requests, Alembic Sales’ revenue and volume for all of these products was very small, driven by poor economics, and its goal was to provide sustainable supply to the market to meet the increased demand.	None	None	None	None	None	None	None	None	None	None	None	Product was not acquired. This is Alembic ANDA.
Rx0000235	Alembic Pharmaceuticals, Inc.	06/30/2019	62332004190	Irbesartan 75mg Tablet 90ct	04/17/2019	148.38	180.00	None	Non-innovator Multiple Source Drug	0	1	1. Additional costs of manufacturing and production incurred by its parent Alembic Pharmaceutical, Ltd. Including a) additional cost of key starting materials used to manufacture active ingredients driven by lack of supply from China; b)costs to change Alembic Pharmaceutical, Ltd.’s manufacturing process to eliminate use of recovered solvents in manufacturing; c) additional capital investment for manufacturing of these Sartan products of approximately $200,000 to $300,000 per year; and d) longer and more stringent quality testing requirements mandated by FDA for Sartan products. 2. Any financial penalties and charges to Alembic Sales associated with a WAC price increase. 3. WAC Price of competing products.	None	High volume of requests received from customers to supply these products as quickly as possible. Prior to this increased volume of customer requests, Alembic Sales’ revenue and volume for all of these products was very small, driven by poor economics, and its goal was to provide sustainable supply to the market to meet the increased demand.	None	None	None	None	None	None	None	None	None	None	None	Product was not acquired. This is Alembic ANDA.
Rx0000235	Alembic Pharmaceuticals, Inc.	06/30/2019	62332005130	Irbesartan/Hydrochlorothiazide 150mg-12.5mg Tablet 30ct	04/08/2019	66.30	90.00	None	Non-innovator Multiple Source Drug	48	None	1. Additional costs of manufacturing and production incurred by its parent Alembic Pharmaceutical, Ltd. Including a) additional cost of key starting materials used to manufacture active ingredients driven by lack of supply from China; b)costs to change Alembic Pharmaceutical, Ltd.’s manufacturing process to eliminate use of recovered solvents in manufacturing; c) additional capital investment for manufacturing of these Sartan products of approximately $200,000 to $300,000 per year; and d) longer and more stringent quality testing requirements mandated by FDA for Sartan products. 2. Any financial penalties and charges to Alembic Sales associated with a WAC price increase. 3. WAC Price of competing products.	None	High volume of requests received from customers to supply these products as quickly as possible. Prior to this increased volume of customer requests, Alembic Sales’ revenue and volume for all of these products was very small, driven by poor economics, and its goal was to provide sustainable supply to the market to meet the increased demand.	None	None	None	None	None	None	None	None	None	None	None	Product was not acquired. This is Alembic ANDA.
Rx0000235	Alembic Pharmaceuticals, Inc.	06/30/2019	62332005190	Irbesartan/Hydrochlorothiazide 150mg-12.5mg Tablet 90ct	04/08/2019	201.30	270.00	None	Non-innovator Multiple Source Drug	936	None	1. Additional costs of manufacturing and production incurred by its parent Alembic Pharmaceutical, Ltd. Including a) additional cost of key starting materials used to manufacture active ingredients driven by lack of supply from China; b)costs to change Alembic Pharmaceutical, Ltd.’s manufacturing process to eliminate use of recovered solvents in manufacturing; c) additional capital investment for manufacturing of these Sartan products of approximately $200,000 to $300,000 per year; and d) longer and more stringent quality testing requirements mandated by FDA for Sartan products. 2. Any financial penalties and charges to Alembic Sales associated with a WAC price increase. 3. WAC Price of competing products.	None	High volume of requests received from customers to supply these products as quickly as possible. Prior to this increased volume of customer requests, Alembic Sales’ revenue and volume for all of these products was very small, driven by poor economics, and its goal was to provide sustainable supply to the market to meet the increased demand.	None	None	None	None	None	None	None	None	None	None	None	Product was not acquired. This is Alembic ANDA.
Rx0000235	Alembic Pharmaceuticals, Inc.	06/30/2019	62332005230	Irbesartan/Hydrochlorothiazide 300mg-12.5mg Tablet 30ct	04/08/2019	51.30	97.50	None	Non-innovator Multiple Source Drug	10356	None	1. Additional costs of manufacturing and production incurred by its parent Alembic Pharmaceutical, Ltd. Including a) additional cost of key starting materials used to manufacture active ingredients driven by lack of supply from China; b)costs to change Alembic Pharmaceutical, Ltd.’s manufacturing process to eliminate use of recovered solvents in manufacturing; c) additional capital investment for manufacturing of these Sartan products of approximately $200,000 to $300,000 per year; and d) longer and more stringent quality testing requirements mandated by FDA for Sartan products. 2. Any financial penalties and charges to Alembic Sales associated with a WAC price increase. 3. WAC Price of competing products.	None	High volume of requests received from customers to supply these products as quickly as possible. Prior to this increased volume of customer requests, Alembic Sales’ revenue and volume for all of these products was very small, driven by poor economics, and its goal was to provide sustainable supply to the market to meet the increased demand.	None	None	None	None	None	None	None	None	None	None	None	Product was not acquired. This is Alembic ANDA.
Rx0000235	Alembic Pharmaceuticals, Inc.	06/30/2019	62332005290	Irbesartan/Hydrochlorothiazide 300mg-12.5mg Tablet 90ct	04/08/2019	157.20	292.50	None	Non-innovator Multiple Source Drug	1860	None	1. Additional costs of manufacturing and production incurred by its parent Alembic Pharmaceutical, Ltd. Including a) additional cost of key starting materials used to manufacture active ingredients driven by lack of supply from China; b)costs to change Alembic Pharmaceutical, Ltd.’s manufacturing process to eliminate use of recovered solvents in manufacturing; c) additional capital investment for manufacturing of these Sartan products of approximately $200,000 to $300,000 per year; and d) longer and more stringent quality testing requirements mandated by FDA for Sartan products. 2. Any financial penalties and charges to Alembic Sales associated with a WAC price increase. 3. WAC Price of competing products.	None	High volume of requests received from customers to supply these products as quickly as possible. Prior to this increased volume of customer requests, Alembic Sales’ revenue and volume for all of these products was very small, driven by poor economics, and its goal was to provide sustainable supply to the market to meet the increased demand.	None	None	None	None	None	None	None	None	None	None	None	Product was not acquired. This is Alembic ANDA.
Rx0000235	Alembic Pharmaceuticals, Inc.	09/30/2019	62332004930	Losartan Potassium/Hydrochlorothiazide 100mg-12.5mg Tablet 30ct	07/15/2019	36.03	41.25	None	Non-innovator Multiple Source Drug	6732	None	1. Additional costs of manufacturing and production incurred by its parent Alembic Pharmaceutical, Ltd. Including a) additional cost of key starting materials used to manufacture active ingredients driven by lack of supply from China; b)costs to change Alembic Pharmaceutical, Ltd.’s manufacturing process to eliminate use of recovered solvents in manufacturing; c) additional capital investment for manufacturing of these Sartan products of approximately $200,000 to $300,000 per year; and d) longer and more stringent quality testing requirements mandated by FDA for Sartan products. 2. Any financial penalties and charges to Alembic Sales associated with a WAC price increase. 3. WAC Price of competing products.	None	High volume of requests received from customers to supply these products as quickly as possible. Prior to this increased volume of customer requests, Alembic Sales’ revenue and volume for all of these products was very small, driven by poor economics, and its goal was to provide sustainable supply to the market to meet the increased demand.	None	None	None	None	None	None	None	None	None	None	None	Product was not acquired. This is Alembic ANDA.
Rx0000235	Alembic Pharmaceuticals, Inc.	09/30/2019	62332004990	Losartan Potassium/Hydrochlorothiazide 100mg-12.5mg Tablet 90ct	07/15/2019	110.47	123.75	None	Non-innovator Multiple Source Drug	2028	None	1. Additional costs of manufacturing and production incurred by its parent Alembic Pharmaceutical, Ltd. Including a) additional cost of key starting materials used to manufacture active ingredients driven by lack of supply from China; b)costs to change Alembic Pharmaceutical, Ltd.’s manufacturing process to eliminate use of recovered solvents in manufacturing; c) additional capital investment for manufacturing of these Sartan products of approximately $200,000 to $300,000 per year; and d) longer and more stringent quality testing requirements mandated by FDA for Sartan products. 2. Any financial penalties and charges to Alembic Sales associated with a WAC price increase. 3. WAC Price of competing products.	None	High volume of requests received from customers to supply these products as quickly as possible. Prior to this increased volume of customer requests, Alembic Sales’ revenue and volume for all of these products was very small, driven by poor economics, and its goal was to provide sustainable supply to the market to meet the increased demand.	None	None	None	None	None	None	None	None	None	None	None	Product was not acquired. This is Alembic ANDA.
Rx0000235	Alembic Pharmaceuticals, Inc.	09/30/2019	62332005030	Losartan Potassium/Hydrochlorothiazide 100mg-25mg Tablet 30ct	07/15/2019	36.03	41.25	None	Non-innovator Multiple Source Drug	17784	None	1. Additional costs of manufacturing and production incurred by its parent Alembic Pharmaceutical, Ltd. Including a) additional cost of key starting materials used to manufacture active ingredients driven by lack of supply from China; b)costs to change Alembic Pharmaceutical, Ltd.’s manufacturing process to eliminate use of recovered solvents in manufacturing; c) additional capital investment for manufacturing of these Sartan products of approximately $200,000 to $300,000 per year; and d) longer and more stringent quality testing requirements mandated by FDA for Sartan products. 2. Any financial penalties and charges to Alembic Sales associated with a WAC price increase. 3. WAC Price of competing products.	None	High volume of requests received from customers to supply these products as quickly as possible. Prior to this increased volume of customer requests, Alembic Sales’ revenue and volume for all of these products was very small, driven by poor economics, and its goal was to provide sustainable supply to the market to meet the increased demand.	None	None	None	None	None	None	None	None	None	None	None	Product was not acquired. This is Alembic ANDA.
Rx0000235	Alembic Pharmaceuticals, Inc.	09/30/2019	62332005090	Losartan Potassium/Hydrochlorothiazide 100mg-25mg Tablet 90ct	07/15/2019	110.35	123.75	None	Non-innovator Multiple Source Drug	3456	None	1. Additional costs of manufacturing and production incurred by its parent Alembic Pharmaceutical, Ltd. Including a) additional cost of key starting materials used to manufacture active ingredients driven by lack of supply from China; b)costs to change Alembic Pharmaceutical, Ltd.’s manufacturing process to eliminate use of recovered solvents in manufacturing; c) additional capital investment for manufacturing of these Sartan products of approximately $200,000 to $300,000 per year; and d) longer and more stringent quality testing requirements mandated by FDA for Sartan products. 2. Any financial penalties and charges to Alembic Sales associated with a WAC price increase. 3. WAC Price of competing products.	None	High volume of requests received from customers to supply these products as quickly as possible. Prior to this increased volume of customer requests, Alembic Sales’ revenue and volume for all of these products was very small, driven by poor economics, and its goal was to provide sustainable supply to the market to meet the increased demand.	None	None	None	None	None	None	None	None	None	None	None	Product was not acquired. This is Alembic ANDA.
Rx0000039	Alkermes, Inc	03/31/2019	65757040103	ARISTADA 441 mg/ 1.6mL extended-release injectable suspension	02/22/2019	73.28	1294.73	10/26/2030	Single Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	Aristada was developed in-house
Rx0000039	Alkermes, Inc	03/31/2019	65757040203	ARISTADA 662 mg/2.4mL extended-release injectable suspension	02/22/2019	110.01	1943.56	10/26/2030	Single Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	Aristada was developed in-house
Rx0000039	Alkermes, Inc	03/31/2019	65757040303	ARISTADA 882 mg/3.2mL extended-release injectable suspension	02/22/2019	146.57	2589.46	10/26/2030	Single Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	Aristada was developed in-house
Rx0000020	Allergan	03/31/2019	00430047801	ACTONEL-150 mg-1-CAPSULE,DELAYED RELEASE	01/01/2019	17.25	369.33	None	Innovator Multiple Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	All products have been owned or launched by Allergan in the past 5 years inclusive of Actavis and Allergan who merged in 2015
Rx0000020	Allergan	03/31/2019	00430047802	ACTONEL-150 mg-3-CAPSULE,DELAYED RELEASE	01/01/2019	51.76	1108.00	None	Innovator Multiple Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	All products have been owned or launched by Allergan in the past 5 years inclusive of Actavis and Allergan who merged in 2015
Rx0000020	Allergan	03/31/2019	00430047207	ACTONEL-35 mg-12-CAPSULE,DELAYED RELEASE	01/01/2019	47.78	1022.92	None	Innovator Multiple Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	All products have been owned or launched by Allergan in the past 5 years inclusive of Actavis and Allergan who merged in 2015
Rx0000020	Allergan	03/31/2019	00430047203	ACTONEL-35 mg-4-CAPSULE,DELAYED RELEASE	01/01/2019	15.93	340.98	None	Innovator Multiple Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	All products have been owned or launched by Allergan in the past 5 years inclusive of Actavis and Allergan who merged in 2015
Rx0000020	Allergan	03/31/2019	00430047115	ACTONEL-5 mg-30-CAPSULE,DELAYED RELEASE	01/01/2019	17.08	365.56	None	Innovator Multiple Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	All products have been owned or launched by Allergan in the past 5 years inclusive of Actavis and Allergan who merged in 2015
Rx0000020	Allergan	03/31/2019	00023350730	ACUVAIL-0.45 %-30-DROPPERETTE, SINGLE-USE DROP DISPENSER	01/01/2019	14.87	318.31	03/07/2028	Single Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	All products have been owned or launched by Allergan in the past 5 years inclusive of Actavis and Allergan who merged in 2015
Rx0000020	Allergan	03/31/2019	00023932110	ALPHAGAN P-0.1 %-10-CAPSULE,DELAYED RELEASE	01/01/2019	27.74	319.78	01/10/2020	Single Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	All products have been owned or launched by Allergan in the past 5 years inclusive of Actavis and Allergan who merged in 2015
Rx0000020	Allergan	03/31/2019	00023932115	ALPHAGAN P-0.1 %-15-CAPSULE,DELAYED RELEASE	01/01/2019	41.62	479.74	01/10/2020	Single Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	All products have been owned or launched by Allergan in the past 5 years inclusive of Actavis and Allergan who merged in 2015
Rx0000020	Allergan	03/31/2019	00023932105	ALPHAGAN P-0.1 %-5-CAPSULE,DELAYED RELEASE	01/01/2019	13.88	159.96	01/10/2020	Single Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	All products have been owned or launched by Allergan in the past 5 years inclusive of Actavis and Allergan who merged in 2015
Rx0000020	Allergan	03/31/2019	00023917710	ALPHAGAN P-0.15 %-10-CAPSULE,DELAYED RELEASE	01/01/2019	29.58	340.99	01/28/2022	Innovator Multiple Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	All products have been owned or launched by Allergan in the past 5 years inclusive of Actavis and Allergan who merged in 2015
Rx0000020	Allergan	03/31/2019	00023917715	ALPHAGAN P-0.15 %-15-CAPSULE,DELAYED RELEASE	01/01/2019	44.38	511.53	01/28/2022	Innovator Multiple Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	All products have been owned or launched by Allergan in the past 5 years inclusive of Actavis and Allergan who merged in 2015
Rx0000020	Allergan	03/31/2019	00023917705	ALPHAGAN P-0.15 %-5-CAPSULE,DELAYED RELEASE	01/01/2019	14.80	170.54	01/28/2022	Innovator Multiple Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	All products have been owned or launched by Allergan in the past 5 years inclusive of Actavis and Allergan who merged in 2015
Rx0000020	Allergan	03/31/2019	52544007660	ANDRODERM-2 mg/24 hour-60-CAPSULE,DELAYED RELEASE	01/01/2019	53.43	615.90	None	Single Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	All products have been owned or launched by Allergan in the past 5 years inclusive of Actavis and Allergan who merged in 2015
Rx0000020	Allergan	03/31/2019	00023599060	ANDRODERM-2 mg/24 hour-60-PATCH, TRANSDERMAL 24 HOURS	01/01/2019	53.43	615.90	None	Single Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	All products have been owned or launched by Allergan in the past 5 years inclusive of Actavis and Allergan who merged in 2015
Rx0000020	Allergan	03/31/2019	52544007730	ANDRODERM-4 mg/24 hour-30-CAPSULE,DELAYED RELEASE	01/01/2019	53.43	615.90	None	Single Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	All products have been owned or launched by Allergan in the past 5 years inclusive of Actavis and Allergan who merged in 2015
Rx0000020	Allergan	03/31/2019	00023599230	ANDRODERM-4 mg/24 hour-30-PATCH, TRANSDERMAL 24 HOURS	01/01/2019	53.43	615.90	None	Single Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	All products have been owned or launched by Allergan in the past 5 years inclusive of Actavis and Allergan who merged in 2015
Rx0000020	Allergan	03/31/2019	00456046101	ARMOUR THYROID-120 mg-100-CAPSULE,DELAYED RELEASE	01/01/2019	13.33	153.62	None	Innovator Multiple Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	All products have been owned or launched by Allergan in the past 5 years inclusive of Actavis and Allergan who merged in 2015
Rx0000020	Allergan	03/31/2019	00456045701	ARMOUR THYROID-15 mg-100-CAPSULE,DELAYED RELEASE	01/01/2019	5.57	64.24	None	Innovator Multiple Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	All products have been owned or launched by Allergan in the past 5 years inclusive of Actavis and Allergan who merged in 2015
Rx0000020	Allergan	03/31/2019	00456045801	ARMOUR THYROID-30 mg-100-CAPSULE,DELAYED RELEASE	01/01/2019	6.54	75.42	None	Innovator Multiple Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	All products have been owned or launched by Allergan in the past 5 years inclusive of Actavis and Allergan who merged in 2015
Rx0000020	Allergan	03/31/2019	00456045901	ARMOUR THYROID-60 mg-100-CAPSULE,DELAYED RELEASE	01/01/2019	7.27	83.79	None	Innovator Multiple Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	All products have been owned or launched by Allergan in the past 5 years inclusive of Actavis and Allergan who merged in 2015
Rx0000020	Allergan	03/31/2019	00456046001	ARMOUR THYROID-90 mg-100-CAPSULE,DELAYED RELEASE	01/01/2019	11.39	131.27	None	Innovator Multiple Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	All products have been owned or launched by Allergan in the past 5 years inclusive of Actavis and Allergan who merged in 2015
Rx0000020	Allergan	03/31/2019	00430078327	ASACOL HD-800 mg-180-CAPSULE,DELAYED RELEASE	01/01/2019	146.84	1692.50	11/15/2021	Innovator Multiple Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	All products have been owned or launched by Allergan in the past 5 years inclusive of Actavis and Allergan who merged in 2015
Rx0000020	Allergan	03/31/2019	00023590118	ASACOL HD-800 mg-180-TABLET, DELAYED RELEASE (ENTERIC COATED)	01/01/2019	146.84	1692.50	11/15/2021	Innovator Multiple Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	All products have been owned or launched by Allergan in the past 5 years inclusive of Actavis and Allergan who merged in 2015
Rx0000020	Allergan	03/31/2019	00430097903	ATELVIA-35 mg-4-CAPSULE,DELAYED RELEASE	01/01/2019	12.45	266.56	01/09/2028	Innovator Multiple Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	All products have been owned or launched by Allergan in the past 5 years inclusive of Actavis and Allergan who merged in 2015
Rx0000020	Allergan	03/31/2019	00456270001	AVYCAZ-2.5 gram-1-CAPSULE,DELAYED RELEASE	01/01/2019	31.13	358.81	06/15/2032	Single Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	All products have been owned or launched by Allergan in the past 5 years inclusive of Actavis and Allergan who merged in 2015
Rx0000020	Allergan	03/31/2019	00456270010	AVYCAZ-2.5 gram-1-CAPSULE,DELAYED RELEASE	01/01/2019	311.30	3588.09	06/15/2032	Single Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	All products have been owned or launched by Allergan in the past 5 years inclusive of Actavis and Allergan who merged in 2015
Rx0000020	Allergan	03/31/2019	58914008052	BENTYL-10 mg/mL-2-CAPSULE,DELAYED RELEASE	01/01/2019	19.63	420.29	None	Single Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	All products have been owned or launched by Allergan in the past 5 years inclusive of Actavis and Allergan who merged in 2015
Rx0000020	Allergan	03/31/2019	00023031304	BLEPHAMIDE S.O.P.-10 %-0.2 %-3.5-OINTMENT (GRAM)	01/01/2019	6.80	145.49	None	Single Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	All products have been owned or launched by Allergan in the past 5 years inclusive of Actavis and Allergan who merged in 2015
Rx0000020	Allergan	03/31/2019	11980002210	BLEPHAMIDE-10 %-0.2 %-10-CAPSULE,DELAYED RELEASE	01/01/2019	13.59	290.98	None	Single Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	All products have been owned or launched by Allergan in the past 5 years inclusive of Actavis and Allergan who merged in 2015
Rx0000020	Allergan	03/31/2019	11980002205	BLEPHAMIDE-10 %-0.2 %-5-CAPSULE,DELAYED RELEASE	01/01/2019	6.80	145.49	None	Single Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	All products have been owned or launched by Allergan in the past 5 years inclusive of Actavis and Allergan who merged in 2015
Rx0000020	Allergan	03/31/2019	00456141030	BYSTOLIC-10 mg-30-CAPSULE,DELAYED RELEASE	01/01/2019	12.43	143.24	12/17/2021	Single Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	All products have been owned or launched by Allergan in the past 5 years inclusive of Actavis and Allergan who merged in 2015
Rx0000020	Allergan	03/31/2019	00456141090	BYSTOLIC-10 mg-90-CAPSULE,DELAYED RELEASE	01/01/2019	37.28	429.71	12/17/2021	Single Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	All products have been owned or launched by Allergan in the past 5 years inclusive of Actavis and Allergan who merged in 2015
Rx0000020	Allergan	03/31/2019	00456140263	BYSTOLIC-2.5 mg-100-CAPSULE,DELAYED RELEASE	01/01/2019	42.21	486.53	12/17/2021	Single Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	All products have been owned or launched by Allergan in the past 5 years inclusive of Actavis and Allergan who merged in 2015
Rx0000020	Allergan	03/31/2019	00456140230	BYSTOLIC-2.5 mg-30-CAPSULE,DELAYED RELEASE	01/01/2019	12.43	143.24	12/17/2021	Single Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	All products have been owned or launched by Allergan in the past 5 years inclusive of Actavis and Allergan who merged in 2015
Rx0000020	Allergan	03/31/2019	00456142030	BYSTOLIC-20 mg-30-CAPSULE,DELAYED RELEASE	01/01/2019	12.43	143.24	12/17/2021	Single Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	All products have been owned or launched by Allergan in the past 5 years inclusive of Actavis and Allergan who merged in 2015
Rx0000020	Allergan	03/31/2019	00456142090	BYSTOLIC-20 mg-90-CAPSULE,DELAYED RELEASE	01/01/2019	37.28	429.71	12/17/2021	Single Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	All products have been owned or launched by Allergan in the past 5 years inclusive of Actavis and Allergan who merged in 2015
Rx0000020	Allergan	03/31/2019	00456140563	BYSTOLIC-5 mg-100-CAPSULE,DELAYED RELEASE	01/01/2019	42.21	486.53	12/17/2021	Single Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	All products have been owned or launched by Allergan in the past 5 years inclusive of Actavis and Allergan who merged in 2015
Rx0000020	Allergan	03/31/2019	00456140530	BYSTOLIC-5 mg-30-CAPSULE,DELAYED RELEASE	01/01/2019	12.43	143.24	12/17/2021	Single Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	All products have been owned or launched by Allergan in the past 5 years inclusive of Actavis and Allergan who merged in 2015
Rx0000020	Allergan	03/31/2019	00456140590	BYSTOLIC-5 mg-90-CAPSULE,DELAYED RELEASE	01/01/2019	37.28	429.71	12/17/2021	Single Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	All products have been owned or launched by Allergan in the past 5 years inclusive of Actavis and Allergan who merged in 2015
Rx0000020	Allergan	03/31/2019	58914050156	CANASA-1,000 mg-30-CAPSULE,DELAYED RELEASE	01/01/2019	100.79	1161.78	06/06/2028	Innovator Multiple Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	All products have been owned or launched by Allergan in the past 5 years inclusive of Actavis and Allergan who merged in 2015
Rx0000020	Allergan	03/31/2019	58914050142	CANASA-1,000 mg-42-CAPSULE,DELAYED RELEASE	01/01/2019	141.11	1626.51	06/06/2028	Innovator Multiple Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	All products have been owned or launched by Allergan in the past 5 years inclusive of Actavis and Allergan who merged in 2015
Rx0000020	Allergan	03/31/2019	58914017014	CARAFATE-1 gram/10 mL-420-CAPSULE,DELAYED RELEASE	01/01/2019	18.16	209.28	None	Single Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	All products have been owned or launched by Allergan in the past 5 years inclusive of Actavis and Allergan who merged in 2015
Rx0000020	Allergan	03/31/2019	58914017110	CARAFATE-1 gram-100-CAPSULE,DELAYED RELEASE	01/01/2019	33.71	388.51	None	Innovator Multiple Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	All products have been owned or launched by Allergan in the past 5 years inclusive of Actavis and Allergan who merged in 2015
Rx0000020	Allergan	03/31/2019	00456401001	CELEXA-10 mg-100-CAPSULE,DELAYED RELEASE	01/01/2019	42.40	907.71	None	Innovator Multiple Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	All products have been owned or launched by Allergan in the past 5 years inclusive of Actavis and Allergan who merged in 2015
Rx0000020	Allergan	03/31/2019	00456402001	CELEXA-20 mg-100-CAPSULE,DELAYED RELEASE	01/01/2019	44.19	946.10	None	Innovator Multiple Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	All products have been owned or launched by Allergan in the past 5 years inclusive of Actavis and Allergan who merged in 2015
Rx0000020	Allergan	03/31/2019	00456404001	CELEXA-40 mg-100-CAPSULE,DELAYED RELEASE	01/01/2019	46.12	987.29	None	Innovator Multiple Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	All products have been owned or launched by Allergan in the past 5 years inclusive of Actavis and Allergan who merged in 2015
Rx0000020	Allergan	03/31/2019	00023921110	COMBIGAN-0.2 %-0.5 %-10-CAPSULE,DELAYED RELEASE	01/01/2019	30.60	352.68	04/19/2022	Single Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	All products have been owned or launched by Allergan in the past 5 years inclusive of Actavis and Allergan who merged in 2015
Rx0000020	Allergan	03/31/2019	00023921115	COMBIGAN-0.2 %-0.5 %-15-CAPSULE,DELAYED RELEASE	01/01/2019	45.89	528.98	04/19/2022	Single Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	All products have been owned or launched by Allergan in the past 5 years inclusive of Actavis and Allergan who merged in 2015
Rx0000020	Allergan	03/31/2019	00023921105	COMBIGAN-0.2 %-0.5 %-5-CAPSULE,DELAYED RELEASE	01/01/2019	15.30	176.33	04/19/2022	Single Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	All products have been owned or launched by Allergan in the past 5 years inclusive of Actavis and Allergan who merged in 2015
Rx0000020	Allergan	03/31/2019	00023611803	CONDYLOX-0.5 %-3.5-CAPSULE,DELAYED RELEASE	01/01/2019	29.58	633.34	None	Single Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	All products have been owned or launched by Allergan in the past 5 years inclusive of Actavis and Allergan who merged in 2015
Rx0000020	Allergan	03/31/2019	52544025524	CRINONE-4 %-1.125-CAPSULE,DELAYED RELEASE	01/01/2019	5.02	107.52	None	Single Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	All products have been owned or launched by Allergan in the past 5 years inclusive of Actavis and Allergan who merged in 2015
Rx0000020	Allergan	03/31/2019	00023615108	CRINONE-8 %-1.125-CAPSULE,DELAYED RELEASE	01/01/2019	20.94	448.20	None	Single Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	All products have been owned or launched by Allergan in the past 5 years inclusive of Actavis and Allergan who merged in 2015
Rx0000020	Allergan	03/31/2019	52544025612	CRINONE-8 %-1.125-CAPSULE,DELAYED RELEASE	01/01/2019	20.94	448.20	None	Single Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	All products have been owned or launched by Allergan in the past 5 years inclusive of Actavis and Allergan who merged in 2015
Rx0000020	Allergan	03/31/2019	00023585318	DELZICOL-400 mg-180-CAPSULE (WITH DELAYED RELEASE TABLETS)	01/01/2019	60.58	698.31	04/13/2020	Single Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	All products have been owned or launched by Allergan in the past 5 years inclusive of Actavis and Allergan who merged in 2015
Rx0000020	Allergan	03/31/2019	00430375414	ESTRACE-0.01 %-42.5-CAPSULE,DELAYED RELEASE	01/01/2019	29.91	344.78	None	Innovator Multiple Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	All products have been owned or launched by Allergan in the past 5 years inclusive of Actavis and Allergan who merged in 2015
Rx0000020	Allergan	03/31/2019	00430072024	ESTRACE-0.5 mg-100-CAPSULE,DELAYED RELEASE	01/01/2019	25.46	545.10	None	Innovator Multiple Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	All products have been owned or launched by Allergan in the past 5 years inclusive of Actavis and Allergan who merged in 2015
Rx0000020	Allergan	03/31/2019	00430072124	ESTRACE-1 mg-100-CAPSULE,DELAYED RELEASE	01/01/2019	25.46	545.10	None	Innovator Multiple Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	All products have been owned or launched by Allergan in the past 5 years inclusive of Actavis and Allergan who merged in 2015
Rx0000020	Allergan	03/31/2019	00430072224	ESTRACE-2 mg-100-CAPSULE,DELAYED RELEASE	01/01/2019	32.68	699.69	None	Innovator Multiple Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	All products have been owned or launched by Allergan in the past 5 years inclusive of Actavis and Allergan who merged in 2015
Rx0000020	Allergan	03/31/2019	00456221230	FETZIMA-120 mg-30-CAPSULE,DELAYED RELEASE	01/01/2019	34.08	392.80	05/23/2032	Single Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	All products have been owned or launched by Allergan in the past 5 years inclusive of Actavis and Allergan who merged in 2015
Rx0000020	Allergan	03/31/2019	00456220228	FETZIMA-20 mg (2)-40 mg (26)-28-CAPSULE,DELAYED RELEASE	01/01/2019	31.81	366.62	05/23/2032	Single Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	All products have been owned or launched by Allergan in the past 5 years inclusive of Actavis and Allergan who merged in 2015
Rx0000020	Allergan	03/31/2019	00456222030	FETZIMA-20 mg-30-CAPSULE,DELAYED RELEASE	01/01/2019	34.08	392.80	05/23/2032	Single Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	All products have been owned or launched by Allergan in the past 5 years inclusive of Actavis and Allergan who merged in 2015
Rx0000020	Allergan	03/31/2019	00456224030	FETZIMA-40 mg-30-CAPSULE,DELAYED RELEASE	01/01/2019	34.08	392.80	05/23/2032	Single Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	All products have been owned or launched by Allergan in the past 5 years inclusive of Actavis and Allergan who merged in 2015
Rx0000020	Allergan	03/31/2019	00456228030	FETZIMA-80 mg-30-CAPSULE,DELAYED RELEASE	01/01/2019	34.08	392.80	05/23/2032	Single Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	All products have been owned or launched by Allergan in the past 5 years inclusive of Actavis and Allergan who merged in 2015
Rx0000020	Allergan	03/31/2019	52544095601	FIORINAL WITH CODEINE #3-30 mg-50 mg-325 mg-40 mg-100-CAPSULE,DELAYED RELEASE	01/01/2019	52.97	1133.91	None	Innovator Multiple Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	All products have been owned or launched by Allergan in the past 5 years inclusive of Actavis and Allergan who merged in 2015
Rx0000020	Allergan	03/31/2019	52544095501	FIORINAL-50 mg-325 mg-40 mg-100-CAPSULE,DELAYED RELEASE	01/01/2019	25.27	541.03	None	Innovator Multiple Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	All products have been owned or launched by Allergan in the past 5 years inclusive of Actavis and Allergan who merged in 2015
Rx0000020	Allergan	03/31/2019	11980022810	FML FORTE-0.25 %-10-CAPSULE,DELAYED RELEASE	01/01/2019	14.27	305.53	None	Single Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	All products have been owned or launched by Allergan in the past 5 years inclusive of Actavis and Allergan who merged in 2015
Rx0000020	Allergan	03/31/2019	11980022805	FML FORTE-0.25 %-5-CAPSULE,DELAYED RELEASE	01/01/2019	7.14	152.76	None	Single Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	All products have been owned or launched by Allergan in the past 5 years inclusive of Actavis and Allergan who merged in 2015
Rx0000020	Allergan	03/31/2019	00023031604	FML S.O.P.-0.1 %-3.5-OINTMENT (GRAM)	01/01/2019	7.14	152.76	None	Single Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	All products have been owned or launched by Allergan in the past 5 years inclusive of Actavis and Allergan who merged in 2015
Rx0000020	Allergan	03/31/2019	11980021110	FML-0.1 %-10-CAPSULE,DELAYED RELEASE	01/01/2019	14.27	305.53	None	Innovator Multiple Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	All products have been owned or launched by Allergan in the past 5 years inclusive of Actavis and Allergan who merged in 2015
Rx0000020	Allergan	03/31/2019	11980021105	FML-0.1 %-5-CAPSULE,DELAYED RELEASE	01/01/2019	7.14	152.76	None	Innovator Multiple Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	All products have been owned or launched by Allergan in the past 5 years inclusive of Actavis and Allergan who merged in 2015
Rx0000020	Allergan	03/31/2019	52544008430	GELNIQUE-10 % (100 mg/gram)-1-CAPSULE,DELAYED RELEASE	01/01/2019	18.48	395.53	03/26/2031	Single Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	All products have been owned or launched by Allergan in the past 5 years inclusive of Actavis and Allergan who merged in 2015
Rx0000020	Allergan	03/31/2019	00023586111	GELNIQUE-10 % (100 mg/gram)-1-GEL IN PACKET (GRAM)	01/01/2019	18.48	395.53	03/26/2031	Single Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	All products have been owned or launched by Allergan in the past 5 years inclusive of Actavis and Allergan who merged in 2015
Rx0000020	Allergan	03/31/2019	00023581230	GELNIQUE-100 mg/gram per actuation (10 %)-30-GEL IN METERED-DOSE PUMP	01/01/2019	18.48	395.53	03/26/2031	Single Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	All products have been owned or launched by Allergan in the past 5 years inclusive of Actavis and Allergan who merged in 2015
Rx0000020	Allergan	03/31/2019	52544020431	GENERESS FE-0.8 mg-25 mcg (24)/75 mg (~24.7 mg iron)(4)-28-CAPSULE,DELAYED RELEASE	01/01/2019	22.93	490.85	None	Innovator Multiple Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	All products have been owned or launched by Allergan in the past 5 years inclusive of Actavis and Allergan who merged in 2015
Rx0000020	Allergan	03/31/2019	00023429003	LASTACAFT-0.25 %-3-DROPS	01/01/2019	10.53	225.39	12/23/2027	Single Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	All products have been owned or launched by Allergan in the past 5 years inclusive of Actavis and Allergan who merged in 2015
Rx0000020	Allergan	03/31/2019	00456201001	LEXAPRO-10 mg-100-CAPSULE,DELAYED RELEASE	01/01/2019	99.54	1147.35	02/12/2023	Innovator Multiple Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	All products have been owned or launched by Allergan in the past 5 years inclusive of Actavis and Allergan who merged in 2015
Rx0000020	Allergan	03/31/2019	00456202001	LEXAPRO-20 mg-100-CAPSULE,DELAYED RELEASE	01/01/2019	103.87	1197.27	02/12/2023	Innovator Multiple Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	All products have been owned or launched by Allergan in the past 5 years inclusive of Actavis and Allergan who merged in 2015
Rx0000020	Allergan	03/31/2019	00456200501	LEXAPRO-5 mg-100-CAPSULE,DELAYED RELEASE	01/01/2019	95.21	1097.38	02/12/2023	Innovator Multiple Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	All products have been owned or launched by Allergan in the past 5 years inclusive of Actavis and Allergan who merged in 2015
Rx0000020	Allergan	03/31/2019	52544003554	LILETTA-19.5 mcg/24 hour (5 years) 52 mg-1-CAPSULE,DELAYED RELEASE	01/01/2019	65.02	749.40	03/22/2034	Innovator Multiple Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	All products have been owned or launched by Allergan in the past 5 years inclusive of Actavis and Allergan who merged in 2015
Rx0000020	Allergan	03/31/2019	00023585801	LILETTA-19.5 mcg/24 hour (5 years) 52 mg-1-INTRAUTERINE DEVICE	01/01/2019	65.02	749.40	03/22/2034	Single Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	All products have been owned or launched by Allergan in the past 5 years inclusive of Actavis and Allergan who merged in 2015
Rx0000020	Allergan	03/31/2019	00456120130	LINZESS-145 mcg-30-CAPSULE,DELAYED RELEASE	01/01/2019	36.77	423.83	08/16/2033	Single Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	All products have been owned or launched by Allergan in the past 5 years inclusive of Actavis and Allergan who merged in 2015
Rx0000020	Allergan	03/31/2019	00456120230	LINZESS-290 mcg-30-CAPSULE,DELAYED RELEASE	01/01/2019	36.77	423.83	08/16/2033	Single Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	All products have been owned or launched by Allergan in the past 5 years inclusive of Actavis and Allergan who merged in 2015
Rx0000020	Allergan	03/31/2019	00456120330	LINZESS-72 mcg-30-CAPSULE,DELAYED RELEASE	01/01/2019	36.77	423.83	08/16/2033	Single Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	All products have been owned or launched by Allergan in the past 5 years inclusive of Actavis and Allergan who merged in 2015
Rx0000020	Allergan	03/31/2019	00430042014	LO LOESTRIN FE-1 mg-10 mcg (24)/10 mcg (2)/75 mg (2)-28-CAPSULE,DELAYED RELEASE	01/01/2019	61.04	703.59	02/02/2029	Single Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	All products have been owned or launched by Allergan in the past 5 years inclusive of Actavis and Allergan who merged in 2015
Rx0000020	Allergan	03/31/2019	00023320503	LUMIGAN-0.01 %-2.5-DROPS	01/01/2019	17.09	196.97	03/16/2025	Single Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	All products have been owned or launched by Allergan in the past 5 years inclusive of Actavis and Allergan who merged in 2015
Rx0000020	Allergan	03/31/2019	00023320505	LUMIGAN-0.01 %-5-DROPS	01/01/2019	34.16	393.78	03/16/2025	Single Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	All products have been owned or launched by Allergan in the past 5 years inclusive of Actavis and Allergan who merged in 2015
Rx0000020	Allergan	03/31/2019	00023320508	LUMIGAN-0.01 %-7.5-DROPS	01/01/2019	51.24	590.64	03/16/2025	Single Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	All products have been owned or launched by Allergan in the past 5 years inclusive of Actavis and Allergan who merged in 2015
Rx0000020	Allergan	03/31/2019	00430054050	MINASTRIN 24 FE-1 mg-20 mcg (24)/75 mg (4)-28-CAPSULE,DELAYED RELEASE	01/01/2019	41.49	888.13	04/06/2019	Innovator Multiple Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	All products have been owned or launched by Allergan in the past 5 years inclusive of Actavis and Allergan who merged in 2015
Rx0000020	Allergan	03/31/2019	00456430001	MONUROL-3 gram-1-CAPSULE,DELAYED RELEASE	01/01/2019	7.54	86.92	None	Single Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	All products have been owned or launched by Allergan in the past 5 years inclusive of Actavis and Allergan who merged in 2015
Rx0000020	Allergan	03/31/2019	00456341433	NAMENDA XR-14 mg-30-CAPSULE,DELAYED RELEASE	01/01/2019	40.32	464.77	09/24/2029	Innovator Multiple Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	All products have been owned or launched by Allergan in the past 5 years inclusive of Actavis and Allergan who merged in 2015
Rx0000020	Allergan	03/31/2019	00456341490	NAMENDA XR-14 mg-90-CAPSULE,DELAYED RELEASE	01/01/2019	120.97	1394.32	09/24/2029	Innovator Multiple Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	All products have been owned or launched by Allergan in the past 5 years inclusive of Actavis and Allergan who merged in 2015
Rx0000020	Allergan	03/31/2019	00456342133	NAMENDA XR-21 mg-30-CAPSULE,DELAYED RELEASE	01/01/2019	40.32	464.77	09/24/2029	Innovator Multiple Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	All products have been owned or launched by Allergan in the past 5 years inclusive of Actavis and Allergan who merged in 2015
Rx0000020	Allergan	03/31/2019	00456342833	NAMENDA XR-28 mg-30-CAPSULE,DELAYED RELEASE	01/01/2019	40.32	464.77	09/24/2029	Innovator Multiple Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	All products have been owned or launched by Allergan in the past 5 years inclusive of Actavis and Allergan who merged in 2015
Rx0000020	Allergan	03/31/2019	00456342890	NAMENDA XR-28 mg-90-CAPSULE,DELAYED RELEASE	01/01/2019	120.97	1394.32	09/24/2029	Innovator Multiple Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	All products have been owned or launched by Allergan in the past 5 years inclusive of Actavis and Allergan who merged in 2015
Rx0000020	Allergan	03/31/2019	00456340029	NAMENDA XR-7 mg (7)-14 mg (7)-21 mg (7)-28 mg (7)-28-CAPSULE,DELAYED RELEASE	01/01/2019	37.64	433.80	None	Innovator Multiple Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	All products have been owned or launched by Allergan in the past 5 years inclusive of Actavis and Allergan who merged in 2015
Rx0000020	Allergan	03/31/2019	00456340733	NAMENDA XR-7 mg-30-CAPSULE,DELAYED RELEASE	01/01/2019	40.32	464.77	09/24/2029	Innovator Multiple Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	All products have been owned or launched by Allergan in the past 5 years inclusive of Actavis and Allergan who merged in 2015
Rx0000020	Allergan	03/31/2019	00456121430	NAMZARIC-14 mg-10 mg-30-CAPSULE,DELAYED RELEASE	01/01/2019	40.14	462.66	12/05/2029	Single Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	All products have been owned or launched by Allergan in the past 5 years inclusive of Actavis and Allergan who merged in 2015
Rx0000020	Allergan	03/31/2019	00456122130	NAMZARIC-21 mg-10 mg-30-CAPSULE,DELAYED RELEASE	01/01/2019	40.14	462.66	12/05/2029	Single Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	All products have been owned or launched by Allergan in the past 5 years inclusive of Actavis and Allergan who merged in 2015
Rx0000020	Allergan	03/31/2019	00456122830	NAMZARIC-28 mg-10 mg-30-CAPSULE,DELAYED RELEASE	01/01/2019	40.14	462.66	12/05/2029	Single Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	All products have been owned or launched by Allergan in the past 5 years inclusive of Actavis and Allergan who merged in 2015
Rx0000020	Allergan	03/31/2019	00456122929	NAMZARIC-7 mg-10 mg (7)/14 mg-10 mg (7)/21 mg-10 mg(7)/28 mg-10 mg(7)-28-CAPSULE,DELAYED RELEASE	01/01/2019	37.46	431.81	12/05/2029	Single Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	All products have been owned or launched by Allergan in the past 5 years inclusive of Actavis and Allergan who merged in 2015
Rx0000020	Allergan	03/31/2019	00456120730	NAMZARIC-7 mg-10 mg-30-CAPSULE,DELAYED RELEASE	01/01/2019	40.14	462.66	12/05/2029	Single Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	All products have been owned or launched by Allergan in the past 5 years inclusive of Actavis and Allergan who merged in 2015
Rx0000020	Allergan	03/31/2019	00023615301	OXYTROL-3.9 mg/24 hour-1-CAPSULE,DELAYED RELEASE	01/01/2019	3.97	84.98	04/26/2020	Single Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	All products have been owned or launched by Allergan in the past 5 years inclusive of Actavis and Allergan who merged in 2015
Rx0000020	Allergan	03/31/2019	52544092054	OXYTROL-3.9 mg/24 hour-1-CAPSULE,DELAYED RELEASE	01/01/2019	3.97	84.98	04/26/2020	Single Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	All products have been owned or launched by Allergan in the past 5 years inclusive of Actavis and Allergan who merged in 2015
Rx0000020	Allergan	03/31/2019	00023615308	OXYTROL-3.9 mg/24 hour-8-CAPSULE,DELAYED RELEASE	01/01/2019	31.76	679.85	04/26/2020	Single Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	All products have been owned or launched by Allergan in the past 5 years inclusive of Actavis and Allergan who merged in 2015
Rx0000020	Allergan	03/31/2019	52544092008	OXYTROL-3.9 mg/24 hour-8-CAPSULE,DELAYED RELEASE	01/01/2019	31.76	679.85	04/26/2020	Single Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	All products have been owned or launched by Allergan in the past 5 years inclusive of Actavis and Allergan who merged in 2015
Rx0000020	Allergan	03/31/2019	11980018010	PRED FORTE-1 %-10-CAPSULE,DELAYED RELEASE	01/01/2019	13.59	290.98	None	Innovator Multiple Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	All products have been owned or launched by Allergan in the past 5 years inclusive of Actavis and Allergan who merged in 2015
Rx0000020	Allergan	03/31/2019	11980018015	PRED FORTE-1 %-15-CAPSULE,DELAYED RELEASE	01/01/2019	20.39	436.47	None	Innovator Multiple Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	All products have been owned or launched by Allergan in the past 5 years inclusive of Actavis and Allergan who merged in 2015
Rx0000020	Allergan	03/31/2019	11980018005	PRED FORTE-1 %-5-CAPSULE,DELAYED RELEASE	01/01/2019	6.80	145.49	None	Innovator Multiple Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	All products have been owned or launched by Allergan in the past 5 years inclusive of Actavis and Allergan who merged in 2015
Rx0000020	Allergan	03/31/2019	11980017410	PRED MILD-0.12 %-10-CAPSULE,DELAYED RELEASE	01/01/2019	13.59	290.98	None	Single Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	All products have been owned or launched by Allergan in the past 5 years inclusive of Actavis and Allergan who merged in 2015
Rx0000020	Allergan	03/31/2019	11980017405	PRED MILD-0.12 %-5-CAPSULE,DELAYED RELEASE	01/01/2019	6.80	145.49	None	Single Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	All products have been owned or launched by Allergan in the past 5 years inclusive of Actavis and Allergan who merged in 2015
Rx0000020	Allergan	03/31/2019	00023006604	PRED-G-0.3 %-0.6 %-3.5-OINTMENT (GRAM)	01/01/2019	6.80	145.49	None	Single Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	All products have been owned or launched by Allergan in the past 5 years inclusive of Actavis and Allergan who merged in 2015
Rx0000020	Allergan	03/31/2019	00023010605	PRED-G-0.3 %-1 %-5-SUSPENSION, DROPS(FINAL DOSAGE FORM)(ML)	01/01/2019	6.80	145.49	None	Single Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	All products have been owned or launched by Allergan in the past 5 years inclusive of Actavis and Allergan who merged in 2015
Rx0000020	Allergan	03/31/2019	58914060120	PYLERA-140 mg-125 mg-125 mg-120-CAPSULE,DELAYED RELEASE	01/01/2019	43.05	921.54	None	Single Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	All products have been owned or launched by Allergan in the past 5 years inclusive of Actavis and Allergan who merged in 2015
Rx0000020	Allergan	03/31/2019	00023614730	RAPAFLO-4 mg-30-CAPSULE,DELAYED RELEASE	01/01/2019	12.21	261.48	None	Innovator Multiple Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	All products have been owned or launched by Allergan in the past 5 years inclusive of Actavis and Allergan who merged in 2015
Rx0000020	Allergan	03/31/2019	52544015130	RAPAFLO-4 mg-30-CAPSULE,DELAYED RELEASE	01/01/2019	12.21	261.48	None	Single Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	All products have been owned or launched by Allergan in the past 5 years inclusive of Actavis and Allergan who merged in 2015
Rx0000020	Allergan	03/31/2019	00023614230	RAPAFLO-8 mg-30-CAPSULE,DELAYED RELEASE	01/01/2019	12.21	261.48	None	Innovator Multiple Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	All products have been owned or launched by Allergan in the past 5 years inclusive of Actavis and Allergan who merged in 2015
Rx0000020	Allergan	03/31/2019	52544015230	RAPAFLO-8 mg-30-CAPSULE,DELAYED RELEASE	01/01/2019	12.21	261.48	None	Single Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	All products have been owned or launched by Allergan in the past 5 years inclusive of Actavis and Allergan who merged in 2015
Rx0000020	Allergan	03/31/2019	00023614290	RAPAFLO-8 mg-90-CAPSULE,DELAYED RELEASE	01/01/2019	36.64	784.40	None	Innovator Multiple Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	All products have been owned or launched by Allergan in the past 5 years inclusive of Actavis and Allergan who merged in 2015
Rx0000020	Allergan	03/31/2019	52544015219	RAPAFLO-8 mg-90-CAPSULE,DELAYED RELEASE	01/01/2019	36.64	784.40	None	Innovator Multiple Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	All products have been owned or launched by Allergan in the past 5 years inclusive of Actavis and Allergan who merged in 2015
Rx0000020	Allergan	03/31/2019	58914030180	RECTIV-0.4 % (w/w)-30-CAPSULE,DELAYED RELEASE	01/01/2019	29.93	640.74	None	Single Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	All products have been owned or launched by Allergan in the past 5 years inclusive of Actavis and Allergan who merged in 2015
Rx0000020	Allergan	03/31/2019	00023530105	RESTASIS MULTIDOSE-0.05 %-5.5-DROPS	01/01/2019	48.39	557.72	05/11/2034	Single Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	All products have been owned or launched by Allergan in the past 5 years inclusive of Actavis and Allergan who merged in 2015
Rx0000020	Allergan	03/31/2019	00023916330	RESTASIS-0.05 %-30-CAPSULE,DELAYED RELEASE	01/01/2019	24.19	278.85	08/27/2024	Single Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	All products have been owned or launched by Allergan in the past 5 years inclusive of Actavis and Allergan who merged in 2015
Rx0000020	Allergan	03/31/2019	00023916360	RESTASIS-0.05 %-60-CAPSULE,DELAYED RELEASE	01/01/2019	48.39	557.72	08/27/2024	Single Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	All products have been owned or launched by Allergan in the past 5 years inclusive of Actavis and Allergan who merged in 2015
Rx0000020	Allergan	03/31/2019	00430021014	SARAFEM-10 mg-28-CAPSULE,DELAYED RELEASE	01/01/2019	27.31	584.74	None	Innovator Multiple Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	All products have been owned or launched by Allergan in the past 5 years inclusive of Actavis and Allergan who merged in 2015
Rx0000020	Allergan	03/31/2019	00430022014	SARAFEM-20 mg-28-CAPSULE,DELAYED RELEASE	01/01/2019	27.31	584.74	None	Innovator Multiple Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	All products have been owned or launched by Allergan in the past 5 years inclusive of Actavis and Allergan who merged in 2015
Rx0000020	Allergan	03/31/2019	00456151060	SAVELLA-100 mg-60-CAPSULE,DELAYED RELEASE	01/01/2019	33.14	381.93	09/19/2029	Single Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	All products have been owned or launched by Allergan in the past 5 years inclusive of Actavis and Allergan who merged in 2015
Rx0000020	Allergan	03/31/2019	00456150055	SAVELLA-12.5 mg (5)-25 mg (8)-50 mg (42)-55-CAPSULE,DELAYED RELEASE	01/01/2019	30.37	350.10	09/19/2029	Single Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	All products have been owned or launched by Allergan in the past 5 years inclusive of Actavis and Allergan who merged in 2015
Rx0000020	Allergan	03/31/2019	00456151260	SAVELLA-12.5 mg-60-CAPSULE,DELAYED RELEASE	01/01/2019	33.14	381.93	09/19/2029	Single Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	All products have been owned or launched by Allergan in the past 5 years inclusive of Actavis and Allergan who merged in 2015
Rx0000020	Allergan	03/31/2019	00456152560	SAVELLA-25 mg-60-CAPSULE,DELAYED RELEASE	01/01/2019	33.14	381.93	09/19/2029	Single Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	All products have been owned or launched by Allergan in the past 5 years inclusive of Actavis and Allergan who merged in 2015
Rx0000020	Allergan	03/31/2019	00456155060	SAVELLA-50 mg-60-CAPSULE,DELAYED RELEASE	01/01/2019	33.14	381.93	09/19/2029	Single Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	All products have been owned or launched by Allergan in the past 5 years inclusive of Actavis and Allergan who merged in 2015
Rx0000020	Allergan	03/31/2019	00023586230	TAYTULLA-1 mg-20 mcg (24)/75 mg (4)-28-CAPSULE	01/01/2019	81.10	934.74	03/29/2020	Single Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	All products have been owned or launched by Allergan in the past 5 years inclusive of Actavis and Allergan who merged in 2015
Rx0000020	Allergan	03/31/2019	00456040001	TEFLARO-400 mg-1-CAPSULE,DELAYED RELEASE	01/01/2019	16.67	192.12	02/10/2031	Single Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	All products have been owned or launched by Allergan in the past 5 years inclusive of Actavis and Allergan who merged in 2015
Rx0000020	Allergan	03/31/2019	00456040010	TEFLARO-400 mg-1-CAPSULE,DELAYED RELEASE	01/01/2019	166.68	1921.21	02/10/2031	Single Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	All products have been owned or launched by Allergan in the past 5 years inclusive of Actavis and Allergan who merged in 2015
Rx0000020	Allergan	03/31/2019	00456060001	TEFLARO-600 mg-1-CAPSULE,DELAYED RELEASE	01/01/2019	16.67	192.12	02/10/2031	Single Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	All products have been owned or launched by Allergan in the past 5 years inclusive of Actavis and Allergan who merged in 2015
Rx0000020	Allergan	03/31/2019	00456060010	TEFLARO-600 mg-1-CAPSULE,DELAYED RELEASE	01/01/2019	166.68	1921.21	02/10/2031	Single Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	All products have been owned or launched by Allergan in the past 5 years inclusive of Actavis and Allergan who merged in 2015
Rx0000020	Allergan	03/31/2019	58914079010	URSO FORTE-500 mg-100-CAPSULE,DELAYED RELEASE	01/01/2019	45.59	975.95	None	Innovator Multiple Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	All products have been owned or launched by Allergan in the past 5 years inclusive of Actavis and Allergan who merged in 2015
Rx0000020	Allergan	03/31/2019	58914078510	URSO-250 mg-100-CAPSULE,DELAYED RELEASE	01/01/2019	25.73	550.74	None	Innovator Multiple Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	All products have been owned or launched by Allergan in the past 5 years inclusive of Actavis and Allergan who merged in 2015
Rx0000020	Allergan	03/31/2019	61874010060	VIBERZI-100 mg-60-CAPSULE,DELAYED RELEASE	01/01/2019	108.85	1254.66	03/25/2028	Single Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	All products have been owned or launched by Allergan in the past 5 years inclusive of Actavis and Allergan who merged in 2015
Rx0000020	Allergan	03/31/2019	61874007560	VIBERZI-75 mg-60-CAPSULE,DELAYED RELEASE	01/01/2019	108.85	1254.66	03/25/2028	Single Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	All products have been owned or launched by Allergan in the past 5 years inclusive of Actavis and Allergan who merged in 2015
Rx0000020	Allergan	03/31/2019	00456110130	VIIBRYD-10 mg (7)-20 mg (23)-30-CAPSULE,DELAYED RELEASE	01/01/2019	23.62	272.24	06/05/2022	Single Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	All products have been owned or launched by Allergan in the past 5 years inclusive of Actavis and Allergan who merged in 2015
Rx0000020	Allergan	03/31/2019	00456111030	VIIBRYD-10 mg-30-CAPSULE,DELAYED RELEASE	01/01/2019	23.62	272.24	06/05/2022	Single Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	All products have been owned or launched by Allergan in the past 5 years inclusive of Actavis and Allergan who merged in 2015
Rx0000020	Allergan	03/31/2019	00456112030	VIIBRYD-20 mg-30-CAPSULE,DELAYED RELEASE	01/01/2019	23.62	272.24	06/05/2022	Single Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	All products have been owned or launched by Allergan in the past 5 years inclusive of Actavis and Allergan who merged in 2015
Rx0000020	Allergan	03/31/2019	00456114030	VIIBRYD-40 mg-30-CAPSULE,DELAYED RELEASE	01/01/2019	23.62	272.24	06/05/2022	Single Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	All products have been owned or launched by Allergan in the past 5 years inclusive of Actavis and Allergan who merged in 2015
Rx0000020	Allergan	03/31/2019	00023611001	ZENPEP-10,000 unit-32,000 unit-42,000 unit-100-CAPSULE,DELAYED RELEASE	01/01/2019	29.07	335.02	02/20/2028	Single Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	All products have been owned or launched by Allergan in the past 5 years inclusive of Actavis and Allergan who merged in 2015
Rx0000020	Allergan	03/31/2019	42865030602	ZENPEP-10,000 unit-34,000 unit-55,000 unit-100-CAPSULE,DELAYED RELEASE	01/01/2019	29.07	335.02	02/20/2028	Single Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	All products have been owned or launched by Allergan in the past 5 years inclusive of Actavis and Allergan who merged in 2015
Rx0000020	Allergan	03/31/2019	00023611101	ZENPEP-15,000 unit-47,000 unit-63,000 unit-100-CAPSULE,DELAYED RELEASE	01/01/2019	41.98	483.87	02/20/2028	Single Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	All products have been owned or launched by Allergan in the past 5 years inclusive of Actavis and Allergan who merged in 2015
Rx0000020	Allergan	03/31/2019	42865030202	ZENPEP-15,000 unit-51,000 unit-82,000 unit-100-CAPSULE,DELAYED RELEASE	01/01/2019	41.98	483.87	02/20/2028	Single Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	All products have been owned or launched by Allergan in the past 5 years inclusive of Actavis and Allergan who merged in 2015
Rx0000020	Allergan	03/31/2019	00023611201	ZENPEP-20,000 unit-63,000 unit-84,000 unit-100-CAPSULE,DELAYED RELEASE	01/01/2019	57.02	657.27	02/20/2028	Single Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	All products have been owned or launched by Allergan in the past 5 years inclusive of Actavis and Allergan who merged in 2015
Rx0000020	Allergan	03/31/2019	42865030302	ZENPEP-20,000 unit-68,000 unit-109,000 unit-100-CAPSULE,DELAYED RELEASE	01/01/2019	57.02	657.27	02/20/2028	Single Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	All products have been owned or launched by Allergan in the past 5 years inclusive of Actavis and Allergan who merged in 2015
Rx0000020	Allergan	03/31/2019	00023611601	ZENPEP-25,000 unit-79,000 unit-105,000 unit-100-CAPSULE,DELAYED RELEASE	01/01/2019	70.56	813.34	02/20/2028	Single Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	All products have been owned or launched by Allergan in the past 5 years inclusive of Actavis and Allergan who merged in 2015
Rx0000020	Allergan	03/31/2019	42865030502	ZENPEP-25,000 unit-85,000 unit-136,000 unit-100-CAPSULE,DELAYED RELEASE	01/01/2019	70.56	813.34	02/20/2028	Single Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	All products have been owned or launched by Allergan in the past 5 years inclusive of Actavis and Allergan who merged in 2015
Rx0000020	Allergan	03/31/2019	00023611301	ZENPEP-3,000 unit-10,000 unit-14,000 unit-100-CAPSULE,DELAYED RELEASE	01/01/2019	15.41	177.63	02/20/2028	Single Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	All products have been owned or launched by Allergan in the past 5 years inclusive of Actavis and Allergan who merged in 2015
Rx0000020	Allergan	03/31/2019	42865030402	ZENPEP-3,000 unit-10,000 unit-16,000 unit-100-CAPSULE,DELAYED RELEASE	01/01/2019	15.41	177.63	02/20/2028	Single Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	All products have been owned or launched by Allergan in the past 5 years inclusive of Actavis and Allergan who merged in 2015
Rx0000020	Allergan	03/31/2019	00023611401	ZENPEP-40,000 unit-126,000 unit-168,000 unit-100-CAPSULE,DELAYED RELEASE	01/01/2019	112.54	1297.15	02/20/2028	Single Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	All products have been owned or launched by Allergan in the past 5 years inclusive of Actavis and Allergan who merged in 2015
Rx0000020	Allergan	03/31/2019	42865030702	ZENPEP-40,000 unit-136,000 unit-218,000 unit-100-CAPSULE,DELAYED RELEASE	01/01/2019	112.54	1297.15	02/20/2028	Single Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	All products have been owned or launched by Allergan in the past 5 years inclusive of Actavis and Allergan who merged in 2015
Rx0000020	Allergan	03/31/2019	00023611501	ZENPEP-5,000 unit-17,000 unit-24,000 unit-100-CAPSULE,DELAYED RELEASE	01/01/2019	14.70	169.48	02/20/2028	Single Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	All products have been owned or launched by Allergan in the past 5 years inclusive of Actavis and Allergan who merged in 2015
Rx0000020	Allergan	03/31/2019	42865030002	ZENPEP-5,000 unit-17,000 unit-27,000 unit-100-CAPSULE,DELAYED RELEASE	01/01/2019	14.70	169.48	02/20/2028	Single Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	All products have been owned or launched by Allergan in the past 5 years inclusive of Actavis and Allergan who merged in 2015
Rx0000037	AMAG Pharmaceuticals, Inc.	03/31/2019	59338077501	ferumoxytol 510MG/17 mL Feraheme 510mg Each	01/01/2019	27.46	942.79	06/30/2023	Single Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	Feraheme was developed by AMAG and not subject to acquisition reporting
Rx0000037	AMAG Pharmaceuticals, Inc.	06/30/2019	59338077501	ferumoxytol 510MG/17 mL Feraheme 510mg Each	04/01/2019	28.28	971.07	06/30/2023	Single Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	Feraheme was developed by AMAG and not subject to acquisition reporting
Rx0000037	AMAG Pharmaceuticals, Inc.	09/30/2019	59338077501	ferumoxytol 510MG/17 mL Feraheme 510mg Each	07/01/2019	29.13	1000.20	06/30/2023	Single Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	Feraheme was developed by AMAG and not subject to acquisition reporting. As a part of our business model at AMAG Pharmaceuticals, we perform additional research to monitor safety, understand real life experiences, and develop better delivery mechanisms, dosage, and improved product formulations. We may also conduct additional clinical trials to expand product labels in the same therapeutic area or in a new indications. Often the investment in such endeavors is spread over many years and cannot be captured in a single change in WAC. As a result of these efforts, AMAG received FDA approval for an expanded label for Feraheme in February 2018 to allow treatment of all eligible adults with iron deficiency anemia. This sNDA approval doubles the number of patients who could benefit from Feraheme to include both CKD and non-CKD patients
Rx0000037	AMAG Pharmaceuticals, Inc.	12/31/2019	59338077501	ferumoxytol 510MG/17 mL Feraheme 510mg Each	10/01/2019	30.01	1030.21	06/30/2023	Single Source Drug	None	1	Pricing is a complex construct which requires a broad analysis of many factors across the organization. Changes in our WAC, or list price, for a product may not be solely dependent on or determined by the factors related to the product impacted by the price increase. As a part of our business model at AMAG Pharmaceuticals, we perform additional research to monitor safety, understand real life experiences, and develop better delivery mechanisms, dosage, and improved product formulations. We may also conduct additional clinical trials to expand product labels in the same therapeutic area or in a new indications. Often the investment in such endeavors is spread over many years and cannot be captured in a single change in WAC. For example, as a result of these types of activities, we received FDA approval for an expanded label for Feraheme in early 2018 to allow treatment of all eligible adults with iron deficiency anemia. The distribution of patients across Commercial and Government insurers and the reimbursement landscape for prescribers are constantly changing and must be taken into consideration to the extent they are known or can be anticipated. Pricing decisions may include current trends and anticipated changes in the discounts, service fees, and rebates that are paid to insurers, group purchasing organizations, pharmacy benefit managers, government agencies, hospitals, physicians, wholesalers, pharmacies and other third parties to ensure that patients are able to have broad access and receive appropriate levels of care and support in connection with our products. Finally, a key consideration in determining a WAC change for Feraheme is based on the fact that Medicare Average Sales Price (ASP) is the primary reimbursement basis for most prescribers of Feraheme. Our strategy is to maintain a stable ASP for Feraheme, as this is critical to ensure continued broad access for patients. The reported ASP changes on a quarterly basis and is impacted by many of the factors identified above relating to the level of discounts and fees paid, as well as demand and forecasted inventory.	None	This WAC increase is not necessitated by a change or improvement in the prescription drug.	None	None	None	None	None	None	None	None	None	None	None	Feraheme was developed by AMAG and not subject to acquisition reporting
Rx0000037	AMAG Pharmaceuticals, Inc.	03/31/2019	59338077510	ferumoxytol 510MG/17 mL Feraheme 510mg/17 mL CTN/10	01/01/2019	274.60	9427.90	06/30/2023	Single Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	Feraheme was developed by AMAG and not subject to acquisition reporting
Rx0000037	AMAG Pharmaceuticals, Inc.	06/30/2019	59338077510	ferumoxytol 510MG/17 mL Feraheme 510mg/17 mL CTN/10	04/01/2019	282.80	9710.70	06/30/2023	Single Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	Feraheme was developed by AMAG and not subject to acquisition reporting
Rx0000037	AMAG Pharmaceuticals, Inc.	09/30/2019	59338077510	ferumoxytol 510MG/17 mL Feraheme 510mg/17 mL CTN/10	07/01/2019	291.32	10002.02	06/30/2023	Single Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	Feraheme was developed by AMAG and not subject to acquisition reporting. As a part of our business model at AMAG Pharmaceuticals, we perform additional research to monitor safety, understand real life experiences, and develop better delivery mechanisms, dosage, and improved product formulations. We may also conduct additional clinical trials to expand product labels in the same therapeutic area or in a new indications. Often the investment in such endeavors is spread over many years and cannot be captured in a single change in WAC. As a result of these efforts, AMAG received FDA approval for an expanded label for Feraheme in February 2018 to allow treatment of all eligible adults with iron deficiency anemia. This sNDA approval doubles the number of patients who could benefit from Feraheme to include both CKD and non-CKD patients
Rx0000037	AMAG Pharmaceuticals, Inc.	12/31/2019	59338077510	ferumoxytol 510MG/17 mL Feraheme 510mg/17 mL CTN/10	10/01/2019	300.06	10302.08	06/30/2023	Single Source Drug	None	1	Pricing is a complex construct which requires a broad analysis of many factors across the organization. Changes in our WAC, or list price, for a product may not be solely dependent on or determined by the factors related to the product impacted by the price increase. As a part of our business model at AMAG Pharmaceuticals, we perform additional research to monitor safety, understand real life experiences, and develop better delivery mechanisms, dosage, and improved product formulations. We may also conduct additional clinical trials to expand product labels in the same therapeutic area or in a new indications. Often the investment in such endeavors is spread over many years and cannot be captured in a single change in WAC. For example, as a result of these types of activities, we received FDA approval for an expanded label for Feraheme in early 2018 to allow treatment of all eligible adults with iron deficiency anemia. The distribution of patients across Commercial and Government insurers and the reimbursement landscape for prescribers are constantly changing and must be taken into consideration to the extent they are known or can be anticipated. Pricing decisions may include current trends and anticipated changes in the discounts, service fees, and rebates that are paid to insurers, group purchasing organizations, pharmacy benefit managers, government agencies, hospitals, physicians, wholesalers, pharmacies and other third parties to ensure that patients are able to have broad access and receive appropriate levels of care and support in connection with our products. Finally, a key consideration in determining a WAC change for Feraheme is based on the fact that Medicare Average Sales Price (ASP) is the primary reimbursement basis for most prescribers of Feraheme. Our strategy is to maintain a stable ASP for Feraheme, as this is critical to ensure continued broad access for patients. The reported ASP changes on a quarterly basis and is impacted by many of the factors identified above relating to the level of discounts and fees paid, as well as demand and forecasted inventory.	None	This WAC increase is not necessitated by a change or improvement in the prescription drug.	None	None	None	None	None	None	None	None	None	None	None	Feraheme was developed by AMAG and not subject to acquisition reporting
Rx0000050	Amarin Pharma, Inc.	12/31/2019	52937000120	Vascepa(Icosapent ethyl) 120 1g	12/31/2019	27.33	330.98	06/28/2033	Single Source Drug	3158163	None	None	1	None	1	None	None	None	None	None	None	None	None	None	https://reports.siera.oshpd.ca.gov/api/report/drug-pricing/attachment?id=336	VASCEPA is an ethyl ester of eicosapentaenoic acid (EPA) indicated as an adjunct to diet to reduce triglyceride (TG) levels, developed, and manufactured by Amarin Pharmaceuticals.
Rx0000050	Amarin Pharma, Inc.	12/31/2019	52937000340	Vascepa(Icosapent ethyl) 240 500 mg	12/31/2019	31.97	387.24	06/28/2033	Single Source Drug	34858	None	None	1	None	1	None	None	None	None	None	None	None	None	None	https://reports.siera.oshpd.ca.gov/api/report/drug-pricing/attachment?id=337	VASCEPA is an ethyl ester of eicosapentaenoic acid (EPA) indicated as an adjunct to diet to reduce triglyceride (TG) levels, developed, and manufactured by Amarin Pharmaceuticals.
Rx0000231	American Health Packaging	12/31/2019	68084037301	Acetaminophen & Codeine Phosphate Tablet CIII 300mg/60mg 100UD	12/13/2019	33.79	92.50	None	Non-innovator Multiple Source Drug	3545	None	Market Conditions	None	No change or improvement in the drug product	None	None	None	None	None	None	None	None	None	None	None	The acquisition fields do not need to be filled out because the drug was not acquired within the previous 5 years. All the fields that are left blank are due to "Not Applicable".
Rx0000231	American Health Packaging	12/31/2019	68084077725	Acetaminophen ER Tablet 650mg 30UD	12/05/2019	6.45	25.13	None	Non-innovator Multiple Source Drug	3382	None	Market Conditions	None	No change or improvement in the drug product	None	None	None	None	None	None	None	None	None	None	None	The acquisition fields do not need to be filled out because the drug was not acquired within the previous 5 years. All the fields that are left blank are due to "Not Applicable".
Rx0000231	American Health Packaging	12/31/2019	68084010701	Acyclovir Capsule 200mg 100UD	12/13/2019	4.67	34.08	None	Non-innovator Multiple Source Drug	6413	None	Market Conditions	None	No change or improvement in the drug product	None	None	None	None	None	None	None	None	None	None	None	The acquisition fields do not need to be filled out because the drug was not acquired within the previous 5 years. All the fields that are left blank are due to "Not Applicable".
Rx0000231	American Health Packaging	03/31/2019	60687028621	Bromocriptine Mesylate Tablet 2.5mg 30UD	03/27/2019	59.82	206.88	None	Non-innovator Multiple Source Drug	3081	None	Market Conditions	None	No change or improvement in the drug product	None	None	None	None	None	None	None	None	None	None	None	The acquisition fields do not need to be filled out because the drug was not acquired within the previous 5 years. All the fields that are left blank are due to "Not Applicable".
Rx0000231	American Health Packaging	12/31/2019	68084028101	Carbidopa & Levodopa ER Tablet 25mg/100mg 100UD	12/05/2019	47.29	78.44	None	Non-innovator Multiple Source Drug	8151	None	Market Conditions	None	No change or improvement in the drug product	None	None	None	None	None	None	None	None	None	None	None	The acquisition fields do not need to be filled out because the drug was not acquired within the previous 5 years. All the fields that are left blank are due to "Not Applicable".
Rx0000231	American Health Packaging	09/30/2019	68084024401	Clindamycin HCl Capsule 300mg 100UD	08/01/2019	19.71	110.58	None	Non-innovator Multiple Source Drug	4662	None	Market Conditions	None	No change or improvement in the drug product	None	None	None	None	None	None	None	None	None	None	None	The acquisition fields do not need to be filled out because the drug was not acquired within the previous 5 years. All the fields that are left blank are due to "Not Applicable".
Rx0000231	American Health Packaging	12/31/2019	60687042321	Clobazam Tablet CIV 10mg 30UD	12/05/2019	11.25	65.00	None	Non-innovator Multiple Source Drug	0	1	Market Conditions	None	No change or improvement in the drug product	None	None	None	None	None	None	None	None	None	None	None	The acquisition fields do not need to be filled out because the drug was not acquired within the previous 5 years. All the fields that are left blank are due to "Not Applicable".
Rx0000231	American Health Packaging	12/31/2019	60687035825	Colchicine Capsule 0.6mg 30UD	11/08/2019	37.12	204.00	None	Non-innovator Multiple Source Drug	3321	None	Market Conditions	None	No change or improvement in the drug product	None	None	None	None	None	None	None	None	None	None	None	The acquisition fields do not need to be filled out because the drug was not acquired within the previous 5 years. All the fields that are left blank are due to "Not Applicable".
Rx0000231	American Health Packaging	12/31/2019	68084060621	Desmopressin Acetate Tablet 0.1mg 30UD	11/08/2019	13.06	56.98	None	Non-innovator Multiple Source Drug	5246	None	Market Conditions	None	No change or improvement in the drug product	None	None	None	None	None	None	None	None	None	None	None	The acquisition fields do not need to be filled out because the drug was not acquired within the previous 5 years. All the fields that are left blank are due to "Not Applicable".
Rx0000231	American Health Packaging	12/31/2019	68084033301	Diclofenac Sodium DR Tablet 75mg 100UD	12/05/2019	13.55	67.05	None	Non-innovator Multiple Source Drug	1259	None	Market Conditions	None	No change or improvement in the drug product	None	None	None	None	None	None	None	None	None	None	None	The acquisition fields do not need to be filled out because the drug was not acquired within the previous 5 years. All the fields that are left blank are due to "Not Applicable".
Rx0000231	American Health Packaging	09/30/2019	60687036901	Dicyclomine HCl Capsule 10mg 100UD	09/27/2019	9.57	54.94	None	Non-innovator Multiple Source Drug	1743	None	Market Conditions	None	No change or improvement in the drug product	None	None	None	None	None	None	None	None	None	None	None	The acquisition fields do not need to be filled out because the drug was not acquired within the previous 5 years. All the fields that are left blank are due to "Not Applicable".
Rx0000231	American Health Packaging	09/30/2019	60687022801	Diltiazem HCI Capsule ER 24h 300mg 100UD	09/12/2019	29.58	158.99	None	Non-innovator Multiple Source Drug	2204	None	Market Conditions	None	No change or improvement in the drug product	None	None	None	None	None	None	None	None	None	None	None	The acquisition fields do not need to be filled out because the drug was not acquired within the previous 5 years. All the fields that are left blank are due to "Not Applicable".
Rx0000231	American Health Packaging	03/31/2019	68084074332	Doxycycline Capsule 100mg 20UD	03/05/2019	8.63	29.81	None	Non-innovator Multiple Source Drug	14708	None	Market Conditions	None	No change or improvement in the drug product	None	None	None	None	None	None	None	None	None	None	None	The acquisition fields do not need to be filled out because the drug was not acquired within the previous 5 years. All the fields that are left blank are due to "Not Applicable".
Rx0000231	American Health Packaging	12/31/2019	68084032921	Fenofibrate Capsule 200mg 30UD	12/05/2019	35.23	150.00	None	Non-innovator Multiple Source Drug	1761	None	Market Conditions	None	No change or improvement in the drug product	None	None	None	None	None	None	None	None	None	None	None	The acquisition fields do not need to be filled out because the drug was not acquired within the previous 5 years. All the fields that are left blank are due to "Not Applicable".
Rx0000231	American Health Packaging	03/31/2019	68084028801	Fludrocortisone Acetate Tablet 0.1mg 100UD	03/05/2019	14.16	84.38	None	Non-innovator Multiple Source Drug	16476	None	Market Conditions	None	No change or improvement in the drug product	None	None	None	None	None	None	None	None	None	None	None	The acquisition fields do not need to be filled out because the drug was not acquired within the previous 5 years. All the fields that are left blank are due to "Not Applicable".
Rx0000231	American Health Packaging	09/30/2019	68084072921	Galantamine Tablet 4mg 30UD	08/01/2019	44.47	105.00	None	Non-innovator Multiple Source Drug	1695	None	Market Conditions	None	No change or improvement in the drug product	None	None	None	None	None	None	None	None	None	None	None	The acquisition fields do not need to be filled out because the drug was not acquired within the previous 5 years. All the fields that are left blank are due to "Not Applicable".
Rx0000231	American Health Packaging	12/31/2019	68084011201	Glipizide ER Tablet 10mg 100UD	12/05/2019	15.50	88.44	None	Non-innovator Multiple Source Drug	2238	None	Market Conditions	None	No change or improvement in the drug product	None	None	None	None	None	None	None	None	None	None	None	The acquisition fields do not need to be filled out because the drug was not acquired within the previous 5 years. All the fields that are left blank are due to "Not Applicable".
Rx0000231	American Health Packaging	06/30/2019	68084029521	Glipizide ER Tablet 2.5mg 30UD	05/13/2019	4.25	34.00	None	Non-innovator Multiple Source Drug	0	1	Market Conditions	None	No change or improvement in the drug product	None	None	None	None	None	None	None	None	None	None	None	Price increase >16% when factoring previous two years of price changes. The acquisition fields do not need to be filled out because the drug was not acquired within the previous 5 years. All the fields that are left blank are due to "Not Applicable".
Rx0000231	American Health Packaging	03/31/2019	68084074825	Guanfacine Tablet 1mg 30UD	03/05/2019	22.21	46.90	None	Non-innovator Multiple Source Drug	8106	None	Market Conditions	None	No change or improvement in the drug product	None	None	None	None	None	None	None	None	None	None	None	The acquisition fields do not need to be filled out because the drug was not acquired within the previous 5 years. All the fields that are left blank are due to "Not Applicable".
Rx0000231	American Health Packaging	06/30/2019	68084025021	Haloperidol Tablet 20mg 30UD	05/23/2019	34.28	139.81	None	Non-innovator Multiple Source Drug	4597	None	Market Conditions	None	No change or improvement in the drug product	None	None	None	None	None	None	None	None	None	None	None	The acquisition fields do not need to be filled out because the drug was not acquired within the previous 5 years. All the fields that are left blank are due to "Not Applicable".
Rx0000231	American Health Packaging	06/30/2019	60687016101	Haloperidol Tablet 5mg 100UD	05/29/2019	26.29	91.00	None	Non-innovator Multiple Source Drug	12693	None	Market Conditions	None	No change or improvement in the drug product	None	None	None	None	None	None	None	None	None	None	None	The acquisition fields do not need to be filled out because the drug was not acquired within the previous 5 years. All the fields that are left blank are due to "Not Applicable".
Rx0000231	American Health Packaging	09/30/2019	68084084701	Hydroxyzine Pamoate Capsule 25mg 100UD	09/27/2019	25.32	50.00	None	Non-innovator Multiple Source Drug	24756	None	Market Conditions	None	No change or improvement in the drug product	None	None	None	None	None	None	None	None	None	None	None	The acquisition fields do not need to be filled out because the drug was not acquired within the previous 5 years. All the fields that are left blank are due to "Not Applicable".
Rx0000231	American Health Packaging	03/31/2019	68001037400	ISOSORBIDE DINITRATE TAB 10MG 100	03/28/2019	28.89	86.68	None	Non-innovator Multiple Source Drug	0	1	Market Conditions	None	No change or improvement in the drug product	None	02/27/2019	Blue Point Laboratories	350955	None	BluePoint Laboratories and AHP are both owned by AmerisourceBergen - the acquisition price listed is the Q1 total for all units received within Q1 2019. AHP is the US distributor for Bluepoint product.	57.79	None	2019	57.79	None	Bluepoint Laboratories is a sibling company with AHP as its US distributor and is the responsible party for distribution of their products.
Rx0000231	American Health Packaging	03/31/2019	68001037500	ISOSORBIDE DINITRATE TAB 20MG 100	03/28/2019	31.78	95.35	None	Non-innovator Multiple Source Drug	0	1	Market Conditions	None	No change or improvement in the drug product	None	02/27/2019	Blue Point Laboratories	448145	None	BluePoint Laboratories and AHP are both owned by AmerisourceBergen - the acquisition price listed is the Q1 total for all units received within Q1 2019. AHP is the US distributor for Bluepoint product.	63.57	None	2019	63.57	None	Bluepoint Laboratories is a sibling company with AHP as its US distributor and is the responsible party for distribution of their products.
Rx0000231	American Health Packaging	03/31/2019	68001033708	LISINOPRIL TAB 40 MG 1000	02/11/2019	47.30	116.36	None	Non-innovator Multiple Source Drug	22870	None	Market Conditions	None	No change or improvement in the drug product	None	03/18/2019	Blue Point Laboratories	207786	None	BluePoint Laboratories and AHP are both owned by AmerisourceBergen - the acquisition price listed is the Q1 total for all units received within Q1 2019. AHP is the US distributor for Bluepoint product.	116.36	None	2017	116.36	None	Bluepoint Laboratories is a sibling company with AHP as its US distributor and is the responsible party for distribution of their products.
Rx0000231	American Health Packaging	03/31/2019	68001033308	LISINOPRIL TAB 5 MG 1000	02/11/2019	6.80	37.41	None	Non-innovator Multiple Source Drug	22686	None	Market Conditions	None	No change or improvement in the drug product	None	03/15/2019	Blue Point Laboratories	245872	None	BluePoint Laboratories and AHP are both owned by AmerisourceBergen - the acquisition price listed is the Q1 total for all units received within Q1 2019. AHP is the US distributor for Bluepoint product.	30.61	None	2017	30.61	None	Bluepoint Laboratories is a sibling company with AHP as its US distributor and is the responsible party for distribution of their products.
Rx0000231	American Health Packaging	12/31/2019	68084073801	Methadone HCl Tablet CII 10mg 100UD	12/05/2019	4.38	30.26	None	Non-innovator Multiple Source Drug	14073	None	Market Conditions	None	No change or improvement in the drug product	None	None	None	None	None	None	None	None	None	None	None	The acquisition fields do not need to be filled out because the drug was not acquired within the previous 5 years. All the fields that are left blank are due to "Not Applicable".
Rx0000231	American Health Packaging	09/30/2019	60687035701	Methimazole Tablet 5mg 100UD	09/04/2019	13.35	50.00	None	Non-innovator Multiple Source Drug	700	None	Market Conditions	None	No change or improvement in the drug product	None	None	None	None	None	None	None	None	None	None	None	The acquisition fields do not need to be filled out because the drug was not acquired within the previous 5 years. All the fields that are left blank are due to "Not Applicable".
Rx0000231	American Health Packaging	09/30/2019	68084067601	Metoclopramide Tablet 10mg 100UD	09/04/2019	19.00	40.00	None	Non-innovator Multiple Source Drug	13788	None	Market Conditions	None	No change or improvement in the drug product	None	None	None	None	None	None	None	None	None	None	None	The acquisition fields do not need to be filled out because the drug was not acquired within the previous 5 years. All the fields that are left blank are due to "Not Applicable".
Rx0000231	American Health Packaging	12/31/2019	68084004001	Misoprostol Tablet 100mcg 100UD	12/05/2019	70.33	206.58	None	Non-innovator Multiple Source Drug	7108	None	Market Conditions	None	No change or improvement in the drug product	None	None	None	None	None	None	None	None	None	None	None	The acquisition fields do not need to be filled out because the drug was not acquired within the previous 5 years. All the fields that are left blank are due to "Not Applicable".
Rx0000231	American Health Packaging	12/31/2019	68084004101	Misoprostol Tablet 200mcg 100UD	12/05/2019	67.14	227.14	None	Non-innovator Multiple Source Drug	15565	None	Market Conditions	None	No change or improvement in the drug product	None	None	None	None	None	None	None	None	None	None	None	The acquisition fields do not need to be filled out because the drug was not acquired within the previous 5 years. All the fields that are left blank are due to "Not Applicable".
Rx0000231	American Health Packaging	03/31/2019	60687037401	Nabumetone Tablet 500mg 100UD	02/18/2019	39.11	105.00	None	Non-innovator Multiple Source Drug	0	1	Market Conditions	None	No change or improvement in the drug product	None	None	None	None	None	None	None	None	None	None	None	The acquisition fields do not need to be filled out because the drug was not acquired within the previous 5 years. All the fields that are left blank are due to "Not Applicable".
Rx0000231	American Health Packaging	03/31/2019	68001031800	NADOLOL TAB 40MG 100	03/28/2019	103.06	320.94	None	Non-innovator Multiple Source Drug	2062	None	Market Conditions	None	No change or improvement in the drug product	None	02/04/2019	Blue Point Laboratories	444930	None	BluePoint Laboratories and AHP are both owned by AmerisourceBergen - the acquisition price listed is the Q1 total for all units received within Q1 2019. AHP is the US distributor for Bluepoint product.	320.94	None	2017	320.94	None	Bluepoint Laboratories is a sibling company with AHP as its US distributor and is the responsible party for distribution of their products.
Rx0000231	American Health Packaging	03/31/2019	68084059701	Nifedipine ER Tablet 30mg 100UD	03/14/2019	47.84	149.00	None	Non-innovator Multiple Source Drug	14896	None	Market Conditions	None	No change or improvement in the drug product	None	None	None	None	None	None	None	None	None	None	None	The acquisition fields do not need to be filled out because the drug was not acquired within the previous 5 years. All the fields that are left blank are due to "Not Applicable".
Rx0000231	American Health Packaging	03/31/2019	68084059801	Nifedipine ER Tablet 60mg 100UD	03/14/2019	72.83	247.25	None	Non-innovator Multiple Source Drug	5829	None	Market Conditions	None	No change or improvement in the drug product	None	None	None	None	None	None	None	None	None	None	None	The acquisition fields do not need to be filled out because the drug was not acquired within the previous 5 years. All the fields that are left blank are due to "Not Applicable".
Rx0000231	American Health Packaging	03/31/2019	68084060321	Nifedipine ER Tablet 90mg 30UD	03/14/2019	35.69	93.63	None	Non-innovator Multiple Source Drug	8873	None	Market Conditions	None	No change or improvement in the drug product	None	None	None	None	None	None	None	None	None	None	None	The acquisition fields do not need to be filled out because the drug was not acquired within the previous 5 years. All the fields that are left blank are due to "Not Applicable".
Rx0000231	American Health Packaging	12/31/2019	62584081201	Oxazepam Capsule CIV 10mg 100UD	12/05/2019	42.50	198.75	None	Non-innovator Multiple Source Drug	2113	None	Market Conditions	None	No change or improvement in the drug product	None	None	None	None	None	None	None	None	None	None	None	The acquisition fields do not need to be filled out because the drug was not acquired within the previous 5 years. All the fields that are left blank are due to "Not Applicable".
Rx0000231	American Health Packaging	12/31/2019	62584081301	Oxazepam Capsule CIV 15mg 100UD	12/05/2019	37.48	218.73	None	Non-innovator Multiple Source Drug	4681	None	Market Conditions	None	No change or improvement in the drug product	None	None	None	None	None	None	None	None	None	None	None	The acquisition fields do not need to be filled out because the drug was not acquired within the previous 5 years. All the fields that are left blank are due to "Not Applicable".
Rx0000231	American Health Packaging	12/31/2019	62584081401	Oxazepam Capsule CIV 30mg 100UD	12/05/2019	64.18	242.80	None	Non-innovator Multiple Source Drug	1104	None	Market Conditions	None	No change or improvement in the drug product	None	None	None	None	None	None	None	None	None	None	None	The acquisition fields do not need to be filled out because the drug was not acquired within the previous 5 years. All the fields that are left blank are due to "Not Applicable".
Rx0000231	American Health Packaging	09/30/2019	68084084501	Oxcarbazepine Tablet 150mg 100UD	09/04/2019	21.54	53.85	None	Non-innovator Multiple Source Drug	9550	None	Market Conditions	None	No change or improvement in the drug product	None	None	None	None	None	None	None	None	None	None	None	The acquisition fields do not need to be filled out because the drug was not acquired within the previous 5 years. All the fields that are left blank are due to "Not Applicable".
Rx0000231	American Health Packaging	09/30/2019	68084085301	Oxcarbazepine Tablet 300mg 100UD	09/04/2019	26.62	88.31	None	Non-innovator Multiple Source Drug	16133	None	Market Conditions	None	No change or improvement in the drug product	None	None	None	None	None	None	None	None	None	None	None	The acquisition fields do not need to be filled out because the drug was not acquired within the previous 5 years. All the fields that are left blank are due to "Not Applicable".
Rx0000231	American Health Packaging	09/30/2019	68084086701	Oxcarbazepine Tablet 600mg 100UD	09/04/2019	46.61	155.07	None	Non-innovator Multiple Source Drug	6626	None	Market Conditions	None	No change or improvement in the drug product	None	None	None	None	None	None	None	None	None	None	None	The acquisition fields do not need to be filled out because the drug was not acquired within the previous 5 years. All the fields that are left blank are due to "Not Applicable".
Rx0000231	American Health Packaging	12/31/2019	68084004601	Paroxetine HCl Tablet 30mg 100UD	12/13/2019	14.82	94.82	None	Non-innovator Multiple Source Drug	783	None	Market Conditions	None	No change or improvement in the drug product	None	None	None	None	None	None	None	None	None	None	None	The acquisition fields do not need to be filled out because the drug was not acquired within the previous 5 years. All the fields that are left blank are due to "Not Applicable".
Rx0000231	American Health Packaging	12/31/2019	68084063201	Potassium Chloride ER Tablet 10mEq K 100UD	12/05/2019	25.71	73.21	None	Non-innovator Multiple Source Drug	21782	None	Market Conditions	None	No change or improvement in the drug product	None	None	None	None	None	None	None	None	None	None	None	The acquisition fields do not need to be filled out because the drug was not acquired within the previous 5 years. All the fields that are left blank are due to "Not Applicable".
Rx0000231	American Health Packaging	12/31/2019	68084096425	Propylthiouracil Tablet 50mg 30UD	12/05/2019	19.00	84.00	None	Non-innovator Multiple Source Drug	4089	None	Market Conditions	None	No change or improvement in the drug product	None	None	None	None	None	None	None	None	None	None	None	The acquisition fields do not need to be filled out because the drug was not acquired within the previous 5 years. All the fields that are left blank are due to "Not Applicable".
Rx0000231	American Health Packaging	09/30/2019	60687023101	Sertraline Tablet 25mg 100UD	09/04/2019	11.23	37.43	None	Non-innovator Multiple Source Drug	20735	None	Market Conditions	None	No change or improvement in the drug product	None	None	None	None	None	None	None	None	None	None	None	The acquisition fields do not need to be filled out because the drug was not acquired within the previous 5 years. All the fields that are left blank are due to "Not Applicable".
Rx0000231	American Health Packaging	09/30/2019	60687024201	Sertraline Tablet 50mg 100UD	09/04/2019	12.52	39.19	None	Non-innovator Multiple Source Drug	91066	None	Market Conditions	None	No change or improvement in the drug product	None	None	None	None	None	None	None	None	None	None	None	The acquisition fields do not need to be filled out because the drug was not acquired within the previous 5 years. All the fields that are left blank are due to "Not Applicable".
Rx0000231	American Health Packaging	09/30/2019	68084034401	Topiramate Tablet 100mg 100UD	08/01/2019	22.46	47.46	None	Non-innovator Multiple Source Drug	22870	None	Market Conditions	None	No change or improvement in the drug product	None	None	None	None	None	None	None	None	None	None	None	The acquisition fields do not need to be filled out because the drug was not acquired within the previous 5 years. All the fields that are left blank are due to "Not Applicable".
Rx0000231	American Health Packaging	09/30/2019	68084034201	Topiramate Tablet 25mg 100UD	08/01/2019	12.76	29.76	None	Non-innovator Multiple Source Drug	32279	None	Market Conditions	None	No change or improvement in the drug product	None	None	None	None	None	None	None	None	None	None	None	The acquisition fields do not need to be filled out because the drug was not acquired within the previous 5 years. All the fields that are left blank are due to "Not Applicable".
Rx0000128	American Regent	09/30/2019	00517065001	Ferric Carboxymaltose 750 MG/15ML Solution 15 ML UD	07/01/2019	31.29	1074.25	02/15/2028	Single Source Drug	183439	None	American Regent’s US Standards of Business Conduct (available at https://dsi.com/documents/376460/376852/DSI_SOBC.pdf/248ffd7a-3614-e6cc-bf02-4dd99641a79b) reflects that it is committed to pricing its products fairly and appropriately, and acts independently when setting prices, by factoring in costs, market conditions, customer responses, and the state of competition	None	None	1	None	None	None	None	None	None	None	None	None	None	Injectafer is not an acquired product. American Regent is the NDA holder of this NDC.
Rx0000069	Amgen	03/31/2019	58406042541	''ENBREL 25 mg (1mL) VIAL (EA), 1 pk''	01/17/2019	37.76	646.76	04/24/2029	Single Source Drug	None	1	"Amgen's sense of overall societal responsibility shapes our pricing decisions, which are guided by four principles of responsible pricing: Captures the value of the product: We will set prices for our therapies based on their full value, capturing all clinical, humanistic, and economic benefits; Funds continued scientific innovation: Our pricing will support aggressive investment in the discovery of innovative medicines to treat grievous illnesses; Ensures patient access: Our pricing will balance affordability and availability of patient assistance programs to help ensure patient access to our medicines; Reflects market dynamics: We will manage price in response to competition and evolving reimbursement"	None	None	1	None	None	None	None	None	None	None	None	None	None	Not acquired within the last five years
Rx0000069	Amgen	03/31/2019	58406042534	''ENBREL 25 mg (1mL) VIAL (EA), 4 pk''	01/17/2019	151.03	2587.03	04/24/2029	Single Source Drug	None	1	"Amgen's sense of overall societal responsibility shapes our pricing decisions, which are guided by four principles of responsible pricing: Captures the value of the product: We will set prices for our therapies based on their full value, capturing all clinical, humanistic, and economic benefits; Funds continued scientific innovation: Our pricing will support aggressive investment in the discovery of innovative medicines to treat grievous illnesses; Ensures patient access: Our pricing will balance affordability and availability of patient assistance programs to help ensure patient access to our medicines; Reflects market dynamics: We will manage price in response to competition and evolving reimbursement"	None	None	1	None	None	None	None	None	None	None	None	None	None	Not acquired within the last five years
Rx0000069	Amgen	03/31/2019	58406045501	''ENBREL 25 mg/0.5mL (0.51mL) SYRINGE (mL), 1 pk''	01/17/2019	37.76	646.76	04/24/2029	Single Source Drug	None	1	"Amgen's sense of overall societal responsibility shapes our pricing decisions, which are guided by four principles of responsible pricing: Captures the value of the product: We will set prices for our therapies based on their full value, capturing all clinical, humanistic, and economic benefits; Funds continued scientific innovation: Our pricing will support aggressive investment in the discovery of innovative medicines to treat grievous illnesses; Ensures patient access: Our pricing will balance affordability and availability of patient assistance programs to help ensure patient access to our medicines; Reflects market dynamics: We will manage price in response to competition and evolving reimbursement"	None	None	1	None	None	None	None	None	None	None	None	None	None	Not acquired within the last five years
Rx0000069	Amgen	03/31/2019	58406045504	''ENBREL 25 mg/0.5mL (0.51mL) SYRINGE (mL), 4 pk''	01/17/2019	151.03	2587.03	04/24/2029	Single Source Drug	None	1	"Amgen's sense of overall societal responsibility shapes our pricing decisions, which are guided by four principles of responsible pricing: Captures the value of the product: We will set prices for our therapies based on their full value, capturing all clinical, humanistic, and economic benefits; Funds continued scientific innovation: Our pricing will support aggressive investment in the discovery of innovative medicines to treat grievous illnesses; Ensures patient access: Our pricing will balance affordability and availability of patient assistance programs to help ensure patient access to our medicines; Reflects market dynamics: We will manage price in response to competition and evolving reimbursement"	None	None	1	None	None	None	None	None	None	None	None	None	None	Not acquired within the last five years
Rx0000069	Amgen	03/31/2019	58406043501	''ENBREL 50 mg/mL (0.98mL) SYRINGE (mL), 1 pk''	01/17/2019	75.52	1293.52	04/24/2029	Single Source Drug	None	1	"Amgen's sense of overall societal responsibility shapes our pricing decisions, which are guided by four principles of responsible pricing: Captures the value of the product: We will set prices for our therapies based on their full value, capturing all clinical, humanistic, and economic benefits; Funds continued scientific innovation: Our pricing will support aggressive investment in the discovery of innovative medicines to treat grievous illnesses; Ensures patient access: Our pricing will balance affordability and availability of patient assistance programs to help ensure patient access to our medicines; Reflects market dynamics: We will manage price in response to competition and evolving reimbursement"	None	None	1	None	None	None	None	None	None	None	None	None	None	Not acquired within the last five years
Rx0000069	Amgen	03/31/2019	58406044501	''ENBREL 50 mg/mL (0.98mL) SYRINGE (mL), 1 pk''	01/17/2019	75.52	1293.52	04/24/2029	Single Source Drug	None	1	"Amgen's sense of overall societal responsibility shapes our pricing decisions, which are guided by four principles of responsible pricing: Captures the value of the product: We will set prices for our therapies based on their full value, capturing all clinical, humanistic, and economic benefits; Funds continued scientific innovation: Our pricing will support aggressive investment in the discovery of innovative medicines to treat grievous illnesses; Ensures patient access: Our pricing will balance affordability and availability of patient assistance programs to help ensure patient access to our medicines; Reflects market dynamics: We will manage price in response to competition and evolving reimbursement"	None	None	1	None	None	None	None	None	None	None	None	None	None	Not acquired within the last five years
Rx0000069	Amgen	03/31/2019	58406043504	''ENBREL 50 mg/mL (0.98mL) SYRINGE (mL), 4 pk''	01/17/2019	302.06	5174.06	04/24/2029	Single Source Drug	None	1	"Amgen's sense of overall societal responsibility shapes our pricing decisions, which are guided by four principles of responsible pricing: Captures the value of the product: We will set prices for our therapies based on their full value, capturing all clinical, humanistic, and economic benefits; Funds continued scientific innovation: Our pricing will support aggressive investment in the discovery of innovative medicines to treat grievous illnesses; Ensures patient access: Our pricing will balance affordability and availability of patient assistance programs to help ensure patient access to our medicines; Reflects market dynamics: We will manage price in response to competition and evolving reimbursement"	None	None	1	None	None	None	None	None	None	None	None	None	None	Not acquired within the last five years
Rx0000069	Amgen	03/31/2019	58406044504	''ENBREL 50 mg/mL (0.98mL) SYRINGE (mL), 4 pk''	01/17/2019	302.06	5174.06	04/24/2029	Single Source Drug	None	1	"Amgen's sense of overall societal responsibility shapes our pricing decisions, which are guided by four principles of responsible pricing: Captures the value of the product: We will set prices for our therapies based on their full value, capturing all clinical, humanistic, and economic benefits; Funds continued scientific innovation: Our pricing will support aggressive investment in the discovery of innovative medicines to treat grievous illnesses; Ensures patient access: Our pricing will balance affordability and availability of patient assistance programs to help ensure patient access to our medicines; Reflects market dynamics: We will manage price in response to competition and evolving reimbursement"	None	None	1	None	None	None	None	None	None	None	None	None	None	Not acquired within the last five years
Rx0000069	Amgen	03/31/2019	76075010201	''KYPROLIS 30 mg (2 mg/mL) VIAL (EA), 1 pk''	01/17/2019	33.81	1160.83	12/07/2027	Single Source Drug	None	1	"Amgen's sense of overall societal responsibility shapes our pricing decisions, which are guided by four principles of responsible pricing: Captures the value of the product: We will set prices for our therapies based on their full value, capturing all clinical, humanistic, and economic benefits; Funds continued scientific innovation: Our pricing will support aggressive investment in the discovery of innovative medicines to treat grievous illnesses; Ensures patient access: Our pricing will balance affordability and availability of patient assistance programs to help ensure patient access to our medicines; Reflects market dynamics: We will manage price in response to competition and evolving reimbursement"	None	None	1	None	None	None	None	None	None	None	None	None	None	Not acquired within the last five years
Rx0000069	Amgen	03/31/2019	76075010101	''KYPROLIS 60 mg VIAL (EA), 1 pk''	01/17/2019	67.62	2321.66	12/07/2027	Single Source Drug	None	1	"Amgen's sense of overall societal responsibility shapes our pricing decisions, which are guided by four principles of responsible pricing: Captures the value of the product: We will set prices for our therapies based on their full value, capturing all clinical, humanistic, and economic benefits; Funds continued scientific innovation: Our pricing will support aggressive investment in the discovery of innovative medicines to treat grievous illnesses; Ensures patient access: Our pricing will balance affordability and availability of patient assistance programs to help ensure patient access to our medicines; Reflects market dynamics: We will manage price in response to competition and evolving reimbursement"	None	None	1	None	None	None	None	None	None	None	None	None	None	Not acquired within the last five years
Rx0000069	Amgen	03/31/2019	55513022101	''NPLATE 250 mcg (0.5mL) VIAL (EA), 1 pk''	01/17/2019	54.13	1858.58	01/19/2022	Single Source Drug	None	1	"Amgen's sense of overall societal responsibility shapes our pricing decisions, which are guided by four principles of responsible pricing: Captures the value of the product: We will set prices for our therapies based on their full value, capturing all clinical, humanistic, and economic benefits; Funds continued scientific innovation: Our pricing will support aggressive investment in the discovery of innovative medicines to treat grievous illnesses; Ensures patient access: Our pricing will balance affordability and availability of patient assistance programs to help ensure patient access to our medicines; Reflects market dynamics: We will manage price in response to competition and evolving reimbursement"	None	None	1	None	None	None	None	None	None	None	None	None	None	Not acquired within the last five years
Rx0000069	Amgen	03/31/2019	55513022201	''NPLATE 500 mcg (1.0mL) VIAL (EA), 1 pk''	01/17/2019	108.26	3717.16	01/19/2022	Single Source Drug	None	1	"Amgen's sense of overall societal responsibility shapes our pricing decisions, which are guided by four principles of responsible pricing: Captures the value of the product: We will set prices for our therapies based on their full value, capturing all clinical, humanistic, and economic benefits; Funds continued scientific innovation: Our pricing will support aggressive investment in the discovery of innovative medicines to treat grievous illnesses; Ensures patient access: Our pricing will balance affordability and availability of patient assistance programs to help ensure patient access to our medicines; Reflects market dynamics: We will manage price in response to competition and evolving reimbursement"	None	None	1	None	None	None	None	None	None	None	None	None	None	Developed by Amgen
Rx0000069	Amgen	03/31/2019	55513071001	''PROLIA 60 mg (1.0mL) SYRINGE (mL), 1 pk''	01/17/2019	35.51	1219.06	02/19/2025	Single Source Drug	None	1	"Amgen's sense of overall societal responsibility shapes our pricing decisions, which are guided by four principles of responsible pricing: Captures the value of the product: We will set prices for our therapies based on their full value, capturing all clinical, humanistic, and economic benefits; Funds continued scientific innovation: Our pricing will support aggressive investment in the discovery of innovative medicines to treat grievous illnesses; Ensures patient access: Our pricing will balance affordability and availability of patient assistance programs to help ensure patient access to our medicines; Reflects market dynamics: We will manage price in response to competition and evolving reimbursement"	None	None	1	None	None	None	None	None	None	None	None	None	None	Developed by Amgen
Rx0000122	Amneal Pharmaceuticals	03/31/2019	53746066901	Acebutolol HCl Oral Capsule 200 MG 100	02/06/2019	40.90	65.00	None	Non-innovator Multiple Source Drug	105216	None	Manufacturing costs and market conditions require increase to remain on market	None	None	1	None	None	None	None	None	None	None	None	None	None	Column 12 Blank - No change to the product Columns 14 -22 Blank - Products were not acquired from another company.
Rx0000122	Amneal Pharmaceuticals	03/31/2019	65162066910	Acebutolol HCl Oral Capsule 200 MG 100	01/25/2019	40.90	65.00	None	Non-innovator Multiple Source Drug	11383	None	Manufacturing costs and market conditions require increase to remain on market	None	None	1	None	None	None	None	None	None	None	None	None	None	Column 12 Blank - No change to the product Columns 14 -22 Blank - Products were not acquired from another company.
Rx0000122	Amneal Pharmaceuticals	03/31/2019	53746067001	Acebutolol HCl Oral Capsule 400 MG 100	02/06/2019	55.82	86.00	None	Innovator Multiple Source Drug	20151	None	Manufacturing costs and market conditions require increase to remain on market	None	None	1	None	None	None	None	None	None	None	None	None	None	Column 12 Blank - No change to the product Columns 14 -22 Blank - Products were not acquired from another company.
Rx0000122	Amneal Pharmaceuticals	03/31/2019	65162067010	Acebutolol HCl Oral Capsule 400 MG 100	01/25/2019	55.82	86.00	None	Innovator Multiple Source Drug	11172	None	Manufacturing costs and market conditions require increase to remain on market	None	None	1	None	None	None	None	None	None	None	None	None	None	Column 12 Blank - No change to the product Columns 14 -22 Blank - Products were not acquired from another company.
Rx0000122	Amneal Pharmaceuticals	03/31/2019	60846020101	Activella (estradiol/norethindrone acetate) Tablets 0.5mg/.01mg 1 Dial x 28 tabs	01/04/2019	23.03	255.61	None	Innovator Multiple Source Drug	8952	None	Manufacturing costs and market conditions require increase to remain on market	None	None	1	None	None	None	None	None	None	None	None	None	None	Column 12 Blank - No change to the product Columns 14 -22 Blank - Products were not acquired from another company.
Rx0000122	Amneal Pharmaceuticals	03/31/2019	60846020201	Activella (estradiol/norethindrone acetate) Tablets 1.0mg/.05mg 1 Dial x 28 tabs	01/04/2019	25.31	280.95	None	Innovator Multiple Source Drug	7957	None	Manufacturing costs and market conditions require increase to remain on market	None	None	1	None	None	None	None	None	None	None	None	None	None	Column 12 Blank - No change to the product Columns 14 -22 Blank - Products were not acquired from another company.
Rx0000122	Amneal Pharmaceuticals	03/31/2019	52054055022	Albenza Oral Tablet 200 MG 2Tabs	01/04/2019	43.72	485.34	None	Innovator Multiple Source Drug	316688	None	Manufacturing costs and market conditions require increase to remain on market	None	None	1	None	None	None	None	None	None	None	None	None	None	Column 12 Blank - No change to the product Columns 14 -22 Blank - Products were not acquired from another company.
Rx0000122	Amneal Pharmaceuticals	03/31/2019	52054051309	Dexedrine Oral Capsule Extended Release 24 Hour 10 MG 90 caps	01/04/2019	190.05	2109.72	None	Innovator Multiple Source Drug	2649	None	Manufacturing costs and market conditions require increase to remain on market	None	None	1	None	None	None	None	None	None	None	None	None	None	Column 12 Blank - No change to the product Columns 14 -22 Blank - Products were not acquired from another company.
Rx0000122	Amneal Pharmaceuticals	03/31/2019	52054051409	Dexedrine Oral Capsule Extended Release 24 Hour 15 MG 90 caps	01/04/2019	190.05	2109.72	None	Innovator Multiple Source Drug	4223	None	Manufacturing costs and market conditions require increase to remain on market	None	None	1	None	None	None	None	None	None	None	None	None	None	Column 12 Blank - No change to the product Columns 14 -22 Blank - Products were not acquired from another company.
Rx0000122	Amneal Pharmaceuticals	03/31/2019	52054051209	Dexedrine Oral Capsule Extended Release 24 Hour 5 MG 90 caps	01/04/2019	190.05	2109.72	None	Innovator Multiple Source Drug	515	None	Manufacturing costs and market conditions require increase to remain on market	None	None	1	None	None	None	None	None	None	None	None	None	None	Column 12 Blank - No change to the product Columns 14 -22 Blank - Products were not acquired from another company.
Rx0000122	Amneal Pharmaceuticals	03/31/2019	65162071110	Guanfacine HCl Oral Tablet 1 MG 100	02/06/2019	35.60	56.00	None	Innovator Multiple Source Drug	372489	None	Manufacturing costs and market conditions require increase to remain on market	None	None	1	None	None	None	None	None	None	None	None	None	None	Column 12 Blank - No change to the product Columns 14 -22 Blank - Products were not acquired from another company.
Rx0000122	Amneal Pharmaceuticals	03/31/2019	65162071310	Guanfacine HCl Oral Tablet 2 MG 100	02/06/2019	58.40	87.00	None	Non-innovator Multiple Source Drug	109752	None	Manufacturing costs and market conditions require increase to remain on market	None	None	1	None	None	None	None	None	None	None	None	None	None	Column 12 Blank - No change to the product Columns 14 -22 Blank - Products were not acquired from another company.
Rx0000122	Amneal Pharmaceuticals	03/31/2019	53746046605	Ibuprofen Oral Tablet 800 MG 500	03/28/2019	11.75	80.25	None	Non-innovator Multiple Source Drug	194	None	Manufacturing costs and market conditions require increase to remain on market	None	None	1	None	None	None	None	None	None	None	None	None	None	Column 12 Blank - No change to the product Columns 14 -22 Blank - Products were not acquired from another company.
Rx0000122	Amneal Pharmaceuticals	03/31/2019	65162046650	Ibuprofen Oral Tablet 800 MG 500	03/28/2019	11.75	80.25	None	Non-innovator Multiple Source Drug	237540	None	Manufacturing costs and market conditions require increase to remain on market	None	None	1	None	None	None	None	None	None	None	None	None	None	Column 12 Blank - No change to the product Columns 14 -22 Blank - Products were not acquired from another company.
Rx0000122	Amneal Pharmaceuticals	03/31/2019	60846030115	Nizatidine Oral Solution 15mg/mL 480 Bottle	01/04/2019	45.65	506.78	None	Non-innovator Multiple Source Drug	7206	None	Manufacturing costs and market conditions require increase to remain on market	None	None	1	None	None	None	None	None	None	None	None	None	None	Column 12 Blank - No change to the product Columns 14 -22 Blank - Products were not acquired from another company.
Rx0000122	Amneal Pharmaceuticals	03/31/2019	60846088201	Prandin® (repaglinide tablets) 1mg 100 Tabs	01/04/2019	71.40	792.64	None	Non-innovator Multiple Source Drug	5667	None	Manufacturing costs and market conditions require increase to remain on market	None	None	1	05/07/2018	Gemini Laboratories, LLC	None	None	Amneal does not have the ability to separate the portion of the total acquisition price allocated to the individual drug products. Total amount was 117000000	656.26	625.61	2013	339.25	None	Column 12 Blank - No change to the product
Rx0000122	Amneal Pharmaceuticals	03/31/2019	60846088401	Prandin® (repaglinide tablets) 2mg 100 Tab	01/04/2019	71.40	792.64	None	Non-innovator Multiple Source Drug	9733	None	Manufacturing costs and market conditions require increase to remain on market	None	None	1	05/07/2018	Gemini Laboratories, LLC	None	None	Amneal does not have the ability to separate the portion of the total acquisition price allocated to the individual drug products. Total amount was 117000000	656.26	625.61	2013	339.25	None	Column 12 Blank - No change to the product
Rx0000122	Amneal Pharmaceuticals	03/31/2019	60846050101	Pyridium® (phenazopyridine HCL) 100mg 100 Tab	01/04/2019	71.40	443.43	None	Non-innovator Multiple Source Drug	2557	None	Manufacturing costs and market conditions require increase to remain on market	None	None	1	None	None	None	None	None	None	None	None	None	None	Column 12 Blank - No change to the product Columns 14 -22 Blank - Products were not acquired from another company.
Rx0000122	Amneal Pharmaceuticals	03/31/2019	60846050201	Pyridium® (phenazopyridine HCL) 200mg 100 Tab	01/04/2019	51.36	570.13	None	Non-innovator Multiple Source Drug	3459	None	Manufacturing costs and market conditions require increase to remain on market	None	None	1	None	None	None	None	None	None	None	None	None	None	Column 12 Blank - No change to the product Columns 14 -22 Blank - Products were not acquired from another company.
Rx0000122	Amneal Pharmaceuticals	03/31/2019	64896066101	Rytary 23.75mg/95mg ER Cap 100ct	01/04/2019	28.88	320.56	12/26/2028	Single Source Drug	206350	None	Manufacturing costs and market conditions require increase to remain on market	None	None	1	None	None	None	None	None	None	None	None	None	None	Column 12 Blank - No change to the product Columns 14 -22 Blank - Products were not acquired from another company.
Rx0000122	Amneal Pharmaceuticals	03/31/2019	64896066201	Rytary 36.25mg/145mg ER Cap 100ct	01/04/2019	28.88	320.56	12/26/2028	Single Source Drug	205662	None	Manufacturing costs and market conditions require increase to remain on market	None	None	1	None	None	None	None	None	None	None	None	None	None	Column 12 Blank - No change to the product Columns 14 -22 Blank - Products were not acquired from another company.
Rx0000122	Amneal Pharmaceuticals	03/31/2019	64896066301	Rytary 48.75mg/195mg ER Cap 100ct	01/04/2019	28.88	320.56	12/26/2028	Single Source Drug	233657	None	Manufacturing costs and market conditions require increase to remain on market	None	None	1	None	None	None	None	None	None	None	None	None	None	Column 12 Blank - No change to the product Columns 14 -22 Blank - Products were not acquired from another company.
Rx0000122	Amneal Pharmaceuticals	03/31/2019	64896066401	Rytary 61.25mg/245mg ER Cap 100ct	01/04/2019	36.28	402.79	12/26/2028	Single Source Drug	100797	None	Manufacturing costs and market conditions require increase to remain on market	None	None	1	None	None	None	None	None	None	None	None	None	None	Column 12 Blank - No change to the product Columns 14 -22 Blank - Products were not acquired from another company.
Rx0000122	Amneal Pharmaceuticals	06/30/2019	65162055650	Temazepam Oral Capsule 15 MG 500	05/08/2019	37.30	64.30	None	Non-innovator Multiple Source Drug	0	1	Manufacturing costs and market conditions require increase to remain on market	None	No change	None	None	None	None	None	None	None	None	None	None	None	Product not acquired from another company. No changes were made to the product .This was a relaunch so there was no unit sales volume during this time frame.
Rx0000122	Amneal Pharmaceuticals	06/30/2019	65162055750	Temazepam Oral Capsule 30 MG 500	05/08/2019	42.25	76.90	None	Non-innovator Multiple Source Drug	0	1	Manufacturing costs and market conditions require increase to remain on market	None	No change	None	None	None	None	None	None	None	None	None	None	None	Product not acquired from another company. No changes were made to the product. This was a relaunch so there was no unit sales volume during this time frame.
Rx0000271	Apotex Corp	06/30/2019	60505058204	MOXIFLOXACIN HCL OP/SLN 0.5% 3ML	04/11/2019	33.47	66.94	None	Non-innovator Multiple Source Drug	2099287	None	None	1	None	1	None	None	None	None	None	None	None	None	None	None	None
Rx0000132	Arbor Pharmaceuticals, LLC	12/31/2019	53451010301	HORIZANT Oral Tablet Extended Release 300 MG, 30 tablets in a bottle	10/01/2019	23.31	411.84	06/10/2029	Single Source Drug	59056	None	Increases in rate of inflation, continued investment in innvotion, post-marketing regulatory commitments and requiremens, ongoing pharmacovigilance, market conditions and dynamics	None	None	1	07/05/2016	Xenoport, Inc.	467000000	None	Price was for both product strengths and additional IP and assets	330.40	280.00	2014	162.07	None	All information is provided by Arbor to the best of our knowledge at the time of submission. WAC is reported at the package level not the unit level. Arbor provides this report consistent with its understanding and interpretation of California SB 17 Chapter 603 Chapter 9 § 127681 and its provisions. In providing this report, Arbor does not waive any rights that it may have at law or in equity with respect to the applicability, interpretation, or application of California SB 17 Chapter 603 Chapter 9 § 127681 as it may relate to Arbor or any of its affiliates now or in the future. Arbor, on behalf of itself and affiliates, expressly reserves all such rights. Arbor believes that this submission and of all Arbor related information set forth in this submission is confidential and proprietary, commercial or financial information not subject to disclosure, including under the California Public Records Act (Government Code Section 6250 et seq.) and applicable laws pertaining to trade secrets. We request that the confidentiality of this submission and of all Arbor’s related information herein be maintained to the maximum extent permitted by law. When any of this information is requested, whether under the California Public Records Act (Government Code Section 6250 et seq.) or otherwise, we request that Arbor is notified of the request and afforded the opportunity to submit objections to disclosure.
Rx0000132	Arbor Pharmaceuticals, LLC	12/31/2019	53451010101	HORIZANT Oral Tablet Extended Release 600 MG, 30 tablets in a bottle	10/01/2019	23.31	411.84	06/10/2029	Single Source Drug	215303	None	Increases in rate of inflation, continued investment in innvotion, post-marketing regulatory commitments and requiremens, ongoing pharmacovigilance, market conditions and dynamics	None	None	1	07/05/2016	Xenoport, Inc.	467000000	None	Price was for both product strengths and additional IP and assets	330.40	280.00	2011	99.00	None	All information is provided by Arbor to the best of our knowledge at the time of submission. WAC is reported at the package level not the unit level. Pricing for 2011 is based on information that Arbor obtained in conjunction with the acquisition of Horizant based on publicly available information available at the time. That information is no longer available and Arbor is relying on its records from that time in making this submission. Arbor provides this report consistent with its understanding and interpretation of California SB 17 Chapter 603 Chapter 9 § 127681 and its provisions. In providing this report, Arbor does not waive any rights that it may have at law or in equity with respect to the applicability, interpretation, or application of California SB 17 Chapter 603 Chapter 9 § 127681 as it may relate to Arbor or any of its affiliates now or in the future. Arbor, on behalf of itself and affiliates, expressly reserves all such rights. Arbor believes that this submission and of all Arbor related information set forth in this submission is confidential and proprietary, commercial or financial information not subject to disclosure, including under the California Public Records Act (Government Code Section 6250 et seq.) and applicable laws pertaining to trade secrets. We request that the confidentiality of this submission and of all Arbor’s related information herein be maintained to the maximum extent permitted by law. When any of this information is requested, whether under the California Public Records Act (Government Code Section 6250 et seq.) or otherwise, we request that Arbor is notified of the request and afforded the opportunity to submit objections to disclosure.
Rx0000274	Artesa Labs, LLC	12/31/2019	57883040105	Keralac Cream, (urea 47%), Cream, 142 g	12/19/2019	40.03	693.00	None	Innovator Multiple Source Drug	4098	None	Raw materials, regulations	None	None	1	08/01/2017	Mission Pharmacal Company	None	1	None	594.15	None	2014	395.00	None	None
Rx0000274	Artesa Labs, LLC	12/31/2019	57893031210	MimyX Cream, n/a, Cream, 100 g	12/19/2019	30.00	520.00	None	Single Source Drug	8772	None	Raw materials, regulations	None	None	1	None	None	None	None	None	None	None	None	None	None	None
Rx0000274	Artesa Labs, LLC	12/31/2019	57893031060	Nolix Cream, (flurandrenolide 0.05%), Cream, 120 g	12/19/2019	54.82	956.00	None	Non-innovator Multiple Source Drug	2070	None	Raw materials, regulations	None	None	1	None	None	None	None	None	None	None	None	None	None	None
Rx0000274	Artesa Labs, LLC	12/31/2019	57893031112	Nolix Lotion, (flurandrenolide 0.05%), Lotion, 120 mL	12/19/2019	42.12	729.00	None	Non-innovator Multiple Source Drug	3342	None	Raw materials, regulations	None	None	1	None	None	None	None	None	None	None	None	None	None	None
Rx0000274	Artesa Labs, LLC	12/31/2019	57883040210	Plexion Cleanser, (sodium sulfacetamide 9.8%, sulfur 4.8%), Cleanser, 285 g	12/19/2019	40.03	693.00	None	Innovator Multiple Source Drug	65946	None	Raw materials, regulations	None	None	1	08/01/2017	Mission Pharmacal Company	None	1	None	594.15	None	2014	395.00	None	None
Rx0000274	Artesa Labs, LLC	12/31/2019	57883040460	Plexion Cleansing Cloths, (sodium sulfacetamide 9.8%, sulfur 4.8%), Cloths, 60 ct. (4 g each)	12/19/2019	42.82	752.00	None	Single Source Drug	5964	None	Raw materials, regulations	None	None	1	08/01/2017	Mission Pharmacal Company	None	1	None	645.30	None	2014	395.00	None	None
Rx0000274	Artesa Labs, LLC	12/31/2019	57883040302	Plexion Cream, (sodium sulfacetamide 9.8%, sulfur 4.8%), Cream, 57 g	12/19/2019	36.33	641.00	None	Innovator Multiple Source Drug	8168	None	Raw materials, regulations	None	None	1	08/01/2017	Mission Pharmacal Company	None	1	None	550.20	None	2014	435.00	None	None
Rx0000274	Artesa Labs, LLC	12/31/2019	57883040502	Plexion Lotion, (sodium sulfacetamide 9.8%, sulfur 4.8%), Lotion, 57 g	12/19/2019	39.93	699.00	None	Innovator Multiple Source Drug	6918	None	Raw materials, regulations	None	None	1	08/01/2017	Mission Pharmacal Company	None	1	None	599.70	None	2014	435.00	None	None
Rx0000274	Artesa Labs, LLC	12/31/2019	57893030399	Riax Foam 5.5%, (benzoyl peroxide 5.5%), Form, 100 g	12/19/2019	30.87	543.00	None	Single Source Drug	4176	None	Raw materials, regulations	None	None	1	None	None	None	None	None	None	None	None	None	None	None
Rx0000274	Artesa Labs, LLC	12/31/2019	57893030499	Riax Foam 9.5%, (benzoyl peroxide 9.5%), Form, 100 g	12/19/2019	30.87	543.00	None	Single Source Drug	6246	None	Raw materials, regulations	None	None	1	None	None	None	None	None	None	None	None	None	None	None
Rx0000274	Artesa Labs, LLC	12/31/2019	57893030006	SelRx Shampoo, (selenium sulfide 2.3%), Shampoo, 180 mL	12/19/2019	34.72	604.00	None	Innovator Multiple Source Drug	7240	None	Raw materials, regulations	None	None	1	None	None	None	None	None	None	None	None	None	None	None
Rx0000274	Artesa Labs, LLC	12/31/2019	57893030108	Utopic Cream, (urea 41%), Cream, 227 g	12/19/2019	49.96	883.00	None	Innovator Multiple Source Drug	7524	None	Raw materials, regulations	None	None	1	None	None	None	None	None	None	None	None	None	None	None
Rx0000274	Artesa Labs, LLC	12/31/2019	57893030230	Vytone Cream, (hydrocortisone acetate 1.9%, iodoquinol 1%), 30 ct. (2 g each)	12/19/2019	48.43	854.00	None	Innovator Multiple Source Drug	9636	None	Raw materials, regulations	None	None	1	None	None	None	None	None	None	None	None	None	None	None
Rx0000147	ASCEND Therapeutics US, LLC	12/31/2019	17139040004	Binosto (alendronate sodium) Effervescent tablet for oral solution, 70mg, 4 tablets in 1 carton	11/27/2019	98.40	300.00	08/11/2023	Single Source Drug	None	1	None	1	None	1	09/15/2019	Mission Pharmacal Company	None	1	None	201.60	201.60	2012	140.00	None	None
Rx0000075	Assertio Therapeutics, Inc.	03/31/2019	13913001201	Cambia (diclofenac potassium), 50MG, Oral, 1 Packet	02/08/2019	6.81	75.62	06/16/2026	Single Source Drug	1139039	None	None	1	None	1	None	None	None	None	None	None	None	None	None	None	This drug was not acquired in the past 5 years
Rx0000075	Assertio Therapeutics, Inc.	03/31/2019	13913000419	Gralise (gabapentin), 300MG, Oral Tablet, 90 Ct Bottle	02/08/2019	75.62	839.42	02/26/2024	Single Source Drug	1969210	None	None	1	None	1	None	None	None	None	None	None	None	None	None	None	This drug was not acquired in the past 5 years
Rx0000075	Assertio Therapeutics, Inc.	03/31/2019	13913000519	Gralise (gabapentin), 600MG, Oral Tablet, 90 Ct Bottle	02/08/2019	75.62	839.42	02/26/2024	Single Source Drug	15463198	None	None	1	None	1	None	None	None	None	None	None	None	None	None	None	This drug was not acquired in the past 5 years
Rx0000075	Assertio Therapeutics, Inc.	03/31/2019	13913000812	Zipsor (diclofenac potassium), 25MG, Oral Capsule, 100 Ct Bottle	02/08/2019	128.73	1429.07	02/24/2029	Single Source Drug	2365310	None	None	1	None	1	None	None	None	None	None	None	None	None	None	None	This drug was not acquired in the past 5 years
Rx0000048	Astellas Pharma US, Inc.	03/31/2019	00469032014	CRESEMBA®186mg 14 Capsules	01/08/2019	73.36	1295.91	10/31/2020	Single Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	The information contained in this report is subject to the following limitations and assumptions. (1) Consistent with the relevant statutes and regulations, all information contained in this report is limited to that which Astellas believes is otherwise in the public domain or publicly available. (2) The patent expiration date contained in this report is limited to the patent information reported in the federal Food and Drug Administration’s Orange Book, as of April 22, 2019. As a result, the reported patent expiration date is limited to issued U.S. patents. Further, the reported patent expiration date does not reflect any pending patent applications, future filed patent applications, patent term extensions, data exclusivity (including orphan drug, pediatric, or other exclusivity), or patent-related litigation, each of which is speculative and which may extend or shorten the reported expiration date. (3) This product was not acquired, therefore columns 14-21 are intentionally left blank.
Rx0000048	Astellas Pharma US, Inc.	03/31/2019	00469052014	CRESEMBA®186mg 14 Capsules	01/08/2019	73.36	1295.91	10/31/2020	Single Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	The information contained in this report is subject to the following limitations and assumptions. (1) Consistent with the relevant statutes and regulations, all information contained in this report is limited to that which Astellas believes is otherwise in the public domain or publicly available. (2) The patent expiration date contained in this report is limited to the patent information reported in the federal Food and Drug Administration’s Orange Book, as of April 22, 2019. As a result, the reported patent expiration date is limited to issued U.S. patents. Further, the reported patent expiration date does not reflect any pending patent applications, future filed patent applications, patent term extensions, data exclusivity (including orphan drug, pediatric, or other exclusivity), or patent-related litigation, each of which is speculative and which may extend or shorten the reported expiration date. (3) This product was not acquired, therefore columns 14-21 are intentionally left blank.
Rx0000048	Astellas Pharma US, Inc.	03/31/2019	00469042099	CRESEMBA®372mg Vial	01/08/2019	17.85	315.39	10/31/2020	Single Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	The information contained in this report is subject to the following limitations and assumptions. (1) Consistent with the relevant statutes and regulations, all information contained in this report is limited to that which Astellas believes is otherwise in the public domain or publicly available. (2) The patent expiration date contained in this report is limited to the patent information reported in the federal Food and Drug Administration’s Orange Book, as of April 22, 2019. As a result, the reported patent expiration date is limited to issued U.S. patents. Further, the reported patent expiration date does not reflect any pending patent applications, future filed patent applications, patent term extensions, data exclusivity (including orphan drug, pediatric, or other exclusivity), or patent-related litigation, each of which is speculative and which may extend or shorten the reported expiration date. (3) This product was not acquired, therefore columns 14-21 are intentionally left blank.
Rx0000048	Astellas Pharma US, Inc.	03/31/2019	00469260171	Myrbetriq®25mg 100 Tablet	01/08/2019	105.77	1280.98	10/30/2028	Single Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	The information contained in this report is subject to the following limitations and assumptions. (1) Consistent with the relevant statutes and regulations, all information contained in this report is limited to that which Astellas believes is otherwise in the public domain or publicly available. (2) The patent expiration date contained in this report is limited to the patent information reported in the federal Food and Drug Administration’s Orange Book, as of April 22, 2019. As a result, the reported patent expiration date is limited to issued U.S. patents. Further, the reported patent expiration date does not reflect any pending patent applications, future filed patent applications, patent term extensions, data exclusivity (including orphan drug, pediatric, or other exclusivity), or patent-related litigation, each of which is speculative and which may extend or shorten the reported expiration date. (3) This product was not acquired, therefore columns 14-21 are intentionally left blank.
Rx0000048	Astellas Pharma US, Inc.	03/31/2019	00469260130	Myrbetriq®25mg 30 Tablet	01/08/2019	31.73	384.29	10/30/2028	Single Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	The information contained in this report is subject to the following limitations and assumptions. (1) Consistent with the relevant statutes and regulations, all information contained in this report is limited to that which Astellas believes is otherwise in the public domain or publicly available. (2) The patent expiration date contained in this report is limited to the patent information reported in the federal Food and Drug Administration’s Orange Book, as of April 22, 2019. As a result, the reported patent expiration date is limited to issued U.S. patents. Further, the reported patent expiration date does not reflect any pending patent applications, future filed patent applications, patent term extensions, data exclusivity (including orphan drug, pediatric, or other exclusivity), or patent-related litigation, each of which is speculative and which may extend or shorten the reported expiration date. (3) This product was not acquired, therefore columns 14-21 are intentionally left blank.
Rx0000048	Astellas Pharma US, Inc.	03/31/2019	00469260190	Myrbetriq®25mg 90 Tablet	01/08/2019	95.19	1152.87	10/30/2028	Single Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	The information contained in this report is subject to the following limitations and assumptions. (1) Consistent with the relevant statutes and regulations, all information contained in this report is limited to that which Astellas believes is otherwise in the public domain or publicly available. (2) The patent expiration date contained in this report is limited to the patent information reported in the federal Food and Drug Administration’s Orange Book, as of April 22, 2019. As a result, the reported patent expiration date is limited to issued U.S. patents. Further, the reported patent expiration date does not reflect any pending patent applications, future filed patent applications, patent term extensions, data exclusivity (including orphan drug, pediatric, or other exclusivity), or patent-related litigation, each of which is speculative and which may extend or shorten the reported expiration date. (3) This product was not acquired, therefore columns 14-21 are intentionally left blank.
Rx0000048	Astellas Pharma US, Inc.	03/31/2019	00469260271	Myrbetriq®50mg 100 Tablet	01/08/2019	105.77	1280.98	10/30/2028	Single Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	The information contained in this report is subject to the following limitations and assumptions. (1) Consistent with the relevant statutes and regulations, all information contained in this report is limited to that which Astellas believes is otherwise in the public domain or publicly available. (2) The patent expiration date contained in this report is limited to the patent information reported in the federal Food and Drug Administration’s Orange Book, as of April 22, 2019. As a result, the reported patent expiration date is limited to issued U.S. patents. Further, the reported patent expiration date does not reflect any pending patent applications, future filed patent applications, patent term extensions, data exclusivity (including orphan drug, pediatric, or other exclusivity), or patent-related litigation, each of which is speculative and which may extend or shorten the reported expiration date. (3) This product was not acquired, therefore columns 14-21 are intentionally left blank.
Rx0000048	Astellas Pharma US, Inc.	03/31/2019	00469260230	Myrbetriq®50mg 30 Tablet	01/08/2019	31.73	384.29	10/30/2028	Single Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	The information contained in this report is subject to the following limitations and assumptions. (1) Consistent with the relevant statutes and regulations, all information contained in this report is limited to that which Astellas believes is otherwise in the public domain or publicly available. (2) The patent expiration date contained in this report is limited to the patent information reported in the federal Food and Drug Administration’s Orange Book, as of April 22, 2019. As a result, the reported patent expiration date is limited to issued U.S. patents. Further, the reported patent expiration date does not reflect any pending patent applications, future filed patent applications, patent term extensions, data exclusivity (including orphan drug, pediatric, or other exclusivity), or patent-related litigation, each of which is speculative and which may extend or shorten the reported expiration date. (3) This product was not acquired, therefore columns 14-21 are intentionally left blank.
Rx0000048	Astellas Pharma US, Inc.	03/31/2019	00469260290	Myrbetriq®50mg 90 Tablet	01/08/2019	95.19	1152.87	10/30/2028	Single Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	The information contained in this report is subject to the following limitations and assumptions. (1) Consistent with the relevant statutes and regulations, all information contained in this report is limited to that which Astellas believes is otherwise in the public domain or publicly available. (2) The patent expiration date contained in this report is limited to the patent information reported in the federal Food and Drug Administration’s Orange Book, as of April 22, 2019. As a result, the reported patent expiration date is limited to issued U.S. patents. Further, the reported patent expiration date does not reflect any pending patent applications, future filed patent applications, patent term extensions, data exclusivity (including orphan drug, pediatric, or other exclusivity), or patent-related litigation, each of which is speculative and which may extend or shorten the reported expiration date. (3) This product was not acquired, therefore columns 14-21 are intentionally left blank.
Rx0000048	Astellas Pharma US, Inc.	03/31/2019	00469060773	Prograf®0.5mg 100 Capsules	01/08/2019	2.98	301.62	None	Innovator Multiple Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	The information contained in this report is subject to the following limitations and assumptions. (1) Consistent with the relevant statutes and regulations, all information contained in this report is limited to that which Astellas believes is otherwise in the public domain or publicly available. (2) The patent expiration date contained in this report is limited to the patent information reported in the federal Food and Drug Administration’s Orange Book, as of April 22, 2019. As a result, the reported patent expiration date is limited to issued U.S. patents. Further, the reported patent expiration date does not reflect any pending patent applications, future filed patent applications, patent term extensions, data exclusivity (including orphan drug, pediatric, or other exclusivity), or patent-related litigation, each of which is speculative and which may extend or shorten the reported expiration date. (3) This product was not acquired, therefore columns 14-21 are intentionally left blank.
Rx0000048	Astellas Pharma US, Inc.	03/31/2019	00469061711	Prograf®1mg 100 Capsules	01/08/2019	5.97	603.24	None	Innovator Multiple Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	The information contained in this report is subject to the following limitations and assumptions. (1) Consistent with the relevant statutes and regulations, all information contained in this report is limited to that which Astellas believes is otherwise in the public domain or publicly available. (2) The patent expiration date contained in this report is limited to the patent information reported in the federal Food and Drug Administration’s Orange Book, as of April 22, 2019. As a result, the reported patent expiration date is limited to issued U.S. patents. Further, the reported patent expiration date does not reflect any pending patent applications, future filed patent applications, patent term extensions, data exclusivity (including orphan drug, pediatric, or other exclusivity), or patent-related litigation, each of which is speculative and which may extend or shorten the reported expiration date. (3) This product was not acquired, therefore columns 14-21 are intentionally left blank.
Rx0000048	Astellas Pharma US, Inc.	03/31/2019	00469061773	Prograf®1mg 100 Capsules	01/08/2019	5.97	603.24	None	Innovator Multiple Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	The information contained in this report is subject to the following limitations and assumptions. (1) Consistent with the relevant statutes and regulations, all information contained in this report is limited to that which Astellas believes is otherwise in the public domain or publicly available. (2) The patent expiration date contained in this report is limited to the patent information reported in the federal Food and Drug Administration’s Orange Book, as of April 22, 2019. As a result, the reported patent expiration date is limited to issued U.S. patents. Further, the reported patent expiration date does not reflect any pending patent applications, future filed patent applications, patent term extensions, data exclusivity (including orphan drug, pediatric, or other exclusivity), or patent-related litigation, each of which is speculative and which may extend or shorten the reported expiration date. (3) This product was not acquired, therefore columns 14-21 are intentionally left blank.
Rx0000048	Astellas Pharma US, Inc.	03/31/2019	00469301601	Prograf®5mg 10 1ML Ampules	01/08/2019	20.58	2079.09	None	Innovator Multiple Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	The information contained in this report is subject to the following limitations and assumptions. (1) Consistent with the relevant statutes and regulations, all information contained in this report is limited to that which Astellas believes is otherwise in the public domain or publicly available. (2) The patent expiration date contained in this report is limited to the patent information reported in the federal Food and Drug Administration’s Orange Book, as of April 22, 2019. As a result, the reported patent expiration date is limited to issued U.S. patents. Further, the reported patent expiration date does not reflect any pending patent applications, future filed patent applications, patent term extensions, data exclusivity (including orphan drug, pediatric, or other exclusivity), or patent-related litigation, each of which is speculative and which may extend or shorten the reported expiration date. (3) This product was not acquired, therefore columns 14-21 are intentionally left blank.
Rx0000048	Astellas Pharma US, Inc.	03/31/2019	00469065711	Prograf®5mg 100 Capsules	01/08/2019	29.87	3016.22	None	Innovator Multiple Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	The information contained in this report is subject to the following limitations and assumptions. (1) Consistent with the relevant statutes and regulations, all information contained in this report is limited to that which Astellas believes is otherwise in the public domain or publicly available. (2) The patent expiration date contained in this report is limited to the patent information reported in the federal Food and Drug Administration’s Orange Book, as of April 22, 2019. As a result, the reported patent expiration date is limited to issued U.S. patents. Further, the reported patent expiration date does not reflect any pending patent applications, future filed patent applications, patent term extensions, data exclusivity (including orphan drug, pediatric, or other exclusivity), or patent-related litigation, each of which is speculative and which may extend or shorten the reported expiration date. (3) This product was not acquired, therefore columns 14-21 are intentionally left blank.
Rx0000048	Astellas Pharma US, Inc.	03/31/2019	00469065773	Prograf®5mg 100 Capsules	01/08/2019	29.87	3016.22	None	Innovator Multiple Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	The information contained in this report is subject to the following limitations and assumptions. (1) Consistent with the relevant statutes and regulations, all information contained in this report is limited to that which Astellas believes is otherwise in the public domain or publicly available. (2) The patent expiration date contained in this report is limited to the patent information reported in the federal Food and Drug Administration’s Orange Book, as of April 22, 2019. As a result, the reported patent expiration date is limited to issued U.S. patents. Further, the reported patent expiration date does not reflect any pending patent applications, future filed patent applications, patent term extensions, data exclusivity (including orphan drug, pediatric, or other exclusivity), or patent-related litigation, each of which is speculative and which may extend or shorten the reported expiration date. (3) This product was not acquired, therefore columns 14-21 are intentionally left blank.
Rx0000048	Astellas Pharma US, Inc.	03/31/2019	51248015152	VESIcare®10mg 100 Tablet	01/08/2019	72.73	1285.03	None	Single Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	The information contained in this report is subject to the following limitations and assumptions. (1) Consistent with the relevant statutes and regulations, all information contained in this report is limited to that which Astellas believes is otherwise in the public domain or publicly available. (2) The patent expiration date contained in this report is limited to the patent information reported in the federal Food and Drug Administration’s Orange Book, as of April 22, 2019. As a result, the reported patent expiration date is limited to issued U.S. patents. Further, the reported patent expiration date does not reflect any pending patent applications, future filed patent applications, patent term extensions, data exclusivity (including orphan drug, pediatric, or other exclusivity), or patent-related litigation, each of which is speculative and which may extend or shorten the reported expiration date. (3) This product was not acquired, therefore columns 14-21 are intentionally left blank.
Rx0000048	Astellas Pharma US, Inc.	03/31/2019	51248015101	VESIcare®10mg 30 Tablet	01/08/2019	21.82	385.51	None	Single Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	The information contained in this report is subject to the following limitations and assumptions. (1) Consistent with the relevant statutes and regulations, all information contained in this report is limited to that which Astellas believes is otherwise in the public domain or publicly available. (2) The patent expiration date contained in this report is limited to the patent information reported in the federal Food and Drug Administration’s Orange Book, as of April 22, 2019. As a result, the reported patent expiration date is limited to issued U.S. patents. Further, the reported patent expiration date does not reflect any pending patent applications, future filed patent applications, patent term extensions, data exclusivity (including orphan drug, pediatric, or other exclusivity), or patent-related litigation, each of which is speculative and which may extend or shorten the reported expiration date. (3) This product was not acquired, therefore columns 14-21 are intentionally left blank.
Rx0000048	Astellas Pharma US, Inc.	03/31/2019	51248015103	VESIcare®10mg 90 Tablet	01/08/2019	65.46	1156.53	None	Single Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	The information contained in this report is subject to the following limitations and assumptions. (1) Consistent with the relevant statutes and regulations, all information contained in this report is limited to that which Astellas believes is otherwise in the public domain or publicly available. (2) The patent expiration date contained in this report is limited to the patent information reported in the federal Food and Drug Administration’s Orange Book, as of April 22, 2019. As a result, the reported patent expiration date is limited to issued U.S. patents. Further, the reported patent expiration date does not reflect any pending patent applications, future filed patent applications, patent term extensions, data exclusivity (including orphan drug, pediatric, or other exclusivity), or patent-related litigation, each of which is speculative and which may extend or shorten the reported expiration date. (3) This product was not acquired, therefore columns 14-21 are intentionally left blank.
Rx0000048	Astellas Pharma US, Inc.	03/31/2019	51248015052	VESIcare®5mg 100 Tablet	01/08/2019	72.73	1285.03	None	Single Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	The information contained in this report is subject to the following limitations and assumptions. (1) Consistent with the relevant statutes and regulations, all information contained in this report is limited to that which Astellas believes is otherwise in the public domain or publicly available. (2) The patent expiration date contained in this report is limited to the patent information reported in the federal Food and Drug Administration’s Orange Book, as of April 22, 2019. As a result, the reported patent expiration date is limited to issued U.S. patents. Further, the reported patent expiration date does not reflect any pending patent applications, future filed patent applications, patent term extensions, data exclusivity (including orphan drug, pediatric, or other exclusivity), or patent-related litigation, each of which is speculative and which may extend or shorten the reported expiration date. (3) This product was not acquired, therefore columns 14-21 are intentionally left blank.
Rx0000048	Astellas Pharma US, Inc.	03/31/2019	51248015001	VESIcare®5mg 30 Tablet	01/08/2019	21.82	385.51	None	Single Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	The information contained in this report is subject to the following limitations and assumptions. (1) Consistent with the relevant statutes and regulations, all information contained in this report is limited to that which Astellas believes is otherwise in the public domain or publicly available. (2) The patent expiration date contained in this report is limited to the patent information reported in the federal Food and Drug Administration’s Orange Book, as of April 22, 2019. As a result, the reported patent expiration date is limited to issued U.S. patents. Further, the reported patent expiration date does not reflect any pending patent applications, future filed patent applications, patent term extensions, data exclusivity (including orphan drug, pediatric, or other exclusivity), or patent-related litigation, each of which is speculative and which may extend or shorten the reported expiration date. (3) This product was not acquired, therefore columns 14-21 are intentionally left blank.
Rx0000048	Astellas Pharma US, Inc.	03/31/2019	51248015003	VESIcare®5mg 90 Tablet	01/08/2019	65.46	1156.53	None	Single Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	The information contained in this report is subject to the following limitations and assumptions. (1) Consistent with the relevant statutes and regulations, all information contained in this report is limited to that which Astellas believes is otherwise in the public domain or publicly available. (2) The patent expiration date contained in this report is limited to the patent information reported in the federal Food and Drug Administration’s Orange Book, as of April 22, 2019. As a result, the reported patent expiration date is limited to issued U.S. patents. Further, the reported patent expiration date does not reflect any pending patent applications, future filed patent applications, patent term extensions, data exclusivity (including orphan drug, pediatric, or other exclusivity), or patent-related litigation, each of which is speculative and which may extend or shorten the reported expiration date. (3) This product was not acquired, therefore columns 14-21 are intentionally left blank.
Rx0000048	Astellas Pharma US, Inc.	03/31/2019	00469012599	XTANDI®40mg 120 Capsules	01/08/2019	643.41	11548.60	08/13/2027	Single Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	The information contained in this report is subject to the following limitations and assumptions. (1) Consistent with the relevant statutes and regulations, all information contained in this report is limited to that which Astellas believes is otherwise in the public domain or publicly available. (2) The patent expiration date contained in this report is limited to the patent information reported in the federal Food and Drug Administration’s Orange Book, as of April 22, 2019. As a result, the reported patent expiration date is limited to issued U.S. patents. Further, the reported patent expiration date does not reflect any pending patent applications, future filed patent applications, patent term extensions, data exclusivity (including orphan drug, pediatric, or other exclusivity), or patent-related litigation, each of which is speculative and which may extend or shorten the reported expiration date. (3) This product was not acquired, therefore columns 14-21 are intentionally left blank.
Rx0000015	AstraZeneca	03/31/2019	00310621030	Farxiga 10mg	01/01/2019	27.87	492.41	10/04/2025	Single Source Drug	1289346480	None	AstraZeneca makes decisions on price revisions annually based on market conditions, a common practice across the industry. These decisions are designed to help us invest in bringing new medicines to market to address unmet patient needs and improve the lives of patients. When making pricing decisions AstraZeneca takes the following actions: - We take into account not only the budget impact to payers but also consider patient out of pocket costs to ensure that our treatments reach the patients who need them. - We seek feedback from payers and providers through meetings, advisory boards, and third party research. - We price responsibly and in line with current treatment costs where treatment options exist. - We consider factors such as Annual CPI-U rates and increases in manufacturing and transportation costs. - We reinvest into R&D to identify future medicines to improve the lives of patients.	None	AstraZeneca is a science-led biopharmaceutical business, and our innovative medicines are used by millions of patients worldwide. Patients and science are at the heart of everything we do, and we put careful consideration into determining the value and ultimately the cost of our medicines. Many factors go into these decisions such as the benefits our medicines provide and their potential to reduce healthcare spending on other costlier medical procedures. Equally important, these decisions enable us to invest in discovering and developing future innovative medicines where new treatments are needed.	None	02/01/2014	Bristol-Myers Squibb	2700000000	None	AstraZeneca paid Bristol-Myers Squibb $2.7 billion of initial consideration. AstraZeneca has also agreed to pay up to $1.4 billion in regulatory, launch and sales payments, and various sales-related royalty payments up until 2025, $600 million of which relates to the approval of Farxiga in the US. In addition, AstraZeneca may make payments of up to $225 million when certain assets are subsequently transferred.	289.20	None	2014	289.20	None	None
Rx0000015	AstraZeneca	03/31/2019	00310620530	Farxiga 5mg	01/01/2019	27.87	492.41	10/04/2025	Single Source Drug	599751771	None	AstraZeneca makes decisions on price revisions annually based on market conditions, a common practice across the industry. These decisions are designed to help us invest in bringing new medicines to market to address unmet patient needs and improve the lives of patients. When making pricing decisions AstraZeneca takes the following actions: - We take into account not only the budget impact to payers but also consider patient out of pocket costs to ensure that our treatments reach the patients who need them. - We seek feedback from payers and providers through meetings, advisory boards, and third party research. - We price responsibly and in line with current treatment costs where treatment options exist. - We consider factors such as Annual CPI-U rates and increases in manufacturing and transportation costs. - We reinvest into R&D to identify future medicines to improve the lives of patients.	None	AstraZeneca is a science-led biopharmaceutical business, and our innovative medicines are used by millions of patients worldwide. Patients and science are at the heart of everything we do, and we put careful consideration into determining the value and ultimately the cost of our medicines. Many factors go into these decisions such as the benefits our medicines provide and their potential to reduce healthcare spending on other costlier medical procedures. Equally important, these decisions enable us to invest in discovering and developing future innovative medicines where new treatments are needed.	None	02/01/2014	Bristol-Myers Squibb	2700000000	None	AstraZeneca paid Bristol-Myers Squibb $2.7 billion of initial consideration. AstraZeneca has also agreed to pay up to $1.4 billion in regulatory, launch and sales payments, and various sales-related royalty payments up until 2025, $600 million of which relates to the approval of Farxiga in the US. In addition, AstraZeneca may make payments of up to $225 million when certain assets are subsequently transferred.	289.20	None	2014	289.20	None	None
Rx0000015	AstraZeneca	03/31/2019	00310628030	Xigduo XR 10-1000mg	01/01/2019	27.87	492.41	10/04/2025	Single Source Drug	129626100	None	AstraZeneca makes decisions on price revisions annually based on market conditions, a common practice across the industry. These decisions are designed to help us invest in bringing new medicines to market to address unmet patient needs and improve the lives of patients. When making pricing decisions AstraZeneca takes the following actions: - We take into account not only the budget impact to payers but also consider patient out of pocket costs to ensure that our treatments reach the patients who need them. - We seek feedback from payers and providers through meetings, advisory boards, and third party research. - We price responsibly and in line with current treatment costs where treatment options exist. - We consider factors such as Annual CPI-U rates and increases in manufacturing and transportation costs. - We reinvest into R&D to identify future medicines to improve the lives of patients.	None	AstraZeneca is a science-led biopharmaceutical business, and our innovative medicines are used by millions of patients worldwide. Patients and science are at the heart of everything we do, and we put careful consideration into determining the value and ultimately the cost of our medicines. Many factors go into these decisions such as the benefits our medicines provide and their potential to reduce healthcare spending on other costlier medical procedures. Equally important, these decisions enable us to invest in discovering and developing future innovative medicines where new treatments are needed.	None	None	None	None	None	None	None	None	None	None	None	AstraZeneca developed this NDC, it was not acquired within the last five years.
Rx0000015	AstraZeneca	03/31/2019	00310627030	Xigduo XR 10-500mg	01/01/2019	27.87	492.41	10/04/2025	Single Source Drug	13322599	None	AstraZeneca makes decisions on price revisions annually based on market conditions, a common practice across the industry. These decisions are designed to help us invest in bringing new medicines to market to address unmet patient needs and improve the lives of patients. When making pricing decisions AstraZeneca takes the following actions: - We take into account not only the budget impact to payers but also consider patient out of pocket costs to ensure that our treatments reach the patients who need them. - We seek feedback from payers and providers through meetings, advisory boards, and third party research. - We price responsibly and in line with current treatment costs where treatment options exist. - We consider factors such as Annual CPI-U rates and increases in manufacturing and transportation costs. - We reinvest into R&D to identify future medicines to improve the lives of patients.	None	AstraZeneca is a science-led biopharmaceutical business, and our innovative medicines are used by millions of patients worldwide. Patients and science are at the heart of everything we do, and we put careful consideration into determining the value and ultimately the cost of our medicines. Many factors go into these decisions such as the benefits our medicines provide and their potential to reduce healthcare spending on other costlier medical procedures. Equally important, these decisions enable us to invest in discovering and developing future innovative medicines where new treatments are needed.	None	None	None	None	None	None	None	None	None	None	None	AstraZeneca developed this NDC, it was not acquired within the last five years.
Rx0000015	AstraZeneca	03/31/2019	00310626060	Xigduo XR 5-1000mg	01/01/2019	27.87	492.41	10/04/2025	Single Source Drug	212483946	None	AstraZeneca makes decisions on price revisions annually based on market conditions, a common practice across the industry. These decisions are designed to help us invest in bringing new medicines to market to address unmet patient needs and improve the lives of patients. When making pricing decisions AstraZeneca takes the following actions: - We take into account not only the budget impact to payers but also consider patient out of pocket costs to ensure that our treatments reach the patients who need them. - We seek feedback from payers and providers through meetings, advisory boards, and third party research. - We price responsibly and in line with current treatment costs where treatment options exist. - We consider factors such as Annual CPI-U rates and increases in manufacturing and transportation costs. - We reinvest into R&D to identify future medicines to improve the lives of patients.	None	AstraZeneca is a science-led biopharmaceutical business, and our innovative medicines are used by millions of patients worldwide. Patients and science are at the heart of everything we do, and we put careful consideration into determining the value and ultimately the cost of our medicines. Many factors go into these decisions such as the benefits our medicines provide and their potential to reduce healthcare spending on other costlier medical procedures. Equally important, these decisions enable us to invest in discovering and developing future innovative medicines where new treatments are needed.	None	None	None	None	None	None	None	None	None	None	None	AstraZeneca developed this NDC, it was not acquired within the last five years.
Rx0000015	AstraZeneca	03/31/2019	00310625030	Xigduo XR 5-500mg	01/01/2019	27.87	492.41	10/04/2025	Single Source Drug	22269231	None	AstraZeneca makes decisions on price revisions annually based on market conditions, a common practice across the industry. These decisions are designed to help us invest in bringing new medicines to market to address unmet patient needs and improve the lives of patients. When making pricing decisions AstraZeneca takes the following actions: - We take into account not only the budget impact to payers but also consider patient out of pocket costs to ensure that our treatments reach the patients who need them. - We seek feedback from payers and providers through meetings, advisory boards, and third party research. - We price responsibly and in line with current treatment costs where treatment options exist. - We consider factors such as Annual CPI-U rates and increases in manufacturing and transportation costs. - We reinvest into R&D to identify future medicines to improve the lives of patients.	None	AstraZeneca is a science-led biopharmaceutical business, and our innovative medicines are used by millions of patients worldwide. Patients and science are at the heart of everything we do, and we put careful consideration into determining the value and ultimately the cost of our medicines. Many factors go into these decisions such as the benefits our medicines provide and their potential to reduce healthcare spending on other costlier medical procedures. Equally important, these decisions enable us to invest in discovering and developing future innovative medicines where new treatments are needed.	None	None	None	None	None	None	None	None	None	None	None	AstraZeneca developed this NDC, it was not acquired within the last five years.
Rx0000058	Avanir Pharmaceuiticals	06/30/2019	64597030160	NUEDEXTA (Dextromethorphan hydrobromide 20 mg and quinidine sulfate 10 mg), Bottles of 60 capsules	05/01/2019	76.00	1174.00	08/13/2026	Single Source Drug	None	1	None	1	This WAC increase is not necessitated by a change or improvement in the prescription drug.	None	None	None	None	None	None	None	None	None	None	None	NOTE: columns 14-22 are intentionally blank since our product does not meet the requirements for completing these columns.
Rx0000108	AvKare	12/31/2019	50268068515	Prochlorperazine Maleate 10 MG Tablet 50 EA UD	10/29/2019	30.22	73.93	None	Non-innovator Multiple Source Drug	1578	None	Increase in Cost of Goods	None	There was no significant changes or improvements to this drug	None	None	None	None	None	None	None	None	None	None	None	This drug was not acquired
Rx0000108	AvKare	12/31/2019	50268068415	Prochlorperazine Maleate 5 MG Tablet 50 EA UD	10/29/2019	25.90	67.14	None	Non-innovator Multiple Source Drug	1236	None	Increase in Cost of Goods	None	There was no significant changes or improvements to this drug	None	None	None	None	None	None	None	None	None	None	None	This drug was not acquired
Rx0000013	B. Braun Medical Inc.	09/30/2019	00264780020	0.9% NACL INJ USP 250ML	07/01/2019	5.12	54.96	None	Non-innovator Multiple Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	*The case prices noted herein are B. Braun’s distributor in-to-stock prices for its authorized distributors, as published by third party database companies, such as Red Book, First Databank, Medi-Span and Gold Standard. B. Braun’s distributor in-to-stock prices may not represent actual transaction prices, and do not include prompt pay or other discounts, rebates, chargebacks, or other reductions in price. By providing a distributor in-to-stock price, B. Braun does not make any representation or suggestion concerning the amount for which any healthcare provider should be or should seek to be reimbursed or the likelihood of coverage or reimbursement for any referenced product. These prices should not be considered a reflection of the actual selling prices for products purchased from B. Braun or B. Braun’s view of the actual prices at which B. Braun’s products may be resold by wholesalers or other customers. ** This NDC was not acquired by B. Braun within the last 5 years.
Rx0000013	B. Braun Medical Inc.	09/30/2019	00264180032	0.9% NACL INJ. PAB 100ML IN 150ML BAG	07/01/2019	24.91	120.96	None	Non-innovator Multiple Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	*The case prices noted herein are B. Braun’s distributor in-to-stock prices for its authorized distributors, as published by third party database companies, such as Red Book, First Databank, Medi-Span and Gold Standard. B. Braun’s distributor in-to-stock prices may not represent actual transaction prices, and do not include prompt pay or other discounts, rebates, chargebacks, or other reductions in price. By providing a distributor in-to-stock price, B. Braun does not make any representation or suggestion concerning the amount for which any healthcare provider should be or should seek to be reimbursed or the likelihood of coverage or reimbursement for any referenced product. These prices should not be considered a reflection of the actual selling prices for products purchased from B. Braun or B. Braun’s view of the actual prices at which B. Braun’s products may be resold by wholesalers or other customers. ** This NDC was not acquired by B. Braun within the last 5 years.
Rx0000013	B. Braun Medical Inc.	09/30/2019	00264180031	0.9% NACL INJ. PAB 50ML IN 100ML BAG	07/01/2019	34.94	158.76	None	Non-innovator Multiple Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	*The case prices noted herein are B. Braun’s distributor in-to-stock prices for its authorized distributors, as published by third party database companies, such as Red Book, First Databank, Medi-Span and Gold Standard. B. Braun’s distributor in-to-stock prices may not represent actual transaction prices, and do not include prompt pay or other discounts, rebates, chargebacks, or other reductions in price. By providing a distributor in-to-stock price, B. Braun does not make any representation or suggestion concerning the amount for which any healthcare provider should be or should seek to be reimbursed or the likelihood of coverage or reimbursement for any referenced product. These prices should not be considered a reflection of the actual selling prices for products purchased from B. Braun or B. Braun’s view of the actual prices at which B. Braun’s products may be resold by wholesalers or other customers. ** This NDC was not acquired by B. Braun within the last 5 years.
Rx0000013	B. Braun Medical Inc.	09/30/2019	00264738860	0.9% SODIUM CHLORIDE IRR, USP, 3L BAG	07/01/2019	4.36	52.36	None	Non-innovator Multiple Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	*The case prices noted herein are B. Braun’s distributor in-to-stock prices for its authorized distributors, as published by third party database companies, such as Red Book, First Databank, Medi-Span and Gold Standard. B. Braun’s distributor in-to-stock prices may not represent actual transaction prices, and do not include prompt pay or other discounts, rebates, chargebacks, or other reductions in price. By providing a distributor in-to-stock price, B. Braun does not make any representation or suggestion concerning the amount for which any healthcare provider should be or should seek to be reimbursed or the likelihood of coverage or reimbursement for any referenced product. These prices should not be considered a reflection of the actual selling prices for products purchased from B. Braun or B. Braun’s view of the actual prices at which B. Braun’s products may be resold by wholesalers or other customers. ** This NDC was not acquired by B. Braun within the last 5 years.
Rx0000013	B. Braun Medical Inc.	09/30/2019	00264314311	1G CEFTAZIDIME FOR INJ USP/DEX INJ USP	07/01/2019	90.81	357.60	None	Non-innovator Multiple Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	*The case prices noted herein are B. Braun’s distributor in-to-stock prices for its authorized distributors, as published by third party database companies, such as Red Book, First Databank, Medi-Span and Gold Standard. B. Braun’s distributor in-to-stock prices may not represent actual transaction prices, and do not include prompt pay or other discounts, rebates, chargebacks, or other reductions in price. By providing a distributor in-to-stock price, B. Braun does not make any representation or suggestion concerning the amount for which any healthcare provider should be or should seek to be reimbursed or the likelihood of coverage or reimbursement for any referenced product. These prices should not be considered a reflection of the actual selling prices for products purchased from B. Braun or B. Braun’s view of the actual prices at which B. Braun’s products may be resold by wholesalers or other customers. ** This NDC was not acquired by B. Braun within the last 5 years.
Rx0000013	B. Braun Medical Inc.	09/30/2019	00264314511	2G CEFTAZIDIME FOR INJ USP/DEX INJ USP	07/01/2019	32.92	416.88	None	Non-innovator Multiple Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	*The case prices noted herein are B. Braun’s distributor in-to-stock prices for its authorized distributors, as published by third party database companies, such as Red Book, First Databank, Medi-Span and Gold Standard. B. Braun’s distributor in-to-stock prices may not represent actual transaction prices, and do not include prompt pay or other discounts, rebates, chargebacks, or other reductions in price. By providing a distributor in-to-stock price, B. Braun does not make any representation or suggestion concerning the amount for which any healthcare provider should be or should seek to be reimbursed or the likelihood of coverage or reimbursement for any referenced product. These prices should not be considered a reflection of the actual selling prices for products purchased from B. Braun or B. Braun’s view of the actual prices at which B. Braun’s products may be resold by wholesalers or other customers. ** This NDC was not acquired by B. Braun within the last 5 years.
Rx0000013	B. Braun Medical Inc.	09/30/2019	00264751000	5% DEXTROSE INJ USP 1L	07/01/2019	10.40	36.84	None	Non-innovator Multiple Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	*The case prices noted herein are B. Braun’s distributor in-to-stock prices for its authorized distributors, as published by third party database companies, such as Red Book, First Databank, Medi-Span and Gold Standard. B. Braun’s distributor in-to-stock prices may not represent actual transaction prices, and do not include prompt pay or other discounts, rebates, chargebacks, or other reductions in price. By providing a distributor in-to-stock price, B. Braun does not make any representation or suggestion concerning the amount for which any healthcare provider should be or should seek to be reimbursed or the likelihood of coverage or reimbursement for any referenced product. These prices should not be considered a reflection of the actual selling prices for products purchased from B. Braun or B. Braun’s view of the actual prices at which B. Braun’s products may be resold by wholesalers or other customers. ** This NDC was not acquired by B. Braun within the last 5 years.
Rx0000013	B. Braun Medical Inc.	09/30/2019	00264151032	5%D INJ PAB 100ML IN 150ML BAG	07/01/2019	29.32	120.96	None	Non-innovator Multiple Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	*The case prices noted herein are B. Braun’s distributor in-to-stock prices for its authorized distributors, as published by third party database companies, such as Red Book, First Databank, Medi-Span and Gold Standard. B. Braun’s distributor in-to-stock prices may not represent actual transaction prices, and do not include prompt pay or other discounts, rebates, chargebacks, or other reductions in price. By providing a distributor in-to-stock price, B. Braun does not make any representation or suggestion concerning the amount for which any healthcare provider should be or should seek to be reimbursed or the likelihood of coverage or reimbursement for any referenced product. These prices should not be considered a reflection of the actual selling prices for products purchased from B. Braun or B. Braun’s view of the actual prices at which B. Braun’s products may be resold by wholesalers or other customers. ** This NDC was not acquired by B. Braun within the last 5 years.
Rx0000013	B. Braun Medical Inc.	09/30/2019	00264151031	5%D INJ PAB 50ML IN 100ML BAG	07/01/2019	38.47	158.76	None	Non-innovator Multiple Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	*The case prices noted herein are B. Braun’s distributor in-to-stock prices for its authorized distributors, as published by third party database companies, such as Red Book, First Databank, Medi-Span and Gold Standard. B. Braun’s distributor in-to-stock prices may not represent actual transaction prices, and do not include prompt pay or other discounts, rebates, chargebacks, or other reductions in price. By providing a distributor in-to-stock price, B. Braun does not make any representation or suggestion concerning the amount for which any healthcare provider should be or should seek to be reimbursed or the likelihood of coverage or reimbursement for any referenced product. These prices should not be considered a reflection of the actual selling prices for products purchased from B. Braun or B. Braun’s view of the actual prices at which B. Braun’s products may be resold by wholesalers or other customers. ** This NDC was not acquired by B. Braun within the last 5 years.
Rx0000013	B. Braun Medical Inc.	09/30/2019	00264310311	CEFAZOLIN 1 GM IN DUPLEX	07/01/2019	72.96	219.84	None	Non-innovator Multiple Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	*The case prices noted herein are B. Braun’s distributor in-to-stock prices for its authorized distributors, as published by third party database companies, such as Red Book, First Databank, Medi-Span and Gold Standard. B. Braun’s distributor in-to-stock prices may not represent actual transaction prices, and do not include prompt pay or other discounts, rebates, chargebacks, or other reductions in price. By providing a distributor in-to-stock price, B. Braun does not make any representation or suggestion concerning the amount for which any healthcare provider should be or should seek to be reimbursed or the likelihood of coverage or reimbursement for any referenced product. These prices should not be considered a reflection of the actual selling prices for products purchased from B. Braun or B. Braun’s view of the actual prices at which B. Braun’s products may be resold by wholesalers or other customers. ** This NDC was not acquired by B. Braun within the last 5 years.
Rx0000013	B. Braun Medical Inc.	09/30/2019	00264310511	CEFAZOLIN 2G IN DUPLEX	07/01/2019	54.24	274.56	None	Non-innovator Multiple Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	*The case prices noted herein are B. Braun’s distributor in-to-stock prices for its authorized distributors, as published by third party database companies, such as Red Book, First Databank, Medi-Span and Gold Standard. B. Braun’s distributor in-to-stock prices may not represent actual transaction prices, and do not include prompt pay or other discounts, rebates, chargebacks, or other reductions in price. By providing a distributor in-to-stock price, B. Braun does not make any representation or suggestion concerning the amount for which any healthcare provider should be or should seek to be reimbursed or the likelihood of coverage or reimbursement for any referenced product. These prices should not be considered a reflection of the actual selling prices for products purchased from B. Braun or B. Braun’s view of the actual prices at which B. Braun’s products may be resold by wholesalers or other customers. ** This NDC was not acquired by B. Braun within the last 5 years.
Rx0000013	B. Braun Medical Inc.	09/30/2019	00264319311	CEFEPIME 1G FOR INJECTION USP	07/01/2019	84.18	382.32	None	Non-innovator Multiple Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	*The case prices noted herein are B. Braun’s distributor in-to-stock prices for its authorized distributors, as published by third party database companies, such as Red Book, First Databank, Medi-Span and Gold Standard. B. Braun’s distributor in-to-stock prices may not represent actual transaction prices, and do not include prompt pay or other discounts, rebates, chargebacks, or other reductions in price. By providing a distributor in-to-stock price, B. Braun does not make any representation or suggestion concerning the amount for which any healthcare provider should be or should seek to be reimbursed or the likelihood of coverage or reimbursement for any referenced product. These prices should not be considered a reflection of the actual selling prices for products purchased from B. Braun or B. Braun’s view of the actual prices at which B. Braun’s products may be resold by wholesalers or other customers. ** This NDC was not acquired by B. Braun within the last 5 years.
Rx0000013	B. Braun Medical Inc.	09/30/2019	00264319511	CEFEPIME 2G FOR INJECTION USP	07/01/2019	133.25	582.96	None	Non-innovator Multiple Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	*The case prices noted herein are B. Braun’s distributor in-to-stock prices for its authorized distributors, as published by third party database companies, such as Red Book, First Databank, Medi-Span and Gold Standard. B. Braun’s distributor in-to-stock prices may not represent actual transaction prices, and do not include prompt pay or other discounts, rebates, chargebacks, or other reductions in price. By providing a distributor in-to-stock price, B. Braun does not make any representation or suggestion concerning the amount for which any healthcare provider should be or should seek to be reimbursed or the likelihood of coverage or reimbursement for any referenced product. These prices should not be considered a reflection of the actual selling prices for products purchased from B. Braun or B. Braun’s view of the actual prices at which B. Braun’s products may be resold by wholesalers or other customers. ** This NDC was not acquired by B. Braun within the last 5 years.
Rx0000013	B. Braun Medical Inc.	09/30/2019	00264317311	CEFOTETAN FOR INJ.(1G)DEXTROSE INJECTION	07/01/2019	50.84	435.36	None	Non-innovator Multiple Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	*The case prices noted herein are B. Braun’s distributor in-to-stock prices for its authorized distributors, as published by third party database companies, such as Red Book, First Databank, Medi-Span and Gold Standard. B. Braun’s distributor in-to-stock prices may not represent actual transaction prices, and do not include prompt pay or other discounts, rebates, chargebacks, or other reductions in price. By providing a distributor in-to-stock price, B. Braun does not make any representation or suggestion concerning the amount for which any healthcare provider should be or should seek to be reimbursed or the likelihood of coverage or reimbursement for any referenced product. These prices should not be considered a reflection of the actual selling prices for products purchased from B. Braun or B. Braun’s view of the actual prices at which B. Braun’s products may be resold by wholesalers or other customers. ** This NDC was not acquired by B. Braun within the last 5 years.
Rx0000013	B. Braun Medical Inc.	09/30/2019	00264317511	CEFOTETAN FOR INJ.(2G)DEXTROSE INJECTION	07/01/2019	72.63	622.56	None	Non-innovator Multiple Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	*The case prices noted herein are B. Braun’s distributor in-to-stock prices for its authorized distributors, as published by third party database companies, such as Red Book, First Databank, Medi-Span and Gold Standard. B. Braun’s distributor in-to-stock prices may not represent actual transaction prices, and do not include prompt pay or other discounts, rebates, chargebacks, or other reductions in price. By providing a distributor in-to-stock price, B. Braun does not make any representation or suggestion concerning the amount for which any healthcare provider should be or should seek to be reimbursed or the likelihood of coverage or reimbursement for any referenced product. These prices should not be considered a reflection of the actual selling prices for products purchased from B. Braun or B. Braun’s view of the actual prices at which B. Braun’s products may be resold by wholesalers or other customers. ** This NDC was not acquired by B. Braun within the last 5 years.
Rx0000013	B. Braun Medical Inc.	09/30/2019	00264315511	CEFTRIAXONE FOR INJ(2G) DEXTROSE FOR INJ	07/01/2019	133.51	584.16	None	Non-innovator Multiple Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	*The case prices noted herein are B. Braun’s distributor in-to-stock prices for its authorized distributors, as published by third party database companies, such as Red Book, First Databank, Medi-Span and Gold Standard. B. Braun’s distributor in-to-stock prices may not represent actual transaction prices, and do not include prompt pay or other discounts, rebates, chargebacks, or other reductions in price. By providing a distributor in-to-stock price, B. Braun does not make any representation or suggestion concerning the amount for which any healthcare provider should be or should seek to be reimbursed or the likelihood of coverage or reimbursement for any referenced product. These prices should not be considered a reflection of the actual selling prices for products purchased from B. Braun or B. Braun’s view of the actual prices at which B. Braun’s products may be resold by wholesalers or other customers. ** This NDC was not acquired by B. Braun within the last 5 years.
Rx0000013	B. Braun Medical Inc.	09/30/2019	00264315311	CEFTRIAXONE FOR INJ.(1G)DEXTROSE FOR INJ	07/01/2019	57.26	360.72	None	Non-innovator Multiple Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	*The case prices noted herein are B. Braun’s distributor in-to-stock prices for its authorized distributors, as published by third party database companies, such as Red Book, First Databank, Medi-Span and Gold Standard. B. Braun’s distributor in-to-stock prices may not represent actual transaction prices, and do not include prompt pay or other discounts, rebates, chargebacks, or other reductions in price. By providing a distributor in-to-stock price, B. Braun does not make any representation or suggestion concerning the amount for which any healthcare provider should be or should seek to be reimbursed or the likelihood of coverage or reimbursement for any referenced product. These prices should not be considered a reflection of the actual selling prices for products purchased from B. Braun or B. Braun’s view of the actual prices at which B. Braun’s products may be resold by wholesalers or other customers. ** This NDC was not acquired by B. Braun within the last 5 years.
Rx0000013	B. Braun Medical Inc.	03/31/2019	00264957710	Heparin in Dextrose Injection	01/01/2019	46.85	281.09	None	Non-innovator Multiple Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	The case prices noted herein are B. Braun Medical Inc.’s (“B. Braun”) distributor in-to-stock prices for its authorized distributors, as published by third party database companies, such as Red Book, First Databank, Medi-Span and Gold Standard. B. Braun’s distributor in-to-stock prices may not represent actual transaction prices, and do not include prompt pay or other discounts, rebates, chargebacks, or other reductions in price. By providing a distributor in-to-stock price, B. Braun does not make any representation or suggestion concerning the amount for which any healthcare provider should be or should seek to be reimbursed or the likelihood of coverage or reimbursement for any referenced product. These prices should not be considered a reflection of the actual selling prices for products purchased from B. Braun or B. Braun’s view of the actual prices at which B. Braun’s products may be resold by wholesalers or other customers.
Rx0000013	B. Braun Medical Inc.	09/30/2019	00264958720	HEPARIN SODIUM 100 UNITS/ML IN 5% DEX	07/01/2019	92.64	337.44	None	Non-innovator Multiple Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	*The case prices noted herein are B. Braun’s distributor in-to-stock prices for its authorized distributors, as published by third party database companies, such as Red Book, First Databank, Medi-Span and Gold Standard. B. Braun’s distributor in-to-stock prices may not represent actual transaction prices, and do not include prompt pay or other discounts, rebates, chargebacks, or other reductions in price. By providing a distributor in-to-stock price, B. Braun does not make any representation or suggestion concerning the amount for which any healthcare provider should be or should seek to be reimbursed or the likelihood of coverage or reimbursement for any referenced product. These prices should not be considered a reflection of the actual selling prices for products purchased from B. Braun or B. Braun’s view of the actual prices at which B. Braun’s products may be resold by wholesalers or other customers. ** This NDC was not acquired by B. Braun within the last 5 years.
Rx0000013	B. Braun Medical Inc.	09/30/2019	00264957710	HEPARIN SODIUM 50 UNITS/ML IN 5% DEX	07/01/2019	39.55	320.64	None	Non-innovator Multiple Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	*The case prices noted herein are B. Braun’s distributor in-to-stock prices for its authorized distributors, as published by third party database companies, such as Red Book, First Databank, Medi-Span and Gold Standard. B. Braun’s distributor in-to-stock prices may not represent actual transaction prices, and do not include prompt pay or other discounts, rebates, chargebacks, or other reductions in price. By providing a distributor in-to-stock price, B. Braun does not make any representation or suggestion concerning the amount for which any healthcare provider should be or should seek to be reimbursed or the likelihood of coverage or reimbursement for any referenced product. These prices should not be considered a reflection of the actual selling prices for products purchased from B. Braun or B. Braun’s view of the actual prices at which B. Braun’s products may be resold by wholesalers or other customers. ** This NDC was not acquired by B. Braun within the last 5 years.
Rx0000013	B. Braun Medical Inc.	03/31/2019	00264958720	Heparin Sodium in 5% Dextrose Injection (100 U/ML)	01/01/2019	40.80	244.80	None	Non-innovator Multiple Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	The case prices noted herein are B. Braun’s distributor in-to-stock prices for its authorized distributors, as published by third party database companies, such as Red Book, First Databank, Medi-Span and Gold Standard. B. Braun’s distributor in-to-stock prices may not represent actual transaction prices, and do not include prompt pay or other discounts, rebates, chargebacks, or other reductions in price. By providing a distributor in-to-stock price, B. Braun does not make any representation or suggestion concerning the amount for which any healthcare provider should be or should seek to be reimbursed or the likelihood of coverage or reimbursement for any referenced product. These prices should not be considered a reflection of the actual selling prices for products purchased from B. Braun or B. Braun’s view of the actual prices at which B. Braun’s products may be resold by wholesalers or other customers.
Rx0000013	B. Braun Medical Inc.	09/30/2019	00264738960	LACTATED RINGERS IRRIGATION, USP,3L BAG	07/01/2019	13.78	56.28	None	Non-innovator Multiple Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	*The case prices noted herein are B. Braun’s distributor in-to-stock prices for its authorized distributors, as published by third party database companies, such as Red Book, First Databank, Medi-Span and Gold Standard. B. Braun’s distributor in-to-stock prices may not represent actual transaction prices, and do not include prompt pay or other discounts, rebates, chargebacks, or other reductions in price. By providing a distributor in-to-stock price, B. Braun does not make any representation or suggestion concerning the amount for which any healthcare provider should be or should seek to be reimbursed or the likelihood of coverage or reimbursement for any referenced product. These prices should not be considered a reflection of the actual selling prices for products purchased from B. Braun or B. Braun’s view of the actual prices at which B. Braun’s products may be resold by wholesalers or other customers. ** This NDC was not acquired by B. Braun within the last 5 years.
Rx0000013	B. Braun Medical Inc.	09/30/2019	00264191507	PROCALAMINE INJ SSGL 1L	07/01/2019	43.51	205.44	06/20/2020	Single Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	*The case prices noted herein are B. Braun’s distributor in-to-stock prices for its authorized distributors, as published by third party database companies, such as Red Book, First Databank, Medi-Span and Gold Standard. B. Braun’s distributor in-to-stock prices may not represent actual transaction prices, and do not include prompt pay or other discounts, rebates, chargebacks, or other reductions in price. By providing a distributor in-to-stock price, B. Braun does not make any representation or suggestion concerning the amount for which any healthcare provider should be or should seek to be reimbursed or the likelihood of coverage or reimbursement for any referenced product. These prices should not be considered a reflection of the actual selling prices for products purchased from B. Braun or B. Braun’s view of the actual prices at which B. Braun’s products may be resold by wholesalers or other customers. ** This NDC was not acquired by B. Braun within the last 5 years.
Rx0000096	Bausch + Lomb, Inc.	03/31/2019	24208035305	ALREX® (loteprednol etabonate ophthalmic suspension 0.2%)	01/18/2019	12.77	225.60	None	Single Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	The product was not acquired within the last 5 years.
Rx0000096	Bausch + Lomb, Inc.	03/31/2019	24208035310	ALREX® (loteprednol etabonate ophthalmic suspension 0.2%)	01/18/2019	25.54	451.19	None	Single Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	The product was not acquired within the last 5 years.
Rx0000096	Bausch + Lomb, Inc.	03/31/2019	24208062901	BEPREVE™ Ophthalmic Solution USP, 1.5%	01/18/2019	23.50	415.18	09/05/2024	Innovator Multiple Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	The product was not acquired within the last 5 years.
Rx0000096	Bausch + Lomb, Inc.	03/31/2019	24208062902	BEPREVE™ Ophthalmic Solution USP, 1.5%	01/18/2019	12.29	217.08	09/06/2024	Innovator Multiple Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	The product was not acquired within the last 5 years.
Rx0000096	Bausch + Lomb, Inc.	03/31/2019	24208044605	BESIVANCE® (besifloxacin ophthalmic suspension 0.6%)	01/18/2019	9.59	169.36	11/07/2030	Single Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	The product was not acquired within the last 5 years.
Rx0000096	Bausch + Lomb, Inc.	03/31/2019	24208000401	ISTALOL™ Ophthalmic Solution USP, 0.5%	01/18/2019	9.76	172.42	None	Innovator Multiple Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	The product was not acquired within the last 5 years.
Rx0000096	Bausch + Lomb, Inc.	03/31/2019	24208000403	ISTALOL™ Ophthalmic Solution USP, 0.5%	01/18/2019	19.52	344.81	None	Innovator Multiple Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	The product was not acquired within the last 5 years.
Rx0000096	Bausch + Lomb, Inc.	03/31/2019	24208080060	LACRISERT® (hydroxypropyl cellulose ophthalmic insert), 5mg	01/18/2019	28.38	501.36	None	Single Source Drug	None	1	None	1	None	1	02/05/2016	Aton Pharma, Inc.	None	1	None	398.10	None	2006	49.20	None	1.The product was introduced to the market before acquisition by Bausch + Lomb, Inc. The year of introduction and WAC at introduction contained in this report is the only information available to Bausch + Lomb. Bausch + Lomb has no knowledge of the actual date of introduction nor the WAC at introduction.
Rx0000096	Bausch + Lomb, Inc.	03/31/2019	24208050307	LOTEMAX® (loteprednol etabonate ophthalmic Gel 0.5%)	01/18/2019	10.80	190.73	None	Single Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	The product was not acquired within the last 5 years.
Rx0000096	Bausch + Lomb, Inc.	03/31/2019	24208044335	LOTEMAX® (loteprednol etabonate ophthalmic Ointment 0.5%)	01/18/2019	15.19	268.38	None	Single Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	The product was not acquired within the last 5 years.
Rx0000096	Bausch + Lomb, Inc.	03/31/2019	24208029905	LOTEMAX® (loteprednol etabonate ophthalmic suspension 0.5%)	01/18/2019	13.46	237.72	None	Innovator Multiple Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	The product was not acquired within the last 5 years.
Rx0000096	Bausch + Lomb, Inc.	03/31/2019	24208029910	LOTEMAX® (loteprednol etabonate ophthalmic suspension 0.5%)	01/18/2019	26.91	475.39	None	Innovator Multiple Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	The product was not acquired within the last 5 years.
Rx0000096	Bausch + Lomb, Inc.	03/31/2019	24208029915	LOTEMAX® (loteprednol etabonate ophthalmic suspension 0.5%)	01/18/2019	40.01	706.78	None	Innovator Multiple Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	The product was not acquired within the last 5 years.
Rx0000096	Bausch + Lomb, Inc.	03/31/2019	24208053920	MIOCHOL®-E Intraocular Solution Reconstituted 20mg vial	01/18/2019	4.71	98.90	None	Single Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	The product was not acquired within the last 5 years.
Rx0000096	Bausch + Lomb, Inc.	03/31/2019	24208060203	PROLENSA™ (bromfenac ophthalmic solution) 0.07% 3mL	01/18/2019	15.09	266.67	11/11/2033	Single Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	The product was not acquired within the last 5 years.
Rx0000096	Bausch + Lomb, Inc.	03/31/2019	24208081205	TIMOPTIC® (Timolol Maleate Ophthalmic Solution) 0.25%, 5mL	01/18/2019	9.85	174.04	None	Innovator Multiple Source Drug	None	1	None	1	None	1	02/26/2018	Aton Pharma, Inc.	None	1	None	164.19	None	2009	14.94	None	1.The product was introduced to the market before acquisition by Bausch + Lomb, Inc. The year of introduction and WAC at introduction contained in this report is the only information available to Bausch + Lomb. Bausch + Lomb has no knowledge of the actual date of introduction nor the WAC at introduction.
Rx0000096	Bausch + Lomb, Inc.	03/31/2019	24208081310	TIMOPTIC® (Timolol Maleate Ophthalmic Solution) 0.50%, 10mL	01/18/2019	13.66	241.31	None	Innovator Multiple Source Drug	None	1	None	1	None	1	02/26/2018	Aton Pharma, Inc.	None	1	None	227.65	None	2009	34.30	None	1.The product was introduced to the market before acquisition by Bausch + Lomb, Inc. The year of introduction and WAC at introduction contained in this report is the only information available to Bausch + Lomb. Bausch + Lomb has no knowledge of the actual date of introduction nor the WAC at introduction.
Rx0000096	Bausch + Lomb, Inc.	03/31/2019	24208081305	TIMOPTIC® (Timolol Maleate Ophthalmic Solution) 0.50%, 5mL	01/18/2019	10.66	188.34	None	Innovator Multiple Source Drug	None	1	None	1	None	1	02/26/2018	Aton Pharma, Inc.	None	1	None	177.68	None	2009	17.68	None	1.The product was introduced to the market before acquisition by Bausch + Lomb, Inc. The year of introduction and WAC at introduction contained in this report is the only information available to Bausch + Lomb. Bausch + Lomb has no knowledge of the actual date of introduction nor the WAC at introduction.
Rx0000096	Bausch + Lomb, Inc.	03/31/2019	24208081425	TIMOPTIC-XE® (Timolol Maleate Ophthalmic Gel Forming Solution) 0.25%, 5mL	01/18/2019	11.53	203.62	None	Innovator Multiple Source Drug	None	1	None	1	None	1	11/06/2015	Aton Pharma, Inc.	None	1	None	332.12	None	2009	23.55	None	1.The product was introduced to the market before acquisition by Bausch + Lomb, Inc. The year of introduction and WAC at introduction contained in this report is the only information available to Bausch + Lomb. Bausch + Lomb has no knowledge of the actual date of introduction nor the WAC at introduction.
Rx0000096	Bausch + Lomb, Inc.	03/31/2019	24208081605	TIMOPTIC-XE® (Timolol Maleate Ophthalmic Gel Forming Solution) 0.50%, 5mL	01/18/2019	12.63	223.13	None	Innovator Multiple Source Drug	None	1	None	1	None	1	08/19/2015	Aton Pharma, Inc.	None	1	None	378.73	None	2009	28.00	None	1.The product was introduced to the market before acquisition by Bausch + Lomb, Inc. The year of introduction and WAC at introduction contained in this report is the only information available to Bausch + Lomb. Bausch + Lomb has no knowledge of the actual date of introduction nor the WAC at introduction.
Rx0000096	Bausch + Lomb, Inc.	03/31/2019	24208000202	VITRASE® Solution 2x200 Units/ML	01/18/2019	9.38	196.93	None	Single Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	The product was not acquired within the last 5 years.
Rx0000096	Bausch + Lomb, Inc.	03/31/2019	24208053535	ZIRGAN™ (Ganciclovir Ophthalmic Gel 0.15%)	01/18/2019	19.88	351.26	None	Single Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	The product was not acquired within the last 5 years.
Rx0000096	Bausch + Lomb, Inc.	03/31/2019	24208035805	ZYLET® (loteprednol etabonate 0.5% and tobramycin 0.3% ophthalmic Suspension)	01/18/2019	14.00	247.39	None	Single Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	The product was not acquired within the last 5 years.
Rx0000096	Bausch + Lomb, Inc.	03/31/2019	24208035810	ZYLET® (loteprednol etabonate 0.5% and tobramycin 0.3% ophthalmic Suspension)	01/18/2019	28.01	494.80	None	Single Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	The product was not acquired within the last 5 years.
Rx0000024	Bayer	03/31/2019	50419048201	Angeliq Oral Tablet 0.25-0.5 MG	01/07/2019	8.87	186.18	10/22/2031	Single Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	None
Rx0000024	Bayer	03/31/2019	50419048203	Angeliq Oral Tablet 0.25-0.5 MG	01/07/2019	26.60	558.52	10/22/2031	Single Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	None
Rx0000024	Bayer	03/31/2019	50419048301	Angeliq Oral Tablet 0.5-1 MG	01/07/2019	8.87	186.18	10/22/2031	Single Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	None
Rx0000024	Bayer	03/31/2019	50419048303	Angeliq Oral Tablet 0.5-1 MG	01/07/2019	26.60	558.52	10/22/2031	Single Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	None
Rx0000024	Bayer	03/31/2019	50419052401	Betaseron Subcutaneous Kit 0.3 MG	01/15/2019	35.03	542.64	None	Innovator Multiple Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	None
Rx0000024	Bayer	03/31/2019	50419052435	Betaseron Subcutaneous Kit 0.3 MG	01/15/2019	490.35	7596.85	None	Innovator Multiple Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	None
Rx0000024	Bayer	03/31/2019	50419040701	Beyaz Oral Tablet 3-0.02-0.451 MG	01/07/2019	9.99	209.82	02/08/2030	Single Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	None
Rx0000024	Bayer	03/31/2019	50419040703	Beyaz Oral Tablet 3-0.02-0.451 MG	01/07/2019	29.97	629.46	02/08/2030	Single Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	None
Rx0000024	Bayer	03/31/2019	50419077701	Cipro Oral Suspension Reconstituted 250 MG/5ML (5%)	01/07/2019	6.21	130.40	None	Innovator Multiple Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	None
Rx0000024	Bayer	03/31/2019	50419077301	Cipro Oral Suspension Reconstituted 500 MG/5ML (10%)	01/07/2019	7.25	152.32	None	Innovator Multiple Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	None
Rx0000024	Bayer	03/31/2019	50419049104	Climara Pro Transdermal Patch Weekly 0.045-0.015 MG/DAY	01/07/2019	10.06	211.29	None	Single Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	None
Rx0000024	Bayer	03/31/2019	50419045404	Climara Transdermal Patch Weekly 0.025 MG/24HR	01/07/2019	6.28	131.81	None	Innovator Multiple Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	None
Rx0000024	Bayer	03/31/2019	50419045604	Climara Transdermal Patch Weekly 0.0375 MG/24HR	01/07/2019	6.28	131.81	None	Innovator Multiple Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	None
Rx0000024	Bayer	03/31/2019	50419045101	Climara Transdermal Patch Weekly 0.05 MG/24HR	01/07/2019	1.57	32.95	None	Innovator Multiple Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	None
Rx0000024	Bayer	03/31/2019	50419045104	Climara Transdermal Patch Weekly 0.05 MG/24HR	01/07/2019	6.28	131.81	None	Innovator Multiple Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	None
Rx0000024	Bayer	03/31/2019	50419045904	Climara Transdermal Patch Weekly 0.06 MG/24HR	01/07/2019	6.28	131.81	None	Innovator Multiple Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	None
Rx0000024	Bayer	03/31/2019	50419045304	Climara Transdermal Patch Weekly 0.075 MG/24HR	01/07/2019	6.28	131.81	None	Innovator Multiple Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	None
Rx0000024	Bayer	03/31/2019	50419045201	Climara Transdermal Patch Weekly 0.1 MG/24HR	01/07/2019	1.57	32.95	None	Innovator Multiple Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	None
Rx0000024	Bayer	03/31/2019	50419045204	Climara Transdermal Patch Weekly 0.1 MG/24HR	01/07/2019	6.28	131.81	None	Innovator Multiple Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	None
Rx0000024	Bayer	03/31/2019	50419040901	Natazia Oral Tablet 3/2-2/2-3/1 MG	01/07/2019	9.99	209.82	01/30/2028	Single Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	None
Rx0000024	Bayer	03/31/2019	50419040903	Natazia Oral Tablet 3/2-2/2-3/1 MG	01/07/2019	29.97	629.46	01/30/2028	Single Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	None
Rx0000024	Bayer	06/30/2019	50419048858	NexAVAR Oral Tablet 200 MG	06/01/2019	560.83	19231.20	09/10/2028	Single Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	None
Rx0000024	Bayer	06/30/2019	50419017101	Stivarga Oral Tablet 40 MG	06/01/2019	168.45	5788.44	07/09/2032	Single Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	None
Rx0000024	Bayer	06/30/2019	50419017103	Stivarga Oral Tablet 40 MG	06/01/2019	505.34	17365.32	07/09/2032	Single Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	None
Rx0000024	Bayer	03/31/2019	50419040201	Yasmin 28 Oral Tablet 3-0.03 MG	01/07/2019	5.67	119.09	08/31/2020	Single Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	None
Rx0000024	Bayer	03/31/2019	50419040203	Yasmin 28 Oral Tablet 3-0.03 MG	01/07/2019	17.01	357.27	08/31/2020	Single Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	None
Rx0000024	Bayer	03/31/2019	50419040501	YAZ Oral Tablet 3-0.02 MG	01/07/2019	6.85	143.84	08/31/2020	Single Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	None
Rx0000024	Bayer	03/31/2019	50419040503	YAZ Oral Tablet 3-0.02 MG	01/07/2019	20.55	431.52	08/31/2020	Single Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	None
Rx0000373	Bio Products Laboratory Limited	12/31/2019	64208823407	Gammaplex 5% Intravenous Solution 10 GM/200ML	11/11/2019	85.90	1727.10	None	Single Source Drug	0	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	Consistent with CA law and regulations, this report is limited to information that is otherwise in the public domain or publicly available. The product at issue was developed by the company and not acquired from a third party; therefore, the product acquisition fields in the report are not applicable and have been left blank. The company submits this report in good faith, without waiver of its objections to, or its right to interpret Cal. Health & Safety Code §§ 127677-79 and the implementing regulations.”
Rx0000373	Bio Products Laboratory Limited	12/31/2019	64208823408	Gammaplex 5% Intravenous Solution 20 GM/400ML	11/11/2019	171.80	3454.20	None	Single Source Drug	0	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	Consistent with CA law and regulations, this report is limited to information that is otherwise in the public domain or publicly available. The product at issue was developed by the company and not acquired from a third party; therefore, the product acquisition fields in the report are not applicable and have been left blank. The company submits this report in good faith, without waiver of its objections to, or its right to interpret Cal. Health & Safety Code §§ 127677-79 and the implementing regulations.”
Rx0000373	Bio Products Laboratory Limited	12/31/2019	64208823406	Gammaplex 5% Intravenous Solution 5 GM/100ML	11/11/2019	42.95	863.55	None	Single Source Drug	0	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	Consistent with CA law and regulations, this report is limited to information that is otherwise in the public domain or publicly available. The product at issue was developed by the company and not acquired from a third party; therefore, the product acquisition fields in the report are not applicable and have been left blank. The company submits this report in good faith, without waiver of its objections to, or its right to interpret Cal. Health & Safety Code §§ 127677-79 and the implementing regulations.”
Rx0000373	Bio Products Laboratory Limited	12/31/2019	64208823403	Gammaplex Intravenous Solution 10 GM/200ML	11/11/2019	85.90	1727.10	None	Single Source Drug	0	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	Consistent with CA law and regulations, this report is limited to information that is otherwise in the public domain or publicly available. The product at issue was developed by the company and not acquired from a third party; therefore, the product acquisition fields in the report are not applicable and have been left blank. The company submits this report in good faith, without waiver of its objections to, or its right to interpret Cal. Health & Safety Code §§ 127677-79 and the implementing regulations.”
Rx0000373	Bio Products Laboratory Limited	12/31/2019	64208823404	Gammaplex Intravenous Solution 20 GM/400ML	11/11/2019	171.80	3454.20	None	Single Source Drug	0	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	Consistent with CA law and regulations, this report is limited to information that is otherwise in the public domain or publicly available. The product at issue was developed by the company and not acquired from a third party; therefore, the product acquisition fields in the report are not applicable and have been left blank. The company submits this report in good faith, without waiver of its objections to, or its right to interpret Cal. Health & Safety Code §§ 127677-79 and the implementing regulations.”
Rx0000373	Bio Products Laboratory Limited	12/31/2019	64208823402	Gammaplex Intravenous Solution 5 GM/100ML	11/11/2019	42.95	863.55	None	Single Source Drug	0	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	Consistent with CA law and regulations, this report is limited to information that is otherwise in the public domain or publicly available. The product at issue was developed by the company and not acquired from a third party; therefore, the product acquisition fields in the report are not applicable and have been left blank. The company submits this report in good faith, without waiver of its objections to, or its right to interpret Cal. Health & Safety Code §§ 127677-79 and the implementing regulations.”
Rx0000099	Biogen	03/31/2019	59627011103	Avonex® (interferon beta-1a) Lyophilized Formulation Administration Pack (4 x 30 mcg vial, IM injection)	01/01/2019	135.80	6925.75	09/15/2026	Single Source Drug	None	1	Multiple factors are considered when determining price increases, including the continued level of R&D investment in the product, as well as the product’s value to patients, present and future benefits to society, and fulfilling Biogen’s commitment to innovation, affordability and sustainability.  Note that due to channel mix and increasing discounts and allowances, the net price increase this year in Biogen’s MS portfolio in totality is under 2% year over year.	None	This increase was not necessitated by a change or improvement in the product.	None	None	None	None	None	None	None	None	None	None	None	Avonex was not acquired by Biogen from another company in the last 5 years.
Rx0000099	Biogen	03/31/2019	59627033304	Avonex® (interferon beta-1a) PEN™ Prefilled Autoinjector Administration Pack (4 x 30 mcg syringe, IM injection)	01/01/2019	135.80	6925.75	09/15/2026	Single Source Drug	None	1	Multiple factors are considered when determining price increases, including the continued level of R&D investment in the product, as well as the product’s value to patients, present and future benefits to society, and fulfilling Biogen’s commitment to innovation, affordability and sustainability.  Note that due to channel mix and increasing discounts and allowances, the net price increase this year in Biogen’s MS portfolio in totality is under 2% year over year.	None	This increase was not necessitated by a change or improvement in the product.	None	None	None	None	None	None	None	None	None	None	None	Avonex was not acquired by Biogen from another company in the last 5 years.
Rx0000099	Biogen	03/31/2019	59627022205	Avonex® (interferon beta-1a) Prefilled Syringe Administration Pack (4 x 30 mcg syringe, IM injection)	01/01/2019	135.80	6925.75	09/15/2026	Single Source Drug	None	1	Multiple factors are considered when determining price increases, including the continued level of R&D investment in the product, as well as the product’s value to patients, present and future benefits to society, and fulfilling Biogen’s commitment to innovation, affordability and sustainability.  Note that due to channel mix and increasing discounts and allowances, the net price increase this year in Biogen’s MS portfolio in totality is under 2% year over year.	None	This increase was not necessitated by a change or improvement in the product.	None	None	None	None	None	None	None	None	None	None	None	Avonex was not acquired by Biogen from another company in the last 5 years.
Rx0000099	Biogen	03/31/2019	64406001101	Plegridy® (peginterferon beta-1a) PEN, Maintenance Pack	01/01/2019	135.80	6925.75	06/16/2027	Single Source Drug	None	1	Multiple factors are considered when determining price increases, including the continued level of R&D investment in the product, as well as the product’s value to patients, present and future benefits to society, and fulfilling Biogen’s commitment to innovation, affordability and sustainability.  Note that due to channel mix and increasing discounts and allowances, the net price increase this year in Biogen’s MS portfolio in totality is under 2% year over year.	None	This increase was not necessitated by a change or improvement in the product.	None	None	None	None	None	None	None	None	None	None	None	Plegridy was not acquired by Biogen from another company in the last 5 years.
Rx0000099	Biogen	03/31/2019	64406001201	Plegridy® (peginterferon beta-1a) PEN, Starter Pack	01/01/2019	135.80	6925.75	06/16/2027	Single Source Drug	None	1	Multiple factors are considered when determining price increases, including the continued level of R&D investment in the product, as well as the product’s value to patients, present and future benefits to society, and fulfilling Biogen’s commitment to innovation, affordability and sustainability.  Note that due to channel mix and increasing discounts and allowances, the net price increase this year in Biogen’s MS portfolio in totality is under 2% year over year.	None	This increase was not necessitated by a change or improvement in the product.	None	None	None	None	None	None	None	None	None	None	None	Plegridy was not acquired by Biogen from another company in the last 5 years.
Rx0000099	Biogen	03/31/2019	64406001501	Plegridy® (peginterferon beta-1a) Prefilled Syringe, Maintenance Pack	01/01/2019	135.80	6925.75	06/16/2027	Single Source Drug	None	1	Multiple factors are considered when determining price increases, including the continued level of R&D investment in the product, as well as the product’s value to patients, present and future benefits to society, and fulfilling Biogen’s commitment to innovation, affordability and sustainability.  Note that due to channel mix and increasing discounts and allowances, the net price increase this year in Biogen’s MS portfolio in totality is under 2% year over year.	None	This increase was not necessitated by a change or improvement in the product.	None	None	None	None	None	None	None	None	None	None	None	Plegridy was not acquired by Biogen from another company in the last 5 years.
Rx0000099	Biogen	03/31/2019	64406001601	Plegridy® (peginterferon beta-1a) Prefilled Syringe, Starter Pack	01/01/2019	135.80	6925.75	06/16/2027	Single Source Drug	None	1	Multiple factors are considered when determining price increases, including the continued level of R&D investment in the product, as well as the product’s value to patients, present and future benefits to society, and fulfilling Biogen’s commitment to innovation, affordability and sustainability.  Note that due to channel mix and increasing discounts and allowances, the net price increase this year in Biogen’s MS portfolio in totality is under 2% year over year.	None	This increase was not necessitated by a change or improvement in the product.	None	None	None	None	None	None	None	None	None	None	None	Plegridy was not acquired by Biogen from another company in the last 5 years.
Rx0000099	Biogen	03/31/2019	64406000501	Tecfidera® (dimethyl fumarate) Half Dose (120 mg) Capsules: 7-day bottle of 14 capsules	01/01/2019	103.10	1821.80	02/27/2028	Single Source Drug	None	1	Multiple factors are considered when determining price increases, including the continued level of R&D investment in the product, as well as the product’s value to patients, present and future benefits to society, and fulfilling Biogen’s commitment to innovation, affordability and sustainability.  Note that due to channel mix and increasing discounts and allowances, the net price increase this year in Biogen’s MS portfolio in totality is under 2% year over year.	None	This increase was not necessitated by a change or improvement in the product.	None	None	None	None	None	None	None	None	None	None	None	Tecfidera was not acquired by Biogen from another company in the last 5 years.
Rx0000099	Biogen	03/31/2019	64406000602	Tecfidera® (dimethyl fumarate) Regular Dose (240 mg) Capsules: 30-day bottle of 60 capsules	01/01/2019	441.90	7807.45	02/27/2028	Single Source Drug	None	1	Multiple factors are considered when determining price increases, including the continued level of R&D investment in the product, as well as the product’s value to patients, present and future benefits to society, and fulfilling Biogen’s commitment to innovation, affordability and sustainability.  Note that due to channel mix and increasing discounts and allowances, the net price increase this year in Biogen’s MS portfolio in totality is under 2% year over year.	None	This increase was not necessitated by a change or improvement in the product.	None	None	None	None	None	None	None	None	None	None	None	Tecfidera was not acquired by Biogen from another company in the last 5 years.
Rx0000099	Biogen	03/31/2019	64406000703	Tecfidera® (dimethyl fumarate) Starter Pack (30 day): 7-day bottle 120 mg capsules, quantity 14 and 23-day bottle 240 mg capsules, quantity 46	01/01/2019	441.90	7807.45	02/27/2028	Single Source Drug	None	1	Multiple factors are considered when determining price increases, including the continued level of R&D investment in the product, as well as the product’s value to patients, present and future benefits to society, and fulfilling Biogen’s commitment to innovation, affordability and sustainability.  Note that due to channel mix and increasing discounts and allowances, the net price increase this year in Biogen’s MS portfolio in totality is under 2% year over year.	None	This increase was not necessitated by a change or improvement in the product.	None	None	None	None	None	None	None	None	None	None	None	Tecfidera was not acquired by Biogen from another company in the last 5 years.
Rx0000038	Boehringer Ingelheim	03/31/2019	00597000160	AGGRENOX 25 MG-200 MG CAPSULE	01/01/2019	41.77	563.88	None	Innovator Multiple Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	https://reports.siera.oshpd.ca.gov/api/report/drug-pricing/attachment?id=149	For Column F there are no unexpired patents for this product per the Orange Book. Not acquired within the last five years.
Rx0000038	Boehringer Ingelheim	03/31/2019	00597000201	APTIVUS 100 MG/ML SOLUTION	01/01/2019	31.56	557.63	10/29/2019	Single Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	https://reports.siera.oshpd.ca.gov/api/report/drug-pricing/attachment?id=151	For Column F as reflected in the FDA publication, Approved Drug Products with Therapeutic Equivalence Evaluations (the “Orange Book”), the latest patent expiration is provided. Not acquired within the last five years.
Rx0000038	Boehringer Ingelheim	03/31/2019	00597000302	APTIVUS 250 MG CAPSULE	01/01/2019	94.70	1672.98	10/29/2019	Single Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	https://reports.siera.oshpd.ca.gov/api/report/drug-pricing/attachment?id=150	For Column F as reflected in the FDA publication, Approved Drug Products with Therapeutic Equivalence Evaluations (the “Orange Book”), the latest patent expiration is provided. Not acquired within the last five years.
Rx0000038	Boehringer Ingelheim	03/31/2019	00597008717	ATROVENT 17 MCG HFA INHALER	01/01/2019	28.75	388.10	01/17/2030	Single Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	https://reports.siera.oshpd.ca.gov/api/report/drug-pricing/attachment?id=152	For Column F as reflected in the FDA publication, Approved Drug Products with Therapeutic Equivalence Evaluations (the “Orange Book”), the latest patent expiration is provided. Not acquired within the last five years.
Rx0000038	Boehringer Ingelheim	03/31/2019	00597000601	CATAPRES 0.1 MG TABLET	01/01/2019	20.12	271.57	None	Innovator Multiple Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	https://reports.siera.oshpd.ca.gov/api/report/drug-pricing/attachment?id=156	For Column F there are no unexpired patents for this product per the Orange Book. Not acquired within the last five years.
Rx0000038	Boehringer Ingelheim	03/31/2019	00597000701	CATAPRES 0.2 MG TABLET	01/01/2019	30.78	415.48	None	Innovator Multiple Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	https://reports.siera.oshpd.ca.gov/api/report/drug-pricing/attachment?id=157	For Column F there are no unexpired patents for this product per the Orange Book. Not acquired within the last five years.
Rx0000038	Boehringer Ingelheim	03/31/2019	00597001101	CATAPRES 0.3 MG TABLET	01/01/2019	38.62	521.37	None	Innovator Multiple Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	https://reports.siera.oshpd.ca.gov/api/report/drug-pricing/attachment?id=158	For Column F there are no unexpired patents for this product per the Orange Book. Not acquired within the last five years.
Rx0000038	Boehringer Ingelheim	03/31/2019	00597003134	CATAPRES-TTS 1 PATCH	01/01/2019	19.50	263.28	None	Innovator Multiple Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	https://reports.siera.oshpd.ca.gov/api/report/drug-pricing/attachment?id=153	For Column F there are no unexpired patents for this product per the Orange Book. Not acquired within the last five years.
Rx0000038	Boehringer Ingelheim	03/31/2019	00597003234	CATAPRES-TTS 2 PATCH	01/01/2019	32.84	443.31	None	Innovator Multiple Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	https://reports.siera.oshpd.ca.gov/api/report/drug-pricing/attachment?id=154	For Column F there are no unexpired patents for this product per the Orange Book. Not acquired within the last five years.
Rx0000038	Boehringer Ingelheim	03/31/2019	00597003334	CATAPRES-TTS 3 PATCH	01/01/2019	45.55	614.96	None	Innovator Multiple Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	https://reports.siera.oshpd.ca.gov/api/report/drug-pricing/attachment?id=155	For Column F there are no unexpired patents for this product per the Orange Book. Not acquired within the last five years.
Rx0000038	Boehringer Ingelheim	03/31/2019	00597002402	COMBIVENT RESPIMAT 20-100 MCG	01/01/2019	29.80	402.31	10/16/2030	Single Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	https://reports.siera.oshpd.ca.gov/api/report/drug-pricing/attachment?id=159	For Column F as reflected in the FDA publication, Approved Drug Products with Therapeutic Equivalence Evaluations (the “Orange Book”), the latest patent expiration is provided. Not acquired within the last five years.
Rx0000038	Boehringer Ingelheim	03/31/2019	00597014130	GILOTRIF 20 MG TABLET	01/01/2019	652.38	8807.15	07/05/2030	Single Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	https://reports.siera.oshpd.ca.gov/api/report/drug-pricing/attachment?id=160	For Column F as reflected in the FDA publication, Approved Drug Products with Therapeutic Equivalence Evaluations (the “Orange Book”), the latest patent expiration is provided. Not acquired within the last five years.
Rx0000038	Boehringer Ingelheim	03/31/2019	00597013730	GILOTRIF 30 MG TABLET	01/01/2019	652.38	8807.15	07/05/2030	Single Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	https://reports.siera.oshpd.ca.gov/api/report/drug-pricing/attachment?id=161	For Column F as reflected in the FDA publication, Approved Drug Products with Therapeutic Equivalence Evaluations (the “Orange Book”), the latest patent expiration is provided. Not acquired within the last five years.
Rx0000038	Boehringer Ingelheim	03/31/2019	00597013830	GILOTRIF 40 MG TABLET	01/01/2019	652.38	8807.15	07/05/2030	Single Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	https://reports.siera.oshpd.ca.gov/api/report/drug-pricing/attachment?id=162	For Column F as reflected in the FDA publication, Approved Drug Products with Therapeutic Equivalence Evaluations (the “Orange Book”), the latest patent expiration is provided. Not acquired within the last five years.
Rx0000038	Boehringer Ingelheim	03/31/2019	00597015230	JARDIANCE 10 MG TABLET	01/01/2019	27.90	492.85	06/11/2034	Single Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	https://reports.siera.oshpd.ca.gov/api/report/drug-pricing/attachment?id=163	For Column F as reflected in the FDA publication, Approved Drug Products with Therapeutic Equivalence Evaluations (the “Orange Book”), the latest patent expiration is provided. Not acquired within the last five years.
Rx0000038	Boehringer Ingelheim	03/31/2019	00597015237	JARDIANCE 10 MG TABLET	01/01/2019	27.90	492.85	06/11/2034	Single Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	https://reports.siera.oshpd.ca.gov/api/report/drug-pricing/attachment?id=164	For Column F as reflected in the FDA publication, Approved Drug Products with Therapeutic Equivalence Evaluations (the “Orange Book”), the latest patent expiration is provided. Not acquired within the last five years.
Rx0000038	Boehringer Ingelheim	03/31/2019	00597015290	JARDIANCE 10 MG TABLET	01/01/2019	83.69	1478.54	06/11/2034	Single Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	https://reports.siera.oshpd.ca.gov/api/report/drug-pricing/attachment?id=165	For Column F as reflected in the FDA publication, Approved Drug Products with Therapeutic Equivalence Evaluations (the “Orange Book”), the latest patent expiration is provided. Not acquired within the last five years.
Rx0000038	Boehringer Ingelheim	03/31/2019	00597015330	JARDIANCE 25 MG TABLET	01/01/2019	27.90	492.85	06/11/2034	Single Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	https://reports.siera.oshpd.ca.gov/api/report/drug-pricing/attachment?id=166	For Column F as reflected in the FDA publication, Approved Drug Products with Therapeutic Equivalence Evaluations (the “Orange Book”), the latest patent expiration is provided. Not acquired within the last five years.
Rx0000038	Boehringer Ingelheim	03/31/2019	00597015337	JARDIANCE 25 MG TABLET	01/01/2019	27.90	492.85	06/11/2034	Single Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	https://reports.siera.oshpd.ca.gov/api/report/drug-pricing/attachment?id=167	For Column F as reflected in the FDA publication, Approved Drug Products with Therapeutic Equivalence Evaluations (the “Orange Book”), the latest patent expiration is provided. Not acquired within the last five years.
Rx0000038	Boehringer Ingelheim	03/31/2019	00597015390	JARDIANCE 25 MG TABLET	01/01/2019	83.69	1478.54	06/11/2034	Single Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	https://reports.siera.oshpd.ca.gov/api/report/drug-pricing/attachment?id=168	For Column F as reflected in the FDA publication, Approved Drug Products with Therapeutic Equivalence Evaluations (the “Orange Book”), the latest patent expiration is provided. Not acquired within the last five years.
Rx0000038	Boehringer Ingelheim	03/31/2019	00597014818	JENTADUETO 2.5 MG-1,000 MG TAB	01/01/2019	74.07	1308.51	06/04/2030	Single Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	https://reports.siera.oshpd.ca.gov/api/report/drug-pricing/attachment?id=173	For Column F as reflected in the FDA publication, Approved Drug Products with Therapeutic Equivalence Evaluations (the “Orange Book”), the latest patent expiration is provided. Not acquired within the last five years.
Rx0000038	Boehringer Ingelheim	03/31/2019	00597014860	JENTADUETO 2.5 MG-1,000 MG TAB	01/01/2019	24.69	436.17	06/04/2030	Single Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	https://reports.siera.oshpd.ca.gov/api/report/drug-pricing/attachment?id=174	For Column F as reflected in the FDA publication, Approved Drug Products with Therapeutic Equivalence Evaluations (the “Orange Book”), the latest patent expiration is provided. Not acquired within the last five years.
Rx0000038	Boehringer Ingelheim	03/31/2019	00597014618	JENTADUETO 2.5 MG-500 MG TAB	01/01/2019	74.07	1308.51	06/04/2030	Single Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	https://reports.siera.oshpd.ca.gov/api/report/drug-pricing/attachment?id=169	For Column F as reflected in the FDA publication, Approved Drug Products with Therapeutic Equivalence Evaluations (the “Orange Book”), the latest patent expiration is provided. Not acquired within the last five years.
Rx0000038	Boehringer Ingelheim	03/31/2019	00597014660	JENTADUETO 2.5 MG-500 MG TAB	01/01/2019	24.69	436.17	06/04/2030	Single Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	https://reports.siera.oshpd.ca.gov/api/report/drug-pricing/attachment?id=170	For Column F as reflected in the FDA publication, Approved Drug Products with Therapeutic Equivalence Evaluations (the “Orange Book”), the latest patent expiration is provided. Not acquired within the last five years.
Rx0000038	Boehringer Ingelheim	03/31/2019	00597014718	JENTADUETO 2.5 MG-850 MG TAB	01/01/2019	74.07	1308.51	06/04/2030	Single Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	https://reports.siera.oshpd.ca.gov/api/report/drug-pricing/attachment?id=171	For Column F as reflected in the FDA publication, Approved Drug Products with Therapeutic Equivalence Evaluations (the “Orange Book”), the latest patent expiration is provided. Not acquired within the last five years.
Rx0000038	Boehringer Ingelheim	03/31/2019	00597014760	JENTADUETO 2.5 MG-850 MG TAB	01/01/2019	24.69	436.17	06/04/2030	Single Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	https://reports.siera.oshpd.ca.gov/api/report/drug-pricing/attachment?id=172	For Column F as reflected in the FDA publication, Approved Drug Products with Therapeutic Equivalence Evaluations (the “Orange Book”), the latest patent expiration is provided. Not acquired within the last five years.
Rx0000038	Boehringer Ingelheim	03/31/2019	00597027073	JENTADUETO XR 2.5 MG-1,000 MG	01/01/2019	24.69	436.17	03/06/2033	Single Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	https://reports.siera.oshpd.ca.gov/api/report/drug-pricing/attachment?id=175	For Column F as reflected in the FDA publication, Approved Drug Products with Therapeutic Equivalence Evaluations (the “Orange Book”), the latest patent expiration is provided. Not acquired within the last five years.
Rx0000038	Boehringer Ingelheim	03/31/2019	00597027094	JENTADUETO XR 2.5 MG-1,000 MG	01/01/2019	74.07	1308.51	03/06/2033	Single Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	https://reports.siera.oshpd.ca.gov/api/report/drug-pricing/attachment?id=176	For Column F as reflected in the FDA publication, Approved Drug Products with Therapeutic Equivalence Evaluations (the “Orange Book”), the latest patent expiration is provided. Not acquired within the last five years.
Rx0000038	Boehringer Ingelheim	03/31/2019	00597027533	JENTADUETO XR 5 MG-1,000 MG TB	01/01/2019	24.69	436.17	03/06/2033	Single Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	https://reports.siera.oshpd.ca.gov/api/report/drug-pricing/attachment?id=177	For Column F as reflected in the FDA publication, Approved Drug Products with Therapeutic Equivalence Evaluations (the “Orange Book”), the latest patent expiration is provided. Not acquired within the last five years.
Rx0000038	Boehringer Ingelheim	03/31/2019	00597027581	JENTADUETO XR 5 MG-1,000 MG TB	01/01/2019	74.07	1308.51	03/06/2033	Single Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	https://reports.siera.oshpd.ca.gov/api/report/drug-pricing/attachment?id=178	For Column F as reflected in the FDA publication, Approved Drug Products with Therapeutic Equivalence Evaluations (the “Orange Book”), the latest patent expiration is provided. Not acquired within the last five years.
Rx0000038	Boehringer Ingelheim	03/31/2019	00597003937	MICARDIS 20 MG TABLET	01/01/2019	15.98	215.77	01/10/2020	Innovator Multiple Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	https://reports.siera.oshpd.ca.gov/api/report/drug-pricing/attachment?id=179	For Column F as reflected in the FDA publication, Approved Drug Products with Therapeutic Equivalence Evaluations (the “Orange Book”), the latest patent expiration is provided. Not acquired within the last five years.
Rx0000038	Boehringer Ingelheim	03/31/2019	00597004037	MICARDIS 40 MG TABLET	01/01/2019	15.98	215.77	01/10/2020	Innovator Multiple Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	https://reports.siera.oshpd.ca.gov/api/report/drug-pricing/attachment?id=180	For Column F as reflected in the FDA publication, Approved Drug Products with Therapeutic Equivalence Evaluations (the “Orange Book”), the latest patent expiration is provided. Not acquired within the last five years.
Rx0000038	Boehringer Ingelheim	03/31/2019	00597004137	MICARDIS 80 MG TABLET	01/01/2019	15.98	215.77	10/06/2022	Innovator Multiple Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	https://reports.siera.oshpd.ca.gov/api/report/drug-pricing/attachment?id=181	For Column F as reflected in the FDA publication, Approved Drug Products with Therapeutic Equivalence Evaluations (the “Orange Book”), the latest patent expiration is provided. Not acquired within the last five years.
Rx0000038	Boehringer Ingelheim	03/31/2019	00597004337	MICARDIS HCT 40-12.5 MG TABLET	01/01/2019	15.98	215.77	01/10/2020	Innovator Multiple Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	https://reports.siera.oshpd.ca.gov/api/report/drug-pricing/attachment?id=183	For Column F as reflected in the FDA publication, Approved Drug Products with Therapeutic Equivalence Evaluations (the “Orange Book”), the latest patent expiration is provided. Not acquired within the last five years.
Rx0000038	Boehringer Ingelheim	03/31/2019	00597004437	MICARDIS HCT 80-12.5 MG TABLET	01/01/2019	15.98	215.77	01/10/2020	Innovator Multiple Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	https://reports.siera.oshpd.ca.gov/api/report/drug-pricing/attachment?id=184	For Column F as reflected in the FDA publication, Approved Drug Products with Therapeutic Equivalence Evaluations (the “Orange Book”), the latest patent expiration is provided. Not acquired within the last five years.
Rx0000038	Boehringer Ingelheim	03/31/2019	00597004237	MICARDIS HCT 80-25 MG TABLET	01/01/2019	15.98	215.77	None	Innovator Multiple Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	https://reports.siera.oshpd.ca.gov/api/report/drug-pricing/attachment?id=182	For Column F there are no unexpired patents for this product per the Orange Book. Not acquired within the last five years.
Rx0000038	Boehringer Ingelheim	03/31/2019	00597018390	MIRAPEX 0.125 MG TABLET	01/01/2019	46.81	631.88	None	Innovator Multiple Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	https://reports.siera.oshpd.ca.gov/api/report/drug-pricing/attachment?id=186	For Column F there are no unexpired patents for this product per the Orange Book. Not acquired within the last five years.
Rx0000038	Boehringer Ingelheim	03/31/2019	00597018461	MIRAPEX 0.25 MG TABLET	01/01/2019	54.60	737.05	None	Innovator Multiple Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	https://reports.siera.oshpd.ca.gov/api/report/drug-pricing/attachment?id=187	For Column F there are no unexpired patents for this product per the Orange Book. Not acquired within the last five years.
Rx0000038	Boehringer Ingelheim	03/31/2019	00597018490	MIRAPEX 0.25 MG TABLET	01/01/2019	46.81	631.88	None	Innovator Multiple Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	https://reports.siera.oshpd.ca.gov/api/report/drug-pricing/attachment?id=188	For Column F there are no unexpired patents for this product per the Orange Book. Not acquired within the last five years.
Rx0000038	Boehringer Ingelheim	03/31/2019	00597018561	MIRAPEX 0.5 MG TABLET	01/01/2019	54.60	737.05	None	Innovator Multiple Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	https://reports.siera.oshpd.ca.gov/api/report/drug-pricing/attachment?id=189	For Column F there are no unexpired patents for this product per the Orange Book. Not acquired within the last five years.
Rx0000038	Boehringer Ingelheim	03/31/2019	00597018590	MIRAPEX 0.5 MG TABLET	01/01/2019	46.81	631.88	None	Innovator Multiple Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	https://reports.siera.oshpd.ca.gov/api/report/drug-pricing/attachment?id=190	For Column F there are no unexpired patents for this product per the Orange Book. Not acquired within the last five years.
Rx0000038	Boehringer Ingelheim	03/31/2019	00597010190	MIRAPEX 0.75 MG TABLET	01/01/2019	46.81	631.88	None	Innovator Multiple Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	https://reports.siera.oshpd.ca.gov/api/report/drug-pricing/attachment?id=185	For Column F there are no unexpired patents for this product per the Orange Book. Not acquired within the last five years.
Rx0000038	Boehringer Ingelheim	03/31/2019	00597019061	MIRAPEX 1 MG TABLET	01/01/2019	54.60	737.05	None	Innovator Multiple Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	https://reports.siera.oshpd.ca.gov/api/report/drug-pricing/attachment?id=191	For Column F there are no unexpired patents for this product per the Orange Book. Not acquired within the last five years.
Rx0000038	Boehringer Ingelheim	03/31/2019	00597019090	MIRAPEX 1 MG TABLET	01/01/2019	46.81	631.88	None	Innovator Multiple Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	https://reports.siera.oshpd.ca.gov/api/report/drug-pricing/attachment?id=192	For Column F there are no unexpired patents for this product per the Orange Book. Not acquired within the last five years.
Rx0000038	Boehringer Ingelheim	03/31/2019	00597019161	MIRAPEX 1.5 MG TABLET	01/01/2019	54.60	737.05	None	Innovator Multiple Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	https://reports.siera.oshpd.ca.gov/api/report/drug-pricing/attachment?id=193	For Column F there are no unexpired patents for this product per the Orange Book. After researching the highlighted compliance issues regarding the five year history and the two missing dates, it has been determined that the data we have supplied is correct. Not acquired within the last five years.
Rx0000038	Boehringer Ingelheim	03/31/2019	00597019190	MIRAPEX 1.5 MG TABLET	01/01/2019	46.81	631.88	None	Innovator Multiple Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	https://reports.siera.oshpd.ca.gov/api/report/drug-pricing/attachment?id=194	For Column F there are no unexpired patents for this product per the Orange Book. Not acquired within the last five years.
Rx0000038	Boehringer Ingelheim	03/31/2019	00597010917	MIRAPEX ER 0.375 MG TABLET	01/01/2019	10.33	139.48	09/08/2029	Innovator Multiple Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	https://reports.siera.oshpd.ca.gov/api/report/drug-pricing/attachment?id=195	For Column F as reflected in the FDA publication, Approved Drug Products with Therapeutic Equivalence Evaluations (the “Orange Book”), the latest patent expiration is provided. Not acquired within the last five years.
Rx0000038	Boehringer Ingelheim	03/31/2019	00597010930	MIRAPEX ER 0.375 MG TABLET	01/01/2019	44.29	597.86	09/08/2029	Innovator Multiple Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	https://reports.siera.oshpd.ca.gov/api/report/drug-pricing/attachment?id=196	For Column F as reflected in the FDA publication, Approved Drug Products with Therapeutic Equivalence Evaluations (the “Orange Book”), the latest patent expiration is provided. Not acquired within the last five years.
Rx0000038	Boehringer Ingelheim	03/31/2019	00597028517	MIRAPEX ER 0.75 MG TABLET	01/01/2019	10.33	139.48	09/08/2029	Innovator Multiple Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	https://reports.siera.oshpd.ca.gov/api/report/drug-pricing/attachment?id=201	For Column F as reflected in the FDA publication, Approved Drug Products with Therapeutic Equivalence Evaluations (the “Orange Book”), the latest patent expiration is provided. Not acquired within the last five years.
Rx0000038	Boehringer Ingelheim	03/31/2019	00597028530	MIRAPEX ER 0.75 MG TABLET	01/01/2019	44.29	597.86	09/08/2029	Innovator Multiple Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	https://reports.siera.oshpd.ca.gov/api/report/drug-pricing/attachment?id=202	For Column F as reflected in the FDA publication, Approved Drug Products with Therapeutic Equivalence Evaluations (the “Orange Book”), the latest patent expiration is provided. Not acquired within the last five years.
Rx0000038	Boehringer Ingelheim	03/31/2019	00597011317	MIRAPEX ER 1.5 MG TABLET	01/01/2019	10.33	139.48	09/08/2029	Innovator Multiple Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	https://reports.siera.oshpd.ca.gov/api/report/drug-pricing/attachment?id=197	For Column F as reflected in the FDA publication, Approved Drug Products with Therapeutic Equivalence Evaluations (the “Orange Book”), the latest patent expiration is provided. Not acquired within the last five years.
Rx0000038	Boehringer Ingelheim	03/31/2019	00597011330	MIRAPEX ER 1.5 MG TABLET	01/01/2019	44.29	597.86	09/08/2029	Innovator Multiple Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	https://reports.siera.oshpd.ca.gov/api/report/drug-pricing/attachment?id=198	For Column F as reflected in the FDA publication, Approved Drug Products with Therapeutic Equivalence Evaluations (the “Orange Book”), the latest patent expiration is provided. Not acquired within the last five years.
Rx0000038	Boehringer Ingelheim	03/31/2019	00597028630	MIRAPEX ER 2.25 MG TABLET	01/01/2019	44.29	597.86	09/08/2029	Innovator Multiple Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	https://reports.siera.oshpd.ca.gov/api/report/drug-pricing/attachment?id=203	For Column F as reflected in the FDA publication, Approved Drug Products with Therapeutic Equivalence Evaluations (the “Orange Book”), the latest patent expiration is provided. Not acquired within the last five years.
Rx0000038	Boehringer Ingelheim	03/31/2019	00597011530	MIRAPEX ER 3 MG TABLET	01/01/2019	44.29	597.86	09/08/2029	Innovator Multiple Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	https://reports.siera.oshpd.ca.gov/api/report/drug-pricing/attachment?id=199	For Column F as reflected in the FDA publication, Approved Drug Products with Therapeutic Equivalence Evaluations (the “Orange Book”), the latest patent expiration is provided. Not acquired within the last five years.
Rx0000038	Boehringer Ingelheim	03/31/2019	00597028730	MIRAPEX ER 3.75 MG TABLET	01/01/2019	44.29	597.86	09/08/2029	Innovator Multiple Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	https://reports.siera.oshpd.ca.gov/api/report/drug-pricing/attachment?id=204	For Column F as reflected in the FDA publication, Approved Drug Products with Therapeutic Equivalence Evaluations (the “Orange Book”), the latest patent expiration is provided. Not acquired within the last five years.
Rx0000038	Boehringer Ingelheim	03/31/2019	00597011630	MIRAPEX ER 4.5 MG TABLET	01/01/2019	44.29	597.86	09/08/2029	Innovator Multiple Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	https://reports.siera.oshpd.ca.gov/api/report/drug-pricing/attachment?id=200	For Column F as reflected in the FDA publication, Approved Drug Products with Therapeutic Equivalence Evaluations (the “Orange Book”), the latest patent expiration is provided. Not acquired within the last five years.
Rx0000038	Boehringer Ingelheim	03/31/2019	00597003001	MOBIC 15 MG TABLET	01/01/2019	95.58	1290.37	None	Innovator Multiple Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	https://reports.siera.oshpd.ca.gov/api/report/drug-pricing/attachment?id=206	For Column F there are no unexpired patents for this product per the Orange Book. Not acquired within the last five years.
Rx0000038	Boehringer Ingelheim	03/31/2019	00597002901	MOBIC 7.5 MG TABLET	01/01/2019	62.51	843.90	None	Innovator Multiple Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	https://reports.siera.oshpd.ca.gov/api/report/drug-pricing/attachment?id=205	For Column F there are no unexpired patents for this product per the Orange Book. Not acquired within the last five years.
Rx0000038	Boehringer Ingelheim	03/31/2019	00597010854	PRADAXA 110 MG CAPSULE	01/01/2019	32.05	432.62	01/20/2031	Single Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	https://reports.siera.oshpd.ca.gov/api/report/drug-pricing/attachment?id=207	For Column F as reflected in the FDA publication, Approved Drug Products with Therapeutic Equivalence Evaluations (the “Orange Book”), the latest patent expiration is provided. Not acquired within the last five years.
Rx0000038	Boehringer Ingelheim	03/31/2019	00597010860	PRADAXA 110 MG CAPSULE	01/01/2019	32.05	432.62	01/20/2031	Single Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	https://reports.siera.oshpd.ca.gov/api/report/drug-pricing/attachment?id=208	For Column F as reflected in the FDA publication, Approved Drug Products with Therapeutic Equivalence Evaluations (the “Orange Book”), the latest patent expiration is provided. Not acquired within the last five years.
Rx0000038	Boehringer Ingelheim	03/31/2019	00597036055	PRADAXA 150 MG CAPSULE	01/01/2019	32.05	432.62	01/20/2031	Single Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	https://reports.siera.oshpd.ca.gov/api/report/drug-pricing/attachment?id=211	For Column F as reflected in the FDA publication, Approved Drug Products with Therapeutic Equivalence Evaluations (the “Orange Book”), the latest patent expiration is provided. Not acquired within the last five years.
Rx0000038	Boehringer Ingelheim	03/31/2019	00597035509	PRADAXA 75 MG CAPSULE	01/01/2019	32.05	432.62	01/20/2031	Single Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	https://reports.siera.oshpd.ca.gov/api/report/drug-pricing/attachment?id=209	For Column F as reflected in the FDA publication, Approved Drug Products with Therapeutic Equivalence Evaluations (the “Orange Book”), the latest patent expiration is provided. Not acquired within the last five years.
Rx0000038	Boehringer Ingelheim	03/31/2019	00597035556	PRADAXA 75 MG CAPSULE	01/01/2019	32.05	432.62	01/20/2031	Single Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	https://reports.siera.oshpd.ca.gov/api/report/drug-pricing/attachment?id=210	For Column F as reflected in the FDA publication, Approved Drug Products with Therapeutic Equivalence Evaluations (the “Orange Book”), the latest patent expiration is provided. Not acquired within the last five years.
Rx0000038	Boehringer Ingelheim	03/31/2019	00597007541	SPIRIVA 18 MCG CP-HANDIHALER	01/01/2019	31.81	429.47	04/19/2030	Single Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	https://reports.siera.oshpd.ca.gov/api/report/drug-pricing/attachment?id=213	For Column F as reflected in the FDA publication, Approved Drug Products with Therapeutic Equivalence Evaluations (the “Orange Book”), the latest patent expiration is provided. Not acquired within the last five years.
Rx0000038	Boehringer Ingelheim	03/31/2019	00597007547	SPIRIVA 18 MCG CP-HANDIHALER	01/01/2019	95.44	1288.41	04/19/2030	Single Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	https://reports.siera.oshpd.ca.gov/api/report/drug-pricing/attachment?id=214	For Column F as reflected in the FDA publication, Approved Drug Products with Therapeutic Equivalence Evaluations (the “Orange Book”), the latest patent expiration is provided. Not acquired within the last five years.
Rx0000038	Boehringer Ingelheim	03/31/2019	00597016061	SPIRIVA RESPIMAT 1.25 MCG INH	01/01/2019	31.81	429.47	10/16/2030	Single Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	https://reports.siera.oshpd.ca.gov/api/report/drug-pricing/attachment?id=217	For Column F as reflected in the FDA publication, Approved Drug Products with Therapeutic Equivalence Evaluations (the “Orange Book”), the latest patent expiration is provided. Not acquired within the last five years.
Rx0000038	Boehringer Ingelheim	03/31/2019	00597010061	SPIRIVA RESPIMAT 2.5 MCG INH	01/01/2019	31.81	429.47	10/16/2030	Single Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	https://reports.siera.oshpd.ca.gov/api/report/drug-pricing/attachment?id=216	For Column F as reflected in the FDA publication, Approved Drug Products with Therapeutic Equivalence Evaluations (the “Orange Book”), the latest patent expiration is provided. Not acquired within the last five years.
Rx0000038	Boehringer Ingelheim	03/31/2019	00597015561	STIOLTO RESPIMAT INHAL SPRAY	01/01/2019	29.46	397.66	10/16/2030	Single Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	https://reports.siera.oshpd.ca.gov/api/report/drug-pricing/attachment?id=218	For Column F as reflected in the FDA publication, Approved Drug Products with Therapeutic Equivalence Evaluations (the “Orange Book”), the latest patent expiration is provided. Not acquired within the last five years.
Rx0000038	Boehringer Ingelheim	03/31/2019	00597019261	STRIVERDI RESPIMAT INHAL SPRAY	01/01/2019	15.69	211.83	10/16/2030	Single Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	https://reports.siera.oshpd.ca.gov/api/report/drug-pricing/attachment?id=219	For Column F as reflected in the FDA publication, Approved Drug Products with Therapeutic Equivalence Evaluations (the “Orange Book”), the latest patent expiration is provided. Not acquired within the last five years.
Rx0000038	Boehringer Ingelheim	03/31/2019	00597016818	SYNJARDY 12.5-1,000 MG TABLET	01/01/2019	83.69	1478.54	04/15/2027	Single Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	https://reports.siera.oshpd.ca.gov/api/report/drug-pricing/attachment?id=222	For Column F as reflected in the FDA publication, Approved Drug Products with Therapeutic Equivalence Evaluations (the “Orange Book”), the latest patent expiration is provided. Not acquired within the last five years.
Rx0000038	Boehringer Ingelheim	03/31/2019	00597016860	SYNJARDY 12.5-1,000 MG TABLET	01/01/2019	27.90	492.85	04/15/2027	Single Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	https://reports.siera.oshpd.ca.gov/api/report/drug-pricing/attachment?id=223	For Column F as reflected in the FDA publication, Approved Drug Products with Therapeutic Equivalence Evaluations (the “Orange Book”), the latest patent expiration is provided. Not acquired within the last five years.
Rx0000038	Boehringer Ingelheim	03/31/2019	00597018018	SYNJARDY 12.5-500 MG TABLET	01/01/2019	83.69	1478.54	04/15/2027	Single Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	https://reports.siera.oshpd.ca.gov/api/report/drug-pricing/attachment?id=226	For Column F as reflected in the FDA publication, Approved Drug Products with Therapeutic Equivalence Evaluations (the “Orange Book”), the latest patent expiration is provided. Not acquired within the last five years.
Rx0000038	Boehringer Ingelheim	03/31/2019	00597018060	SYNJARDY 12.5-500 MG TABLET	01/01/2019	27.90	492.85	04/15/2027	Single Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	https://reports.siera.oshpd.ca.gov/api/report/drug-pricing/attachment?id=227	For Column F as reflected in the FDA publication, Approved Drug Products with Therapeutic Equivalence Evaluations (the “Orange Book”), the latest patent expiration is provided. Not acquired within the last five years.
Rx0000038	Boehringer Ingelheim	03/31/2019	00597017518	SYNJARDY 5-1,000 MG TABLET	01/01/2019	83.69	1478.54	04/15/2027	Single Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	https://reports.siera.oshpd.ca.gov/api/report/drug-pricing/attachment?id=224	For Column F as reflected in the FDA publication, Approved Drug Products with Therapeutic Equivalence Evaluations (the “Orange Book”), the latest patent expiration is provided. Not acquired within the last five years.
Rx0000038	Boehringer Ingelheim	03/31/2019	00597017560	SYNJARDY 5-1,000 MG TABLET	01/01/2019	27.90	492.85	04/15/2027	Single Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	https://reports.siera.oshpd.ca.gov/api/report/drug-pricing/attachment?id=225	For Column F as reflected in the FDA publication, Approved Drug Products with Therapeutic Equivalence Evaluations (the “Orange Book”), the latest patent expiration is provided. Not acquired within the last five years.
Rx0000038	Boehringer Ingelheim	03/31/2019	00597015918	SYNJARDY 5-500 MG TABLET	01/01/2019	83.69	1478.54	04/15/2027	Single Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	https://reports.siera.oshpd.ca.gov/api/report/drug-pricing/attachment?id=220	For Column F as reflected in the FDA publication, Approved Drug Products with Therapeutic Equivalence Evaluations (the “Orange Book”), the latest patent expiration is provided. Not acquired within the last five years.
Rx0000038	Boehringer Ingelheim	03/31/2019	00597015960	SYNJARDY 5-500 MG TABLET	01/01/2019	27.90	492.85	04/15/2027	Single Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	https://reports.siera.oshpd.ca.gov/api/report/drug-pricing/attachment?id=221	For Column F as reflected in the FDA publication, Approved Drug Products with Therapeutic Equivalence Evaluations (the “Orange Book”), the latest patent expiration is provided. Not acquired within the last five years.
Rx0000038	Boehringer Ingelheim	03/31/2019	00597014030	TRADJENTA 5 MG TABLET	01/01/2019	24.69	436.17	03/05/2031	Single Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	https://reports.siera.oshpd.ca.gov/api/report/drug-pricing/attachment?id=228	For Column F as reflected in the FDA publication, Approved Drug Products with Therapeutic Equivalence Evaluations (the “Orange Book”), the latest patent expiration is provided. Not acquired within the last five years.
Rx0000038	Boehringer Ingelheim	03/31/2019	00597014061	TRADJENTA 5 MG TABLET	01/01/2019	82.30	1453.90	03/05/2031	Single Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	https://reports.siera.oshpd.ca.gov/api/report/drug-pricing/attachment?id=229	For Column F as reflected in the FDA publication, Approved Drug Products with Therapeutic Equivalence Evaluations (the “Orange Book”), the latest patent expiration is provided. Not acquired within the last five years.
Rx0000038	Boehringer Ingelheim	03/31/2019	00597014090	TRADJENTA 5 MG TABLET	01/01/2019	74.07	1308.51	03/05/2031	Single Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	https://reports.siera.oshpd.ca.gov/api/report/drug-pricing/attachment?id=230	For Column F as reflected in the FDA publication, Approved Drug Products with Therapeutic Equivalence Evaluations (the “Orange Book”), the latest patent expiration is provided. Not acquired within the last five years.
Rx0000038	Boehringer Ingelheim	03/31/2019	00597012537	TWYNSTA 40-10 MG TABLET	01/01/2019	17.20	232.17	None	Innovator Multiple Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	https://reports.siera.oshpd.ca.gov/api/report/drug-pricing/attachment?id=232	For Column F there are no unexpired patents for this product per the Orange Book. Not acquired within the last five years.
Rx0000038	Boehringer Ingelheim	03/31/2019	00597012437	TWYNSTA 40-5 MG TABLET	01/01/2019	17.20	232.17	None	Innovator Multiple Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	https://reports.siera.oshpd.ca.gov/api/report/drug-pricing/attachment?id=231	For Column F there are no unexpired patents for this product per the Orange Book. Not acquired within the last five years.
Rx0000038	Boehringer Ingelheim	03/31/2019	00597012737	TWYNSTA 80-10 MG TABLET	01/01/2019	17.20	232.17	None	Innovator Multiple Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	https://reports.siera.oshpd.ca.gov/api/report/drug-pricing/attachment?id=234	For Column F there are no unexpired patents for this product per the Orange Book. Not acquired within the last five years.
Rx0000038	Boehringer Ingelheim	03/31/2019	00597012637	TWYNSTA 80-5 MG TABLET	01/01/2019	17.20	232.17	None	Innovator Multiple Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	https://reports.siera.oshpd.ca.gov/api/report/drug-pricing/attachment?id=233	For Column F there are no unexpired patents for this product per the Orange Book. Not acquired within the last five years.
Rx0000038	Boehringer Ingelheim	03/31/2019	00597004646	VIRAMUNE 200 MG TABLET	01/01/2019	11.97	211.43	None	Innovator Multiple Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	https://reports.siera.oshpd.ca.gov/api/report/drug-pricing/attachment?id=235	For Column F there are no unexpired patents for this product per the Orange Book. Not acquired within the last five years.
Rx0000038	Boehringer Ingelheim	03/31/2019	00597004660	VIRAMUNE 200 MG TABLET	01/01/2019	51.28	906.02	None	Innovator Multiple Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	https://reports.siera.oshpd.ca.gov/api/report/drug-pricing/attachment?id=236	For Column F there are no unexpired patents for this product per the Orange Book. Not acquired within the last five years.
Rx0000038	Boehringer Ingelheim	03/31/2019	00597004724	VIRAMUNE 50 MG/5 ML SUSP	01/01/2019	11.11	196.23	None	Innovator Multiple Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	https://reports.siera.oshpd.ca.gov/api/report/drug-pricing/attachment?id=237	For Column F there are no unexpired patents for this product per the Orange Book. Not acquired within the last five years.
Rx0000038	Boehringer Ingelheim	03/31/2019	00597012990	VIRAMUNE XR 100 MG TABLET	01/01/2019	47.57	840.32	None	Innovator Multiple Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	https://reports.siera.oshpd.ca.gov/api/report/drug-pricing/attachment?id=239	For Column F there are no unexpired patents for this product per the Orange Book. Not acquired within the last five years.
Rx0000038	Boehringer Ingelheim	03/31/2019	00597012330	VIRAMUNE XR 400 MG TABLET	01/01/2019	47.57	840.32	None	Innovator Multiple Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	https://reports.siera.oshpd.ca.gov/api/report/drug-pricing/attachment?id=238	For Column F there are no unexpired patents for this product per the Orange Book. Not acquired within the last five years.
Rx0000078	Bristol Myers Squibb	03/31/2019	00003089321	ELIQUIS (Apixaban) 2.5 MG Tablet, Bottle of 60 Tablets	01/01/2019	25.14	444.17	02/24/2031	Single Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	This product was developed by BMS
Rx0000078	Bristol Myers Squibb	03/31/2019	00003089331	ELIQUIS (Apixaban) 2.5 MG Tablet, Bottle x 100 Tablets	01/01/2019	41.91	740.34	02/24/2031	Single Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	This product was developed by BMS
Rx0000078	Bristol Myers Squibb	03/31/2019	00003089470	ELIQUIS (Apixaban) 5 MG Tablet Bottle of 74 Tablets	01/01/2019	31.01	547.82	02/24/2031	Single Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	This product was developed by BMS
Rx0000078	Bristol Myers Squibb	03/31/2019	00003376474	ELIQUIS (Apixaban) 5 MG Tablet, 74 Tablets (1 blister pack of 42 tablets and 1 blister pack of 32 tablets)	01/01/2019	31.01	547.82	02/24/2031	Single Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	This product was developed by BMS
Rx0000078	Bristol Myers Squibb	03/31/2019	00003089421	ELIQUIS (Apixaban) 5 MG Tablet, Bottle of 60 Tablets	01/01/2019	25.14	444.17	02/24/2031	Single Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	This product was developed by BMS
Rx0000078	Bristol Myers Squibb	03/31/2019	00003089431	ELIQUIS (Apixaban) 5 MG Tablet, Hospital Unit-Dose Blister Package of 100	01/01/2019	41.91	740.34	02/24/2031	Single Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	This product was developed by BMS
Rx0000078	Bristol Myers Squibb	03/31/2019	00003218851	ORENCIA (Abatacept) 125 MG/ML Solution, 1ML Single Dose Prefilled Auto-injector, Package of 4 Auto-Injectors	01/01/2019	247.86	4378.89	02/18/2018	Single Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	This product was developed by BMS
Rx0000078	Bristol Myers Squibb	03/31/2019	00003218811	ORENCIA (Abatacept) 125 MG/ML Solution, 1ml Single Dose Prefilled Syringe Package of 4 Syringes	01/01/2019	247.86	4378.89	02/18/2018	Single Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	This product was developed by BMS
Rx0000078	Bristol Myers Squibb	03/31/2019	00003218710	ORENCIA (Abatacept) 250 MG Solution Vial W/ Syringe, Package contains 1 Vial	01/01/2019	62.78	1109.03	02/18/2018	Single Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	This product was developed by BMS
Rx0000078	Bristol Myers Squibb	03/31/2019	00003281411	ORENCIA (Abatacept) 50 MG/0.4ML Solution, 0.4ML Single Dose Prefilled Syringe, Package of 4 Syringes	01/01/2019	247.86	4378.89	02/18/2018	Single Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	This product was developed by BMS
Rx0000078	Bristol Myers Squibb	03/31/2019	00003281811	ORENCIA (Abatacept) 87.5 MG/0.7ML Solution, 0.7ML Single Dose Prefilled Syringe, Package of 4 Syringes	01/01/2019	247.86	4378.89	02/18/2018	Single Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	This product was developed by BMS
Rx0000078	Bristol Myers Squibb	03/31/2019	00003085222	SPRYCEL (Dasatinib) 100 MG Tablet, Bottle of 30 Tablets	01/01/2019	774.72	13686.79	09/28/2026	Single Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	This product was developed by BMS
Rx0000078	Bristol Myers Squibb	03/31/2019	00003085722	SPRYCEL (Dasatinib) 140 MG Tablet, Bottle of 30 Tablets	01/01/2019	774.72	13686.79	09/28/2026	Single Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	This product was developed by BMS
Rx0000078	Bristol Myers Squibb	03/31/2019	00003052711	SPRYCEL (Dasatinib) 20 MG Tablet, Bottle of 60 Tablets	01/01/2019	429.85	7593.95	09/28/2026	Single Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	This product was developed by BMS
Rx0000078	Bristol Myers Squibb	03/31/2019	00003052811	SPRYCEL (Dasatinib) 50 MG Tablet, Bottle of 60 Tablets	01/01/2019	859.69	15187.87	09/28/2026	Single Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	This product was developed by BMS
Rx0000078	Bristol Myers Squibb	03/31/2019	00003052411	SPRYCEL (Dasatinib) 70 MG Tablet, Bottle of 60 Tablets	01/01/2019	859.69	15187.87	09/28/2026	Single Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	This product was developed by BMS
Rx0000078	Bristol Myers Squibb	03/31/2019	00003085522	SPRYCEL (Dasatinib) 80 MG Tablet, Bottle of 30 Tablets	01/01/2019	774.72	13686.79	09/28/2026	Single Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	This product was developed by BMS
Rx0000137	Celgene	03/31/2019	59572063255	Apremilast 10 & 20 & 30 MG Tablet Therapy Pack 55 EA UU	01/03/2019	114.91	3398.00	05/29/2034	Single Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	The information contained in this report is subject to the following limitations and assumptions: (1) Consistent with the relevant statutes and regulations, all information contained in this report is limited to that which Celgene believes is otherwise in the public domain or publicly available. (2) The patent expiration date contained in this report is limited to the patent information reported in the federal Food and Drug Administration’s Orange Book, as of September 27th, 2019. As a result, the reported patent expiration date is limited to issued U.S. patents. Further, the reported patent expiration date does not reflect any pending patents, patent term extensions, pediatric exclusivity, or patent-related litigation, each of which is speculative and which may extend or shorten the reported expiration date. (3) Celgene did not acquire this product from another manufacturer within the previous five years. As a result, Celgene has left columns 14-22 blank because they are not applicable to this product. In 2018, total U.S. sales for Otezla were $1.275 billion.
Rx0000137	Celgene	03/31/2019	59572063106	Apremilast 30 MG Tablet 60 EA	01/03/2019	114.91	3398.00	05/29/2034	Single Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	The information contained in this report is subject to the following limitations and assumptions: (1) Consistent with the relevant statutes and regulations, all information contained in this report is limited to that which Celgene believes is otherwise in the public domain or publicly available. (2) The patent expiration date contained in this report is limited to the patent information reported in the federal Food and Drug Administration’s Orange Book, as of September 27th, 2019. As a result, the reported patent expiration date is limited to issued U.S. patents. Further, the reported patent expiration date does not reflect any pending patents, patent term extensions, pediatric exclusivity, or patent-related litigation, each of which is speculative and which may extend or shorten the reported expiration date. (3) Celgene did not acquire this product from another manufacturer within the previous five years. As a result, Celgene has left columns 14-22 blank because they are not applicable to this product. In 2018, total U.S. sales for Otezla were $1.275 billion.
Rx0000137	Celgene	03/31/2019	59572041000	Lenalidomide 10 MG Capsule 100 EA	01/03/2019	2434.17	71981.98	03/08/2028	Single Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	The information contained in this report is subject to the following limitations and assumptions: (1) Consistent with the relevant statutes and regulations, all information contained in this report is limited to that which Celgene believes is otherwise in the public domain or publicly available. (2) The patent expiration date contained in this report is limited to the patent information reported in the federal Food and Drug Administration’s Orange Book, as of September 27th, 2019. As a result, the reported patent expiration date is limited to issued U.S. patents. Further, the reported patent expiration date does not reflect any pending patents, patent term extensions, pediatric exclusivity, or patent-related litigation, each of which is speculative and which may extend or shorten the reported expiration date. (3) Celgene did not acquire this product from another manufacturer within the previous five years. As a result, Celgene has left columns 14-22 blank because they are not applicable to this product. In 2018, total U.S. sales for Revlimid were $6.469 billion.
Rx0000137	Celgene	03/31/2019	59572041028	Lenalidomide 10 MG Capsule 28 EA	01/03/2019	681.57	20154.94	03/08/2028	Single Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	The information contained in this report is subject to the following limitations and assumptions: (1) Consistent with the relevant statutes and regulations, all information contained in this report is limited to that which Celgene believes is otherwise in the public domain or publicly available. (2) The patent expiration date contained in this report is limited to the patent information reported in the federal Food and Drug Administration’s Orange Book, as of September 27th, 2019. As a result, the reported patent expiration date is limited to issued U.S. patents. Further, the reported patent expiration date does not reflect any pending patents, patent term extensions, pediatric exclusivity, or patent-related litigation, each of which is speculative and which may extend or shorten the reported expiration date. (3) Celgene did not acquire this product from another manufacturer within the previous five years. As a result, Celgene has left columns 14-22 blank because they are not applicable to this product. In 2018, total U.S. sales for Revlimid were $6.469 billion.
Rx0000137	Celgene	03/31/2019	59572041500	Lenalidomide 15 MG Capsule 100 EA	01/03/2019	2434.17	71981.98	03/08/2028	Single Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	The information contained in this report is subject to the following limitations and assumptions: (1) Consistent with the relevant statutes and regulations, all information contained in this report is limited to that which Celgene believes is otherwise in the public domain or publicly available. (2) The patent expiration date contained in this report is limited to the patent information reported in the federal Food and Drug Administration’s Orange Book, as of September 27th, 2019. As a result, the reported patent expiration date is limited to issued U.S. patents. Further, the reported patent expiration date does not reflect any pending patents, patent term extensions, pediatric exclusivity, or patent-related litigation, each of which is speculative and which may extend or shorten the reported expiration date. (3) Celgene did not acquire this product from another manufacturer within the previous five years. As a result, Celgene has left columns 14-22 blank because they are not applicable to this product. In 2018, total U.S. sales for Revlimid were $6.469 billion.
Rx0000137	Celgene	03/31/2019	59572041521	Lenalidomide 15 MG Capsule 21 EA	01/03/2019	511.18	15116.23	03/08/2028	Single Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	The information contained in this report is subject to the following limitations and assumptions: (1) Consistent with the relevant statutes and regulations, all information contained in this report is limited to that which Celgene believes is otherwise in the public domain or publicly available. (2) The patent expiration date contained in this report is limited to the patent information reported in the federal Food and Drug Administration’s Orange Book, as of September 27th, 2019. As a result, the reported patent expiration date is limited to issued U.S. patents. Further, the reported patent expiration date does not reflect any pending patents, patent term extensions, pediatric exclusivity, or patent-related litigation, each of which is speculative and which may extend or shorten the reported expiration date. (3) Celgene did not acquire this product from another manufacturer within the previous five years. As a result, Celgene has left columns 14-22 blank because they are not applicable to this product. In 2018, total U.S. sales for Revlimid were $6.469 billion.
Rx0000137	Celgene	03/31/2019	59572040200	Lenalidomide 2.5 MG Capsule 100 EA	01/03/2019	2434.17	71981.98	03/08/2028	Single Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	The information contained in this report is subject to the following limitations and assumptions: (1) Consistent with the relevant statutes and regulations, all information contained in this report is limited to that which Celgene believes is otherwise in the public domain or publicly available. (2) The patent expiration date contained in this report is limited to the patent information reported in the federal Food and Drug Administration’s Orange Book, as of September 27th, 2019. As a result, the reported patent expiration date is limited to issued U.S. patents. Further, the reported patent expiration date does not reflect any pending patents, patent term extensions, pediatric exclusivity, or patent-related litigation, each of which is speculative and which may extend or shorten the reported expiration date. (3) Celgene did not acquire this product from another manufacturer within the previous five years. As a result, Celgene has left columns 14-22 blank because they are not applicable to this product. In 2018, total U.S. sales for Revlimid were $6.469 billion.
Rx0000137	Celgene	03/31/2019	59572040228	Lenalidomide 2.5 MG Capsule 28 EA	01/03/2019	681.57	20154.94	03/08/2028	Single Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	The information contained in this report is subject to the following limitations and assumptions: (1) Consistent with the relevant statutes and regulations, all information contained in this report is limited to that which Celgene believes is otherwise in the public domain or publicly available. (2) The patent expiration date contained in this report is limited to the patent information reported in the federal Food and Drug Administration’s Orange Book, as of September 27th, 2019. As a result, the reported patent expiration date is limited to issued U.S. patents. Further, the reported patent expiration date does not reflect any pending patents, patent term extensions, pediatric exclusivity, or patent-related litigation, each of which is speculative and which may extend or shorten the reported expiration date. (3) Celgene did not acquire this product from another manufacturer within the previous five years. As a result, Celgene has left columns 14-22 blank because they are not applicable to this product. In 2018, total U.S. sales for Revlimid were $6.469 billion.
Rx0000137	Celgene	03/31/2019	59572042000	Lenalidomide 20 MG Capsule 100 EA	01/03/2019	2434.17	71981.98	03/08/2028	Single Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	The information contained in this report is subject to the following limitations and assumptions: (1) Consistent with the relevant statutes and regulations, all information contained in this report is limited to that which Celgene believes is otherwise in the public domain or publicly available. (2) The patent expiration date contained in this report is limited to the patent information reported in the federal Food and Drug Administration’s Orange Book, as of September 27th, 2019. As a result, the reported patent expiration date is limited to issued U.S. patents. Further, the reported patent expiration date does not reflect any pending patents, patent term extensions, pediatric exclusivity, or patent-related litigation, each of which is speculative and which may extend or shorten the reported expiration date. (3) Celgene did not acquire this product from another manufacturer within the previous five years. As a result, Celgene has left columns 14-22 blank because they are not applicable to this product. In 2018, total U.S. sales for Revlimid were $6.469 billion.
Rx0000137	Celgene	03/31/2019	59572042021	Lenalidomide 20 MG Capsule 21 EA	01/03/2019	511.18	15116.23	03/08/2028	Single Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	The information contained in this report is subject to the following limitations and assumptions: (1) Consistent with the relevant statutes and regulations, all information contained in this report is limited to that which Celgene believes is otherwise in the public domain or publicly available. (2) The patent expiration date contained in this report is limited to the patent information reported in the federal Food and Drug Administration’s Orange Book, as of September 27th, 2019. As a result, the reported patent expiration date is limited to issued U.S. patents. Further, the reported patent expiration date does not reflect any pending patents, patent term extensions, pediatric exclusivity, or patent-related litigation, each of which is speculative and which may extend or shorten the reported expiration date. (3) Celgene did not acquire this product from another manufacturer within the previous five years. As a result, Celgene has left columns 14-22 blank because they are not applicable to this product. In 2018, total U.S. sales for Revlimid were $6.469 billion.
Rx0000137	Celgene	03/31/2019	59572042500	Lenalidomide 25 MG Capsule 100 EA	01/03/2019	2434.17	71981.98	03/08/2028	Single Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	The information contained in this report is subject to the following limitations and assumptions: (1) Consistent with the relevant statutes and regulations, all information contained in this report is limited to that which Celgene believes is otherwise in the public domain or publicly available. (2) The patent expiration date contained in this report is limited to the patent information reported in the federal Food and Drug Administration’s Orange Book, as of September 27th, 2019. As a result, the reported patent expiration date is limited to issued U.S. patents. Further, the reported patent expiration date does not reflect any pending patents, patent term extensions, pediatric exclusivity, or patent-related litigation, each of which is speculative and which may extend or shorten the reported expiration date. (3) Celgene did not acquire this product from another manufacturer within the previous five years. As a result, Celgene has left columns 14-22 blank because they are not applicable to this product. In 2018, total U.S. sales for Revlimid were $6.469 billion.
Rx0000137	Celgene	03/31/2019	59572042521	Lenalidomide 25 MG Capsule 21 EA	01/03/2019	511.18	15116.23	03/08/2028	Single Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	The information contained in this report is subject to the following limitations and assumptions: (1) Consistent with the relevant statutes and regulations, all information contained in this report is limited to that which Celgene believes is otherwise in the public domain or publicly available. (2) The patent expiration date contained in this report is limited to the patent information reported in the federal Food and Drug Administration’s Orange Book, as of September 27th, 2019. As a result, the reported patent expiration date is limited to issued U.S. patents. Further, the reported patent expiration date does not reflect any pending patents, patent term extensions, pediatric exclusivity, or patent-related litigation, each of which is speculative and which may extend or shorten the reported expiration date. (3) Celgene did not acquire this product from another manufacturer within the previous five years. As a result, Celgene has left columns 14-22 blank because they are not applicable to this product. In 2018, total U.S. sales for Revlimid were $6.469 billion.
Rx0000137	Celgene	03/31/2019	59572040500	Lenalidomide 5 MG Capsule 100 EA	01/03/2019	2434.17	71981.98	03/08/2028	Single Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	The information contained in this report is subject to the following limitations and assumptions: (1) Consistent with the relevant statutes and regulations, all information contained in this report is limited to that which Celgene believes is otherwise in the public domain or publicly available. (2) The patent expiration date contained in this report is limited to the patent information reported in the federal Food and Drug Administration’s Orange Book, as of September 27th, 2019. As a result, the reported patent expiration date is limited to issued U.S. patents. Further, the reported patent expiration date does not reflect any pending patents, patent term extensions, pediatric exclusivity, or patent-related litigation, each of which is speculative and which may extend or shorten the reported expiration date. (3) Celgene did not acquire this product from another manufacturer within the previous five years. As a result, Celgene has left columns 14-22 blank because they are not applicable to this product. In 2018, total U.S. sales for Revlimid were $6.469 billion.
Rx0000137	Celgene	03/31/2019	59572040528	Lenalidomide 5 MG Capsule 28 EA	01/03/2019	681.57	20154.94	03/08/2028	Single Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	The information contained in this report is subject to the following limitations and assumptions: (1) Consistent with the relevant statutes and regulations, all information contained in this report is limited to that which Celgene believes is otherwise in the public domain or publicly available. (2) The patent expiration date contained in this report is limited to the patent information reported in the federal Food and Drug Administration’s Orange Book, as of September 27th, 2019. As a result, the reported patent expiration date is limited to issued U.S. patents. Further, the reported patent expiration date does not reflect any pending patents, patent term extensions, pediatric exclusivity, or patent-related litigation, each of which is speculative and which may extend or shorten the reported expiration date. (3) Celgene did not acquire this product from another manufacturer within the previous five years. As a result, Celgene has left columns 14-22 blank because they are not applicable to this product. In 2018, total U.S. sales for Revlimid were $6.469 billion.
Rx0000137	Celgene	03/31/2019	68817013450	Paclitaxel Protein-Bound Particles 100 MG Suspension Reconstituted 1 EA UD	01/03/2019	46.60	1378.01	01/12/2034	Single Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	The information contained in this report is subject to the following limitations and assumptions: (1) Consistent with the relevant statutes and regulations, all information contained in this report is limited to that which Celgene believes is otherwise in the public domain or publicly available. (2) The patent expiration date contained in this report is limited to the patent information reported in the federal Food and Drug Administration’s Orange Book, as of September 27th, 2019. As a result, the reported patent expiration date is limited to issued U.S. patents. Further, the reported patent expiration date does not reflect any pending patents, patent term extensions, pediatric exclusivity, or patent-related litigation, each of which is speculative and which may extend or shorten the reported expiration date. (3) Celgene did not acquire this product from another manufacturer within the previous five years. As a result, Celgene has left columns 14-22 blank because they are not applicable to this product. In 2018, total U.S. sales for Abraxane was $663 million.
Rx0000137	Celgene	03/31/2019	59572050100	Pomalidomide 1 MG Capsule 100 EA	01/03/2019	2770.79	81936.32	06/21/2031	Single Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	The information contained in this report is subject to the following limitations and assumptions: (1) Consistent with the relevant statutes and regulations, all information contained in this report is limited to that which Celgene believes is otherwise in the public domain or publicly available. (2) The patent expiration date contained in this report is limited to the patent information reported in the federal Food and Drug Administration’s Orange Book, as of September 27th, 2019. As a result, the reported patent expiration date is limited to issued U.S. patents. Further, the reported patent expiration date does not reflect any pending patents, patent term extensions, pediatric exclusivity, or patent-related litigation, each of which is speculative and which may extend or shorten the reported expiration date. (3) Celgene did not acquire this product from another manufacturer within the previous five years. As a result, Celgene has left columns 14-22 blank because they are not applicable to this product. In 2018, total U.S. sales for Pomalyst were $1.391 billion.
Rx0000137	Celgene	03/31/2019	59572050121	Pomalidomide 1 MG Capsule 21 EA	01/03/2019	581.87	17206.63	06/21/2031	Single Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	The information contained in this report is subject to the following limitations and assumptions: (1) Consistent with the relevant statutes and regulations, all information contained in this report is limited to that which Celgene believes is otherwise in the public domain or publicly available. (2) The patent expiration date contained in this report is limited to the patent information reported in the federal Food and Drug Administration’s Orange Book, as of September 27th, 2019. As a result, the reported patent expiration date is limited to issued U.S. patents. Further, the reported patent expiration date does not reflect any pending patents, patent term extensions, pediatric exclusivity, or patent-related litigation, each of which is speculative and which may extend or shorten the reported expiration date. (3) Celgene did not acquire this product from another manufacturer within the previous five years. As a result, Celgene has left columns 14-22 blank because they are not applicable to this product. In 2018, total U.S. sales for Pomalyst were $1.391 billion.
Rx0000137	Celgene	03/31/2019	59572050200	Pomalidomide 2 MG Capsule 100 EA	01/03/2019	2770.79	81936.32	06/21/2031	Single Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	The information contained in this report is subject to the following limitations and assumptions: (1) Consistent with the relevant statutes and regulations, all information contained in this report is limited to that which Celgene believes is otherwise in the public domain or publicly available. (2) The patent expiration date contained in this report is limited to the patent information reported in the federal Food and Drug Administration’s Orange Book, as of September 27th, 2019. As a result, the reported patent expiration date is limited to issued U.S. patents. Further, the reported patent expiration date does not reflect any pending patents, patent term extensions, pediatric exclusivity, or patent-related litigation, each of which is speculative and which may extend or shorten the reported expiration date. (3) Celgene did not acquire this product from another manufacturer within the previous five years. As a result, Celgene has left columns 14-22 blank because they are not applicable to this product. In 2018, total U.S. sales for Pomalyst were $1.391 billion.
Rx0000137	Celgene	03/31/2019	59572050221	Pomalidomide 2 MG Capsule 21 EA	01/03/2019	581.87	17206.63	06/21/2031	Single Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	The information contained in this report is subject to the following limitations and assumptions: (1) Consistent with the relevant statutes and regulations, all information contained in this report is limited to that which Celgene believes is otherwise in the public domain or publicly available. (2) The patent expiration date contained in this report is limited to the patent information reported in the federal Food and Drug Administration’s Orange Book, as of September 27th, 2019. As a result, the reported patent expiration date is limited to issued U.S. patents. Further, the reported patent expiration date does not reflect any pending patents, patent term extensions, pediatric exclusivity, or patent-related litigation, each of which is speculative and which may extend or shorten the reported expiration date. (3) Celgene did not acquire this product from another manufacturer within the previous five years. As a result, Celgene has left columns 14-22 blank because they are not applicable to this product. In 2018, total U.S. sales for Pomalyst were $1.391 billion.
Rx0000137	Celgene	03/31/2019	59572050300	Pomalidomide 3 MG Capsule 100 EA	01/03/2019	2770.79	81936.32	06/21/2031	Single Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	The information contained in this report is subject to the following limitations and assumptions: (1) Consistent with the relevant statutes and regulations, all information contained in this report is limited to that which Celgene believes is otherwise in the public domain or publicly available. (2) The patent expiration date contained in this report is limited to the patent information reported in the federal Food and Drug Administration’s Orange Book, as of September 27th, 2019. As a result, the reported patent expiration date is limited to issued U.S. patents. Further, the reported patent expiration date does not reflect any pending patents, patent term extensions, pediatric exclusivity, or patent-related litigation, each of which is speculative and which may extend or shorten the reported expiration date. (3) Celgene did not acquire this product from another manufacturer within the previous five years. As a result, Celgene has left columns 14-22 blank because they are not applicable to this product. In 2018, total U.S. sales for Pomalyst were $1.391 billion.
Rx0000137	Celgene	03/31/2019	59572050321	Pomalidomide 3 MG Capsule 21 EA	01/03/2019	581.87	17206.63	06/21/2031	Single Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	The information contained in this report is subject to the following limitations and assumptions: (1) Consistent with the relevant statutes and regulations, all information contained in this report is limited to that which Celgene believes is otherwise in the public domain or publicly available. (2) The patent expiration date contained in this report is limited to the patent information reported in the federal Food and Drug Administration’s Orange Book, as of September 27th, 2019. As a result, the reported patent expiration date is limited to issued U.S. patents. Further, the reported patent expiration date does not reflect any pending patents, patent term extensions, pediatric exclusivity, or patent-related litigation, each of which is speculative and which may extend or shorten the reported expiration date. (3) Celgene did not acquire this product from another manufacturer within the previous five years. As a result, Celgene has left columns 14-22 blank because they are not applicable to this product. In 2018, total U.S. sales for Pomalyst were $1.391 billion.
Rx0000137	Celgene	03/31/2019	59572050400	Pomalidomide 4 MG Capsule 100 EA	01/03/2019	2770.79	81936.32	06/21/2031	Single Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	The information contained in this report is subject to the following limitations and assumptions: (1) Consistent with the relevant statutes and regulations, all information contained in this report is limited to that which Celgene believes is otherwise in the public domain or publicly available. (2) The patent expiration date contained in this report is limited to the patent information reported in the federal Food and Drug Administration’s Orange Book, as of September 27th, 2019. As a result, the reported patent expiration date is limited to issued U.S. patents. Further, the reported patent expiration date does not reflect any pending patents, patent term extensions, pediatric exclusivity, or patent-related litigation, each of which is speculative and which may extend or shorten the reported expiration date. (3) Celgene did not acquire this product from another manufacturer within the previous five years. As a result, Celgene has left columns 14-22 blank because they are not applicable to this product. In 2018, total U.S. sales for Pomalyst were $1.391 billion.
Rx0000137	Celgene	03/31/2019	59572050421	Pomalidomide 4 MG Capsule 21 EA	01/03/2019	581.87	17206.63	06/21/2031	Single Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	The information contained in this report is subject to the following limitations and assumptions: (1) Consistent with the relevant statutes and regulations, all information contained in this report is limited to that which Celgene believes is otherwise in the public domain or publicly available. (2) The patent expiration date contained in this report is limited to the patent information reported in the federal Food and Drug Administration’s Orange Book, as of September 27th, 2019. As a result, the reported patent expiration date is limited to issued U.S. patents. Further, the reported patent expiration date does not reflect any pending patents, patent term extensions, pediatric exclusivity, or patent-related litigation, each of which is speculative and which may extend or shorten the reported expiration date. (3) Celgene did not acquire this product from another manufacturer within the previous five years. As a result, Celgene has left columns 14-22 blank because they are not applicable to this product. In 2018, total U.S. sales for Pomalyst were $1.391 billion.
Rx0000080	Cipla USA, Inc.	06/30/2019	69097080540	AZACITIDINE FOR INJ 100MG/VIAL	04/16/2019	105.00	210.00	None	Non-innovator Multiple Source Drug	27696	None	This product was not launched into the market until after the WAC change on 4/16/2020. Therefore, there was no product sold into the market at the old WAC. The WAC change was a result of further market analysis prior to launch.	None	There was no significant change or improvement to this drug	None	None	None	None	None	None	None	None	None	None	None	Not Acquired
Rx0000080	Cipla USA, Inc.	03/31/2019	69097086283	Calcium Acetate Tablet	03/04/2019	29.03	120.00	None	Non-innovator Multiple Source Drug	9394000	None	Increase in API Cost	None	Increase in API Cost	None	None	None	None	None	None	None	None	None	None	https://reports.siera.oshpd.ca.gov/api/report/drug-pricing/attachment?id=27	None
Rx0000146	Circassia Pharmaceuticals	09/30/2019	72124000202	Tudorza Pressair Inhalation Powder 400mcg 30 actuations	07/01/2019	84.12	260.00	03/13/2029	Single Source Drug	None	1	None	1	None	1	06/17/2019	AstraZeneca	218840450	None	The acquisition price amount entered reflects the price of a combination portfolio acquisition which includes future royalties based on estimated sales.	175.88	170.75	2015	140.70	None	Circassia Pharmaceuticals acquired the rights to Tudorza Pressair from AstraZeneca effective 7/1/19. The WAC effective date reported by MediSpan (6/28/19) reflects the date Circassia listed the price of Tudorza to ensure Circassia met the quarterly administrative timeline updates that are performed by the pricing agencies. Circassia wanted to ensure that this information was available for the new NDC and new WAC effective, July 1st, however, Tudorza under the new NDC was not visible in wholesaler order systems nor available to customers for purchase until 7/1/19. Please let us know if you have additional questions regarding this issue. As previously stated, effective 7/1/19, Circassia Pharmaceuticals acquired Tudorza Pressair from AstraZeneca. Prior to 7/1/19, the NDC, owned by AstraZeneca, was 00310-0800-39. Beginning 7/1/19, the NDC, owned by Circassia, is 72124-0002-02.
Rx0000146	Circassia Pharmaceuticals	09/30/2019	72124000201	Tudorza Pressair Inhalation Powder 400mcg 60 actuations	07/01/2019	168.25	520.00	03/13/2029	Single Source Drug	None	1	None	1	None	1	06/17/2019	AstraZeneca	218840450	None	The acquisition price amount entered reflects the price of a combination portfolio acquisition which includes future royalties based on estimated sales.	351.75	341.51	2015	281.40	None	Circassia Pharmaceuticals acquired the rights to Tudorza Pressair from AstraZeneca effective 7/1/19. The WAC effective date reported by MediSpan (6/28/19) reflects the date Circassia listed the price of Tudorza to ensure Circassia met the quarterly administrative timeline updates that are performed by the pricing agencies. Circassia wanted to ensure that this information was available for the new NDC and new WAC effective, July 1st, however, Tudorza under the new NDC was not visible in wholesaler order systems nor available to customers for purchase until 7/1/19. Please let us know if you have additional questions regarding this issue. As previously stated, effective 7/1/19, Circassia Pharmaceuticals acquired Tudorza Pressair from AstraZeneca. Prior to 7/1/19, the NDC, owned by AstraZeneca, was 00310-0800-60. Beginning 7/1/19, the NDC, owned by Circassia, is 72124-0002-01.
Rx0000320	CMP Pharma	12/31/2019	46287002004	CaroSpir spironolactone oral suspension 25mg/5ml 18ml	10/01/2019	26.50	320.80	10/28/2036	Single Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	None
Rx0000320	CMP Pharma	12/31/2019	46287002001	CaroSpir spironolactone oral suspension 25mg/5ml 473ml	10/01/2019	95.30	1154.80	10/28/2036	Single Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	None
Rx0000320	CMP Pharma	12/31/2019	46287000604	Sodium Polystyrene Suspension 120ml enema kit	11/01/2019	38.30	78.80	None	Non-innovator Multiple Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	None
Rx0000320	CMP Pharma	12/31/2019	46287000601	Sodium Polystyrene Suspension 473ml	11/01/2019	64.60	132.60	None	Non-innovator Multiple Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	None
Rx0000320	CMP Pharma	12/31/2019	46287000660	Sodium Polystyrene Suspension 60ml unit dose X 10	11/01/2019	85.40	175.40	None	Non-innovator Multiple Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	None
Rx0000200	Collegium Pharmaceuticals	03/31/2019	69865024502	NUCYNTA ER-100MG-100 TABLET	01/01/2019	75.26	760.20	09/22/2028	Single Source Drug	None	1	We have never been profitable and have incurred net losses in each year since inception.  Xtampza ER is an abuse-deterrent, extended-release, oral formulation of oxycodone approved by the FDA in April 2016 for the management of pain severe enough to require daily, around-the-clock, long-term opioid treatment and for which alternative treatment options are inadequate. Substantially all of our net losses resulted from costs incurred from research and development programs to obtain and maintain regulatory approval for Xtampza ER, and from selling, general and administrative costs associated with our operations.  These factors, along with the increasing demands for rebates in order to provide improved access to patients, were considered in deciding to increase the wholesale acquisition cost of Xtampza ER.	None	None	1	None	None	None	None	None	None	None	None	None	None	None
Rx0000200	Collegium Pharmaceuticals	03/31/2019	69865025002	NUCYNTA ER-150MG-100 TABLET	01/01/2019	97.10	980.79	09/22/2028	Single Source Drug	None	1	We have never been profitable and have incurred net losses in each year since inception.  Xtampza ER is an abuse-deterrent, extended-release, oral formulation of oxycodone approved by the FDA in April 2016 for the management of pain severe enough to require daily, around-the-clock, long-term opioid treatment and for which alternative treatment options are inadequate. Substantially all of our net losses resulted from costs incurred from research and development programs to obtain and maintain regulatory approval for Xtampza ER, and from selling, general and administrative costs associated with our operations.  These factors, along with the increasing demands for rebates in order to provide improved access to patients, were considered in deciding to increase the wholesale acquisition cost of Xtampza ER.	None	None	1	None	None	None	None	None	None	None	None	None	None	None
Rx0000200	Collegium Pharmaceuticals	03/31/2019	69865026002	NUCYNTA ER-200MG-100 TABLET	01/01/2019	123.26	1245.06	09/22/2028	Single Source Drug	None	1	We have never been profitable and have incurred net losses in each year since inception.  Xtampza ER is an abuse-deterrent, extended-release, oral formulation of oxycodone approved by the FDA in April 2016 for the management of pain severe enough to require daily, around-the-clock, long-term opioid treatment and for which alternative treatment options are inadequate. Substantially all of our net losses resulted from costs incurred from research and development programs to obtain and maintain regulatory approval for Xtampza ER, and from selling, general and administrative costs associated with our operations.  These factors, along with the increasing demands for rebates in order to provide improved access to patients, were considered in deciding to increase the wholesale acquisition cost of Xtampza ER.	None	None	1	None	None	None	None	None	None	None	None	None	None	None
Rx0000200	Collegium Pharmaceuticals	03/31/2019	69865026501	NUCYNTA ER-250MG-100 TABLET	01/01/2019	154.21	1557.70	09/22/2028	Single Source Drug	None	1	We have never been profitable and have incurred net losses in each year since inception.  Xtampza ER is an abuse-deterrent, extended-release, oral formulation of oxycodone approved by the FDA in April 2016 for the management of pain severe enough to require daily, around-the-clock, long-term opioid treatment and for which alternative treatment options are inadequate. Substantially all of our net losses resulted from costs incurred from research and development programs to obtain and maintain regulatory approval for Xtampza ER, and from selling, general and administrative costs associated with our operations.  These factors, along with the increasing demands for rebates in order to provide improved access to patients, were considered in deciding to increase the wholesale acquisition cost of Xtampza ER.	None	None	1	None	None	None	None	None	None	None	None	None	None	None
Rx0000200	Collegium Pharmaceuticals	03/31/2019	69865024002	NUCYNTA ER-50MG-100 TABLET	01/01/2019	40.69	411.05	09/22/2028	Single Source Drug	None	1	We have never been profitable and have incurred net losses in each year since inception.  Xtampza ER is an abuse-deterrent, extended-release, oral formulation of oxycodone approved by the FDA in April 2016 for the management of pain severe enough to require daily, around-the-clock, long-term opioid treatment and for which alternative treatment options are inadequate. Substantially all of our net losses resulted from costs incurred from research and development programs to obtain and maintain regulatory approval for Xtampza ER, and from selling, general and administrative costs associated with our operations.  These factors, along with the increasing demands for rebates in order to provide improved access to patients, were considered in deciding to increase the wholesale acquisition cost of Xtampza ER.	None	None	1	None	None	None	None	None	None	None	None	None	None	None
Rx0000200	Collegium Pharmaceuticals	03/31/2019	69865023002	NUCYNTA IR-100MG-100 TABLET	01/01/2019	98.07	990.64	06/27/2025	Single Source Drug	None	1	We have never been profitable and have incurred net losses in each year since inception.  Xtampza ER is an abuse-deterrent, extended-release, oral formulation of oxycodone approved by the FDA in April 2016 for the management of pain severe enough to require daily, around-the-clock, long-term opioid treatment and for which alternative treatment options are inadequate. Substantially all of our net losses resulted from costs incurred from research and development programs to obtain and maintain regulatory approval for Xtampza ER, and from selling, general and administrative costs associated with our operations.  These factors, along with the increasing demands for rebates in order to provide improved access to patients, were considered in deciding to increase the wholesale acquisition cost of Xtampza ER.	None	None	1	None	None	None	None	None	None	None	None	None	None	None
Rx0000200	Collegium Pharmaceuticals	03/31/2019	69865021002	NUCYNTA IR-50MG-100 TABLET	01/01/2019	62.98	636.15	06/27/2025	Single Source Drug	None	1	We have never been profitable and have incurred net losses in each year since inception.  Xtampza ER is an abuse-deterrent, extended-release, oral formulation of oxycodone approved by the FDA in April 2016 for the management of pain severe enough to require daily, around-the-clock, long-term opioid treatment and for which alternative treatment options are inadequate. Substantially all of our net losses resulted from costs incurred from research and development programs to obtain and maintain regulatory approval for Xtampza ER, and from selling, general and administrative costs associated with our operations.  These factors, along with the increasing demands for rebates in order to provide improved access to patients, were considered in deciding to increase the wholesale acquisition cost of Xtampza ER.	None	None	1	None	None	None	None	None	None	None	None	None	None	None
Rx0000200	Collegium Pharmaceuticals	03/31/2019	69865022002	NUCYNTA IR-75MG-100 TABLET	01/01/2019	73.58	743.28	06/27/2025	Single Source Drug	None	1	We have never been profitable and have incurred net losses in each year since inception.  Xtampza ER is an abuse-deterrent, extended-release, oral formulation of oxycodone approved by the FDA in April 2016 for the management of pain severe enough to require daily, around-the-clock, long-term opioid treatment and for which alternative treatment options are inadequate. Substantially all of our net losses resulted from costs incurred from research and development programs to obtain and maintain regulatory approval for Xtampza ER, and from selling, general and administrative costs associated with our operations.  These factors, along with the increasing demands for rebates in order to provide improved access to patients, were considered in deciding to increase the wholesale acquisition cost of Xtampza ER.	None	None	1	None	None	None	None	None	None	None	None	None	None	None
Rx0000200	Collegium Pharmaceuticals	03/31/2019	24510011510	XTAMPZA ER-13.5MG-100 CAPSULES	01/01/2019	59.09	655.98	09/02/2036	Single Source Drug	None	1	We have never been profitable and have incurred net losses in each year since inception.  Xtampza ER is an abuse-deterrent, extended-release, oral formulation of oxycodone approved by the FDA in April 2016 for the management of pain severe enough to require daily, around-the-clock, long-term opioid treatment and for which alternative treatment options are inadequate. Substantially all of our net losses resulted from costs incurred from research and development programs to obtain and maintain regulatory approval for Xtampza ER, and from selling, general and administrative costs associated with our operations.  These factors, along with the increasing demands for rebates in order to provide improved access to patients, were considered in deciding to increase the wholesale acquisition cost of Xtampza ER.	None	None	1	None	None	None	None	None	None	None	None	None	None	None
Rx0000200	Collegium Pharmaceuticals	03/31/2019	24510012010	XTAMPZA ER-18MG-100 CAPSULES	01/01/2019	74.94	831.89	09/02/2036	Single Source Drug	None	1	We have never been profitable and have incurred net losses in each year since inception.  Xtampza ER is an abuse-deterrent, extended-release, oral formulation of oxycodone approved by the FDA in April 2016 for the management of pain severe enough to require daily, around-the-clock, long-term opioid treatment and for which alternative treatment options are inadequate. Substantially all of our net losses resulted from costs incurred from research and development programs to obtain and maintain regulatory approval for Xtampza ER, and from selling, general and administrative costs associated with our operations.  These factors, along with the increasing demands for rebates in order to provide improved access to patients, were considered in deciding to increase the wholesale acquisition cost of Xtampza ER.	None	None	1	None	None	None	None	None	None	None	None	None	None	None
Rx0000200	Collegium Pharmaceuticals	03/31/2019	24510013010	XTAMPZA ER-27MG-100 CAPSULES	01/01/2019	104.25	1157.23	09/02/2036	Single Source Drug	None	1	We have never been profitable and have incurred net losses in each year since inception.  Xtampza ER is an abuse-deterrent, extended-release, oral formulation of oxycodone approved by the FDA in April 2016 for the management of pain severe enough to require daily, around-the-clock, long-term opioid treatment and for which alternative treatment options are inadequate. Substantially all of our net losses resulted from costs incurred from research and development programs to obtain and maintain regulatory approval for Xtampza ER, and from selling, general and administrative costs associated with our operations.  These factors, along with the increasing demands for rebates in order to provide improved access to patients, were considered in deciding to increase the wholesale acquisition cost of Xtampza ER.	None	None	1	None	None	None	None	None	None	None	None	None	None	None
Rx0000200	Collegium Pharmaceuticals	03/31/2019	24510014010	XTAMPZA ER-36MG-100 CAPSULES	01/01/2019	128.31	1424.38	09/02/2036	Single Source Drug	None	1	We have never been profitable and have incurred net losses in each year since inception.  Xtampza ER is an abuse-deterrent, extended-release, oral formulation of oxycodone approved by the FDA in April 2016 for the management of pain severe enough to require daily, around-the-clock, long-term opioid treatment and for which alternative treatment options are inadequate. Substantially all of our net losses resulted from costs incurred from research and development programs to obtain and maintain regulatory approval for Xtampza ER, and from selling, general and administrative costs associated with our operations.  These factors, along with the increasing demands for rebates in order to provide improved access to patients, were considered in deciding to increase the wholesale acquisition cost of Xtampza ER.	None	None	1	None	None	None	None	None	None	None	None	None	None	None
Rx0000200	Collegium Pharmaceuticals	03/31/2019	24510011010	XTAMPZA ER-9MG-100 CAPSULES	01/01/2019	40.15	445.70	09/02/2036	Single Source Drug	None	1	We have never been profitable and have incurred net losses in each year since inception.  Xtampza ER is an abuse-deterrent, extended-release, oral formulation of oxycodone approved by the FDA in April 2016 for the management of pain severe enough to require daily, around-the-clock, long-term opioid treatment and for which alternative treatment options are inadequate. Substantially all of our net losses resulted from costs incurred from research and development programs to obtain and maintain regulatory approval for Xtampza ER, and from selling, general and administrative costs associated with our operations.  These factors, along with the increasing demands for rebates in order to provide improved access to patients, were considered in deciding to increase the wholesale acquisition cost of Xtampza ER.	None	None	1	None	None	None	None	None	None	None	None	None	None	None
Rx0000154	Corcept Therapeutics Incorporated	09/30/2019	76346007302	Korlym (mifepristone) 300mg Tablets 280-ct Bottles	08/01/2019	11480.00	139720.00	08/22/2038	Single Source Drug	None	1	Corcept is committed to discovering, developing and making available to patients and physicians medicines that treat serious disorders for which there are few – or no – good treatment options. In setting Korlym’s price, we weigh (i) the increased cost of administrative and commercial activities, (ii) the increased cost of discovering and developing innovative new drug candidates and (iii) our commitment that no patient be denied Korlym for financial reasons.	None	N/A	None	None	None	None	None	None	None	None	None	None	None	WAC is reported at the package level. The information provided herein is provided to the best of our knowledge as of submission and based on our interpretation of applicable statutory and regulatory provisions. Information designated as confidential has been designated as such based on our understanding and belief that the subject information is non-public. Our provision of information shall not be interpreted as a waiver of any of our rights available under state, federal, or other applicable law with respect to the information contained herein or with respect to California SB 17, all of which we expressly reserve. Patent expiration dates do not reflect any pending patent applications, future filed patent applications, patent term extensions, data exclusivity (including orphan drug, pediatric, or other exclusivity), or patent-related litigation, each of which is speculative and which may extend or shorten the reported expiration date. The drug was developed by Corcept.
Rx0000154	Corcept Therapeutics Incorporated	09/30/2019	76346007301	Korlym (mifepristone) 300mg Tablets 28-ct Bottles	08/01/2019	1148.00	13972.00	08/22/2038	Single Source Drug	None	1	Corcept is committed to discovering, developing and making available to patients and physicians medicines that treat serious disorders for which there are few – or no – good treatment options. In setting Korlym’s price, we weigh (i) the increased cost of administrative and commercial activities, (ii) the increased cost of discovering and developing innovative new drug candidates and (iii) our commitment that no patient be denied Korlym for financial reasons.	None	N/A	None	None	None	None	None	None	None	None	None	None	None	WAC is reported at the package level. The information provided herein is provided to the best of our knowledge as of submission and based on our interpretation of applicable statutory and regulatory provisions. Information designated as confidential has been designated as such based on our understanding and belief that the subject information is non-public. Our provision of information shall not be interpreted as a waiver of any of our rights available under state, federal, or other applicable law with respect to the information contained herein or with respect to California SB 17, all of which we expressly reserve. Patent expiration dates do not reflect any pending patent applications, future filed patent applications, patent term extensions, data exclusivity (including orphan drug, pediatric, or other exclusivity), or patent-related litigation, each of which is speculative and which may extend or shorten the reported expiration date. The drug was developed by Corcept.
Rx0000184	Cosette Pharmaceuticals, Inc.	12/31/2019	00713016612	MIGERGOT (Ergotamine Tartrate and Caffeine) Suppository, 2mg/100mg	11/04/2019	70.23	140.46	None	Single Source Drug	None	1	Operating primarily as a manufacturer of generic and over-the-counter drug products, Cosette Pharmaceuticals has a history of providing cost effective, high quality medications that help patients affected by various medical conditions. With that purpose in mind, Cosette carefully and holistically evaluates and weighs a variety of factors when pricing its medications, including: maintaining accessibility and affordability of its products for both patients and payors, market conditions, the overall increase in the cost of labor and goods, the required capital investment in manufacturing facilities and systems, and most importantly, the funding of research and new product development designed to meet the needs of patients and healthcare professionals today and in the future. It is critical to note that research and new product development is a high-risk endeavor, with significant costs being incurred on medications that eventually fail due to clinical, technical or commercial reasons. By considering all of these factors in pricing decisions, Cosette is taking the necessary steps to ensure the long-term availability of high quality prescription and over-the-counter drug products within its portfolio.	None	None	1	06/28/2019	Horizon Therapeutics PLC	None	1	None	70.23	39.96	1983	0.01	None	WAC of the Product when it was introduced in 1983 is unknown. Per recommendation of Rodney Garcia, while the WAC Five Year History recites Cosette's NDC number, it actually incorporates three separate NDC numbers from the following owners: Horizon, Crealta and G&W.
Rx0000181	Currax Pharmaceuticals LLC	12/31/2019	42847085009	Treximet 9 tab/pk (sumatriptan/naproxen) 85 mg/500 mg	10/25/2019	96.67	1062.90	04/02/2026	Single Source Drug	None	1	None	1	None	1	04/30/2019	Pernix Pharmaceuticals	79600000	None	The acquisition price reflects the total assets purchased out of bankruptcy - not the price limited to this single NDC.	967.23	880.09	2015	625.50	None	Currax Pharmaceuticals LLC dba Cypress, Hawthorn and Macoven, acquired asset out of bankruptcy on April 30, 2019 from Pernix Pharmaceuticals. All pricing history prior to April 30, 2019 is not Currax Pharmaceuticals LLC's history. For the sake of clarity, Currax Pharmaceuticals LLC is providing the five year history as required by the regulation and based upon pricing history as provided by MediSpan. Currax Pharmaceuticals LLC maintains no liability for pricing and pricing history prior to April 30, 2019. Since the acquisition was in bankruptcy, the asset purchase amount for the product is not reported nor public.
Rx0000068	Egalet US, Inc.	03/31/2019	42211010111	Oral Suspension Indocin 25 mg/5mL (237mL per Bottle)	02/01/2019	891.98	1783.96	None	Non-innovator Multiple Source Drug	4588	None	None	1	None	1	01/31/2019	Iroko Pharmaceuticals, Inc.	87000000	None	What Egalet US Inc. has provided in Field #16 is an estimate of a portion of the purchase price of the product acquired from Iroko. This does not include the following additional costs: - Significant ongoing royalty payments on net sales - Additional debt burden of $55M and royalty payments associated with this debt - Cost of acquired inventory - Bankruptcy restructuring costs in connection with acquisition - Assumption of additional liabilities in connection with acquisition - Post-marketing and development costs - Commercial infrastructure costs - Intellectual Property litigation and maintenance costs - Costs to comply with regulatory requirements - Significant increase in manufacturing costs	891.98	None	1985	232.17	None	Comment on #20 and #21: Egalet utilized its access to pricing compendia (as well as solicited the assistance of a consultant to do so) in order to provide values for these requests. Based on these searches, Egalet is unable to access WAC pricing for this product when introduced to the market. Therefore: - Egalet provided the FDA Approval Date per the Orange Book for Year Drug Introduced to Market for #20 - Egalet provided the earliest WAC price readily accessible via pricing compendia portals for the NDC (in this case, 4/2/2013) for #21 General Comment on report: Egalet US Inc. has generated substantial net losses and negative cash flow from operations since inception, filed for bankruptcy protection and continues to incur significant expenses related to ongoing operations for its products. For the years ended December 31, 2018 and 2017, we reported a net loss of approximately $95.5 million and $69.4 million, respectively.
Rx0000068	Egalet US, Inc.	03/31/2019	69344011311	Oxaydo 5 mg/1 Tablet (100 per Bottle)	01/01/2019	66.15	734.34	03/16/2025	Innovator Multiple Source Drug	7461	None	None	1	None	1	01/07/2015	Acura Pharmaceuticals, Inc.	7500000	None	In addition to the upfront cash payment of $7.5M, Egalet US Inc. is also required to pay royalty of single-digit to double-digit percent based on sales thresholds. Upfront acquisition payment also does not include the following additional expenses associated with the purchase and ongoing maintenance of the product: - Significant sales milestone payments - Significant post-marketing requirement and development costs - Debt burden, maintenance and servicing costs to finance the original purchase - Second debt burden, maintenance and servicing costs, along with additional royalty payments on sales, associated with financing ongoing operations - Commercial infrastructure costs - Intellectual Property litigation and maintenance costs - Costs to comply with regulatory requirements - Co-payment assistance program utilization costs - Manufacturing costs	425.00	None	2011	425.00	None	Comment on #20 and #21: Egalet utilized its access to pricing compendia (as well as solicited the assistance of a consultant to do so) in order to provide values for these requests. Based on these searches, Egalet is unable to access WAC pricing for this product when introduced to the market. Therefore: - Egalet provided the FDA Approval Date per the Orange Book for Year Drug Introduced to Market for #20 - Egalet provided the earliest WAC price readily accessible via pricing compendia portals for the NDC (in this case, 9/11/2015) for #21 General Comment on report: Egalet US Inc. has generated substantial net losses and negative cash flow from operations since inception, filed for bankruptcy protection and continues to incur significant expenses related to ongoing operations for its products. For the years ended December 31, 2018 and 2017, we reported a net loss of approximately $95.5 million and $69.4 million, respectively.
Rx0000068	Egalet US, Inc.	03/31/2019	69344021311	Oxaydo 7.5mg/1 Tablet (100 per Bottle)	01/01/2019	99.12	1100.31	03/16/2025	Innovator Multiple Source Drug	15438	None	None	1	None	1	01/07/2015	Acura Pharmaceuticals, Inc.	7500000	None	In addition to the upfront cash payment of $7.5M, Egalet US Inc. is also required to pay royalty of single-digit to double-digit percent based on sales thresholds. Upfront acquisition payment also does not include the following additional expenses associated with the purchase and ongoing maintenance of the product: - Significant sales milestone payments - Significant post-marketing requirement and development costs - Debt burden, maintenance and servicing costs to finance the purchase - Second debt burden, maintenance and servicing costs, along with additional royalty payments on sales, associated with financing ongoing operations - Commercial infrastructure costs - Intellectual Property litigation and maintenance costs - Costs to comply with regulatory requirements - Co-payment assistance program utilization costs - Manufacturing costs	638.00	None	2011	638.00	None	Comment on #20 and #21: Egalet utilized its access to pricing compendia (as well as solicited the assistance of a consultant to do so) in order to provide values for these requests. Based on these searches, Egalet is unable to access WAC pricing for this product when introduced to the market. Therefore: - Egalet provided the FDA Approval Date per the Orange Book for Year Drug Introduced to Market for #20 - Egalet provided the earliest WAC price readily accessible via pricing compendia portals for the NDC (in this case, 9/11/2015) for #21 General Comment on report: Egalet US Inc. has generated substantial net losses and negative cash flow from operations since inception, filed for bankruptcy protection and continues to incur significant expenses related to ongoing operations for its products. For the years ended December 31, 2018 and 2017, we reported a net loss of approximately $95.5 million and $69.4 million, respectively.
Rx0000068	Egalet US, Inc.	03/31/2019	69344014443	Sprix 15.75mg/1 Spray, Metered (5 Bottles per Carton)	01/01/2019	160.94	1786.64	None	Innovator Multiple Source Drug	11677	None	None	1	None	1	01/08/2015	Luitpold Pharmaceuticals, Inc.	7000000	None	In addition to the upfront cash payment of $7M, Egalet US Inc. is also required to pay a fixed, single-digit royalty on net sales. Upfront acquisition payment also does not include the following additional expenses associated with the purchase and ongoing maintenance of the product: - Transition services - Debt burden, maintenance and servicing costs to finance the purchase - Second debt burden, maintenance and servicing costs, along with additional royalty payments on sales, associated with financing ongoing operations commercial infrastructure costs - Intellectual Property litigation and maintenance costs - Costs to comply with regulatory requirements - Co-payment assistance program utilization costs - Component and manufacturing costs	1413.00	None	2010	1413.00	None	Comment on #20 and #21: Egalet utilized its access to pricing compendia (as well as solicited the assistance of a consultant to do so) in order to provide values for these requests. Based on these searches, Egalet is unable to access WAC pricing for this product when introduced to the market. Therefore: - Egalet provided the FDA Approval Date per the Orange Book for Year Drug Introduced to Market for #20 - Egalet provided the earliest WAC price readily accessible via pricing compendia portals for the NDC (in this case, 9/15/2015) for #21 General Comment on report: Egalet US Inc. has generated substantial net losses and negative cash flow from operations since inception, filed for bankruptcy protection and continues to incur significant expenses related to ongoing operations for its products. For the years ended December 31, 2018 and 2017, we reported a net loss of approximately $95.5 million and $69.4 million, respectively.
Rx0000068	Egalet US, Inc.	03/31/2019	42211010243	Suppository Indocin 50mg/1 (30 Supp in Box)	02/01/2019	2550.00	5100.00	None	Non-innovator Multiple Source Drug	12923	None	None	1	None	1	01/31/2019	Iroko Pharmaceuticals, Inc.	87000000	None	What Egalet US Inc. has provided in Field #16 is an estimate of a portion of the purchase price of the product acquired from Iroko. This does not include the following additional costs: - Significant ongoing royalty payments on net sales - Additional debt burden of $55M and royalty payments associated with this debt - Cost of acquired inventory - Bankruptcy restructuring costs in connection with acquisition - Assumption of additional liabilities in connection with acquisition - Post-marketing and development costs - Commercial infrastructure costs - Intellectual Property litigation and maintenance costs - Costs to comply with regulatory requirements - Significant increase in manufacturing costs	2550.00	None	1984	309.62	None	Comment on #20 and #21: Egalet utilized its access to pricing compendia (as well as solicited the assistance of a consultant to do so) in order to provide values for these requests. Based on these searches, Egalet is unable to access WAC pricing for this product when introduced to the market. Therefore: - Egalet provided the FDA Approval Date per the Orange Book for Year Drug Introduced to Market for #20 - Egalet provided the earliest WAC price readily accessible via pricing compendia portals for the NDC (in this case, 4/2/2013) for #21 General Comment on report: Egalet US Inc. has generated substantial net losses and negative cash flow from operations since inception, filed for bankruptcy protection and continues to incur significant expenses related to ongoing operations for its products. For the years ended December 31, 2018 and 2017, we reported a net loss of approximately $95.5 million and $69.4 million, respectively.
Rx0000068	Egalet US, Inc.	03/31/2019	42211020129	Tivorbex 20mg/1 Capsule (90 per Bottle)	02/01/2019	193.36	650.00	04/23/2030	Innovator Multiple Source Drug	1962	None	None	1	None	1	01/31/2019	Iroko Pharmaceuticals, Inc.	87000000	None	What Egalet US Inc. has provided in Field #16 is an estimate of a portion of the purchase price of the product acquired from Iroko. This does not include the following additional costs: - Significant ongoing royalty payments on net sales - Additional debt burden of $55M and royalty payments associated with this debt - Cost of acquired inventory - Bankruptcy restructuring costs in connection with acquisition - Assumption of additional liabilities in connection with acquisition - Post-marketing and development costs - Commercial infrastructure costs - Intellectual Property litigation and maintenance costs - Costs to comply with regulatory requirements - Co-payment assistance program utilization costs - Significant increase in manufacturing costs	456.64	None	2014	292.50	None	Comment on #20 and #21: Egalet utilized its access to pricing compendia (as well as solicited the assistance of a consultant to do so) in order to provide values for these requests. Based on these searches, Egalet is unable to access WAC pricing for this product when introduced to the market. Therefore: - Egalet provided the FDA Approval Date per the Orange Book for Year Drug Introduced to Market for #20 - Egalet provided the earliest WAC price readily accessible via pricing compendia portals for the NDC (in this case, 5/4/2015) for #21 General Comment on report: Egalet US Inc. has generated substantial net losses and negative cash flow from operations since inception, filed for bankruptcy protection and continues to incur significant expenses related to ongoing operations for its products. For the years ended December 31, 2018 and 2017, we reported a net loss of approximately $95.5 million and $69.4 million, respectively.
Rx0000068	Egalet US, Inc.	03/31/2019	42211020229	Tivorbex 40mg/1 Capsule (90 per Bottle)	02/01/2019	193.36	650.00	04/23/2030	Innovator Multiple Source Drug	4476	None	None	1	None	1	01/31/2019	Iroko Pharmaceuticals, Inc.	87000000	None	What Egalet US Inc. has provided in Field #16 is an estimate of a portion of the purchase price of the product acquired from Iroko. This does not include the following additional costs: - Significant ongoing royalty payments on net sales - Additional debt burden of $55M and royalty payments associated with this debt - Cost of acquired inventory - Bankruptcy restructuring costs in connection with acquisition - Assumption of additional liabilities in connection with acquisition - Post-marketing and development costs - Commercial infrastructure costs - Intellectual Property litigation and maintenance costs - Costs to comply with regulatory requirements - Co-payment assistance program utilization costs - Significant increase in manufacturing costs	456.64	None	2014	292.50	None	Comment on #20 and #21: Egalet utilized its access to pricing compendia (as well as solicited the assistance of a consultant to do so) in order to provide values for these requests. Based on these searches, Egalet is unable to access WAC pricing for this product when introduced to the market. Therefore: - Egalet provided the FDA Approval Date per the Orange Book for Year Drug Introduced to Market for #20 - Egalet provided the earliest WAC price readily accessible via pricing compendia portals for the NDC (in this case, 5/4/2015) for #21 General Comment on report: Egalet US Inc. has generated substantial net losses and negative cash flow from operations since inception, filed for bankruptcy protection and continues to incur significant expenses related to ongoing operations for its products. For the years ended December 31, 2018 and 2017, we reported a net loss of approximately $95.5 million and $69.4 million, respectively.
Rx0000068	Egalet US, Inc.	03/31/2019	42211020329	Zorvolex 18mg/1 Capsule (90 per Bottle)	02/01/2019	266.95	650.00	04/23/2030	Innovator Multiple Source Drug	15537	None	None	1	None	1	01/31/2019	Iroko Pharmaceuticals, Inc.	87000000	None	What Egalet US Inc. has provided in Field #16 is an estimate of a portion of the purchase price of the product acquired from Iroko. This does not include the following additional costs: - Significant ongoing royalty payments on net sales - Additional debt burden of $55M and royalty payments associated with this debt - Cost of acquired inventory - Bankruptcy restructuring costs in connection with acquisition - Assumption of additional liabilities in connection with acquisition - Post-marketing and development costs - Commercial infrastructure costs - Intellectual Property litigation and maintenance costs - Costs to comply with regulatory requirements - Co-payment assistance program utilization costs - Significant increase in manufacturing costs	383.05	None	2013	225.00	None	Comment on #20 and #21: Egalet utilized its access to pricing compendia (as well as solicited the assistance of a consultant to do so) in order to provide values for these requests. Based on these searches, Egalet is unable to access WAC pricing for this product when introduced to the market. Therefore: - Egalet provided the FDA Approval Date per the Orange Book for Year Drug Introduced to Market for #20 - Egalet provided the earliest WAC price readily accessible via pricing compendia portals for the NDC (in this case, 10/28/2013) for #21 General Comment on report: Egalet US Inc. has generated substantial net losses and negative cash flow from operations since inception, filed for bankruptcy protection and continues to incur significant expenses related to ongoing operations for its products. For the years ended December 31, 2018 and 2017, we reported a net loss of approximately $95.5 million and $69.4 million, respectively.
Rx0000068	Egalet US, Inc.	03/31/2019	42211020429	Zorvolex 35mg/1 Capsule (90 per Bottle)	02/01/2019	266.95	650.00	04/23/2030	Innovator Multiple Source Drug	87468	None	None	1	None	1	01/31/2019	Iroko Pharmaceuticals, Inc.	87000000	None	What Egalet US Inc. has provided in Field #16 is an estimate of a portion of the purchase price of the product acquired from Iroko. This does not include the following additional costs: - Significant ongoing royalty payments on net sales - Additional debt burden of $55M and royalty payments associated with this debt - Cost of acquired inventory - Bankruptcy restructuring costs in connection with acquisition - Assumption of additional liabilities in connection with acquisition - Post-marketing and development costs - Commercial infrastructure costs - Intellectual Property litigation and maintenance costs - Costs to comply with regulatory requirements - Co-payment assistance program utilization costs - Significant increase in manufacturing costs	383.05	None	2013	225.00	None	Comment on #20 and #21: Egalet utilized its access to pricing compendia (as well as solicited the assistance of a consultant to do so) in order to provide values for these requests. Based on these searches, Egalet is unable to access WAC pricing for this product when introduced to the market. Therefore: - Egalet provided the FDA Approval Date per the Orange Book for Year Drug Introduced to Market for #20 - Egalet provided the earliest WAC price readily accessible via pricing compendia portals for the NDC (in this case, 10/28/2013) for #21 General Comment on report: Egalet US Inc. has generated substantial net losses and negative cash flow from operations since inception, filed for bankruptcy protection and continues to incur significant expenses related to ongoing operations for its products. For the years ended December 31, 2018 and 2017, we reported a net loss of approximately $95.5 million and $69.4 million, respectively.
Rx0000076	Eisai Inc.	03/31/2019	62856058252	BANZEL (rufinamide) 200MG TABLET; bottles of 120	03/08/2019	58.00	1442.00	05/14/2023	Single Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	Fields related to product acquired within the previous five year period are not applicable.
Rx0000076	Eisai Inc.	03/31/2019	62856058446	BANZEL (rufinamide) 40 mg/mL SUSPENSION ORAL; bottle of 460mL	03/08/2019	63.00	1600.00	05/14/2023	Single Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	Fields related to product acquired within the previous five year period are not applicable.
Rx0000076	Eisai Inc.	03/31/2019	62856058352	BANZEL (rufinamide) 400MG TABLET; bottles of 120	03/08/2019	116.00	2884.00	05/14/2023	Single Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	Fields related to product acquired within the previous five year period are not applicable.
Rx0000076	Eisai Inc.	03/31/2019	62856052960	BELVIQ (lorcaserin hydrochloride) 10-mg tablets for oral use CIV; bottle of 60	03/08/2019	19.96	299.60	02/07/2033	Single Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	Fields related to product acquired within the previous five year period are not applicable.
Rx0000076	Eisai Inc.	03/31/2019	62856053530	BELVIQ XR (lorcaserin hydrochloride) 20-mg extended-release tablets for oral use CIV; bottle of 30	03/08/2019	19.96	299.60	02/07/2033	Single Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	Fields related to product acquired within the previous five year period are not applicable.
Rx0000076	Eisai Inc.	06/30/2019	62856071030	LENVIMA (lenvatinib) 10 mg/day (10 mg x 1) 30 day supply	06/19/2019	819.00	18374.00	08/26/2035	Single Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	Fields related to product acquired within the previous five year period are not applicable.
Rx0000076	Eisai Inc.	06/30/2019	62856071430	LENVIMA (lenvatinib) 14 mg/day (10 mg x 1 and 4 mg x 1) 30 day supply	06/19/2019	819.00	18374.00	08/26/2035	Single Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	Fields related to product acquired within the previous five year period are not applicable.
Rx0000076	Eisai Inc.	06/30/2019	62856071830	LENVIMA (lenvatinib) 18 mg/day (10 mg x 1 and 4 mg x 2) 30 day supply	06/19/2019	819.00	18374.00	08/26/2035	Single Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	Fields related to product acquired within the previous five year period are not applicable.
Rx0000076	Eisai Inc.	06/30/2019	62856072030	LENVIMA (lenvatinib) 20 mg/day (10 mg x 2) 30 day supply	06/19/2019	819.00	18374.00	08/26/2035	Single Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	Fields related to product acquired within the previous five year period are not applicable.
Rx0000076	Eisai Inc.	06/30/2019	62856072430	LENVIMA (lenvatinib) 24 mg/day (10 mg x 2 and 4 mg x 1) 30 day supply	06/19/2019	819.00	18374.00	08/26/2035	Single Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	Fields related to product acquired within the previous five year period are not applicable.
Rx0000076	Eisai Inc.	06/30/2019	62856070830	LENVIMA (lenvatinib) 8 mg/day (4 mg x 2) 30 day supply	06/19/2019	819.00	18374.00	08/26/2035	Single Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	Fields related to product acquired within the previous five year period are not applicable.
Rx0000091	Endo Pharmaceuticals Inc.	03/31/2019	52244040410	Acrivastine & Pseudoephedrine 8-60 MG Capsule 100 EA	01/04/2019	49.15	545.60	None	Single Source Drug	None	1	None	1	The price increase was not necessitated by a change or improvement in the drug	None	01/29/2015	Auxilium Pharmaceuticals	None	None	1) Endo acquired Auxilium Pharmaceuticals on 1/29/15. As a part of Endo’s acquisition of Auxilium Pharmaceuticals, Endo acquired this product. However, Endo is unable to provide the purchase price for this product since Endo does not have a methodology to allocate the purchase price of Auxilium Pharmaceuticals to the individual assets or products acquired from Auxilium Pharmaceuticals. As a result, Endo has left the “Acquisition Price” field for this product blank. 2) For “Year Introduced”, Endo is providing the year in which first price point is published in the pricing compendia database for the labeler code / product / product presentation.	339.70	None	1995	39.52	None	The information contained in this report is subject to the following limitations and assumptions. (1) Consistent with the relevant statutes and regulations, all information contained in this report is limited to that which Endo believes is otherwise in the public domain or publicly available. (2) The Orange Book indicates that, as of 4/24/19, the Orange Book database does not contain unexpired patents for this product. As a result, Endo has left the “Patent Expiration Date” field for this product blank.
Rx0000091	Endo Pharmaceuticals Inc.	12/31/2019	67979051143	Aveed, 750 mg/3mL (250mg/1mL) solution, single use vial	10/07/2019	56.86	1229.17	03/14/2027	Single Source Drug	None	1	None	1	The price increase was not necessitated by a change or improvement in the drug.	None	None	None	None	None	None	None	None	None	None	None	The information contained in this report is subject to the following limitations and assumptions. (1) Consistent with the relevant statutes and regulations, all information contained in this report is limited to that which Endo believes is otherwise in the public domain or publicly available. (2) The patent expiration date contained in this report is limited to the patent information reported in the federal Food and Drug Administration’s Orange Book, as of 1/17/2020. As a result, the reported patent expiration date is limited to issued U.S. patents. Further, the reported patent expiration date does not reflect any pending patents, patent term extensions, pediatric exclusivity, or patent-related litigation, each of which is speculative and which may extend or shorten the reported expiration date.
Rx0000091	Endo Pharmaceuticals Inc.	06/30/2019	67979051143	Aveed,750 mg/3 mL single use inj.	04/01/2019	54.23	1172.31	03/14/2027	Single Source Drug	None	1	None	1	The price increase was not necessitated by a change or improvement in the drug	None	None	None	None	None	None	None	None	None	None	None	The information contained in this report is subject to the following limitations and assumptions. (1) Consistent with the relevant statutes and regulations, all information contained in this report is limited to that which Endo believes is otherwise in the public domain or publicly available. (2) The patent expiration date contained in this report is limited to the patent information reported in the federal Food and Drug Administration’s Orange Book, as of 8/5/19. As a result, the reported patent expiration date is limited to issued U.S. patents. Further, the reported patent expiration date does not reflect any pending patents, patent term extensions, pediatric exclusivity, or patent-related litigation, each of which is speculative and which may extend or shorten the reported expiration date.
Rx0000091	Endo Pharmaceuticals Inc.	03/31/2019	49884027082	Cyanocobalamin 500 MCG/0.1ML Solution 1 EA UU	01/04/2019	27.36	585.78	08/01/2024	Single Source Drug	None	1	None	1	The price increase was not necessitated by a change or improvement in the drug	None	09/28/2015	PAR Pharmaceuticals	None	None	1) Endo acquired PAR Pharmaceuticals on 9/25/15. As a part of Endo’s acquisition of PAR Pharmaceuticals, Endo acquired this product. However, Endo is unable to provide the purchase price for this product since Endo does not have a methodology to allocate the purchase price of PAR Pharmaceuticals to the individual assets or products acquired from PAR Pharmaceuticals. As a result, Endo has left the “Acquisition Price” field for this product blank. 2) For “Year Introduced”, Endo is providing the year in which first price point is published in the pricing compendia database for the labeler code / product / product presentation.	396.88	None	2014	361.13	None	The information contained in this report is subject to the following limitations and assumptions. (1) Consistent with the relevant statutes and regulations, all information contained in this report is limited to that which Endo believes is otherwise in the public domain or publicly available. (2) The patent expiration date contained in this report is limited to the patent information reported in the federal Food and Drug Administration’s Orange Book, as of 4/24/19. As a result, the reported patent expiration date is limited to issued U.S. patents. Further, the reported patent expiration date does not reflect any pending patents, patent term extensions, pediatric exclusivity, or patent-related litigation, each of which is speculative and which may extend or shorten the reported expiration date.
Rx0000091	Endo Pharmaceuticals Inc.	03/31/2019	63481002509	Frovatriptan Succinate 2.5 MG Tablet 9 EA UU	01/04/2019	72.10	800.39	None	Innovator Multiple Source Drug	None	1	None	1	The price increase was not necessitated by a change or improvement in the drug	None	None	None	None	None	None	None	None	None	None	None	The information contained in this report is subject to the following limitations and assumptions. (1) Consistent with the relevant statutes and regulations, all information contained in this report is limited to that which Endo believes is otherwise in the public domain or publicly available. (2) The Orange Book indicates that, as of 4/24/19, the Orange Book database does not contain unexpired patents for this product. As a result, Endo has left the patent expiration date field for this product blank. 3) This NDC was not acquired within the last five years. As a result, Endo left the "acquisition" related fields for this product blank.
Rx0000091	Endo Pharmaceuticals Inc.	03/31/2019	52244092010	Isosorbide Dinitrate 40 MG Capsule Extended Release 100 EA	01/04/2019	38.19	423.93	None	Single Source Drug	None	1	None	1	The price increase was not necessitated by a change or improvement in the drug	None	None	None	None	None	None	None	None	None	None	None	The information contained in this report is subject to the following limitations and assumptions. (1) Consistent with the relevant statutes and regulations, all information contained in this report is limited to that which Endo believes is otherwise in the public domain or publicly available. (2) The Orange Book indicates that, as of 4/24/19, the Orange Book database does not contain unexpired patents for this product. As a result, Endo has left the “Patent Expiration Date” field for this product blank. 3) This NDC was not acquired within the last five years. As a result, Endo left the "acquisition" related fields for this product blank.
Rx0000091	Endo Pharmaceuticals Inc.	03/31/2019	63481068706	Lidocaine 5 % Patch 30 EA UU	01/04/2019	71.10	545.11	None	Innovator Multiple Source Drug	None	1	None	1	The price increase was not necessitated by a change or improvement in the drug	None	None	None	None	None	None	None	None	None	None	None	The information contained in this report is subject to the following limitations and assumptions. (1) Consistent with the relevant statutes and regulations, all information contained in this report is limited to that which Endo believes is otherwise in the public domain or publicly available. (2) The Orange Book indicates that, as of 4/24/19, the Orange Book database does not contain unexpired patents for this product. As a result, Endo has left the “Patent Expiration Date” field for this product blank. 3) This NDC was not acquired within the last five years. As a result, Endo left the "acquisition" related fields for this product blank.
Rx0000091	Endo Pharmaceuticals Inc.	03/31/2019	63481016038	Megestrol Acetate (Appetite) 625 MG/5ML Suspension 150 ML UU	01/04/2019	109.34	1213.78	04/22/2024	Innovator Multiple Source Drug	None	1	None	1	The price increase was not necessitated by a change or improvement in the drug	None	09/28/2015	PAR Pharmaceuticals	None	None	1) Endo acquired PAR Pharmaceuticals on 9/25/15. As a part of Endo’s acquisition of PAR Pharmaceuticals, Endo acquired this product. However, Endo is unable to provide the purchase price for this product since Endo does not have a methodology to allocate the purchase price of PAR Pharmaceuticals to the individual assets or products acquired from PAR Pharmaceuticals. As a result, Endo has left the “Acquisition Price” field for this product blank. 2) For “Year Introduced”, Endo is providing the year in which first price point is published in the pricing compendia database for the labeler code / product / product presentation.	832.05	None	2005	390.00	None	The information contained in this report is subject to the following limitations and assumptions. (1) Consistent with the relevant statutes and regulations, all information contained in this report is limited to that which Endo believes is otherwise in the public domain or publicly available. (2) The patent expiration date contained in this report is limited to the patent information reported in the federal Food and Drug Administration’s Orange Book, as of 4/24/19. As a result, the reported patent expiration date is limited to issued U.S. patents. Further, the reported patent expiration date does not reflect any pending patents, patent term extensions, pediatric exclusivity, or patent-related litigation, each of which is speculative and which may extend or shorten the reported expiration date.
Rx0000091	Endo Pharmaceuticals Inc.	03/31/2019	52244042910	Methocarbamol 500 MG Tablet 100 EA	01/04/2019	16.96	188.24	None	Innovator Multiple Source Drug	None	1	None	1	The price increase was not necessitated by a change or improvement in the drug	None	01/29/2015	Auxilium Pharmaceuticals	None	None	1) Endo acquired Auxilium Pharmaceuticals on 1/29/15. As a part of Endo’s acquisition of Auxilium Pharmaceuticals, Endo acquired this product. However, Endo is unable to provide the purchase price for this product since Endo does not have a methodology to allocate the purchase price of Auxilium Pharmaceuticals to the individual assets or products acquired from Auxilium Pharmaceuticals. As a result, Endo has left the “Acquisition Price” field for this product blank. 2) For “Year Introduced”, Endo is providing the year in which first price point is published in the pricing compendia database for the labeler code / product / product presentation.	141.81	None	2003	62.53	None	The information contained in this report is subject to the following limitations and assumptions. (1) Consistent with the relevant statutes and regulations, all information contained in this report is limited to that which Endo believes is otherwise in the public domain or publicly available. (2) The Orange Book indicates that, as of 4/24/19, the Orange Book database does not contain unexpired patents for this product. As a result, Endo has left the “Patent Expiration Date” field for this product blank.
Rx0000091	Endo Pharmaceuticals Inc.	03/31/2019	52244044910	Methocarbamol 750 MG Tablet 100 EA	01/04/2019	24.24	269.08	None	Innovator Multiple Source Drug	None	1	None	1	The price increase was not necessitated by a change or improvement in the drug	None	01/29/2015	Auxilium Pharmaceuticals	None	None	1) Endo acquired Auxilium Pharmaceuticals on 1/29/15. As a part of Endo’s acquisition of Auxilium Pharmaceuticals, Endo acquired this product. However, Endo is unable to provide the purchase price for this product since Endo does not have a methodology to allocate the purchase price of Auxilium Pharmaceuticals to the individual assets or products acquired from Auxilium Pharmaceuticals. As a result, Endo has left the “Acquisition Price” field for this product blank. 2) For “Year Introduced”, Endo is providing the year in which first price point is published in the pricing compendia database for the labeler code / product / product presentation.	202.71	None	2002	89.37	None	The information contained in this report is subject to the following limitations and assumptions. (1) Consistent with the relevant statutes and regulations, all information contained in this report is limited to that which Endo believes is otherwise in the public domain or publicly available. (2) The Orange Book indicates that, as of 4/24/19, the Orange Book database does not contain unexpired patents for this product. As a result, Endo has left the “Patent Expiration Date” field for this product blank.
Rx0000091	Endo Pharmaceuticals Inc.	03/31/2019	63481042105	Neomycin-Colistin-HC-Thonzonium 3.3-3-10-0.5 MG/ML Suspension 10 ML UU	01/04/2019	20.87	231.65	None	Single Source Drug	None	1	None	1	The price increase was not necessitated by a change or improvement in the drug	None	09/28/2015	PAR Pharmaceuticals	None	None	1) Endo acquired PAR Pharmaceuticals on 9/25/15. As a part of Endo’s acquisition of PAR Pharmaceuticals, Endo acquired this product. However, Endo is unable to provide the purchase price for this product since Endo does not have a methodology to allocate the purchase price of PAR Pharmaceuticals to the individual assets or products acquired from PAR Pharmaceuticals. As a result, Endo has left the “Acquisition Price” field for this product blank. 2) For “Year Introduced”, Endo is providing the year in which first price point is published in the pricing compendia database for the labeler code / product / product presentation.	158.79	None	1998	27.50	None	The information contained in this report is subject to the following limitations and assumptions. (1) Consistent with the relevant statutes and regulations, all information contained in this report is limited to that which Endo believes is otherwise in the public domain or publicly available. (2) The Orange Book indicates that, as of 4/24/19, the Orange Book database does not contain unexpired patents for this product. As a result, Endo has left the patent expiration date field for this product blank.
Rx0000091	Endo Pharmaceuticals Inc.	03/31/2019	63481062970	Oxycodone w/ Acetaminophen 10-325 MG Tablet 100 EA	01/04/2019	305.49	2342.06	None	Non-innovator Multiple Source Drug	None	1	None	1	The price increase was not necessitated by a change or improvement in the drug	None	None	None	None	None	None	None	None	None	None	None	The information contained in this report is subject to the following limitations and assumptions. (1) Consistent with the relevant statutes and regulations, all information contained in this report is limited to that which Endo believes is otherwise in the public domain or publicly available. (2) The Orange Book indicates that, as of 4/24/19, the Orange Book database does not contain unexpired patents for this product. As a result, Endo has left the “Patent Expiration Date” field for this product blank. 3) This NDC was not acquired within the last five years. As a result, Endo left the "acquisition" related fields for this product blank.
Rx0000091	Endo Pharmaceuticals Inc.	03/31/2019	63481062770	Oxycodone w/ Acetaminophen 2.5-325 MG Tablet 100 EA	01/04/2019	154.51	1184.57	None	Non-innovator Multiple Source Drug	None	1	None	1	The price increase was not necessitated by a change or improvement in the drug	None	None	None	None	None	None	None	None	None	None	None	The information contained in this report is subject to the following limitations and assumptions. (1) Consistent with the relevant statutes and regulations, all information contained in this report is limited to that which Endo believes is otherwise in the public domain or publicly available. (2) The Orange Book indicates that, as of 4/24/19, the Orange Book database does not contain unexpired patents for this product. As a result, Endo has left the “Patent Expiration Date” field for this product blank. 3) This NDC was not acquired within the last five years. As a result, Endo left the "acquisition" related fields for this product blank.
Rx0000091	Endo Pharmaceuticals Inc.	03/31/2019	63481062370	Oxycodone w/ Acetaminophen 5-325 MG Tablet 100 EA	01/04/2019	216.25	1657.89	None	Non-innovator Multiple Source Drug	None	1	None	1	The price increase was not necessitated by a change or improvement in the drug	None	None	None	None	None	None	None	None	None	None	None	The information contained in this report is subject to the following limitations and assumptions. (1) Consistent with the relevant statutes and regulations, all information contained in this report is limited to that which Endo believes is otherwise in the public domain or publicly available. (2) The Orange Book indicates that, as of 4/24/19, the Orange Book database does not contain unexpired patents for this product. As a result, Endo has left the “Patent Expiration Date” field for this product blank. 3) This NDC was not acquired within the last five years. As a result, Endo left the "acquisition" related fields for this product blank.
Rx0000091	Endo Pharmaceuticals Inc.	03/31/2019	63481062385	Oxycodone w/ Acetaminophen 5-325 MG Tablet 500 EA	01/04/2019	1054.03	8080.91	None	Non-innovator Multiple Source Drug	None	1	None	1	The price increase was not necessitated by a change or improvement in the drug	None	None	None	None	None	None	None	None	None	None	None	The information contained in this report is subject to the following limitations and assumptions. (1) Consistent with the relevant statutes and regulations, all information contained in this report is limited to that which Endo believes is otherwise in the public domain or publicly available. (2) The Orange Book indicates that, as of 4/24/19, the Orange Book database does not contain unexpired patents for this product. As a result, Endo has left the “Patent Expiration Date” field for this product blank. 3) This NDC was not acquired within the last five years. As a result, Endo left the "acquisition" related fields for this product blank.
Rx0000091	Endo Pharmaceuticals Inc.	03/31/2019	63481062870	Oxycodone w/ Acetaminophen 7.5-325 MG Tablet 100 EA	01/04/2019	233.63	1791.13	None	Non-innovator Multiple Source Drug	None	1	None	1	The price increase was not necessitated by a change or improvement in the drug	None	None	None	None	None	None	None	None	None	None	None	The information contained in this report is subject to the following limitations and assumptions. (1) Consistent with the relevant statutes and regulations, all information contained in this report is limited to that which Endo believes is otherwise in the public domain or publicly available. (2) The Orange Book indicates that, as of 4/24/19, the Orange Book database does not contain unexpired patents for this product. As a result, Endo has left the “Patent Expiration Date” field for this product blank. 3) This NDC was not acquired within the last five years. As a result, Endo left the "acquisition" related fields for this product blank.
Rx0000091	Endo Pharmaceuticals Inc.	03/31/2019	63481061370	Oxymorphone HCl 10 MG Tablet 100 EA	01/04/2019	123.72	1373.40	None	Innovator Multiple Source Drug	None	1	None	1	The price increase was not necessitated by a change or improvement in the drug	None	None	None	None	None	None	None	None	None	None	None	The information contained in this report is subject to the following limitations and assumptions. (1) Consistent with the relevant statutes and regulations, all information contained in this report is limited to that which Endo believes is otherwise in the public domain or publicly available. (2) The Orange Book indicates that, as of 4/24/19, the Orange Book database does not contain unexpired patents for this product. As a result, Endo has left the “Patent Expiration Date” field for this product blank. 3) This NDC was not acquired within the last five years. As a result, Endo left the "acquisition" related fields for this product blank.
Rx0000091	Endo Pharmaceuticals Inc.	03/31/2019	63481061270	Oxymorphone HCl 5 MG Tablet 100 EA	01/04/2019	68.14	756.42	None	Innovator Multiple Source Drug	None	1	None	1	The price increase was not necessitated by a change or improvement in the drug	None	None	None	None	None	None	None	None	None	None	None	The information contained in this report is subject to the following limitations and assumptions. (1) Consistent with the relevant statutes and regulations, all information contained in this report is limited to that which Endo believes is otherwise in the public domain or publicly available. (2) The Orange Book indicates that, as of 4/24/19, the Orange Book database does not contain unexpired patents for this product. As a result, Endo has left the patent expiration date field for this product blank. 3) This NDC was not acquired within the last five years. As a result, Endo left the "acquisition" related fields for this product blank.
Rx0000091	Endo Pharmaceuticals Inc.	12/31/2019	67979000201	Supprelin LA, 50 mg implant, ea	10/07/2019	1727.52	37346.56	06/16/2026	Single Source Drug	None	1	None	1	The price increase was not necessitated by a change or improvement in the drug.	None	None	None	None	None	None	None	None	None	None	None	The information contained in this report is subject to the following limitations and assumptions. (1) Consistent with the relevant statutes and regulations, all information contained in this report is limited to that which Endo believes is otherwise in the public domain or publicly available. (2) The patent expiration date contained in this report is limited to the patent information reported in the federal Food and Drug Administration’s Orange Book, as of 1/17/2020. As a result, the reported patent expiration date is limited to issued U.S. patents. Further, the reported patent expiration date does not reflect any pending patents, patent term extensions, pediatric exclusivity, or patent-related litigation, each of which is speculative and which may extend or shorten the reported expiration date. (3) Endo did not acquire this product from another manufacturer within the previous five years. As a result, Endo has left columns N-U blank because they are not applicable to this product.
Rx0000091	Endo Pharmaceuticals Inc.	06/30/2019	67979000201	Supprelin LA, 50mg Kit	04/01/2019	1647.61	35619.04	06/16/2026	Single Source Drug	None	1	None	1	The price increase was not necessitated by a change or improvement in the drug	None	None	None	None	None	None	None	None	None	None	None	The information contained in this report is subject to the following limitations and assumptions. (1) Consistent with the relevant statutes and regulations, all information contained in this report is limited to that which Endo believes is otherwise in the public domain or publicly available. (2) The patent expiration date contained in this report is limited to the patent information reported in the federal Food and Drug Administration’s Orange Book, as of 8/5/19. As a result, the reported patent expiration date is limited to issued U.S. patents. Further, the reported patent expiration date does not reflect any pending patents, patent term extensions, pediatric exclusivity, or patent-related litigation, each of which is speculative and which may extend or shorten the reported expiration date. (3) Endo did not acquire this product from another manufacturer within the previous five years. As a result, Endo has left columns N-U blank because they are not applicable to this product.
Rx0000091	Endo Pharmaceuticals Inc.	03/31/2019	52244003060	Testosterone 30 MG Miscellaneous 60 EA	01/04/2019	71.75	796.53	08/23/2019	Single Source Drug	None	1	None	1	The price increase was not necessitated by a change or improvement in the drug	None	01/29/2015	Auxilium Pharmaceuticals	None	None	1) Endo acquired Auxilium Pharmaceuticals on 1/29/15. As a part of Endo’s acquisition of Auxilium Pharmaceuticals, Endo acquired this product. However, Endo is unable to provide the purchase price for this product since Endo does not have a methodology to allocate the purchase price of Auxilium Pharmaceuticals to the individual assets or products acquired from Auxilium Pharmaceuticals. As a result, Endo has left the “Acquisition Price” field for this product blank. 2) For “Year Introduced”, Endo is providing the year in which first price point is published in the pricing compendia database for the labeler code / product / product presentation.	495.94	None	2003	152.24	None	The information contained in this report is subject to the following limitations and assumptions. (1) Consistent with the relevant statutes and regulations, all information contained in this report is limited to that which Endo believes is otherwise in the public domain or publicly available. (2) The patent expiration date contained in this report is limited to the patent information reported in the federal Food and Drug Administration’s Orange Book, as of 4/24/19. As a result, the reported patent expiration date is limited to issued U.S. patents. Further, the reported patent expiration date does not reflect any pending patents, patent term extensions, pediatric exclusivity, or patent-related litigation, each of which is speculative and which may extend or shorten the reported expiration date.
Rx0000091	Endo Pharmaceuticals Inc.	03/31/2019	52244010010	Theophylline 100 MG Capsule Extended Release 24 Hour 100 EA	01/04/2019	19.78	219.60	None	Non-innovator Multiple Source Drug	None	1	None	1	The price increase was not necessitated by a change or improvement in the drug	None	01/29/2015	Auxilium Pharmaceuticals	None	None	1) Endo acquired Auxilium Pharmaceuticals on 1/29/15. As a part of Endo’s acquisition of Auxilium Pharmaceuticals, Endo acquired this product. However, Endo is unable to provide the purchase price for this product since Endo does not have a methodology to allocate the purchase price of Auxilium Pharmaceuticals to the individual assets or products acquired from Auxilium Pharmaceuticals. As a result, Endo has left the “Acquisition Price” field for this product blank. 2) For “Year Introduced”, Endo is providing the year in which first price point is published in the pricing compendia database for the labeler code / product / product presentation.	136.73	None	1994	17.04	None	The information contained in this report is subject to the following limitations and assumptions. (1) Consistent with the relevant statutes and regulations, all information contained in this report is limited to that which Endo believes is otherwise in the public domain or publicly available. (2) The Orange Book indicates that, as of 4/24/19, the Orange Book database does not contain unexpired patents for this product. As a result, Endo has left the patent expiration date field for this product blank.
Rx0000091	Endo Pharmaceuticals Inc.	03/31/2019	52244020010	Theophylline 200 MG Capsule Extended Release 24 Hour 100 EA	01/04/2019	29.40	326.37	None	Non-innovator Multiple Source Drug	None	1	None	1	The price increase was not necessitated by a change or improvement in the drug	None	01/29/2015	Auxilium Pharmaceuticals	None	None	1) Endo acquired Auxilium Pharmaceuticals on 1/29/15. As a part of Endo’s acquisition of Auxilium Pharmaceuticals, Endo acquired this product. However, Endo is unable to provide the purchase price for this product since Endo does not have a methodology to allocate the purchase price of Auxilium Pharmaceuticals to the individual assets or products acquired from Auxilium Pharmaceuticals. 2) For “Year Introduced”, Endo is providing the year in which first price point is published in the pricing compendia database for the labeler code / product / product presentation.	203.21	None	1994	25.41	None	The information contained in this report is subject to the following limitations and assumptions. (1) Consistent with the relevant statutes and regulations, all information contained in this report is limited to that which Endo believes is otherwise in the public domain or publicly available. (2) The Orange Book indicates that, as of 4/24/19, the Orange Book database does not contain unexpired patents for this product. As a result, Endo has left the “Patent Expiration Date” field for this product blank.
Rx0000091	Endo Pharmaceuticals Inc.	03/31/2019	52244030010	Theophylline 300 MG Capsule Extended Release 24 Hour 100 EA	01/04/2019	36.14	401.14	None	Non-innovator Multiple Source Drug	None	1	None	1	The price increase was not necessitated by a change or improvement in the drug	None	01/29/2015	Auxilium Pharmaceuticals	None	None	1) Endo acquired Auxilium Pharmaceuticals on 1/29/15. As a part of Endo’s acquisition of Auxilium Pharmaceuticals, Endo acquired this product. However, Endo is unable to provide the purchase price for this product since Endo does not have a methodology to allocate the purchase price of Auxilium Pharmaceuticals to the individual assets or products acquired from Auxilium Pharmaceuticals. As a result, Endo has left the “Acquisition Price” field for this product blank. 2) For “Year Introduced”, Endo is providing the year in which first price point is published in the pricing compendia database for the labeler code / product / product presentation.	249.75	None	1994	30.15	None	The information contained in this report is subject to the following limitations and assumptions. (1) Consistent with the relevant statutes and regulations, all information contained in this report is limited to that which Endo believes is otherwise in the public domain or publicly available. (2) The Orange Book indicates that, as of 4/24/19, the Orange Book database does not contain unexpired patents for this product. As a result, Endo has left the patent expiration date field for this product blank.
Rx0000091	Endo Pharmaceuticals Inc.	03/31/2019	52244040010	Theophylline 400 MG Capsule Extended Release 24 Hour 100 EA	01/04/2019	50.85	564.45	None	Non-innovator Multiple Source Drug	None	1	None	1	The price increase was not necessitated by a change or improvement in the drug	None	01/29/2015	Auxilium Pharmaceuticals	None	None	1) Endo acquired Auxilium Pharmaceuticals on 1/29/15. As a part of Endo’s acquisition of Auxilium Pharmaceuticals, Endo acquired this product. However, Endo is unable to provide the purchase price for this product since Endo does not have a methodology to allocate the purchase price of Auxilium Pharmaceuticals to the individual assets or products acquired from Auxilium Pharmaceuticals. As a result, Endo has left the “Acquisition Price” field for this product blank. 2) For “Year Introduced”, Endo is providing the year in which first price point is published in the pricing compendia database for the labeler code / product / product presentation.	351.43	None	1994	42.68	None	The information contained in this report is subject to the following limitations and assumptions. (1) Consistent with the relevant statutes and regulations, all information contained in this report is limited to that which Endo believes is otherwise in the public domain or publicly available. (2) The Orange Book indicates that, as of 4/24/19, the Orange Book database does not contain unexpired patents for this product. As a result, Endo has left the “Patent Expiration Date” field for this product blank.
Rx0000091	Endo Pharmaceuticals Inc.	12/31/2019	67979000101	Valstar, 40 mg/1ml solution, 4x5mL	10/07/2019	281.20	6079.14	None	Single Source Drug	None	1	None	1	The price increase was not necessitated by a change or improvement in the drug.	None	None	None	None	None	None	None	None	None	None	None	The information contained in this report is subject to the following limitations and assumptions. (1) Consistent with the relevant statutes and regulations, all information contained in this report is limited to that which Endo believes is otherwise in the public domain or publicly available. (2) The Orange Book indicates that, as of 1/17/2020, the Orange Book database does not contain unexpired patents for this product. As a result, Endo has left the patent expiration date field for this product blank.(3) Endo did not acquire this product from another manufacturer within the previous five years. As a result, Endo has left columns N-U blank because they are not applicable to this product.
Rx0000091	Endo Pharmaceuticals Inc.	06/30/2019	67979000101	Valstar, 4x5mL vials	04/01/2019	268.19	5797.94	None	Single Source Drug	None	1	None	1	The price increase was not necessitated by a change or improvement in the drug	None	None	None	None	None	None	None	None	None	None	None	The information contained in this report is subject to the following limitations and assumptions. (1) Consistent with the relevant statutes and regulations, all information contained in this report is limited to that which Endo believes is otherwise in the public domain or publicly available. (2) The Orange Book indicates that, as of 8/5/19, the Orange Book database does not contain unexpired patents for this product. As a result, Endo has left the patent expiration date field for this product blank.(3) Endo did not acquire this product from another manufacturer within the previous five years. As a result, Endo has left columns N-U blank because they are not applicable to this product.
Rx0000091	Endo Pharmaceuticals Inc.	06/30/2019	67979050001	Vantas, 50 mg implant	04/01/2019	195.59	4228.32	None	Single Source Drug	None	1	None	1	The price increase was not necessitated by a change or improvement in the drug	None	None	None	None	None	None	None	None	None	None	None	The information contained in this report is subject to the following limitations and assumptions. (1) Consistent with the relevant statutes and regulations, all information contained in this report is limited to that which Endo believes is otherwise in the public domain or publicly available. (2) The Orange Book indicates that, as of 8/5/19, the Orange Book database does not contain unexpired patents for this product. As a result, Endo has left the patent expiration date field for this product blank. (3) Endo did not acquire this product from another manufacturer within the previous five years. As a result, Endo has left columns N-U blank because they are not applicable to this product.”
Rx0000091	Endo Pharmaceuticals Inc.	12/31/2019	67979050001	Vantas, 50 mg implant, ea	10/07/2019	205.07	4433.39	None	Single Source Drug	None	1	None	1	The price increase was not necessitated by a change or improvement in the drug.	None	None	None	None	None	None	None	None	None	None	None	The information contained in this report is subject to the following limitations and assumptions. (1) Consistent with the relevant statutes and regulations, all information contained in this report is limited to that which Endo believes is otherwise in the public domain or publicly available. (2) The Orange Book indicates that, as of 1/17/2020, the Orange Book database does not contain unexpired patents for this product. As a result, Endo has left the patent expiration date field for this product blank. (3) Endo did not acquire this product from another manufacturer within the previous five years. As a result, Endo has left columns N-U blank because they are not applicable to this product.”
Rx0000091	Endo Pharmaceuticals Inc.	06/30/2019	66887000301	Xiaflex, 0.9 mg Vial	04/01/2019	168.58	4491.19	None	Single Source Drug	None	1	None	1	The price increase was not necessitated by a change or improvement in the drug	None	01/29/2015	Auxilium Pharmaceuticals	None	None	Endo acquired Auxilium Pharmaceuticals on 1/29/15. As a part of Endo’s acquisition of Auxilium Pharmaceuticals, Endo acquired this product. However, Endo is unable to provide the purchase price for this product since Endo does not have a methodology to allocate the purchase price of Auxilium Pharmaceuticals to the individual assets or products acquired from Auxilium Pharmaceuticals. As a result, Endo has left the “Acquisition Price” field for this product blank.	3331.25	3331.25	2010	3250.00	None	The information contained in this report is subject to the following limitations and assumptions. (1) Consistent with the relevant statutes and regulations, all information contained in this report is limited to that which Endo believes is otherwise in the public domain or publicly available. (2) The federal Food and Drug Administration’s Purple Book does not require the listing of patents or their expiration dates for any product, including Xiaflex. The patent expiration date for any patent potentially associated with Xiaflex would also depend on pending patents, patent term extensions, pediatric exclusivity, or patent-related litigation, each of which is speculative and which may extend or shorten such an expiration date. As a result, Endo has left the patent expiration date field for this product blank. (3) For “Year Introduced”, Endo is providing the year in which first price point is published in the pricing compendia database for the labeler code / product / product presentation.
Rx0000091	Endo Pharmaceuticals Inc.	12/31/2019	66887000301	Xiaflex, 0.9mg powder for solution, single use vial	10/07/2019	175.16	4666.35	None	Single Source Drug	None	1	None	1	The price increase was not necessitated by a change or improvement in the drug.	None	01/29/2015	Auxilium Pharmaceuticals	None	None	Endo acquired Auxilium Pharmaceuticals on 1/29/15. As a part of Endo’s acquisition of Auxilium Pharmaceuticals, Endo acquired this product. However, Endo is unable to provide the purchase price for this product since Endo does not have a methodology to allocate the purchase price of Auxilium Pharmaceuticals to the individual assets or products acquired from Auxilium Pharmaceuticals. As a result, Endo has left the “Acquisition Price” field for this product blank.	3331.25	3331.25	2010	3250.00	None	The information contained in this report is subject to the following limitations and assumptions. (1) Consistent with the relevant statutes and regulations, all information contained in this report is limited to that which Endo believes is otherwise in the public domain or publicly available. (2) The federal Food and Drug Administration’s Purple Book does not require the listing of patents or their expiration dates for any product, including Xiaflex. The patent expiration date for any patent potentially associated with Xiaflex would also depend on pending patents, patent term extensions, pediatric exclusivity, or patent-related litigation, each of which is speculative and which may extend or shorten such an expiration date. As a result, Endo has left the patent expiration date field for this product blank. (3) For “Year Introduced”, Endo is providing the year in which first price point is published in the pricing compendia database for the labeler code / product / product presentation.
Rx0000094	Epic Pharma	03/31/2019	42806008101	Benzphetamine Hydrochloride 50mg Oral tablet	02/17/2019	122.65	210.00	None	Non-innovator Multiple Source Drug	1595	None	Change in market dynamics.	None	Change in market dynamics.	None	None	None	None	None	None	None	None	None	None	None	Drug is developed by Epic Pharma.
Rx0000094	Epic Pharma	03/31/2019	42806008130	Benzphetamine Hydrochloride 50mg Oral tablet	02/17/2019	48.80	75.00	None	Non-innovator Multiple Source Drug	2214	None	Change in market dynamics.	None	Change in market dynamics.	None	None	None	None	None	None	None	None	None	None	None	Drug is developed by Epic Pharma.
Rx0000094	Epic Pharma	12/31/2019	42806014301	Demeclocycline HCL 150mg 100 Tab Epic	11/15/2019	633.15	1266.30	None	Non-innovator Multiple Source Drug	2172	None	Change in market dynamics	None	No change / improvement made to drug.	None	None	None	None	None	None	None	None	None	None	None	Epic Pharma developed these drugs
Rx0000094	Epic Pharma	12/31/2019	42806014448	Demeclocycline HCL 300mg 48 Tab Epic	11/15/2019	550.20	1100.40	None	Non-innovator Multiple Source Drug	4092	None	Change in market dynamics	None	No change / improvement made to drug.	None	None	None	None	None	None	None	None	None	None	None	Epic Pharma developed these drugs
Rx0000094	Epic Pharma	03/31/2019	42806005801	Flavoxate Hydrochloride 100mg Oral tablet	02/17/2019	70.00	160.00	None	Non-innovator Multiple Source Drug	4152	None	Change in market dynamics.	None	Change in market dynamics.	None	None	None	None	None	None	None	None	None	None	None	Drug is developed by Epic Pharma.
Rx0000094	Epic Pharma	06/30/2019	42806050109	Nicardipine Hydrochloride 20mg Oral capsule	06/28/2019	637.16	796.85	None	Non-innovator Multiple Source Drug	3157	None	Change in market dynamics	None	No change / improvement made to drug.	None	None	None	None	None	None	None	None	None	None	None	Drug was not acquired.
Rx0000094	Epic Pharma	06/30/2019	42806050209	Nicardipine Hydrochloride 30mg Oral capsule	06/28/2019	912.55	1141.26	None	Non-innovator Multiple Source Drug	1308	None	Change in market dynamics	None	No change / improvement made to drug.	None	None	None	None	None	None	None	None	None	None	None	Drug was not acquired.
Rx0000094	Epic Pharma	03/31/2019	42806001396	Sodium Polystyrene Sulfonate 453.6g Powder for Oral susp/PWD	02/17/2019	26.49	131.49	None	Non-innovator Multiple Source Drug	1368	None	Change in market dynamics.	None	Change in market dynamics.	None	None	None	None	None	None	None	None	None	None	None	Drug is developed by Epic Pharma.
Rx0000094	Epic Pharma	12/31/2019	42806012201	Sotalol Hcl (AF) 120mg 100 Tab Epic	11/15/2019	78.39	130.65	None	Non-innovator Multiple Source Drug	5303	None	Change in market dynamics	None	No change / improvement made to drug.	None	None	None	None	None	None	None	None	None	None	None	Epic Pharma developed these drugs
Rx0000094	Epic Pharma	12/31/2019	42806012301	Sotalol Hcl (AF) 160mg 100 Tab Epic	11/15/2019	98.03	163.38	None	Non-innovator Multiple Source Drug	1980	None	Change in market dynamics	None	No change / improvement made to drug.	None	None	None	None	None	None	None	None	None	None	None	Epic Pharma developed these drugs
Rx0000094	Epic Pharma	12/31/2019	42806012101	Sotalol Hcl (AF) 80mg 100 Tab Epic	11/15/2019	58.77	97.95	None	Non-innovator Multiple Source Drug	12719	None	Change in market dynamics	None	No change / improvement made to drug.	None	None	None	None	None	None	None	None	None	None	None	Epic Pharma developed these drugs
Rx0000104	EUSA Pharma (US) LLC	12/31/2019	57894042001	SYLVANT 100MG VIAL US	10/01/2019	92.96	1071.47	08/01/2027	Single Source Drug	4342	None	No factors to report	None	No change improvements	None	12/22/2018	Janssen Biotech	115000000	None	Acquisition price of $115,000,000 ($115 Million) includes both NDCs 57894-0420-01 and 57894-0421-01	910.24	883.73	2014	833.00	None	None
Rx0000104	EUSA Pharma (US) LLC	12/31/2019	57894042101	SYLVANT 400MG VIAL US	10/01/2019	371.83	4285.87	08/01/2027	Single Source Drug	5536	None	No factors to report	None	No change improvements	None	12/22/2018	Janssen Biotech	115000000	None	Acquisition price of $115,000,000 ($115 Million) includes both NDCs 57894-0420-01 and 57894-0421-01	3640.96	3534.92	2014	3332.00	None	None
Rx0000010	Exelixis, Inc.	09/30/2019	42388002426	CABOMETYX 20MG 30 TAB BTL EACH	07/01/2019	826.44	19191.85	07/09/2033	Single Source Drug	None	1	Exelixis' Mission: Exelixis strives to accelerate the discovery, development and commercialization of new medicines for difficult-to-treat cancers. That mission, however, entails tremendous risk of failure and research and development costs that total in the billions of dollars. At the present time, CABOMETYX and COMETRIQ are the only products that Exelixis sells and comprise the vast majority of Exelixis' revenue. Exelixis is committed to spending the largest portion of this revenue on drug discovery research and clinical development, and to pricing CABOMETYX consistent with its value when compared to competitive products approved for similar conditions. Drug Discovery Factors: Having recently constructed new laboratory facilities, Exelixis re-launched its drug discovery activities in 2018 and is working to discover the next generation of cancer therapies. Exelixis considered the investments necessary to undertake and support these drug discovery efforts when it contemplated changes to CABOMETYX's wholesale acquisition cost. CABOMETYX Development Factors: Since the initial commercial launch of CABOMETYX, Exelixis has received extensive additional data demonstrating that cabozantinib shows activity in an extremely broad and diverse collection of additional cancers. Alone and in combination with other therapies, it is currently being studied in over 100 clinical trials for over 20 different forms of cancer. Exelixis considered the cost of this clinical development program, and the need to expand it to reach CABOMETYX's full potential for treating the largest number of cancer patients, when it contemplated changes to the wholesale acquisition cost of CABOMETYX. CABOMETYX Value Factors: CABOMETYX has been approved by the FDA to treat patients with liver and kidney cancer and has shown impressive efficacy relative to its competitors in treating patients with these life threatening diseases. It is the only drug of its kind to improve overall survival in a statistically significant manner in both kidney and liver cancer. When Exelixis contemplated a change to the wholesale acquisition cost for CABOMETYX, Exelixis considered the clinical value proposition of CABOMETYX relative to its competitor prescription drugs, as well as the competitive market generally and the existing price points of competitors. CABOMETYX Cost Factors: At Exelixis, we are committed to ensuring that all patients in need can access our medicines. To ensure that the supply of CABOMETYX for our customers, and ultimately, patients is safe and uninterrupted, Exelixis has expanded its supply chain network, establishing redundancies to prevent supply disruption. In addition, Exelixis has and continues to incur increasing costs in manufacturing due to volatility in the cost of raw materials and other inputs. When Exelixis contemplated changes to the wholesale acquisition cost of CABOMETYX, Exelixis considered these investments in expanding and improving our manufacturing capabilities and supply chain, as well as rising manufacturing costs.	None	It is Exelixis' stated mission to develop innovative, effective, tolerable and durable treatments for patients with cancer. To accomplish this, Exelixis has and continues to increase our investments in innovative research and development activities. In pre-clinical and clinical testing, Cabometyx (cabozantinib) has shown promising activity against many forms of cancer and Exelixis is therefore engaged in a very broad clinical development program aimed at improving Cabometyx by exploring the medicine's full therapeutic potential to help patients. To fund that program, and otherwise support our other research, development and business operations, it is necessary for Exelixis to increase the wholesale acquisition cost of Cabometyx when market conditions permit such an increase.	None	None	None	None	None	None	None	None	None	None	None	Exelixis did not acquire this product from another manufacturer within the previous five years. As a result, Exelixis has left columns N-U blank because they are not applicable to this product. The patent expiration date contained in this report is limited to the patent information reported in the federal Food and Drug Administration's Orange Book, as of 10/30/19. As a result, the reported patent expiration date is limited to issued U.S. patents. Further, the reported patent expiration date does not reflect any pending patents, patent term extensions, pediatric exclusivity, or patent-related litigation, each of which is speculative and which may extend or shorten the reported expiration date
Rx0000010	Exelixis, Inc.	09/30/2019	42388002526	CABOMETYX 40MG 30 TAB BTL EACH	07/01/2019	826.44	19191.85	07/09/2033	Single Source Drug	None	1	Exelixis' Mission: Exelixis strives to accelerate the discovery, development and commercialization of new medicines for difficult-to-treat cancers. That mission, however, entails tremendous risk of failure and research and development costs that total in the billions of dollars. At the present time, CABOMETYX and COMETRIQ are the only products that Exelixis sells and comprise the vast majority of Exelixis' revenue. Exelixis is committed to spending the largest portion of this revenue on drug discovery research and clinical development, and to pricing CABOMETYX consistent with its value when compared to competitive products approved for similar conditions. Drug Discovery Factors: Having recently constructed new laboratory facilities, Exelixis re-launched its drug discovery activities in 2018 and is working to discover the next generation of cancer therapies. Exelixis considered the investments necessary to undertake and support these drug discovery efforts when it contemplated changes to CABOMETYX's wholesale acquisition cost. CABOMETYX Development Factors: Since the initial commercial launch of CABOMETYX, Exelixis has received extensive additional data demonstrating that cabozantinib shows activity in an extremely broad and diverse collection of additional cancers. Alone and in combination with other therapies, it is currently being studied in over 100 clinical trials for over 20 different forms of cancer. Exelixis considered the cost of this clinical development program, and the need to expand it to reach CABOMETYX's full potential for treating the largest number of cancer patients, when it contemplated changes to the wholesale acquisition cost of CABOMETYX. CABOMETYX Value Factors: CABOMETYX has been approved by the FDA to treat patients with liver and kidney cancer and has shown impressive efficacy relative to its competitors in treating patients with these life threatening diseases. It is the only drug of its kind to improve overall survival in a statistically significant manner in both kidney and liver cancer. When Exelixis contemplated a change to the wholesale acquisition cost for CABOMETYX, Exelixis considered the clinical value proposition of CABOMETYX relative to its competitor prescription drugs, as well as the competitive market generally and the existing price points of competitors. CABOMETYX Cost Factors: At Exelixis, we are committed to ensuring that all patients in need can access our medicines. To ensure that the supply of CABOMETYX for our customers, and ultimately, patients is safe and uninterrupted, Exelixis has expanded its supply chain network, establishing redundancies to prevent supply disruption. In addition, Exelixis has and continues to incur increasing costs in manufacturing due to volatility in the cost of raw materials and other inputs. When Exelixis contemplated changes to the wholesale acquisition cost of CABOMETYX, Exelixis considered these investments in expanding and improving our manufacturing capabilities and supply chain, as well as rising manufacturing costs.	None	It is Exelixis' stated mission to develop innovative, effective, tolerable and durable treatments for patients with cancer. To accomplish this, Exelixis has and continues to increase our investments in innovative research and development activities. In pre-clinical and clinical testing, Cabometyx (cabozantinib) has shown promising activity against many forms of cancer and Exelixis is therefore engaged in a very broad clinical development program aimed at improving Cabometyx by exploring the medicine's full therapeutic potential to help patients. To fund that program, and otherwise support our other research, development and business operations, it is necessary for Exelixis to increase the wholesale acquisition cost of Cabometyx when market conditions permit such an increase.	None	None	None	None	None	None	None	None	None	None	None	Exelixis did not acquire this product from another manufacturer within the previous five years. As a result, Exelixis has left columns N-U blank because they are not applicable to this product. The patent expiration date contained in this report is limited to the patent information reported in the federal Food and Drug Administration's Orange Book, as of 10/30/19. As a result, the reported patent expiration date is limited to issued U.S. patents. Further, the reported patent expiration date does not reflect any pending patents, patent term extensions, pediatric exclusivity, or patent-related litigation, each of which is speculative and which may extend or shorten the reported expiration date
Rx0000010	Exelixis, Inc.	09/30/2019	42388002326	CABOMETYX 60MG 30 TAB BTL EACH	07/01/2019	826.44	19191.85	07/09/2033	Single Source Drug	None	1	Exelixis' Mission: Exelixis strives to accelerate the discovery, development and commercialization of new medicines for difficult-to-treat cancers. That mission, however, entails tremendous risk of failure and research and development costs that total in the billions of dollars. At the present time, CABOMETYX and COMETRIQ are the only products that Exelixis sells and comprise the vast majority of Exelixis' revenue. Exelixis is committed to spending the largest portion of this revenue on drug discovery research and clinical development, and to pricing CABOMETYX consistent with its value when compared to competitive products approved for similar conditions. Drug Discovery Factors: Having recently constructed new laboratory facilities, Exelixis re-launched its drug discovery activities in 2018 and is working to discover the next generation of cancer therapies. Exelixis considered the investments necessary to undertake and support these drug discovery efforts when it contemplated changes to CABOMETYX's wholesale acquisition cost. CABOMETYX Development Factors: Since the initial commercial launch of CABOMETYX, Exelixis has received extensive additional data demonstrating that cabozantinib shows activity in an extremely broad and diverse collection of additional cancers. Alone and in combination with other therapies, it is currently being studied in over 100 clinical trials for over 20 different forms of cancer. Exelixis considered the cost of this clinical development program, and the need to expand it to reach CABOMETYX's full potential for treating the largest number of cancer patients, when it contemplated changes to the wholesale acquisition cost of CABOMETYX. CABOMETYX Value Factors: CABOMETYX has been approved by the FDA to treat patients with liver and kidney cancer and has shown impressive efficacy relative to its competitors in treating patients with these life threatening diseases. It is the only drug of its kind to improve overall survival in a statistically significant manner in both kidney and liver cancer. When Exelixis contemplated a change to the wholesale acquisition cost for CABOMETYX, Exelixis considered the clinical value proposition of CABOMETYX relative to its competitor prescription drugs, as well as the competitive market generally and the existing price points of competitors. CABOMETYX Cost Factors: At Exelixis, we are committed to ensuring that all patients in need can access our medicines. To ensure that the supply of CABOMETYX for our customers, and ultimately, patients is safe and uninterrupted, Exelixis has expanded its supply chain network, establishing redundancies to prevent supply disruption. In addition, Exelixis has and continues to incur increasing costs in manufacturing due to volatility in the cost of raw materials and other inputs. When Exelixis contemplated changes to the wholesale acquisition cost of CABOMETYX, Exelixis considered these investments in expanding and improving our manufacturing capabilities and supply chain, as well as rising manufacturing costs.	None	It is Exelixis' stated mission to develop innovative, effective, tolerable and durable treatments for patients with cancer. To accomplish this, Exelixis has and continues to increase our investments in innovative research and development activities. In pre-clinical and clinical testing, Cabometyx (cabozantinib) has shown promising activity against many forms of cancer and Exelixis is therefore engaged in a very broad clinical development program aimed at improving Cabometyx by exploring the medicine's full therapeutic potential to help patients. To fund that program, and otherwise support our other research, development and business operations, it is necessary for Exelixis to increase the wholesale acquisition cost of Cabometyx when market conditions permit such an increase.	None	None	None	None	None	None	None	None	None	None	None	Exelixis did not acquire this product from another manufacturer within the previous five years. As a result, Exelixis has left columns N-U blank because they are not applicable to this product. The patent expiration date contained in this report is limited to the patent information reported in the federal Food and Drug Administration's Orange Book, as of 10/30/19. As a result, the reported patent expiration date is limited to issued U.S. patents. Further, the reported patent expiration date does not reflect any pending patents, patent term extensions, pediatric exclusivity, or patent-related litigation, each of which is speculative and which may extend or shorten the reported expiration date
Rx0000063	Ferring Pharmaceuticals	03/31/2019	55566280001	Cervidil 10MG VAGINAL INSERT (dinoprostone, 10mg)	01/08/2019	35.62	410.59	None	Single Source Drug	None	1	None	1	None	1	10/01/2015	Allergan PLC	None	1	None	306.27	None	1995	140.00	None	None
Rx0000063	Ferring Pharmaceuticals	03/31/2019	55566650003	Endometrin 100 MG SUPPOSITORY (progesteron vaginal inserts 100 mg)	01/08/2019	14.14	249.70	11/17/2019	Single Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	None
Rx0000063	Ferring Pharmaceuticals	06/30/2019	55566750102	MENOPUR (menotropins for injection)	04/19/2019	55.95	988.25	None	Single Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	Note: The package WAC price represents 5 Vials of Menopur.
Rx0000129	Fresenius Kabi USA LLC	06/30/2019	63323036061	Calcium Gluconate 10g 100mL Plastic Vial	06/07/2019	300.00	900.00	None	Innovator Multiple Source Drug	None	1	None	1	No	None	None	None	None	None	None	None	None	None	None	None	The information contained in this report is subject to the following limitations and assumptions. (1) Consistent with the relevant statutes and regulations, all information contained in this report is limited to that which Fresenius Kabi USA (“Fresenius Kabi”) believes is otherwise in the public domain or publicly available. Where possible, Fresenius Kabi has used the non-public indicator to indicate it does not believe the corresponding data element is otherwise in the public domain or publicly available. (2) For Column F, Fresenius Kabi did not provide a patent expiration date for products that have lost patent exclusivity. (3) For Columns N-U, Fresenius Kabi has not provided a response for "drug products" (as defined in the regulations) that were not acquired in their finished form from an unrelated company in the previous 5 years. (4) Fresenius Kabi USA's product portfolio, including this product, consists primarily of sterile injectable products administered during a patient's inpatient hospital stay. Such hospital stays are subject to variability depending upon a particular patient's needs. The dosing requirements as set forth in the prescribing information for these products are given as a range, based in large part on the number of days of the patient's admission. As such, Fresenius Kabi has based its calculations for purposes of this submission on the recommended dosage for the average length of stay within range present in the product's prescribing information. For example, if a product's prescribing information requires the administration of 1 vial of drug product per day over the course of a 3 to 5 day admission, Fresenius Kabi has based the calculation on 1 vial administered during a 4-day patient admission (an average of the 3-5 day range).
Rx0000129	Fresenius Kabi USA LLC	06/30/2019	63323036059	Calcium Gluconate 5g 50mL SDV Plastic	06/07/2019	187.50	562.50	None	Innovator Multiple Source Drug	None	1	None	1	No	None	None	None	None	None	None	None	None	None	None	None	The information contained in this report is subject to the following limitations and assumptions. (1) Consistent with the relevant statutes and regulations, all information contained in this report is limited to that which Fresenius Kabi USA (“Fresenius Kabi”) believes is otherwise in the public domain or publicly available. Where possible, Fresenius Kabi has used the non-public indicator to indicate it does not believe the corresponding data element is otherwise in the public domain or publicly available. (2) For Column F, Fresenius Kabi did not provide a patent expiration date for products that have lost patent exclusivity. (3) For Columns N-U, Fresenius Kabi has not provided a response for "drug products" (as defined in the regulations) that were not acquired in their finished form from an unrelated company in the previous 5 years. (4) Fresenius Kabi USA's product portfolio, including this product, consists primarily of sterile injectable products administered during a patient's inpatient hospital stay. Such hospital stays are subject to variability depending upon a particular patient's needs. The dosing requirements as set forth in the prescribing information for these products are given as a range, based in large part on the number of days of the patient's admission. As such, Fresenius Kabi has based its calculations for purposes of this submission on the recommended dosage for the average length of stay within range present in the product's prescribing information. For example, if a product's prescribing information requires the administration of 1 vial of drug product per day over the course of a 3 to 5 day admission, Fresenius Kabi has based the calculation on 1 vial administered during a 4-day patient admission (an average of the 3-5 day range).
Rx0000129	Fresenius Kabi USA LLC	09/30/2019	63323001095	Gentamicin 800mg 20mL MDV Premier Pro Rx (package size 25 vials)	08/30/2019	102.00	556.75	None	Non-innovator Multiple Source Drug	None	1	None	1	No	None	None	None	None	None	None	None	None	None	None	None	The information contained in this report is subject to the following limitations and assumptions. (1) Consistent with the relevant statutes and regulations, all information contained in this report is limited to that which Fresenius Kabi USA (“Fresenius Kabi”) believes is otherwise in the public domain or publicly available. Where possible, Fresenius Kabi has used the non-public indicator to indicate it does not believe the corresponding data element is otherwise in the public domain or publicly available. (2) For Column F, Fresenius Kabi did not provide a patent expiration date for products that have lost patent exclusivity. (3) For Columns N-U, Fresenius Kabi has not provided a response for "drug products" (as defined in the regulations) that were not acquired in their finished form from an unrelated company in the previous 5 years. (4) Fresenius Kabi USA's product portfolio, including this product, consists primarily of sterile injectable products administered during a patient's inpatient hospital stay. Such hospital stays are subject to variability depending upon a particular patient's needs. The dosing requirements as set forth in the prescribing information for these products are given as a range, based in large part on the number of days of the patient's admission. As such, Fresenius Kabi has based its calculations for purposes of this submission on the recommended dosage for the average length of stay within range present in the product's prescribing information. For example, if a product's prescribing information requires the administration of 1 vial of drug product per day over the course of a 3 to 5 day admission, Fresenius Kabi has based the calculation on 1 vial administered during a 4-day patient admission (an average of the 3-5 day range). (5) Please note that although the WAC pricing provided in this submission is at that pack level for this reporting purpose, none of these products are administered at a pack level for course of therapy purposes.
Rx0000129	Fresenius Kabi USA LLC	06/30/2019	63323045909	Heparin Sodium 40,000USP 4mL MDV	04/26/2019	67.50	248.75	None	Innovator Multiple Source Drug	None	1	None	1	No	None	None	None	None	None	None	None	None	None	None	None	The information contained in this report is subject to the following limitations and assumptions. (1) Consistent with the relevant statutes and regulations, all information contained in this report is limited to that which Fresenius Kabi USA (“Fresenius Kabi”) believes is otherwise in the public domain or publicly available. Where possible, Fresenius Kabi has used the non-public indicator to indicate it does not believe the corresponding data element is otherwise in the public domain or publicly available. (2) For Column F, Fresenius Kabi did not provide a patent expiration date for products that have lost patent exclusivity. (3) For Columns N-U, Fresenius Kabi has not provided a response for "drug products" (as defined in the regulations) that were not acquired in their finished form from an unrelated company in the previous 5 years. (4) Fresenius Kabi USA's product portfolio, including this product, consists primarily of sterile injectable products administered during a patient's inpatient hospital stay. Such hospital stays are subject to variability depending upon a particular patient's needs. The dosing requirements as set forth in the prescribing information for these products are given as a range, based in large part on the number of days of the patient's admission. As such, Fresenius Kabi has based its calculations for purposes of this submission on the recommended dosage for the average length of stay within range present in the product's prescribing information. For example, if a product's prescribing information requires the administration of 1 vial of drug product per day over the course of a 3 to 5 day admission, Fresenius Kabi has based the calculation on 1 vial administered during a 4-day patient admission (an average of the 3-5 day range).
Rx0000129	Fresenius Kabi USA LLC	12/31/2019	63323026255	Heparin Sodium Inj NovaPlus Liquid 5000 usp 3mL	10/01/2019	16.25	50.00	None	Innovator Multiple Source Drug	None	1	None	1	No	None	None	None	None	None	None	None	None	None	None	None	None
Rx0000129	Fresenius Kabi USA LLC	09/30/2019	76045010810	Simplist® Heparin Sodium Injection, USP 5,000 Units 1 mL. (package size: 24 injections)	07/17/2019	32.88	92.40	None	Non-innovator Multiple Source Drug	None	1	None	1	No	None	01/07/2016	Becton Dickinson and Company	None	1	This product was acquired when we purchased BDRx, Inc. The terms of this deal were not made public. The agreement was in the form of a stock deal, not an asset deal, so there is no way to determine the cost of this molecule individually.	59.52	None	2016	59.52	None	The information contained in this report is subject to the following limitations and assumptions. (1) Consistent with the relevant statutes and regulations, all information contained in this report is limited to that which Fresenius Kabi USA (“Fresenius Kabi”) believes is otherwise in the public domain or publicly available. Where possible, Fresenius Kabi has used the non-public indicator to indicate it does not believe the corresponding data element is otherwise in the public domain or publicly available. (2) For Column F, Fresenius Kabi did not provide a patent expiration date for products that have lost patent exclusivity. (3) Fresenius Kabi USA's product portfolio, including this product, consists primarily of sterile injectable products administered during a patient's inpatient hospital stay. Such hospital stays are subject to variability depending upon a particular patient's needs. The dosing requirements as set forth in the prescribing information for these products are given as a range, based in large part on the number of days of the patient's admission. As such, Fresenius Kabi has based its calculations for purposes of this submission on the recommended dosage for the average length of stay within range present in the product's prescribing information. For example, if a product's prescribing information requires the administration of 1 vial of drug product per day over the course of a 3 to 5 day admission, Fresenius Kabi has based the calculation on 1 vial administered during a 4-day patient admission (an average of the 3-5 day range). (4) Please note that although the WAC pricing provided in this submission is at that pack level for this reporting purpose, none of these products are administered at a pack level for course of therapy purposes. (5) This product was not launched by prior manufacturer. It was first introduced to the market by Fresenius Kabi 11 months after the acquisition.
Rx0000129	Fresenius Kabi USA LLC	06/30/2019	76045010710	Simplist® Ketorolac Tromethamine Injection, USP 15 mg 1 mL	04/26/2019	23.04	80.64	04/23/2032	Non-innovator Multiple Source Drug	None	1	None	1	No	None	None	None	None	None	None	None	None	None	None	None	The information contained in this report is subject to the following limitations and assumptions. (1) Consistent with the relevant statutes and regulations, all information contained in this report is limited to that which Fresenius Kabi USA (“Fresenius Kabi”) believes is otherwise in the public domain or publicly available. Where possible, Fresenius Kabi has used the non-public indicator to indicate it does not believe the corresponding data element is otherwise in the public domain or publicly available. (2) For Column F, Fresenius Kabi did not provide a patent expiration date for products that have lost patent exclusivity. (3) For Columns N-U, Fresenius Kabi has not provided a response for "drug products" (as defined in the regulations) that were not acquired in their finished form from an unrelated company in the previous 5 years. (4) Fresenius Kabi USA's product portfolio, including this product, consists primarily of sterile injectable products administered during a patient's inpatient hospital stay. Such hospital stays are subject to variability depending upon a particular patient's needs. The dosing requirements as set forth in the prescribing information for these products are given as a range, based in large part on the number of days of the patient's admission. As such, Fresenius Kabi has based its calculations for purposes of this submission on the recommended dosage for the average length of stay within range present in the product's prescribing information. For example, if a product's prescribing information requires the administration of 1 vial of drug product per day over the course of a 3 to 5 day admission, Fresenius Kabi has based the calculation on 1 vial administered during a 4-day patient admission (an average of the 3-5 day range). (5) The patent for this product applies to the primary container (syringe), not the molecule.
Rx0000129	Fresenius Kabi USA LLC	09/30/2019	63323030502	Tobramycin 20mg 2mL Pediatric MDV (package size: 25 vials)	08/30/2019	36.50	132.00	None	Non-innovator Multiple Source Drug	None	1	None	1	No	None	None	None	None	None	None	None	None	None	None	None	The information contained in this report is subject to the following limitations and assumptions. (1) Consistent with the relevant statutes and regulations, all information contained in this report is limited to that which Fresenius Kabi USA (“Fresenius Kabi”) believes is otherwise in the public domain or publicly available. Where possible, Fresenius Kabi has used the non-public indicator to indicate it does not believe the corresponding data element is otherwise in the public domain or publicly available. (2) For Column F, Fresenius Kabi did not provide a patent expiration date for products that have lost patent exclusivity. (3) For Columns N-U, Fresenius Kabi has not provided a response for "drug products" (as defined in the regulations) that were not acquired in their finished form from an unrelated company in the previous 5 years. (4) Fresenius Kabi USA's product portfolio, including this product, consists primarily of sterile injectable products administered during a patient's inpatient hospital stay. Such hospital stays are subject to variability depending upon a particular patient's needs. The dosing requirements as set forth in the prescribing information for these products are given as a range, based in large part on the number of days of the patient's admission. As such, Fresenius Kabi has based its calculations for purposes of this submission on the recommended dosage for the average length of stay within range present in the product's prescribing information. For example, if a product's prescribing information requires the administration of 1 vial of drug product per day over the course of a 3 to 5 day admission, Fresenius Kabi has based the calculation on 1 vial administered during a 4-day patient admission (an average of the 3-5 day range). (5) Please note that although the WAC pricing provided in this submission is at that pack level for this reporting purpose, none of these products are administered at a pack level for course of therapy purposes.
Rx0000100	Fresenius Medical Care	03/31/2019	49230064331	PHOSLYRA 667MG/5ML ORAL SOLUTION 473ML BOTTLE	01/01/2019	7.04	147.86	02/23/2030	Single Source Drug	None	1	The increase in Wholesale Acquisition Cost (WAC) for the products is due to increases in the costs of manufacturing and distribution, specifically including increases in the cost of the active pharmaceutical ingredients (API) of the products, increases in shipping for the products, and increases in costs to market the products.	None	THIS WAC INCREASE IS NOT NECCESSITATED BY A CHANGE OR IMPROVEMENT IN THE PRESCRIPTION DRUG	None	None	None	None	None	None	None	None	None	None	None	Please note that this report and its contents are exempted from disclosure under the California Public Records Act, Cal. Gov. Code § 6250 et seq. (“PRA”) as the material contains and constitutes FUSA’s proprietary commercial information and otherwise would not be in the public interest to disclose. Please contact Domenic Gaeta at domenic.gaeta@fmc-na.com regarding any PRA requests so that we may take appropriate steps to protect such information. Fresenius Medical Care did not acquire Phoslyra in the prior five year period.
Rx0000100	Fresenius Medical Care	12/31/2019	49230064331	PHOSLYRA 667MG/5ML ORAL SOLUTION 473ML BOTTLE	10/01/2019	6.89	154.75	02/23/2030	Single Source Drug	None	1	The increase in Wholesale Acquisition Cost (WAC) for the products is due to increases in the costs of manufacturing and distribution, specifically including increases in the cost of the active pharmaceutical ingredients (API) of the products, increases in shipping for the products, and increases in costs to market the products.	None	This WAC increase is not necessitated by a change or improvement in the prescription drug.	None	None	None	None	None	None	None	None	None	None	None	Please note that this report and its contents are exempted from disclosure under the California Public Records Act, Cal. Gov. Code § 6250 et seq. (“PRA”) as the material contains and constitutes FUSA’s proprietary commercial information and otherwise would not be in the public interest to disclose. Please contact Domenic Gaeta at domenic.gaeta@fmc-na.com regarding any PRA requests so that we may take appropriate steps to protect such information. Fresenius Medical Care did not acquire Phoslyra in the prior five year period.
Rx0000100	Fresenius Medical Care	03/31/2019	49230064551	VELPHORO 500MG CHEWABLE TABLETS 90 TABLET BOTTLE	01/01/2019	56.92	1195.31	01/23/2030	Single Source Drug	None	1	The increase in Wholesale Acquisition Cost (WAC) for the products is due to increases in the costs of manufacturing and distribution, specifically including increases in the cost of the active pharmaceutical ingredients (API) of the products, increases in shipping for the products, and increases in costs to market the products.	None	THIS WAC INCREASE IS NOT NECCESSITATED BY A CHANGE OR IMPROVEMENT IN THE PRESCRIPTION DRUG	None	01/10/2014	Vifor Fresenius Medical Care Renal Pharma Ltd.	None	1	n/a	855.00	None	2014	855.00	None	Please note that this report and its contents are exempted from disclosure under the California Public Records Act, Cal. Gov. Code § 6250 et seq. (“PRA”) as the material contains and constitutes FUSA’s proprietary commercial information and otherwise would not be in the public interest to disclose. Please contact Domenic Gaeta at domenic.gaeta@fmc-na.com regarding any PRA requests so that we may take appropriate steps to protect such information. Fresenius is the authorized distributor for Velphoro.
Rx0000100	Fresenius Medical Care	12/31/2019	49230064551	VELPHORO 500MG CHEWABLE TABLETS 90 TABLET BOTTLE	10/01/2019	55.70	1251.01	01/23/2030	Single Source Drug	None	1	The increase in Wholesale Acquisition Cost (WAC) for the products is due to increases in the costs of manufacturing and distribution, specifically including increases in the cost of the active pharmaceutical ingredients (API) of the products, increases in shipping for the products, and increases in costs to market the products.	None	This WAC increase is not necessitated by a change or improvement in the prescription drug.	None	None	None	None	None	None	None	None	None	None	None	Please note that this report and its contents are exempted from disclosure under the California Public Records Act, Cal. Gov. Code § 6250 et seq. (“PRA”) as the material contains and constitutes FUSA’s proprietary commercial information and otherwise would not be in the public interest to disclose. Please contact Domenic Gaeta at domenic.gaeta@fmc-na.com regarding any PRA requests so that we may take appropriate steps to protect such information. Fresenius Medical Care is the authorized distributor for Velphoro. Fresenius Medical Care did not acquire Velphoro in the prior five year period.
Rx0000260	Galderma Laboratories	06/30/2019	00299590645	Epiduo?Forte Gel 0.1% / 2.5% Pump 45GM (Adapalene and Benzoyl Peroxide) 3 mg/g, 25 mg/g	04/05/2019	25.90	554.25	12/23/2022	Single Source Drug	None	1	None	1	None	None	None	None	None	None	None	None	None	None	None	None	Drug developed by Galderma
Rx0000260	Galderma Laboratories	06/30/2019	00299598030	Mirvaso? Topical Gel 0.33% 30GM (Brimonidine) 5 mg/g	04/05/2019	23.45	501.15	03/25/2031	Single Source Drug	None	1	None	1	None	None	None	None	None	None	None	None	None	None	None	None	Drug developed by Galderma
Rx0000260	Galderma Laboratories	06/30/2019	00299598035	Mirvaso? Topical Gel 0.33% 30GM PUMP (Brimonidine) 5 mg/g	04/05/2019	23.45	501.15	03/25/2031	Single Source Drug	None	1	None	1	None	None	None	None	None	None	None	None	None	None	None	None	Drug developed by Galderma
Rx0000260	Galderma Laboratories	06/30/2019	00299382230	Oracea? Capsules 40MG (Doxycycline, USP) 40 mg/1	04/05/2019	34.55	738.95	12/19/2027	Single Source Drug	None	1	None	1	None	None	None	None	None	None	None	None	None	None	None	None	Drug purchased by Galderma more than five years ago
Rx0000034	Genentech USA	09/30/2019	50242013601	Actemra 200mg (10mL)	07/01/2019	27.30	1119.33	None	Single Source Drug	None	1	We take decisions related to the prices of our medicines very seriously. Taking a carefully considered approach to the list price of our medicines is the best thing we as a manufacturer can do to enable broad access to patients. When determining pricing, we consider a number of factors including: how well the medicine works and how it compares to other available treatments; the financial resources required to continue discovering new medicines for people with serious diseases; and how to ensure that the price doesn’t prevent our medicines from getting to people who need them. We strive for the right balance between ensuring people have access to the medicines they need, while investing in future breakthroughs.	None	We continue to invest in significant and sustained research for each of our medicines after they first become available. We follow the science to determine how they might help people with other diseases who need new medicines and also how we might make even better medicines. When determining pricing for a new vial size or a new method of action, we take into consideration the price of the existing medicine.	None	None	None	None	None	None	None	None	None	None	https://reports.siera.oshpd.ca.gov/api/report/drug-pricing/attachment?id=315, https://reports.siera.oshpd.ca.gov/api/report/drug-pricing/attachment?id=323	Patent expiration (column 6) and Unit Sales in US (column 8) are not filled out numerically as the information is not publicly available. The acquisition fields are left blank as the drug product was not acquired from a third party. There are two drug products with a price increase but do not have a five year history. Please see the supporting documents for additional information.
Rx0000034	Genentech USA	09/30/2019	50242013701	Actemra 400 mg (20mL)	07/01/2019	54.60	2238.65	None	Single Source Drug	None	1	We take decisions related to the prices of our medicines very seriously. Taking a carefully considered approach to the list price of our medicines is the best thing we as a manufacturer can do to enable broad access to patients. When determining pricing, we consider a number of factors including: how well the medicine works and how it compares to other available treatments; the financial resources required to continue discovering new medicines for people with serious diseases; and how to ensure that the price doesn’t prevent our medicines from getting to people who need them. We strive for the right balance between ensuring people have access to the medicines they need, while investing in future breakthroughs.	None	We continue to invest in significant and sustained research for each of our medicines after they first become available. We follow the science to determine how they might help people with other diseases who need new medicines and also how we might make even better medicines. When determining pricing for a new vial size or a new method of action, we take into consideration the price of the existing medicine.	None	None	None	None	None	None	None	None	None	None	https://reports.siera.oshpd.ca.gov/api/report/drug-pricing/attachment?id=316, https://reports.siera.oshpd.ca.gov/api/report/drug-pricing/attachment?id=324	Patent expiration (column 6) and Unit Sales in US (column 8) are not filled out numerically as the information is not publicly available. The acquisition fields are left blank as the drug product was not acquired from a third party. There are two drug products with a price increase but do not have a five year history. Please see the supporting documents for additional information.
Rx0000034	Genentech USA	09/30/2019	50242013501	Actemra 80 mg (4mL)	07/01/2019	10.92	447.73	None	Single Source Drug	None	1	We take decisions related to the prices of our medicines very seriously. Taking a carefully considered approach to the list price of our medicines is the best thing we as a manufacturer can do to enable broad access to patients. When determining pricing, we consider a number of factors including: how well the medicine works and how it compares to other available treatments; the financial resources required to continue discovering new medicines for people with serious diseases; and how to ensure that the price doesn’t prevent our medicines from getting to people who need them. We strive for the right balance between ensuring people have access to the medicines they need, while investing in future breakthroughs.	None	We continue to invest in significant and sustained research for each of our medicines after they first become available. We follow the science to determine how they might help people with other diseases who need new medicines and also how we might make even better medicines. When determining pricing for a new vial size or a new method of action, we take into consideration the price of the existing medicine.	None	None	None	None	None	None	None	None	None	None	https://reports.siera.oshpd.ca.gov/api/report/drug-pricing/attachment?id=314, https://reports.siera.oshpd.ca.gov/api/report/drug-pricing/attachment?id=322	Patent expiration (column 6) and Unit Sales in US (column 8) are not filled out numerically as the information is not publicly available. The acquisition fields are left blank as the drug product was not acquired from a third party. There are two drug products with a price increase but do not have a five year history. Please see the supporting documents for additional information.
Rx0000034	Genentech USA	09/30/2019	50242013801	Actemra SC 162 mg (0.9 mL)	07/01/2019	29.54	1014.26	None	Single Source Drug	None	1	We take decisions related to the prices of our medicines very seriously. Taking a carefully considered approach to the list price of our medicines is the best thing we as a manufacturer can do to enable broad access to patients. When determining pricing, we consider a number of factors including: how well the medicine works and how it compares to other available treatments; the financial resources required to continue discovering new medicines for people with serious diseases; and how to ensure that the price doesn’t prevent our medicines from getting to people who need them. We strive for the right balance between ensuring people have access to the medicines they need, while investing in future breakthroughs.	None	We continue to invest in significant and sustained research for each of our medicines after they first become available. We follow the science to determine how they might help people with other diseases who need new medicines and also how we might make even better medicines. When determining pricing for a new vial size or a new method of action, we take into consideration the price of the existing medicine.	None	None	None	None	None	None	None	None	None	None	https://reports.siera.oshpd.ca.gov/api/report/drug-pricing/attachment?id=317, https://reports.siera.oshpd.ca.gov/api/report/drug-pricing/attachment?id=325	Patent expiration (column 6) and Unit Sales in US (column 8) are not filled out numerically as the information is not publicly available. The acquisition fields are left blank as the drug product was not acquired from a third party. There are two drug products with a price increase but do not have a five year history. Please see the supporting documents for additional information.
Rx0000034	Genentech USA	09/30/2019	50242007001	Gazyva 1,000 mg (40mL)	07/01/2019	96.81	6551.00	None	Single Source Drug	None	1	We take decisions related to the prices of our medicines very seriously. Taking a carefully considered approach to the list price of our medicines is the best thing we as a manufacturer can do to enable broad access to patients. When determining pricing, we consider a number of factors including: how well the medicine works and how it compares to other available treatments; the financial resources required to continue discovering new medicines for people with serious diseases; and how to ensure that the price doesn’t prevent our medicines from getting to people who need them. We strive for the right balance between ensuring people have access to the medicines they need, while investing in future breakthroughs.	None	We continue to invest in significant and sustained research for each of our medicines after they first become available. We follow the science to determine how they might help people with other diseases who need new medicines and also how we might make even better medicines. When determining pricing for a new vial size or a new method of action, we take into consideration the price of the existing medicine.	None	None	None	None	None	None	None	None	None	None	https://reports.siera.oshpd.ca.gov/api/report/drug-pricing/attachment?id=328	Patent expiration (column 6) and Unit Sales in US (column 8) are not filled out numerically as the information is not publicly available. The acquisition fields are left blank as the drug product was not acquired from a third party. There are two drug products with a price increase but do not have a five year history. Please see the supporting documents for additional information.
Rx0000034	Genentech USA	09/30/2019	50242012001	TNKase 50 mg 1VILY US	07/01/2019	175.86	6037.73	None	Single Source Drug	None	1	We take decisions related to the prices of our medicines very seriously. Taking a carefully considered approach to the list price of our medicines is the best thing we as a manufacturer can do to enable broad access to patients. When determining pricing, we consider a number of factors including: how well the medicine works and how it compares to other available treatments; the financial resources required to continue discovering new medicines for people with serious diseases; and how to ensure that the price doesn’t prevent our medicines from getting to people who need them. We strive for the right balance between ensuring people have access to the medicines they need, while investing in future breakthroughs..	None	We continue to invest in significant and sustained research for each of our medicines after they first become available. We follow the science to determine how they might help people with other diseases who need new medicines and also how we might make even better medicines. When determining pricing for a new vial size or a new method of action, we take into consideration the price of the existing medicine.	None	None	None	None	None	None	None	None	None	None	https://reports.siera.oshpd.ca.gov/api/report/drug-pricing/attachment?id=321, https://reports.siera.oshpd.ca.gov/api/report/drug-pricing/attachment?id=329	Patent expiration (column 6) and Unit Sales in US (column 8) are not filled out numerically as the information is not publicly available. The acquisition fields are left blank as the drug product was not acquired from a third party. There are two drug products with a price increase but do not have a five year history. Please see the supporting documents for additional information.
Rx0000087	Gilead Sciences, Inc.	03/31/2019	61958200201	DESCOVY (emtricitabine tenofovir alafenamide) tablets	03/16/2019	82.11	1757.90	08/15/2032	Single Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	The information provided in this report is subject to general limitations and assumptions Gilead has shared with OSHPD. The limitations and assumptions address gaps in guidance related to the definition and interpretation of various data elements within the WAC Increase Report. Additionally, consistent with the relevant statutes and regulations, the information provided in this report is limited to that which Gilead believes is in the public domain or otherwise publicly available. Lastly, Gilead has not provided a response to the drug acquisition related data fields for this drug product because Gilead did not acquire this drug product within the previous five years.
Rx0000087	Gilead Sciences, Inc.	03/31/2019	61958190101	GENVOYA (elvitegravir cobicistat emtricitabine tenofovir alafenamide) tablets	03/16/2019	144.34	3089.99	10/04/2032	Single Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	The information provided in this report is subject to general limitations and assumptions Gilead has shared with OSHPD. The limitations and assumptions address gaps in guidance related to the definition and interpretation of various data elements within the WAC Increase Report. Additionally, consistent with the relevant statutes and regulations, the information provided in this report is limited to that which Gilead believes is in the public domain or otherwise publicly available. Lastly, Gilead has not provided a response to the drug acquisition related data fields for this drug product because Gilead did not acquire this drug product within the previous five years.
Rx0000087	Gilead Sciences, Inc.	03/31/2019	61958050101	HEPSERA (adefovir dipivoxil) tablets	03/16/2019	69.34	1484.35	07/23/2018	Non-innovator Multiple Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	The information provided in this report is subject to general limitations and assumptions Gilead has shared with OSHPD. The limitations and assumptions address gaps in guidance related to the definition and interpretation of various data elements within the WAC Increase Report. Additionally, consistent with the relevant statutes and regulations, the information provided in this report is limited to that which Gilead believes is in the public domain or otherwise publicly available. Lastly, Gilead has not provided a response to the drug acquisition related data fields for this drug product because Gilead did not acquire this drug product within the previous five years.
Rx0000087	Gilead Sciences, Inc.	03/31/2019	61958210101	ODEFSEY (emtricitabine rilprivirine tenofovir alafenamide) tablets	03/16/2019	131.36	2812.13	08/15/2032	Single Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	The information provided in this report is subject to general limitations and assumptions Gilead has shared with OSHPD. The limitations and assumptions address gaps in guidance related to the definition and interpretation of various data elements within the WAC Increase Report. Additionally, consistent with the relevant statutes and regulations, the information provided in this report is limited to that which Gilead believes is in the public domain or otherwise publicly available. Lastly, Gilead has not provided a response to the drug acquisition related data fields for this drug product because Gilead did not acquire this drug product within the previous five years.
Rx0000087	Gilead Sciences, Inc.	03/31/2019	61958070301	TRUVADA (emtricitabine 100mg/tenofovir disoproxil fumarate 150mg) tablets	03/16/2019	82.11	1757.90	09/09/2021	Single Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	The information provided in this report is subject to general limitations and assumptions Gilead has shared with OSHPD. The limitations and assumptions address gaps in guidance related to the definition and interpretation of various data elements within the WAC Increase Report. Additionally, consistent with the relevant statutes and regulations, the information provided in this report is limited to that which Gilead believes is in the public domain or otherwise publicly available. Lastly, Gilead has not provided a response to the drug acquisition related data fields for this drug product because Gilead did not acquire this drug product within the previous five years.
Rx0000087	Gilead Sciences, Inc.	03/31/2019	61958070401	TRUVADA (emtricitabine 133mg/tenofovir disoproxil fumarate 200mg) tablets	03/16/2019	82.11	1757.90	09/09/2021	Single Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	The information provided in this report is subject to general limitations and assumptions Gilead has shared with OSHPD. The limitations and assumptions address gaps in guidance related to the definition and interpretation of various data elements within the WAC Increase Report. Additionally, consistent with the relevant statutes and regulations, the information provided in this report is limited to that which Gilead believes is in the public domain or otherwise publicly available. Lastly, Gilead has not provided a response to the drug acquisition related data fields for this drug product because Gilead did not acquire this drug product within the previous five years.
Rx0000087	Gilead Sciences, Inc.	03/31/2019	61958070501	TRUVADA (emtricitabine 167 mg/tenofovir disoproxil fumarate 250mg) tablets	03/16/2019	82.11	1757.90	09/09/2021	Single Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	The information provided in this report is subject to general limitations and assumptions Gilead has shared with OSHPD. The limitations and assumptions address gaps in guidance related to the definition and interpretation of various data elements within the WAC Increase Report. Additionally, consistent with the relevant statutes and regulations, the information provided in this report is limited to that which Gilead believes is in the public domain or otherwise publicly available. Lastly, Gilead has not provided a response to the drug acquisition related data fields for this drug product because Gilead did not acquire this drug product within the previous five years.
Rx0000087	Gilead Sciences, Inc.	03/31/2019	61958070101	TRUVADA (emtricitabine 200mg/tenofovir disoproxil fumarate 300mg) tablets	03/16/2019	82.11	1757.90	01/13/2024	Single Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	The information provided in this report is subject to general limitations and assumptions Gilead has shared with OSHPD. The limitations and assumptions address gaps in guidance related to the definition and interpretation of various data elements within the WAC Increase Report. Additionally, consistent with the relevant statutes and regulations, the information provided in this report is limited to that which Gilead believes is in the public domain or otherwise publicly available. Lastly, Gilead has not provided a response to the drug acquisition related data fields for this drug product because Gilead did not acquire this drug product within the previous five years.
Rx0000087	Gilead Sciences, Inc.	03/31/2019	61958140101	TYBOST (cobicistat) tablets	03/16/2019	10.77	230.66	09/03/2029	Single Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	The information provided in this report is subject to general limitations and assumptions Gilead has shared with OSHPD. The limitations and assumptions address gaps in guidance related to the definition and interpretation of various data elements within the WAC Increase Report. Additionally, consistent with the relevant statutes and regulations, the information provided in this report is limited to that which Gilead believes is in the public domain or otherwise publicly available. Lastly, Gilead has not provided a response to the drug acquisition related data fields for this drug product because Gilead did not acquire this drug product within the previous five years.
Rx0000087	Gilead Sciences, Inc.	03/31/2019	61958040401	VIREAD (tenofovir disoproxil fumarate) 150mg tablets	03/16/2019	51.78	1108.50	07/25/2018	Non-innovator Multiple Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	The information provided in this report is subject to general limitations and assumptions Gilead has shared with OSHPD. The limitations and assumptions address gaps in guidance related to the definition and interpretation of various data elements within the WAC Increase Report. Additionally, consistent with the relevant statutes and regulations, the information provided in this report is limited to that which Gilead believes is in the public domain or otherwise publicly available. Lastly, Gilead has not provided a response to the drug acquisition related data fields for this drug product because Gilead did not acquire this drug product within the previous five years.
Rx0000087	Gilead Sciences, Inc.	03/31/2019	61958040501	VIREAD (tenofovir disoproxil fumarate) 200mg tablets	03/16/2019	51.78	1108.50	07/25/2018	Non-innovator Multiple Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	The information provided in this report is subject to general limitations and assumptions Gilead has shared with OSHPD. The limitations and assumptions address gaps in guidance related to the definition and interpretation of various data elements within the WAC Increase Report. Additionally, consistent with the relevant statutes and regulations, the information provided in this report is limited to that which Gilead believes is in the public domain or otherwise publicly available. Lastly, Gilead has not provided a response to the drug acquisition related data fields for this drug product because Gilead did not acquire this drug product within the previous five years.
Rx0000087	Gilead Sciences, Inc.	03/31/2019	61958040601	VIREAD (tenofovir disoproxil fumarate) 250mg tablets	03/16/2019	51.78	1108.50	07/25/2018	Non-innovator Multiple Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	The information provided in this report is subject to general limitations and assumptions Gilead has shared with OSHPD. The limitations and assumptions address gaps in guidance related to the definition and interpretation of various data elements within the WAC Increase Report. Additionally, consistent with the relevant statutes and regulations, the information provided in this report is limited to that which Gilead believes is in the public domain or otherwise publicly available. Lastly, Gilead has not provided a response to the drug acquisition related data fields for this drug product because Gilead did not acquire this drug product within the previous five years.
Rx0000087	Gilead Sciences, Inc.	03/31/2019	61958040101	VIREAD (tenofovir disoproxil fumarate) 300mg tablets	03/16/2019	55.87	1196.09	07/25/2018	Non-innovator Multiple Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	The information provided in this report is subject to general limitations and assumptions Gilead has shared with OSHPD. The limitations and assumptions address gaps in guidance related to the definition and interpretation of various data elements within the WAC Increase Report. Additionally, consistent with the relevant statutes and regulations, the information provided in this report is limited to that which Gilead believes is in the public domain or otherwise publicly available. Lastly, Gilead has not provided a response to the drug acquisition related data fields for this drug product because Gilead did not acquire this drug product within the previous five years.
Rx0000087	Gilead Sciences, Inc.	03/31/2019	61958040301	VIREAD (tenofovir disoproxil fumarate) powder	03/16/2019	30.46	652.18	07/25/2018	Non-innovator Multiple Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	The information provided in this report is subject to general limitations and assumptions Gilead has shared with OSHPD. The limitations and assumptions address gaps in guidance related to the definition and interpretation of various data elements within the WAC Increase Report. Additionally, consistent with the relevant statutes and regulations, the information provided in this report is limited to that which Gilead believes is in the public domain or otherwise publicly available. Lastly, Gilead has not provided a response to the drug acquisition related data fields for this drug product because Gilead did not acquire this drug product within the previous five years.
Rx0000088	Gilead Sciences, LLC	03/31/2019	15584010101	ATRIPLA (efavirenz emtricitabine tenofovir disoproxil fumarate) tablets	03/16/2019	133.48	2857.55	04/28/2029	Single Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	The information provided in this report is subject to general limitations and assumptions Gilead has shared with OSHPD. The limitations and assumptions address gaps in guidance related to the definition and interpretation of various data elements within the WAC Increase Report. Additionally, consistent with the relevant statutes and regulations, the information provided in this report is limited to that which Gilead believes is in the public domain or otherwise publicly available. Lastly, Gilead has not provided a response to the drug acquisition related data fields for this drug product because Gilead did not acquire this drug product within the previous five years.
Rx0000029	GlaxoSmithKline	03/31/2019	00173086910	ANORO ELLIPT AER 62.5-25	01/01/2019	11.93	409.59	11/29/2030	Single Source Drug	None	1	None	1	The price increase listed are not related to any identified or claimed change or improvement	None	None	None	None	None	None	None	None	None	None	None	Note on Acquisition Fields: This drug was developed by GSK, therefore the following fields related to drug acquisition have been left blank: ACQUISITION_DATE, ACQUIRED_FROM_COMPANY, ACQUISITION_PRICE, ACQUISITION_PRICE_NONPUBLIC, ACQUISITION_PRICE_COMMENT, WAC_AT_ACQUISITION, YEAR_INTRODUCED, WAC_AT_INTRODUCTION.
Rx0000029	GlaxoSmithKline	03/31/2019	00173087410	ARNUITY ELPT INH 100MCG	01/01/2019	5.06	173.56	10/11/2030	Single Source Drug	None	1	None	1	The price increase listed are not related to any identified or claimed change or improvement	None	None	None	None	None	None	None	None	None	None	None	Note on Acquisition Fields: This drug was developed by GSK, therefore the following fields related to drug acquisition have been left blank: ACQUISITION_DATE, ACQUIRED_FROM_COMPANY, ACQUISITION_PRICE, ACQUISITION_PRICE_NONPUBLIC, ACQUISITION_PRICE_COMMENT, WAC_AT_ACQUISITION, YEAR_INTRODUCED, WAC_AT_INTRODUCTION.
Rx0000029	GlaxoSmithKline	03/31/2019	00173087414	ARNUITY ELPT INH 100MCG	01/01/2019	2.36	80.99	10/11/2030	Single Source Drug	None	1	None	1	The price increase listed are not related to any identified or claimed change or improvement	None	None	None	None	None	None	None	None	None	None	None	Note on Acquisition Fields: This drug was developed by GSK, therefore the following fields related to drug acquisition have been left blank: ACQUISITION_DATE, ACQUIRED_FROM_COMPANY, ACQUISITION_PRICE, ACQUISITION_PRICE_NONPUBLIC, ACQUISITION_PRICE_COMMENT, WAC_AT_ACQUISITION, YEAR_INTRODUCED, WAC_AT_INTRODUCTION.
Rx0000029	GlaxoSmithKline	03/31/2019	00173087610	ARNUITY ELPT INH 200MCG	01/01/2019	6.77	232.36	10/11/2030	Single Source Drug	None	1	None	1	The price increase listed are not related to any identified or claimed change or improvement	None	None	None	None	None	None	None	None	None	None	None	Note on Acquisition Fields: This drug was developed by GSK, therefore the following fields related to drug acquisition have been left blank: ACQUISITION_DATE, ACQUIRED_FROM_COMPANY, ACQUISITION_PRICE, ACQUISITION_PRICE_NONPUBLIC, ACQUISITION_PRICE_COMMENT, WAC_AT_ACQUISITION, YEAR_INTRODUCED, WAC_AT_INTRODUCTION.
Rx0000029	GlaxoSmithKline	03/31/2019	00173087614	ARNUITY ELPT INH 200MCG	01/01/2019	3.16	108.44	10/11/2030	Single Source Drug	None	1	None	1	The price increase listed are not related to any identified or claimed change or improvement	None	None	None	None	None	None	None	None	None	None	None	Note on Acquisition Fields: This drug was developed by GSK, therefore the following fields related to drug acquisition have been left blank: ACQUISITION_DATE, ACQUIRED_FROM_COMPANY, ACQUISITION_PRICE, ACQUISITION_PRICE_NONPUBLIC, ACQUISITION_PRICE_COMMENT, WAC_AT_ACQUISITION, YEAR_INTRODUCED, WAC_AT_INTRODUCTION.
Rx0000029	GlaxoSmithKline	03/31/2019	00173071204	AVODART CAP 0.5MG	01/01/2019	17.31	594.32	None	Innovator Multiple Source Drug	None	1	None	1	The price increase listed are not related to any identified or claimed change or improvement	None	None	None	None	None	None	None	None	None	None	None	Note on Acquisition Fields: This drug was developed by GSK, therefore the following fields related to drug acquisition have been left blank: ACQUISITION_DATE, ACQUIRED_FROM_COMPANY, ACQUISITION_PRICE, ACQUISITION_PRICE_NONPUBLIC, ACQUISITION_PRICE_COMMENT, WAC_AT_ACQUISITION, YEAR_INTRODUCED, WAC_AT_INTRODUCTION.
Rx0000029	GlaxoSmithKline	03/31/2019	00173071215	AVODART CAP 0.5MG	01/01/2019	5.77	198.14	None	Innovator Multiple Source Drug	None	1	None	1	The price increase listed are not related to any identified or claimed change or improvement	None	None	None	None	None	None	None	None	None	None	None	Note on Acquisition Fields: This drug was developed by GSK, therefore the following fields related to drug acquisition have been left blank: ACQUISITION_DATE, ACQUIRED_FROM_COMPANY, ACQUISITION_PRICE, ACQUISITION_PRICE_NONPUBLIC, ACQUISITION_PRICE_COMMENT, WAC_AT_ACQUISITION, YEAR_INTRODUCED, WAC_AT_INTRODUCTION.
Rx0000029	GlaxoSmithKline	03/31/2019	00173085910	BREO ELLIPTA INH 100-25	01/01/2019	10.23	351.27	10/11/2030	Single Source Drug	None	1	None	1	The price increase listed are not related to any identified or claimed change or improvement	None	None	None	None	None	None	None	None	None	None	None	Note on Acquisition Fields: This drug was developed by GSK, therefore the following fields related to drug acquisition have been left blank: ACQUISITION_DATE, ACQUIRED_FROM_COMPANY, ACQUISITION_PRICE, ACQUISITION_PRICE_NONPUBLIC, ACQUISITION_PRICE_COMMENT, WAC_AT_ACQUISITION, YEAR_INTRODUCED, WAC_AT_INTRODUCTION.
Rx0000029	GlaxoSmithKline	03/31/2019	00173085914	BREO ELLIPTA INH 100-25	01/01/2019	3.94	135.32	10/11/2030	Single Source Drug	None	1	None	1	The price increase listed are not related to any identified or claimed change or improvement	None	None	None	None	None	None	None	None	None	None	None	Note on Acquisition Fields: This drug was developed by GSK, therefore the following fields related to drug acquisition have been left blank: ACQUISITION_DATE, ACQUIRED_FROM_COMPANY, ACQUISITION_PRICE, ACQUISITION_PRICE_NONPUBLIC, ACQUISITION_PRICE_COMMENT, WAC_AT_ACQUISITION, YEAR_INTRODUCED, WAC_AT_INTRODUCTION.
Rx0000029	GlaxoSmithKline	03/31/2019	00173088210	BREO ELLIPTA INH 200-25	01/01/2019	10.23	351.27	10/11/2030	Single Source Drug	None	1	None	1	The price increase listed are not related to any identified or claimed change or improvement	None	None	None	None	None	None	None	None	None	None	None	Note on Acquisition Fields: This drug was developed by GSK, therefore the following fields related to drug acquisition have been left blank: ACQUISITION_DATE, ACQUIRED_FROM_COMPANY, ACQUISITION_PRICE, ACQUISITION_PRICE_NONPUBLIC, ACQUISITION_PRICE_COMMENT, WAC_AT_ACQUISITION, YEAR_INTRODUCED, WAC_AT_INTRODUCTION.
Rx0000029	GlaxoSmithKline	03/31/2019	00173088214	BREO ELLIPTA INH 200-25	01/01/2019	3.94	135.32	10/11/2030	Single Source Drug	None	1	None	1	The price increase listed are not related to any identified or claimed change or improvement	None	None	None	None	None	None	None	None	None	None	None	Note on Acquisition Fields: This drug was developed by GSK, therefore the following fields related to drug acquisition have been left blank: ACQUISITION_DATE, ACQUIRED_FROM_COMPANY, ACQUISITION_PRICE, ACQUISITION_PRICE_NONPUBLIC, ACQUISITION_PRICE_COMMENT, WAC_AT_ACQUISITION, YEAR_INTRODUCED, WAC_AT_INTRODUCTION.
Rx0000029	GlaxoSmithKline	03/31/2019	00007414120	COREG TAB 12.5MG	01/01/2019	14.39	494.15	None	Innovator Multiple Source Drug	None	1	None	1	The price increase listed are not related to any identified or claimed change or improvement	None	None	None	None	None	None	None	None	None	None	None	Note on Acquisition Fields: This drug was developed by GSK, therefore the following fields related to drug acquisition have been left blank: ACQUISITION_DATE, ACQUIRED_FROM_COMPANY, ACQUISITION_PRICE, ACQUISITION_PRICE_NONPUBLIC, ACQUISITION_PRICE_COMMENT, WAC_AT_ACQUISITION, YEAR_INTRODUCED, WAC_AT_INTRODUCTION.
Rx0000029	GlaxoSmithKline	03/31/2019	00007414220	COREG TAB 25MG	01/01/2019	14.39	494.15	None	Innovator Multiple Source Drug	None	1	None	1	The price increase listed are not related to any identified or claimed change or improvement	None	None	None	None	None	None	None	None	None	None	None	Note on Acquisition Fields: This drug was developed by GSK, therefore the following fields related to drug acquisition have been left blank: ACQUISITION_DATE, ACQUIRED_FROM_COMPANY, ACQUISITION_PRICE, ACQUISITION_PRICE_NONPUBLIC, ACQUISITION_PRICE_COMMENT, WAC_AT_ACQUISITION, YEAR_INTRODUCED, WAC_AT_INTRODUCTION.
Rx0000029	GlaxoSmithKline	03/31/2019	00007413920	COREG TAB 3.125MG	01/01/2019	14.39	494.15	None	Innovator Multiple Source Drug	None	1	None	1	The price increase listed are not related to any identified or claimed change or improvement	None	None	None	None	None	None	None	None	None	None	None	Note on Acquisition Fields: This drug was developed by GSK, therefore the following fields related to drug acquisition have been left blank: ACQUISITION_DATE, ACQUIRED_FROM_COMPANY, ACQUISITION_PRICE, ACQUISITION_PRICE_NONPUBLIC, ACQUISITION_PRICE_COMMENT, WAC_AT_ACQUISITION, YEAR_INTRODUCED, WAC_AT_INTRODUCTION.
Rx0000029	GlaxoSmithKline	03/31/2019	00007414020	COREG TAB 6.25MG	01/01/2019	14.39	494.15	None	Innovator Multiple Source Drug	None	1	None	1	The price increase listed are not related to any identified or claimed change or improvement	None	None	None	None	None	None	None	None	None	None	None	Note on Acquisition Fields: This drug was developed by GSK, therefore the following fields related to drug acquisition have been left blank: ACQUISITION_DATE, ACQUIRED_FROM_COMPANY, ACQUISITION_PRICE, ACQUISITION_PRICE_NONPUBLIC, ACQUISITION_PRICE_COMMENT, WAC_AT_ACQUISITION, YEAR_INTRODUCED, WAC_AT_INTRODUCTION.
Rx0000029	GlaxoSmithKline	03/31/2019	00173060200	FLOVENT DISK AER 100MCG	01/01/2019	3.17	108.97	None	Single Source Drug	None	1	None	1	The price increase listed are not related to any identified or claimed change or improvement	None	None	None	None	None	None	None	None	None	None	None	Note on Acquisition Fields: This drug was developed by GSK, therefore the following fields related to drug acquisition have been left blank: ACQUISITION_DATE, ACQUIRED_FROM_COMPANY, ACQUISITION_PRICE, ACQUISITION_PRICE_NONPUBLIC, ACQUISITION_PRICE_COMMENT, WAC_AT_ACQUISITION, YEAR_INTRODUCED, WAC_AT_INTRODUCTION.
Rx0000029	GlaxoSmithKline	03/31/2019	00173060202	FLOVENT DISK AER 100MCG	01/01/2019	5.45	187.18	None	Single Source Drug	None	1	None	1	The price increase listed are not related to any identified or claimed change or improvement	None	None	None	None	None	None	None	None	None	None	None	Note on Acquisition Fields: This drug was developed by GSK, therefore the following fields related to drug acquisition have been left blank: ACQUISITION_DATE, ACQUIRED_FROM_COMPANY, ACQUISITION_PRICE, ACQUISITION_PRICE_NONPUBLIC, ACQUISITION_PRICE_COMMENT, WAC_AT_ACQUISITION, YEAR_INTRODUCED, WAC_AT_INTRODUCTION.
Rx0000029	GlaxoSmithKline	03/31/2019	00173060100	FLOVENT DISK AER 250MCG	01/01/2019	4.25	145.93	None	Single Source Drug	None	1	None	1	The price increase listed are not related to any identified or claimed change or improvement	None	None	None	None	None	None	None	None	None	None	None	Note on Acquisition Fields: This drug was developed by GSK, therefore the following fields related to drug acquisition have been left blank: ACQUISITION_DATE, ACQUIRED_FROM_COMPANY, ACQUISITION_PRICE, ACQUISITION_PRICE_NONPUBLIC, ACQUISITION_PRICE_COMMENT, WAC_AT_ACQUISITION, YEAR_INTRODUCED, WAC_AT_INTRODUCTION.
Rx0000029	GlaxoSmithKline	03/31/2019	00173060102	FLOVENT DISK AER 250MCG	01/01/2019	7.30	250.59	None	Single Source Drug	None	1	None	1	The price increase listed are not related to any identified or claimed change or improvement	None	None	None	None	None	None	None	None	None	None	None	Note on Acquisition Fields: This drug was developed by GSK, therefore the following fields related to drug acquisition have been left blank: ACQUISITION_DATE, ACQUIRED_FROM_COMPANY, ACQUISITION_PRICE, ACQUISITION_PRICE_NONPUBLIC, ACQUISITION_PRICE_COMMENT, WAC_AT_ACQUISITION, YEAR_INTRODUCED, WAC_AT_INTRODUCTION.
Rx0000029	GlaxoSmithKline	03/31/2019	00173060002	FLOVENT DISK AER 50MCG	01/01/2019	5.17	177.49	None	Single Source Drug	None	1	None	1	The price increase listed are not related to any identified or claimed change or improvement	None	None	None	None	None	None	None	None	None	None	None	Note on Acquisition Fields: This drug was developed by GSK, therefore the following fields related to drug acquisition have been left blank: ACQUISITION_DATE, ACQUIRED_FROM_COMPANY, ACQUISITION_PRICE, ACQUISITION_PRICE_NONPUBLIC, ACQUISITION_PRICE_COMMENT, WAC_AT_ACQUISITION, YEAR_INTRODUCED, WAC_AT_INTRODUCTION.
Rx0000029	GlaxoSmithKline	03/31/2019	00173071920	FLOVENT HFA AER 110MCG	01/01/2019	7.30	250.59	08/26/2026	Single Source Drug	None	1	None	1	The price increase listed are not related to any identified or claimed change or improvement	None	None	None	None	None	None	None	None	None	None	None	Note on Acquisition Fields: This drug was developed by GSK, therefore the following fields related to drug acquisition have been left blank: ACQUISITION_DATE, ACQUIRED_FROM_COMPANY, ACQUISITION_PRICE, ACQUISITION_PRICE_NONPUBLIC, ACQUISITION_PRICE_COMMENT, WAC_AT_ACQUISITION, YEAR_INTRODUCED, WAC_AT_INTRODUCTION.
Rx0000029	GlaxoSmithKline	03/31/2019	00173072020	FLOVENT HFA AER 220MCG	01/01/2019	11.34	389.23	08/26/2026	Single Source Drug	None	1	None	1	The price increase listed are not related to any identified or claimed change or improvement	None	None	None	None	None	None	None	None	None	None	None	Note on Acquisition Fields: This drug was developed by GSK, therefore the following fields related to drug acquisition have been left blank: ACQUISITION_DATE, ACQUIRED_FROM_COMPANY, ACQUISITION_PRICE, ACQUISITION_PRICE_NONPUBLIC, ACQUISITION_PRICE_COMMENT, WAC_AT_ACQUISITION, YEAR_INTRODUCED, WAC_AT_INTRODUCTION.
Rx0000029	GlaxoSmithKline	03/31/2019	00173071820	FLOVENT HFA AER 44MCG	01/01/2019	5.45	187.18	08/26/2026	Single Source Drug	None	1	None	1	The price increase listed are not related to any identified or claimed change or improvement	None	None	None	None	None	None	None	None	None	None	None	Note on Acquisition Fields: This drug was developed by GSK, therefore the following fields related to drug acquisition have been left blank: ACQUISITION_DATE, ACQUIRED_FROM_COMPANY, ACQUISITION_PRICE, ACQUISITION_PRICE_NONPUBLIC, ACQUISITION_PRICE_COMMENT, WAC_AT_ACQUISITION, YEAR_INTRODUCED, WAC_AT_INTRODUCTION.
Rx0000029	GlaxoSmithKline	03/31/2019	00173073900	IMITREX INJ 4MG/0.5	01/01/2019	11.89	408.29	None	Innovator Multiple Source Drug	None	1	None	1	The price increase listed are not related to any identified or claimed change or improvement	None	None	None	None	None	None	None	None	None	None	None	Note on Acquisition Fields: This drug was developed by GSK, therefore the following fields related to drug acquisition have been left blank: ACQUISITION_DATE, ACQUIRED_FROM_COMPANY, ACQUISITION_PRICE, ACQUISITION_PRICE_NONPUBLIC, ACQUISITION_PRICE_COMMENT, WAC_AT_ACQUISITION, YEAR_INTRODUCED, WAC_AT_INTRODUCTION.
Rx0000029	GlaxoSmithKline	03/31/2019	00173073902	IMITREX INJ 4MG/0.5	01/01/2019	11.26	386.69	None	Innovator Multiple Source Drug	None	1	None	1	The price increase listed are not related to any identified or claimed change or improvement	None	None	None	None	None	None	None	None	None	None	None	Note on Acquisition Fields: This drug was developed by GSK, therefore the following fields related to drug acquisition have been left blank: ACQUISITION_DATE, ACQUIRED_FROM_COMPANY, ACQUISITION_PRICE, ACQUISITION_PRICE_NONPUBLIC, ACQUISITION_PRICE_COMMENT, WAC_AT_ACQUISITION, YEAR_INTRODUCED, WAC_AT_INTRODUCTION.
Rx0000029	GlaxoSmithKline	03/31/2019	00173044902	IMITREX INJ 6MG/0.5	01/01/2019	27.73	952.20	None	Innovator Multiple Source Drug	None	1	None	1	The price increase listed are not related to any identified or claimed change or improvement	None	None	None	None	None	None	None	None	None	None	None	Note on Acquisition Fields: This drug was developed by GSK, therefore the following fields related to drug acquisition have been left blank: ACQUISITION_DATE, ACQUIRED_FROM_COMPANY, ACQUISITION_PRICE, ACQUISITION_PRICE_NONPUBLIC, ACQUISITION_PRICE_COMMENT, WAC_AT_ACQUISITION, YEAR_INTRODUCED, WAC_AT_INTRODUCTION.
Rx0000029	GlaxoSmithKline	03/31/2019	00173047800	IMITREX INJ 6MG/0.5	01/01/2019	11.26	386.69	None	Innovator Multiple Source Drug	None	1	None	1	The price increase listed are not related to any identified or claimed change or improvement	None	None	None	None	None	None	None	None	None	None	None	Note on Acquisition Fields: This drug was developed by GSK, therefore the following fields related to drug acquisition have been left blank: ACQUISITION_DATE, ACQUIRED_FROM_COMPANY, ACQUISITION_PRICE, ACQUISITION_PRICE_NONPUBLIC, ACQUISITION_PRICE_COMMENT, WAC_AT_ACQUISITION, YEAR_INTRODUCED, WAC_AT_INTRODUCTION.
Rx0000029	GlaxoSmithKline	03/31/2019	00173047900	IMITREX INJ 6MG/0.5	01/01/2019	11.89	408.29	None	Innovator Multiple Source Drug	None	1	None	1	The price increase listed are not related to any identified or claimed change or improvement	None	None	None	None	None	None	None	None	None	None	None	Note on Acquisition Fields: This drug was developed by GSK, therefore the following fields related to drug acquisition have been left blank: ACQUISITION_DATE, ACQUIRED_FROM_COMPANY, ACQUISITION_PRICE, ACQUISITION_PRICE_NONPUBLIC, ACQUISITION_PRICE_COMMENT, WAC_AT_ACQUISITION, YEAR_INTRODUCED, WAC_AT_INTRODUCTION.
Rx0000029	GlaxoSmithKline	03/31/2019	00173052300	IMITREX SPR 20MG/ACT	01/01/2019	14.25	489.13	None	Single Source Drug	None	1	None	1	The price increase listed are not related to any identified or claimed change or improvement	None	None	None	None	None	None	None	None	None	None	None	Note on Acquisition Fields: This drug was developed by GSK, therefore the following fields related to drug acquisition have been left blank: ACQUISITION_DATE, ACQUIRED_FROM_COMPANY, ACQUISITION_PRICE, ACQUISITION_PRICE_NONPUBLIC, ACQUISITION_PRICE_COMMENT, WAC_AT_ACQUISITION, YEAR_INTRODUCED, WAC_AT_INTRODUCTION.
Rx0000029	GlaxoSmithKline	03/31/2019	00173052400	IMITREX SPR 5MG/ACT	01/01/2019	14.25	489.13	None	Single Source Drug	None	1	None	1	The price increase listed are not related to any identified or claimed change or improvement	None	None	None	None	None	None	None	None	None	None	None	Note on Acquisition Fields: This drug was developed by GSK, therefore the following fields related to drug acquisition have been left blank: ACQUISITION_DATE, ACQUIRED_FROM_COMPANY, ACQUISITION_PRICE, ACQUISITION_PRICE_NONPUBLIC, ACQUISITION_PRICE_COMMENT, WAC_AT_ACQUISITION, YEAR_INTRODUCED, WAC_AT_INTRODUCTION.
Rx0000029	GlaxoSmithKline	03/31/2019	00173073701	IMITREX TAB 100MG	01/01/2019	17.12	587.84	None	Innovator Multiple Source Drug	None	1	None	1	The price increase listed are not related to any identified or claimed change or improvement	None	None	None	None	None	None	None	None	None	None	None	Note on Acquisition Fields: This drug was developed by GSK, therefore the following fields related to drug acquisition have been left blank: ACQUISITION_DATE, ACQUIRED_FROM_COMPANY, ACQUISITION_PRICE, ACQUISITION_PRICE_NONPUBLIC, ACQUISITION_PRICE_COMMENT, WAC_AT_ACQUISITION, YEAR_INTRODUCED, WAC_AT_INTRODUCTION.
Rx0000029	GlaxoSmithKline	03/31/2019	00173073601	IMITREX TAB 50MG	01/01/2019	17.12	587.84	None	Innovator Multiple Source Drug	None	1	None	1	The price increase listed are not related to any identified or claimed change or improvement	None	None	None	None	None	None	None	None	None	None	None	Note on Acquisition Fields: This drug was developed by GSK, therefore the following fields related to drug acquisition have been left blank: ACQUISITION_DATE, ACQUIRED_FROM_COMPANY, ACQUISITION_PRICE, ACQUISITION_PRICE_NONPUBLIC, ACQUISITION_PRICE_COMMENT, WAC_AT_ACQUISITION, YEAR_INTRODUCED, WAC_AT_INTRODUCTION.
Rx0000029	GlaxoSmithKline	03/31/2019	00173080913	JALYN CAP	01/01/2019	5.77	198.14	None	Innovator Multiple Source Drug	None	1	None	1	The price increase listed are not related to any identified or claimed change or improvement	None	None	None	None	None	None	None	None	None	None	None	Note on Acquisition Fields: This drug was developed by GSK, therefore the following fields related to drug acquisition have been left blank: ACQUISITION_DATE, ACQUIRED_FROM_COMPANY, ACQUISITION_PRICE, ACQUISITION_PRICE_NONPUBLIC, ACQUISITION_PRICE_COMMENT, WAC_AT_ACQUISITION, YEAR_INTRODUCED, WAC_AT_INTRODUCTION.
Rx0000029	GlaxoSmithKline	03/31/2019	00173080959	JALYN CAP	01/01/2019	17.31	594.32	None	Innovator Multiple Source Drug	None	1	None	1	The price increase listed are not related to any identified or claimed change or improvement	None	None	None	None	None	None	None	None	None	None	None	Note on Acquisition Fields: This drug was developed by GSK, therefore the following fields related to drug acquisition have been left blank: ACQUISITION_DATE, ACQUIRED_FROM_COMPANY, ACQUISITION_PRICE, ACQUISITION_PRICE_NONPUBLIC, ACQUISITION_PRICE_COMMENT, WAC_AT_ACQUISITION, YEAR_INTRODUCED, WAC_AT_INTRODUCTION.
Rx0000029	GlaxoSmithKline	03/31/2019	00173052700	LAMICTAL CHW 25MG	01/01/2019	38.64	1326.68	None	Innovator Multiple Source Drug	None	1	None	1	The price increase listed are not related to any identified or claimed change or improvement	None	None	None	None	None	None	None	None	None	None	None	Note on Acquisition Fields: This drug was developed by GSK, therefore the following fields related to drug acquisition have been left blank: ACQUISITION_DATE, ACQUIRED_FROM_COMPANY, ACQUISITION_PRICE, ACQUISITION_PRICE_NONPUBLIC, ACQUISITION_PRICE_COMMENT, WAC_AT_ACQUISITION, YEAR_INTRODUCED, WAC_AT_INTRODUCTION.
Rx0000029	GlaxoSmithKline	03/31/2019	00173052600	LAMICTAL CHW 5MG	01/01/2019	35.99	1235.82	None	Innovator Multiple Source Drug	None	1	None	1	The price increase listed are not related to any identified or claimed change or improvement	None	None	None	None	None	None	None	None	None	None	None	Note on Acquisition Fields: This drug was developed by GSK, therefore the following fields related to drug acquisition have been left blank: ACQUISITION_DATE, ACQUIRED_FROM_COMPANY, ACQUISITION_PRICE, ACQUISITION_PRICE_NONPUBLIC, ACQUISITION_PRICE_COMMENT, WAC_AT_ACQUISITION, YEAR_INTRODUCED, WAC_AT_INTRODUCTION.
Rx0000029	GlaxoSmithKline	03/31/2019	00173063310	LAMICTAL KIT START 35	01/01/2019	13.02	447.04	None	Innovator Multiple Source Drug	None	1	None	1	The price increase listed are not related to any identified or claimed change or improvement	None	None	None	None	None	None	None	None	None	None	None	Note on Acquisition Fields: This drug was developed by GSK, therefore the following fields related to drug acquisition have been left blank: ACQUISITION_DATE, ACQUIRED_FROM_COMPANY, ACQUISITION_PRICE, ACQUISITION_PRICE_NONPUBLIC, ACQUISITION_PRICE_COMMENT, WAC_AT_ACQUISITION, YEAR_INTRODUCED, WAC_AT_INTRODUCTION.
Rx0000029	GlaxoSmithKline	03/31/2019	00173059402	LAMICTAL KIT START 49	01/01/2019	18.60	638.54	None	Innovator Multiple Source Drug	None	1	None	1	The price increase listed are not related to any identified or claimed change or improvement	None	None	None	None	None	None	None	None	None	None	None	Note on Acquisition Fields: This drug was developed by GSK, therefore the following fields related to drug acquisition have been left blank: ACQUISITION_DATE, ACQUIRED_FROM_COMPANY, ACQUISITION_PRICE, ACQUISITION_PRICE_NONPUBLIC, ACQUISITION_PRICE_COMMENT, WAC_AT_ACQUISITION, YEAR_INTRODUCED, WAC_AT_INTRODUCTION.
Rx0000029	GlaxoSmithKline	03/31/2019	00173081728	LAMICTAL KIT START 98	01/01/2019	37.20	1277.07	None	Innovator Multiple Source Drug	None	1	None	1	The price increase listed are not related to any identified or claimed change or improvement	None	None	None	None	None	None	None	None	None	None	None	Note on Acquisition Fields: This drug was developed by GSK, therefore the following fields related to drug acquisition have been left blank: ACQUISITION_DATE, ACQUIRED_FROM_COMPANY, ACQUISITION_PRICE, ACQUISITION_PRICE_NONPUBLIC, ACQUISITION_PRICE_COMMENT, WAC_AT_ACQUISITION, YEAR_INTRODUCED, WAC_AT_INTRODUCTION.
Rx0000029	GlaxoSmithKline	03/31/2019	00173077800	LAMICTAL ODT KIT	01/01/2019	15.65	537.16	None	Innovator Multiple Source Drug	None	1	None	1	The price increase listed are not related to any identified or claimed change or improvement	None	None	None	None	None	None	None	None	None	None	None	Note on Acquisition Fields: This drug was developed by GSK, therefore the following fields related to drug acquisition have been left blank: ACQUISITION_DATE, ACQUIRED_FROM_COMPANY, ACQUISITION_PRICE, ACQUISITION_PRICE_NONPUBLIC, ACQUISITION_PRICE_COMMENT, WAC_AT_ACQUISITION, YEAR_INTRODUCED, WAC_AT_INTRODUCTION.
Rx0000029	GlaxoSmithKline	03/31/2019	00173077900	LAMICTAL ODT KIT	01/01/2019	10.95	376.03	None	Innovator Multiple Source Drug	None	1	None	1	The price increase listed are not related to any identified or claimed change or improvement	None	None	None	None	None	None	None	None	None	None	None	Note on Acquisition Fields: This drug was developed by GSK, therefore the following fields related to drug acquisition have been left blank: ACQUISITION_DATE, ACQUIRED_FROM_COMPANY, ACQUISITION_PRICE, ACQUISITION_PRICE_NONPUBLIC, ACQUISITION_PRICE_COMMENT, WAC_AT_ACQUISITION, YEAR_INTRODUCED, WAC_AT_INTRODUCTION.
Rx0000029	GlaxoSmithKline	03/31/2019	00173077602	LAMICTAL ODT TAB 100MG	01/01/2019	10.72	368.14	None	Innovator Multiple Source Drug	None	1	None	1	The price increase listed are not related to any identified or claimed change or improvement	None	None	None	None	None	None	None	None	None	None	None	Note on Acquisition Fields: This drug was developed by GSK, therefore the following fields related to drug acquisition have been left blank: ACQUISITION_DATE, ACQUIRED_FROM_COMPANY, ACQUISITION_PRICE, ACQUISITION_PRICE_NONPUBLIC, ACQUISITION_PRICE_COMMENT, WAC_AT_ACQUISITION, YEAR_INTRODUCED, WAC_AT_INTRODUCTION.
Rx0000029	GlaxoSmithKline	03/31/2019	00173077702	LAMICTAL ODT TAB 200MG	01/01/2019	12.80	439.31	None	Innovator Multiple Source Drug	None	1	None	1	The price increase listed are not related to any identified or claimed change or improvement	None	None	None	None	None	None	None	None	None	None	None	Note on Acquisition Fields: This drug was developed by GSK, therefore the following fields related to drug acquisition have been left blank: ACQUISITION_DATE, ACQUIRED_FROM_COMPANY, ACQUISITION_PRICE, ACQUISITION_PRICE_NONPUBLIC, ACQUISITION_PRICE_COMMENT, WAC_AT_ACQUISITION, YEAR_INTRODUCED, WAC_AT_INTRODUCTION.
Rx0000029	GlaxoSmithKline	03/31/2019	00173077202	LAMICTAL ODT TAB 25MG	01/01/2019	9.39	322.34	None	Innovator Multiple Source Drug	None	1	None	1	The price increase listed are not related to any identified or claimed change or improvement	None	None	None	None	None	None	None	None	None	None	None	Note on Acquisition Fields: This drug was developed by GSK, therefore the following fields related to drug acquisition have been left blank: ACQUISITION_DATE, ACQUIRED_FROM_COMPANY, ACQUISITION_PRICE, ACQUISITION_PRICE_NONPUBLIC, ACQUISITION_PRICE_COMMENT, WAC_AT_ACQUISITION, YEAR_INTRODUCED, WAC_AT_INTRODUCTION.
Rx0000029	GlaxoSmithKline	03/31/2019	00173077402	LAMICTAL ODT TAB 50MG	01/01/2019	10.06	345.26	None	Innovator Multiple Source Drug	None	1	None	1	The price increase listed are not related to any identified or claimed change or improvement	None	None	None	None	None	None	None	None	None	None	None	Note on Acquisition Fields: This drug was developed by GSK, therefore the following fields related to drug acquisition have been left blank: ACQUISITION_DATE, ACQUIRED_FROM_COMPANY, ACQUISITION_PRICE, ACQUISITION_PRICE_NONPUBLIC, ACQUISITION_PRICE_COMMENT, WAC_AT_ACQUISITION, YEAR_INTRODUCED, WAC_AT_INTRODUCTION.
Rx0000029	GlaxoSmithKline	03/31/2019	00173064255	LAMICTAL TAB 100MG	01/01/2019	42.49	1458.88	None	Innovator Multiple Source Drug	None	1	None	1	The price increase listed are not related to any identified or claimed change or improvement	None	None	None	None	None	None	None	None	None	None	None	Note on Acquisition Fields: This drug was developed by GSK, therefore the following fields related to drug acquisition have been left blank: ACQUISITION_DATE, ACQUIRED_FROM_COMPANY, ACQUISITION_PRICE, ACQUISITION_PRICE_NONPUBLIC, ACQUISITION_PRICE_COMMENT, WAC_AT_ACQUISITION, YEAR_INTRODUCED, WAC_AT_INTRODUCTION.
Rx0000029	GlaxoSmithKline	03/31/2019	00173064360	LAMICTAL TAB 150MG	01/01/2019	27.94	959.38	None	Innovator Multiple Source Drug	None	1	None	1	The price increase listed are not related to any identified or claimed change or improvement	None	None	None	None	None	None	None	None	None	None	None	Note on Acquisition Fields: This drug was developed by GSK, therefore the following fields related to drug acquisition have been left blank: ACQUISITION_DATE, ACQUIRED_FROM_COMPANY, ACQUISITION_PRICE, ACQUISITION_PRICE_NONPUBLIC, ACQUISITION_PRICE_COMMENT, WAC_AT_ACQUISITION, YEAR_INTRODUCED, WAC_AT_INTRODUCTION.
Rx0000029	GlaxoSmithKline	03/31/2019	00173064460	LAMICTAL TAB 200MG	01/01/2019	30.42	1044.38	None	Innovator Multiple Source Drug	None	1	None	1	The price increase listed are not related to any identified or claimed change or improvement	None	None	None	None	None	None	None	None	None	None	None	Note on Acquisition Fields: This drug was developed by GSK, therefore the following fields related to drug acquisition have been left blank: ACQUISITION_DATE, ACQUIRED_FROM_COMPANY, ACQUISITION_PRICE, ACQUISITION_PRICE_NONPUBLIC, ACQUISITION_PRICE_COMMENT, WAC_AT_ACQUISITION, YEAR_INTRODUCED, WAC_AT_INTRODUCTION.
Rx0000029	GlaxoSmithKline	03/31/2019	00173063302	LAMICTAL TAB 25MG	01/01/2019	37.20	1277.19	None	Innovator Multiple Source Drug	None	1	None	1	The price increase listed are not related to any identified or claimed change or improvement	None	None	None	None	None	None	None	None	None	None	None	Note on Acquisition Fields: This drug was developed by GSK, therefore the following fields related to drug acquisition have been left blank: ACQUISITION_DATE, ACQUIRED_FROM_COMPANY, ACQUISITION_PRICE, ACQUISITION_PRICE_NONPUBLIC, ACQUISITION_PRICE_COMMENT, WAC_AT_ACQUISITION, YEAR_INTRODUCED, WAC_AT_INTRODUCTION.
Rx0000029	GlaxoSmithKline	03/31/2019	00173075800	LAMICTAL XR KIT	01/01/2019	11.45	393.16	06/14/2028	Innovator Multiple Source Drug	None	1	None	1	The price increase listed are not related to any identified or claimed change or improvement	None	None	None	None	None	None	None	None	None	None	None	Note on Acquisition Fields: This drug was developed by GSK, therefore the following fields related to drug acquisition have been left blank: ACQUISITION_DATE, ACQUIRED_FROM_COMPANY, ACQUISITION_PRICE, ACQUISITION_PRICE_NONPUBLIC, ACQUISITION_PRICE_COMMENT, WAC_AT_ACQUISITION, YEAR_INTRODUCED, WAC_AT_INTRODUCTION.
Rx0000029	GlaxoSmithKline	03/31/2019	00173075900	LAMICTAL XR KIT	01/01/2019	32.71	1123.13	06/14/2028	Innovator Multiple Source Drug	None	1	None	1	The price increase listed are not related to any identified or claimed change or improvement	None	None	None	None	None	None	None	None	None	None	None	Note on Acquisition Fields: This drug was developed by GSK, therefore the following fields related to drug acquisition have been left blank: ACQUISITION_DATE, ACQUIRED_FROM_COMPANY, ACQUISITION_PRICE, ACQUISITION_PRICE_NONPUBLIC, ACQUISITION_PRICE_COMMENT, WAC_AT_ACQUISITION, YEAR_INTRODUCED, WAC_AT_INTRODUCTION.
Rx0000029	GlaxoSmithKline	03/31/2019	00173076000	LAMICTAL XR KIT	01/01/2019	16.36	561.59	06/14/2028	Innovator Multiple Source Drug	None	1	None	1	The price increase listed are not related to any identified or claimed change or improvement	None	None	None	None	None	None	None	None	None	None	None	Note on Acquisition Fields: This drug was developed by GSK, therefore the following fields related to drug acquisition have been left blank: ACQUISITION_DATE, ACQUIRED_FROM_COMPANY, ACQUISITION_PRICE, ACQUISITION_PRICE_NONPUBLIC, ACQUISITION_PRICE_COMMENT, WAC_AT_ACQUISITION, YEAR_INTRODUCED, WAC_AT_INTRODUCTION.
Rx0000029	GlaxoSmithKline	03/31/2019	00173075600	LAMICTAL XR TAB 100MG	01/01/2019	21.03	721.88	06/14/2028	Innovator Multiple Source Drug	None	1	None	1	The price increase listed are not related to any identified or claimed change or improvement	None	None	None	None	None	None	None	None	None	None	None	Note on Acquisition Fields: This drug was developed by GSK, therefore the following fields related to drug acquisition have been left blank: ACQUISITION_DATE, ACQUIRED_FROM_COMPANY, ACQUISITION_PRICE, ACQUISITION_PRICE_NONPUBLIC, ACQUISITION_PRICE_COMMENT, WAC_AT_ACQUISITION, YEAR_INTRODUCED, WAC_AT_INTRODUCTION.
Rx0000029	GlaxoSmithKline	03/31/2019	00173075700	LAMICTAL XR TAB 200MG	01/01/2019	22.42	769.80	06/14/2028	Innovator Multiple Source Drug	None	1	None	1	The price increase listed are not related to any identified or claimed change or improvement	None	None	None	None	None	None	None	None	None	None	None	Note on Acquisition Fields: This drug was developed by GSK, therefore the following fields related to drug acquisition have been left blank: ACQUISITION_DATE, ACQUIRED_FROM_COMPANY, ACQUISITION_PRICE, ACQUISITION_PRICE_NONPUBLIC, ACQUISITION_PRICE_COMMENT, WAC_AT_ACQUISITION, YEAR_INTRODUCED, WAC_AT_INTRODUCTION.
Rx0000029	GlaxoSmithKline	03/31/2019	00173078100	LAMICTAL XR TAB 250MG	01/01/2019	30.58	1049.76	06/14/2028	Innovator Multiple Source Drug	None	1	None	1	The price increase listed are not related to any identified or claimed change or improvement	None	None	None	None	None	None	None	None	None	None	None	Note on Acquisition Fields: This drug was developed by GSK, therefore the following fields related to drug acquisition have been left blank: ACQUISITION_DATE, ACQUIRED_FROM_COMPANY, ACQUISITION_PRICE, ACQUISITION_PRICE_NONPUBLIC, ACQUISITION_PRICE_COMMENT, WAC_AT_ACQUISITION, YEAR_INTRODUCED, WAC_AT_INTRODUCTION.
Rx0000029	GlaxoSmithKline	03/31/2019	00173075400	LAMICTAL XR TAB 25MG	01/01/2019	9.82	337.00	06/14/2028	Innovator Multiple Source Drug	None	1	None	1	The price increase listed are not related to any identified or claimed change or improvement	None	None	None	None	None	None	None	None	None	None	None	Note on Acquisition Fields: This drug was developed by GSK, therefore the following fields related to drug acquisition have been left blank: ACQUISITION_DATE, ACQUIRED_FROM_COMPANY, ACQUISITION_PRICE, ACQUISITION_PRICE_NONPUBLIC, ACQUISITION_PRICE_COMMENT, WAC_AT_ACQUISITION, YEAR_INTRODUCED, WAC_AT_INTRODUCTION.
Rx0000029	GlaxoSmithKline	03/31/2019	00173076100	LAMICTAL XR TAB 300MG	01/01/2019	33.63	1154.72	06/14/2028	Innovator Multiple Source Drug	None	1	None	1	The price increase listed are not related to any identified or claimed change or improvement	None	None	None	None	None	None	None	None	None	None	None	Note on Acquisition Fields: This drug was developed by GSK, therefore the following fields related to drug acquisition have been left blank: ACQUISITION_DATE, ACQUIRED_FROM_COMPANY, ACQUISITION_PRICE, ACQUISITION_PRICE_NONPUBLIC, ACQUISITION_PRICE_COMMENT, WAC_AT_ACQUISITION, YEAR_INTRODUCED, WAC_AT_INTRODUCTION.
Rx0000029	GlaxoSmithKline	03/31/2019	00173075500	LAMICTAL XR TAB 50MG	01/01/2019	19.63	673.92	06/14/2028	Innovator Multiple Source Drug	None	1	None	1	The price increase listed are not related to any identified or claimed change or improvement	None	None	None	None	None	None	None	None	None	None	None	Note on Acquisition Fields: This drug was developed by GSK, therefore the following fields related to drug acquisition have been left blank: ACQUISITION_DATE, ACQUIRED_FROM_COMPANY, ACQUISITION_PRICE, ACQUISITION_PRICE_NONPUBLIC, ACQUISITION_PRICE_COMMENT, WAC_AT_ACQUISITION, YEAR_INTRODUCED, WAC_AT_INTRODUCTION.
Rx0000029	GlaxoSmithKline	03/31/2019	00173066518	MEPRON SUS	01/01/2019	43.86	1506.00	None	Innovator Multiple Source Drug	None	1	None	1	The price increase listed are not related to any identified or claimed change or improvement	None	None	None	None	None	None	None	None	None	None	None	Note on Acquisition Fields: This drug was developed by GSK, therefore the following fields related to drug acquisition have been left blank: ACQUISITION_DATE, ACQUIRED_FROM_COMPANY, ACQUISITION_PRICE, ACQUISITION_PRICE_NONPUBLIC, ACQUISITION_PRICE_COMMENT, WAC_AT_ACQUISITION, YEAR_INTRODUCED, WAC_AT_INTRODUCTION.
Rx0000029	GlaxoSmithKline	03/31/2019	00173052000	SEREVENT DIS AER 50MCG	01/01/2019	6.66	228.78	None	Single Source Drug	None	1	None	1	The price increase listed are not related to any identified or claimed change or improvement	None	None	None	None	None	None	None	None	None	None	None	Note on Acquisition Fields: This drug was developed by GSK, therefore the following fields related to drug acquisition have been left blank: ACQUISITION_DATE, ACQUIRED_FROM_COMPANY, ACQUISITION_PRICE, ACQUISITION_PRICE_NONPUBLIC, ACQUISITION_PRICE_COMMENT, WAC_AT_ACQUISITION, YEAR_INTRODUCED, WAC_AT_INTRODUCTION.
Rx0000029	GlaxoSmithKline	03/31/2019	00173052100	SEREVENT DIS AER 50MCG	01/01/2019	11.29	387.53	None	Single Source Drug	None	1	None	1	The price increase listed are not related to any identified or claimed change or improvement	None	None	None	None	None	None	None	None	None	None	None	Note on Acquisition Fields: This drug was developed by GSK, therefore the following fields related to drug acquisition have been left blank: ACQUISITION_DATE, ACQUIRED_FROM_COMPANY, ACQUISITION_PRICE, ACQUISITION_PRICE_NONPUBLIC, ACQUISITION_PRICE_COMMENT, WAC_AT_ACQUISITION, YEAR_INTRODUCED, WAC_AT_INTRODUCTION.
Rx0000029	GlaxoSmithKline	03/31/2019	00173056504	VALTREX TAB 1GM	01/01/2019	18.79	645.10	None	Innovator Multiple Source Drug	None	1	None	1	The price increase listed are not related to any identified or claimed change or improvement	None	None	None	None	None	None	None	None	None	None	None	Note on Acquisition Fields: This drug was developed by GSK, therefore the following fields related to drug acquisition have been left blank: ACQUISITION_DATE, ACQUIRED_FROM_COMPANY, ACQUISITION_PRICE, ACQUISITION_PRICE_NONPUBLIC, ACQUISITION_PRICE_COMMENT, WAC_AT_ACQUISITION, YEAR_INTRODUCED, WAC_AT_INTRODUCTION.
Rx0000029	GlaxoSmithKline	03/31/2019	00173056510	VALTREX TAB 1GM	01/01/2019	56.37	1935.31	None	Innovator Multiple Source Drug	None	1	None	1	The price increase listed are not related to any identified or claimed change or improvement	None	None	None	None	None	None	None	None	None	None	None	Note on Acquisition Fields: This drug was developed by GSK, therefore the following fields related to drug acquisition have been left blank: ACQUISITION_DATE, ACQUIRED_FROM_COMPANY, ACQUISITION_PRICE, ACQUISITION_PRICE_NONPUBLIC, ACQUISITION_PRICE_COMMENT, WAC_AT_ACQUISITION, YEAR_INTRODUCED, WAC_AT_INTRODUCTION.
Rx0000029	GlaxoSmithKline	03/31/2019	00173093308	VALTREX TAB 500MG	01/01/2019	10.74	368.62	None	Innovator Multiple Source Drug	None	1	None	1	The price increase listed are not related to any identified or claimed change or improvement	None	None	None	None	None	None	None	None	None	None	None	Note on Acquisition Fields: This drug was developed by GSK, therefore the following fields related to drug acquisition have been left blank: ACQUISITION_DATE, ACQUIRED_FROM_COMPANY, ACQUISITION_PRICE, ACQUISITION_PRICE_NONPUBLIC, ACQUISITION_PRICE_COMMENT, WAC_AT_ACQUISITION, YEAR_INTRODUCED, WAC_AT_INTRODUCTION.
Rx0000029	GlaxoSmithKline	03/31/2019	00173093310	VALTREX TAB 500MG	01/01/2019	32.21	1105.77	None	Innovator Multiple Source Drug	None	1	None	1	The price increase listed are not related to any identified or claimed change or improvement	None	None	None	None	None	None	None	None	None	None	None	Note on Acquisition Fields: This drug was developed by GSK, therefore the following fields related to drug acquisition have been left blank: ACQUISITION_DATE, ACQUIRED_FROM_COMPANY, ACQUISITION_PRICE, ACQUISITION_PRICE_NONPUBLIC, ACQUISITION_PRICE_COMMENT, WAC_AT_ACQUISITION, YEAR_INTRODUCED, WAC_AT_INTRODUCTION.
Rx0000029	GlaxoSmithKline	03/31/2019	00173093356	VALTREX TAB 500MG	01/01/2019	36.58	1256.07	None	Innovator Multiple Source Drug	None	1	None	1	The price increase listed are not related to any identified or claimed change or improvement	None	None	None	None	None	None	None	None	None	None	None	Note on Acquisition Fields: This drug was developed by GSK, therefore the following fields related to drug acquisition have been left blank: ACQUISITION_DATE, ACQUIRED_FROM_COMPANY, ACQUISITION_PRICE, ACQUISITION_PRICE_NONPUBLIC, ACQUISITION_PRICE_COMMENT, WAC_AT_ACQUISITION, YEAR_INTRODUCED, WAC_AT_INTRODUCTION.
Rx0000029	GlaxoSmithKline	03/31/2019	00173094755	WELLBUTRIN TAB 100MG SR	01/01/2019	12.10	415.46	None	Innovator Multiple Source Drug	None	1	None	1	The price increase listed are not related to any identified or claimed change or improvement	None	None	None	None	None	None	None	None	None	None	None	Note on Acquisition Fields: This drug was developed by GSK, therefore the following fields related to drug acquisition have been left blank: ACQUISITION_DATE, ACQUIRED_FROM_COMPANY, ACQUISITION_PRICE, ACQUISITION_PRICE_NONPUBLIC, ACQUISITION_PRICE_COMMENT, WAC_AT_ACQUISITION, YEAR_INTRODUCED, WAC_AT_INTRODUCTION.
Rx0000029	GlaxoSmithKline	03/31/2019	00173013555	WELLBUTRIN TAB 150MG SR	01/01/2019	12.97	445.27	None	Innovator Multiple Source Drug	None	1	None	1	The price increase listed are not related to any identified or claimed change or improvement	None	None	None	None	None	None	None	None	None	None	None	Note on Acquisition Fields: This drug was developed by GSK, therefore the following fields related to drug acquisition have been left blank: ACQUISITION_DATE, ACQUIRED_FROM_COMPANY, ACQUISITION_PRICE, ACQUISITION_PRICE_NONPUBLIC, ACQUISITION_PRICE_COMMENT, WAC_AT_ACQUISITION, YEAR_INTRODUCED, WAC_AT_INTRODUCTION.
Rx0000029	GlaxoSmithKline	03/31/2019	00173072200	WELLBUTRIN TAB 200MG SR	01/01/2019	24.08	826.85	None	Innovator Multiple Source Drug	None	1	None	1	The price increase listed are not related to any identified or claimed change or improvement	None	None	None	None	None	None	None	None	None	None	None	Note on Acquisition Fields: This drug was developed by GSK, therefore the following fields related to drug acquisition have been left blank: ACQUISITION_DATE, ACQUIRED_FROM_COMPANY, ACQUISITION_PRICE, ACQUISITION_PRICE_NONPUBLIC, ACQUISITION_PRICE_COMMENT, WAC_AT_ACQUISITION, YEAR_INTRODUCED, WAC_AT_INTRODUCTION.
Rx0000144	Helsinn Therapeutics, Inc	09/30/2019	69639012001	Valchlor 0.02% Gel 60gm tube	09/26/2019	273.68	4183.46	07/08/2029	Single Source Drug	8575	None	The increase in WAC is based on business factors, including the cost of funding assistance programs for eligible patients and clinical research, including research relating to potential new indications.	None	None	1	03/20/2018	Actelion Pharmaceuticals, Ltd.	330000000	None	None	3654.00	3355.00	2013	3165.00	None	None
Rx0000119	Heron Therapeutics, Inc.	12/31/2019	47426020101	CINVANTI; 130 mg; single-dose vial	10/01/2019	7.72	351.47	None	Single Source Drug	278108	None	Increase due to market factors	None	There were no noted changes to the drug.	None	None	None	None	None	None	None	None	None	None	None	Product was developed by Heron
Rx0000119	Heron Therapeutics, Inc.	06/30/2019	47426010106	Granisetron extended-release injection	06/01/2019	90.42	3706.86	None	Single Source Drug	14393	None	Increase due to market factors.	None	There were no noted changes to the drug.	None	None	None	None	None	None	None	None	None	None	None	Product was developed by Heron
Rx0000119	Heron Therapeutics, Inc.	12/31/2019	47426010106	Sustol (granisetron) ER injection. 10 mg/.4mL. 6 kits/carton.	12/15/2019	92.67	3799.53	None	Single Source Drug	14393	None	Increase due to market factors.	None	There were no noted changes to the drug.	None	None	None	None	None	None	None	None	None	None	None	Product was developed by Heron
Rx0000178	Hikma Pharmaceuticals USA Inc	03/31/2019	00143978710	Enalaprilat Intravenous Injectable 1.25 MG/1ML, 10 Vials	01/01/2019	9.23	40.00	None	Non-innovator Multiple Source Drug	None	1	None	1	This WAC increase is not necessitated by a change or improvement in the prescription drug.	None	None	None	None	None	None	None	None	None	None	None	Hikma is limiting its response to that which is otherwise in the public domain or publicly available. Hikma did not acquire this product.
Rx0000178	Hikma Pharmaceuticals USA Inc	03/31/2019	00143978610	Enalaprilat Intravenous Injectable 1.25 MG/2ML, 10 Vials	01/01/2019	16.49	71.44	None	Non-innovator Multiple Source Drug	None	1	None	1	This WAC increase is not necessitated by a change or improvement in the prescription drug.	None	None	None	None	None	None	None	None	None	None	None	Hikma is limiting its response to that which is otherwise in the public domain or publicly available. Hikma did not acquire this product.
Rx0000178	Hikma Pharmaceuticals USA Inc	09/30/2019	00641039112	Heparin Sodium (Porcine) Injection Solution 1000 UNIT/ML. 25 Vials	07/12/2019	17.05	51.15	None	Non-innovator Multiple Source Drug	None	1	None	1	This WAC increase is not necessitated by a change or improvement in the prescription drug.	None	None	None	None	None	None	None	None	None	None	None	Hikma is limiting its response to that which is otherwise in the public domain or publicly available. Hikma did not acquire this product.
Rx0000178	Hikma Pharmaceuticals USA Inc	09/30/2019	00641246055	Heparin Sodium (Porcine) Injection Solution 5000 UNIT/ML, 25 Vials	07/12/2019	41.15	210.00	None	Non-innovator Multiple Source Drug	None	1	None	1	This WAC increase is not necessitated by a change or improvement in the prescription drug.	None	None	None	None	None	None	None	None	None	None	None	Hikma is limiting its response to that which is otherwise in the public domain or publicly available. Hikma did not acquire this product.
Rx0000178	Hikma Pharmaceuticals USA Inc	03/31/2019	00641605425	Meperidine HCl Injection Solution 100 MG/ML, 25 Vials	01/01/2019	5.93	65.87	None	Non-innovator Multiple Source Drug	None	1	None	1	This WAC increase is not necessitated by a change or improvement in the prescription drug.	None	None	None	None	None	None	None	None	None	None	None	Hikma is limiting its response to that which is otherwise in the public domain or publicly available. Hikma did not acquire this product.
Rx0000178	Hikma Pharmaceuticals USA Inc	03/31/2019	00641605225	Meperidine HCl Injection Solution 25 MG/ML, 25 Vials	01/01/2019	5.20	57.70	None	Non-innovator Multiple Source Drug	None	1	None	1	This WAC increase is not necessitated by a change or improvement in the prescription drug.	None	None	None	None	None	None	None	None	None	None	None	Hikma is limiting its response to that which is otherwise in the public domain or publicly available. Hikma did not acquire this product.
Rx0000178	Hikma Pharmaceuticals USA Inc	03/31/2019	00641605325	Meperidine HCl Injection Solution 50 MG/ML, 25 Vials	01/01/2019	5.41	60.10	None	Non-innovator Multiple Source Drug	None	1	None	1	This WAC increase is not necessitated by a change or improvement in the prescription drug.	None	None	None	None	None	None	None	None	None	None	None	Hikma is limiting its response to that which is otherwise in the public domain or publicly available. Hikma did not acquire this product.
Rx0000178	Hikma Pharmaceuticals USA Inc	09/30/2019	00054021125	Protriptyline HCl Oral Tablet 10 MG, 100 Tablets	09/06/2019	232.75	477.75	None	Non-innovator Multiple Source Drug	None	1	None	1	This WAC increase is not necessitated by a change or improvement in the prescription drug.	None	None	None	None	None	None	None	None	None	None	None	Hikma is limiting its response to that which is otherwise in the public domain or publicly available. Hikma did not acquire this product.
Rx0000178	Hikma Pharmaceuticals USA Inc	09/30/2019	00054021025	Protriptyline HCl Oral Tablet 5 MG, 100 Tablets	09/06/2019	232.75	477.75	None	Non-innovator Multiple Source Drug	None	1	None	1	This WAC increase is not necessitated by a change or improvement in the prescription drug.	None	None	None	None	None	None	None	None	None	None	None	Hikma is limiting its response to that which is otherwise in the public domain or publicly available. Hikma did not acquire this product.
Rx0000145	Horizon Therapeutics USA, Inc.	09/30/2019	75987008010	Drug product name: KRYSTEXXA. Drug product strength: 1 mL sterile concentrate for dilution containing 8 mg of pegloticase protein, expressed in uricase protein amounts. Drug product dosage form: vial. Drug product package size: 2 mL single use vial.	07/01/2019	1055.78	22602.00	None	Single Source Drug	None	1	None	1	None	1	01/13/2016	Crealta Holdings LLC	None	1	Horizon acquired this particular product as part of the overall acquisition of Crealta Holdings LLC, and its acquisition price was incorporated into that deal’s overall purchase price of approximately $510 million with no means of individually identifying the purchase price of this asset.	14000.00	14000.00	2010	2300.00	None	Consistent with the relevant statutes and regulations, all information contained in this report is limited to that which Horizon believes is otherwise in the public domain or publicly available. Please note the Patent Expiration date for KRYSTEXXA is not publicly available.
Rx0000160	Incyte Corporation	12/31/2019	50881001060	Jakafi (Ruxolitinib) 10mg tablet / 60 count bottle	10/01/2019	309.00	13504.00	06/12/2028	Single Source Drug	None	1	Incyte is driven by rigorous science and our pricing decisions allow us to invest in scientific advancements in areas of high unmet medical need. Incyte responsibly prices our medicines and makes price revisions with consideration to market conditions, patient access, and the clinical value that our medicines deliver to patients.	None	This WAC increase is not necessitated by a change or improvement in the prescription drug.	None	None	None	None	None	None	None	None	None	None	None	For Column F as reflected in the FDA publication, Approved Drug Products with Therapeutic Equivalence Evaluations (the “Orange Book”), the latest patent expiration is provided. Not acquired within the last five years.
Rx0000160	Incyte Corporation	12/31/2019	50881001560	Jakafi (Ruxolitinib) 15mg tablet / 60 count bottle	10/01/2019	309.00	13504.00	06/12/2028	Single Source Drug	None	1	Incyte is driven by rigorous science and our pricing decisions allow us to invest in scientific advancements in areas of high unmet medical need. Incyte responsibly prices our medicines and makes price revisions with consideration to market conditions, patient access, and the clinical value that our medicines deliver to patients.	None	This WAC increase is not necessitated by a change or improvement in the prescription drug.	None	None	None	None	None	None	None	None	None	None	None	For Column F as reflected in the FDA publication, Approved Drug Products with Therapeutic Equivalence Evaluations (the “Orange Book”), the latest patent expiration is provided. Not acquired within the last five years.
Rx0000160	Incyte Corporation	12/31/2019	50881002060	Jakafi (Ruxolitinib) 20mg tablet / 60 count bottle	10/01/2019	309.00	13504.00	06/12/2028	Single Source Drug	None	1	Incyte is driven by rigorous science and our pricing decisions allow us to invest in scientific advancements in areas of high unmet medical need. Incyte responsibly prices our medicines and makes price revisions with consideration to market conditions, patient access, and the clinical value that our medicines deliver to patients.	None	This WAC increase is not necessitated by a change or improvement in the prescription drug.	None	None	None	None	None	None	None	None	None	None	None	For Column F as reflected in the FDA publication, Approved Drug Products with Therapeutic Equivalence Evaluations (the “Orange Book”), the latest patent expiration is provided. Not acquired within the last five years.
Rx0000160	Incyte Corporation	12/31/2019	50881002560	Jakafi (Ruxolitinib) 25mg tablet / 60 count bottle	10/01/2019	309.00	13504.00	06/12/2028	Single Source Drug	None	1	Incyte is driven by rigorous science and our pricing decisions allow us to invest in scientific advancements in areas of high unmet medical need. Incyte responsibly prices our medicines and makes price revisions with consideration to market conditions, patient access, and the clinical value that our medicines deliver to patients.	None	This WAC increase is not necessitated by a change or improvement in the prescription drug.	None	None	None	None	None	None	None	None	None	None	None	For Column F as reflected in the FDA publication, Approved Drug Products with Therapeutic Equivalence Evaluations (the “Orange Book”), the latest patent expiration is provided. Not acquired within the last five years.
Rx0000160	Incyte Corporation	12/31/2019	50881000560	Jakafi (Ruxolitinib) 5mg tablet / 60 count bottle	10/01/2019	309.00	13504.00	06/12/2028	Single Source Drug	None	1	Incyte is driven by rigorous science and our pricing decisions allow us to invest in scientific advancements in areas of high unmet medical need. Incyte responsibly prices our medicines and makes price revisions with consideration to market conditions, patient access, and the clinical value that our medicines deliver to patients.	None	This WAC increase is not necessitated by a change or improvement in the prescription drug.	None	None	None	None	None	None	None	None	None	None	None	For Column F as reflected in the FDA publication, Approved Drug Products with Therapeutic Equivalence Evaluations (the “Orange Book”), the latest patent expiration is provided. Not acquired within the last five years.
Rx0000040	Ingenus Pharmaceuticals, LLC	09/30/2019	50742051330	Nitro-Dur Patch 0.1mg/hr 30 ct	08/01/2019	129.20	520.73	None	Single Source Drug	372	None	Increased overhead, expenses, and distribution costs causing need for price increase	None	No changes made	None	08/31/2017	USPharma	2000000	None	The acquisition price provided was for the acquisition of the Nitro-Dur product line from USPharma and is not a SKU specific figure	262.77	138.30	2017	262.77	None	Patent expiration date: as this product is pre-patent, we do not have a patent expiration date to provide Year Introduced to Market: only the 0.3mg sold in 2017, the rest of the SKUs were first sold in 2018. However, we loaded all SKUs to the Gold Standard with 2017 effective dates. Therefore, we have listed 2017 as the introduction year
Rx0000040	Ingenus Pharmaceuticals, LLC	09/30/2019	50742051430	Nitro-Dur Patch 0.2mg/hr 30 ct	08/01/2019	139.01	560.26	None	Single Source Drug	960	None	Increased overhead, expenses, and distribution costs causing need for price increase	None	No changes made	None	08/31/2017	USPharma	2000000	None	The acquisition price provided was for the acquisition of the Nitro-Dur product line from USPharma and is not a SKU specific figure	282.72	140.40	2017	282.72	None	Patent expiration date: as this product is pre-patent, we do not have a patent expiration date to provide Year Introduced to Market: only the 0.3mg sold in 2017, the rest of the SKUs were first sold in 2018. However, we loaded all SKUs to the Gold Standard with 2017 effective dates. Therefore, we have listed 2017 as the introduction year
Rx0000040	Ingenus Pharmaceuticals, LLC	09/30/2019	50742051530	Nitro-Dur Patch 0.3mg/hr 30 ct	08/01/2019	155.83	628.04	None	Single Source Drug	6744	None	Increased overhead, expenses, and distribution costs causing need for price increase	None	No changes made	None	08/31/2017	USPharma	2000000	None	The acquisition price provided was for the acquisition of the Nitro-Dur product line from USPharma and is not a SKU specific figure	316.92	157.50	2017	316.92	None	Patent expiration date: as this product is pre-patent, we do not have a patent expiration date to provide Year Introduced to Market: only the 0.3mg sold in 2017, the rest of the SKUs were first sold in 2018. However, we loaded all SKUs to the Gold Standard with 2017 effective dates. Therefore, we have listed 2017 as the introduction year
Rx0000040	Ingenus Pharmaceuticals, LLC	09/30/2019	50742051630	Nitro-Dur Patch 0.4mg/hr 30 ct	08/01/2019	155.83	628.04	None	Single Source Drug	510	None	Increased overhead, expenses, and distribution costs causing need for price increase	None	No changes made	None	08/31/2017	USPharma	2000000	None	The acquisition price provided was for the acquisition of the Nitro-Dur product line from USPharma and is not a SKU specific figure	316.92	157.50	2017	316.92	None	Patent expiration date: as this product is pre-patent, we do not have a patent expiration date to provide Year Introduced to Market: only the 0.3mg sold in 2017, the rest of the SKUs were first sold in 2018. However, we loaded all SKUs to the Gold Standard with 2017 effective dates. Therefore, we have listed 2017 as the introduction year
Rx0000040	Ingenus Pharmaceuticals, LLC	09/30/2019	50742051730	Nitro-Dur Patch 0.6mg/hr 30 ct	08/01/2019	169.00	681.13	None	Single Source Drug	420	None	Increased overhead, expenses, and distribution costs causing need for price increase	None	No changes made	None	08/31/2017	USPharma	2000000	None	The acquisition price provided was for the acquisition of the Nitro-Dur product line from USPharma and is not a SKU specific figure	343.71	170.70	2017	343.71	None	Patent expiration date: as this product is pre-patent, we do not have a patent expiration date to provide Year Introduced to Market: only the 0.3mg sold in 2017, the rest of the SKUs were first sold in 2018. However, we loaded all SKUs to the Gold Standard with 2017 effective dates. Therefore, we have listed 2017 as the introduction year
Rx0000040	Ingenus Pharmaceuticals, LLC	09/30/2019	50742051830	Nitro-Dur Patch 0.8mg/hr 30 ct	08/01/2019	169.00	681.13	None	Single Source Drug	4056	None	Increased overhead, expenses, and distribution costs causing need for price increase	None	No changes made	None	08/31/2017	USPharma	2000000	None	The acquisition price provided was for the acquisition of the Nitro-Dur product line from USPharma and is not a SKU specific figure	343.71	170.70	2017	343.71	None	Patent expiration date: as this product is pre-patent, we do not have a patent expiration date to provide
Rx0000266	Intercept Pharmaceuticals, Inc.	09/30/2019	69516001030	OCALIVA (obeticholic acid), 10mg tablets, 30 count bottle	08/15/2019	322.77	6909.83	04/26/2036	Single Source Drug	None	1	Intercept’s pricing decisions take into careful consideration a variety of interdependent factors, including R&D investments, clinical/economic value, patient affordability, and current market dynamics.	None	This WAC increase was not necessitated by a change or improvement in the product. Intercept’s goal is to set prices at levels that allow patients to access medicines prescribed for them, while allowing for sustained funding of research and development.	None	None	None	None	None	None	None	None	None	None	None	The drug was developed by the manufacturer; therefore the acquisition related fields are blank. Per State requirements, the information reported is limited to that which is otherwise in the public domain or publicly available.
Rx0000266	Intercept Pharmaceuticals, Inc.	09/30/2019	69516000530	OCALIVA (obeticholic acid), 5mg tablets, 30 count bottle	08/15/2019	322.77	6909.83	04/26/2036	Single Source Drug	None	1	Intercept’s pricing decisions take into careful consideration a variety of interdependent factors, including R&D investments, clinical/economic value, patient affordability, and current market dynamics.	None	This WAC increase was not necessitated by a change or improvement in the product. Intercept’s goal is to set prices at levels that allow patients to access medicines prescribed for them, while allowing for sustained funding of research and development.	None	None	None	None	None	None	None	None	None	None	None	The drug was developed by the manufacturer; therefore the acquisition related fields are blank. Per State requirements, the information reported is limited to that which is otherwise in the public domain or publicly available.
Rx0000084	Ipsen Biopharmaceuticals, Inc.	03/31/2019	15054104005	Drug product name: Increlex. Drug product strength: 10 mg/ml. Drug product dosage form: vial. Drug product package size: 4ml.	01/01/2019	403.01	4464.00	None	Single Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	The information provided in response to 22 CCR § 96070(b)(6) is based upon patents listed in the FDA Orange Book. The product was not acquired by Ipsen within the previous five years.
Rx0000084	Ipsen Biopharmaceuticals, Inc.	03/31/2019	15054004301	Drug product name: Onivyde. Drug product strength: 43 mg/10 ml (4.3 mg/ml). Drug product dosage form: vial. Drug product package size: 10ml.	01/01/2019	194.00	2152.00	06/12/2033	Single Source Drug	None	1	None	1	None	1	04/03/2017	Merrimack Pharmaceuticals	None	1	For purposes of 22 CCR § 96070(b)(12)(c) (requirement to report the purchase price of the relevant drug, if the drug was acquired by the manufacturer within the previous five years), Ipsen purchased the global oncology assets of Merrimack Pharmaceuticals in April 2017, including Onivyde. The purchase price of the drug product (as Ipsen understands that data element) is not in the public domain or otherwise publicly available. However, information regarding Ipsen’s purchase of the assets from Merrimack Pharmaceuticals is available on p. 97, Note 12.1.1 of section 3.2.5, of the Registration Document located at: https://www.ipsen.com/websites/Ipsen_Online/wp-content/uploads/2018/03/15164935/IPSEN_DDR_2017_VA_complet_clean-003.pdf	1652.40	None	2015	1620.00	None	The information provided in response to 22 CCR § 96070(b)(6) is based upon patents listed in the FDA Orange Book. The information provided in response to 22 CCR § 96070(b)(11) contains price increases for the drug product when the NDC for the product was 69171-0398-01
Rx0000084	Ipsen Biopharmaceuticals, Inc.	03/31/2019	15054112003	Drug product name: Somatuline Depot. Drug product strength: 120 mg/0.5 ml. Drug product dosage form: syringe. Drug product package size: .50 ml.	01/01/2019	718.00	7967.00	03/08/2020	Single Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	Ipsen has provided the WAC history for the relevant NDC going back to January 2, 2015. The NDC at issue did not exist before that date. The information provided in response to 22 CCR § 96070(b)(6) is based upon patents listed in the FDA Orange Book. The product was not acquired by Ipsen within the previous five years.
Rx0000084	Ipsen Biopharmaceuticals, Inc.	03/31/2019	15054106003	Drug product name: Somatuline Depot. Drug product strength: 60 mg/0.2 ml. Drug product dosage form: syringe. Drug product package size: .20 ml.	01/01/2019	457.00	5072.00	03/08/2020	Single Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	Ipsen has provided the WAC history for the relevant NDC going back to January 2, 2015. The NDC at issue did not exist before that date. The information provided in response to 22 CCR § 96070(b)(6) is based upon patents listed in the FDA Orange Book. The product was not acquired by Ipsen within the previous five years.
Rx0000084	Ipsen Biopharmaceuticals, Inc.	03/31/2019	15054109003	Drug product name: Somatuline Depot. Drug product strength: 90 mg/0.3 ml. Drug product dosage form: syringe. Drug product package size: .30 ml.	01/01/2019	609.00	6756.00	03/08/2020	Single Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	Ipsen has provided the WAC history for the relevant NDC going back to January 2, 2015. The NDC at issue did not exist before that date. The information provided in response to 22 CCR § 96070(b)(6) is based upon patents listed in the FDA Orange Book. The product was not acquired by Ipsen within the previous five years.
Rx0000008	Jazz Pharmaceuticals, Inc.	03/31/2019	68727010001	Xyrem	01/04/2019	302.08	4617.44	09/15/2033	Single Source Drug	1404866000	None	None	1	A change or improvement to the drug did not necessitate the price increase	None	None	None	None	None	None	None	None	None	None	None	The patent expiration date contained in this report is limited to the patent information reported in the federal Food and Drug Administration’s Orange Book, as of April 30, 2019. As a result, the reported patent expiration date is limited to issued U.S. patents. Further, the reported patent expiration date does not reflect any pending patents, patent term extensions, pediatric exclusivity, or patent-related litigation, each of which is speculative and which may extend or shorten the reported expiration date. The drug was not was acquired from another manufacturer within the last five years.
Rx0000008	Jazz Pharmaceuticals, Inc.	09/30/2019	68727010001	Xyrem 500 MG/ML Oral Solution 180 ml	07/10/2019	92.35	4709.79	09/15/2033	Single Source Drug	1404866000	None	None	1	A change or improvement to the drug did not necessitate the price increase	None	None	None	None	None	None	None	None	None	None	None	The patent expiration date contained in this report is limited to the patent information reported in the federal Food and Drug Administration’s Orange Book, as of April 30, 2019. As a result, the reported patent expiration date is limited to issued U.S. patents. Further, the reported patent expiration date does not reflect any pending patents, patent term extensions, pediatric exclusivity, or patent-related litigation, each of which is speculative and which may extend or shorten the reported expiration date. The drug was not was acquired from another manufacturer within the last five years.
Rx0000060	Kyowa Kirin, Inc.	03/31/2019	42747072601	Sancuso (Granisetron Transdermal System) 3.1 mg/24 hrs 7-day patch	02/12/2019	16.00	549.55	01/22/2025	Single Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	The NDC was not acquired within the last five years.
Rx0000083	Laboratoire HRA Pharma	03/31/2019	76336008060	Antineoplastic	03/01/2019	359.05	839.00	None	Single Source Drug	None	1	None	1	None	1	03/16/2018	Bristol Myers Squibb	None	1	No comment	479.95	None	1970	None	None	Column 6: Patent(s) expired. Product FDA approved 1970. Column 21: WAC at Intro to Market unknown. Introducted to U.S. market in 1970.
Rx0000083	Laboratoire HRA Pharma	09/30/2019	76336008060	Lysodren (mitotane) 100 mg tablets	07/01/2019	359.05	839.00	None	Single Source Drug	None	1	None	1	None	1	03/14/2018	Bristol Myers Squibb	None	1	None	479.95	479.95	1970	157.44	None	The exact year of BMS's Lysodren introduction is not known. Lysodren was FDA approved in 1970.
Rx0000083	Laboratoire HRA Pharma	06/30/2019	76336045518	Metopirone (metryapone) 250 mg capsules	04/09/2019	34.59	383.95	01/01/1981	Single Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	HRA Pharma acquired Metopirone from Novartis in 2011 (exact date unknown).
Rx0000083	Laboratoire HRA Pharma	09/30/2019	76336045518	Metopirone (metryapone) 250 mg capsules	07/01/2019	34.56	383.95	01/01/1981	Single Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	HRA Pharma acquired Metopirone from Novartis in 2011 (exact date unknown).
Rx0000089	Lannett Company, Inc.	03/31/2019	54838052340	Fluoxetine Oral Solution 20mg/5ml	01/11/2019	60.00	69.00	None	Non-innovator Multiple Source Drug	None	1	New serialization/software costs, production line enhancements were factors in the price increase. Continued supply of market demand not sustainable without a price adjustment.	None	n/a	None	None	None	None	None	None	None	None	None	None	None	No other price increases over that last five years other than the last one in 1/11/2019
Rx0000089	Lannett Company, Inc.	03/31/2019	54838050115	Haloperidol Oral Solution 2mg/ml	01/11/2019	14.87	20.86	None	Non-innovator Multiple Source Drug	None	1	Product API cost increases, new serialization/software costs, production line enhancements were factors in the price increase. Continued supply of market demand not sustainable without a price adjustment.	None	n/a	None	None	None	None	None	None	None	None	None	None	None	No other price increases over that last five years other than the last one in 1/11/2019
Rx0000089	Lannett Company, Inc.	03/31/2019	54838050140	Haloperidol Oral Solution 2mg/ml	01/11/2019	19.33	28.32	None	Non-innovator Multiple Source Drug	None	1	Product API cost increases, new serialization/software costs, production line enhancements were factors in the price increase. Continued supply of market demand not sustainable without a price adjustment.	None	n/a	None	None	None	None	None	None	None	None	None	None	None	No other price increases over that last five years other than the last one in 1/11/2019
Rx0000089	Lannett Company, Inc.	03/31/2019	54838055080	Ranitidine Syrup 15mg/ml	01/11/2019	57.00	75.00	None	Non-innovator Multiple Source Drug	None	1	New serialization/software costs, production line enhancements were factors in the price increase. Continued supply of market demand not sustainable without a price adjustment.	None	n/a	None	None	None	None	None	None	None	None	None	None	None	No other price increases over that last five years other than the last one in 1/11/2019
Rx0000009	Lantheus Medical Imaging, Inc.	03/31/2019	11994001104	Definity® Vial for (Perflutren Lipid Microsphere) Injectable Solution	01/01/2019	91.99	1011.92	03/16/2037	Single Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	None
Rx0000009	Lantheus Medical Imaging, Inc.	03/31/2019	11994001116	Definity® Vial for (Perflutren Lipid Microsphere) Injectable Solution	01/01/2019	367.97	4047.67	03/16/2037	Single Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	None
Rx0000009	Lantheus Medical Imaging, Inc.	03/31/2019	11994012106	Gallium-67 (Gallium Citrate Ga67 Injection)	01/01/2019	72.10	793.13	None	Innovator Multiple Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	None
Rx0000009	Lantheus Medical Imaging, Inc.	03/31/2019	11994012108	Gallium-67 (Gallium Citrate Ga67 Injection)	01/01/2019	96.13	1057.48	None	Innovator Multiple Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	None
Rx0000009	Lantheus Medical Imaging, Inc.	03/31/2019	11994012113	Gallium-67 (Gallium Citrate Ga67 Injection)	01/01/2019	144.19	1586.12	None	Innovator Multiple Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	None
Rx0000009	Lantheus Medical Imaging, Inc.	03/31/2019	11994012119	Gallium-67 (Gallium Citrate Ga67 Injection)	01/01/2019	216.30	2379.25	None	Innovator Multiple Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	None
Rx0000009	Lantheus Medical Imaging, Inc.	03/31/2019	11994009101	LEU TechneLite® (Technetium Tc99m Generator)	01/01/2019	320.61	6735.05	07/01/2029	Innovator Multiple Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	None
Rx0000009	Lantheus Medical Imaging, Inc.	03/31/2019	11994009103	LEU TechneLite® (Technetium Tc99m Generator)	01/01/2019	374.70	7868.63	07/01/2029	Innovator Multiple Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	None
Rx0000009	Lantheus Medical Imaging, Inc.	03/31/2019	11994009104	LEU TechneLite® (Technetium Tc99m Generator)	01/01/2019	404.60	8496.69	07/01/2029	Innovator Multiple Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	None
Rx0000009	Lantheus Medical Imaging, Inc.	03/31/2019	11994009105	LEU TechneLite® (Technetium Tc99m Generator)	01/01/2019	435.65	9148.64	07/01/2029	Innovator Multiple Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	None
Rx0000009	Lantheus Medical Imaging, Inc.	03/31/2019	11994009106	LEU TechneLite® (Technetium Tc99m Generator)	01/01/2019	492.06	10333.31	07/01/2029	Innovator Multiple Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	None
Rx0000009	Lantheus Medical Imaging, Inc.	03/31/2019	11994009107	LEU TechneLite® (Technetium Tc99m Generator)	01/01/2019	576.47	12105.91	07/01/2029	Innovator Multiple Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	None
Rx0000009	Lantheus Medical Imaging, Inc.	03/31/2019	11994009109	LEU TechneLite® (Technetium Tc99m Generator)	01/01/2019	701.50	14731.49	07/01/2029	Innovator Multiple Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	None
Rx0000009	Lantheus Medical Imaging, Inc.	03/31/2019	11994009110	LEU TechneLite® (Technetium Tc99m Generator)	01/01/2019	824.78	17320.35	07/01/2029	Innovator Multiple Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	None
Rx0000009	Lantheus Medical Imaging, Inc.	03/31/2019	11994009111	LEU TechneLite® (Technetium Tc99m Generator)	01/01/2019	1014.48	21304.05	07/01/2029	Innovator Multiple Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	None
Rx0000009	Lantheus Medical Imaging, Inc.	03/31/2019	11994009112	LEU TechneLite® (Technetium Tc99m Generator)	01/01/2019	1247.81	26203.96	07/01/2029	Innovator Multiple Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	None
Rx0000009	Lantheus Medical Imaging, Inc.	03/31/2019	11994009136	LEU TechneLite® (Technetium Tc99m Generator)	01/01/2019	206.40	4334.38	07/01/2029	Innovator Multiple Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	None
Rx0000009	Lantheus Medical Imaging, Inc.	03/31/2019	11994009173	LEU TechneLite® (Technetium Tc99m Generator)	01/01/2019	260.42	5468.91	07/01/2029	Innovator Multiple Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	None
Rx0000009	Lantheus Medical Imaging, Inc.	03/31/2019	11994009192	LEU TechneLite® (Technetium Tc99m Generator)	01/01/2019	286.29	6012.16	07/01/2029	Innovator Multiple Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	None
Rx0000009	Lantheus Medical Imaging, Inc.	03/31/2019	11994000602	NEUROLITE® (Kit for the Preparation of Technetium Tc99m Bicisate for Injection)	01/01/2019	538.14	5919.57	None	Single Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	None
Rx0000009	Lantheus Medical Imaging, Inc.	03/31/2019	11994001601	QUADRAMET® (Samarium Sm 153 Lexidronam Injection)	01/01/2019	1383.42	15217.64	None	Single Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	None
Rx0000009	Lantheus Medical Imaging, Inc.	03/31/2019	11994009001	TechneLite® (Technetium Tc99m Generator)	01/01/2019	259.41	5447.56	07/01/2029	Innovator Multiple Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	None
Rx0000009	Lantheus Medical Imaging, Inc.	03/31/2019	11994009003	TechneLite® (Technetium Tc99m Generator)	01/01/2019	303.06	6364.35	07/01/2029	Innovator Multiple Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	None
Rx0000009	Lantheus Medical Imaging, Inc.	03/31/2019	11994009004	TechneLite® (Technetium Tc99m Generator)	01/01/2019	327.25	6872.33	07/01/2029	Innovator Multiple Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	None
Rx0000009	Lantheus Medical Imaging, Inc.	03/31/2019	11994009005	TechneLite® (Technetium Tc99m Generator)	01/01/2019	352.36	7399.66	07/01/2029	Innovator Multiple Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	None
Rx0000009	Lantheus Medical Imaging, Inc.	03/31/2019	11994009006	TechneLite® (Technetium Tc99m Generator)	01/01/2019	397.99	8357.82	07/01/2029	Innovator Multiple Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	None
Rx0000009	Lantheus Medical Imaging, Inc.	03/31/2019	11994009007	TechneLite® (Technetium Tc99m Generator)	01/01/2019	466.27	9791.55	07/01/2029	Innovator Multiple Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	None
Rx0000009	Lantheus Medical Imaging, Inc.	03/31/2019	11994009009	TechneLite® (Technetium Tc99m Generator)	01/01/2019	567.39	11915.18	07/01/2029	Innovator Multiple Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	None
Rx0000009	Lantheus Medical Imaging, Inc.	03/31/2019	11994009010	TechneLite® (Technetium Tc99m Generator)	01/01/2019	667.10	14009.11	07/01/2029	Innovator Multiple Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	None
Rx0000009	Lantheus Medical Imaging, Inc.	03/31/2019	11994009011	TechneLite® (Technetium Tc99m Generator)	01/01/2019	820.53	17231.22	07/01/2029	Innovator Multiple Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	None
Rx0000009	Lantheus Medical Imaging, Inc.	03/31/2019	11994009012	TechneLite® (Technetium Tc99m Generator)	01/01/2019	1009.26	21194.36	07/01/2029	Innovator Multiple Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	None
Rx0000009	Lantheus Medical Imaging, Inc.	03/31/2019	11994009036	TechneLite® (Technetium Tc99m Generator)	01/01/2019	166.94	3505.77	07/01/2029	Innovator Multiple Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	None
Rx0000009	Lantheus Medical Imaging, Inc.	03/31/2019	11994009073	TechneLite® (Technetium Tc99m Generator)	01/01/2019	210.64	4423.37	07/01/2029	Innovator Multiple Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	None
Rx0000009	Lantheus Medical Imaging, Inc.	03/31/2019	11994009092	TechneLite® (Technetium Tc99m Generator)	01/01/2019	231.56	4862.76	07/01/2029	Innovator Multiple Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	None
Rx0000009	Lantheus Medical Imaging, Inc.	03/31/2019	11994012711	Xenon-133 (Xenon Xe 133 Gas)	01/01/2019	25.63	281.89	None	Innovator Multiple Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	None
Rx0000009	Lantheus Medical Imaging, Inc.	03/31/2019	11994012715	Xenon-133 (Xenon Xe 133 Gas)	01/01/2019	95.32	1048.56	None	Innovator Multiple Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	None
Rx0000009	Lantheus Medical Imaging, Inc.	03/31/2019	11994012821	Xenon-133 (Xenon Xe 133 Gas)	01/01/2019	41.55	457.09	None	Innovator Multiple Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	None
Rx0000009	Lantheus Medical Imaging, Inc.	03/31/2019	11994012825	Xenon-133 (Xenon Xe 133 Gas)	01/01/2019	194.13	2135.40	None	Innovator Multiple Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	None
Rx0000196	Lexicon Pharmaceuticals	09/30/2019	70183012584	XERMELO Telotristat Ethyl 250 mg 84 tablets	07/02/2019	1089.00	6253.00	12/11/2027	Single Source Drug	None	1	None	1	no change	None	None	None	None	None	None	None	None	None	None	None	Product developed internally. No acquisition.
Rx0000025	Lundbeck LLC	03/31/2019	67386082019	Northera 100mg. 90 Capsules	01/07/2019	233.70	2594.26	02/18/2021	Single Source Drug	None	1	"Our industry is different from almost any other, in that the price for a product often increases over time. That may seem counterintuitive until you realize that drugs are different from cars, computers or clothing. Once we bring a product to patients, that begins another series of investments so we can follow the progress and safety of patients taking the drug, develop better formulations that benefit the patient community, investigate its application to other indications and more. Price increases are what pay for those investments across our industry."	None	This WAC increase is not necessitated by a change or improvement in the prescription drug.	None	06/23/2014	"Chelsea Therapeutics International, Ltd."	None	1	"The Acquisition Price was left blank since Lundbeck acquired the rights to Northera through the purchase of Chelsea Therapeutics International, Ltd. for USD 6.44 per share in cash and non-transferable contingent value rights that may pay up to an additional USD 1.5 per share upon achievement of certain sales milestones, in each case without interest and subject to any required withholding of taxes."	1409.00	None	2014	1409.00	None	WAC at acquisition is the same as WAC at introduction given that Northera did not launch until after acquisition.
Rx0000025	Lundbeck LLC	03/31/2019	67386082119	Northera 200mg. 90 Capsules	01/07/2019	467.39	5188.51	02/18/2021	Single Source Drug	None	1	"Our industry is different from almost any other, in that the price for a product often increases over time. That may seem counterintuitive until you realize that drugs are different from cars, computers or clothing. Once we bring a product to patients, that begins another series of investments so we can follow the progress and safety of patients taking the drug, develop better formulations that benefit the patient community, investigate its application to other indications and more. Price increases are what pay for those investments across our industry."	None	This WAC increase is not necessitated by a change or improvement in the prescription drug.	None	06/23/2014	"Chelsea Therapeutics International, Ltd."	None	1	"The Acquisition Price was left blank since Lundbeck acquired the rights to Northera through the purchase of Chelsea Therapeutics International, Ltd. for USD 6.44 per share in cash and non-transferable contingent value rights that may pay up to an additional USD 1.5 per share upon achievement of certain sales milestones, in each case without interest and subject to any required withholding of taxes."	2818.00	None	2014	2818.00	None	WAC at acquisition is the same as WAC at introduction given that Northera did not launch until after acquisition.
Rx0000025	Lundbeck LLC	03/31/2019	67386082219	Northera 300mg. 90 Capsules	01/07/2019	701.09	7782.78	02/18/2021	Single Source Drug	None	1	"Our industry is different from almost any other, in that the price for a product often increases over time. That may seem counterintuitive until you realize that drugs are different from cars, computers or clothing. Once we bring a product to patients, that begins another series of investments so we can follow the progress and safety of patients taking the drug, develop better formulations that benefit the patient community, investigate its application to other indications and more. Price increases are what pay for those investments across our industry."	None	This WAC increase is not necessitated by a change or improvement in the prescription drug.	None	06/23/2014	"Chelsea Therapeutics International, Ltd."	None	1	"The Acquisition Price was left blank since Lundbeck acquired the rights to Northera through the purchase of Chelsea Therapeutics International, Ltd. for USD 6.44 per share in cash and non-transferable contingent value rights that may pay up to an additional USD 1.5 per share upon achievement of certain sales milestones, in each case without interest and subject to any required withholding of taxes."	4227.00	None	2014	4227.00	None	WAC at acquisition is the same as WAC at introduction given that Northera did not launch until after acquisition.
Rx0000025	Lundbeck LLC	03/31/2019	67386031401	Onfi 10mg. 100 Tablets	01/07/2019	181.22	2011.74	None	Innovator Multiple Source Drug	None	1	"Our industry is different from almost any other, in that the price for a product often increases over time. That may seem counterintuitive until you realize that drugs are different from cars, computers or clothing. Once we bring a product to patients, that begins another series of investments so we can follow the progress and safety of patients taking the drug, develop better formulations that benefit the patient community, investigate its application to other indications and more. Price increases are what pay for those investments across our industry."	None	This WAC increase is not necessitated by a change or improvement in the prescription drug.	None	None	None	None	None	None	None	None	None	None	None	None
Rx0000025	Lundbeck LLC	03/31/2019	67386031501	Onfi 20mg. 100 Tablets	01/07/2019	362.44	4023.44	None	Innovator Multiple Source Drug	None	1	"Our industry is different from almost any other, in that the price for a product often increases over time. That may seem counterintuitive until you realize that drugs are different from cars, computers or clothing. Once we bring a product to patients, that begins another series of investments so we can follow the progress and safety of patients taking the drug, develop better formulations that benefit the patient community, investigate its application to other indications and more. Price increases are what pay for those investments across our industry."	None	This WAC increase is not necessitated by a change or improvement in the prescription drug.	None	None	None	None	None	None	None	None	None	None	None	None
Rx0000025	Lundbeck LLC	03/31/2019	67386031321	Onfi Oral Suspension 2.5mg/mL 120mL Bottle	01/07/2019	95.22	1056.99	None	Innovator Multiple Source Drug	None	1	"Our industry is different from almost any other, in that the price for a product often increases over time. That may seem counterintuitive until you realize that drugs are different from cars, computers or clothing. Once we bring a product to patients, that begins another series of investments so we can follow the progress and safety of patients taking the drug, develop better formulations that benefit the patient community, investigate its application to other indications and more. Price increases are what pay for those investments across our industry."	None	This WAC increase is not necessitated by a change or improvement in the prescription drug.	None	None	None	None	None	None	None	None	None	None	None	None
Rx0000025	Lundbeck LLC	03/31/2019	67386011101	Sabril 500mg. 100 Tablets	01/07/2019	1316.25	14611.73	None	Innovator Multiple Source Drug	None	1	"Our industry is different from almost any other, in that the price for a product often increases over time. That may seem counterintuitive until you realize that drugs are different from cars, computers or clothing. Once we bring a product to patients, that begins another series of investments so we can follow the progress and safety of patients taking the drug, develop better formulations that benefit the patient community, investigate its application to other indications and more. Price increases are what pay for those investments across our industry."	None	This WAC increase is not necessitated by a change or improvement in the prescription drug.	None	None	None	None	None	None	None	None	None	None	None	None
Rx0000025	Lundbeck LLC	03/31/2019	67386021165	Sabril 500mg. 50 Packets 500mg. each	01/07/2019	658.13	7305.87	None	Innovator Multiple Source Drug	None	1	"Our industry is different from almost any other, in that the price for a product often increases over time. That may seem counterintuitive until you realize that drugs are different from cars, computers or clothing. Once we bring a product to patients, that begins another series of investments so we can follow the progress and safety of patients taking the drug, develop better formulations that benefit the patient community, investigate its application to other indications and more. Price increases are what pay for those investments across our industry."	None	This WAC increase is not necessitated by a change or improvement in the prescription drug.	None	None	None	None	None	None	None	None	None	None	None	None
Rx0000025	Lundbeck LLC	03/31/2019	67386042101	Xenazine 12.5mg. 112 Tablets	01/07/2019	1270.09	14099.29	None	Innovator Multiple Source Drug	None	1	"Our industry is different from almost any other, in that the price for a product often increases over time. That may seem counterintuitive until you realize that drugs are different from cars, computers or clothing. Once we bring a product to patients, that begins another series of investments so we can follow the progress and safety of patients taking the drug, develop better formulations that benefit the patient community, investigate its application to other indications and more. Price increases are what pay for those investments across our industry."	None	This WAC increase is not necessitated by a change or improvement in the prescription drug.	None	None	None	None	None	None	None	None	None	None	None	None
Rx0000025	Lundbeck LLC	03/31/2019	67386042201	Xenazine 25.0mg. 112 Tablets	01/07/2019	2540.18	28198.58	None	Innovator Multiple Source Drug	None	1	"Our industry is different from almost any other, in that the price for a product often increases over time. That may seem counterintuitive until you realize that drugs are different from cars, computers or clothing. Once we bring a product to patients, that begins another series of investments so we can follow the progress and safety of patients taking the drug, develop better formulations that benefit the patient community, investigate its application to other indications and more. Price increases are what pay for those investments across our industry."	None	This WAC increase is not necessitated by a change or improvement in the prescription drug.	None	None	None	None	None	None	None	None	None	None	None	None
Rx0000190	Mallinckrodt ARD LLC	12/31/2019	63004871001	ACTHAR GEL 5ML INJECTION,1 MDV	12/31/2019	972.00	39864.00	None	Single Source Drug	None	1	None	1	Mallinckrodt has voluntarily made a public pledge on responsible drug pricing and innovation which is our social contract to those we serve and which can be found at https://www.mallinckrodt.com/corporate-responsibility/pledge-on-drug-pricing--innovation/. Our commitment is to price our innovative products responsibly while providing broad patient access. In so doing, we continue to invest in innovation that brings value to patients, providers, and the U.S. healthcare system through research and development, quality manufacturing, as well as through patient education and disease awareness. The current price increase for Acthar is not necessitated by a change or improvement to the drug but by the larger principles set forth in our pledge.	None	08/14/2014	Questcor Pharmaceuticals, Inc.	5900000000	None	Acquisition Price field reflects the total price paid for all of Questcor inclusive of Acthar Gel.	31626.00	None	2013	28686.00	None	None
Rx0000052	Mallinckrodt Hospital Products Inc.	03/31/2019	43825010201	OFIRMEV INJECTION 1000MG/100ML (10mg/ml) (24 vials/case)	02/11/2019	79.49	1043.00	06/06/2021	Single Source Drug	None	1	None	1	Mallinckrodt has voluntarily made a public pledge on responsible drug pricing and innovation which is our social contract to those we serve and which can be found at https://www.mallinckrodt.com/corporate-responsibility/pledge-on-drug-pricing--innovation/. Our commitment is to price our innovative products responsibly while providing broad patient access. In so doing, we continue to invest in innovation that brings value to patients, providers, and the U.S. healthcare system through research and development, quality manufacturing, as well as through patient education and disease awareness. The current price increase for Ofirmev is not necessitated by a change or improvement to the drug but by the larger principles set forth in our pledge.	None	03/19/2014	Cadence Pharmaceuticals, Inc.	1400000000	None	None	14.75	None	2011	10.75	None	None
Rx0000072	Mayne Pharma Inc	12/31/2019	51862006901	ESTAZOLAM 1MG TABLETS 100	11/06/2019	303.52	473.58	None	Non-innovator Multiple Source Drug	5700	None	CHANGING MARKET DYNAMICS	None	NONE	None	08/03/2016	ALLERGAN	None	None	Estazolam was acquired as part of a portfolio of drugs from Allergan and Teva with at a total cost of $652 million.	80.85	80.85	1999	39.69	None	None
Rx0000072	Mayne Pharma Inc	12/31/2019	51862007001	ESTAZOLAM 2MG TABLETS 100	11/06/2019	284.15	473.58	None	Non-innovator Multiple Source Drug	25800	None	CHANGING MARKET DYNAMICS	None	NONE	None	08/03/2016	ALLERGAN	None	None	Estazolam was acquired as part of a portfolio of drugs from Allergan and Teva with at a total cost of $652 million.	90.08	90.08	1999	43.75	None	None
Rx0000072	Mayne Pharma Inc	03/31/2019	51862026301	METHYLPHENIDATE EXTENDED RELEASE 20MG CAPSULES 100	03/19/2019	404.93	858.87	None	Non-innovator Multiple Source Drug	36287	None	CHANGING MARKET DYNAMICS	None	NONE	None	08/03/2016	ALLERGAN	None	1	Methylphenidate LA was acquired as part of a portfolio of drugs from Allergan and Teva with at a total cost of $652 million.	453.94	453.94	2012	453.94	None	None
Rx0000072	Mayne Pharma Inc	03/31/2019	51862026401	METHYLPHENIDATE EXTENDED RELEASE 30MG CAPSULES 100	03/19/2019	414.16	878.43	None	Non-innovator Multiple Source Drug	25668	None	CHANGING MARKET DYNAMICS	None	NONE	None	08/03/2016	ALLERGAN	None	1	Methylphenidate LA was acquired as part of a portfolio of drugs from Allergan and Teva with at a total cost of $652 million.	464.27	464.27	2012	464.27	None	None
Rx0000072	Mayne Pharma Inc	03/31/2019	51862026501	METHYLPHENIDATE EXTENDED RELEASE 40MG CAPSULES 100	03/19/2019	425.66	902.83	None	Non-innovator Multiple Source Drug	18552	None	CHANGING MARKET DYNAMICS	None	NONE	None	08/03/2016	ALLERGAN	None	1	Methylphenidate LA was acquired as part of a portfolio of drugs from Allergan and Teva with at a total cost of $652 million.	477.17	477.17	2012	477.17	None	None
Rx0000382	Melinta Therapeutics, LLC	12/31/2019	70842016010	MINOCIN (Minocycline-Hydrochloride) is administered via intravenous form and packaged as 10 VIAL in 1 CARTON > 1 INJECTION in 1 VIAL (1mg dose)	10/01/2019	159.78	1935.11	05/12/2031	Single Source Drug	None	1	Melinta seeks to provide innovative therapies to people impacted by acute and life-threatening illnesses. We are committed to the responsible pricing of our products, and our pricing methodology includes consideration of several financial and nonfinancial factors. Initial pricing, as well as any change in pricing, aims to reflect the clinical value of the product to patients and the healthcare system, while at the same time ensuring patient access. Financial factors include both our current investments in MINOCIN (minocycline) for Injection, as well as consideration for potential future investments in research or other lifecycle related matters that may be necessary.	None	None - see cost increase factors statement.	None	01/05/2018	The Medicines Company	None	1	None	1544.13	1544.13	2015	1470.60	None	None
Rx0000051	MILLICENT U.S., INC.	06/30/2019	72495020105	FEMRING 0.05MG/DAY (ESTRADIOL ACETATE VAGINAL RING) for 3 months usage, package size 1	04/20/2019	41.70	485.37	12/19/2015	Single Source Drug	None	1	None	1	None	1	05/18/2018	Allergan	None	1	None	443.67	443.67	2003	76.50	None	None
Rx0000051	MILLICENT U.S., INC.	06/30/2019	72495020210	FEMRING 0.10MG/DAY (ESTRADIOL ACETATE VAGINAL RING) for 3 months usage, package size 1	04/20/2019	44.44	517.23	12/19/2015	Single Source Drug	None	1	None	1	None	1	05/18/2018	Allergan	None	1	None	472.79	472.79	2003	81.50	None	None
Rx0000044	Mylan Institutional Inc	09/30/2019	67457022005	Isosulfan Blue 1% 50mg/5mL Liq 6s SUV	07/16/2019	466.98	5773.55	12/15/2028	Non-innovator Multiple Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	Mylan Institutional Inc. owns and sells the product through Mylan Institutional LLC, and the product has been owned and sold by Mylan Institutional LLC for the past five years. Mylan Institutional Inc. and Mylan Institutional LLC are both indirectly wholly-owned subsidiaries of Mylan N.V. FDA publishes, in the Orange Book, patent information for drugs approved under section 505(b) of the Federal Food, Drug, and Cosmetic Act (FFDCA) as a NDA. Mylan’s product was approved under section 505(j) of the FFDCA as an ANDA.
Rx0000044	Mylan Institutional Inc	09/30/2019	67457025905	Isosulfan Blue N+ 1% 50mg/5mL Liq 6s SUV	07/16/2019	466.98	5773.55	12/15/2028	Non-innovator Multiple Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	Mylan Institutional Inc. owns and sells the product through Mylan Institutional LLC, and the product has been owned and sold by Mylan Institutional LLC for the past five years. Mylan Institutional Inc. and Mylan Institutional LLC are both indirectly wholly-owned subsidiaries of Mylan N.V. FDA publishes, in the Orange Book, patent information for drugs approved under section 505(b) of the Federal Food, Drug, and Cosmetic Act (FFDCA) as a NDA. Mylan’s product was approved under section 505(j) of the FFDCA as an ANDA. The product launched on 11/13/2015 and the 5-year WAC history report reflects this launch date. Medispan incorrectly lists a WAC with an effective date of 07/26/2010 that is for NDC 67457-0220-05. Medispan also incorrectly lists a WAC increase for 04/01/2015.
Rx0000044	Mylan Institutional Inc	09/30/2019	67457058605	Isosulfan Blue PRX 1% 50mg/5mL Liq 6s SUV	07/16/2019	466.98	5773.55	12/15/2028	Non-innovator Multiple Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	Mylan Institutional Inc. owns and sells the product through Mylan Institutional LLC, and the product has been owned and sold by Mylan Institutional LLC for the past five years. Mylan Institutional Inc. and Mylan Institutional LLC are both indirectly wholly-owned subsidiaries of Mylan N.V. FDA publishes, in the Orange Book, patent information for drugs approved under section 505(b) of the Federal Food, Drug, and Cosmetic Act (FFDCA) as a NDA. Mylan’s product was approved under section 505(j) of the FFDCA as an ANDA. The product launched on 11/13/2015 and the 5-year WAC history report reflects this launch date. Medispan incorrectly lists a WAC with an effective date of 03/20/2015.
Rx0000046	Mylan Specialty LP	09/30/2019	49502060530	Perforomist 20mcg/2mL 30x1	07/16/2019	24.31	510.45	06/22/2021	Single Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	The product has been owned and sold by Mylan Specialty L.P., an indirectly wholly-owned subsidiary of Mylan N.V. for the past five years.
Rx0000046	Mylan Specialty LP	09/30/2019	49502060561	Perforomist 20mcg/2mL 60x1	07/16/2019	48.61	1020.86	06/22/2021	Single Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	The product has been owned and sold by Mylan Specialty L.P., an indirectly wholly-owned subsidiary of Mylan N.V. for the past five years.
Rx0000046	Mylan Specialty LP	09/30/2019	00037682210	Proctofoam HC 1% 10g	07/16/2019	7.12	149.59	None	Non-innovator Multiple Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	Mylan Specialty L.P. owns and sells the product through Meda Pharmaceuticals, Inc. (“Meda”), and the product has been owned and sold by Meda for the past five years. Mylan Specialty L.P. and Meda are both indirectly wholly-owned subsidiaries of Mylan N.V. On August 5, 2016, Mylan N.V. (“Mylan”) completed the settlement of its recommended public offer to the shareholders of Meda to tender all of their shares in Meda to Mylan. Product underwent NDC change on 10/8/14 from Expired NDC: 68220-0142-10 to updated NDC: 0037-6822-10. As both NDCs were active during the 5-year price history for this product, the 68220-0142-10 NDC had an increase on 9/26/14 that is reported under the updated NDC with the 10/8/14 NDC change effective date in the 5-year price history report attached.
Rx0000106	Neos Therapeutics, Inc.	12/31/2019	70165002030	Amphetamine Tab Extended Release Disintegrating 12.5 MG, 30 Each, Unit-Dose, Box	10/02/2019	21.04	360.00	06/28/2032	Single Source Drug	57947	None	The price is being increased due to increased manufacturing costs, increased distribution costs and increased costs from operations.	None	No significant change/improvement has been made to the drug.	None	None	None	None	None	None	None	None	None	None	None	None
Rx0000106	Neos Therapeutics, Inc.	12/31/2019	70165002530	Amphetamine Tab Extended Release Disintegrating 15.7 MG, 30 Each, Unit-Dose, Box	10/02/2019	21.04	360.00	06/28/2032	Single Source Drug	41574	None	The price is being increased due to increased manufacturing costs, increased distribution costs and increased costs from operations.	None	No significant change/improvement has been made to the drug.	None	None	None	None	None	None	None	None	None	None	None	None
Rx0000106	Neos Therapeutics, Inc.	12/31/2019	70165003030	Amphetamine Tab Extended Release Disintegrating 18.8 MG, 30 Each, Unit-Dose, Box	10/02/2019	21.04	360.00	06/28/2032	Single Source Drug	54773	None	The price is being increased due to increased manufacturing costs, increased distribution costs and increased costs from operations.	None	No significant change/improvement has been made to the drug.	None	None	None	None	None	None	None	None	None	None	None	None
Rx0000106	Neos Therapeutics, Inc.	12/31/2019	70165000530	Amphetamine Tab Extended Release Disintegrating 3.1 MG, 30 Each, Unit-Dose, Box	10/02/2019	21.04	360.00	06/28/2032	Single Source Drug	16182	None	The price is being increased due to increased manufacturing costs, increased distribution costs and increased costs from operations.	None	No significant change/improvement has been made to the drug.	None	None	None	None	None	None	None	None	None	None	None	None
Rx0000106	Neos Therapeutics, Inc.	12/31/2019	70165001030	Amphetamine Tab Extended Release Disintegrating 6.3 MG, 30 Each, Unit-Dose, Box	10/02/2019	21.04	360.00	06/28/2032	Single Source Drug	43882	None	The price is being increased due to increased manufacturing costs, increased distribution costs and increased costs from operations.	None	No significant change/improvement has been made to the drug.	None	None	None	None	None	None	None	None	None	None	None	None
Rx0000106	Neos Therapeutics, Inc.	12/31/2019	70165001530	Amphetamine Tab Extended Release Disintegrating 9.4 MG, 30 Each, Unit-Dose, Box	10/02/2019	21.04	360.00	06/28/2032	Single Source Drug	47478	None	The price is being increased due to increased manufacturing costs, increased distribution costs and increased costs from operations.	None	No significant change/improvement has been made to the drug.	None	None	None	None	None	None	None	None	None	None	None	None
Rx0000420	Nielsen BioSciences, Inc.	06/30/2019	59584013801	Candin Skin Test Antigen liquid 1U/0.1mL 1.0mL	04/01/2019	16.00	208.00	None	Single Source Drug	30808	None	When pricing its products Nielsen takes into consideration multiple factors - including but not limited to: research and development (or asset acquisition) investments including required royalties; regulatory compliance fees and costs; manufacturing costs; discounts fees and other expenses associated with distribution and to facilitate patient access to the product; competition; general economic conditions and trends including inflation rates; the clinical and economic value of the product; and overall corporate business goals.	None	None	None	None	None	None	None	None	None	None	None	None	None	None
Rx0000420	Nielsen BioSciences, Inc.	06/30/2019	59584014001	Spherusol Skin Test Antigen liquid 1.27mg/0.1mL 1.0mL	05/01/2019	58.00	787.00	None	Single Source Drug	3672	None	When pricing its products Nielsen takes into consideration multiple factors - including but not limited to: research and development (or asset acquisition) investments including required royalties; regulatory compliance fees and costs; manufacturing costs; discounts fees and other expenses associated with distribution and to facilitate patient access to the product; competition; general economic conditions and trends including inflation rates; the clinical and economic value of the product; and overall corporate business goals.	None	None	None	None	None	None	None	None	None	None	None	None	None	None
Rx0000226	Nostrum Laboratories, Inc.	06/30/2019	70408018534	Promethazine-Codeine Oral Solution 6.25-10mg/5ml 473ml	04/29/2019	130.55	170.55	None	Non-innovator Multiple Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	The product was acquired on December 15th, 2015
Rx0000073	Novartis	03/31/2019	00078056751	Afinitor 10mg	01/15/2019	1163.46	15706.71	07/01/2028	Single Source Drug	40705	None	Increases in rate of inflation, continued investment in innovation, post-marketing regulatory commitments, ongoing pharmacovigilance, market conditions and dynamics	None	Not applicable	None	None	None	None	None	None	None	None	None	None	None	All information is provided by Novartis to the best of our knowledge at the time of submission. WAC is reported at the package level not the unit level. Novartis provides this report consistent with its understanding and interpretation of California SB 17 Chapter 603 Chapter 9 § 127681 and its provisions. In providing this report, Novartis does not waive any rights that it may have at law or in equity with respect to the applicability, interpretation, or application of California SB 17 Chapter 603 Chapter 9 § 127681 as it may relate to Novartis or any of its affiliates now or in the future. Novartis, on behalf of itself and affiliates, expressly reservesAll such rights. We believe that this submission and ofAll Novartis related information herein is confidential and proprietary, commercial or financial information not subject to disclosure, including under the California Public Records Act (Government Code Section 6250 et seq.) and applicable laws pertaining to trade secrets. We request that the confidentiality of this submission and ofAll Novartis’ related information herein be maintained to the maximum extent permitted by law. When any of this information is requested, whether under the California Public Records Act (Government Code Section 6250 et seq.) or otherwise, we request that Novartis is notified of the request and afforded the opportunity to submit objections to disclosure.
Rx0000073	Novartis	03/31/2019	00078059451	Afinitor 2.5mg	01/15/2019	1112.31	15016.22	07/01/2028	Single Source Drug	4919	None	Increases in rate of inflation, continued investment in innovation, post-marketing regulatory commitments, ongoing pharmacovigilance, market conditions and dynamics	None	Not applicable	None	None	None	None	None	None	None	None	None	None	None	All information is provided by Novartis to the best of our knowledge at the time of submission. WAC is reported at the package level not the unit level. Novartis provides this report consistent with its understanding and interpretation of California SB 17 Chapter 603 Chapter 9 § 127681 and its provisions. In providing this report, Novartis does not waive any rights that it may have at law or in equity with respect to the applicability, interpretation, or application of California SB 17 Chapter 603 Chapter 9 § 127681 as it may relate to Novartis or any of its affiliates now or in the future. Novartis, on behalf of itself and affiliates, expressly reservesAll such rights. We believe that this submission and ofAll Novartis related information herein is confidential and proprietary, commercial or financial information not subject to disclosure, including under the California Public Records Act (Government Code Section 6250 et seq.) and applicable laws pertaining to trade secrets. We request that the confidentiality of this submission and ofAll Novartis’ related information herein be maintained to the maximum extent permitted by law. When any of this information is requested, whether under the California Public Records Act (Government Code Section 6250 et seq.) or otherwise, we request that Novartis is notified of the request and afforded the opportunity to submit objections to disclosure.
Rx0000073	Novartis	03/31/2019	00078056651	Afinitor 5mg	01/15/2019	1163.46	15706.71	07/01/2028	Single Source Drug	24034	None	Increases in rate of inflation, continued investment in innovation, post-marketing regulatory commitments, ongoing pharmacovigilance, market conditions and dynamics	None	Not applicable	None	None	None	None	None	None	None	None	None	None	None	All information is provided by Novartis to the best of our knowledge at the time of submission. WAC is reported at the package level not the unit level. Novartis provides this report consistent with its understanding and interpretation of California SB 17 Chapter 603 Chapter 9 § 127681 and its provisions. In providing this report, Novartis does not waive any rights that it may have at law or in equity with respect to the applicability, interpretation, or application of California SB 17 Chapter 603 Chapter 9 § 127681 as it may relate to Novartis or any of its affiliates now or in the future. Novartis, on behalf of itself and affiliates, expressly reservesAll such rights. We believe that this submission and ofAll Novartis related information herein is confidential and proprietary, commercial or financial information not subject to disclosure, including under the California Public Records Act (Government Code Section 6250 et seq.) and applicable laws pertaining to trade secrets. We request that the confidentiality of this submission and ofAll Novartis’ related information herein be maintained to the maximum extent permitted by law. When any of this information is requested, whether under the California Public Records Act (Government Code Section 6250 et seq.) or otherwise, we request that Novartis is notified of the request and afforded the opportunity to submit objections to disclosure.
Rx0000073	Novartis	03/31/2019	00078062051	Afinitor 7.5mg	01/15/2019	1163.46	15706.71	07/01/2028	Single Source Drug	9617	None	Increases in rate of inflation, continued investment in innovation, post-marketing regulatory commitments, ongoing pharmacovigilance, market conditions and dynamics	None	Not applicable	None	None	None	None	None	None	None	None	None	None	None	All information is provided by Novartis to the best of our knowledge at the time of submission. WAC is reported at the package level not the unit level. Novartis provides this report consistent with its understanding and interpretation of California SB 17 Chapter 603 Chapter 9 § 127681 and its provisions. In providing this report, Novartis does not waive any rights that it may have at law or in equity with respect to the applicability, interpretation, or application of California SB 17 Chapter 603 Chapter 9 § 127681 as it may relate to Novartis or any of its affiliates now or in the future. Novartis, on behalf of itself and affiliates, expressly reservesAll such rights. We believe that this submission and ofAll Novartis related information herein is confidential and proprietary, commercial or financial information not subject to disclosure, including under the California Public Records Act (Government Code Section 6250 et seq.) and applicable laws pertaining to trade secrets. We request that the confidentiality of this submission and ofAll Novartis’ related information herein be maintained to the maximum extent permitted by law. When any of this information is requested, whether under the California Public Records Act (Government Code Section 6250 et seq.) or otherwise, we request that Novartis is notified of the request and afforded the opportunity to submit objections to disclosure.
Rx0000073	Novartis	03/31/2019	00078062651	Afinitor Disperz 2mg	01/15/2019	1106.77	14941.34	03/27/2023	Single Source Drug	2264	None	Increases in rate of inflation, continued investment in innovation, post-marketing regulatory commitments, ongoing pharmacovigilance, market conditions and dynamics	None	Not applicable	None	None	None	None	None	None	None	None	None	None	None	All information is provided by Novartis to the best of our knowledge at the time of submission. WAC is reported at the package level not the unit level. Novartis provides this report consistent with its understanding and interpretation of California SB 17 Chapter 603 Chapter 9 § 127681 and its provisions. In providing this report, Novartis does not waive any rights that it may have at law or in equity with respect to the applicability, interpretation, or application of California SB 17 Chapter 603 Chapter 9 § 127681 as it may relate to Novartis or any of its affiliates now or in the future. Novartis, on behalf of itself and affiliates, expressly reservesAll such rights. We believe that this submission and ofAll Novartis related information herein is confidential and proprietary, commercial or financial information not subject to disclosure, including under the California Public Records Act (Government Code Section 6250 et seq.) and applicable laws pertaining to trade secrets. We request that the confidentiality of this submission and ofAll Novartis’ related information herein be maintained to the maximum extent permitted by law. When any of this information is requested, whether under the California Public Records Act (Government Code Section 6250 et seq.) or otherwise, we request that Novartis is notified of the request and afforded the opportunity to submit objections to disclosure.
Rx0000073	Novartis	03/31/2019	00078062751	Afinitor Disperz 3mg	01/15/2019	1117.85	15091.01	03/27/2023	Single Source Drug	1317	None	Increases in rate of inflation, continued investment in innovation, post-marketing regulatory commitments, ongoing pharmacovigilance, market conditions and dynamics	None	Not applicable	None	None	None	None	None	None	None	None	None	None	None	All information is provided by Novartis to the best of our knowledge at the time of submission. WAC is reported at the package level not the unit level. Novartis provides this report consistent with its understanding and interpretation of California SB 17 Chapter 603 Chapter 9 § 127681 and its provisions. In providing this report, Novartis does not waive any rights that it may have at law or in equity with respect to the applicability, interpretation, or application of California SB 17 Chapter 603 Chapter 9 § 127681 as it may relate to Novartis or any of its affiliates now or in the future. Novartis, on behalf of itself and affiliates, expressly reservesAll such rights. We believe that this submission and ofAll Novartis related information herein is confidential and proprietary, commercial or financial information not subject to disclosure, including under the California Public Records Act (Government Code Section 6250 et seq.) and applicable laws pertaining to trade secrets. We request that the confidentiality of this submission and ofAll Novartis’ related information herein be maintained to the maximum extent permitted by law. When any of this information is requested, whether under the California Public Records Act (Government Code Section 6250 et seq.) or otherwise, we request that Novartis is notified of the request and afforded the opportunity to submit objections to disclosure.
Rx0000073	Novartis	03/31/2019	00078062851	Afinitor Disperz 5mg	01/15/2019	1163.46	15706.71	03/27/2023	Single Source Drug	2274	None	Increases in rate of inflation, continued investment in innovation, post-marketing regulatory commitments, ongoing pharmacovigilance, market conditions and dynamics	None	Not applicable	None	None	None	None	None	None	None	None	None	None	None	All information is provided by Novartis to the best of our knowledge at the time of submission. WAC is reported at the package level not the unit level. Novartis provides this report consistent with its understanding and interpretation of California SB 17 Chapter 603 Chapter 9 § 127681 and its provisions. In providing this report, Novartis does not waive any rights that it may have at law or in equity with respect to the applicability, interpretation, or application of California SB 17 Chapter 603 Chapter 9 § 127681 as it may relate to Novartis or any of its affiliates now or in the future. Novartis, on behalf of itself and affiliates, expressly reservesAll such rights. We believe that this submission and ofAll Novartis related information herein is confidential and proprietary, commercial or financial information not subject to disclosure, including under the California Public Records Act (Government Code Section 6250 et seq.) and applicable laws pertaining to trade secrets. We request that the confidentiality of this submission and ofAll Novartis’ related information herein be maintained to the maximum extent permitted by law. When any of this information is requested, whether under the California Public Records Act (Government Code Section 6250 et seq.) or otherwise, we request that Novartis is notified of the request and afforded the opportunity to submit objections to disclosure.
Rx0000073	Novartis	03/31/2019	00065027510	Azopt 1% 10mL	01/15/2019	22.84	308.38	04/24/2013	Single Source Drug	862600	None	Increases in rate of inflation, continued investment in innovation, post-marketing regulatory commitments, ongoing pharmacovigilance, market conditions and dynamics	None	Not applicable	None	None	None	None	None	None	None	None	None	None	None	All information is provided by Novartis to the best of our knowledge at the time of submission. WAC is reported at the package level not the unit level. Novartis provides this report consistent with its understanding and interpretation of California SB 17 Chapter 603 Chapter 9 § 127681 and its provisions. In providing this report, Novartis does not waive any rights that it may have at law or in equity with respect to the applicability, interpretation, or application of California SB 17 Chapter 603 Chapter 9 § 127681 as it may relate to Novartis or any of its affiliates now or in the future. Novartis, on behalf of itself and affiliates, expressly reservesAll such rights. We believe that this submission and ofAll Novartis related information herein is confidential and proprietary, commercial or financial information not subject to disclosure, including under the California Public Records Act (Government Code Section 6250 et seq.) and applicable laws pertaining to trade secrets. We request that the confidentiality of this submission and ofAll Novartis’ related information herein be maintained to the maximum extent permitted by law. When any of this information is requested, whether under the California Public Records Act (Government Code Section 6250 et seq.) or otherwise, we request that Novartis is notified of the request and afforded the opportunity to submit objections to disclosure. Products were acquired from Alcon as portfolio. Product was on the market at the time of the acquisition. Acquisition of portfolio was finalized 8/27/2010. This is prior to the 5 year reporting period.
Rx0000073	Novartis	03/31/2019	00065027515	Azopt 1% 15mL	01/15/2019	34.26	462.52	04/24/2013	Single Source Drug	125099	None	Increases in rate of inflation, continued investment in innovation, post-marketing regulatory commitments, ongoing pharmacovigilance, market conditions and dynamics	None	Not applicable	None	None	None	None	None	None	None	None	None	None	None	All information is provided by Novartis to the best of our knowledge at the time of submission. WAC is reported at the package level not the unit level. Novartis provides this report consistent with its understanding and interpretation of California SB 17 Chapter 603 Chapter 9 § 127681 and its provisions. In providing this report, Novartis does not waive any rights that it may have at law or in equity with respect to the applicability, interpretation, or application of California SB 17 Chapter 603 Chapter 9 § 127681 as it may relate to Novartis or any of its affiliates now or in the future. Novartis, on behalf of itself and affiliates, expressly reservesAll such rights. We believe that this submission and ofAll Novartis related information herein is confidential and proprietary, commercial or financial information not subject to disclosure, including under the California Public Records Act (Government Code Section 6250 et seq.) and applicable laws pertaining to trade secrets. We request that the confidentiality of this submission and ofAll Novartis’ related information herein be maintained to the maximum extent permitted by law. When any of this information is requested, whether under the California Public Records Act (Government Code Section 6250 et seq.) or otherwise, we request that Novartis is notified of the request and afforded the opportunity to submit objections to disclosure. Products were acquired from Alcon as portfolio. Product was on the market at the time of the acquisition. Acquisition of portfolio was finalized 8/27/2010. This is prior to the 5 year reporting period.
Rx0000073	Novartis	03/31/2019	00065853110	CIPRO®*HC Otic 0.2% / 1%	01/15/2019	17.88	315.87	06/06/2015	Single Source Drug	101653	None	Increases in rate of inflation, continued investment in innovation, post-marketing regulatory commitments, ongoing pharmacovigilance, market conditions and dynamics	None	Not applicable	None	None	None	None	None	None	None	None	None	None	None	All information is provided by Novartis to the best of our knowledge at the time of submission. WAC is reported at the package level not the unit level. Novartis provides this report consistent with its understanding and interpretation of California SB 17 Chapter 603 Chapter 9 § 127681 and its provisions. In providing this report, Novartis does not waive any rights that it may have at law or in equity with respect to the applicability, interpretation, or application of California SB 17 Chapter 603 Chapter 9 § 127681 as it may relate to Novartis or any of its affiliates now or in the future. Novartis, on behalf of itself and affiliates, expressly reservesAll such rights. We believe that this submission and ofAll Novartis related information herein is confidential and proprietary, commercial or financial information not subject to disclosure, including under the California Public Records Act (Government Code Section 6250 et seq.) and applicable laws pertaining to trade secrets. We request that the confidentiality of this submission and ofAll Novartis’ related information herein be maintained to the maximum extent permitted by law. When any of this information is requested, whether under the California Public Records Act (Government Code Section 6250 et seq.) or otherwise, we request that Novartis is notified of the request and afforded the opportunity to submit objections to disclosure. Products were acquired from Alcon as portfolio. Product was on the market at the time of the acquisition. Acquisition of portfolio was finalized 8/27/2010. This is prior to the 5 year reporting period.
Rx0000073	Novartis	03/31/2019	00065853302	CIPRODEX 0.3% / 0.1%	01/15/2019	17.49	236.10	06/04/2025	Single Source Drug	2456190	None	Increases in rate of inflation, continued investment in innovation, post-marketing regulatory commitments, ongoing pharmacovigilance, market conditions and dynamics	None	Not applicable	None	None	None	None	None	None	None	None	None	None	None	All information is provided by Novartis to the best of our knowledge at the time of submission. WAC is reported at the package level not the unit level. Novartis provides this report consistent with its understanding and interpretation of California SB 17 Chapter 603 Chapter 9 § 127681 and its provisions. In providing this report, Novartis does not waive any rights that it may have at law or in equity with respect to the applicability, interpretation, or application of California SB 17 Chapter 603 Chapter 9 § 127681 as it may relate to Novartis or any of its affiliates now or in the future. Novartis, on behalf of itself and affiliates, expressly reservesAll such rights. We believe that this submission and ofAll Novartis related information herein is confidential and proprietary, commercial or financial information not subject to disclosure, including under the California Public Records Act (Government Code Section 6250 et seq.) and applicable laws pertaining to trade secrets. We request that the confidentiality of this submission and ofAll Novartis’ related information herein be maintained to the maximum extent permitted by law. When any of this information is requested, whether under the California Public Records Act (Government Code Section 6250 et seq.) or otherwise, we request that Novartis is notified of the request and afforded the opportunity to submit objections to disclosure. Products were acquired from Alcon as portfolio. Product was on the market at the time of the acquisition. Acquisition of portfolio was finalized 8/27/2010. This is prior to the 5 year reporting period.
Rx0000073	Novartis	03/31/2019	00078063968	Cosentyx 150mg/ml (Sensoready Pen x1)	01/15/2019	466.53	5178.91	05/05/2033	Single Source Drug	100219	None	Increases in rate of inflation, continued investment in innovation, post-marketing regulatory commitments, ongoing pharmacovigilance, market conditions and dynamics	None	Not applicable	None	None	None	None	None	None	None	None	None	None	None	All information is provided by Novartis to the best of our knowledge at the time of submission. WAC is reported at the package level not the unit level. Novartis provides this report consistent with its understanding and interpretation of California SB 17 Chapter 603 Chapter 9 § 127681 and its provisions. In providing this report, Novartis does not waive any rights that it may have at law or in equity with respect to the applicability, interpretation, or application of California SB 17 Chapter 603 Chapter 9 § 127681 as it may relate to Novartis or any of its affiliates now or in the future. Novartis, on behalf of itself and affiliates, expressly reservesAll such rights. We believe that this submission and ofAll Novartis related information herein is confidential and proprietary, commercial or financial information not subject to disclosure, including under the California Public Records Act (Government Code Section 6250 et seq.) and applicable laws pertaining to trade secrets. We request that the confidentiality of this submission and ofAll Novartis’ related information herein be maintained to the maximum extent permitted by law. When any of this information is requested, whether under the California Public Records Act (Government Code Section 6250 et seq.) or otherwise, we request that Novartis is notified of the request and afforded the opportunity to submit objections to disclosure.
Rx0000073	Novartis	03/31/2019	00078063941	Cosentyx 150mg/ml (Sensoready Pen x2)	01/15/2019	466.53	5178.91	05/05/2033	Single Source Drug	445341	None	Increases in rate of inflation, continued investment in innovation, post-marketing regulatory commitments, ongoing pharmacovigilance, market conditions and dynamics	None	Not applicable	None	None	None	None	None	None	None	None	None	None	None	All information is provided by Novartis to the best of our knowledge at the time of submission. WAC is reported at the package level not the unit level. Novartis provides this report consistent with its understanding and interpretation of California SB 17 Chapter 603 Chapter 9 § 127681 and its provisions. In providing this report, Novartis does not waive any rights that it may have at law or in equity with respect to the applicability, interpretation, or application of California SB 17 Chapter 603 Chapter 9 § 127681 as it may relate to Novartis or any of its affiliates now or in the future. Novartis, on behalf of itself and affiliates, expressly reservesAll such rights. We believe that this submission and ofAll Novartis related information herein is confidential and proprietary, commercial or financial information not subject to disclosure, including under the California Public Records Act (Government Code Section 6250 et seq.) and applicable laws pertaining to trade secrets. We request that the confidentiality of this submission and ofAll Novartis’ related information herein be maintained to the maximum extent permitted by law. When any of this information is requested, whether under the California Public Records Act (Government Code Section 6250 et seq.) or otherwise, we request that Novartis is notified of the request and afforded the opportunity to submit objections to disclosure.
Rx0000073	Novartis	03/31/2019	00078063997	Cosentyx 150mg/ml (Syringe x1)	01/15/2019	466.53	5178.91	05/05/2033	Single Source Drug	24196	None	Increases in rate of inflation, continued investment in innovation, post-marketing regulatory commitments, ongoing pharmacovigilance, market conditions and dynamics	None	Not applicable	None	None	None	None	None	None	None	None	None	None	None	All information is provided by Novartis to the best of our knowledge at the time of submission. WAC is reported at the package level not the unit level. Novartis provides this report consistent with its understanding and interpretation of California SB 17 Chapter 603 Chapter 9 § 127681 and its provisions. In providing this report, Novartis does not waive any rights that it may have at law or in equity with respect to the applicability, interpretation, or application of California SB 17 Chapter 603 Chapter 9 § 127681 as it may relate to Novartis or any of its affiliates now or in the future. Novartis, on behalf of itself and affiliates, expressly reservesAll such rights. We believe that this submission and ofAll Novartis related information herein is confidential and proprietary, commercial or financial information not subject to disclosure, including under the California Public Records Act (Government Code Section 6250 et seq.) and applicable laws pertaining to trade secrets. We request that the confidentiality of this submission and ofAll Novartis’ related information herein be maintained to the maximum extent permitted by law. When any of this information is requested, whether under the California Public Records Act (Government Code Section 6250 et seq.) or otherwise, we request that Novartis is notified of the request and afforded the opportunity to submit objections to disclosure.
Rx0000073	Novartis	03/31/2019	00078063998	Cosentyx 150mg/ml (Syringe x2)	01/15/2019	466.53	5178.91	05/05/2033	Single Source Drug	62077	None	Increases in rate of inflation, continued investment in innovation, post-marketing regulatory commitments, ongoing pharmacovigilance, market conditions and dynamics	None	Not applicable	None	None	None	None	None	None	None	None	None	None	None	All information is provided by Novartis to the best of our knowledge at the time of submission. WAC is reported at the package level not the unit level. Novartis provides this report consistent with its understanding and interpretation of California SB 17 Chapter 603 Chapter 9 § 127681 and its provisions. In providing this report, Novartis does not waive any rights that it may have at law or in equity with respect to the applicability, interpretation, or application of California SB 17 Chapter 603 Chapter 9 § 127681 as it may relate to Novartis or any of its affiliates now or in the future. Novartis, on behalf of itself and affiliates, expressly reservesAll such rights. We believe that this submission and ofAll Novartis related information herein is confidential and proprietary, commercial or financial information not subject to disclosure, including under the California Public Records Act (Government Code Section 6250 et seq.) and applicable laws pertaining to trade secrets. We request that the confidentiality of this submission and ofAll Novartis’ related information herein be maintained to the maximum extent permitted by law. When any of this information is requested, whether under the California Public Records Act (Government Code Section 6250 et seq.) or otherwise, we request that Novartis is notified of the request and afforded the opportunity to submit objections to disclosure.
Rx0000073	Novartis	03/31/2019	00078035934	Diovan 160mg	01/15/2019	43.02	760.10	12/18/2017	Innovator Multiple Source Drug	53106	None	Increases in rate of inflation, continued investment in innovation, post-marketing regulatory commitments, ongoing pharmacovigilance, market conditions and dynamics	None	Not applicable	None	None	None	None	None	None	None	None	None	None	None	All information is provided by Novartis to the best of our knowledge at the time of submission. WAC is reported at the package level not the unit level. Novartis provides this report consistent with its understanding and interpretation of California SB 17 Chapter 603 Chapter 9 § 127681 and its provisions. In providing this report, Novartis does not waive any rights that it may have at law or in equity with respect to the applicability, interpretation, or application of California SB 17 Chapter 603 Chapter 9 § 127681 as it may relate to Novartis or any of its affiliates now or in the future. Novartis, on behalf of itself and affiliates, expressly reservesAll such rights. We believe that this submission and ofAll Novartis related information herein is confidential and proprietary, commercial or financial information not subject to disclosure, including under the California Public Records Act (Government Code Section 6250 et seq.) and applicable laws pertaining to trade secrets. We request that the confidentiality of this submission and ofAll Novartis’ related information herein be maintained to the maximum extent permitted by law. When any of this information is requested, whether under the California Public Records Act (Government Code Section 6250 et seq.) or otherwise, we request that Novartis is notified of the request and afforded the opportunity to submit objections to disclosure.
Rx0000073	Novartis	03/31/2019	00078036034	Diovan 320mg	01/15/2019	54.43	961.59	12/18/2017	Innovator Multiple Source Drug	28511	None	Increases in rate of inflation, continued investment in innovation, post-marketing regulatory commitments, ongoing pharmacovigilance, market conditions and dynamics	None	Not applicable	None	None	None	None	None	None	None	None	None	None	None	All information is provided by Novartis to the best of our knowledge at the time of submission. WAC is reported at the package level not the unit level. Novartis provides this report consistent with its understanding and interpretation of California SB 17 Chapter 603 Chapter 9 § 127681 and its provisions. In providing this report, Novartis does not waive any rights that it may have at law or in equity with respect to the applicability, interpretation, or application of California SB 17 Chapter 603 Chapter 9 § 127681 as it may relate to Novartis or any of its affiliates now or in the future. Novartis, on behalf of itself and affiliates, expressly reservesAll such rights. We believe that this submission and ofAll Novartis related information herein is confidential and proprietary, commercial or financial information not subject to disclosure, including under the California Public Records Act (Government Code Section 6250 et seq.) and applicable laws pertaining to trade secrets. We request that the confidentiality of this submission and ofAll Novartis’ related information herein be maintained to the maximum extent permitted by law. When any of this information is requested, whether under the California Public Records Act (Government Code Section 6250 et seq.) or otherwise, we request that Novartis is notified of the request and afforded the opportunity to submit objections to disclosure.
Rx0000073	Novartis	03/31/2019	00078042315	Diovan 40mg	01/15/2019	11.16	197.11	12/18/2017	Innovator Multiple Source Drug	33507	None	Increases in rate of inflation, continued investment in innovation, post-marketing regulatory commitments, ongoing pharmacovigilance, market conditions and dynamics	None	Not applicable	None	None	None	None	None	None	None	None	None	None	None	All information is provided by Novartis to the best of our knowledge at the time of submission. WAC is reported at the package level not the unit level. Novartis provides this report consistent with its understanding and interpretation of California SB 17 Chapter 603 Chapter 9 § 127681 and its provisions. In providing this report, Novartis does not waive any rights that it may have at law or in equity with respect to the applicability, interpretation, or application of California SB 17 Chapter 603 Chapter 9 § 127681 as it may relate to Novartis or any of its affiliates now or in the future. Novartis, on behalf of itself and affiliates, expressly reservesAll such rights. We believe that this submission and ofAll Novartis related information herein is confidential and proprietary, commercial or financial information not subject to disclosure, including under the California Public Records Act (Government Code Section 6250 et seq.) and applicable laws pertaining to trade secrets. We request that the confidentiality of this submission and ofAll Novartis’ related information herein be maintained to the maximum extent permitted by law. When any of this information is requested, whether under the California Public Records Act (Government Code Section 6250 et seq.) or otherwise, we request that Novartis is notified of the request and afforded the opportunity to submit objections to disclosure.
Rx0000073	Novartis	03/31/2019	00078035834	Diovan 80mg	01/15/2019	40.01	706.86	12/18/2017	Innovator Multiple Source Drug	39159	None	Increases in rate of inflation, continued investment in innovation, post-marketing regulatory commitments, ongoing pharmacovigilance, market conditions and dynamics	None	Not applicable	None	None	None	None	None	None	None	None	None	None	None	All information is provided by Novartis to the best of our knowledge at the time of submission. WAC is reported at the package level not the unit level. Novartis provides this report consistent with its understanding and interpretation of California SB 17 Chapter 603 Chapter 9 § 127681 and its provisions. In providing this report, Novartis does not waive any rights that it may have at law or in equity with respect to the applicability, interpretation, or application of California SB 17 Chapter 603 Chapter 9 § 127681 as it may relate to Novartis or any of its affiliates now or in the future. Novartis, on behalf of itself and affiliates, expressly reservesAll such rights. We believe that this submission and ofAll Novartis related information herein is confidential and proprietary, commercial or financial information not subject to disclosure, including under the California Public Records Act (Government Code Section 6250 et seq.) and applicable laws pertaining to trade secrets. We request that the confidentiality of this submission and ofAll Novartis’ related information herein be maintained to the maximum extent permitted by law. When any of this information is requested, whether under the California Public Records Act (Government Code Section 6250 et seq.) or otherwise, we request that Novartis is notified of the request and afforded the opportunity to submit objections to disclosure.
Rx0000073	Novartis	03/31/2019	00078031534	Diovan HCT 160/12.5mg	01/15/2019	48.96	864.89	12/18/2017	Innovator Multiple Source Drug	14702	None	Increases in rate of inflation, continued investment in innovation, post-marketing regulatory commitments, ongoing pharmacovigilance, market conditions and dynamics	None	Not applicable	None	None	None	None	None	None	None	None	None	None	None	All information is provided by Novartis to the best of our knowledge at the time of submission. WAC is reported at the package level not the unit level. Novartis provides this report consistent with its understanding and interpretation of California SB 17 Chapter 603 Chapter 9 § 127681 and its provisions. In providing this report, Novartis does not waive any rights that it may have at law or in equity with respect to the applicability, interpretation, or application of California SB 17 Chapter 603 Chapter 9 § 127681 as it may relate to Novartis or any of its affiliates now or in the future. Novartis, on behalf of itself and affiliates, expressly reservesAll such rights. We believe that this submission and ofAll Novartis related information herein is confidential and proprietary, commercial or financial information not subject to disclosure, including under the California Public Records Act (Government Code Section 6250 et seq.) and applicable laws pertaining to trade secrets. We request that the confidentiality of this submission and ofAll Novartis’ related information herein be maintained to the maximum extent permitted by law. When any of this information is requested, whether under the California Public Records Act (Government Code Section 6250 et seq.) or otherwise, we request that Novartis is notified of the request and afforded the opportunity to submit objections to disclosure.
Rx0000073	Novartis	03/31/2019	00078038334	Diovan HCT 160/25mg	01/15/2019	55.52	980.84	12/18/2017	Innovator Multiple Source Drug	7625	None	Increases in rate of inflation, continued investment in innovation, post-marketing regulatory commitments, ongoing pharmacovigilance, market conditions and dynamics	None	Not applicable	None	None	None	None	None	None	None	None	None	None	None	All information is provided by Novartis to the best of our knowledge at the time of submission. WAC is reported at the package level not the unit level. Novartis provides this report consistent with its understanding and interpretation of California SB 17 Chapter 603 Chapter 9 § 127681 and its provisions. In providing this report, Novartis does not waive any rights that it may have at law or in equity with respect to the applicability, interpretation, or application of California SB 17 Chapter 603 Chapter 9 § 127681 as it may relate to Novartis or any of its affiliates now or in the future. Novartis, on behalf of itself and affiliates, expressly reservesAll such rights. We believe that this submission and ofAll Novartis related information herein is confidential and proprietary, commercial or financial information not subject to disclosure, including under the California Public Records Act (Government Code Section 6250 et seq.) and applicable laws pertaining to trade secrets. We request that the confidentiality of this submission and ofAll Novartis’ related information herein be maintained to the maximum extent permitted by law. When any of this information is requested, whether under the California Public Records Act (Government Code Section 6250 et seq.) or otherwise, we request that Novartis is notified of the request and afforded the opportunity to submit objections to disclosure.
Rx0000073	Novartis	03/31/2019	00078047134	Diovan HCT 320/12.5mg	01/15/2019	62.03	1095.79	12/18/2017	Innovator Multiple Source Drug	4168	None	Increases in rate of inflation, continued investment in innovation, post-marketing regulatory commitments, ongoing pharmacovigilance, market conditions and dynamics	None	Not applicable	None	None	None	None	None	None	None	None	None	None	None	All information is provided by Novartis to the best of our knowledge at the time of submission. WAC is reported at the package level not the unit level. Novartis provides this report consistent with its understanding and interpretation of California SB 17 Chapter 603 Chapter 9 § 127681 and its provisions. In providing this report, Novartis does not waive any rights that it may have at law or in equity with respect to the applicability, interpretation, or application of California SB 17 Chapter 603 Chapter 9 § 127681 as it may relate to Novartis or any of its affiliates now or in the future. Novartis, on behalf of itself and affiliates, expressly reservesAll such rights. We believe that this submission and ofAll Novartis related information herein is confidential and proprietary, commercial or financial information not subject to disclosure, including under the California Public Records Act (Government Code Section 6250 et seq.) and applicable laws pertaining to trade secrets. We request that the confidentiality of this submission and ofAll Novartis’ related information herein be maintained to the maximum extent permitted by law. When any of this information is requested, whether under the California Public Records Act (Government Code Section 6250 et seq.) or otherwise, we request that Novartis is notified of the request and afforded the opportunity to submit objections to disclosure.
Rx0000073	Novartis	03/31/2019	00078047234	Diovan HCT 320/25mg	01/15/2019	70.37	1243.17	12/18/2017	Innovator Multiple Source Drug	8923	None	Increases in rate of inflation, continued investment in innovation, post-marketing regulatory commitments, ongoing pharmacovigilance, market conditions and dynamics	None	Not applicable	None	None	None	None	None	None	None	None	None	None	None	All information is provided by Novartis to the best of our knowledge at the time of submission. WAC is reported at the package level not the unit level. Novartis provides this report consistent with its understanding and interpretation of California SB 17 Chapter 603 Chapter 9 § 127681 and its provisions. In providing this report, Novartis does not waive any rights that it may have at law or in equity with respect to the applicability, interpretation, or application of California SB 17 Chapter 603 Chapter 9 § 127681 as it may relate to Novartis or any of its affiliates now or in the future. Novartis, on behalf of itself and affiliates, expressly reservesAll such rights. We believe that this submission and ofAll Novartis related information herein is confidential and proprietary, commercial or financial information not subject to disclosure, including under the California Public Records Act (Government Code Section 6250 et seq.) and applicable laws pertaining to trade secrets. We request that the confidentiality of this submission and ofAll Novartis’ related information herein be maintained to the maximum extent permitted by law. When any of this information is requested, whether under the California Public Records Act (Government Code Section 6250 et seq.) or otherwise, we request that Novartis is notified of the request and afforded the opportunity to submit objections to disclosure.
Rx0000073	Novartis	03/31/2019	00078031434	Diovan HCT 80/12.5mg	01/15/2019	45.00	794.92	12/18/2017	Innovator Multiple Source Drug	8335	None	Increases in rate of inflation, continued investment in innovation, post-marketing regulatory commitments, ongoing pharmacovigilance, market conditions and dynamics	None	Not applicable	None	None	None	None	None	None	None	None	None	None	None	All information is provided by Novartis to the best of our knowledge at the time of submission. WAC is reported at the package level not the unit level. Novartis provides this report consistent with its understanding and interpretation of California SB 17 Chapter 603 Chapter 9 § 127681 and its provisions. In providing this report, Novartis does not waive any rights that it may have at law or in equity with respect to the applicability, interpretation, or application of California SB 17 Chapter 603 Chapter 9 § 127681 as it may relate to Novartis or any of its affiliates now or in the future. Novartis, on behalf of itself and affiliates, expressly reservesAll such rights. We believe that this submission and ofAll Novartis related information herein is confidential and proprietary, commercial or financial information not subject to disclosure, including under the California Public Records Act (Government Code Section 6250 et seq.) and applicable laws pertaining to trade secrets. We request that the confidentiality of this submission and ofAll Novartis’ related information herein be maintained to the maximum extent permitted by law. When any of this information is requested, whether under the California Public Records Act (Government Code Section 6250 et seq.) or otherwise, we request that Novartis is notified of the request and afforded the opportunity to submit objections to disclosure.
Rx0000073	Novartis	03/31/2019	00065924007	Durezol 0.05% 5mL	01/15/2019	13.82	186.54	11/18/2019	Single Source Drug	1132752	None	Increases in rate of inflation, continued investment in innovation, post-marketing regulatory commitments, ongoing pharmacovigilance, market conditions and dynamics	None	Not applicable	None	None	None	None	None	None	None	None	None	None	None	All information is provided by Novartis to the best of our knowledge at the time of submission. WAC is reported at the package level not the unit level. Novartis provides this report consistent with its understanding and interpretation of California SB 17 Chapter 603 Chapter 9 § 127681 and its provisions. In providing this report, Novartis does not waive any rights that it may have at law or in equity with respect to the applicability, interpretation, or application of California SB 17 Chapter 603 Chapter 9 § 127681 as it may relate to Novartis or any of its affiliates now or in the future. Novartis, on behalf of itself and affiliates, expressly reservesAll such rights. We believe that this submission and ofAll Novartis related information herein is confidential and proprietary, commercial or financial information not subject to disclosure, including under the California Public Records Act (Government Code Section 6250 et seq.) and applicable laws pertaining to trade secrets. We request that the confidentiality of this submission and ofAll Novartis’ related information herein be maintained to the maximum extent permitted by law. When any of this information is requested, whether under the California Public Records Act (Government Code Section 6250 et seq.) or otherwise, we request that Novartis is notified of the request and afforded the opportunity to submit objections to disclosure. Products were acquired from Alcon as portfolio. Acquisition of portfolio was finalized 8/27/2010. This is prior to the 5 year reporting period.
Rx0000073	Novartis	03/31/2019	00078065967	Entresto 24/26mg - 180 Each Bottle	01/15/2019	137.59	1527.36	05/27/2027	Single Source Drug	23309	None	Increases in rate of inflation, continued investment in innovation, post-marketing regulatory commitments, ongoing pharmacovigilance, market conditions and dynamics	None	Not applicable	None	None	None	None	None	None	None	None	None	None	None	All information is provided by Novartis to the best of our knowledge at the time of submission. WAC is reported at the package level not the unit level. Novartis provides this report consistent with its understanding and interpretation of California SB 17 Chapter 603 Chapter 9 § 127681 and its provisions. In providing this report, Novartis does not waive any rights that it may have at law or in equity with respect to the applicability, interpretation, or application of California SB 17 Chapter 603 Chapter 9 § 127681 as it may relate to Novartis or any of its affiliates now or in the future. Novartis, on behalf of itself and affiliates, expressly reservesAll such rights. We believe that this submission and ofAll Novartis related information herein is confidential and proprietary, commercial or financial information not subject to disclosure, including under the California Public Records Act (Government Code Section 6250 et seq.) and applicable laws pertaining to trade secrets. We request that the confidentiality of this submission and ofAll Novartis’ related information herein be maintained to the maximum extent permitted by law. When any of this information is requested, whether under the California Public Records Act (Government Code Section 6250 et seq.) or otherwise, we request that Novartis is notified of the request and afforded the opportunity to submit objections to disclosure.
Rx0000073	Novartis	03/31/2019	00078065920	Entresto 24/26mg - 60 Each Bottle	01/15/2019	45.86	509.12	05/27/2027	Single Source Drug	917623	None	Increases in rate of inflation, continued investment in innovation, post-marketing regulatory commitments, ongoing pharmacovigilance, market conditions and dynamics	None	Not applicable	None	None	None	None	None	None	None	None	None	None	None	All information is provided by Novartis to the best of our knowledge at the time of submission. WAC is reported at the package level not the unit level. Novartis provides this report consistent with its understanding and interpretation of California SB 17 Chapter 603 Chapter 9 § 127681 and its provisions. In providing this report, Novartis does not waive any rights that it may have at law or in equity with respect to the applicability, interpretation, or application of California SB 17 Chapter 603 Chapter 9 § 127681 as it may relate to Novartis or any of its affiliates now or in the future. Novartis, on behalf of itself and affiliates, expressly reservesAll such rights. We believe that this submission and ofAll Novartis related information herein is confidential and proprietary, commercial or financial information not subject to disclosure, including under the California Public Records Act (Government Code Section 6250 et seq.) and applicable laws pertaining to trade secrets. We request that the confidentiality of this submission and ofAll Novartis’ related information herein be maintained to the maximum extent permitted by law. When any of this information is requested, whether under the California Public Records Act (Government Code Section 6250 et seq.) or otherwise, we request that Novartis is notified of the request and afforded the opportunity to submit objections to disclosure.
Rx0000073	Novartis	03/31/2019	00078077767	Entresto 49/51mg - 180 Each Bottle	01/15/2019	137.59	1527.36	05/27/2027	Single Source Drug	26020	None	Increases in rate of inflation, continued investment in innovation, post-marketing regulatory commitments, ongoing pharmacovigilance, market conditions and dynamics	None	Not applicable	None	None	None	None	None	None	None	None	None	None	None	All information is provided by Novartis to the best of our knowledge at the time of submission. WAC is reported at the package level not the unit level. Novartis provides this report consistent with its understanding and interpretation of California SB 17 Chapter 603 Chapter 9 § 127681 and its provisions. In providing this report, Novartis does not waive any rights that it may have at law or in equity with respect to the applicability, interpretation, or application of California SB 17 Chapter 603 Chapter 9 § 127681 as it may relate to Novartis or any of its affiliates now or in the future. Novartis, on behalf of itself and affiliates, expressly reservesAll such rights. We believe that this submission and ofAll Novartis related information herein is confidential and proprietary, commercial or financial information not subject to disclosure, including under the California Public Records Act (Government Code Section 6250 et seq.) and applicable laws pertaining to trade secrets. We request that the confidentiality of this submission and ofAll Novartis’ related information herein be maintained to the maximum extent permitted by law. When any of this information is requested, whether under the California Public Records Act (Government Code Section 6250 et seq.) or otherwise, we request that Novartis is notified of the request and afforded the opportunity to submit objections to disclosure.
Rx0000073	Novartis	03/31/2019	00078077720	Entresto 49/51mg - 60 Each Bottle	01/15/2019	45.86	509.12	05/27/2027	Single Source Drug	599199	None	Increases in rate of inflation, continued investment in innovation, post-marketing regulatory commitments, ongoing pharmacovigilance, market conditions and dynamics	None	Not applicable	None	None	None	None	None	None	None	None	None	None	None	All information is provided by Novartis to the best of our knowledge at the time of submission. WAC is reported at the package level not the unit level. Novartis provides this report consistent with its understanding and interpretation of California SB 17 Chapter 603 Chapter 9 § 127681 and its provisions. In providing this report, Novartis does not waive any rights that it may have at law or in equity with respect to the applicability, interpretation, or application of California SB 17 Chapter 603 Chapter 9 § 127681 as it may relate to Novartis or any of its affiliates now or in the future. Novartis, on behalf of itself and affiliates, expressly reservesAll such rights. We believe that this submission and ofAll Novartis related information herein is confidential and proprietary, commercial or financial information not subject to disclosure, including under the California Public Records Act (Government Code Section 6250 et seq.) and applicable laws pertaining to trade secrets. We request that the confidentiality of this submission and ofAll Novartis’ related information herein be maintained to the maximum extent permitted by law. When any of this information is requested, whether under the California Public Records Act (Government Code Section 6250 et seq.) or otherwise, we request that Novartis is notified of the request and afforded the opportunity to submit objections to disclosure.
Rx0000073	Novartis	03/31/2019	00078069667	Entresto 97/103mg - 180 Each Bottle	01/15/2019	137.59	1527.36	05/27/2027	Single Source Drug	23469	None	Increases in rate of inflation, continued investment in innovation, post-marketing regulatory commitments, ongoing pharmacovigilance, market conditions and dynamics	None	Not applicable	None	None	None	None	None	None	None	None	None	None	None	All information is provided by Novartis to the best of our knowledge at the time of submission. WAC is reported at the package level not the unit level. Novartis provides this report consistent with its understanding and interpretation of California SB 17 Chapter 603 Chapter 9 § 127681 and its provisions. In providing this report, Novartis does not waive any rights that it may have at law or in equity with respect to the applicability, interpretation, or application of California SB 17 Chapter 603 Chapter 9 § 127681 as it may relate to Novartis or any of its affiliates now or in the future. Novartis, on behalf of itself and affiliates, expressly reservesAll such rights. We believe that this submission and ofAll Novartis related information herein is confidential and proprietary, commercial or financial information not subject to disclosure, including under the California Public Records Act (Government Code Section 6250 et seq.) and applicable laws pertaining to trade secrets. We request that the confidentiality of this submission and ofAll Novartis’ related information herein be maintained to the maximum extent permitted by law. When any of this information is requested, whether under the California Public Records Act (Government Code Section 6250 et seq.) or otherwise, we request that Novartis is notified of the request and afforded the opportunity to submit objections to disclosure.
Rx0000073	Novartis	03/31/2019	00078069620	Entresto 97/103mg - 60 Each Bottle	01/15/2019	45.86	509.12	05/27/2027	Single Source Drug	408813	None	Increases in rate of inflation, continued investment in innovation, post-marketing regulatory commitments, ongoing pharmacovigilance, market conditions and dynamics	None	Not applicable	None	None	None	None	None	None	None	None	None	None	None	All information is provided by Novartis to the best of our knowledge at the time of submission. WAC is reported at the package level not the unit level. Novartis provides this report consistent with its understanding and interpretation of California SB 17 Chapter 603 Chapter 9 § 127681 and its provisions. In providing this report, Novartis does not waive any rights that it may have at law or in equity with respect to the applicability, interpretation, or application of California SB 17 Chapter 603 Chapter 9 § 127681 as it may relate to Novartis or any of its affiliates now or in the future. Novartis, on behalf of itself and affiliates, expressly reservesAll such rights. We believe that this submission and ofAll Novartis related information herein is confidential and proprietary, commercial or financial information not subject to disclosure, including under the California Public Records Act (Government Code Section 6250 et seq.) and applicable laws pertaining to trade secrets. We request that the confidentiality of this submission and ofAll Novartis’ related information herein be maintained to the maximum extent permitted by law. When any of this information is requested, whether under the California Public Records Act (Government Code Section 6250 et seq.) or otherwise, we request that Novartis is notified of the request and afforded the opportunity to submit objections to disclosure.
Rx0000073	Novartis	03/31/2019	00078050315	Exelon Patch 13.3mg	01/15/2019	38.83	686.00	01/08/2019	Innovator Multiple Source Drug	39581	None	Increases in rate of inflation, continued investment in innovation, post-marketing regulatory commitments, ongoing pharmacovigilance, market conditions and dynamics	None	Not applicable	None	None	None	None	None	None	None	None	None	None	None	All information is provided by Novartis to the best of our knowledge at the time of submission. WAC is reported at the package level not the unit level. Novartis provides this report consistent with its understanding and interpretation of California SB 17 Chapter 603 Chapter 9 § 127681 and its provisions. In providing this report, Novartis does not waive any rights that it may have at law or in equity with respect to the applicability, interpretation, or application of California SB 17 Chapter 603 Chapter 9 § 127681 as it may relate to Novartis or any of its affiliates now or in the future. Novartis, on behalf of itself and affiliates, expressly reservesAll such rights. We believe that this submission and ofAll Novartis related information herein is confidential and proprietary, commercial or financial information not subject to disclosure, including under the California Public Records Act (Government Code Section 6250 et seq.) and applicable laws pertaining to trade secrets. We request that the confidentiality of this submission and ofAll Novartis’ related information herein be maintained to the maximum extent permitted by law. When any of this information is requested, whether under the California Public Records Act (Government Code Section 6250 et seq.) or otherwise, we request that Novartis is notified of the request and afforded the opportunity to submit objections to disclosure.
Rx0000073	Novartis	03/31/2019	00078050115	Exelon Patch 4.6mg	01/15/2019	38.83	686.00	01/08/2019	Innovator Multiple Source Drug	62102	None	Increases in rate of inflation, continued investment in innovation, post-marketing regulatory commitments, ongoing pharmacovigilance, market conditions and dynamics	None	Not applicable	None	None	None	None	None	None	None	None	None	None	None	All information is provided by Novartis to the best of our knowledge at the time of submission. WAC is reported at the package level not the unit level. Novartis provides this report consistent with its understanding and interpretation of California SB 17 Chapter 603 Chapter 9 § 127681 and its provisions. In providing this report, Novartis does not waive any rights that it may have at law or in equity with respect to the applicability, interpretation, or application of California SB 17 Chapter 603 Chapter 9 § 127681 as it may relate to Novartis or any of its affiliates now or in the future. Novartis, on behalf of itself and affiliates, expressly reservesAll such rights. We believe that this submission and ofAll Novartis related information herein is confidential and proprietary, commercial or financial information not subject to disclosure, including under the California Public Records Act (Government Code Section 6250 et seq.) and applicable laws pertaining to trade secrets. We request that the confidentiality of this submission and ofAll Novartis’ related information herein be maintained to the maximum extent permitted by law. When any of this information is requested, whether under the California Public Records Act (Government Code Section 6250 et seq.) or otherwise, we request that Novartis is notified of the request and afforded the opportunity to submit objections to disclosure.
Rx0000073	Novartis	03/31/2019	00078050215	Exelon Patch 9.5mg	01/15/2019	38.83	686.00	01/08/2019	Innovator Multiple Source Drug	86757	None	Increases in rate of inflation, continued investment in innovation, post-marketing regulatory commitments, ongoing pharmacovigilance, market conditions and dynamics	None	Not applicable	None	None	None	None	None	None	None	None	None	None	None	All information is provided by Novartis to the best of our knowledge at the time of submission. WAC is reported at the package level not the unit level. Novartis provides this report consistent with its understanding and interpretation of California SB 17 Chapter 603 Chapter 9 § 127681 and its provisions. In providing this report, Novartis does not waive any rights that it may have at law or in equity with respect to the applicability, interpretation, or application of California SB 17 Chapter 603 Chapter 9 § 127681 as it may relate to Novartis or any of its affiliates now or in the future. Novartis, on behalf of itself and affiliates, expressly reservesAll such rights. We believe that this submission and ofAll Novartis related information herein is confidential and proprietary, commercial or financial information not subject to disclosure, including under the California Public Records Act (Government Code Section 6250 et seq.) and applicable laws pertaining to trade secrets. We request that the confidentiality of this submission and ofAll Novartis’ related information herein be maintained to the maximum extent permitted by law. When any of this information is requested, whether under the California Public Records Act (Government Code Section 6250 et seq.) or otherwise, we request that Novartis is notified of the request and afforded the opportunity to submit objections to disclosure.
Rx0000073	Novartis	03/31/2019	00078048915	Exforge 10/160 mg	01/15/2019	17.07	301.64	07/08/2019	Innovator Multiple Source Drug	5961	None	Increases in rate of inflation, continued investment in innovation, post-marketing regulatory commitments, ongoing pharmacovigilance, market conditions and dynamics	None	Not applicable	None	None	None	None	None	None	None	None	None	None	None	All information is provided by Novartis to the best of our knowledge at the time of submission. WAC is reported at the package level not the unit level. Novartis provides this report consistent with its understanding and interpretation of California SB 17 Chapter 603 Chapter 9 § 127681 and its provisions. In providing this report, Novartis does not waive any rights that it may have at law or in equity with respect to the applicability, interpretation, or application of California SB 17 Chapter 603 Chapter 9 § 127681 as it may relate to Novartis or any of its affiliates now or in the future. Novartis, on behalf of itself and affiliates, expressly reservesAll such rights. We believe that this submission and ofAll Novartis related information herein is confidential and proprietary, commercial or financial information not subject to disclosure, including under the California Public Records Act (Government Code Section 6250 et seq.) and applicable laws pertaining to trade secrets. We request that the confidentiality of this submission and ofAll Novartis’ related information herein be maintained to the maximum extent permitted by law. When any of this information is requested, whether under the California Public Records Act (Government Code Section 6250 et seq.) or otherwise, we request that Novartis is notified of the request and afforded the opportunity to submit objections to disclosure.
Rx0000073	Novartis	03/31/2019	00078049115	Exforge 10/320 mg	01/15/2019	21.68	382.93	07/08/2019	Innovator Multiple Source Drug	12067	None	Increases in rate of inflation, continued investment in innovation, post-marketing regulatory commitments, ongoing pharmacovigilance, market conditions and dynamics	None	Not applicable	None	None	None	None	None	None	None	None	None	None	None	All information is provided by Novartis to the best of our knowledge at the time of submission. WAC is reported at the package level not the unit level. Novartis provides this report consistent with its understanding and interpretation of California SB 17 Chapter 603 Chapter 9 § 127681 and its provisions. In providing this report, Novartis does not waive any rights that it may have at law or in equity with respect to the applicability, interpretation, or application of California SB 17 Chapter 603 Chapter 9 § 127681 as it may relate to Novartis or any of its affiliates now or in the future. Novartis, on behalf of itself and affiliates, expressly reservesAll such rights. We believe that this submission and ofAll Novartis related information herein is confidential and proprietary, commercial or financial information not subject to disclosure, including under the California Public Records Act (Government Code Section 6250 et seq.) and applicable laws pertaining to trade secrets. We request that the confidentiality of this submission and ofAll Novartis’ related information herein be maintained to the maximum extent permitted by law. When any of this information is requested, whether under the California Public Records Act (Government Code Section 6250 et seq.) or otherwise, we request that Novartis is notified of the request and afforded the opportunity to submit objections to disclosure.
Rx0000073	Novartis	03/31/2019	00078048815	Exforge 5/160 mg	01/15/2019	15.05	265.91	07/08/2019	Innovator Multiple Source Drug	35502	None	Increases in rate of inflation, continued investment in innovation, post-marketing regulatory commitments, ongoing pharmacovigilance, market conditions and dynamics	None	Not applicable	None	None	None	None	None	None	None	None	None	None	None	All information is provided by Novartis to the best of our knowledge at the time of submission. WAC is reported at the package level not the unit level. Novartis provides this report consistent with its understanding and interpretation of California SB 17 Chapter 603 Chapter 9 § 127681 and its provisions. In providing this report, Novartis does not waive any rights that it may have at law or in equity with respect to the applicability, interpretation, or application of California SB 17 Chapter 603 Chapter 9 § 127681 as it may relate to Novartis or any of its affiliates now or in the future. Novartis, on behalf of itself and affiliates, expressly reservesAll such rights. We believe that this submission and ofAll Novartis related information herein is confidential and proprietary, commercial or financial information not subject to disclosure, including under the California Public Records Act (Government Code Section 6250 et seq.) and applicable laws pertaining to trade secrets. We request that the confidentiality of this submission and ofAll Novartis’ related information herein be maintained to the maximum extent permitted by law. When any of this information is requested, whether under the California Public Records Act (Government Code Section 6250 et seq.) or otherwise, we request that Novartis is notified of the request and afforded the opportunity to submit objections to disclosure.
Rx0000073	Novartis	03/31/2019	00078049015	Exforge 5/320 mg	01/15/2019	19.09	337.28	07/08/2019	Innovator Multiple Source Drug	8485	None	Increases in rate of inflation, continued investment in innovation, post-marketing regulatory commitments, ongoing pharmacovigilance, market conditions and dynamics	None	Not applicable	None	None	None	None	None	None	None	None	None	None	None	All information is provided by Novartis to the best of our knowledge at the time of submission. WAC is reported at the package level not the unit level. Novartis provides this report consistent with its understanding and interpretation of California SB 17 Chapter 603 Chapter 9 § 127681 and its provisions. In providing this report, Novartis does not waive any rights that it may have at law or in equity with respect to the applicability, interpretation, or application of California SB 17 Chapter 603 Chapter 9 § 127681 as it may relate to Novartis or any of its affiliates now or in the future. Novartis, on behalf of itself and affiliates, expressly reservesAll such rights. We believe that this submission and ofAll Novartis related information herein is confidential and proprietary, commercial or financial information not subject to disclosure, including under the California Public Records Act (Government Code Section 6250 et seq.) and applicable laws pertaining to trade secrets. We request that the confidentiality of this submission and ofAll Novartis’ related information herein be maintained to the maximum extent permitted by law. When any of this information is requested, whether under the California Public Records Act (Government Code Section 6250 et seq.) or otherwise, we request that Novartis is notified of the request and afforded the opportunity to submit objections to disclosure.
Rx0000073	Novartis	03/31/2019	00078056215	Exforge HCT 10/160 mg/25 mg	01/15/2019	17.07	301.64	11/16/2023	Innovator Multiple Source Drug	6282	None	Increases in rate of inflation, continued investment in innovation, post-marketing regulatory commitments, ongoing pharmacovigilance, market conditions and dynamics	None	Not applicable	None	None	None	None	None	None	None	None	None	None	https://reports.siera.oshpd.ca.gov/api/report/drug-pricing/attachment?id=429, https://reports.siera.oshpd.ca.gov/api/report/drug-pricing/attachment?id=434	All information is provided by Novartis to the best of our knowledge at the time of submission. WAC is reported at the package level not the unit level. Novartis provides this report consistent with its understanding and interpretation of California SB 17 Chapter 603 Chapter 9 § 127681 and its provisions. In providing this report, Novartis does not waive any rights that it may have at law or in equity with respect to the applicability, interpretation, or application of California SB 17 Chapter 603 Chapter 9 § 127681 as it may relate to Novartis or any of its affiliates now or in the future. Novartis, on behalf of itself and affiliates, expressly reservesAll such rights. We believe that this submission and ofAll Novartis related information herein is confidential and proprietary, commercial or financial information not subject to disclosure, including under the California Public Records Act (Government Code Section 6250 et seq.) and applicable laws pertaining to trade secrets. We request that the confidentiality of this submission and ofAll Novartis’ related information herein be maintained to the maximum extent permitted by law. When any of this information is requested, whether under the California Public Records Act (Government Code Section 6250 et seq.) or otherwise, we request that Novartis is notified of the request and afforded the opportunity to submit objections to disclosure. Please see the supporting documents for supporting evidence regarding the 5-year WAC history.
Rx0000073	Novartis	03/31/2019	00078056115	Exforge HCT 10/160/12.5 mg	01/15/2019	17.07	301.64	11/16/2023	Innovator Multiple Source Drug	1352	None	Increases in rate of inflation, continued investment in innovation, post-marketing regulatory commitments, ongoing pharmacovigilance, market conditions and dynamics	None	Not applicable	None	None	None	None	None	None	None	None	None	None	https://reports.siera.oshpd.ca.gov/api/report/drug-pricing/attachment?id=428, https://reports.siera.oshpd.ca.gov/api/report/drug-pricing/attachment?id=433	All information is provided by Novartis to the best of our knowledge at the time of submission. WAC is reported at the package level not the unit level. Novartis provides this report consistent with its understanding and interpretation of California SB 17 Chapter 603 Chapter 9 § 127681 and its provisions. In providing this report, Novartis does not waive any rights that it may have at law or in equity with respect to the applicability, interpretation, or application of California SB 17 Chapter 603 Chapter 9 § 127681 as it may relate to Novartis or any of its affiliates now or in the future. Novartis, on behalf of itself and affiliates, expressly reservesAll such rights. We believe that this submission and ofAll Novartis related information herein is confidential and proprietary, commercial or financial information not subject to disclosure, including under the California Public Records Act (Government Code Section 6250 et seq.) and applicable laws pertaining to trade secrets. We request that the confidentiality of this submission and ofAll Novartis’ related information herein be maintained to the maximum extent permitted by law. When any of this information is requested, whether under the California Public Records Act (Government Code Section 6250 et seq.) or otherwise, we request that Novartis is notified of the request and afforded the opportunity to submit objections to disclosure. Please see the supporting documents for supporting evidence regarding the 5-year WAC history.
Rx0000073	Novartis	03/31/2019	00078056315	Exforge HCT 10/320 mg/25 mg	01/15/2019	21.68	382.93	11/16/2023	Innovator Multiple Source Drug	6123	None	Increases in rate of inflation, continued investment in innovation, post-marketing regulatory commitments, ongoing pharmacovigilance, market conditions and dynamics	None	Not applicable	None	None	None	None	None	None	None	None	None	None	https://reports.siera.oshpd.ca.gov/api/report/drug-pricing/attachment?id=430, https://reports.siera.oshpd.ca.gov/api/report/drug-pricing/attachment?id=435	All information is provided by Novartis to the best of our knowledge at the time of submission. WAC is reported at the package level not the unit level. Novartis provides this report consistent with its understanding and interpretation of California SB 17 Chapter 603 Chapter 9 § 127681 and its provisions. In providing this report, Novartis does not waive any rights that it may have at law or in equity with respect to the applicability, interpretation, or application of California SB 17 Chapter 603 Chapter 9 § 127681 as it may relate to Novartis or any of its affiliates now or in the future. Novartis, on behalf of itself and affiliates, expressly reservesAll such rights. We believe that this submission and ofAll Novartis related information herein is confidential and proprietary, commercial or financial information not subject to disclosure, including under the California Public Records Act (Government Code Section 6250 et seq.) and applicable laws pertaining to trade secrets. We request that the confidentiality of this submission and ofAll Novartis’ related information herein be maintained to the maximum extent permitted by law. When any of this information is requested, whether under the California Public Records Act (Government Code Section 6250 et seq.) or otherwise, we request that Novartis is notified of the request and afforded the opportunity to submit objections to disclosure. Please see the supporting documents for supporting evidence regarding the 5-year WAC history.
Rx0000073	Novartis	03/31/2019	00078055915	Exforge HCT 5/160/12.5mg	01/15/2019	15.05	265.91	11/16/2023	Innovator Multiple Source Drug	3466	None	Increases in rate of inflation, continued investment in innovation, post-marketing regulatory commitments, ongoing pharmacovigilance, market conditions and dynamics	None	Not applicable	None	None	None	None	None	None	None	None	None	None	https://reports.siera.oshpd.ca.gov/api/report/drug-pricing/attachment?id=426, https://reports.siera.oshpd.ca.gov/api/report/drug-pricing/attachment?id=431	All information is provided by Novartis to the best of our knowledge at the time of submission. WAC is reported at the package level not the unit level. Novartis provides this report consistent with its understanding and interpretation of California SB 17 Chapter 603 Chapter 9 § 127681 and its provisions. In providing this report, Novartis does not waive any rights that it may have at law or in equity with respect to the applicability, interpretation, or application of California SB 17 Chapter 603 Chapter 9 § 127681 as it may relate to Novartis or any of its affiliates now or in the future. Novartis, on behalf of itself and affiliates, expressly reservesAll such rights. We believe that this submission and ofAll Novartis related information herein is confidential and proprietary, commercial or financial information not subject to disclosure, including under the California Public Records Act (Government Code Section 6250 et seq.) and applicable laws pertaining to trade secrets. We request that the confidentiality of this submission and ofAll Novartis’ related information herein be maintained to the maximum extent permitted by law. When any of this information is requested, whether under the California Public Records Act (Government Code Section 6250 et seq.) or otherwise, we request that Novartis is notified of the request and afforded the opportunity to submit objections to disclosure. Please see the supporting documents for supporting evidence regarding the 5-year WAC history.
Rx0000073	Novartis	03/31/2019	00078056015	Exforge HCT 5/160/25 mg	01/15/2019	15.05	265.91	11/16/2023	Innovator Multiple Source Drug	6019	None	Increases in rate of inflation, continued investment in innovation, post-marketing regulatory commitments, ongoing pharmacovigilance, market conditions and dynamics	None	Not applicable	None	None	None	None	None	None	None	None	None	None	https://reports.siera.oshpd.ca.gov/api/report/drug-pricing/attachment?id=427, https://reports.siera.oshpd.ca.gov/api/report/drug-pricing/attachment?id=432	All information is provided by Novartis to the best of our knowledge at the time of submission. WAC is reported at the package level not the unit level. Novartis provides this report consistent with its understanding and interpretation of California SB 17 Chapter 603 Chapter 9 § 127681 and its provisions. In providing this report, Novartis does not waive any rights that it may have at law or in equity with respect to the applicability, interpretation, or application of California SB 17 Chapter 603 Chapter 9 § 127681 as it may relate to Novartis or any of its affiliates now or in the future. Novartis, on behalf of itself and affiliates, expressly reservesAll such rights. We believe that this submission and ofAll Novartis related information herein is confidential and proprietary, commercial or financial information not subject to disclosure, including under the California Public Records Act (Government Code Section 6250 et seq.) and applicable laws pertaining to trade secrets. We request that the confidentiality of this submission and ofAll Novartis’ related information herein be maintained to the maximum extent permitted by law. When any of this information is requested, whether under the California Public Records Act (Government Code Section 6250 et seq.) or otherwise, we request that Novartis is notified of the request and afforded the opportunity to submit objections to disclosure. Please see the supporting documents for supporting evidence regarding the 5-year WAC history.
Rx0000073	Novartis	03/31/2019	00078046815	Exjade 125mg	01/15/2019	93.84	1266.85	04/05/2019	Single Source Drug	4693	None	Increases in rate of inflation, continued investment in innovation, post-marketing regulatory commitments, ongoing pharmacovigilance, market conditions and dynamics	None	Not applicable	None	None	None	None	None	None	None	None	None	None	None	All information is provided by Novartis to the best of our knowledge at the time of submission. WAC is reported at the package level not the unit level. Novartis provides this report consistent with its understanding and interpretation of California SB 17 Chapter 603 Chapter 9 § 127681 and its provisions. In providing this report, Novartis does not waive any rights that it may have at law or in equity with respect to the applicability, interpretation, or application of California SB 17 Chapter 603 Chapter 9 § 127681 as it may relate to Novartis or any of its affiliates now or in the future. Novartis, on behalf of itself and affiliates, expressly reservesAll such rights. We believe that this submission and ofAll Novartis related information herein is confidential and proprietary, commercial or financial information not subject to disclosure, including under the California Public Records Act (Government Code Section 6250 et seq.) and applicable laws pertaining to trade secrets. We request that the confidentiality of this submission and ofAll Novartis’ related information herein be maintained to the maximum extent permitted by law. When any of this information is requested, whether under the California Public Records Act (Government Code Section 6250 et seq.) or otherwise, we request that Novartis is notified of the request and afforded the opportunity to submit objections to disclosure.
Rx0000073	Novartis	03/31/2019	00078046915	Exjade 250mg	01/15/2019	187.68	2533.65	04/05/2019	Single Source Drug	9125	None	Increases in rate of inflation, continued investment in innovation, post-marketing regulatory commitments, ongoing pharmacovigilance, market conditions and dynamics	None	Not applicable	None	None	None	None	None	None	None	None	None	None	None	All information is provided by Novartis to the best of our knowledge at the time of submission. WAC is reported at the package level not the unit level. Novartis provides this report consistent with its understanding and interpretation of California SB 17 Chapter 603 Chapter 9 § 127681 and its provisions. In providing this report, Novartis does not waive any rights that it may have at law or in equity with respect to the applicability, interpretation, or application of California SB 17 Chapter 603 Chapter 9 § 127681 as it may relate to Novartis or any of its affiliates now or in the future. Novartis, on behalf of itself and affiliates, expressly reservesAll such rights. We believe that this submission and ofAll Novartis related information herein is confidential and proprietary, commercial or financial information not subject to disclosure, including under the California Public Records Act (Government Code Section 6250 et seq.) and applicable laws pertaining to trade secrets. We request that the confidentiality of this submission and ofAll Novartis’ related information herein be maintained to the maximum extent permitted by law. When any of this information is requested, whether under the California Public Records Act (Government Code Section 6250 et seq.) or otherwise, we request that Novartis is notified of the request and afforded the opportunity to submit objections to disclosure.
Rx0000073	Novartis	03/31/2019	00078047015	Exjade 500mg	01/15/2019	375.35	5067.20	04/05/2019	Single Source Drug	27583	None	Increases in rate of inflation, continued investment in innovation, post-marketing regulatory commitments, ongoing pharmacovigilance, market conditions and dynamics	None	Not applicable	None	None	None	None	None	None	None	None	None	None	None	All information is provided by Novartis to the best of our knowledge at the time of submission. WAC is reported at the package level not the unit level. Novartis provides this report consistent with its understanding and interpretation of California SB 17 Chapter 603 Chapter 9 § 127681 and its provisions. In providing this report, Novartis does not waive any rights that it may have at law or in equity with respect to the applicability, interpretation, or application of California SB 17 Chapter 603 Chapter 9 § 127681 as it may relate to Novartis or any of its affiliates now or in the future. Novartis, on behalf of itself and affiliates, expressly reservesAll such rights. We believe that this submission and ofAll Novartis related information herein is confidential and proprietary, commercial or financial information not subject to disclosure, including under the California Public Records Act (Government Code Section 6250 et seq.) and applicable laws pertaining to trade secrets. We request that the confidentiality of this submission and ofAll Novartis’ related information herein be maintained to the maximum extent permitted by law. When any of this information is requested, whether under the California Public Records Act (Government Code Section 6250 et seq.) or otherwise, we request that Novartis is notified of the request and afforded the opportunity to submit objections to disclosure.
Rx0000073	Novartis	03/31/2019	00078056912	Extavia .3 mg/vial	01/15/2019	378.25	6682.37	11/07/2021	Single Source Drug	13075	None	Increases in rate of inflation, continued investment in innovation, post-marketing regulatory commitments, ongoing pharmacovigilance, market conditions and dynamics	None	Not applicable	None	None	None	None	None	None	None	None	None	None	None	All information is provided by Novartis to the best of our knowledge at the time of submission. WAC is reported at the package level not the unit level. Novartis provides this report consistent with its understanding and interpretation of California SB 17 Chapter 603 Chapter 9 § 127681 and its provisions. In providing this report, Novartis does not waive any rights that it may have at law or in equity with respect to the applicability, interpretation, or application of California SB 17 Chapter 603 Chapter 9 § 127681 as it may relate to Novartis or any of its affiliates now or in the future. Novartis, on behalf of itself and affiliates, expressly reservesAll such rights. We believe that this submission and ofAll Novartis related information herein is confidential and proprietary, commercial or financial information not subject to disclosure, including under the California Public Records Act (Government Code Section 6250 et seq.) and applicable laws pertaining to trade secrets. We request that the confidentiality of this submission and ofAll Novartis’ related information herein be maintained to the maximum extent permitted by law. When any of this information is requested, whether under the California Public Records Act (Government Code Section 6250 et seq.) or otherwise, we request that Novartis is notified of the request and afforded the opportunity to submit objections to disclosure.
Rx0000073	Novartis	03/31/2019	00078043105	Focalin XR 10mg	01/15/2019	72.86	1287.20	11/01/2019	Innovator Multiple Source Drug	77663	None	Increases in rate of inflation, continued investment in innovation, post-marketing regulatory commitments, ongoing pharmacovigilance, market conditions and dynamics	None	Not applicable	None	None	None	None	None	None	None	None	None	None	None	All information is provided by Novartis to the best of our knowledge at the time of submission. WAC is reported at the package level not the unit level. Novartis provides this report consistent with its understanding and interpretation of California SB 17 Chapter 603 Chapter 9 § 127681 and its provisions. In providing this report, Novartis does not waive any rights that it may have at law or in equity with respect to the applicability, interpretation, or application of California SB 17 Chapter 603 Chapter 9 § 127681 as it may relate to Novartis or any of its affiliates now or in the future. Novartis, on behalf of itself and affiliates, expressly reservesAll such rights. We believe that this submission and ofAll Novartis related information herein is confidential and proprietary, commercial or financial information not subject to disclosure, including under the California Public Records Act (Government Code Section 6250 et seq.) and applicable laws pertaining to trade secrets. We request that the confidentiality of this submission and ofAll Novartis’ related information herein be maintained to the maximum extent permitted by law. When any of this information is requested, whether under the California Public Records Act (Government Code Section 6250 et seq.) or otherwise, we request that Novartis is notified of the request and afforded the opportunity to submit objections to disclosure.
Rx0000073	Novartis	03/31/2019	00078049305	Focalin XR 15mg	01/15/2019	74.93	1323.73	11/01/2019	Innovator Multiple Source Drug	66143	None	Increases in rate of inflation, continued investment in innovation, post-marketing regulatory commitments, ongoing pharmacovigilance, market conditions and dynamics	None	Not applicable	None	None	None	None	None	None	None	None	None	None	None	All information is provided by Novartis to the best of our knowledge at the time of submission. WAC is reported at the package level not the unit level. Novartis provides this report consistent with its understanding and interpretation of California SB 17 Chapter 603 Chapter 9 § 127681 and its provisions. In providing this report, Novartis does not waive any rights that it may have at law or in equity with respect to the applicability, interpretation, or application of California SB 17 Chapter 603 Chapter 9 § 127681 as it may relate to Novartis or any of its affiliates now or in the future. Novartis, on behalf of itself and affiliates, expressly reservesAll such rights. We believe that this submission and ofAll Novartis related information herein is confidential and proprietary, commercial or financial information not subject to disclosure, including under the California Public Records Act (Government Code Section 6250 et seq.) and applicable laws pertaining to trade secrets. We request that the confidentiality of this submission and ofAll Novartis’ related information herein be maintained to the maximum extent permitted by law. When any of this information is requested, whether under the California Public Records Act (Government Code Section 6250 et seq.) or otherwise, we request that Novartis is notified of the request and afforded the opportunity to submit objections to disclosure.
Rx0000073	Novartis	03/31/2019	00078043205	Focalin XR 20mg	01/15/2019	74.93	1323.73	11/01/2019	Innovator Multiple Source Drug	70040	None	Increases in rate of inflation, continued investment in innovation, post-marketing regulatory commitments, ongoing pharmacovigilance, market conditions and dynamics	None	Not applicable	None	None	None	None	None	None	None	None	None	None	None	All information is provided by Novartis to the best of our knowledge at the time of submission. WAC is reported at the package level not the unit level. Novartis provides this report consistent with its understanding and interpretation of California SB 17 Chapter 603 Chapter 9 § 127681 and its provisions. In providing this report, Novartis does not waive any rights that it may have at law or in equity with respect to the applicability, interpretation, or application of California SB 17 Chapter 603 Chapter 9 § 127681 as it may relate to Novartis or any of its affiliates now or in the future. Novartis, on behalf of itself and affiliates, expressly reservesAll such rights. We believe that this submission and ofAll Novartis related information herein is confidential and proprietary, commercial or financial information not subject to disclosure, including under the California Public Records Act (Government Code Section 6250 et seq.) and applicable laws pertaining to trade secrets. We request that the confidentiality of this submission and ofAll Novartis’ related information herein be maintained to the maximum extent permitted by law. When any of this information is requested, whether under the California Public Records Act (Government Code Section 6250 et seq.) or otherwise, we request that Novartis is notified of the request and afforded the opportunity to submit objections to disclosure.
Rx0000073	Novartis	03/31/2019	00078060805	Focalin XR 25mg	01/15/2019	78.68	1389.95	11/01/2019	Innovator Multiple Source Drug	29849	None	Increases in rate of inflation, continued investment in innovation, post-marketing regulatory commitments, ongoing pharmacovigilance, market conditions and dynamics	None	Not applicable	None	None	None	None	None	None	None	None	None	None	None	All information is provided by Novartis to the best of our knowledge at the time of submission. WAC is reported at the package level not the unit level. Novartis provides this report consistent with its understanding and interpretation of California SB 17 Chapter 603 Chapter 9 § 127681 and its provisions. In providing this report, Novartis does not waive any rights that it may have at law or in equity with respect to the applicability, interpretation, or application of California SB 17 Chapter 603 Chapter 9 § 127681 as it may relate to Novartis or any of its affiliates now or in the future. Novartis, on behalf of itself and affiliates, expressly reservesAll such rights. We believe that this submission and ofAll Novartis related information herein is confidential and proprietary, commercial or financial information not subject to disclosure, including under the California Public Records Act (Government Code Section 6250 et seq.) and applicable laws pertaining to trade secrets. We request that the confidentiality of this submission and ofAll Novartis’ related information herein be maintained to the maximum extent permitted by law. When any of this information is requested, whether under the California Public Records Act (Government Code Section 6250 et seq.) or otherwise, we request that Novartis is notified of the request and afforded the opportunity to submit objections to disclosure.
Rx0000073	Novartis	03/31/2019	00078043305	Focalin XR 30mg	01/15/2019	72.18	1275.17	11/01/2019	Innovator Multiple Source Drug	36603	None	Increases in rate of inflation, continued investment in innovation, post-marketing regulatory commitments, ongoing pharmacovigilance, market conditions and dynamics	None	Not applicable	None	None	None	None	None	None	None	None	None	None	None	All information is provided by Novartis to the best of our knowledge at the time of submission. WAC is reported at the package level not the unit level. Novartis provides this report consistent with its understanding and interpretation of California SB 17 Chapter 603 Chapter 9 § 127681 and its provisions. In providing this report, Novartis does not waive any rights that it may have at law or in equity with respect to the applicability, interpretation, or application of California SB 17 Chapter 603 Chapter 9 § 127681 as it may relate to Novartis or any of its affiliates now or in the future. Novartis, on behalf of itself and affiliates, expressly reservesAll such rights. We believe that this submission and ofAll Novartis related information herein is confidential and proprietary, commercial or financial information not subject to disclosure, including under the California Public Records Act (Government Code Section 6250 et seq.) and applicable laws pertaining to trade secrets. We request that the confidentiality of this submission and ofAll Novartis’ related information herein be maintained to the maximum extent permitted by law. When any of this information is requested, whether under the California Public Records Act (Government Code Section 6250 et seq.) or otherwise, we request that Novartis is notified of the request and afforded the opportunity to submit objections to disclosure.
Rx0000073	Novartis	03/31/2019	00078060905	Focalin XR 35mg	01/15/2019	82.61	1459.50	11/01/2019	Innovator Multiple Source Drug	7406	None	Increases in rate of inflation, continued investment in innovation, post-marketing regulatory commitments, ongoing pharmacovigilance, market conditions and dynamics	None	Not applicable	None	None	None	None	None	None	None	None	None	None	None	All information is provided by Novartis to the best of our knowledge at the time of submission. WAC is reported at the package level not the unit level. Novartis provides this report consistent with its understanding and interpretation of California SB 17 Chapter 603 Chapter 9 § 127681 and its provisions. In providing this report, Novartis does not waive any rights that it may have at law or in equity with respect to the applicability, interpretation, or application of California SB 17 Chapter 603 Chapter 9 § 127681 as it may relate to Novartis or any of its affiliates now or in the future. Novartis, on behalf of itself and affiliates, expressly reservesAll such rights. We believe that this submission and ofAll Novartis related information herein is confidential and proprietary, commercial or financial information not subject to disclosure, including under the California Public Records Act (Government Code Section 6250 et seq.) and applicable laws pertaining to trade secrets. We request that the confidentiality of this submission and ofAll Novartis’ related information herein be maintained to the maximum extent permitted by law. When any of this information is requested, whether under the California Public Records Act (Government Code Section 6250 et seq.) or otherwise, we request that Novartis is notified of the request and afforded the opportunity to submit objections to disclosure.
Rx0000073	Novartis	03/31/2019	00078043405	Focalin XR 40mg	01/15/2019	82.61	1459.50	11/01/2019	Innovator Multiple Source Drug	17314	None	Increases in rate of inflation, continued investment in innovation, post-marketing regulatory commitments, ongoing pharmacovigilance, market conditions and dynamics	None	Not applicable	None	None	None	None	None	None	None	None	None	None	None	All information is provided by Novartis to the best of our knowledge at the time of submission. WAC is reported at the package level not the unit level. Novartis provides this report consistent with its understanding and interpretation of California SB 17 Chapter 603 Chapter 9 § 127681 and its provisions. In providing this report, Novartis does not waive any rights that it may have at law or in equity with respect to the applicability, interpretation, or application of California SB 17 Chapter 603 Chapter 9 § 127681 as it may relate to Novartis or any of its affiliates now or in the future. Novartis, on behalf of itself and affiliates, expressly reservesAll such rights. We believe that this submission and ofAll Novartis related information herein is confidential and proprietary, commercial or financial information not subject to disclosure, including under the California Public Records Act (Government Code Section 6250 et seq.) and applicable laws pertaining to trade secrets. We request that the confidentiality of this submission and ofAll Novartis’ related information herein be maintained to the maximum extent permitted by law. When any of this information is requested, whether under the California Public Records Act (Government Code Section 6250 et seq.) or otherwise, we request that Novartis is notified of the request and afforded the opportunity to submit objections to disclosure.
Rx0000073	Novartis	03/31/2019	00078043005	Focalin XR 5mg	01/15/2019	71.80	1268.42	11/01/2019	Innovator Multiple Source Drug	34946	None	Increases in rate of inflation, continued investment in innovation, post-marketing regulatory commitments, ongoing pharmacovigilance, market conditions and dynamics	None	Not applicable	None	None	None	None	None	None	None	None	None	None	None	All information is provided by Novartis to the best of our knowledge at the time of submission. WAC is reported at the package level not the unit level. Novartis provides this report consistent with its understanding and interpretation of California SB 17 Chapter 603 Chapter 9 § 127681 and its provisions. In providing this report, Novartis does not waive any rights that it may have at law or in equity with respect to the applicability, interpretation, or application of California SB 17 Chapter 603 Chapter 9 § 127681 as it may relate to Novartis or any of its affiliates now or in the future. Novartis, on behalf of itself and affiliates, expressly reservesAll such rights. We believe that this submission and ofAll Novartis related information herein is confidential and proprietary, commercial or financial information not subject to disclosure, including under the California Public Records Act (Government Code Section 6250 et seq.) and applicable laws pertaining to trade secrets. We request that the confidentiality of this submission and ofAll Novartis’ related information herein be maintained to the maximum extent permitted by law. When any of this information is requested, whether under the California Public Records Act (Government Code Section 6250 et seq.) or otherwise, we request that Novartis is notified of the request and afforded the opportunity to submit objections to disclosure.
Rx0000073	Novartis	03/31/2019	00078060715	Gilenya Capsule 0.5mg	01/15/2019	353.57	8210.64	12/27/2027	Single Source Drug	339976	None	Increases in rate of inflation, continued investment in innovation, post-marketing regulatory commitments, ongoing pharmacovigilance, market conditions and dynamics	None	Not applicable	None	None	None	None	None	None	None	None	None	None	None	All information is provided by Novartis to the best of our knowledge at the time of submission. WAC is reported at the package level not the unit level. Novartis provides this report consistent with its understanding and interpretation of California SB 17 Chapter 603 Chapter 9 § 127681 and its provisions. In providing this report, Novartis does not waive any rights that it may have at law or in equity with respect to the applicability, interpretation, or application of California SB 17 Chapter 603 Chapter 9 § 127681 as it may relate to Novartis or any of its affiliates now or in the future. Novartis, on behalf of itself and affiliates, expressly reservesAll such rights. We believe that this submission and ofAll Novartis related information herein is confidential and proprietary, commercial or financial information not subject to disclosure, including under the California Public Records Act (Government Code Section 6250 et seq.) and applicable laws pertaining to trade secrets. We request that the confidentiality of this submission and ofAll Novartis’ related information herein be maintained to the maximum extent permitted by law. When any of this information is requested, whether under the California Public Records Act (Government Code Section 6250 et seq.) or otherwise, we request that Novartis is notified of the request and afforded the opportunity to submit objections to disclosure.
Rx0000073	Novartis	03/31/2019	00065175007	Ilevro 0.3% 1.7mL	01/15/2019	20.38	275.08	03/31/2032	Single Source Drug	305539	None	Increases in rate of inflation, continued investment in innovation, post-marketing regulatory commitments, ongoing pharmacovigilance, market conditions and dynamics	None	Not applicable	None	None	None	None	None	None	None	None	None	None	None	All information is provided by Novartis to the best of our knowledge at the time of submission. WAC is reported at the package level not the unit level. Novartis provides this report consistent with its understanding and interpretation of California SB 17 Chapter 603 Chapter 9 § 127681 and its provisions. In providing this report, Novartis does not waive any rights that it may have at law or in equity with respect to the applicability, interpretation, or application of California SB 17 Chapter 603 Chapter 9 § 127681 as it may relate to Novartis or any of its affiliates now or in the future. Novartis, on behalf of itself and affiliates, expressly reservesAll such rights. We believe that this submission and ofAll Novartis related information herein is confidential and proprietary, commercial or financial information not subject to disclosure, including under the California Public Records Act (Government Code Section 6250 et seq.) and applicable laws pertaining to trade secrets. We request that the confidentiality of this submission and ofAll Novartis’ related information herein be maintained to the maximum extent permitted by law. When any of this information is requested, whether under the California Public Records Act (Government Code Section 6250 et seq.) or otherwise, we request that Novartis is notified of the request and afforded the opportunity to submit objections to disclosure. Products were acquired from Alcon as portfolio. Acquisition of portfolio was finalized 8/27/2010. This is prior to the 5 year reporting period.
Rx0000073	Novartis	03/31/2019	00065175014	Ilevro 0.3% 3mL	01/15/2019	20.38	275.08	03/31/2032	Single Source Drug	213723	None	Increases in rate of inflation, continued investment in innovation, post-marketing regulatory commitments, ongoing pharmacovigilance, market conditions and dynamics	None	Not applicable	None	None	None	None	None	None	None	None	None	None	None	All information is provided by Novartis to the best of our knowledge at the time of submission. WAC is reported at the package level not the unit level. Novartis provides this report consistent with its understanding and interpretation of California SB 17 Chapter 603 Chapter 9 § 127681 and its provisions. In providing this report, Novartis does not waive any rights that it may have at law or in equity with respect to the applicability, interpretation, or application of California SB 17 Chapter 603 Chapter 9 § 127681 as it may relate to Novartis or any of its affiliates now or in the future. Novartis, on behalf of itself and affiliates, expressly reservesAll such rights. We believe that this submission and ofAll Novartis related information herein is confidential and proprietary, commercial or financial information not subject to disclosure, including under the California Public Records Act (Government Code Section 6250 et seq.) and applicable laws pertaining to trade secrets. We request that the confidentiality of this submission and ofAll Novartis’ related information herein be maintained to the maximum extent permitted by law. When any of this information is requested, whether under the California Public Records Act (Government Code Section 6250 et seq.) or otherwise, we request that Novartis is notified of the request and afforded the opportunity to submit objections to disclosure. Products were acquired from Alcon as portfolio. Acquisition of portfolio was finalized 8/27/2010. This is prior to the 5 year reporting period.
Rx0000073	Novartis	03/31/2019	00078065515	Jadenu 180mg	01/15/2019	187.68	2533.65	11/21/2034	Single Source Drug	30116	None	Increases in rate of inflation, continued investment in innovation, post-marketing regulatory commitments, ongoing pharmacovigilance, market conditions and dynamics	None	Not applicable	None	None	None	None	None	None	None	None	None	None	None	All information is provided by Novartis to the best of our knowledge at the time of submission. WAC is reported at the package level not the unit level. Novartis provides this report consistent with its understanding and interpretation of California SB 17 Chapter 603 Chapter 9 § 127681 and its provisions. In providing this report, Novartis does not waive any rights that it may have at law or in equity with respect to the applicability, interpretation, or application of California SB 17 Chapter 603 Chapter 9 § 127681 as it may relate to Novartis or any of its affiliates now or in the future. Novartis, on behalf of itself and affiliates, expressly reservesAll such rights. We believe that this submission and ofAll Novartis related information herein is confidential and proprietary, commercial or financial information not subject to disclosure, including under the California Public Records Act (Government Code Section 6250 et seq.) and applicable laws pertaining to trade secrets. We request that the confidentiality of this submission and ofAll Novartis’ related information herein be maintained to the maximum extent permitted by law. When any of this information is requested, whether under the California Public Records Act (Government Code Section 6250 et seq.) or otherwise, we request that Novartis is notified of the request and afforded the opportunity to submit objections to disclosure.
Rx0000073	Novartis	03/31/2019	00078065615	Jadenu 360mg	01/15/2019	375.35	5067.20	11/21/2034	Single Source Drug	98334	None	Increases in rate of inflation, continued investment in innovation, post-marketing regulatory commitments, ongoing pharmacovigilance, market conditions and dynamics	None	Not applicable	None	None	None	None	None	None	None	None	None	None	None	All information is provided by Novartis to the best of our knowledge at the time of submission. WAC is reported at the package level not the unit level. Novartis provides this report consistent with its understanding and interpretation of California SB 17 Chapter 603 Chapter 9 § 127681 and its provisions. In providing this report, Novartis does not waive any rights that it may have at law or in equity with respect to the applicability, interpretation, or application of California SB 17 Chapter 603 Chapter 9 § 127681 as it may relate to Novartis or any of its affiliates now or in the future. Novartis, on behalf of itself and affiliates, expressly reservesAll such rights. We believe that this submission and ofAll Novartis related information herein is confidential and proprietary, commercial or financial information not subject to disclosure, including under the California Public Records Act (Government Code Section 6250 et seq.) and applicable laws pertaining to trade secrets. We request that the confidentiality of this submission and ofAll Novartis’ related information herein be maintained to the maximum extent permitted by law. When any of this information is requested, whether under the California Public Records Act (Government Code Section 6250 et seq.) or otherwise, we request that Novartis is notified of the request and afforded the opportunity to submit objections to disclosure.
Rx0000073	Novartis	03/31/2019	00078065415	Jadenu 90mg	01/15/2019	93.84	1266.85	11/21/2034	Single Source Drug	14792	None	Increases in rate of inflation, continued investment in innovation, post-marketing regulatory commitments, ongoing pharmacovigilance, market conditions and dynamics	None	Not applicable	None	None	None	None	None	None	None	None	None	None	None	All information is provided by Novartis to the best of our knowledge at the time of submission. WAC is reported at the package level not the unit level. Novartis provides this report consistent with its understanding and interpretation of California SB 17 Chapter 603 Chapter 9 § 127681 and its provisions. In providing this report, Novartis does not waive any rights that it may have at law or in equity with respect to the applicability, interpretation, or application of California SB 17 Chapter 603 Chapter 9 § 127681 as it may relate to Novartis or any of its affiliates now or in the future. Novartis, on behalf of itself and affiliates, expressly reservesAll such rights. We believe that this submission and ofAll Novartis related information herein is confidential and proprietary, commercial or financial information not subject to disclosure, including under the California Public Records Act (Government Code Section 6250 et seq.) and applicable laws pertaining to trade secrets. We request that the confidentiality of this submission and ofAll Novartis’ related information herein be maintained to the maximum extent permitted by law. When any of this information is requested, whether under the California Public Records Act (Government Code Section 6250 et seq.) or otherwise, we request that Novartis is notified of the request and afforded the opportunity to submit objections to disclosure.
Rx0000073	Novartis	03/31/2019	00078071315	Jadenu Granules 180mg	01/15/2019	187.68	2533.65	04/05/2019	Single Source Drug	1772	None	Increases in rate of inflation, continued investment in innovation, post-marketing regulatory commitments, ongoing pharmacovigilance, market conditions and dynamics	None	Not applicable	None	None	None	None	None	None	None	None	None	None	None	All information is provided by Novartis to the best of our knowledge at the time of submission. WAC is reported at the package level not the unit level. Novartis provides this report consistent with its understanding and interpretation of California SB 17 Chapter 603 Chapter 9 § 127681 and its provisions. In providing this report, Novartis does not waive any rights that it may have at law or in equity with respect to the applicability, interpretation, or application of California SB 17 Chapter 603 Chapter 9 § 127681 as it may relate to Novartis or any of its affiliates now or in the future. Novartis, on behalf of itself and affiliates, expressly reservesAll such rights. We believe that this submission and ofAll Novartis related information herein is confidential and proprietary, commercial or financial information not subject to disclosure, including under the California Public Records Act (Government Code Section 6250 et seq.) and applicable laws pertaining to trade secrets. We request that the confidentiality of this submission and ofAll Novartis’ related information herein be maintained to the maximum extent permitted by law. When any of this information is requested, whether under the California Public Records Act (Government Code Section 6250 et seq.) or otherwise, we request that Novartis is notified of the request and afforded the opportunity to submit objections to disclosure.
Rx0000073	Novartis	03/31/2019	00078072015	Jadenu Granules 360mg	01/15/2019	375.35	5067.20	04/05/2019	Single Source Drug	3271	None	Increases in rate of inflation, continued investment in innovation, post-marketing regulatory commitments, ongoing pharmacovigilance, market conditions and dynamics	None	Not applicable	None	None	None	None	None	None	None	None	None	None	None	All information is provided by Novartis to the best of our knowledge at the time of submission. WAC is reported at the package level not the unit level. Novartis provides this report consistent with its understanding and interpretation of California SB 17 Chapter 603 Chapter 9 § 127681 and its provisions. In providing this report, Novartis does not waive any rights that it may have at law or in equity with respect to the applicability, interpretation, or application of California SB 17 Chapter 603 Chapter 9 § 127681 as it may relate to Novartis or any of its affiliates now or in the future. Novartis, on behalf of itself and affiliates, expressly reservesAll such rights. We believe that this submission and ofAll Novartis related information herein is confidential and proprietary, commercial or financial information not subject to disclosure, including under the California Public Records Act (Government Code Section 6250 et seq.) and applicable laws pertaining to trade secrets. We request that the confidentiality of this submission and ofAll Novartis’ related information herein be maintained to the maximum extent permitted by law. When any of this information is requested, whether under the California Public Records Act (Government Code Section 6250 et seq.) or otherwise, we request that Novartis is notified of the request and afforded the opportunity to submit objections to disclosure.
Rx0000073	Novartis	03/31/2019	00078072715	Jadenu Granules 90mg	01/15/2019	93.84	1266.85	04/05/2019	Single Source Drug	2316	None	Increases in rate of inflation, continued investment in innovation, post-marketing regulatory commitments, ongoing pharmacovigilance, market conditions and dynamics	None	Not applicable	None	None	None	None	None	None	None	None	None	None	None	All information is provided by Novartis to the best of our knowledge at the time of submission. WAC is reported at the package level not the unit level. Novartis provides this report consistent with its understanding and interpretation of California SB 17 Chapter 603 Chapter 9 § 127681 and its provisions. In providing this report, Novartis does not waive any rights that it may have at law or in equity with respect to the applicability, interpretation, or application of California SB 17 Chapter 603 Chapter 9 § 127681 as it may relate to Novartis or any of its affiliates now or in the future. Novartis, on behalf of itself and affiliates, expressly reservesAll such rights. We believe that this submission and ofAll Novartis related information herein is confidential and proprietary, commercial or financial information not subject to disclosure, including under the California Public Records Act (Government Code Section 6250 et seq.) and applicable laws pertaining to trade secrets. We request that the confidentiality of this submission and ofAll Novartis’ related information herein be maintained to the maximum extent permitted by law. When any of this information is requested, whether under the California Public Records Act (Government Code Section 6250 et seq.) or otherwise, we request that Novartis is notified of the request and afforded the opportunity to submit objections to disclosure.
Rx0000073	Novartis	03/31/2019	00078036405	Lotrel 10/20mg	01/15/2019	65.93	1164.73	12/19/2017	Innovator Multiple Source Drug	4681	None	Increases in rate of inflation, continued investment in innovation, post-marketing regulatory commitments, ongoing pharmacovigilance, market conditions and dynamics	None	Not applicable	None	None	None	None	None	None	None	None	None	None	None	All information is provided by Novartis to the best of our knowledge at the time of submission. WAC is reported at the package level not the unit level. Novartis provides this report consistent with its understanding and interpretation of California SB 17 Chapter 603 Chapter 9 § 127681 and its provisions. In providing this report, Novartis does not waive any rights that it may have at law or in equity with respect to the applicability, interpretation, or application of California SB 17 Chapter 603 Chapter 9 § 127681 as it may relate to Novartis or any of its affiliates now or in the future. Novartis, on behalf of itself and affiliates, expressly reservesAll such rights. We believe that this submission and ofAll Novartis related information herein is confidential and proprietary, commercial or financial information not subject to disclosure, including under the California Public Records Act (Government Code Section 6250 et seq.) and applicable laws pertaining to trade secrets. We request that the confidentiality of this submission and ofAll Novartis’ related information herein be maintained to the maximum extent permitted by law. When any of this information is requested, whether under the California Public Records Act (Government Code Section 6250 et seq.) or otherwise, we request that Novartis is notified of the request and afforded the opportunity to submit objections to disclosure.
Rx0000073	Novartis	03/31/2019	00078037905	Lotrel 10/40mg	01/15/2019	72.64	1283.36	12/19/2017	Innovator Multiple Source Drug	3729	None	Increases in rate of inflation, continued investment in innovation, post-marketing regulatory commitments, ongoing pharmacovigilance, market conditions and dynamics	None	Not applicable	None	None	None	None	None	None	None	None	None	None	None	All information is provided by Novartis to the best of our knowledge at the time of submission. WAC is reported at the package level not the unit level. Novartis provides this report consistent with its understanding and interpretation of California SB 17 Chapter 603 Chapter 9 § 127681 and its provisions. In providing this report, Novartis does not waive any rights that it may have at law or in equity with respect to the applicability, interpretation, or application of California SB 17 Chapter 603 Chapter 9 § 127681 as it may relate to Novartis or any of its affiliates now or in the future. Novartis, on behalf of itself and affiliates, expressly reservesAll such rights. We believe that this submission and ofAll Novartis related information herein is confidential and proprietary, commercial or financial information not subject to disclosure, including under the California Public Records Act (Government Code Section 6250 et seq.) and applicable laws pertaining to trade secrets. We request that the confidentiality of this submission and ofAll Novartis’ related information herein be maintained to the maximum extent permitted by law. When any of this information is requested, whether under the California Public Records Act (Government Code Section 6250 et seq.) or otherwise, we request that Novartis is notified of the request and afforded the opportunity to submit objections to disclosure.
Rx0000073	Novartis	03/31/2019	00078040505	Lotrel 5/10mg	01/15/2019	53.74	949.33	12/19/2017	Innovator Multiple Source Drug	2961	None	Increases in rate of inflation, continued investment in innovation, post-marketing regulatory commitments, ongoing pharmacovigilance, market conditions and dynamics	None	Not applicable	None	None	None	None	None	None	None	None	None	None	None	All information is provided by Novartis to the best of our knowledge at the time of submission. WAC is reported at the package level not the unit level. Novartis provides this report consistent with its understanding and interpretation of California SB 17 Chapter 603 Chapter 9 § 127681 and its provisions. In providing this report, Novartis does not waive any rights that it may have at law or in equity with respect to the applicability, interpretation, or application of California SB 17 Chapter 603 Chapter 9 § 127681 as it may relate to Novartis or any of its affiliates now or in the future. Novartis, on behalf of itself and affiliates, expressly reservesAll such rights. We believe that this submission and ofAll Novartis related information herein is confidential and proprietary, commercial or financial information not subject to disclosure, including under the California Public Records Act (Government Code Section 6250 et seq.) and applicable laws pertaining to trade secrets. We request that the confidentiality of this submission and ofAll Novartis’ related information herein be maintained to the maximum extent permitted by law. When any of this information is requested, whether under the California Public Records Act (Government Code Section 6250 et seq.) or otherwise, we request that Novartis is notified of the request and afforded the opportunity to submit objections to disclosure.
Rx0000073	Novartis	03/31/2019	00078040605	Lotrel 5/20mg	01/15/2019	56.75	1002.51	12/19/2017	Innovator Multiple Source Drug	5829	None	Increases in rate of inflation, continued investment in innovation, post-marketing regulatory commitments, ongoing pharmacovigilance, market conditions and dynamics	None	Not applicable	None	None	None	None	None	None	None	None	None	None	None	All information is provided by Novartis to the best of our knowledge at the time of submission. WAC is reported at the package level not the unit level. Novartis provides this report consistent with its understanding and interpretation of California SB 17 Chapter 603 Chapter 9 § 127681 and its provisions. In providing this report, Novartis does not waive any rights that it may have at law or in equity with respect to the applicability, interpretation, or application of California SB 17 Chapter 603 Chapter 9 § 127681 as it may relate to Novartis or any of its affiliates now or in the future. Novartis, on behalf of itself and affiliates, expressly reservesAll such rights. We believe that this submission and ofAll Novartis related information herein is confidential and proprietary, commercial or financial information not subject to disclosure, including under the California Public Records Act (Government Code Section 6250 et seq.) and applicable laws pertaining to trade secrets. We request that the confidentiality of this submission and ofAll Novartis’ related information herein be maintained to the maximum extent permitted by law. When any of this information is requested, whether under the California Public Records Act (Government Code Section 6250 et seq.) or otherwise, we request that Novartis is notified of the request and afforded the opportunity to submit objections to disclosure.
Rx0000073	Novartis	03/31/2019	00078066615	Mekinist 0.5 mg	01/15/2019	158.40	3326.33	01/28/2032	Single Source Drug	16900	None	Increases in rate of inflation, continued investment in innovation, post-marketing regulatory commitments, ongoing pharmacovigilance, market conditions and dynamics	None	Not applicable	None	None	None	None	None	None	None	None	None	None	None	All information is provided by Novartis to the best of our knowledge at the time of submission. WAC is reported at the package level not the unit level. Novartis provides this report consistent with its understanding and interpretation of California SB 17 Chapter 603 Chapter 9 § 127681 and its provisions. In providing this report, Novartis does not waive any rights that it may have at law or in equity with respect to the applicability, interpretation, or application of California SB 17 Chapter 603 Chapter 9 § 127681 as it may relate to Novartis or any of its affiliates now or in the future. Novartis, on behalf of itself and affiliates, expressly reservesAll such rights. We believe that this submission and ofAll Novartis related information herein is confidential and proprietary, commercial or financial information not subject to disclosure, including under the California Public Records Act (Government Code Section 6250 et seq.) and applicable laws pertaining to trade secrets. We request that the confidentiality of this submission and ofAll Novartis’ related information herein be maintained to the maximum extent permitted by law. When any of this information is requested, whether under the California Public Records Act (Government Code Section 6250 et seq.) or otherwise, we request that Novartis is notified of the request and afforded the opportunity to submit objections to disclosure. Products were acquired from GSK as portfolio. Product was on the market at the time of the acquisition; this NDC was not.
Rx0000073	Novartis	03/31/2019	00065000203	Nevanac	01/15/2019	15.38	271.63	01/31/2027	Single Source Drug	80133	None	Increases in rate of inflation, continued investment in innovation, post-marketing regulatory commitments, ongoing pharmacovigilance, market conditions and dynamics	None	Not applicable	None	None	None	None	None	None	None	None	None	None	None	All information is provided by Novartis to the best of our knowledge at the time of submission. WAC is reported at the package level not the unit level. Novartis provides this report consistent with its understanding and interpretation of California SB 17 Chapter 603 Chapter 9 § 127681 and its provisions. In providing this report, Novartis does not waive any rights that it may have at law or in equity with respect to the applicability, interpretation, or application of California SB 17 Chapter 603 Chapter 9 § 127681 as it may relate to Novartis or any of its affiliates now or in the future. Novartis, on behalf of itself and affiliates, expressly reservesAll such rights. We believe that this submission and ofAll Novartis related information herein is confidential and proprietary, commercial or financial information not subject to disclosure, including under the California Public Records Act (Government Code Section 6250 et seq.) and applicable laws pertaining to trade secrets. We request that the confidentiality of this submission and ofAll Novartis’ related information herein be maintained to the maximum extent permitted by law. When any of this information is requested, whether under the California Public Records Act (Government Code Section 6250 et seq.) or otherwise, we request that Novartis is notified of the request and afforded the opportunity to submit objections to disclosure. Products were acquired from Alcon as portfolio. Product was on the market at the time of the acquisition. Acquisition of portfolio was finalized 8/27/2010. This is prior to the 5 year reporting period.
Rx0000073	Novartis	03/31/2019	00065027225	Pataday	01/15/2019	10.56	186.64	05/12/2024	Innovator Multiple Source Drug	123218	None	Increases in rate of inflation, continued investment in innovation, post-marketing regulatory commitments, ongoing pharmacovigilance, market conditions and dynamics	None	Not applicable	None	None	None	None	None	None	None	None	None	None	None	All information is provided by Novartis to the best of our knowledge at the time of submission. WAC is reported at the package level not the unit level. Novartis provides this report consistent with its understanding and interpretation of California SB 17 Chapter 603 Chapter 9 § 127681 and its provisions. In providing this report, Novartis does not waive any rights that it may have at law or in equity with respect to the applicability, interpretation, or application of California SB 17 Chapter 603 Chapter 9 § 127681 as it may relate to Novartis or any of its affiliates now or in the future. Novartis, on behalf of itself and affiliates, expressly reservesAll such rights. We believe that this submission and ofAll Novartis related information herein is confidential and proprietary, commercial or financial information not subject to disclosure, including under the California Public Records Act (Government Code Section 6250 et seq.) and applicable laws pertaining to trade secrets. We request that the confidentiality of this submission and ofAll Novartis’ related information herein be maintained to the maximum extent permitted by law. When any of this information is requested, whether under the California Public Records Act (Government Code Section 6250 et seq.) or otherwise, we request that Novartis is notified of the request and afforded the opportunity to submit objections to disclosure. Products were acquired from Alcon as portfolio. Product was on the market at the time of the acquisition. Acquisition of portfolio was finalized 8/27/2010. This is prior to the 5 year reporting period.
Rx0000073	Novartis	03/31/2019	00065027105	Patanol	01/15/2019	16.45	290.61	12/06/2015	Innovator Multiple Source Drug	38786	None	Increases in rate of inflation, continued investment in innovation, post-marketing regulatory commitments, ongoing pharmacovigilance, market conditions and dynamics	None	Not applicable	None	None	None	None	None	None	None	None	None	None	None	All information is provided by Novartis to the best of our knowledge at the time of submission. WAC is reported at the package level not the unit level. Novartis provides this report consistent with its understanding and interpretation of California SB 17 Chapter 603 Chapter 9 § 127681 and its provisions. In providing this report, Novartis does not waive any rights that it may have at law or in equity with respect to the applicability, interpretation, or application of California SB 17 Chapter 603 Chapter 9 § 127681 as it may relate to Novartis or any of its affiliates now or in the future. Novartis, on behalf of itself and affiliates, expressly reservesAll such rights. We believe that this submission and ofAll Novartis related information herein is confidential and proprietary, commercial or financial information not subject to disclosure, including under the California Public Records Act (Government Code Section 6250 et seq.) and applicable laws pertaining to trade secrets. We request that the confidentiality of this submission and ofAll Novartis’ related information herein be maintained to the maximum extent permitted by law. When any of this information is requested, whether under the California Public Records Act (Government Code Section 6250 et seq.) or otherwise, we request that Novartis is notified of the request and afforded the opportunity to submit objections to disclosure. Products were acquired from Alcon as portfolio. Product was on the market at the time of the acquisition. Acquisition of portfolio was finalized 8/27/2010. This is prior to the 5 year reporting period.
Rx0000073	Novartis	03/31/2019	00065427325	Pazeo 0.007 2.5mL	01/15/2019	14.42	194.71	05/19/2032	Single Source Drug	1160772	None	Increases in rate of inflation, continued investment in innovation, post-marketing regulatory commitments, ongoing pharmacovigilance, market conditions and dynamics	None	Not applicable	None	None	None	None	None	None	None	None	None	None	None	All information is provided by Novartis to the best of our knowledge at the time of submission. WAC is reported at the package level not the unit level. Novartis provides this report consistent with its understanding and interpretation of California SB 17 Chapter 603 Chapter 9 § 127681 and its provisions. In providing this report, Novartis does not waive any rights that it may have at law or in equity with respect to the applicability, interpretation, or application of California SB 17 Chapter 603 Chapter 9 § 127681 as it may relate to Novartis or any of its affiliates now or in the future. Novartis, on behalf of itself and affiliates, expressly reservesAll such rights. We believe that this submission and ofAll Novartis related information herein is confidential and proprietary, commercial or financial information not subject to disclosure, including under the California Public Records Act (Government Code Section 6250 et seq.) and applicable laws pertaining to trade secrets. We request that the confidentiality of this submission and ofAll Novartis’ related information herein be maintained to the maximum extent permitted by law. When any of this information is requested, whether under the California Public Records Act (Government Code Section 6250 et seq.) or otherwise, we request that Novartis is notified of the request and afforded the opportunity to submit objections to disclosure. Products were acquired from Alcon as portfolio. Acquisition of portfolio was finalized 8/27/2010. This is prior to the 5 year reporting period.
Rx0000073	Novartis	03/31/2019	00078068415	Promacta 12.5 mg	01/15/2019	364.92	4926.47	02/01/2028	Single Source Drug	6735	None	Increases in rate of inflation, continued investment in innovation, post-marketing regulatory commitments, ongoing pharmacovigilance, market conditions and dynamics	None	Not applicable	None	None	None	None	None	None	None	None	None	None	None	All information is provided by Novartis to the best of our knowledge at the time of submission. WAC is reported at the package level not the unit level. Novartis provides this report consistent with its understanding and interpretation of California SB 17 Chapter 603 Chapter 9 § 127681 and its provisions. In providing this report, Novartis does not waive any rights that it may have at law or in equity with respect to the applicability, interpretation, or application of California SB 17 Chapter 603 Chapter 9 § 127681 as it may relate to Novartis or any of its affiliates now or in the future. Novartis, on behalf of itself and affiliates, expressly reservesAll such rights. We believe that this submission and ofAll Novartis related information herein is confidential and proprietary, commercial or financial information not subject to disclosure, including under the California Public Records Act (Government Code Section 6250 et seq.) and applicable laws pertaining to trade secrets. We request that the confidentiality of this submission and ofAll Novartis’ related information herein be maintained to the maximum extent permitted by law. When any of this information is requested, whether under the California Public Records Act (Government Code Section 6250 et seq.) or otherwise, we request that Novartis is notified of the request and afforded the opportunity to submit objections to disclosure. Products were acquired from GSK as portfolio. Product was on the market at the time of the acquisition; this NDC was not.
Rx0000073	Novartis	03/31/2019	00078068515	Promacta 25 mg	01/15/2019	364.92	4926.47	02/01/2028	Single Source Drug	32813	None	Increases in rate of inflation, continued investment in innovation, post-marketing regulatory commitments, ongoing pharmacovigilance, market conditions and dynamics	None	Not applicable	None	None	None	None	None	None	None	None	None	None	None	All information is provided by Novartis to the best of our knowledge at the time of submission. WAC is reported at the package level not the unit level. Novartis provides this report consistent with its understanding and interpretation of California SB 17 Chapter 603 Chapter 9 § 127681 and its provisions. In providing this report, Novartis does not waive any rights that it may have at law or in equity with respect to the applicability, interpretation, or application of California SB 17 Chapter 603 Chapter 9 § 127681 as it may relate to Novartis or any of its affiliates now or in the future. Novartis, on behalf of itself and affiliates, expressly reservesAll such rights. We believe that this submission and ofAll Novartis related information herein is confidential and proprietary, commercial or financial information not subject to disclosure, including under the California Public Records Act (Government Code Section 6250 et seq.) and applicable laws pertaining to trade secrets. We request that the confidentiality of this submission and ofAll Novartis’ related information herein be maintained to the maximum extent permitted by law. When any of this information is requested, whether under the California Public Records Act (Government Code Section 6250 et seq.) or otherwise, we request that Novartis is notified of the request and afforded the opportunity to submit objections to disclosure. Products were acquired from GSK as portfolio. Product was on the market at the time of the acquisition; this NDC was not.
Rx0000073	Novartis	03/31/2019	00078068615	Promacta 50 mg	01/15/2019	660.40	8915.34	02/01/2028	Single Source Drug	42737	None	Increases in rate of inflation, continued investment in innovation, post-marketing regulatory commitments, ongoing pharmacovigilance, market conditions and dynamics	None	Not applicable	None	None	None	None	None	None	None	None	None	None	None	All information is provided by Novartis to the best of our knowledge at the time of submission. WAC is reported at the package level not the unit level. Novartis provides this report consistent with its understanding and interpretation of California SB 17 Chapter 603 Chapter 9 § 127681 and its provisions. In providing this report, Novartis does not waive any rights that it may have at law or in equity with respect to the applicability, interpretation, or application of California SB 17 Chapter 603 Chapter 9 § 127681 as it may relate to Novartis or any of its affiliates now or in the future. Novartis, on behalf of itself and affiliates, expressly reservesAll such rights. We believe that this submission and ofAll Novartis related information herein is confidential and proprietary, commercial or financial information not subject to disclosure, including under the California Public Records Act (Government Code Section 6250 et seq.) and applicable laws pertaining to trade secrets. We request that the confidentiality of this submission and ofAll Novartis’ related information herein be maintained to the maximum extent permitted by law. When any of this information is requested, whether under the California Public Records Act (Government Code Section 6250 et seq.) or otherwise, we request that Novartis is notified of the request and afforded the opportunity to submit objections to disclosure. Products were acquired from GSK as portfolio. Product was on the market at the time of the acquisition; this NDC was not.
Rx0000073	Novartis	03/31/2019	00078068715	Promacta 75 mg	01/15/2019	990.59	13373.01	02/01/2028	Single Source Drug	19289	None	Increases in rate of inflation, continued investment in innovation, post-marketing regulatory commitments, ongoing pharmacovigilance, market conditions and dynamics	None	Not applicable	None	None	None	None	None	None	None	None	None	None	None	All information is provided by Novartis to the best of our knowledge at the time of submission. WAC is reported at the package level not the unit level. Novartis provides this report consistent with its understanding and interpretation of California SB 17 Chapter 603 Chapter 9 § 127681 and its provisions. In providing this report, Novartis does not waive any rights that it may have at law or in equity with respect to the applicability, interpretation, or application of California SB 17 Chapter 603 Chapter 9 § 127681 as it may relate to Novartis or any of its affiliates now or in the future. Novartis, on behalf of itself and affiliates, expressly reservesAll such rights. We believe that this submission and ofAll Novartis related information herein is confidential and proprietary, commercial or financial information not subject to disclosure, including under the California Public Records Act (Government Code Section 6250 et seq.) and applicable laws pertaining to trade secrets. We request that the confidentiality of this submission and ofAll Novartis’ related information herein be maintained to the maximum extent permitted by law. When any of this information is requested, whether under the California Public Records Act (Government Code Section 6250 et seq.) or otherwise, we request that Novartis is notified of the request and afforded the opportunity to submit objections to disclosure. Products were acquired from GSK as portfolio. Product was on the market at the time of the acquisition; this NDC was not.
Rx0000073	Novartis	03/31/2019	00078081181	Sandostatin LAR Depot 10mg (Diluent Filled Syringe)	01/15/2019	140.17	3255.10	01/30/2017	Single Source Drug	8369	None	Increases in rate of inflation, continued investment in innovation, post-marketing regulatory commitments, ongoing pharmacovigilance, market conditions and dynamics	None	Not applicable	None	None	None	None	None	None	None	None	None	None	None	All information is provided by Novartis to the best of our knowledge at the time of submission. WAC is reported at the package level not the unit level. Novartis provides this report consistent with its understanding and interpretation of California SB 17 Chapter 603 Chapter 9 § 127681 and its provisions. In providing this report, Novartis does not waive any rights that it may have at law or in equity with respect to the applicability, interpretation, or application of California SB 17 Chapter 603 Chapter 9 § 127681 as it may relate to Novartis or any of its affiliates now or in the future. Novartis, on behalf of itself and affiliates, expressly reservesAll such rights. We believe that this submission and ofAll Novartis related information herein is confidential and proprietary, commercial or financial information not subject to disclosure, including under the California Public Records Act (Government Code Section 6250 et seq.) and applicable laws pertaining to trade secrets. We request that the confidentiality of this submission and ofAll Novartis’ related information herein be maintained to the maximum extent permitted by law. When any of this information is requested, whether under the California Public Records Act (Government Code Section 6250 et seq.) or otherwise, we request that Novartis is notified of the request and afforded the opportunity to submit objections to disclosure.
Rx0000073	Novartis	03/31/2019	00078081881	Sandostatin LAR Depot 20mg (Diluent Filled Syringe)	01/15/2019	183.65	4264.74	01/30/2017	Single Source Drug	114384	None	Increases in rate of inflation, continued investment in innovation, post-marketing regulatory commitments, ongoing pharmacovigilance, market conditions and dynamics	None	Not applicable	None	None	None	None	None	None	None	None	None	None	None	All information is provided by Novartis to the best of our knowledge at the time of submission. WAC is reported at the package level not the unit level. Novartis provides this report consistent with its understanding and interpretation of California SB 17 Chapter 603 Chapter 9 § 127681 and its provisions. In providing this report, Novartis does not waive any rights that it may have at law or in equity with respect to the applicability, interpretation, or application of California SB 17 Chapter 603 Chapter 9 § 127681 as it may relate to Novartis or any of its affiliates now or in the future. Novartis, on behalf of itself and affiliates, expressly reservesAll such rights. We believe that this submission and ofAll Novartis related information herein is confidential and proprietary, commercial or financial information not subject to disclosure, including under the California Public Records Act (Government Code Section 6250 et seq.) and applicable laws pertaining to trade secrets. We request that the confidentiality of this submission and ofAll Novartis’ related information herein be maintained to the maximum extent permitted by law. When any of this information is requested, whether under the California Public Records Act (Government Code Section 6250 et seq.) or otherwise, we request that Novartis is notified of the request and afforded the opportunity to submit objections to disclosure.
Rx0000073	Novartis	03/31/2019	00078082581	Sandostatin LAR Depot 30mg (Diluent Filled Syringe)	01/15/2019	275.00	6386.14	01/30/2017	Single Source Drug	143662	None	Increases in rate of inflation, continued investment in innovation, post-marketing regulatory commitments, ongoing pharmacovigilance, market conditions and dynamics	None	Not applicable	None	None	None	None	None	None	None	None	None	None	None	All information is provided by Novartis to the best of our knowledge at the time of submission. WAC is reported at the package level not the unit level. Novartis provides this report consistent with its understanding and interpretation of California SB 17 Chapter 603 Chapter 9 § 127681 and its provisions. In providing this report, Novartis does not waive any rights that it may have at law or in equity with respect to the applicability, interpretation, or application of California SB 17 Chapter 603 Chapter 9 § 127681 as it may relate to Novartis or any of its affiliates now or in the future. Novartis, on behalf of itself and affiliates, expressly reservesAll such rights. We believe that this submission and ofAll Novartis related information herein is confidential and proprietary, commercial or financial information not subject to disclosure, including under the California Public Records Act (Government Code Section 6250 et seq.) and applicable laws pertaining to trade secrets. We request that the confidentiality of this submission and ofAll Novartis’ related information herein be maintained to the maximum extent permitted by law. When any of this information is requested, whether under the California Public Records Act (Government Code Section 6250 et seq.) or otherwise, we request that Novartis is notified of the request and afforded the opportunity to submit objections to disclosure.
Rx0000073	Novartis	03/31/2019	00065414727	Simbrinza 1% / 0.2% 8mL	01/15/2019	12.05	162.73	01/30/2017	Single Source Drug	870297	None	Increases in rate of inflation, continued investment in innovation, post-marketing regulatory commitments, ongoing pharmacovigilance, market conditions and dynamics	None	Not applicable	None	None	None	None	None	None	None	None	None	None	None	All information is provided by Novartis to the best of our knowledge at the time of submission. WAC is reported at the package level not the unit level. Novartis provides this report consistent with its understanding and interpretation of California SB 17 Chapter 603 Chapter 9 § 127681 and its provisions. In providing this report, Novartis does not waive any rights that it may have at law or in equity with respect to the applicability, interpretation, or application of California SB 17 Chapter 603 Chapter 9 § 127681 as it may relate to Novartis or any of its affiliates now or in the future. Novartis, on behalf of itself and affiliates, expressly reservesAll such rights. We believe that this submission and ofAll Novartis related information herein is confidential and proprietary, commercial or financial information not subject to disclosure, including under the California Public Records Act (Government Code Section 6250 et seq.) and applicable laws pertaining to trade secrets. We request that the confidentiality of this submission and ofAll Novartis’ related information herein be maintained to the maximum extent permitted by law. When any of this information is requested, whether under the California Public Records Act (Government Code Section 6250 et seq.) or otherwise, we request that Novartis is notified of the request and afforded the opportunity to submit objections to disclosure. Products were acquired from Alcon as portfolio. Acquisition of portfolio was finalized 8/27/2010. This is prior to the 5 year reporting period.
Rx0000073	Novartis	03/31/2019	00078068266	Tafinlar 50 mg	01/15/2019	385.29	8091.04	10/15/2030	Single Source Drug	4581	None	Increases in rate of inflation, continued investment in innovation, post-marketing regulatory commitments, ongoing pharmacovigilance, market conditions and dynamics	None	Not applicable	None	None	None	None	None	None	None	None	None	None	None	All information is provided by Novartis to the best of our knowledge at the time of submission. WAC is reported at the package level not the unit level. Novartis provides this report consistent with its understanding and interpretation of California SB 17 Chapter 603 Chapter 9 § 127681 and its provisions. In providing this report, Novartis does not waive any rights that it may have at law or in equity with respect to the applicability, interpretation, or application of California SB 17 Chapter 603 Chapter 9 § 127681 as it may relate to Novartis or any of its affiliates now or in the future. Novartis, on behalf of itself and affiliates, expressly reservesAll such rights. We believe that this submission and ofAll Novartis related information herein is confidential and proprietary, commercial or financial information not subject to disclosure, including under the California Public Records Act (Government Code Section 6250 et seq.) and applicable laws pertaining to trade secrets. We request that the confidentiality of this submission and ofAll Novartis’ related information herein be maintained to the maximum extent permitted by law. When any of this information is requested, whether under the California Public Records Act (Government Code Section 6250 et seq.) or otherwise, we request that Novartis is notified of the request and afforded the opportunity to submit objections to disclosure. Products were acquired from GSK as portfolio. Product was on the market at the time of the acquisition; this NDC was not.
Rx0000073	Novartis	03/31/2019	00078059287	Tasigna 150mg	01/15/2019	1018.76	13753.29	10/07/2032	Single Source Drug	55098	None	Increases in rate of inflation, continued investment in innovation, post-marketing regulatory commitments, ongoing pharmacovigilance, market conditions and dynamics	None	Not applicable	None	None	None	None	None	None	None	None	None	None	None	All information is provided by Novartis to the best of our knowledge at the time of submission. WAC is reported at the package level not the unit level. Novartis provides this report consistent with its understanding and interpretation of California SB 17 Chapter 603 Chapter 9 § 127681 and its provisions. In providing this report, Novartis does not waive any rights that it may have at law or in equity with respect to the applicability, interpretation, or application of California SB 17 Chapter 603 Chapter 9 § 127681 as it may relate to Novartis or any of its affiliates now or in the future. Novartis, on behalf of itself and affiliates, expressly reservesAll such rights. We believe that this submission and ofAll Novartis related information herein is confidential and proprietary, commercial or financial information not subject to disclosure, including under the California Public Records Act (Government Code Section 6250 et seq.) and applicable laws pertaining to trade secrets. We request that the confidentiality of this submission and ofAll Novartis’ related information herein be maintained to the maximum extent permitted by law. When any of this information is requested, whether under the California Public Records Act (Government Code Section 6250 et seq.) or otherwise, we request that Novartis is notified of the request and afforded the opportunity to submit objections to disclosure.
Rx0000073	Novartis	03/31/2019	00078052687	Tasigna 200mg	01/15/2019	1018.76	13753.29	10/07/2032	Single Source Drug	22313	None	Increases in rate of inflation, continued investment in innovation, post-marketing regulatory commitments, ongoing pharmacovigilance, market conditions and dynamics	None	Not applicable	None	None	None	None	None	None	None	None	None	None	None	All information is provided by Novartis to the best of our knowledge at the time of submission. WAC is reported at the package level not the unit level. Novartis provides this report consistent with its understanding and interpretation of California SB 17 Chapter 603 Chapter 9 § 127681 and its provisions. In providing this report, Novartis does not waive any rights that it may have at law or in equity with respect to the applicability, interpretation, or application of California SB 17 Chapter 603 Chapter 9 § 127681 as it may relate to Novartis or any of its affiliates now or in the future. Novartis, on behalf of itself and affiliates, expressly reservesAll such rights. We believe that this submission and ofAll Novartis related information herein is confidential and proprietary, commercial or financial information not subject to disclosure, including under the California Public Records Act (Government Code Section 6250 et seq.) and applicable laws pertaining to trade secrets. We request that the confidentiality of this submission and ofAll Novartis’ related information herein be maintained to the maximum extent permitted by law. When any of this information is requested, whether under the California Public Records Act (Government Code Section 6250 et seq.) or otherwise, we request that Novartis is notified of the request and afforded the opportunity to submit objections to disclosure.
Rx0000073	Novartis	03/31/2019	00078095166	Tasigna 50mg	01/15/2019	1091.53	14735.62	10/07/2032	Single Source Drug	191	None	Increases in rate of inflation, continued investment in innovation, post-marketing regulatory commitments, ongoing pharmacovigilance, market conditions and dynamics	None	Not applicable	None	None	None	None	None	None	None	None	None	None	None	All information is provided by Novartis to the best of our knowledge at the time of submission. WAC is reported at the package level not the unit level. Novartis provides this report consistent with its understanding and interpretation of California SB 17 Chapter 603 Chapter 9 § 127681 and its provisions. In providing this report, Novartis does not waive any rights that it may have at law or in equity with respect to the applicability, interpretation, or application of California SB 17 Chapter 603 Chapter 9 § 127681 as it may relate to Novartis or any of its affiliates now or in the future. Novartis, on behalf of itself and affiliates, expressly reservesAll such rights. We believe that this submission and ofAll Novartis related information herein is confidential and proprietary, commercial or financial information not subject to disclosure, including under the California Public Records Act (Government Code Section 6250 et seq.) and applicable laws pertaining to trade secrets. We request that the confidentiality of this submission and ofAll Novartis’ related information herein be maintained to the maximum extent permitted by law. When any of this information is requested, whether under the California Public Records Act (Government Code Section 6250 et seq.) or otherwise, we request that Novartis is notified of the request and afforded the opportunity to submit objections to disclosure.
Rx0000073	Novartis	03/31/2019	00078050883	Tegretol 100mg/5ml	01/15/2019	9.24	163.20	10/11/2000	Innovator Multiple Source Drug	34854	None	Increases in rate of inflation, continued investment in innovation, post-marketing regulatory commitments, ongoing pharmacovigilance, market conditions and dynamics	None	Not applicable	None	None	None	None	None	None	None	None	None	None	None	All information is provided by Novartis to the best of our knowledge at the time of submission. WAC is reported at the package level not the unit level. Novartis provides this report consistent with its understanding and interpretation of California SB 17 Chapter 603 Chapter 9 § 127681 and its provisions. In providing this report, Novartis does not waive any rights that it may have at law or in equity with respect to the applicability, interpretation, or application of California SB 17 Chapter 603 Chapter 9 § 127681 as it may relate to Novartis or any of its affiliates now or in the future. Novartis, on behalf of itself and affiliates, expressly reservesAll such rights. We believe that this submission and ofAll Novartis related information herein is confidential and proprietary, commercial or financial information not subject to disclosure, including under the California Public Records Act (Government Code Section 6250 et seq.) and applicable laws pertaining to trade secrets. We request that the confidentiality of this submission and ofAll Novartis’ related information herein be maintained to the maximum extent permitted by law. When any of this information is requested, whether under the California Public Records Act (Government Code Section 6250 et seq.) or otherwise, we request that Novartis is notified of the request and afforded the opportunity to submit objections to disclosure.
Rx0000073	Novartis	03/31/2019	00078050905	Tegretol 200mg	01/15/2019	14.34	253.38	10/11/2000	Innovator Multiple Source Drug	163517	None	Increases in rate of inflation, continued investment in innovation, post-marketing regulatory commitments, ongoing pharmacovigilance, market conditions and dynamics	None	Not applicable	None	None	None	None	None	None	None	None	None	None	None	All information is provided by Novartis to the best of our knowledge at the time of submission. WAC is reported at the package level not the unit level. Novartis provides this report consistent with its understanding and interpretation of California SB 17 Chapter 603 Chapter 9 § 127681 and its provisions. In providing this report, Novartis does not waive any rights that it may have at law or in equity with respect to the applicability, interpretation, or application of California SB 17 Chapter 603 Chapter 9 § 127681 as it may relate to Novartis or any of its affiliates now or in the future. Novartis, on behalf of itself and affiliates, expressly reservesAll such rights. We believe that this submission and ofAll Novartis related information herein is confidential and proprietary, commercial or financial information not subject to disclosure, including under the California Public Records Act (Government Code Section 6250 et seq.) and applicable laws pertaining to trade secrets. We request that the confidentiality of this submission and ofAll Novartis’ related information herein be maintained to the maximum extent permitted by law. When any of this information is requested, whether under the California Public Records Act (Government Code Section 6250 et seq.) or otherwise, we request that Novartis is notified of the request and afforded the opportunity to submit objections to disclosure.
Rx0000073	Novartis	03/31/2019	00078051005	Tegretol-XR 100mg	01/15/2019	7.68	135.63	02/08/2011	Innovator Multiple Source Drug	63308	None	Increases in rate of inflation, continued investment in innovation, post-marketing regulatory commitments, ongoing pharmacovigilance, market conditions and dynamics	None	Not applicable	None	None	None	None	None	None	None	None	None	None	None	All information is provided by Novartis to the best of our knowledge at the time of submission. WAC is reported at the package level not the unit level. Novartis provides this report consistent with its understanding and interpretation of California SB 17 Chapter 603 Chapter 9 § 127681 and its provisions. In providing this report, Novartis does not waive any rights that it may have at law or in equity with respect to the applicability, interpretation, or application of California SB 17 Chapter 603 Chapter 9 § 127681 as it may relate to Novartis or any of its affiliates now or in the future. Novartis, on behalf of itself and affiliates, expressly reservesAll such rights. We believe that this submission and ofAll Novartis related information herein is confidential and proprietary, commercial or financial information not subject to disclosure, including under the California Public Records Act (Government Code Section 6250 et seq.) and applicable laws pertaining to trade secrets. We request that the confidentiality of this submission and ofAll Novartis’ related information herein be maintained to the maximum extent permitted by law. When any of this information is requested, whether under the California Public Records Act (Government Code Section 6250 et seq.) or otherwise, we request that Novartis is notified of the request and afforded the opportunity to submit objections to disclosure.
Rx0000073	Novartis	03/31/2019	00078051105	Tegretol-XR 200mg	01/15/2019	15.32	270.70	02/08/2011	Innovator Multiple Source Drug	103462	None	Increases in rate of inflation, continued investment in innovation, post-marketing regulatory commitments, ongoing pharmacovigilance, market conditions and dynamics	None	Not applicable	None	None	None	None	None	None	None	None	None	None	None	All information is provided by Novartis to the best of our knowledge at the time of submission. WAC is reported at the package level not the unit level. Novartis provides this report consistent with its understanding and interpretation of California SB 17 Chapter 603 Chapter 9 § 127681 and its provisions. In providing this report, Novartis does not waive any rights that it may have at law or in equity with respect to the applicability, interpretation, or application of California SB 17 Chapter 603 Chapter 9 § 127681 as it may relate to Novartis or any of its affiliates now or in the future. Novartis, on behalf of itself and affiliates, expressly reservesAll such rights. We believe that this submission and ofAll Novartis related information herein is confidential and proprietary, commercial or financial information not subject to disclosure, including under the California Public Records Act (Government Code Section 6250 et seq.) and applicable laws pertaining to trade secrets. We request that the confidentiality of this submission and ofAll Novartis’ related information herein be maintained to the maximum extent permitted by law. When any of this information is requested, whether under the California Public Records Act (Government Code Section 6250 et seq.) or otherwise, we request that Novartis is notified of the request and afforded the opportunity to submit objections to disclosure.
Rx0000073	Novartis	03/31/2019	00078051205	Tegretol-XR 400mg	01/15/2019	30.62	540.98	02/08/2011	Innovator Multiple Source Drug	54265	None	Increases in rate of inflation, continued investment in innovation, post-marketing regulatory commitments, ongoing pharmacovigilance, market conditions and dynamics	None	Not applicable	None	None	None	None	None	None	None	None	None	None	None	All information is provided by Novartis to the best of our knowledge at the time of submission. WAC is reported at the package level not the unit level. Novartis provides this report consistent with its understanding and interpretation of California SB 17 Chapter 603 Chapter 9 § 127681 and its provisions. In providing this report, Novartis does not waive any rights that it may have at law or in equity with respect to the applicability, interpretation, or application of California SB 17 Chapter 603 Chapter 9 § 127681 as it may relate to Novartis or any of its affiliates now or in the future. Novartis, on behalf of itself and affiliates, expressly reservesAll such rights. We believe that this submission and ofAll Novartis related information herein is confidential and proprietary, commercial or financial information not subject to disclosure, including under the California Public Records Act (Government Code Section 6250 et seq.) and applicable laws pertaining to trade secrets. We request that the confidentiality of this submission and ofAll Novartis’ related information herein be maintained to the maximum extent permitted by law. When any of this information is requested, whether under the California Public Records Act (Government Code Section 6250 et seq.) or otherwise, we request that Novartis is notified of the request and afforded the opportunity to submit objections to disclosure.
Rx0000073	Novartis	03/31/2019	00065064835	Tobradex ointment 0.3% / 0.1% 3.5g	01/15/2019	12.92	228.21	09/22/2009	Single Source Drug	428077	None	Increases in rate of inflation, continued investment in innovation, post-marketing regulatory commitments, ongoing pharmacovigilance, market conditions and dynamics	None	Not applicable	None	None	None	None	None	None	None	None	None	None	None	All information is provided by Novartis to the best of our knowledge at the time of submission. WAC is reported at the package level not the unit level. Novartis provides this report consistent with its understanding and interpretation of California SB 17 Chapter 603 Chapter 9 § 127681 and its provisions. In providing this report, Novartis does not waive any rights that it may have at law or in equity with respect to the applicability, interpretation, or application of California SB 17 Chapter 603 Chapter 9 § 127681 as it may relate to Novartis or any of its affiliates now or in the future. Novartis, on behalf of itself and affiliates, expressly reservesAll such rights. We believe that this submission and ofAll Novartis related information herein is confidential and proprietary, commercial or financial information not subject to disclosure, including under the California Public Records Act (Government Code Section 6250 et seq.) and applicable laws pertaining to trade secrets. We request that the confidentiality of this submission and ofAll Novartis’ related information herein be maintained to the maximum extent permitted by law. When any of this information is requested, whether under the California Public Records Act (Government Code Section 6250 et seq.) or otherwise, we request that Novartis is notified of the request and afforded the opportunity to submit objections to disclosure. Products were acquired from Alcon as portfolio. Product was on the market at the time of the acquisition. Acquisition of portfolio was finalized 8/27/2010. This is prior to the 5 year reporting period.
Rx0000073	Novartis	03/31/2019	00065026025	Travatan Z 0.00004 2.5mL	01/15/2019	13.62	183.87	10/13/2029	Single Source Drug	2415488	None	Increases in rate of inflation, continued investment in innovation, post-marketing regulatory commitments, ongoing pharmacovigilance, market conditions and dynamics	None	Not applicable	None	None	None	None	None	None	None	None	None	None	None	All information is provided by Novartis to the best of our knowledge at the time of submission. WAC is reported at the package level not the unit level. Novartis provides this report consistent with its understanding and interpretation of California SB 17 Chapter 603 Chapter 9 § 127681 and its provisions. In providing this report, Novartis does not waive any rights that it may have at law or in equity with respect to the applicability, interpretation, or application of California SB 17 Chapter 603 Chapter 9 § 127681 as it may relate to Novartis or any of its affiliates now or in the future. Novartis, on behalf of itself and affiliates, expressly reservesAll such rights. We believe that this submission and ofAll Novartis related information herein is confidential and proprietary, commercial or financial information not subject to disclosure, including under the California Public Records Act (Government Code Section 6250 et seq.) and applicable laws pertaining to trade secrets. We request that the confidentiality of this submission and ofAll Novartis’ related information herein be maintained to the maximum extent permitted by law. When any of this information is requested, whether under the California Public Records Act (Government Code Section 6250 et seq.) or otherwise, we request that Novartis is notified of the request and afforded the opportunity to submit objections to disclosure. Products were acquired from Alcon as portfolio. Product was on the market at the time of the acquisition. Acquisition of portfolio was finalized 8/27/2010. This is prior to the 5 year reporting period.
Rx0000073	Novartis	03/31/2019	00065026005	Travatan Z 0.00004 5mL	01/15/2019	27.24	367.72	10/13/2029	Single Source Drug	604258	None	Increases in rate of inflation, continued investment in innovation, post-marketing regulatory commitments, ongoing pharmacovigilance, market conditions and dynamics	None	Not applicable	None	None	None	None	None	None	None	None	None	None	None	All information is provided by Novartis to the best of our knowledge at the time of submission. WAC is reported at the package level not the unit level. Novartis provides this report consistent with its understanding and interpretation of California SB 17 Chapter 603 Chapter 9 § 127681 and its provisions. In providing this report, Novartis does not waive any rights that it may have at law or in equity with respect to the applicability, interpretation, or application of California SB 17 Chapter 603 Chapter 9 § 127681 as it may relate to Novartis or any of its affiliates now or in the future. Novartis, on behalf of itself and affiliates, expressly reservesAll such rights. We believe that this submission and ofAll Novartis related information herein is confidential and proprietary, commercial or financial information not subject to disclosure, including under the California Public Records Act (Government Code Section 6250 et seq.) and applicable laws pertaining to trade secrets. We request that the confidentiality of this submission and ofAll Novartis’ related information herein be maintained to the maximum extent permitted by law. When any of this information is requested, whether under the California Public Records Act (Government Code Section 6250 et seq.) or otherwise, we request that Novartis is notified of the request and afforded the opportunity to submit objections to disclosure. Products were acquired from Alcon as portfolio. Product was on the market at the time of the acquisition. Acquisition of portfolio was finalized 8/27/2010. This is prior to the 5 year reporting period.
Rx0000073	Novartis	03/31/2019	00078045605	Trileptal 150mg	01/15/2019	27.05	477.84	08/12/2018	Innovator Multiple Source Drug	9756	None	Increases in rate of inflation, continued investment in innovation, post-marketing regulatory commitments, ongoing pharmacovigilance, market conditions and dynamics	None	Not applicable	None	None	None	None	None	None	None	None	None	None	None	All information is provided by Novartis to the best of our knowledge at the time of submission. WAC is reported at the package level not the unit level. Novartis provides this report consistent with its understanding and interpretation of California SB 17 Chapter 603 Chapter 9 § 127681 and its provisions. In providing this report, Novartis does not waive any rights that it may have at law or in equity with respect to the applicability, interpretation, or application of California SB 17 Chapter 603 Chapter 9 § 127681 as it may relate to Novartis or any of its affiliates now or in the future. Novartis, on behalf of itself and affiliates, expressly reservesAll such rights. We believe that this submission and ofAll Novartis related information herein is confidential and proprietary, commercial or financial information not subject to disclosure, including under the California Public Records Act (Government Code Section 6250 et seq.) and applicable laws pertaining to trade secrets. We request that the confidentiality of this submission and ofAll Novartis’ related information herein be maintained to the maximum extent permitted by law. When any of this information is requested, whether under the California Public Records Act (Government Code Section 6250 et seq.) or otherwise, we request that Novartis is notified of the request and afforded the opportunity to submit objections to disclosure.
Rx0000073	Novartis	03/31/2019	00078033705	Trileptal 300mg	01/15/2019	49.40	872.71	08/12/2018	Innovator Multiple Source Drug	37237	None	Increases in rate of inflation, continued investment in innovation, post-marketing regulatory commitments, ongoing pharmacovigilance, market conditions and dynamics	None	Not applicable	None	None	None	None	None	None	None	None	None	None	None	All information is provided by Novartis to the best of our knowledge at the time of submission. WAC is reported at the package level not the unit level. Novartis provides this report consistent with its understanding and interpretation of California SB 17 Chapter 603 Chapter 9 § 127681 and its provisions. In providing this report, Novartis does not waive any rights that it may have at law or in equity with respect to the applicability, interpretation, or application of California SB 17 Chapter 603 Chapter 9 § 127681 as it may relate to Novartis or any of its affiliates now or in the future. Novartis, on behalf of itself and affiliates, expressly reservesAll such rights. We believe that this submission and ofAll Novartis related information herein is confidential and proprietary, commercial or financial information not subject to disclosure, including under the California Public Records Act (Government Code Section 6250 et seq.) and applicable laws pertaining to trade secrets. We request that the confidentiality of this submission and ofAll Novartis’ related information herein be maintained to the maximum extent permitted by law. When any of this information is requested, whether under the California Public Records Act (Government Code Section 6250 et seq.) or otherwise, we request that Novartis is notified of the request and afforded the opportunity to submit objections to disclosure.
Rx0000073	Novartis	03/31/2019	00078045705	Trileptal 600mg	01/15/2019	90.79	1603.97	08/12/2018	Innovator Multiple Source Drug	22874	None	Increases in rate of inflation, continued investment in innovation, post-marketing regulatory commitments, ongoing pharmacovigilance, market conditions and dynamics	None	Not applicable	None	None	None	None	None	None	None	None	None	None	None	All information is provided by Novartis to the best of our knowledge at the time of submission. WAC is reported at the package level not the unit level. Novartis provides this report consistent with its understanding and interpretation of California SB 17 Chapter 603 Chapter 9 § 127681 and its provisions. In providing this report, Novartis does not waive any rights that it may have at law or in equity with respect to the applicability, interpretation, or application of California SB 17 Chapter 603 Chapter 9 § 127681 as it may relate to Novartis or any of its affiliates now or in the future. Novartis, on behalf of itself and affiliates, expressly reservesAll such rights. We believe that this submission and ofAll Novartis related information herein is confidential and proprietary, commercial or financial information not subject to disclosure, including under the California Public Records Act (Government Code Section 6250 et seq.) and applicable laws pertaining to trade secrets. We request that the confidentiality of this submission and ofAll Novartis’ related information herein be maintained to the maximum extent permitted by law. When any of this information is requested, whether under the California Public Records Act (Government Code Section 6250 et seq.) or otherwise, we request that Novartis is notified of the request and afforded the opportunity to submit objections to disclosure.
Rx0000073	Novartis	03/31/2019	00078035752	Trileptal-Oral Susp 250ml	01/15/2019	22.75	401.99	06/19/2021	Innovator Multiple Source Drug	69063	None	Increases in rate of inflation, continued investment in innovation, post-marketing regulatory commitments, ongoing pharmacovigilance, market conditions and dynamics	None	Not applicable	None	None	None	None	None	None	None	None	None	None	None	All information is provided by Novartis to the best of our knowledge at the time of submission. WAC is reported at the package level not the unit level. Novartis provides this report consistent with its understanding and interpretation of California SB 17 Chapter 603 Chapter 9 § 127681 and its provisions. In providing this report, Novartis does not waive any rights that it may have at law or in equity with respect to the applicability, interpretation, or application of California SB 17 Chapter 603 Chapter 9 § 127681 as it may relate to Novartis or any of its affiliates now or in the future. Novartis, on behalf of itself and affiliates, expressly reservesAll such rights. We believe that this submission and ofAll Novartis related information herein is confidential and proprietary, commercial or financial information not subject to disclosure, including under the California Public Records Act (Government Code Section 6250 et seq.) and applicable laws pertaining to trade secrets. We request that the confidentiality of this submission and ofAll Novartis’ related information herein be maintained to the maximum extent permitted by law. When any of this information is requested, whether under the California Public Records Act (Government Code Section 6250 et seq.) or otherwise, we request that Novartis is notified of the request and afforded the opportunity to submit objections to disclosure.
Rx0000073	Novartis	03/31/2019	00078067119	Tykerb 250 mg	01/15/2019	448.18	7917.83	09/18/2029	Single Source Drug	13643	None	Increases in rate of inflation, continued investment in innovation, post-marketing regulatory commitments, ongoing pharmacovigilance, market conditions and dynamics	None	Not applicable	None	None	None	None	None	None	None	None	None	None	None	All information is provided by Novartis to the best of our knowledge at the time of submission. WAC is reported at the package level not the unit level. Novartis provides this report consistent with its understanding and interpretation of California SB 17 Chapter 603 Chapter 9 § 127681 and its provisions. In providing this report, Novartis does not waive any rights that it may have at law or in equity with respect to the applicability, interpretation, or application of California SB 17 Chapter 603 Chapter 9 § 127681 as it may relate to Novartis or any of its affiliates now or in the future. Novartis, on behalf of itself and affiliates, expressly reservesAll such rights. We believe that this submission and ofAll Novartis related information herein is confidential and proprietary, commercial or financial information not subject to disclosure, including under the California Public Records Act (Government Code Section 6250 et seq.) and applicable laws pertaining to trade secrets. We request that the confidentiality of this submission and ofAll Novartis’ related information herein be maintained to the maximum extent permitted by law. When any of this information is requested, whether under the California Public Records Act (Government Code Section 6250 et seq.) or otherwise, we request that Novartis is notified of the request and afforded the opportunity to submit objections to disclosure. Products were acquired from GSK as portfolio. Product was on the market at the time of the acquisition; this NDC was not.
Rx0000073	Novartis	03/31/2019	00065401303	Vigamox	01/15/2019	9.86	174.12	03/29/2020	Innovator Multiple Source Drug	370430	None	Increases in rate of inflation, continued investment in innovation, post-marketing regulatory commitments, ongoing pharmacovigilance, market conditions and dynamics	None	Not applicable	None	None	None	None	None	None	None	None	None	None	None	All information is provided by Novartis to the best of our knowledge at the time of submission. WAC is reported at the package level not the unit level. Novartis provides this report consistent with its understanding and interpretation of California SB 17 Chapter 603 Chapter 9 § 127681 and its provisions. In providing this report, Novartis does not waive any rights that it may have at law or in equity with respect to the applicability, interpretation, or application of California SB 17 Chapter 603 Chapter 9 § 127681 as it may relate to Novartis or any of its affiliates now or in the future. Novartis, on behalf of itself and affiliates, expressly reservesAll such rights. We believe that this submission and ofAll Novartis related information herein is confidential and proprietary, commercial or financial information not subject to disclosure, including under the California Public Records Act (Government Code Section 6250 et seq.) and applicable laws pertaining to trade secrets. We request that the confidentiality of this submission and ofAll Novartis’ related information herein be maintained to the maximum extent permitted by law. When any of this information is requested, whether under the California Public Records Act (Government Code Section 6250 et seq.) or otherwise, we request that Novartis is notified of the request and afforded the opportunity to submit objections to disclosure. Products were acquired from Alcon as portfolio. Product was on the market at the time of the acquisition. Acquisition of portfolio was finalized 8/27/2010. This is prior to the 5 year reporting period.
Rx0000073	Novartis	03/31/2019	00078067066	Votrient 200 mg	01/15/2019	968.78	13078.52	12/19/2021	Single Source Drug	42635	None	Increases in rate of inflation, continued investment in innovation, post-marketing regulatory commitments, ongoing pharmacovigilance, market conditions and dynamics	None	Not applicable	None	None	None	None	None	None	None	None	None	None	None	All information is provided by Novartis to the best of our knowledge at the time of submission. WAC is reported at the package level not the unit level. Novartis provides this report consistent with its understanding and interpretation of California SB 17 Chapter 603 Chapter 9 § 127681 and its provisions. In providing this report, Novartis does not waive any rights that it may have at law or in equity with respect to the applicability, interpretation, or application of California SB 17 Chapter 603 Chapter 9 § 127681 as it may relate to Novartis or any of its affiliates now or in the future. Novartis, on behalf of itself and affiliates, expressly reservesAll such rights. We believe that this submission and ofAll Novartis related information herein is confidential and proprietary, commercial or financial information not subject to disclosure, including under the California Public Records Act (Government Code Section 6250 et seq.) and applicable laws pertaining to trade secrets. We request that the confidentiality of this submission and ofAll Novartis’ related information herein be maintained to the maximum extent permitted by law. When any of this information is requested, whether under the California Public Records Act (Government Code Section 6250 et seq.) or otherwise, we request that Novartis is notified of the request and afforded the opportunity to submit objections to disclosure. Products were acquired from GSK as portfolio. Product was on the market at the time of the acquisition; this NDC was not.
Rx0000073	Novartis	12/31/2019	54092060601	Xiidra 50mg/mL	12/03/2019	31.33	553.54	07/25/2033	Single Source Drug	218077	None	Increases in rate of inflation, continued investment in innovation, post-marketing regulatory commitments, ongoing pharmacovigilance, market conditions and dynamics	None	Not applicable	None	06/30/2019	Takada/Shire	5300000000	None	None	522.21	507.00	2016	426.73	None	All information is provided by Novartis to the best of our knowledge at the time of submission. WAC is reported at the package level not the unit level. Novartis provides this report consistent with its understanding and interpretation of California SB 17 Chapter 603 Chapter 9 § 127681 and its provisions. In providing this report, Novartis does not waive any rights that it may have at law or in equity with respect to the applicability, interpretation, or application of California SB 17 Chapter 603 Chapter 9 § 127681 as it may relate to Novartis or any of its affiliates now or in the future. Novartis, on behalf of itself and affiliates, expressly reserves all such rights. We believe that this submission and of all Novartis related information herein is confidential and proprietary, commercial or financial information not subject to disclosure, including under the California Public Records Act (Government Code Section 6250 et seq.) and applicable laws pertaining to trade secrets. We request that the confidentiality of this submission and of all Novartis’ related information herein be maintained to the maximum extent permitted by law. When any of this information is requested, whether under the California Public Records Act (Government Code Section 6250 et seq.) or otherwise, we request that Novartis is notified of the request and afforded the opportunity to submit objections to disclosure.
Rx0000073	Novartis	03/31/2019	00078064070	Zykadia 150mg	01/15/2019	464.62	8208.31	02/02/2032	Single Source Drug	3452	None	Increases in rate of inflation, continued investment in innovation, post-marketing regulatory commitments, ongoing pharmacovigilance, market conditions and dynamics	None	Not applicable	None	None	None	None	None	None	None	None	None	None	None	All information is provided by Novartis to the best of our knowledge at the time of submission. WAC is reported at the package level not the unit level. Novartis provides this report consistent with its understanding and interpretation of California SB 17 Chapter 603 Chapter 9 § 127681 and its provisions. In providing this report, Novartis does not waive any rights that it may have at law or in equity with respect to the applicability, interpretation, or application of California SB 17 Chapter 603 Chapter 9 § 127681 as it may relate to Novartis or any of its affiliates now or in the future. Novartis, on behalf of itself and affiliates, expressly reservesAll such rights. We believe that this submission and ofAll Novartis related information herein is confidential and proprietary, commercial or financial information not subject to disclosure, including under the California Public Records Act (Government Code Section 6250 et seq.) and applicable laws pertaining to trade secrets. We request that the confidentiality of this submission and ofAll Novartis’ related information herein be maintained to the maximum extent permitted by law. When any of this information is requested, whether under the California Public Records Act (Government Code Section 6250 et seq.) or otherwise, we request that Novartis is notified of the request and afforded the opportunity to submit objections to disclosure.
Rx0000017	Noven Therapeutics, LLC	03/31/2019	68968051408	Estradiol & Norethindrone Acetate 0.05-0.14 MG/DAY Patch Twice Weekly 8 EA UU	01/01/2019	17.26	191.61	None	Single Source Drug	None	1	None	1	None	1	08/13/2014	Novartis	None	1	Not a matter of public record	80.50	None	1998	23.75	https://reports.siera.oshpd.ca.gov/api/report/drug-pricing/attachment?id=34	No existing patents WAC at Intro to market for Combipatch, which was launched in 1998, is not available to us. The first listing of WAC price we could find in PriceRx was as follows: Combipatch 0.05 mg-0.14 mg - 68968051408 (which was originally Sanofi Aventis-labeled as 00075051408) had a WAC of $23.75 on 9/17/98. We acquired this product on 8/13/2014. The WAC upon acquisition was $80.50. One full year before we acquired this product, the WAC was $70.06
Rx0000017	Noven Therapeutics, LLC	03/31/2019	68968052508	Estradiol & Norethindrone Acetate 0.05-0.25 MG/DAY Patch Twice Weekly 8 EA UU	01/01/2019	17.26	191.61	None	Single Source Drug	None	1	None	1	None	1	08/13/2014	Novartis	None	1	Not a matter of public record.	80.40	None	1998	23.75	https://reports.siera.oshpd.ca.gov/api/report/drug-pricing/attachment?id=35	No existing patents WAC at Intro to market for Combipatch, which was launched in 1998, is not available to us. The first listing of WAC price we could find in PriceRx was as follows: Combipatch 0.05 mg-0.25 mg - 68968052508 (which was oringianally Sanofi Aventis-labeled as 00075052508) had a WAC of $23.75 on 11/23/98. We acquired this product on 8/13/2014. The WAC upon acquisition was $80.40. One full year before we acquired this product, the WAC was $69.97.
Rx0000017	Noven Therapeutics, LLC	03/31/2019	68968555203	Methylphenidate 10 MG/9HR Patch 30 EA UU	01/01/2019	28.98	362.12	10/07/2025	Single Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	Multiple patents - listed most distant. Drug was developed by Noven.
Rx0000017	Noven Therapeutics, LLC	03/31/2019	68968555203	Methylphenidate 10 MG/9HR Patch 30 EA UU	01/15/2019	4.00	366.12	10/07/2025	Single Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	https://reports.siera.oshpd.ca.gov/api/report/drug-pricing/attachment?id=36	Multiple patents - listed most distant. Drug was developed by Noven.
Rx0000017	Noven Therapeutics, LLC	03/31/2019	68968555303	Methylphenidate 15 MG/9HR Patch 30 EA UU	01/01/2019	28.98	362.12	10/07/2025	Single Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	Multiple patents - listed most distant. Drug was developed by Noven.
Rx0000017	Noven Therapeutics, LLC	03/31/2019	68968555303	Methylphenidate 15 MG/9HR Patch 30 EA UU	01/15/2019	4.00	366.12	10/07/2025	Single Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	https://reports.siera.oshpd.ca.gov/api/report/drug-pricing/attachment?id=37	Multiple patents - listed most distant. Drug was developed by Noven.
Rx0000017	Noven Therapeutics, LLC	03/31/2019	68968555403	Methylphenidate 20 MG/9HR Patch 30 EA UU	01/01/2019	28.98	362.12	10/07/2025	Single Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	Multiple patents - listed most distant. Drug was developed by Noven.
Rx0000017	Noven Therapeutics, LLC	03/31/2019	68968555403	Methylphenidate 20 MG/9HR Patch 30 EA UU	01/15/2019	4.00	366.12	10/07/2025	Single Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	https://reports.siera.oshpd.ca.gov/api/report/drug-pricing/attachment?id=38	Multiple patents - listed most distant. Drug was developed by Noven.
Rx0000017	Noven Therapeutics, LLC	03/31/2019	68968555503	Methylphenidate 30 MG/9HR Patch 30 EA UU	01/01/2019	28.98	362.12	10/07/2025	Single Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	Multiple patents - listed most distant. Drug was developed by Noven.
Rx0000017	Noven Therapeutics, LLC	03/31/2019	68968555503	Methylphenidate 30 MG/9HR Patch 30 EA UU	01/15/2019	4.00	366.12	10/07/2025	Single Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	https://reports.siera.oshpd.ca.gov/api/report/drug-pricing/attachment?id=39	Multiple patents - listed most distant. Drug was developed by Noven.
Rx0000033	Novo	03/31/2019	00169406012	Victoza? 6mg/mL 2x3mL	01/08/2019	34.26	614.52	08/22/2022	Single Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	NNI holds a number of patents related to Victoza. We've included the expiration date for Patent #6268343 which is the compound patent for Victoza. NNI has applied for pediatric exclusivity. If granted, this will add 6 months to all Orange Book exclusivities. NNI is the original manufacturer of this product (Victoza) and did not acquire the product from a different company.
Rx0000033	Novo	03/31/2019	00169406013	Victoza? 6mg/mL 3x3mL	01/08/2019	51.39	921.78	08/22/2022	Single Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	NNI holds a number of patents related to Victoza. We've included the expiration date for Patent #6268343 which is the compound patent for Victoza. NNI has applied for pediatric exclusivity. If granted, this will add 6 months to all Orange Book exclusivities. NNI is the original manufacturer of this product (Victoza) and did not acquire the product from a different company.
Rx0000197	OPKO Pharmaceutucals, LLC	03/31/2019	70301100101	Rayaldee (calcifediol) 30 mcg ER capsules 30 count bottle	01/21/2019	89.00	1082.00	03/14/2034	Single Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	OPKO did not acquire this drug within the last five years.
Rx0000197	OPKO Pharmaceutucals, LLC	03/31/2019	70301100102	Rayaldee (calcifediol) 30 mcg ER capsules 60 count bottle	01/21/2019	178.00	2164.00	03/14/2034	Single Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	OPKO did not acquire this drug within the last five years.
Rx0000067	Otsuka America Pharmaceutical, Inc.	06/30/2019	59148004580	Abilify Maintena 300mg DCS	04/01/2019	81.24	1706.05	10/19/2024	Single Source Drug	None	1	Otsuka is committed to making responsible pricing determinations for our products, including ABILIFY MAINTENA®, and in so doing we consider a range of factors. Otsuka continues to concentrate on areas of unmet medical need in mental health, and cardio-renal. As a general matter, our WAC determinations are influenced by research and development costs (including investments in product and portfolio innovation); manufacturing, distribution, and regulatory costs; market and competitive factors; downstream demands for price concessions/rebates; value to patients and the health care system; and access and affordability. Pricing decisions at Otsuka are made at the executive level in adherence with all federal and state laws. These decisions and underlying considerations are proprietary, and Otsuka does not believe this information is in the public domain or otherwise publicly available. As a result, Otsuka is limiting its response pursuant to Cal. Health and Safety Code § 127679 (b).	None	None	1	None	None	None	None	None	None	None	None	None	None	ABILIFY MAINTENA® was developed by Otsuka.
Rx0000067	Otsuka America Pharmaceutical, Inc.	06/30/2019	59148001871	Abilify Maintena 300mg Kit	04/01/2019	81.24	1706.05	10/19/2024	Single Source Drug	None	1	Otsuka is committed to making responsible pricing determinations for our products, including ABILIFY MAINTENA®, and in so doing we consider a range of factors. Otsuka continues to concentrate on areas of unmet medical need in mental health, and cardio-renal. As a general matter, our WAC determinations are influenced by research and development costs (including investments in product and portfolio innovation); manufacturing, distribution, and regulatory costs; market and competitive factors; downstream demands for price concessions/rebates; value to patients and the health care system; and access and affordability. Pricing decisions at Otsuka are made at the executive level in adherence with all federal and state laws. These decisions and underlying considerations are proprietary, and Otsuka does not believe this information is in the public domain or otherwise publicly available. As a result, Otsuka is limiting its response pursuant to Cal. Health and Safety Code § 127679 (b).	None	None	1	None	None	None	None	None	None	None	None	None	None	ABILIFY MAINTENA® was developed by Otsuka.
Rx0000067	Otsuka America Pharmaceutical, Inc.	06/30/2019	59148007280	Abilify Maintena 400mg DCS	04/01/2019	108.32	2274.73	10/19/2024	Single Source Drug	None	1	Otsuka is committed to making responsible pricing determinations for our products, including ABILIFY MAINTENA®, and in so doing we consider a range of factors. Otsuka continues to concentrate on areas of unmet medical need in mental health, and cardio-renal. As a general matter, our WAC determinations are influenced by research and development costs (including investments in product and portfolio innovation); manufacturing, distribution, and regulatory costs; market and competitive factors; downstream demands for price concessions/rebates; value to patients and the health care system; and access and affordability. Pricing decisions at Otsuka are made at the executive level in adherence with all federal and state laws. These decisions and underlying considerations are proprietary, and Otsuka does not believe this information is in the public domain or otherwise publicly available. As a result, Otsuka is limiting its response pursuant to Cal. Health and Safety Code § 127679 (b).	None	None	1	None	None	None	None	None	None	None	None	None	None	ABILIFY MAINTENA® was developed by Otsuka.
Rx0000067	Otsuka America Pharmaceutical, Inc.	06/30/2019	59148001971	Abilify Maintena 400mg Kit	04/01/2019	108.32	2274.73	10/19/2024	Single Source Drug	None	1	Otsuka is committed to making responsible pricing determinations for our products, including ABILIFY MAINTENA®, and in so doing we consider a range of factors. Otsuka continues to concentrate on areas of unmet medical need in mental health, and cardio-renal. As a general matter, our WAC determinations are influenced by research and development costs (including investments in product and portfolio innovation); manufacturing, distribution, and regulatory costs; market and competitive factors; downstream demands for price concessions/rebates; value to patients and the health care system; and access and affordability. Pricing decisions at Otsuka are made at the executive level in adherence with all federal and state laws. These decisions and underlying considerations are proprietary, and Otsuka does not believe this information is in the public domain or otherwise publicly available. As a result, Otsuka is limiting its response pursuant to Cal. Health and Safety Code § 127679 (b).	None	None	1	None	None	None	None	None	None	None	None	None	None	ABILIFY MAINTENA® was developed by Otsuka.
Rx0000067	Otsuka America Pharmaceutical, Inc.	06/30/2019	59148003513	Rexulti 0.25mg tablets 30 count bottle	04/01/2019	55.47	1164.89	04/12/2026	Single Source Drug	None	1	Otsuka is committed to making responsible pricing determinations for our products, including REXULTI ®, and in so doing we consider a range of factors. Otsuka continues to concentrate on areas of unmet medical need in mental health, and cardio-renal. As a general matter, our WAC determinations are influenced by research and development costs (including investments in product and portfolio innovation); manufacturing, distribution, and regulatory costs; market and competitive factors; downstream demands for price concessions/rebates; value to patients and the health care system; and access and affordability. Pricing decisions at Otsuka are made at the executive level in adherence with all federal and state laws. These decisions and underlying considerations are proprietary, and Otsuka does not believe this information is in the public domain or otherwise publicly available. As a result, Otsuka is limiting its response pursuant to Cal. Health and Safety Code § 127679 (b).	None	None	1	None	None	None	None	None	None	None	None	None	None	REXULTI® was developed by Otsuka. The patent for REXULTI® expires on April 12, 2026 but could be extended to 4Q 2028 if the patent term extension is granted by the US Patent Office.
Rx0000067	Otsuka America Pharmaceutical, Inc.	06/30/2019	59148003613	Rexulti 0.5mg tablets 30 count bottle	04/01/2019	55.47	1164.89	04/12/2026	Single Source Drug	None	1	Otsuka is committed to making responsible pricing determinations for our products, including REXULTI ®, and in so doing we consider a range of factors. Otsuka continues to concentrate on areas of unmet medical need in mental health, and cardio-renal. As a general matter, our WAC determinations are influenced by research and development costs (including investments in product and portfolio innovation); manufacturing, distribution, and regulatory costs; market and competitive factors; downstream demands for price concessions/rebates; value to patients and the health care system; and access and affordability. Pricing decisions at Otsuka are made at the executive level in adherence with all federal and state laws. These decisions and underlying considerations are proprietary, and Otsuka does not believe this information is in the public domain or otherwise publicly available. As a result, Otsuka is limiting its response pursuant to Cal. Health and Safety Code § 127679 (b).	None	None	1	None	None	None	None	None	None	None	None	None	None	REXULTI® was developed by Otsuka. The patent for REXULTI® expires on April 12, 2026 but could be extended to 4Q 2028 if the patent term extension is granted by the US Patent Office.
Rx0000067	Otsuka America Pharmaceutical, Inc.	06/30/2019	59148003713	Rexulti 1mg tablets 30 count bottle	04/01/2019	55.47	1164.89	04/12/2026	Single Source Drug	None	1	Otsuka is committed to making responsible pricing determinations for our products, including REXULTI ®, and in so doing we consider a range of factors. Otsuka continues to concentrate on areas of unmet medical need in mental health, and cardio-renal. As a general matter, our WAC determinations are influenced by research and development costs (including investments in product and portfolio innovation); manufacturing, distribution, and regulatory costs; market and competitive factors; downstream demands for price concessions/rebates; value to patients and the health care system; and access and affordability. Pricing decisions at Otsuka are made at the executive level in adherence with all federal and state laws. These decisions and underlying considerations are proprietary, and Otsuka does not believe this information is in the public domain or otherwise publicly available. As a result, Otsuka is limiting its response pursuant to Cal. Health and Safety Code § 127679 (b).	None	None	1	None	None	None	None	None	None	None	None	None	None	REXULTI® was developed by Otsuka. The patent for REXULTI® expires on April 12, 2026 but could be extended to 4Q 2028 if the patent term extension is granted by the US Patent Office.
Rx0000067	Otsuka America Pharmaceutical, Inc.	06/30/2019	59148003813	Rexulti 2mg tablets 30 count bottle	04/01/2019	55.47	1164.89	04/12/2026	Single Source Drug	None	1	Otsuka is committed to making responsible pricing determinations for our products, including REXULTI ®, and in so doing we consider a range of factors. Otsuka continues to concentrate on areas of unmet medical need in mental health, and cardio-renal. As a general matter, our WAC determinations are influenced by research and development costs (including investments in product and portfolio innovation); manufacturing, distribution, and regulatory costs; market and competitive factors; downstream demands for price concessions/rebates; value to patients and the health care system; and access and affordability. Pricing decisions at Otsuka are made at the executive level in adherence with all federal and state laws. These decisions and underlying considerations are proprietary, and Otsuka does not believe this information is in the public domain or otherwise publicly available. As a result, Otsuka is limiting its response pursuant to Cal. Health and Safety Code § 127679 (b).	None	None	1	None	None	None	None	None	None	None	None	None	None	REXULTI® was developed by Otsuka. The patent for REXULTI® expires on April 12, 2026 but could be extended to 4Q 2028 if the patent term extension is granted by the US Patent Office.
Rx0000067	Otsuka America Pharmaceutical, Inc.	06/30/2019	59148003913	Rexulti 3mg tablets 30 count bottle	04/01/2019	55.47	1164.89	04/12/2026	Single Source Drug	None	1	Otsuka is committed to making responsible pricing determinations for our products, including REXULTI ®, and in so doing we consider a range of factors. Otsuka continues to concentrate on areas of unmet medical need in mental health, and cardio-renal. As a general matter, our WAC determinations are influenced by research and development costs (including investments in product and portfolio innovation); manufacturing, distribution, and regulatory costs; market and competitive factors; downstream demands for price concessions/rebates; value to patients and the health care system; and access and affordability. Pricing decisions at Otsuka are made at the executive level in adherence with all federal and state laws. These decisions and underlying considerations are proprietary, and Otsuka does not believe this information is in the public domain or otherwise publicly available. As a result, Otsuka is limiting its response pursuant to Cal. Health and Safety Code § 127679 (b).	None	None	1	None	None	None	None	None	None	None	None	None	None	REXULTI® was developed by Otsuka. The patent for REXULTI® expires on April 12, 2026 but could be extended to 4Q 2028 if the patent term extension is granted by the US Patent Office.
Rx0000067	Otsuka America Pharmaceutical, Inc.	06/30/2019	59148004013	Rexulti 4mg tablets 30 count bottle	04/01/2019	55.47	1164.89	04/12/2026	Single Source Drug	None	1	Otsuka is committed to making responsible pricing determinations for our products, including REXULTI ®, and in so doing we consider a range of factors. Otsuka continues to concentrate on areas of unmet medical need in mental health, and cardio-renal. As a general matter, our WAC determinations are influenced by research and development costs (including investments in product and portfolio innovation); manufacturing, distribution, and regulatory costs; market and competitive factors; downstream demands for price concessions/rebates; value to patients and the health care system; and access and affordability. Pricing decisions at Otsuka are made at the executive level in adherence with all federal and state laws. These decisions and underlying considerations are proprietary, and Otsuka does not believe this information is in the public domain or otherwise publicly available. As a result, Otsuka is limiting its response pursuant to Cal. Health and Safety Code § 127679 (b).	None	None	1	None	None	None	None	None	None	None	None	None	None	REXULTI® was developed by Otsuka. The patent for REXULTI® expires on April 12, 2026 but could be extended to 4Q 2028 if the patent term extension is granted by the US Patent Office.
Rx0000067	Otsuka America Pharmaceutical, Inc.	03/31/2019	59148002050	Samsca 15mg tablets (blister pack of 10)	01/15/2019	214.67	4507.97	None	Single Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	https://reports.siera.oshpd.ca.gov/api/report/drug-pricing/attachment?id=50	please see attached document for additional information.
Rx0000067	Otsuka America Pharmaceutical, Inc.	03/31/2019	59148002150	Samsca 30mg tablets (blister pack of 10)	01/15/2019	222.69	4676.49	None	Single Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	https://reports.siera.oshpd.ca.gov/api/report/drug-pricing/attachment?id=51	please see attached document for additional information
Rx0000101	Par Pharmaceutical	12/31/2019	42023010301	Adrenalin, Nasal Solution 0.1%, 30 mL, Bottle	11/13/2019	41.76	250.57	None	Non-innovator Multiple Source Drug	None	1	None	1	The price increase was not necessitated by a change or improvement in the drug.	None	None	None	None	None	None	None	None	None	None	None	The information contained in this report is subject to the following limitations and assumptions. (1) Consistent with the relevant statutes and regulations, all information contained in this report is limited to that which Par believes is otherwise in the public domain or publicly available. (2) The Orange Book indicates that, as of 1/17/2020, the Orange Book database does not contain unexpired patents for this product. As a result, Par has left the patent expiration date field for this product blank. (3) Par did not acquire this product from another manufacturer within the previous five years (i.e., sixty months). As a result, Endo has left columns N-U blank because they are not applicable to this product.
Rx0000101	Par Pharmaceutical	06/30/2019	42023017905	Buprenorphine HCl, Injection 0.3 mg/mL 5vl	05/08/2019	8.88	68.10	None	Non-innovator Multiple Source Drug	None	1	None	1	The price increase was not necessitated by a change or improvement in the drug	None	None	None	None	None	None	None	None	None	None	None	The information contained in this report is subject to the following limitations and assumptions. (1) Consistent with the relevant statutes and regulations, all information contained in this report is limited to that which Endo believes is otherwise in the public domain or publicly available. (2) The Orange Book indicates that, as of 8/2/19, the Orange Book database does not contain unexpired patents for this product. As a result, Endo has left the “Patent Expiration Date” field for this product blank. (3) Endo did not acquire this product from another manufacturer. As a result, Endo has left columns N-U blank because they are not applicable to this product.
Rx0000209	Parsolex GMP Center, Inc.	03/31/2019	13845120202	CycloSERINE Capsules, USP 250 mg, 30 capsules per blister pack	02/07/2019	274.00	2090.00	None	Single Source Drug	None	1	None	1	None	None	None	None	None	None	None	None	None	None	None	None	Parsolex is a privately held corporation and, pursuant to applicable law and regulation, has limited the information submitted herein to that which is otherwise in the public domain or publicly available. Parsolex has accordingly marked the “Unit Sales Volume US” and “Cost Increase Factors” fields as non-public. Parsolex has left the “Patent Expiration Date” field blank, because there is none. Parsolex also has left columns 14 through 22 intentionally blank for this submission, as the drug product was not acquired from another manufacturer within the last 5 years.
Rx0000006	Pfizer	03/31/2019	00069046856	Chantix, 0.5 mg Tablet, 56's	01/15/2019	20.06	421.31	08/03/2022	Single Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	The information contained in this report is subject to the following limitations and assumptions. (1) Consistent with the relevant statutes and regulations, all information contained in this report is limited to that which Pfizer believes is otherwise in the public domain or publicly available. Where possible, Pfizer has used the non-public indicator to indicate it does not believe the corresponding data element is otherwise in the public domain or publicly available. (2) For Column 6, Pfizer did not provide a patent expiration date for products that have lost patent exclusivity. (3) For Columns 14-21, Pfizer has not provided a response for products that were not acquired from an unrelated company in the previous 5 years. (4) While Pfizer does not believe factors for a specific drug product’s price increases are in the public domain or publicly available, Pfizer has provided general information about its drug pricing philosophy and policy. More information about Pfizer’s general drug pricing philosophy and policy is available on Pfizer’s website.
Rx0000006	Pfizer	03/31/2019	00069046956	Chantix, 1 mg Tablet, 56's	01/15/2019	20.06	421.31	08/03/2022	Single Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	The information contained in this report is subject to the following limitations and assumptions. (1) Consistent with the relevant statutes and regulations, all information contained in this report is limited to that which Pfizer believes is otherwise in the public domain or publicly available. Where possible, Pfizer has used the non-public indicator to indicate it does not believe the corresponding data element is otherwise in the public domain or publicly available. (2) For Column 6, Pfizer did not provide a patent expiration date for products that have lost patent exclusivity. (3) For Columns 14-21, Pfizer has not provided a response for products that were not acquired from an unrelated company in the previous 5 years. (4) While Pfizer does not believe factors for a specific drug product’s price increases are in the public domain or publicly available, Pfizer has provided general information about its drug pricing philosophy and policy. More information about Pfizer’s general drug pricing philosophy and policy is available on Pfizer’s website.
Rx0000006	Pfizer	03/31/2019	00069046903	Chantix, Continuing Month Box - 1 mg Tablet (4 Continuing weeks), (1x56)	01/15/2019	20.06	421.31	08/03/2022	Single Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	The information contained in this report is subject to the following limitations and assumptions. (1) Consistent with the relevant statutes and regulations, all information contained in this report is limited to that which Pfizer believes is otherwise in the public domain or publicly available. Where possible, Pfizer has used the non-public indicator to indicate it does not believe the corresponding data element is otherwise in the public domain or publicly available. (2) For Column 6, Pfizer did not provide a patent expiration date for products that have lost patent exclusivity. (3) For Columns 14-21, Pfizer has not provided a response for products that were not acquired from an unrelated company in the previous 5 years. (4) While Pfizer does not believe factors for a specific drug product’s price increases are in the public domain or publicly available, Pfizer has provided general information about its drug pricing philosophy and policy. More information about Pfizer’s general drug pricing philosophy and policy is available on Pfizer’s website.
Rx0000006	Pfizer	03/31/2019	00069047103	Chantix, Starting Month Box - 0.5 mg Tablet (1 Starting Week) & 1 mg Tablet (3 Continuing Weeks), (1x11) & 3 (1x42)	01/15/2019	20.06	421.31	08/03/2022	Single Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	The information contained in this report is subject to the following limitations and assumptions. (1) Consistent with the relevant statutes and regulations, all information contained in this report is limited to that which Pfizer believes is otherwise in the public domain or publicly available. Where possible, Pfizer has used the non-public indicator to indicate it does not believe the corresponding data element is otherwise in the public domain or publicly available. (2) For Column 6, Pfizer did not provide a patent expiration date for products that have lost patent exclusivity. (3) For Columns 14-21, Pfizer has not provided a response for products that were not acquired from an unrelated company in the previous 5 years. (4) While Pfizer does not believe factors for a specific drug product’s price increases are in the public domain or publicly available, Pfizer has provided general information about its drug pricing philosophy and policy. More information about Pfizer’s general drug pricing philosophy and policy is available on Pfizer’s website.
Rx0000006	Pfizer	03/31/2019	00071036940	Dilantin, 100 mg Capsule Unit Dose Pak, (10x10)	01/15/2019	6.82	143.16	None	Non-innovator Multiple Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	The information contained in this report is subject to the following limitations and assumptions. (1) Consistent with the relevant statutes and regulations, all information contained in this report is limited to that which Pfizer believes is otherwise in the public domain or publicly available. Where possible, Pfizer has used the non-public indicator to indicate it does not believe the corresponding data element is otherwise in the public domain or publicly available. (2) For Column 6, Pfizer did not provide a patent expiration date for products that have lost patent exclusivity. (3) For Columns 14-21, Pfizer has not provided a response for products that were not acquired from an unrelated company in the previous 5 years. (4) While Pfizer does not believe factors for a specific drug product’s price increases are in the public domain or publicly available, Pfizer has provided general information about its drug pricing philosophy and policy. More information about Pfizer’s general drug pricing philosophy and policy is available on Pfizer’s website.
Rx0000006	Pfizer	03/31/2019	00071036932	Dilantin, 100 mg Capsule, 1000's	01/15/2019	61.78	1297.29	None	Non-innovator Multiple Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	The information contained in this report is subject to the following limitations and assumptions. (1) Consistent with the relevant statutes and regulations, all information contained in this report is limited to that which Pfizer believes is otherwise in the public domain or publicly available. Where possible, Pfizer has used the non-public indicator to indicate it does not believe the corresponding data element is otherwise in the public domain or publicly available. (2) For Column 6, Pfizer did not provide a patent expiration date for products that have lost patent exclusivity. (3) For Columns 14-21, Pfizer has not provided a response for products that were not acquired from an unrelated company in the previous 5 years. (4) While Pfizer does not believe factors for a specific drug product’s price increases are in the public domain or publicly available, Pfizer has provided general information about its drug pricing philosophy and policy. More information about Pfizer’s general drug pricing philosophy and policy is available on Pfizer’s website.
Rx0000006	Pfizer	03/31/2019	00071036924	Dilantin, 100 mg Capsule, 100's	01/15/2019	6.18	129.73	None	Non-innovator Multiple Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	The information contained in this report is subject to the following limitations and assumptions. (1) Consistent with the relevant statutes and regulations, all information contained in this report is limited to that which Pfizer believes is otherwise in the public domain or publicly available. Where possible, Pfizer has used the non-public indicator to indicate it does not believe the corresponding data element is otherwise in the public domain or publicly available. (2) For Column 6, Pfizer did not provide a patent expiration date for products that have lost patent exclusivity. (3) For Columns 14-21, Pfizer has not provided a response for products that were not acquired from an unrelated company in the previous 5 years. (4) While Pfizer does not believe factors for a specific drug product’s price increases are in the public domain or publicly available, Pfizer has provided general information about its drug pricing philosophy and policy. More information about Pfizer’s general drug pricing philosophy and policy is available on Pfizer’s website.
Rx0000006	Pfizer	03/31/2019	00071374066	Dilantin, 30 mg Capsule, 100's	01/15/2019	5.33	111.86	None	Non-innovator Multiple Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	The information contained in this report is subject to the following limitations and assumptions. (1) Consistent with the relevant statutes and regulations, all information contained in this report is limited to that which Pfizer believes is otherwise in the public domain or publicly available. Where possible, Pfizer has used the non-public indicator to indicate it does not believe the corresponding data element is otherwise in the public domain or publicly available. (2) For Column 6, Pfizer did not provide a patent expiration date for products that have lost patent exclusivity. (3) For Columns 14-21, Pfizer has not provided a response for products that were not acquired from an unrelated company in the previous 5 years. (4) While Pfizer does not believe factors for a specific drug product’s price increases are in the public domain or publicly available, Pfizer has provided general information about its drug pricing philosophy and policy. More information about Pfizer’s general drug pricing philosophy and policy is available on Pfizer’s website.
Rx0000006	Pfizer	03/31/2019	00071000740	Dilantin, 50 mg Infatabs Unit Dose Pak, (10x10)	01/15/2019	8.21	172.41	None	Non-innovator Multiple Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	The information contained in this report is subject to the following limitations and assumptions. (1) Consistent with the relevant statutes and regulations, all information contained in this report is limited to that which Pfizer believes is otherwise in the public domain or publicly available. Where possible, Pfizer has used the non-public indicator to indicate it does not believe the corresponding data element is otherwise in the public domain or publicly available. (2) For Column 6, Pfizer did not provide a patent expiration date for products that have lost patent exclusivity. (3) For Columns 14-21, Pfizer has not provided a response for products that were not acquired from an unrelated company in the previous 5 years. (4) While Pfizer does not believe factors for a specific drug product’s price increases are in the public domain or publicly available, Pfizer has provided general information about its drug pricing philosophy and policy. More information about Pfizer’s general drug pricing philosophy and policy is available on Pfizer’s website.
Rx0000006	Pfizer	03/31/2019	00071000724	Dilantin, 50 mg Infatabs, 100's	01/15/2019	5.79	121.56	None	Non-innovator Multiple Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	The information contained in this report is subject to the following limitations and assumptions. (1) Consistent with the relevant statutes and regulations, all information contained in this report is limited to that which Pfizer believes is otherwise in the public domain or publicly available. Where possible, Pfizer has used the non-public indicator to indicate it does not believe the corresponding data element is otherwise in the public domain or publicly available. (2) For Column 6, Pfizer did not provide a patent expiration date for products that have lost patent exclusivity. (3) For Columns 14-21, Pfizer has not provided a response for products that were not acquired from an unrelated company in the previous 5 years. (4) While Pfizer does not believe factors for a specific drug product’s price increases are in the public domain or publicly available, Pfizer has provided general information about its drug pricing philosophy and policy. More information about Pfizer’s general drug pricing philosophy and policy is available on Pfizer’s website.
Rx0000006	Pfizer	03/31/2019	00071221420	Dilantin-125, 125 mg/5 mL Bottle, 8 oz	01/15/2019	7.70	161.69	None	Innovator Multiple Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	The information contained in this report is subject to the following limitations and assumptions. (1) Consistent with the relevant statutes and regulations, all information contained in this report is limited to that which Pfizer believes is otherwise in the public domain or publicly available. Where possible, Pfizer has used the non-public indicator to indicate it does not believe the corresponding data element is otherwise in the public domain or publicly available. (2) For Column 6, Pfizer did not provide a patent expiration date for products that have lost patent exclusivity. (3) For Columns 14-21, Pfizer has not provided a response for products that were not acquired from an unrelated company in the previous 5 years. (4) While Pfizer does not believe factors for a specific drug product’s price increases are in the public domain or publicly available, Pfizer has provided general information about its drug pricing philosophy and policy. More information about Pfizer’s general drug pricing philosophy and policy is available on Pfizer’s website.
Rx0000006	Pfizer	03/31/2019	00008083621	Effexor XR, 150 mg Capsule Extended Release, 30's	01/15/2019	22.99	482.88	None	Innovator Multiple Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	The information contained in this report is subject to the following limitations and assumptions. (1) Consistent with the relevant statutes and regulations, all information contained in this report is limited to that which Pfizer believes is otherwise in the public domain or publicly available. Where possible, Pfizer has used the non-public indicator to indicate it does not believe the corresponding data element is otherwise in the public domain or publicly available. (2) For Column 6, Pfizer did not provide a patent expiration date for products that have lost patent exclusivity. (3) For Columns 14-21, Pfizer has not provided a response for products that were not acquired from an unrelated company in the previous 5 years. (4) While Pfizer does not believe factors for a specific drug product’s price increases are in the public domain or publicly available, Pfizer has provided general information about its drug pricing philosophy and policy. More information about Pfizer’s general drug pricing philosophy and policy is available on Pfizer’s website.
Rx0000006	Pfizer	03/31/2019	00008083622	Effexor XR, 150 mg Capsule Extended Release, 90's	01/15/2019	68.99	1448.73	None	Innovator Multiple Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	The information contained in this report is subject to the following limitations and assumptions. (1) Consistent with the relevant statutes and regulations, all information contained in this report is limited to that which Pfizer believes is otherwise in the public domain or publicly available. Where possible, Pfizer has used the non-public indicator to indicate it does not believe the corresponding data element is otherwise in the public domain or publicly available. (2) For Column 6, Pfizer did not provide a patent expiration date for products that have lost patent exclusivity. (3) For Columns 14-21, Pfizer has not provided a response for products that were not acquired from an unrelated company in the previous 5 years. (4) While Pfizer does not believe factors for a specific drug product’s price increases are in the public domain or publicly available, Pfizer has provided general information about its drug pricing philosophy and policy. More information about Pfizer’s general drug pricing philosophy and policy is available on Pfizer’s website.
Rx0000006	Pfizer	03/31/2019	00008083721	Effexor XR, 37.5 mg Capsule Extended Release, 30's	01/15/2019	18.84	395.65	None	Innovator Multiple Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	The information contained in this report is subject to the following limitations and assumptions. (1) Consistent with the relevant statutes and regulations, all information contained in this report is limited to that which Pfizer believes is otherwise in the public domain or publicly available. Where possible, Pfizer has used the non-public indicator to indicate it does not believe the corresponding data element is otherwise in the public domain or publicly available. (2) For Column 6, Pfizer did not provide a patent expiration date for products that have lost patent exclusivity. (3) For Columns 14-21, Pfizer has not provided a response for products that were not acquired from an unrelated company in the previous 5 years. (4) While Pfizer does not believe factors for a specific drug product’s price increases are in the public domain or publicly available, Pfizer has provided general information about its drug pricing philosophy and policy. More information about Pfizer’s general drug pricing philosophy and policy is available on Pfizer’s website.
Rx0000006	Pfizer	03/31/2019	00008083722	Effexor XR, 37.5 mg Capsule Extended Release, 90's	01/15/2019	56.53	1187.03	None	Innovator Multiple Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	The information contained in this report is subject to the following limitations and assumptions. (1) Consistent with the relevant statutes and regulations, all information contained in this report is limited to that which Pfizer believes is otherwise in the public domain or publicly available. Where possible, Pfizer has used the non-public indicator to indicate it does not believe the corresponding data element is otherwise in the public domain or publicly available. (2) For Column 6, Pfizer did not provide a patent expiration date for products that have lost patent exclusivity. (3) For Columns 14-21, Pfizer has not provided a response for products that were not acquired from an unrelated company in the previous 5 years. (4) While Pfizer does not believe factors for a specific drug product’s price increases are in the public domain or publicly available, Pfizer has provided general information about its drug pricing philosophy and policy. More information about Pfizer’s general drug pricing philosophy and policy is available on Pfizer’s website.
Rx0000006	Pfizer	03/31/2019	00008083321	Effexor XR, 75 mg Capsule Extended Release, 15's	01/15/2019	21.11	443.31	None	Innovator Multiple Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	The information contained in this report is subject to the following limitations and assumptions. (1) Consistent with the relevant statutes and regulations, all information contained in this report is limited to that which Pfizer believes is otherwise in the public domain or publicly available. Where possible, Pfizer has used the non-public indicator to indicate it does not believe the corresponding data element is otherwise in the public domain or publicly available. (2) For Column 6, Pfizer did not provide a patent expiration date for products that have lost patent exclusivity. (3) For Columns 14-21, Pfizer has not provided a response for products that were not acquired from an unrelated company in the previous 5 years. (4) While Pfizer does not believe factors for a specific drug product’s price increases are in the public domain or publicly available, Pfizer has provided general information about its drug pricing philosophy and policy. More information about Pfizer’s general drug pricing philosophy and policy is available on Pfizer’s website.
Rx0000006	Pfizer	03/31/2019	00008083322	Effexor XR, 75 mg Capsule Extended Release, 90's	01/15/2019	63.34	1330.04	None	Innovator Multiple Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	The information contained in this report is subject to the following limitations and assumptions. (1) Consistent with the relevant statutes and regulations, all information contained in this report is limited to that which Pfizer believes is otherwise in the public domain or publicly available. Where possible, Pfizer has used the non-public indicator to indicate it does not believe the corresponding data element is otherwise in the public domain or publicly available. (2) For Column 6, Pfizer did not provide a patent expiration date for products that have lost patent exclusivity. (3) For Columns 14-21, Pfizer has not provided a response for products that were not acquired from an unrelated company in the previous 5 years. (4) While Pfizer does not believe factors for a specific drug product’s price increases are in the public domain or publicly available, Pfizer has provided general information about its drug pricing philosophy and policy. More information about Pfizer’s general drug pricing philosophy and policy is available on Pfizer’s website.
Rx0000006	Pfizer	03/31/2019	00013215036	Estring, 2 mg Ring, 1's	01/15/2019	21.57	452.91	None	Single Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	The information contained in this report is subject to the following limitations and assumptions. (1) Consistent with the relevant statutes and regulations, all information contained in this report is limited to that which Pfizer believes is otherwise in the public domain or publicly available. Where possible, Pfizer has used the non-public indicator to indicate it does not believe the corresponding data element is otherwise in the public domain or publicly available. (2) For Column 6, Pfizer did not provide a patent expiration date for products that have lost patent exclusivity. (3) For Columns 14-21, Pfizer has not provided a response for products that were not acquired from an unrelated company in the previous 5 years. (4) While Pfizer does not believe factors for a specific drug product’s price increases are in the public domain or publicly available, Pfizer has provided general information about its drug pricing philosophy and policy. More information about Pfizer’s general drug pricing philosophy and policy is available on Pfizer’s website.
Rx0000006	Pfizer	03/31/2019	60793085410	Levoxyl, 100 mcg (0.1 mg) Tablet, 1000's	01/15/2019	42.64	895.34	10/02/2023	Non-innovator Multiple Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	The information contained in this report is subject to the following limitations and assumptions. (1) Consistent with the relevant statutes and regulations, all information contained in this report is limited to that which Pfizer believes is otherwise in the public domain or publicly available. Where possible, Pfizer has used the non-public indicator to indicate it does not believe the corresponding data element is otherwise in the public domain or publicly available. (2) For Column 6, Pfizer did not provide a patent expiration date for products that have lost patent exclusivity. (3) For Columns 14-21, Pfizer has not provided a response for products that were not acquired from an unrelated company in the previous 5 years. (4) While Pfizer does not believe factors for a specific drug product’s price increases are in the public domain or publicly available, Pfizer has provided general information about its drug pricing philosophy and policy. More information about Pfizer’s general drug pricing philosophy and policy is available on Pfizer’s website.
Rx0000006	Pfizer	03/31/2019	60793085401	Levoxyl, 100 mcg (0.1 mg) Tablet, 100's	01/15/2019	4.26	89.54	10/02/2023	Non-innovator Multiple Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	The information contained in this report is subject to the following limitations and assumptions. (1) Consistent with the relevant statutes and regulations, all information contained in this report is limited to that which Pfizer believes is otherwise in the public domain or publicly available. Where possible, Pfizer has used the non-public indicator to indicate it does not believe the corresponding data element is otherwise in the public domain or publicly available. (2) For Column 6, Pfizer did not provide a patent expiration date for products that have lost patent exclusivity. (3) For Columns 14-21, Pfizer has not provided a response for products that were not acquired from an unrelated company in the previous 5 years. (4) While Pfizer does not believe factors for a specific drug product’s price increases are in the public domain or publicly available, Pfizer has provided general information about its drug pricing philosophy and policy. More information about Pfizer’s general drug pricing philosophy and policy is available on Pfizer’s website.
Rx0000006	Pfizer	03/31/2019	60793085510	Levoxyl, 112 mcg (0.112 mg) Tablet, 1000's	01/15/2019	49.30	1035.35	10/02/2023	Non-innovator Multiple Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	The information contained in this report is subject to the following limitations and assumptions. (1) Consistent with the relevant statutes and regulations, all information contained in this report is limited to that which Pfizer believes is otherwise in the public domain or publicly available. Where possible, Pfizer has used the non-public indicator to indicate it does not believe the corresponding data element is otherwise in the public domain or publicly available. (2) For Column 6, Pfizer did not provide a patent expiration date for products that have lost patent exclusivity. (3) For Columns 14-21, Pfizer has not provided a response for products that were not acquired from an unrelated company in the previous 5 years. (4) While Pfizer does not believe factors for a specific drug product’s price increases are in the public domain or publicly available, Pfizer has provided general information about its drug pricing philosophy and policy. More information about Pfizer’s general drug pricing philosophy and policy is available on Pfizer’s website.
Rx0000006	Pfizer	03/31/2019	60793085501	Levoxyl, 112 mcg (0.112 mg) Tablet, 100's	01/15/2019	4.93	103.54	10/02/2023	Non-innovator Multiple Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	The information contained in this report is subject to the following limitations and assumptions. (1) Consistent with the relevant statutes and regulations, all information contained in this report is limited to that which Pfizer believes is otherwise in the public domain or publicly available. Where possible, Pfizer has used the non-public indicator to indicate it does not believe the corresponding data element is otherwise in the public domain or publicly available. (2) For Column 6, Pfizer did not provide a patent expiration date for products that have lost patent exclusivity. (3) For Columns 14-21, Pfizer has not provided a response for products that were not acquired from an unrelated company in the previous 5 years. (4) While Pfizer does not believe factors for a specific drug product’s price increases are in the public domain or publicly available, Pfizer has provided general information about its drug pricing philosophy and policy. More information about Pfizer’s general drug pricing philosophy and policy is available on Pfizer’s website.
Rx0000006	Pfizer	03/31/2019	60793085610	Levoxyl, 125 mcg (0.125 mg) Tablet, 1000's	01/15/2019	49.99	1049.72	10/02/2023	Non-innovator Multiple Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	The information contained in this report is subject to the following limitations and assumptions. (1) Consistent with the relevant statutes and regulations, all information contained in this report is limited to that which Pfizer believes is otherwise in the public domain or publicly available. Where possible, Pfizer has used the non-public indicator to indicate it does not believe the corresponding data element is otherwise in the public domain or publicly available. (2) For Column 6, Pfizer did not provide a patent expiration date for products that have lost patent exclusivity. (3) For Columns 14-21, Pfizer has not provided a response for products that were not acquired from an unrelated company in the previous 5 years. (4) While Pfizer does not believe factors for a specific drug product’s price increases are in the public domain or publicly available, Pfizer has provided general information about its drug pricing philosophy and policy. More information about Pfizer’s general drug pricing philosophy and policy is available on Pfizer’s website.
Rx0000006	Pfizer	03/31/2019	60793085601	Levoxyl, 125 mcg (0.125 mg) Tablet, 100's	01/15/2019	5.00	104.96	10/02/2023	Non-innovator Multiple Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	The information contained in this report is subject to the following limitations and assumptions. (1) Consistent with the relevant statutes and regulations, all information contained in this report is limited to that which Pfizer believes is otherwise in the public domain or publicly available. Where possible, Pfizer has used the non-public indicator to indicate it does not believe the corresponding data element is otherwise in the public domain or publicly available. (2) For Column 6, Pfizer did not provide a patent expiration date for products that have lost patent exclusivity. (3) For Columns 14-21, Pfizer has not provided a response for products that were not acquired from an unrelated company in the previous 5 years. (4) While Pfizer does not believe factors for a specific drug product’s price increases are in the public domain or publicly available, Pfizer has provided general information about its drug pricing philosophy and policy. More information about Pfizer’s general drug pricing philosophy and policy is available on Pfizer’s website.
Rx0000006	Pfizer	03/31/2019	60793085710	Levoxyl, 137 mcg (0.137 mg) Tablet, 1000's	01/15/2019	50.68	1064.29	10/02/2023	Non-innovator Multiple Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	The information contained in this report is subject to the following limitations and assumptions. (1) Consistent with the relevant statutes and regulations, all information contained in this report is limited to that which Pfizer believes is otherwise in the public domain or publicly available. Where possible, Pfizer has used the non-public indicator to indicate it does not believe the corresponding data element is otherwise in the public domain or publicly available. (2) For Column 6, Pfizer did not provide a patent expiration date for products that have lost patent exclusivity. (3) For Columns 14-21, Pfizer has not provided a response for products that were not acquired from an unrelated company in the previous 5 years. (4) While Pfizer does not believe factors for a specific drug product’s price increases are in the public domain or publicly available, Pfizer has provided general information about its drug pricing philosophy and policy. More information about Pfizer’s general drug pricing philosophy and policy is available on Pfizer’s website.
Rx0000006	Pfizer	03/31/2019	60793085701	Levoxyl, 137 mcg (0.137 mg) Tablet, 100's	01/15/2019	5.07	106.42	10/02/2023	Non-innovator Multiple Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	The information contained in this report is subject to the following limitations and assumptions. (1) Consistent with the relevant statutes and regulations, all information contained in this report is limited to that which Pfizer believes is otherwise in the public domain or publicly available. Where possible, Pfizer has used the non-public indicator to indicate it does not believe the corresponding data element is otherwise in the public domain or publicly available. (2) For Column 6, Pfizer did not provide a patent expiration date for products that have lost patent exclusivity. (3) For Columns 14-21, Pfizer has not provided a response for products that were not acquired from an unrelated company in the previous 5 years. (4) While Pfizer does not believe factors for a specific drug product’s price increases are in the public domain or publicly available, Pfizer has provided general information about its drug pricing philosophy and policy. More information about Pfizer’s general drug pricing philosophy and policy is available on Pfizer’s website.
Rx0000006	Pfizer	03/31/2019	60793085810	Levoxyl, 150 mcg (0.15 mg) Tablet, 1000's	01/15/2019	51.45	1080.42	10/02/2023	Non-innovator Multiple Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	The information contained in this report is subject to the following limitations and assumptions. (1) Consistent with the relevant statutes and regulations, all information contained in this report is limited to that which Pfizer believes is otherwise in the public domain or publicly available. Where possible, Pfizer has used the non-public indicator to indicate it does not believe the corresponding data element is otherwise in the public domain or publicly available. (2) For Column 6, Pfizer did not provide a patent expiration date for products that have lost patent exclusivity. (3) For Columns 14-21, Pfizer has not provided a response for products that were not acquired from an unrelated company in the previous 5 years. (4) While Pfizer does not believe factors for a specific drug product’s price increases are in the public domain or publicly available, Pfizer has provided general information about its drug pricing philosophy and policy. More information about Pfizer’s general drug pricing philosophy and policy is available on Pfizer’s website.
Rx0000006	Pfizer	03/31/2019	60793085801	Levoxyl, 150 mcg (0.15 mg) Tablet, 100's	01/15/2019	5.15	108.05	10/02/2023	Non-innovator Multiple Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	The information contained in this report is subject to the following limitations and assumptions. (1) Consistent with the relevant statutes and regulations, all information contained in this report is limited to that which Pfizer believes is otherwise in the public domain or publicly available. Where possible, Pfizer has used the non-public indicator to indicate it does not believe the corresponding data element is otherwise in the public domain or publicly available. (2) For Column 6, Pfizer did not provide a patent expiration date for products that have lost patent exclusivity. (3) For Columns 14-21, Pfizer has not provided a response for products that were not acquired from an unrelated company in the previous 5 years. (4) While Pfizer does not believe factors for a specific drug product’s price increases are in the public domain or publicly available, Pfizer has provided general information about its drug pricing philosophy and policy. More information about Pfizer’s general drug pricing philosophy and policy is available on Pfizer’s website.
Rx0000006	Pfizer	03/31/2019	60793085910	Levoxyl, 175 mcg (0.175 mg) Tablet, 1000's	01/15/2019	61.15	1284.08	10/02/2023	Non-innovator Multiple Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	The information contained in this report is subject to the following limitations and assumptions. (1) Consistent with the relevant statutes and regulations, all information contained in this report is limited to that which Pfizer believes is otherwise in the public domain or publicly available. Where possible, Pfizer has used the non-public indicator to indicate it does not believe the corresponding data element is otherwise in the public domain or publicly available. (2) For Column 6, Pfizer did not provide a patent expiration date for products that have lost patent exclusivity. (3) For Columns 14-21, Pfizer has not provided a response for products that were not acquired from an unrelated company in the previous 5 years. (4) While Pfizer does not believe factors for a specific drug product’s price increases are in the public domain or publicly available, Pfizer has provided general information about its drug pricing philosophy and policy. More information about Pfizer’s general drug pricing philosophy and policy is available on Pfizer’s website.
Rx0000006	Pfizer	03/31/2019	60793085901	Levoxyl, 175 mcg (0.175 mg) Tablet, 100's	01/15/2019	6.12	128.42	10/02/2023	Non-innovator Multiple Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	The information contained in this report is subject to the following limitations and assumptions. (1) Consistent with the relevant statutes and regulations, all information contained in this report is limited to that which Pfizer believes is otherwise in the public domain or publicly available. Where possible, Pfizer has used the non-public indicator to indicate it does not believe the corresponding data element is otherwise in the public domain or publicly available. (2) For Column 6, Pfizer did not provide a patent expiration date for products that have lost patent exclusivity. (3) For Columns 14-21, Pfizer has not provided a response for products that were not acquired from an unrelated company in the previous 5 years. (4) While Pfizer does not believe factors for a specific drug product’s price increases are in the public domain or publicly available, Pfizer has provided general information about its drug pricing philosophy and policy. More information about Pfizer’s general drug pricing philosophy and policy is available on Pfizer’s website.
Rx0000006	Pfizer	03/31/2019	60793086010	Levoxyl, 200 mcg (0.2 mg) Tablet, 1000's	01/15/2019	61.27	1286.66	10/02/2023	Non-innovator Multiple Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	The information contained in this report is subject to the following limitations and assumptions. (1) Consistent with the relevant statutes and regulations, all information contained in this report is limited to that which Pfizer believes is otherwise in the public domain or publicly available. Where possible, Pfizer has used the non-public indicator to indicate it does not believe the corresponding data element is otherwise in the public domain or publicly available. (2) For Column 6, Pfizer did not provide a patent expiration date for products that have lost patent exclusivity. (3) For Columns 14-21, Pfizer has not provided a response for products that were not acquired from an unrelated company in the previous 5 years. (4) While Pfizer does not believe factors for a specific drug product’s price increases are in the public domain or publicly available, Pfizer has provided general information about its drug pricing philosophy and policy. More information about Pfizer’s general drug pricing philosophy and policy is available on Pfizer’s website.
Rx0000006	Pfizer	03/31/2019	60793086001	Levoxyl, 200 mcg (0.2 mg) Tablet, 100's	01/15/2019	6.13	128.66	10/02/2023	Non-innovator Multiple Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	The information contained in this report is subject to the following limitations and assumptions. (1) Consistent with the relevant statutes and regulations, all information contained in this report is limited to that which Pfizer believes is otherwise in the public domain or publicly available. Where possible, Pfizer has used the non-public indicator to indicate it does not believe the corresponding data element is otherwise in the public domain or publicly available. (2) For Column 6, Pfizer did not provide a patent expiration date for products that have lost patent exclusivity. (3) For Columns 14-21, Pfizer has not provided a response for products that were not acquired from an unrelated company in the previous 5 years. (4) While Pfizer does not believe factors for a specific drug product’s price increases are in the public domain or publicly available, Pfizer has provided general information about its drug pricing philosophy and policy. More information about Pfizer’s general drug pricing philosophy and policy is available on Pfizer’s website.
Rx0000006	Pfizer	03/31/2019	60793085010	Levoxyl, 25 mcg (0.025 mg) Tablet, 1000's	01/15/2019	33.16	696.29	10/02/2023	Non-innovator Multiple Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	The information contained in this report is subject to the following limitations and assumptions. (1) Consistent with the relevant statutes and regulations, all information contained in this report is limited to that which Pfizer believes is otherwise in the public domain or publicly available. Where possible, Pfizer has used the non-public indicator to indicate it does not believe the corresponding data element is otherwise in the public domain or publicly available. (2) For Column 6, Pfizer did not provide a patent expiration date for products that have lost patent exclusivity. (3) For Columns 14-21, Pfizer has not provided a response for products that were not acquired from an unrelated company in the previous 5 years. (4) While Pfizer does not believe factors for a specific drug product’s price increases are in the public domain or publicly available, Pfizer has provided general information about its drug pricing philosophy and policy. More information about Pfizer’s general drug pricing philosophy and policy is available on Pfizer’s website.
Rx0000006	Pfizer	03/31/2019	60793085001	Levoxyl, 25 mcg (0.025 mg) Tablet, 100's	01/15/2019	3.32	69.62	10/02/2023	Non-innovator Multiple Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	The information contained in this report is subject to the following limitations and assumptions. (1) Consistent with the relevant statutes and regulations, all information contained in this report is limited to that which Pfizer believes is otherwise in the public domain or publicly available. Where possible, Pfizer has used the non-public indicator to indicate it does not believe the corresponding data element is otherwise in the public domain or publicly available. (2) For Column 6, Pfizer did not provide a patent expiration date for products that have lost patent exclusivity. (3) For Columns 14-21, Pfizer has not provided a response for products that were not acquired from an unrelated company in the previous 5 years. (4) While Pfizer does not believe factors for a specific drug product’s price increases are in the public domain or publicly available, Pfizer has provided general information about its drug pricing philosophy and policy. More information about Pfizer’s general drug pricing philosophy and policy is available on Pfizer’s website.
Rx0000006	Pfizer	03/31/2019	60793085110	Levoxyl, 50 mcg (0.05 mg) Tablet, 1000's	01/15/2019	37.64	790.40	10/02/2023	Non-innovator Multiple Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	The information contained in this report is subject to the following limitations and assumptions. (1) Consistent with the relevant statutes and regulations, all information contained in this report is limited to that which Pfizer believes is otherwise in the public domain or publicly available. Where possible, Pfizer has used the non-public indicator to indicate it does not believe the corresponding data element is otherwise in the public domain or publicly available. (2) For Column 6, Pfizer did not provide a patent expiration date for products that have lost patent exclusivity. (3) For Columns 14-21, Pfizer has not provided a response for products that were not acquired from an unrelated company in the previous 5 years. (4) While Pfizer does not believe factors for a specific drug product’s price increases are in the public domain or publicly available, Pfizer has provided general information about its drug pricing philosophy and policy. More information about Pfizer’s general drug pricing philosophy and policy is available on Pfizer’s website.
Rx0000006	Pfizer	03/31/2019	60793085101	Levoxyl, 50 mcg (0.05 mg) Tablet, 100's	01/15/2019	3.76	79.03	10/02/2023	Non-innovator Multiple Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	The information contained in this report is subject to the following limitations and assumptions. (1) Consistent with the relevant statutes and regulations, all information contained in this report is limited to that which Pfizer believes is otherwise in the public domain or publicly available. Where possible, Pfizer has used the non-public indicator to indicate it does not believe the corresponding data element is otherwise in the public domain or publicly available. (2) For Column 6, Pfizer did not provide a patent expiration date for products that have lost patent exclusivity. (3) For Columns 14-21, Pfizer has not provided a response for products that were not acquired from an unrelated company in the previous 5 years. (4) While Pfizer does not believe factors for a specific drug product’s price increases are in the public domain or publicly available, Pfizer has provided general information about its drug pricing philosophy and policy. More information about Pfizer’s general drug pricing philosophy and policy is available on Pfizer’s website.
Rx0000006	Pfizer	03/31/2019	60793085210	Levoxyl, 75 mcg (0.075 mg) Tablet, 1000's	01/15/2019	41.59	873.47	10/02/2023	Non-innovator Multiple Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	The information contained in this report is subject to the following limitations and assumptions. (1) Consistent with the relevant statutes and regulations, all information contained in this report is limited to that which Pfizer believes is otherwise in the public domain or publicly available. Where possible, Pfizer has used the non-public indicator to indicate it does not believe the corresponding data element is otherwise in the public domain or publicly available. (2) For Column 6, Pfizer did not provide a patent expiration date for products that have lost patent exclusivity. (3) For Columns 14-21, Pfizer has not provided a response for products that were not acquired from an unrelated company in the previous 5 years. (4) While Pfizer does not believe factors for a specific drug product’s price increases are in the public domain or publicly available, Pfizer has provided general information about its drug pricing philosophy and policy. More information about Pfizer’s general drug pricing philosophy and policy is available on Pfizer’s website.
Rx0000006	Pfizer	03/31/2019	60793085201	Levoxyl, 75 mcg (0.075 mg) Tablet, 100's	01/15/2019	4.16	87.35	10/02/2023	Non-innovator Multiple Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	The information contained in this report is subject to the following limitations and assumptions. (1) Consistent with the relevant statutes and regulations, all information contained in this report is limited to that which Pfizer believes is otherwise in the public domain or publicly available. Where possible, Pfizer has used the non-public indicator to indicate it does not believe the corresponding data element is otherwise in the public domain or publicly available. (2) For Column 6, Pfizer did not provide a patent expiration date for products that have lost patent exclusivity. (3) For Columns 14-21, Pfizer has not provided a response for products that were not acquired from an unrelated company in the previous 5 years. (4) While Pfizer does not believe factors for a specific drug product’s price increases are in the public domain or publicly available, Pfizer has provided general information about its drug pricing philosophy and policy. More information about Pfizer’s general drug pricing philosophy and policy is available on Pfizer’s website.
Rx0000006	Pfizer	03/31/2019	60793085310	Levoxyl, 88 mcg (0.088 mg) Tablet, 1000's	01/15/2019	42.31	888.52	10/02/2023	Non-innovator Multiple Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	The information contained in this report is subject to the following limitations and assumptions. (1) Consistent with the relevant statutes and regulations, all information contained in this report is limited to that which Pfizer believes is otherwise in the public domain or publicly available. Where possible, Pfizer has used the non-public indicator to indicate it does not believe the corresponding data element is otherwise in the public domain or publicly available. (2) For Column 6, Pfizer did not provide a patent expiration date for products that have lost patent exclusivity. (3) For Columns 14-21, Pfizer has not provided a response for products that were not acquired from an unrelated company in the previous 5 years. (4) While Pfizer does not believe factors for a specific drug product’s price increases are in the public domain or publicly available, Pfizer has provided general information about its drug pricing philosophy and policy. More information about Pfizer’s general drug pricing philosophy and policy is available on Pfizer’s website.
Rx0000006	Pfizer	03/31/2019	60793085301	Levoxyl, 88 mcg (0.088 mg) Tablet, 100's	01/15/2019	4.23	88.85	10/02/2023	Non-innovator Multiple Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	The information contained in this report is subject to the following limitations and assumptions. (1) Consistent with the relevant statutes and regulations, all information contained in this report is limited to that which Pfizer believes is otherwise in the public domain or publicly available. Where possible, Pfizer has used the non-public indicator to indicate it does not believe the corresponding data element is otherwise in the public domain or publicly available. (2) For Column 6, Pfizer did not provide a patent expiration date for products that have lost patent exclusivity. (3) For Columns 14-21, Pfizer has not provided a response for products that were not acquired from an unrelated company in the previous 5 years. (4) While Pfizer does not believe factors for a specific drug product’s price increases are in the public domain or publicly available, Pfizer has provided general information about its drug pricing philosophy and policy. More information about Pfizer’s general drug pricing philosophy and policy is available on Pfizer’s website.
Rx0000006	Pfizer	03/31/2019	00071015540	Lipitor, 10 mg Tablet Unit Dose Pak, 10x10	01/15/2019	52.40	1100.35	None	Innovator Multiple Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	The information contained in this report is subject to the following limitations and assumptions. (1) Consistent with the relevant statutes and regulations, all information contained in this report is limited to that which Pfizer believes is otherwise in the public domain or publicly available. Where possible, Pfizer has used the non-public indicator to indicate it does not believe the corresponding data element is otherwise in the public domain or publicly available. (2) For Column 6, Pfizer did not provide a patent expiration date for products that have lost patent exclusivity. (3) For Columns 14-21, Pfizer has not provided a response for products that were not acquired from an unrelated company in the previous 5 years. (4) While Pfizer does not believe factors for a specific drug product’s price increases are in the public domain or publicly available, Pfizer has provided general information about its drug pricing philosophy and policy. More information about Pfizer’s general drug pricing philosophy and policy is available on Pfizer’s website.
Rx0000006	Pfizer	03/31/2019	00071015523	Lipitor, 10 mg Tablet, 90's	01/15/2019	44.91	943.18	None	Innovator Multiple Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	The information contained in this report is subject to the following limitations and assumptions. (1) Consistent with the relevant statutes and regulations, all information contained in this report is limited to that which Pfizer believes is otherwise in the public domain or publicly available. Where possible, Pfizer has used the non-public indicator to indicate it does not believe the corresponding data element is otherwise in the public domain or publicly available. (2) For Column 6, Pfizer did not provide a patent expiration date for products that have lost patent exclusivity. (3) For Columns 14-21, Pfizer has not provided a response for products that were not acquired from an unrelated company in the previous 5 years. (4) While Pfizer does not believe factors for a specific drug product’s price increases are in the public domain or publicly available, Pfizer has provided general information about its drug pricing philosophy and policy. More information about Pfizer’s general drug pricing philosophy and policy is available on Pfizer’s website.
Rx0000006	Pfizer	03/31/2019	00071015640	Lipitor, 20 mg Tablet Unit Dose Pak, 10x10	01/15/2019	74.75	1569.69	None	Innovator Multiple Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	The information contained in this report is subject to the following limitations and assumptions. (1) Consistent with the relevant statutes and regulations, all information contained in this report is limited to that which Pfizer believes is otherwise in the public domain or publicly available. Where possible, Pfizer has used the non-public indicator to indicate it does not believe the corresponding data element is otherwise in the public domain or publicly available. (2) For Column 6, Pfizer did not provide a patent expiration date for products that have lost patent exclusivity. (3) For Columns 14-21, Pfizer has not provided a response for products that were not acquired from an unrelated company in the previous 5 years. (4) While Pfizer does not believe factors for a specific drug product’s price increases are in the public domain or publicly available, Pfizer has provided general information about its drug pricing philosophy and policy. More information about Pfizer’s general drug pricing philosophy and policy is available on Pfizer’s website.
Rx0000006	Pfizer	03/31/2019	00071015623	Lipitor, 20 mg Tablet, 90's	01/15/2019	64.07	1345.42	None	Innovator Multiple Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	The information contained in this report is subject to the following limitations and assumptions. (1) Consistent with the relevant statutes and regulations, all information contained in this report is limited to that which Pfizer believes is otherwise in the public domain or publicly available. Where possible, Pfizer has used the non-public indicator to indicate it does not believe the corresponding data element is otherwise in the public domain or publicly available. (2) For Column 6, Pfizer did not provide a patent expiration date for products that have lost patent exclusivity. (3) For Columns 14-21, Pfizer has not provided a response for products that were not acquired from an unrelated company in the previous 5 years. (4) While Pfizer does not believe factors for a specific drug product’s price increases are in the public domain or publicly available, Pfizer has provided general information about its drug pricing philosophy and policy. More information about Pfizer’s general drug pricing philosophy and policy is available on Pfizer’s website.
Rx0000006	Pfizer	03/31/2019	00071015740	Lipitor, 40 mg Tablet Unit Dose Pak, 10x10	01/15/2019	74.75	1569.69	None	Innovator Multiple Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	The information contained in this report is subject to the following limitations and assumptions. (1) Consistent with the relevant statutes and regulations, all information contained in this report is limited to that which Pfizer believes is otherwise in the public domain or publicly available. Where possible, Pfizer has used the non-public indicator to indicate it does not believe the corresponding data element is otherwise in the public domain or publicly available. (2) For Column 6, Pfizer did not provide a patent expiration date for products that have lost patent exclusivity. (3) For Columns 14-21, Pfizer has not provided a response for products that were not acquired from an unrelated company in the previous 5 years. (4) While Pfizer does not believe factors for a specific drug product’s price increases are in the public domain or publicly available, Pfizer has provided general information about its drug pricing philosophy and policy. More information about Pfizer’s general drug pricing philosophy and policy is available on Pfizer’s website.
Rx0000006	Pfizer	03/31/2019	00071015773	Lipitor, 40 mg Tablet, 500's	01/15/2019	355.92	7474.39	None	Innovator Multiple Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	The information contained in this report is subject to the following limitations and assumptions. (1) Consistent with the relevant statutes and regulations, all information contained in this report is limited to that which Pfizer believes is otherwise in the public domain or publicly available. Where possible, Pfizer has used the non-public indicator to indicate it does not believe the corresponding data element is otherwise in the public domain or publicly available. (2) For Column 6, Pfizer did not provide a patent expiration date for products that have lost patent exclusivity. (3) For Columns 14-21, Pfizer has not provided a response for products that were not acquired from an unrelated company in the previous 5 years. (4) While Pfizer does not believe factors for a specific drug product’s price increases are in the public domain or publicly available, Pfizer has provided general information about its drug pricing philosophy and policy. More information about Pfizer’s general drug pricing philosophy and policy is available on Pfizer’s website.
Rx0000006	Pfizer	03/31/2019	00071015723	Lipitor, 40 mg Tablet, 90's	01/15/2019	64.07	1345.42	None	Innovator Multiple Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	The information contained in this report is subject to the following limitations and assumptions. (1) Consistent with the relevant statutes and regulations, all information contained in this report is limited to that which Pfizer believes is otherwise in the public domain or publicly available. Where possible, Pfizer has used the non-public indicator to indicate it does not believe the corresponding data element is otherwise in the public domain or publicly available. (2) For Column 6, Pfizer did not provide a patent expiration date for products that have lost patent exclusivity. (3) For Columns 14-21, Pfizer has not provided a response for products that were not acquired from an unrelated company in the previous 5 years. (4) While Pfizer does not believe factors for a specific drug product’s price increases are in the public domain or publicly available, Pfizer has provided general information about its drug pricing philosophy and policy. More information about Pfizer’s general drug pricing philosophy and policy is available on Pfizer’s website.
Rx0000006	Pfizer	03/31/2019	00071015892	Lipitor, 80 mg Tablet Unit Dose Pak, 8x8	01/15/2019	47.84	1004.60	None	Innovator Multiple Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	The information contained in this report is subject to the following limitations and assumptions. (1) Consistent with the relevant statutes and regulations, all information contained in this report is limited to that which Pfizer believes is otherwise in the public domain or publicly available. Where possible, Pfizer has used the non-public indicator to indicate it does not believe the corresponding data element is otherwise in the public domain or publicly available. (2) For Column 6, Pfizer did not provide a patent expiration date for products that have lost patent exclusivity. (3) For Columns 14-21, Pfizer has not provided a response for products that were not acquired from an unrelated company in the previous 5 years. (4) While Pfizer does not believe factors for a specific drug product’s price increases are in the public domain or publicly available, Pfizer has provided general information about its drug pricing philosophy and policy. More information about Pfizer’s general drug pricing philosophy and policy is available on Pfizer’s website.
Rx0000006	Pfizer	03/31/2019	00071015873	Lipitor, 80 mg Tablet, 500's	01/15/2019	355.92	7474.39	None	Innovator Multiple Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	The information contained in this report is subject to the following limitations and assumptions. (1) Consistent with the relevant statutes and regulations, all information contained in this report is limited to that which Pfizer believes is otherwise in the public domain or publicly available. Where possible, Pfizer has used the non-public indicator to indicate it does not believe the corresponding data element is otherwise in the public domain or publicly available. (2) For Column 6, Pfizer did not provide a patent expiration date for products that have lost patent exclusivity. (3) For Columns 14-21, Pfizer has not provided a response for products that were not acquired from an unrelated company in the previous 5 years. (4) While Pfizer does not believe factors for a specific drug product’s price increases are in the public domain or publicly available, Pfizer has provided general information about its drug pricing philosophy and policy. More information about Pfizer’s general drug pricing philosophy and policy is available on Pfizer’s website.
Rx0000006	Pfizer	03/31/2019	00071015823	Lipitor, 80 mg Tablet, 90's	01/15/2019	64.07	1345.42	None	Innovator Multiple Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	The information contained in this report is subject to the following limitations and assumptions. (1) Consistent with the relevant statutes and regulations, all information contained in this report is limited to that which Pfizer believes is otherwise in the public domain or publicly available. Where possible, Pfizer has used the non-public indicator to indicate it does not believe the corresponding data element is otherwise in the public domain or publicly available. (2) For Column 6, Pfizer did not provide a patent expiration date for products that have lost patent exclusivity. (3) For Columns 14-21, Pfizer has not provided a response for products that were not acquired from an unrelated company in the previous 5 years. (4) While Pfizer does not believe factors for a specific drug product’s price increases are in the public domain or publicly available, Pfizer has provided general information about its drug pricing philosophy and policy. More information about Pfizer’s general drug pricing philosophy and policy is available on Pfizer’s website.
Rx0000006	Pfizer	03/31/2019	00071101541	Lyrica, 100 mg Capsule Unit Dose Pak, 10x10	01/15/2019	40.87	858.26	06/30/2019	Single Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	The information contained in this report is subject to the following limitations and assumptions. (1) Consistent with the relevant statutes and regulations, all information contained in this report is limited to that which Pfizer believes is otherwise in the public domain or publicly available. Where possible, Pfizer has used the non-public indicator to indicate it does not believe the corresponding data element is otherwise in the public domain or publicly available. (2) For Column 6, Pfizer did not provide a patent expiration date for products that have lost patent exclusivity. (3) For Columns 14-21, Pfizer has not provided a response for products that were not acquired from an unrelated company in the previous 5 years. (4) While Pfizer does not believe factors for a specific drug product’s price increases are in the public domain or publicly available, Pfizer has provided general information about its drug pricing philosophy and policy. More information about Pfizer’s general drug pricing philosophy and policy is available on Pfizer’s website.
Rx0000006	Pfizer	03/31/2019	00071101568	Lyrica, 100 mg Capsule, 90's	01/15/2019	33.44	702.28	06/30/2019	Single Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	The information contained in this report is subject to the following limitations and assumptions. (1) Consistent with the relevant statutes and regulations, all information contained in this report is limited to that which Pfizer believes is otherwise in the public domain or publicly available. Where possible, Pfizer has used the non-public indicator to indicate it does not believe the corresponding data element is otherwise in the public domain or publicly available. (2) For Column 6, Pfizer did not provide a patent expiration date for products that have lost patent exclusivity. (3) For Columns 14-21, Pfizer has not provided a response for products that were not acquired from an unrelated company in the previous 5 years. (4) While Pfizer does not believe factors for a specific drug product’s price increases are in the public domain or publicly available, Pfizer has provided general information about its drug pricing philosophy and policy. More information about Pfizer’s general drug pricing philosophy and policy is available on Pfizer’s website.
Rx0000006	Pfizer	03/31/2019	00071101641	Lyrica, 150 mg Capsule Unit Dose Pak, 10x10	01/15/2019	40.87	858.26	06/30/2019	Single Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	The information contained in this report is subject to the following limitations and assumptions. (1) Consistent with the relevant statutes and regulations, all information contained in this report is limited to that which Pfizer believes is otherwise in the public domain or publicly available. Where possible, Pfizer has used the non-public indicator to indicate it does not believe the corresponding data element is otherwise in the public domain or publicly available. (2) For Column 6, Pfizer did not provide a patent expiration date for products that have lost patent exclusivity. (3) For Columns 14-21, Pfizer has not provided a response for products that were not acquired from an unrelated company in the previous 5 years. (4) While Pfizer does not believe factors for a specific drug product’s price increases are in the public domain or publicly available, Pfizer has provided general information about its drug pricing philosophy and policy. More information about Pfizer’s general drug pricing philosophy and policy is available on Pfizer’s website.
Rx0000006	Pfizer	03/31/2019	00071101668	Lyrica, 150 mg Capsule, 90's	01/15/2019	33.44	702.28	06/30/2019	Single Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	The information contained in this report is subject to the following limitations and assumptions. (1) Consistent with the relevant statutes and regulations, all information contained in this report is limited to that which Pfizer believes is otherwise in the public domain or publicly available. Where possible, Pfizer has used the non-public indicator to indicate it does not believe the corresponding data element is otherwise in the public domain or publicly available. (2) For Column 6, Pfizer did not provide a patent expiration date for products that have lost patent exclusivity. (3) For Columns 14-21, Pfizer has not provided a response for products that were not acquired from an unrelated company in the previous 5 years. (4) While Pfizer does not believe factors for a specific drug product’s price increases are in the public domain or publicly available, Pfizer has provided general information about its drug pricing philosophy and policy. More information about Pfizer’s general drug pricing philosophy and policy is available on Pfizer’s website.
Rx0000006	Pfizer	03/31/2019	00071102001	Lyrica, 20 mg/mL Bottle, 1's	01/15/2019	46.82	983.20	06/30/2019	Single Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	The information contained in this report is subject to the following limitations and assumptions. (1) Consistent with the relevant statutes and regulations, all information contained in this report is limited to that which Pfizer believes is otherwise in the public domain or publicly available. Where possible, Pfizer has used the non-public indicator to indicate it does not believe the corresponding data element is otherwise in the public domain or publicly available. (2) For Column 6, Pfizer did not provide a patent expiration date for products that have lost patent exclusivity. (3) For Columns 14-21, Pfizer has not provided a response for products that were not acquired from an unrelated company in the previous 5 years. (4) While Pfizer does not believe factors for a specific drug product’s price increases are in the public domain or publicly available, Pfizer has provided general information about its drug pricing philosophy and policy. More information about Pfizer’s general drug pricing philosophy and policy is available on Pfizer’s website.
Rx0000006	Pfizer	03/31/2019	00071101768	Lyrica, 200 mg Capsule, 90's	01/15/2019	33.44	702.28	06/30/2019	Single Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	The information contained in this report is subject to the following limitations and assumptions. (1) Consistent with the relevant statutes and regulations, all information contained in this report is limited to that which Pfizer believes is otherwise in the public domain or publicly available. Where possible, Pfizer has used the non-public indicator to indicate it does not believe the corresponding data element is otherwise in the public domain or publicly available. (2) For Column 6, Pfizer did not provide a patent expiration date for products that have lost patent exclusivity. (3) For Columns 14-21, Pfizer has not provided a response for products that were not acquired from an unrelated company in the previous 5 years. (4) While Pfizer does not believe factors for a specific drug product’s price increases are in the public domain or publicly available, Pfizer has provided general information about its drug pricing philosophy and policy. More information about Pfizer’s general drug pricing philosophy and policy is available on Pfizer’s website.
Rx0000006	Pfizer	03/31/2019	00071101968	Lyrica, 225 mg Capsule, 90's	01/15/2019	33.44	702.28	06/30/2019	Single Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	The information contained in this report is subject to the following limitations and assumptions. (1) Consistent with the relevant statutes and regulations, all information contained in this report is limited to that which Pfizer believes is otherwise in the public domain or publicly available. Where possible, Pfizer has used the non-public indicator to indicate it does not believe the corresponding data element is otherwise in the public domain or publicly available. (2) For Column 6, Pfizer did not provide a patent expiration date for products that have lost patent exclusivity. (3) For Columns 14-21, Pfizer has not provided a response for products that were not acquired from an unrelated company in the previous 5 years. (4) While Pfizer does not believe factors for a specific drug product’s price increases are in the public domain or publicly available, Pfizer has provided general information about its drug pricing philosophy and policy. More information about Pfizer’s general drug pricing philosophy and policy is available on Pfizer’s website.
Rx0000006	Pfizer	03/31/2019	00071101268	Lyrica, 25 mg Capsule, 90's	01/15/2019	33.44	702.28	06/30/2019	Single Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	The information contained in this report is subject to the following limitations and assumptions. (1) Consistent with the relevant statutes and regulations, all information contained in this report is limited to that which Pfizer believes is otherwise in the public domain or publicly available. Where possible, Pfizer has used the non-public indicator to indicate it does not believe the corresponding data element is otherwise in the public domain or publicly available. (2) For Column 6, Pfizer did not provide a patent expiration date for products that have lost patent exclusivity. (3) For Columns 14-21, Pfizer has not provided a response for products that were not acquired from an unrelated company in the previous 5 years. (4) While Pfizer does not believe factors for a specific drug product’s price increases are in the public domain or publicly available, Pfizer has provided general information about its drug pricing philosophy and policy. More information about Pfizer’s general drug pricing philosophy and policy is available on Pfizer’s website.
Rx0000006	Pfizer	03/31/2019	00071101868	Lyrica, 300 mg Capsule, 90's	01/15/2019	33.44	702.28	06/30/2019	Single Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	The information contained in this report is subject to the following limitations and assumptions. (1) Consistent with the relevant statutes and regulations, all information contained in this report is limited to that which Pfizer believes is otherwise in the public domain or publicly available. Where possible, Pfizer has used the non-public indicator to indicate it does not believe the corresponding data element is otherwise in the public domain or publicly available. (2) For Column 6, Pfizer did not provide a patent expiration date for products that have lost patent exclusivity. (3) For Columns 14-21, Pfizer has not provided a response for products that were not acquired from an unrelated company in the previous 5 years. (4) While Pfizer does not believe factors for a specific drug product’s price increases are in the public domain or publicly available, Pfizer has provided general information about its drug pricing philosophy and policy. More information about Pfizer’s general drug pricing philosophy and policy is available on Pfizer’s website.
Rx0000006	Pfizer	03/31/2019	00071101341	Lyrica, 50 mg Capsule Unit Dose Pak, 10x10	01/15/2019	40.87	858.26	06/30/2019	Single Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	The information contained in this report is subject to the following limitations and assumptions. (1) Consistent with the relevant statutes and regulations, all information contained in this report is limited to that which Pfizer believes is otherwise in the public domain or publicly available. Where possible, Pfizer has used the non-public indicator to indicate it does not believe the corresponding data element is otherwise in the public domain or publicly available. (2) For Column 6, Pfizer did not provide a patent expiration date for products that have lost patent exclusivity. (3) For Columns 14-21, Pfizer has not provided a response for products that were not acquired from an unrelated company in the previous 5 years. (4) While Pfizer does not believe factors for a specific drug product’s price increases are in the public domain or publicly available, Pfizer has provided general information about its drug pricing philosophy and policy. More information about Pfizer’s general drug pricing philosophy and policy is available on Pfizer’s website.
Rx0000006	Pfizer	03/31/2019	00071101368	Lyrica, 50 mg Capsule, 90's	01/15/2019	33.44	702.28	06/30/2019	Single Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	The information contained in this report is subject to the following limitations and assumptions. (1) Consistent with the relevant statutes and regulations, all information contained in this report is limited to that which Pfizer believes is otherwise in the public domain or publicly available. Where possible, Pfizer has used the non-public indicator to indicate it does not believe the corresponding data element is otherwise in the public domain or publicly available. (2) For Column 6, Pfizer did not provide a patent expiration date for products that have lost patent exclusivity. (3) For Columns 14-21, Pfizer has not provided a response for products that were not acquired from an unrelated company in the previous 5 years. (4) While Pfizer does not believe factors for a specific drug product’s price increases are in the public domain or publicly available, Pfizer has provided general information about its drug pricing philosophy and policy. More information about Pfizer’s general drug pricing philosophy and policy is available on Pfizer’s website.
Rx0000006	Pfizer	03/31/2019	00071101441	Lyrica, 75 mg Capsule Unit Dose Pak, 10x10	01/15/2019	40.87	858.26	06/30/2019	Single Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	The information contained in this report is subject to the following limitations and assumptions. (1) Consistent with the relevant statutes and regulations, all information contained in this report is limited to that which Pfizer believes is otherwise in the public domain or publicly available. Where possible, Pfizer has used the non-public indicator to indicate it does not believe the corresponding data element is otherwise in the public domain or publicly available. (2) For Column 6, Pfizer did not provide a patent expiration date for products that have lost patent exclusivity. (3) For Columns 14-21, Pfizer has not provided a response for products that were not acquired from an unrelated company in the previous 5 years. (4) While Pfizer does not believe factors for a specific drug product’s price increases are in the public domain or publicly available, Pfizer has provided general information about its drug pricing philosophy and policy. More information about Pfizer’s general drug pricing philosophy and policy is available on Pfizer’s website.
Rx0000006	Pfizer	03/31/2019	00071101468	Lyrica, 75 mg Capsule, 90's	01/15/2019	33.44	702.28	06/30/2019	Single Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	The information contained in this report is subject to the following limitations and assumptions. (1) Consistent with the relevant statutes and regulations, all information contained in this report is limited to that which Pfizer believes is otherwise in the public domain or publicly available. Where possible, Pfizer has used the non-public indicator to indicate it does not believe the corresponding data element is otherwise in the public domain or publicly available. (2) For Column 6, Pfizer did not provide a patent expiration date for products that have lost patent exclusivity. (3) For Columns 14-21, Pfizer has not provided a response for products that were not acquired from an unrelated company in the previous 5 years. (4) While Pfizer does not believe factors for a specific drug product’s price increases are in the public domain or publicly available, Pfizer has provided general information about its drug pricing philosophy and policy. More information about Pfizer’s general drug pricing philosophy and policy is available on Pfizer’s website.
Rx0000006	Pfizer	03/31/2019	00008451001	Mylotarg, 4.5 mg Single Dose Vial, 1's	01/15/2019	246.00	8446.00	None	Single Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	https://reports.siera.oshpd.ca.gov/api/report/drug-pricing/attachment?id=240	The information contained in this report is subject to the following limitations and assumptions. (1) Consistent with the relevant statutes and regulations, all information contained in this report is limited to that which Pfizer believes is otherwise in the public domain or publicly available. Where possible, Pfizer has used the non-public indicator to indicate it does not believe the corresponding data element is otherwise in the public domain or publicly available. (2) For Column 6, Pfizer did not provide a patent expiration date for products that have lost patent exclusivity. (3) For Columns 14-21, Pfizer has not provided a response for products that were not acquired from an unrelated company in the previous 5 years. (4) While Pfizer does not believe factors for a specific drug product’s price increases are in the public domain or publicly available, Pfizer has provided general information about its drug pricing philosophy and policy. More information about Pfizer’s general drug pricing philosophy and policy is available on Pfizer’s website.
Rx0000006	Pfizer	03/31/2019	00071080324	Neurontin, 100 mg Capsule, 100's	01/15/2019	10.63	223.17	None	Innovator Multiple Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	The information contained in this report is subject to the following limitations and assumptions. (1) Consistent with the relevant statutes and regulations, all information contained in this report is limited to that which Pfizer believes is otherwise in the public domain or publicly available. Where possible, Pfizer has used the non-public indicator to indicate it does not believe the corresponding data element is otherwise in the public domain or publicly available. (2) For Column 6, Pfizer did not provide a patent expiration date for products that have lost patent exclusivity. (3) For Columns 14-21, Pfizer has not provided a response for products that were not acquired from an unrelated company in the previous 5 years. (4) While Pfizer does not believe factors for a specific drug product’s price increases are in the public domain or publicly available, Pfizer has provided general information about its drug pricing philosophy and policy. More information about Pfizer’s general drug pricing philosophy and policy is available on Pfizer’s website.
Rx0000006	Pfizer	03/31/2019	00071080524	Neurontin, 300 mg Capsule, 100's	01/15/2019	26.57	558.01	None	Innovator Multiple Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	The information contained in this report is subject to the following limitations and assumptions. (1) Consistent with the relevant statutes and regulations, all information contained in this report is limited to that which Pfizer believes is otherwise in the public domain or publicly available. Where possible, Pfizer has used the non-public indicator to indicate it does not believe the corresponding data element is otherwise in the public domain or publicly available. (2) For Column 6, Pfizer did not provide a patent expiration date for products that have lost patent exclusivity. (3) For Columns 14-21, Pfizer has not provided a response for products that were not acquired from an unrelated company in the previous 5 years. (4) While Pfizer does not believe factors for a specific drug product’s price increases are in the public domain or publicly available, Pfizer has provided general information about its drug pricing philosophy and policy. More information about Pfizer’s general drug pricing philosophy and policy is available on Pfizer’s website.
Rx0000006	Pfizer	03/31/2019	00071080624	Neurontin, 400 mg Capsule, 100's	01/15/2019	31.88	669.42	None	Innovator Multiple Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	The information contained in this report is subject to the following limitations and assumptions. (1) Consistent with the relevant statutes and regulations, all information contained in this report is limited to that which Pfizer believes is otherwise in the public domain or publicly available. Where possible, Pfizer has used the non-public indicator to indicate it does not believe the corresponding data element is otherwise in the public domain or publicly available. (2) For Column 6, Pfizer did not provide a patent expiration date for products that have lost patent exclusivity. (3) For Columns 14-21, Pfizer has not provided a response for products that were not acquired from an unrelated company in the previous 5 years. (4) While Pfizer does not believe factors for a specific drug product’s price increases are in the public domain or publicly available, Pfizer has provided general information about its drug pricing philosophy and policy. More information about Pfizer’s general drug pricing philosophy and policy is available on Pfizer’s website.
Rx0000006	Pfizer	03/31/2019	00071051324	Neurontin, 600 mg Tablet, 100's	01/15/2019	50.48	1060.00	None	Innovator Multiple Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	The information contained in this report is subject to the following limitations and assumptions. (1) Consistent with the relevant statutes and regulations, all information contained in this report is limited to that which Pfizer believes is otherwise in the public domain or publicly available. Where possible, Pfizer has used the non-public indicator to indicate it does not believe the corresponding data element is otherwise in the public domain or publicly available. (2) For Column 6, Pfizer did not provide a patent expiration date for products that have lost patent exclusivity. (3) For Columns 14-21, Pfizer has not provided a response for products that were not acquired from an unrelated company in the previous 5 years. (4) While Pfizer does not believe factors for a specific drug product’s price increases are in the public domain or publicly available, Pfizer has provided general information about its drug pricing philosophy and policy. More information about Pfizer’s general drug pricing philosophy and policy is available on Pfizer’s website.
Rx0000006	Pfizer	03/31/2019	00071040124	Neurontin, 800 mg Tablet, 100's	01/15/2019	60.56	1271.83	None	Innovator Multiple Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	The information contained in this report is subject to the following limitations and assumptions. (1) Consistent with the relevant statutes and regulations, all information contained in this report is limited to that which Pfizer believes is otherwise in the public domain or publicly available. Where possible, Pfizer has used the non-public indicator to indicate it does not believe the corresponding data element is otherwise in the public domain or publicly available. (2) For Column 6, Pfizer did not provide a patent expiration date for products that have lost patent exclusivity. (3) For Columns 14-21, Pfizer has not provided a response for products that were not acquired from an unrelated company in the previous 5 years. (4) While Pfizer does not believe factors for a specific drug product’s price increases are in the public domain or publicly available, Pfizer has provided general information about its drug pricing philosophy and policy. More information about Pfizer’s general drug pricing philosophy and policy is available on Pfizer’s website.
Rx0000006	Pfizer	03/31/2019	00069154041	Norvasc, 10 mg Tablet Unit Dose Pak, (10x10)	01/15/2019	42.67	896.01	None	Innovator Multiple Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	The information contained in this report is subject to the following limitations and assumptions. (1) Consistent with the relevant statutes and regulations, all information contained in this report is limited to that which Pfizer believes is otherwise in the public domain or publicly available. Where possible, Pfizer has used the non-public indicator to indicate it does not believe the corresponding data element is otherwise in the public domain or publicly available. (2) For Column 6, Pfizer did not provide a patent expiration date for products that have lost patent exclusivity. (3) For Columns 14-21, Pfizer has not provided a response for products that were not acquired from an unrelated company in the previous 5 years. (4) While Pfizer does not believe factors for a specific drug product’s price increases are in the public domain or publicly available, Pfizer has provided general information about its drug pricing philosophy and policy. More information about Pfizer’s general drug pricing philosophy and policy is available on Pfizer’s website.
Rx0000006	Pfizer	03/31/2019	00069154068	Norvasc, 10 mg Tablet, 90's	01/15/2019	38.38	806.01	None	Innovator Multiple Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	The information contained in this report is subject to the following limitations and assumptions. (1) Consistent with the relevant statutes and regulations, all information contained in this report is limited to that which Pfizer believes is otherwise in the public domain or publicly available. Where possible, Pfizer has used the non-public indicator to indicate it does not believe the corresponding data element is otherwise in the public domain or publicly available. (2) For Column 6, Pfizer did not provide a patent expiration date for products that have lost patent exclusivity. (3) For Columns 14-21, Pfizer has not provided a response for products that were not acquired from an unrelated company in the previous 5 years. (4) While Pfizer does not believe factors for a specific drug product’s price increases are in the public domain or publicly available, Pfizer has provided general information about its drug pricing philosophy and policy. More information about Pfizer’s general drug pricing philosophy and policy is available on Pfizer’s website.
Rx0000006	Pfizer	03/31/2019	00069152068	Norvasc, 2.5 mg Tablet, 90's	01/15/2019	28.00	587.90	None	Innovator Multiple Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	The information contained in this report is subject to the following limitations and assumptions. (1) Consistent with the relevant statutes and regulations, all information contained in this report is limited to that which Pfizer believes is otherwise in the public domain or publicly available. Where possible, Pfizer has used the non-public indicator to indicate it does not believe the corresponding data element is otherwise in the public domain or publicly available. (2) For Column 6, Pfizer did not provide a patent expiration date for products that have lost patent exclusivity. (3) For Columns 14-21, Pfizer has not provided a response for products that were not acquired from an unrelated company in the previous 5 years. (4) While Pfizer does not believe factors for a specific drug product’s price increases are in the public domain or publicly available, Pfizer has provided general information about its drug pricing philosophy and policy. More information about Pfizer’s general drug pricing philosophy and policy is available on Pfizer’s website.
Rx0000006	Pfizer	03/31/2019	00069153041	Norvasc, 5 mg Tablet Unit Dose Pak, (10x10)	01/15/2019	31.10	653.19	None	Innovator Multiple Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	The information contained in this report is subject to the following limitations and assumptions. (1) Consistent with the relevant statutes and regulations, all information contained in this report is limited to that which Pfizer believes is otherwise in the public domain or publicly available. Where possible, Pfizer has used the non-public indicator to indicate it does not believe the corresponding data element is otherwise in the public domain or publicly available. (2) For Column 6, Pfizer did not provide a patent expiration date for products that have lost patent exclusivity. (3) For Columns 14-21, Pfizer has not provided a response for products that were not acquired from an unrelated company in the previous 5 years. (4) While Pfizer does not believe factors for a specific drug product’s price increases are in the public domain or publicly available, Pfizer has provided general information about its drug pricing philosophy and policy. More information about Pfizer’s general drug pricing philosophy and policy is available on Pfizer’s website.
Rx0000006	Pfizer	03/31/2019	00069153072	Norvasc, 5 mg Tablet, 300's	01/15/2019	93.32	1959.68	None	Innovator Multiple Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	The information contained in this report is subject to the following limitations and assumptions. (1) Consistent with the relevant statutes and regulations, all information contained in this report is limited to that which Pfizer believes is otherwise in the public domain or publicly available. Where possible, Pfizer has used the non-public indicator to indicate it does not believe the corresponding data element is otherwise in the public domain or publicly available. (2) For Column 6, Pfizer did not provide a patent expiration date for products that have lost patent exclusivity. (3) For Columns 14-21, Pfizer has not provided a response for products that were not acquired from an unrelated company in the previous 5 years. (4) While Pfizer does not believe factors for a specific drug product’s price increases are in the public domain or publicly available, Pfizer has provided general information about its drug pricing philosophy and policy. More information about Pfizer’s general drug pricing philosophy and policy is available on Pfizer’s website.
Rx0000006	Pfizer	03/31/2019	00069153068	Norvasc, 5 mg Tablet, 90's	01/15/2019	28.00	587.90	None	Innovator Multiple Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	The information contained in this report is subject to the following limitations and assumptions. (1) Consistent with the relevant statutes and regulations, all information contained in this report is limited to that which Pfizer believes is otherwise in the public domain or publicly available. Where possible, Pfizer has used the non-public indicator to indicate it does not believe the corresponding data element is otherwise in the public domain or publicly available. (2) For Column 6, Pfizer did not provide a patent expiration date for products that have lost patent exclusivity. (3) For Columns 14-21, Pfizer has not provided a response for products that were not acquired from an unrelated company in the previous 5 years. (4) While Pfizer does not believe factors for a specific drug product’s price increases are in the public domain or publicly available, Pfizer has provided general information about its drug pricing philosophy and policy. More information about Pfizer’s general drug pricing philosophy and policy is available on Pfizer’s website.
Rx0000006	Pfizer	03/31/2019	00008122214	Pristiq, 100 mg Tablet Extended Release, 14's	01/15/2019	8.91	187.03	07/05/2027	Innovator Multiple Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	The information contained in this report is subject to the following limitations and assumptions. (1) Consistent with the relevant statutes and regulations, all information contained in this report is limited to that which Pfizer believes is otherwise in the public domain or publicly available. Where possible, Pfizer has used the non-public indicator to indicate it does not believe the corresponding data element is otherwise in the public domain or publicly available. (2) For Column 6, Pfizer did not provide a patent expiration date for products that have lost patent exclusivity. (3) For Columns 14-21, Pfizer has not provided a response for products that were not acquired from an unrelated company in the previous 5 years. (4) While Pfizer does not believe factors for a specific drug product’s price increases are in the public domain or publicly available, Pfizer has provided general information about its drug pricing philosophy and policy. More information about Pfizer’s general drug pricing philosophy and policy is available on Pfizer’s website.
Rx0000006	Pfizer	03/31/2019	00008122230	Pristiq, 100 mg Tablet Extended Release, 30's	01/15/2019	19.09	400.81	07/05/2027	Innovator Multiple Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	The information contained in this report is subject to the following limitations and assumptions. (1) Consistent with the relevant statutes and regulations, all information contained in this report is limited to that which Pfizer believes is otherwise in the public domain or publicly available. Where possible, Pfizer has used the non-public indicator to indicate it does not believe the corresponding data element is otherwise in the public domain or publicly available. (2) For Column 6, Pfizer did not provide a patent expiration date for products that have lost patent exclusivity. (3) For Columns 14-21, Pfizer has not provided a response for products that were not acquired from an unrelated company in the previous 5 years. (4) While Pfizer does not believe factors for a specific drug product’s price increases are in the public domain or publicly available, Pfizer has provided general information about its drug pricing philosophy and policy. More information about Pfizer’s general drug pricing philosophy and policy is available on Pfizer’s website.
Rx0000006	Pfizer	03/31/2019	00008122201	Pristiq, 100 mg Tablet Extended Release, 90's	01/15/2019	57.26	1202.37	07/05/2027	Innovator Multiple Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	The information contained in this report is subject to the following limitations and assumptions. (1) Consistent with the relevant statutes and regulations, all information contained in this report is limited to that which Pfizer believes is otherwise in the public domain or publicly available. Where possible, Pfizer has used the non-public indicator to indicate it does not believe the corresponding data element is otherwise in the public domain or publicly available. (2) For Column 6, Pfizer did not provide a patent expiration date for products that have lost patent exclusivity. (3) For Columns 14-21, Pfizer has not provided a response for products that were not acquired from an unrelated company in the previous 5 years. (4) While Pfizer does not believe factors for a specific drug product’s price increases are in the public domain or publicly available, Pfizer has provided general information about its drug pricing philosophy and policy. More information about Pfizer’s general drug pricing philosophy and policy is available on Pfizer’s website.
Rx0000006	Pfizer	03/31/2019	00008121030	Pristiq, 25 mg Tablet Extended Release, 30's	01/15/2019	19.09	400.81	07/05/2027	Innovator Multiple Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	The information contained in this report is subject to the following limitations and assumptions. (1) Consistent with the relevant statutes and regulations, all information contained in this report is limited to that which Pfizer believes is otherwise in the public domain or publicly available. Where possible, Pfizer has used the non-public indicator to indicate it does not believe the corresponding data element is otherwise in the public domain or publicly available. (2) For Column 6, Pfizer did not provide a patent expiration date for products that have lost patent exclusivity. (3) For Columns 14-21, Pfizer has not provided a response for products that were not acquired from an unrelated company in the previous 5 years. (4) While Pfizer does not believe factors for a specific drug product’s price increases are in the public domain or publicly available, Pfizer has provided general information about its drug pricing philosophy and policy. More information about Pfizer’s general drug pricing philosophy and policy is available on Pfizer’s website.
Rx0000006	Pfizer	03/31/2019	00008121114	Pristiq, 50 mg Tablet Extended Release, 14's	01/15/2019	8.91	187.03	07/05/2027	Innovator Multiple Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	The information contained in this report is subject to the following limitations and assumptions. (1) Consistent with the relevant statutes and regulations, all information contained in this report is limited to that which Pfizer believes is otherwise in the public domain or publicly available. Where possible, Pfizer has used the non-public indicator to indicate it does not believe the corresponding data element is otherwise in the public domain or publicly available. (2) For Column 6, Pfizer did not provide a patent expiration date for products that have lost patent exclusivity. (3) For Columns 14-21, Pfizer has not provided a response for products that were not acquired from an unrelated company in the previous 5 years. (4) While Pfizer does not believe factors for a specific drug product’s price increases are in the public domain or publicly available, Pfizer has provided general information about its drug pricing philosophy and policy. More information about Pfizer’s general drug pricing philosophy and policy is available on Pfizer’s website.
Rx0000006	Pfizer	03/31/2019	00008121130	Pristiq, 50 mg Tablet Extended Release, 30's	01/15/2019	19.09	400.81	07/05/2027	Innovator Multiple Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	The information contained in this report is subject to the following limitations and assumptions. (1) Consistent with the relevant statutes and regulations, all information contained in this report is limited to that which Pfizer believes is otherwise in the public domain or publicly available. Where possible, Pfizer has used the non-public indicator to indicate it does not believe the corresponding data element is otherwise in the public domain or publicly available. (2) For Column 6, Pfizer did not provide a patent expiration date for products that have lost patent exclusivity. (3) For Columns 14-21, Pfizer has not provided a response for products that were not acquired from an unrelated company in the previous 5 years. (4) While Pfizer does not believe factors for a specific drug product’s price increases are in the public domain or publicly available, Pfizer has provided general information about its drug pricing philosophy and policy. More information about Pfizer’s general drug pricing philosophy and policy is available on Pfizer’s website.
Rx0000006	Pfizer	03/31/2019	00008121101	Pristiq, 50 mg Tablet Extended Release, 90's	01/15/2019	57.26	1202.37	07/05/2027	Innovator Multiple Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	The information contained in this report is subject to the following limitations and assumptions. (1) Consistent with the relevant statutes and regulations, all information contained in this report is limited to that which Pfizer believes is otherwise in the public domain or publicly available. Where possible, Pfizer has used the non-public indicator to indicate it does not believe the corresponding data element is otherwise in the public domain or publicly available. (2) For Column 6, Pfizer did not provide a patent expiration date for products that have lost patent exclusivity. (3) For Columns 14-21, Pfizer has not provided a response for products that were not acquired from an unrelated company in the previous 5 years. (4) While Pfizer does not believe factors for a specific drug product’s price increases are in the public domain or publicly available, Pfizer has provided general information about its drug pricing philosophy and policy. More information about Pfizer’s general drug pricing philosophy and policy is available on Pfizer’s website.
Rx0000006	Pfizer	03/31/2019	00008084381	Protonix, 20 mg Tablet Delayed Release, 90's	01/15/2019	64.57	1355.89	None	Innovator Multiple Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	The information contained in this report is subject to the following limitations and assumptions. (1) Consistent with the relevant statutes and regulations, all information contained in this report is limited to that which Pfizer believes is otherwise in the public domain or publicly available. Where possible, Pfizer has used the non-public indicator to indicate it does not believe the corresponding data element is otherwise in the public domain or publicly available. (2) For Column 6, Pfizer did not provide a patent expiration date for products that have lost patent exclusivity. (3) For Columns 14-21, Pfizer has not provided a response for products that were not acquired from an unrelated company in the previous 5 years. (4) While Pfizer does not believe factors for a specific drug product’s price increases are in the public domain or publicly available, Pfizer has provided general information about its drug pricing philosophy and policy. More information about Pfizer’s general drug pricing philosophy and policy is available on Pfizer’s website.
Rx0000006	Pfizer	03/31/2019	00008084402	Protonix, 40 mg Packet, 30's	01/15/2019	21.52	451.94	None	Single Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	The information contained in this report is subject to the following limitations and assumptions. (1) Consistent with the relevant statutes and regulations, all information contained in this report is limited to that which Pfizer believes is otherwise in the public domain or publicly available. Where possible, Pfizer has used the non-public indicator to indicate it does not believe the corresponding data element is otherwise in the public domain or publicly available. (2) For Column 6, Pfizer did not provide a patent expiration date for products that have lost patent exclusivity. (3) For Columns 14-21, Pfizer has not provided a response for products that were not acquired from an unrelated company in the previous 5 years. (4) While Pfizer does not believe factors for a specific drug product’s price increases are in the public domain or publicly available, Pfizer has provided general information about its drug pricing philosophy and policy. More information about Pfizer’s general drug pricing philosophy and policy is available on Pfizer’s website.
Rx0000006	Pfizer	03/31/2019	00008084181	Protonix, 40 mg Tablet Delayed Release, 90's	01/15/2019	64.57	1355.89	None	Innovator Multiple Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	The information contained in this report is subject to the following limitations and assumptions. (1) Consistent with the relevant statutes and regulations, all information contained in this report is limited to that which Pfizer believes is otherwise in the public domain or publicly available. Where possible, Pfizer has used the non-public indicator to indicate it does not believe the corresponding data element is otherwise in the public domain or publicly available. (2) For Column 6, Pfizer did not provide a patent expiration date for products that have lost patent exclusivity. (3) For Columns 14-21, Pfizer has not provided a response for products that were not acquired from an unrelated company in the previous 5 years. (4) While Pfizer does not believe factors for a specific drug product’s price increases are in the public domain or publicly available, Pfizer has provided general information about its drug pricing philosophy and policy. More information about Pfizer’s general drug pricing philosophy and policy is available on Pfizer’s website.
Rx0000006	Pfizer	03/31/2019	00008104010	Rapamune, 0.5 mg Tablet Redipak, 10x10	01/15/2019	73.10	1535.15	None	Innovator Multiple Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	The information contained in this report is subject to the following limitations and assumptions. (1) Consistent with the relevant statutes and regulations, all information contained in this report is limited to that which Pfizer believes is otherwise in the public domain or publicly available. Where possible, Pfizer has used the non-public indicator to indicate it does not believe the corresponding data element is otherwise in the public domain or publicly available. (2) For Column 6, Pfizer did not provide a patent expiration date for products that have lost patent exclusivity. (3) For Columns 14-21, Pfizer has not provided a response for products that were not acquired from an unrelated company in the previous 5 years. (4) While Pfizer does not believe factors for a specific drug product’s price increases are in the public domain or publicly available, Pfizer has provided general information about its drug pricing philosophy and policy. More information about Pfizer’s general drug pricing philosophy and policy is available on Pfizer’s website.
Rx0000006	Pfizer	03/31/2019	00008104005	Rapamune, 0.5 mg Tablet, 100's	01/15/2019	73.10	1535.15	None	Innovator Multiple Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	The information contained in this report is subject to the following limitations and assumptions. (1) Consistent with the relevant statutes and regulations, all information contained in this report is limited to that which Pfizer believes is otherwise in the public domain or publicly available. Where possible, Pfizer has used the non-public indicator to indicate it does not believe the corresponding data element is otherwise in the public domain or publicly available. (2) For Column 6, Pfizer did not provide a patent expiration date for products that have lost patent exclusivity. (3) For Columns 14-21, Pfizer has not provided a response for products that were not acquired from an unrelated company in the previous 5 years. (4) While Pfizer does not believe factors for a specific drug product’s price increases are in the public domain or publicly available, Pfizer has provided general information about its drug pricing philosophy and policy. More information about Pfizer’s general drug pricing philosophy and policy is available on Pfizer’s website.
Rx0000006	Pfizer	03/31/2019	00008104110	Rapamune, 1 mg Tablet Redipak, 10x10	01/15/2019	146.20	3070.11	None	Innovator Multiple Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	The information contained in this report is subject to the following limitations and assumptions. (1) Consistent with the relevant statutes and regulations, all information contained in this report is limited to that which Pfizer believes is otherwise in the public domain or publicly available. Where possible, Pfizer has used the non-public indicator to indicate it does not believe the corresponding data element is otherwise in the public domain or publicly available. (2) For Column 6, Pfizer did not provide a patent expiration date for products that have lost patent exclusivity. (3) For Columns 14-21, Pfizer has not provided a response for products that were not acquired from an unrelated company in the previous 5 years. (4) While Pfizer does not believe factors for a specific drug product’s price increases are in the public domain or publicly available, Pfizer has provided general information about its drug pricing philosophy and policy. More information about Pfizer’s general drug pricing philosophy and policy is available on Pfizer’s website.
Rx0000006	Pfizer	03/31/2019	00008104105	Rapamune, 1 mg Tablet, 100's	01/15/2019	146.20	3070.11	None	Innovator Multiple Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	The information contained in this report is subject to the following limitations and assumptions. (1) Consistent with the relevant statutes and regulations, all information contained in this report is limited to that which Pfizer believes is otherwise in the public domain or publicly available. Where possible, Pfizer has used the non-public indicator to indicate it does not believe the corresponding data element is otherwise in the public domain or publicly available. (2) For Column 6, Pfizer did not provide a patent expiration date for products that have lost patent exclusivity. (3) For Columns 14-21, Pfizer has not provided a response for products that were not acquired from an unrelated company in the previous 5 years. (4) While Pfizer does not believe factors for a specific drug product’s price increases are in the public domain or publicly available, Pfizer has provided general information about its drug pricing philosophy and policy. More information about Pfizer’s general drug pricing philosophy and policy is available on Pfizer’s website.
Rx0000006	Pfizer	03/31/2019	00008104205	Rapamune, 2 mg Tablet, 100's	01/15/2019	292.39	6140.18	None	Innovator Multiple Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	The information contained in this report is subject to the following limitations and assumptions. (1) Consistent with the relevant statutes and regulations, all information contained in this report is limited to that which Pfizer believes is otherwise in the public domain or publicly available. Where possible, Pfizer has used the non-public indicator to indicate it does not believe the corresponding data element is otherwise in the public domain or publicly available. (2) For Column 6, Pfizer did not provide a patent expiration date for products that have lost patent exclusivity. (3) For Columns 14-21, Pfizer has not provided a response for products that were not acquired from an unrelated company in the previous 5 years. (4) While Pfizer does not believe factors for a specific drug product’s price increases are in the public domain or publicly available, Pfizer has provided general information about its drug pricing philosophy and policy. More information about Pfizer’s general drug pricing philosophy and policy is available on Pfizer’s website.
Rx0000006	Pfizer	03/31/2019	00009716601	Somavert, 10 mg/8 mL Syringe, 1's	01/15/2019	10.30	216.33	None	Single Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	The information contained in this report is subject to the following limitations and assumptions. (1) Consistent with the relevant statutes and regulations, all information contained in this report is limited to that which Pfizer believes is otherwise in the public domain or publicly available. Where possible, Pfizer has used the non-public indicator to indicate it does not believe the corresponding data element is otherwise in the public domain or publicly available. (2) For Column 6, Pfizer did not provide a patent expiration date for products that have lost patent exclusivity. (3) For Columns 14-21, Pfizer has not provided a response for products that were not acquired from an unrelated company in the previous 5 years. (4) While Pfizer does not believe factors for a specific drug product’s price increases are in the public domain or publicly available, Pfizer has provided general information about its drug pricing philosophy and policy. More information about Pfizer’s general drug pricing philosophy and policy is available on Pfizer’s website.
Rx0000006	Pfizer	03/31/2019	00009716801	Somavert, 15 mg/8 mL Syringe, 1's	01/15/2019	15.45	324.51	None	Single Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	The information contained in this report is subject to the following limitations and assumptions. (1) Consistent with the relevant statutes and regulations, all information contained in this report is limited to that which Pfizer believes is otherwise in the public domain or publicly available. Where possible, Pfizer has used the non-public indicator to indicate it does not believe the corresponding data element is otherwise in the public domain or publicly available. (2) For Column 6, Pfizer did not provide a patent expiration date for products that have lost patent exclusivity. (3) For Columns 14-21, Pfizer has not provided a response for products that were not acquired from an unrelated company in the previous 5 years. (4) While Pfizer does not believe factors for a specific drug product’s price increases are in the public domain or publicly available, Pfizer has provided general information about its drug pricing philosophy and policy. More information about Pfizer’s general drug pricing philosophy and policy is available on Pfizer’s website.
Rx0000006	Pfizer	03/31/2019	00009718801	Somavert, 20 mg/8 mL Syringe, 1's	01/15/2019	20.60	432.66	None	Single Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	The information contained in this report is subject to the following limitations and assumptions. (1) Consistent with the relevant statutes and regulations, all information contained in this report is limited to that which Pfizer believes is otherwise in the public domain or publicly available. Where possible, Pfizer has used the non-public indicator to indicate it does not believe the corresponding data element is otherwise in the public domain or publicly available. (2) For Column 6, Pfizer did not provide a patent expiration date for products that have lost patent exclusivity. (3) For Columns 14-21, Pfizer has not provided a response for products that were not acquired from an unrelated company in the previous 5 years. (4) While Pfizer does not believe factors for a specific drug product’s price increases are in the public domain or publicly available, Pfizer has provided general information about its drug pricing philosophy and policy. More information about Pfizer’s general drug pricing philosophy and policy is available on Pfizer’s website.
Rx0000006	Pfizer	03/31/2019	00009719901	Somavert, 25 mg/8 mL Syringe, 1's	01/15/2019	25.75	540.83	None	Single Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	The information contained in this report is subject to the following limitations and assumptions. (1) Consistent with the relevant statutes and regulations, all information contained in this report is limited to that which Pfizer believes is otherwise in the public domain or publicly available. Where possible, Pfizer has used the non-public indicator to indicate it does not believe the corresponding data element is otherwise in the public domain or publicly available. (2) For Column 6, Pfizer did not provide a patent expiration date for products that have lost patent exclusivity. (3) For Columns 14-21, Pfizer has not provided a response for products that were not acquired from an unrelated company in the previous 5 years. (4) While Pfizer does not believe factors for a specific drug product’s price increases are in the public domain or publicly available, Pfizer has provided general information about its drug pricing philosophy and policy. More information about Pfizer’s general drug pricing philosophy and policy is available on Pfizer’s website.
Rx0000006	Pfizer	03/31/2019	00009720001	Somavert, 30 mg/8 mL Syringe, 1's	01/15/2019	30.90	648.99	None	Single Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	The information contained in this report is subject to the following limitations and assumptions. (1) Consistent with the relevant statutes and regulations, all information contained in this report is limited to that which Pfizer believes is otherwise in the public domain or publicly available. Where possible, Pfizer has used the non-public indicator to indicate it does not believe the corresponding data element is otherwise in the public domain or publicly available. (2) For Column 6, Pfizer did not provide a patent expiration date for products that have lost patent exclusivity. (3) For Columns 14-21, Pfizer has not provided a response for products that were not acquired from an unrelated company in the previous 5 years. (4) While Pfizer does not believe factors for a specific drug product’s price increases are in the public domain or publicly available, Pfizer has provided general information about its drug pricing philosophy and policy. More information about Pfizer’s general drug pricing philosophy and policy is available on Pfizer’s website.
Rx0000006	Pfizer	03/31/2019	00069024230	Toviaz, 4 mg Tablet Extended Release, 30's	01/15/2019	15.79	331.59	06/07/2027	Single Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	The information contained in this report is subject to the following limitations and assumptions. (1) Consistent with the relevant statutes and regulations, all information contained in this report is limited to that which Pfizer believes is otherwise in the public domain or publicly available. Where possible, Pfizer has used the non-public indicator to indicate it does not believe the corresponding data element is otherwise in the public domain or publicly available. (2) For Column 6, Pfizer did not provide a patent expiration date for products that have lost patent exclusivity. (3) For Columns 14-21, Pfizer has not provided a response for products that were not acquired from an unrelated company in the previous 5 years. (4) While Pfizer does not believe factors for a specific drug product’s price increases are in the public domain or publicly available, Pfizer has provided general information about its drug pricing philosophy and policy. More information about Pfizer’s general drug pricing philosophy and policy is available on Pfizer’s website.
Rx0000006	Pfizer	03/31/2019	00069024430	Toviaz, 8 mg Tablet Extended Release, 30's	01/15/2019	15.79	331.59	06/07/2027	Single Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	The information contained in this report is subject to the following limitations and assumptions. (1) Consistent with the relevant statutes and regulations, all information contained in this report is limited to that which Pfizer believes is otherwise in the public domain or publicly available. Where possible, Pfizer has used the non-public indicator to indicate it does not believe the corresponding data element is otherwise in the public domain or publicly available. (2) For Column 6, Pfizer did not provide a patent expiration date for products that have lost patent exclusivity. (3) For Columns 14-21, Pfizer has not provided a response for products that were not acquired from an unrelated company in the previous 5 years. (4) While Pfizer does not believe factors for a specific drug product’s price increases are in the public domain or publicly available, Pfizer has provided general information about its drug pricing philosophy and policy. More information about Pfizer’s general drug pricing philosophy and policy is available on Pfizer’s website.
Rx0000006	Pfizer	03/31/2019	00069422033	Viagra, 100 mg Tablet Single Pack, 1x30	01/15/2019	101.03	2121.53	10/22/2019	Innovator Multiple Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	The information contained in this report is subject to the following limitations and assumptions. (1) Consistent with the relevant statutes and regulations, all information contained in this report is limited to that which Pfizer believes is otherwise in the public domain or publicly available. Where possible, Pfizer has used the non-public indicator to indicate it does not believe the corresponding data element is otherwise in the public domain or publicly available. (2) For Column 6, Pfizer did not provide a patent expiration date for products that have lost patent exclusivity. (3) For Columns 14-21, Pfizer has not provided a response for products that were not acquired from an unrelated company in the previous 5 years. (4) While Pfizer does not believe factors for a specific drug product’s price increases are in the public domain or publicly available, Pfizer has provided general information about its drug pricing philosophy and policy. More information about Pfizer’s general drug pricing philosophy and policy is available on Pfizer’s website.
Rx0000006	Pfizer	03/31/2019	00069422066	Viagra, 100 mg Tablet, 100's	01/15/2019	336.74	7071.56	10/22/2019	Innovator Multiple Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	The information contained in this report is subject to the following limitations and assumptions. (1) Consistent with the relevant statutes and regulations, all information contained in this report is limited to that which Pfizer believes is otherwise in the public domain or publicly available. Where possible, Pfizer has used the non-public indicator to indicate it does not believe the corresponding data element is otherwise in the public domain or publicly available. (2) For Column 6, Pfizer did not provide a patent expiration date for products that have lost patent exclusivity. (3) For Columns 14-21, Pfizer has not provided a response for products that were not acquired from an unrelated company in the previous 5 years. (4) While Pfizer does not believe factors for a specific drug product’s price increases are in the public domain or publicly available, Pfizer has provided general information about its drug pricing philosophy and policy. More information about Pfizer’s general drug pricing philosophy and policy is available on Pfizer’s website.
Rx0000006	Pfizer	03/31/2019	00069422030	Viagra, 100 mg Tablet, 30's	01/15/2019	101.03	2121.53	10/22/2019	Innovator Multiple Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	The information contained in this report is subject to the following limitations and assumptions. (1) Consistent with the relevant statutes and regulations, all information contained in this report is limited to that which Pfizer believes is otherwise in the public domain or publicly available. Where possible, Pfizer has used the non-public indicator to indicate it does not believe the corresponding data element is otherwise in the public domain or publicly available. (2) For Column 6, Pfizer did not provide a patent expiration date for products that have lost patent exclusivity. (3) For Columns 14-21, Pfizer has not provided a response for products that were not acquired from an unrelated company in the previous 5 years. (4) While Pfizer does not believe factors for a specific drug product’s price increases are in the public domain or publicly available, Pfizer has provided general information about its drug pricing philosophy and policy. More information about Pfizer’s general drug pricing philosophy and policy is available on Pfizer’s website.
Rx0000006	Pfizer	03/31/2019	00069420030	Viagra, 25 mg Tablet, 30's	01/15/2019	101.03	2121.53	10/22/2019	Innovator Multiple Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	The information contained in this report is subject to the following limitations and assumptions. (1) Consistent with the relevant statutes and regulations, all information contained in this report is limited to that which Pfizer believes is otherwise in the public domain or publicly available. Where possible, Pfizer has used the non-public indicator to indicate it does not believe the corresponding data element is otherwise in the public domain or publicly available. (2) For Column 6, Pfizer did not provide a patent expiration date for products that have lost patent exclusivity. (3) For Columns 14-21, Pfizer has not provided a response for products that were not acquired from an unrelated company in the previous 5 years. (4) While Pfizer does not believe factors for a specific drug product’s price increases are in the public domain or publicly available, Pfizer has provided general information about its drug pricing philosophy and policy. More information about Pfizer’s general drug pricing philosophy and policy is available on Pfizer’s website.
Rx0000006	Pfizer	03/31/2019	00069421033	Viagra, 50 mg Tablet Single Pack, 1x30	01/15/2019	101.03	2121.53	10/22/2019	Innovator Multiple Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	The information contained in this report is subject to the following limitations and assumptions. (1) Consistent with the relevant statutes and regulations, all information contained in this report is limited to that which Pfizer believes is otherwise in the public domain or publicly available. Where possible, Pfizer has used the non-public indicator to indicate it does not believe the corresponding data element is otherwise in the public domain or publicly available. (2) For Column 6, Pfizer did not provide a patent expiration date for products that have lost patent exclusivity. (3) For Columns 14-21, Pfizer has not provided a response for products that were not acquired from an unrelated company in the previous 5 years. (4) While Pfizer does not believe factors for a specific drug product’s price increases are in the public domain or publicly available, Pfizer has provided general information about its drug pricing philosophy and policy. More information about Pfizer’s general drug pricing philosophy and policy is available on Pfizer’s website.
Rx0000006	Pfizer	03/31/2019	00069421066	Viagra, 50 mg Tablet, 100's	01/15/2019	336.74	7071.56	10/22/2019	Innovator Multiple Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	The information contained in this report is subject to the following limitations and assumptions. (1) Consistent with the relevant statutes and regulations, all information contained in this report is limited to that which Pfizer believes is otherwise in the public domain or publicly available. Where possible, Pfizer has used the non-public indicator to indicate it does not believe the corresponding data element is otherwise in the public domain or publicly available. (2) For Column 6, Pfizer did not provide a patent expiration date for products that have lost patent exclusivity. (3) For Columns 14-21, Pfizer has not provided a response for products that were not acquired from an unrelated company in the previous 5 years. (4) While Pfizer does not believe factors for a specific drug product’s price increases are in the public domain or publicly available, Pfizer has provided general information about its drug pricing philosophy and policy. More information about Pfizer’s general drug pricing philosophy and policy is available on Pfizer’s website.
Rx0000006	Pfizer	03/31/2019	00069421030	Viagra, 50 mg Tablet, 30's	01/15/2019	101.03	2121.53	10/22/2019	Innovator Multiple Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	The information contained in this report is subject to the following limitations and assumptions. (1) Consistent with the relevant statutes and regulations, all information contained in this report is limited to that which Pfizer believes is otherwise in the public domain or publicly available. Where possible, Pfizer has used the non-public indicator to indicate it does not believe the corresponding data element is otherwise in the public domain or publicly available. (2) For Column 6, Pfizer did not provide a patent expiration date for products that have lost patent exclusivity. (3) For Columns 14-21, Pfizer has not provided a response for products that were not acquired from an unrelated company in the previous 5 years. (4) While Pfizer does not believe factors for a specific drug product’s price increases are in the public domain or publicly available, Pfizer has provided general information about its drug pricing philosophy and policy. More information about Pfizer’s general drug pricing philosophy and policy is available on Pfizer’s website.
Rx0000006	Pfizer	03/31/2019	00009002901	Xanax, 0.25 mg Tablet, 100's	01/15/2019	20.00	420.08	None	Innovator Multiple Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	The information contained in this report is subject to the following limitations and assumptions. (1) Consistent with the relevant statutes and regulations, all information contained in this report is limited to that which Pfizer believes is otherwise in the public domain or publicly available. Where possible, Pfizer has used the non-public indicator to indicate it does not believe the corresponding data element is otherwise in the public domain or publicly available. (2) For Column 6, Pfizer did not provide a patent expiration date for products that have lost patent exclusivity. (3) For Columns 14-21, Pfizer has not provided a response for products that were not acquired from an unrelated company in the previous 5 years. (4) While Pfizer does not believe factors for a specific drug product’s price increases are in the public domain or publicly available, Pfizer has provided general information about its drug pricing philosophy and policy. More information about Pfizer’s general drug pricing philosophy and policy is available on Pfizer’s website.
Rx0000006	Pfizer	03/31/2019	00009002902	Xanax, 0.25 mg Tablet, 500's	01/15/2019	100.02	2100.36	None	Innovator Multiple Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	The information contained in this report is subject to the following limitations and assumptions. (1) Consistent with the relevant statutes and regulations, all information contained in this report is limited to that which Pfizer believes is otherwise in the public domain or publicly available. Where possible, Pfizer has used the non-public indicator to indicate it does not believe the corresponding data element is otherwise in the public domain or publicly available. (2) For Column 6, Pfizer did not provide a patent expiration date for products that have lost patent exclusivity. (3) For Columns 14-21, Pfizer has not provided a response for products that were not acquired from an unrelated company in the previous 5 years. (4) While Pfizer does not believe factors for a specific drug product’s price increases are in the public domain or publicly available, Pfizer has provided general information about its drug pricing philosophy and policy. More information about Pfizer’s general drug pricing philosophy and policy is available on Pfizer’s website.
Rx0000006	Pfizer	03/31/2019	00009005501	Xanax, 0.5 mg Tablet, 100's	01/15/2019	24.92	523.34	None	Innovator Multiple Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	The information contained in this report is subject to the following limitations and assumptions. (1) Consistent with the relevant statutes and regulations, all information contained in this report is limited to that which Pfizer believes is otherwise in the public domain or publicly available. Where possible, Pfizer has used the non-public indicator to indicate it does not believe the corresponding data element is otherwise in the public domain or publicly available. (2) For Column 6, Pfizer did not provide a patent expiration date for products that have lost patent exclusivity. (3) For Columns 14-21, Pfizer has not provided a response for products that were not acquired from an unrelated company in the previous 5 years. (4) While Pfizer does not believe factors for a specific drug product’s price increases are in the public domain or publicly available, Pfizer has provided general information about its drug pricing philosophy and policy. More information about Pfizer’s general drug pricing philosophy and policy is available on Pfizer’s website.
Rx0000006	Pfizer	03/31/2019	00009005503	Xanax, 0.5 mg Tablet, 500's	01/15/2019	124.61	2616.73	None	Innovator Multiple Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	The information contained in this report is subject to the following limitations and assumptions. (1) Consistent with the relevant statutes and regulations, all information contained in this report is limited to that which Pfizer believes is otherwise in the public domain or publicly available. Where possible, Pfizer has used the non-public indicator to indicate it does not believe the corresponding data element is otherwise in the public domain or publicly available. (2) For Column 6, Pfizer did not provide a patent expiration date for products that have lost patent exclusivity. (3) For Columns 14-21, Pfizer has not provided a response for products that were not acquired from an unrelated company in the previous 5 years. (4) While Pfizer does not believe factors for a specific drug product’s price increases are in the public domain or publicly available, Pfizer has provided general information about its drug pricing philosophy and policy. More information about Pfizer’s general drug pricing philosophy and policy is available on Pfizer’s website.
Rx0000006	Pfizer	03/31/2019	00009009001	Xanax, 1 mg Tablet, 100's	01/15/2019	33.25	698.32	None	Innovator Multiple Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	The information contained in this report is subject to the following limitations and assumptions. (1) Consistent with the relevant statutes and regulations, all information contained in this report is limited to that which Pfizer believes is otherwise in the public domain or publicly available. Where possible, Pfizer has used the non-public indicator to indicate it does not believe the corresponding data element is otherwise in the public domain or publicly available. (2) For Column 6, Pfizer did not provide a patent expiration date for products that have lost patent exclusivity. (3) For Columns 14-21, Pfizer has not provided a response for products that were not acquired from an unrelated company in the previous 5 years. (4) While Pfizer does not believe factors for a specific drug product’s price increases are in the public domain or publicly available, Pfizer has provided general information about its drug pricing philosophy and policy. More information about Pfizer’s general drug pricing philosophy and policy is available on Pfizer’s website.
Rx0000006	Pfizer	03/31/2019	00009009004	Xanax, 1 mg Tablet, 500's	01/15/2019	166.27	3491.57	None	Innovator Multiple Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	The information contained in this report is subject to the following limitations and assumptions. (1) Consistent with the relevant statutes and regulations, all information contained in this report is limited to that which Pfizer believes is otherwise in the public domain or publicly available. Where possible, Pfizer has used the non-public indicator to indicate it does not believe the corresponding data element is otherwise in the public domain or publicly available. (2) For Column 6, Pfizer did not provide a patent expiration date for products that have lost patent exclusivity. (3) For Columns 14-21, Pfizer has not provided a response for products that were not acquired from an unrelated company in the previous 5 years. (4) While Pfizer does not believe factors for a specific drug product’s price increases are in the public domain or publicly available, Pfizer has provided general information about its drug pricing philosophy and policy. More information about Pfizer’s general drug pricing philosophy and policy is available on Pfizer’s website.
Rx0000006	Pfizer	03/31/2019	00009009401	Xanax, 2 mg Tablet, 100's	01/15/2019	56.54	1187.32	None	Innovator Multiple Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	The information contained in this report is subject to the following limitations and assumptions. (1) Consistent with the relevant statutes and regulations, all information contained in this report is limited to that which Pfizer believes is otherwise in the public domain or publicly available. Where possible, Pfizer has used the non-public indicator to indicate it does not believe the corresponding data element is otherwise in the public domain or publicly available. (2) For Column 6, Pfizer did not provide a patent expiration date for products that have lost patent exclusivity. (3) For Columns 14-21, Pfizer has not provided a response for products that were not acquired from an unrelated company in the previous 5 years. (4) While Pfizer does not believe factors for a specific drug product’s price increases are in the public domain or publicly available, Pfizer has provided general information about its drug pricing philosophy and policy. More information about Pfizer’s general drug pricing philosophy and policy is available on Pfizer’s website.
Rx0000006	Pfizer	03/31/2019	00069050130	Xeljanz, 11 mg Tablet, 1x30	01/15/2019	384.99	4480.63	12/08/2025	Single Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	The information contained in this report is subject to the following limitations and assumptions. (1) Consistent with the relevant statutes and regulations, all information contained in this report is limited to that which Pfizer believes is otherwise in the public domain or publicly available. Where possible, Pfizer has used the non-public indicator to indicate it does not believe the corresponding data element is otherwise in the public domain or publicly available. (2) For Column 6, Pfizer did not provide a patent expiration date for products that have lost patent exclusivity. (3) For Columns 14-21, Pfizer has not provided a response for products that were not acquired from an unrelated company in the previous 5 years. (4) While Pfizer does not believe factors for a specific drug product’s price increases are in the public domain or publicly available, Pfizer has provided general information about its drug pricing philosophy and policy. More information about Pfizer’s general drug pricing philosophy and policy is available on Pfizer’s website.
Rx0000006	Pfizer	03/31/2019	00069100101	Xeljanz, 5 mg Tablet, 60's	01/15/2019	384.99	4480.63	12/08/2025	Single Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	The information contained in this report is subject to the following limitations and assumptions. (1) Consistent with the relevant statutes and regulations, all information contained in this report is limited to that which Pfizer believes is otherwise in the public domain or publicly available. Where possible, Pfizer has used the non-public indicator to indicate it does not believe the corresponding data element is otherwise in the public domain or publicly available. (2) For Column 6, Pfizer did not provide a patent expiration date for products that have lost patent exclusivity. (3) For Columns 14-21, Pfizer has not provided a response for products that were not acquired from an unrelated company in the previous 5 years. (4) While Pfizer does not believe factors for a specific drug product’s price increases are in the public domain or publicly available, Pfizer has provided general information about its drug pricing philosophy and policy. More information about Pfizer’s general drug pricing philosophy and policy is available on Pfizer’s website.
Rx0000006	Pfizer	03/31/2019	00049491041	Zoloft, 100 mg Tablet Unit Dose Pak, (10x10)	01/15/2019	53.11	1115.23	None	Innovator Multiple Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	The information contained in this report is subject to the following limitations and assumptions. (1) Consistent with the relevant statutes and regulations, all information contained in this report is limited to that which Pfizer believes is otherwise in the public domain or publicly available. Where possible, Pfizer has used the non-public indicator to indicate it does not believe the corresponding data element is otherwise in the public domain or publicly available. (2) For Column 6, Pfizer did not provide a patent expiration date for products that have lost patent exclusivity. (3) For Columns 14-21, Pfizer has not provided a response for products that were not acquired from an unrelated company in the previous 5 years. (4) While Pfizer does not believe factors for a specific drug product’s price increases are in the public domain or publicly available, Pfizer has provided general information about its drug pricing philosophy and policy. More information about Pfizer’s general drug pricing philosophy and policy is available on Pfizer’s website.
Rx0000006	Pfizer	03/31/2019	00049491030	Zoloft, 100 mg Tablet, 30's	01/15/2019	15.93	334.55	None	Innovator Multiple Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	The information contained in this report is subject to the following limitations and assumptions. (1) Consistent with the relevant statutes and regulations, all information contained in this report is limited to that which Pfizer believes is otherwise in the public domain or publicly available. Where possible, Pfizer has used the non-public indicator to indicate it does not believe the corresponding data element is otherwise in the public domain or publicly available. (2) For Column 6, Pfizer did not provide a patent expiration date for products that have lost patent exclusivity. (3) For Columns 14-21, Pfizer has not provided a response for products that were not acquired from an unrelated company in the previous 5 years. (4) While Pfizer does not believe factors for a specific drug product’s price increases are in the public domain or publicly available, Pfizer has provided general information about its drug pricing philosophy and policy. More information about Pfizer’s general drug pricing philosophy and policy is available on Pfizer’s website.
Rx0000006	Pfizer	03/31/2019	00049496030	Zoloft, 25 mg Tablet, 30's	01/15/2019	15.93	334.55	None	Innovator Multiple Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	The information contained in this report is subject to the following limitations and assumptions. (1) Consistent with the relevant statutes and regulations, all information contained in this report is limited to that which Pfizer believes is otherwise in the public domain or publicly available. Where possible, Pfizer has used the non-public indicator to indicate it does not believe the corresponding data element is otherwise in the public domain or publicly available. (2) For Column 6, Pfizer did not provide a patent expiration date for products that have lost patent exclusivity. (3) For Columns 14-21, Pfizer has not provided a response for products that were not acquired from an unrelated company in the previous 5 years. (4) While Pfizer does not believe factors for a specific drug product’s price increases are in the public domain or publicly available, Pfizer has provided general information about its drug pricing philosophy and policy. More information about Pfizer’s general drug pricing philosophy and policy is available on Pfizer’s website.
Rx0000006	Pfizer	03/31/2019	00049490041	Zoloft, 50 mg Tablet Unit Dose Pak, (10x10)	01/15/2019	53.11	1115.23	None	Innovator Multiple Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	The information contained in this report is subject to the following limitations and assumptions. (1) Consistent with the relevant statutes and regulations, all information contained in this report is limited to that which Pfizer believes is otherwise in the public domain or publicly available. Where possible, Pfizer has used the non-public indicator to indicate it does not believe the corresponding data element is otherwise in the public domain or publicly available. (2) For Column 6, Pfizer did not provide a patent expiration date for products that have lost patent exclusivity. (3) For Columns 14-21, Pfizer has not provided a response for products that were not acquired from an unrelated company in the previous 5 years. (4) While Pfizer does not believe factors for a specific drug product’s price increases are in the public domain or publicly available, Pfizer has provided general information about its drug pricing philosophy and policy. More information about Pfizer’s general drug pricing philosophy and policy is available on Pfizer’s website.
Rx0000006	Pfizer	03/31/2019	00049490030	Zoloft, 50 mg Tablet, 30's	01/15/2019	15.93	334.55	None	Innovator Multiple Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	The information contained in this report is subject to the following limitations and assumptions. (1) Consistent with the relevant statutes and regulations, all information contained in this report is limited to that which Pfizer believes is otherwise in the public domain or publicly available. Where possible, Pfizer has used the non-public indicator to indicate it does not believe the corresponding data element is otherwise in the public domain or publicly available. (2) For Column 6, Pfizer did not provide a patent expiration date for products that have lost patent exclusivity. (3) For Columns 14-21, Pfizer has not provided a response for products that were not acquired from an unrelated company in the previous 5 years. (4) While Pfizer does not believe factors for a specific drug product’s price increases are in the public domain or publicly available, Pfizer has provided general information about its drug pricing philosophy and policy. More information about Pfizer’s general drug pricing philosophy and policy is available on Pfizer’s website.
Rx0000135	Pharmaceutical Associates, Inc	03/31/2019	00121154440	Hydrocodone / Apap Oral Solution 5/217mg/10mL 10mL	02/01/2019	59.84	327.21	None	Non-innovator Multiple Source Drug	995	None	to remain competitive as determined by our pricing committee	None	No change or Improvement to product.	None	None	None	None	None	None	None	None	None	None	None	Per email where the listed WAC price change dates do not match Medi-Span price change dates. The dates listed in this report are the dates that the WAC price was changed in our ERP system and customers were charged the new WAC price. The drug was not acquired so the acquisition related fields are empty.
Rx0000135	Pharmaceutical Associates, Inc	03/31/2019	00121231640	Hydrocodone /Apap Oral Solution 7.5/217mg/15mL 15mL	02/01/2019	168.33	330.88	None	Non-innovator Multiple Source Drug	2410	None	to remain competitive as determined by our pricing committee	None	No change or Improvement to product.	None	None	None	None	None	None	None	None	None	None	None	Per email where the listed WAC price change dates do not match Medi-Span price change dates. The dates listed in this report are the dates that the WAC price was changed in our ERP system and customers were charged the new WAC price. The drug was not acquired so the acquisition related fields are empty.
Rx0000135	Pharmaceutical Associates, Inc	03/31/2019	00121059500	Sodium Citrate and Citric Acid Oral Solution 1500/1002mg 15 mL	02/01/2019	69.05	297.70	None	Non-innovator Multiple Source Drug	1687	None	to remain competitive as determined by our pricing committee	None	No change or Improvement to product.	None	None	None	None	None	None	None	None	None	None	None	Per email where the listed WAC price change dates do not match Medi-Span price change dates. The dates listed in this report are the dates that the WAC price was changed in our ERP system and customers were charged the new WAC price. The drug was not acquired so the acquisition related fields are empty.
Rx0000135	Pharmaceutical Associates, Inc	03/31/2019	00121119000	Sodium Citrate and Citric Acid Oral Solution 3000/2004mg 30 mL	02/01/2019	74.94	323.05	None	Non-innovator Multiple Source Drug	3098	None	to remain competitive as determined by our pricing committee	None	No change or Improvement to product.	None	None	None	None	None	None	None	None	None	None	None	Per email where the listed WAC price change dates do not match Medi-Span price change dates. The dates listed in this report are the dates that the WAC price was changed in our ERP system and customers were charged the new WAC price. The drug was not acquired so the acquisition related fields are empty.
Rx0000289	Piramal Critical Care	09/30/2019	66794020641	Ampicillin / Sulbactam For Inj USP 1.5 G	09/20/2019	12.50	65.00	None	Non-innovator Multiple Source Drug	9127	None	Change in market & cost conditions	None	No change or improvement in the drug product	None	None	None	None	None	None	None	None	None	None	None	Pursuant to CA Health & Safety Code ?127681 (c), Piramal is limiting its response to that which is otherwise in the public domain or publicly available. With respect to Patent Expiration Date, this is a generic drug product and this does not apply. This product was not acquired; however, Piramal distributes on a non-exclusive basis. Piramal does not believe this information is publicly available and has not released this information in the public domain. Piramal does not believe this information is publicly available and has not released this information in the public domain.
Rx0000289	Piramal Critical Care	03/31/2019	66794064902	Levothyroxine Sod for Inj 100mcg/vial	01/18/2019	24.95	124.70	None	Innovator Multiple Source Drug	24261	None	Change in market conditions	None	No change or improvement in the drug product	None	01/18/2018	Fera Pharmaceuticals LLC and Oakwood Laboratories LLC	None	1	None	99.75	None	2018	99.75	None	Pursuant to CA Health & Safety Code ?127681 (c), Piramal is limiting its response to that which is otherwise in the public domain or publicly available. With respect to Patent Expiration Date, this is a generic drug product and this does not apply. Piramal acquired rights to this product from Fera Pharmaceuticals and Oakwood Laboratories on January 18, 2018. Piramal does not believe this information is publicly available and has not released this information in the public domain. WAC information from Fera/Oakwood was not available; therefore, based on information provided and confirmed by the State of California, Piramal has inserted $99.75 in column 19 WAC at Acquisition and column 22 WAC at Introduction.
Rx0000056	Purdue Pharma LP	03/31/2019	59011075104	BUTRANS 10MCG/HOUR TDS 4S	01/02/2019	38.25	440.93	None	Innovator Multiple Source Drug	None	1	None	1	None	None	None	None	None	None	None	None	None	None	None	None	General comment on acquisition information: This product was not acquired from another company. General comments on Cost Increase Factors: As a private company, we do not publicly disclose a majority of this information. However, Purdue Pharma LP does continue to make significant investments into the research and development of new medicines to address unmet medical needs of patients. We are focusing our research and development efforts in various therapeutic areas, including oncology, non-pain CNS disorders (insomnia and ADHD), and non-opioid pain medications. Successful development of these therapies could produce both positive impacts for patients with unmet medical needs and the public health.
Rx0000056	Purdue Pharma LP	03/31/2019	59011075804	BUTRANS 15 MCG/HOUR TDS 4S	01/02/2019	55.18	636.04	None	Innovator Multiple Source Drug	None	1	None	1	None	None	None	None	None	None	None	None	None	None	None	None	General comment on acquisition information: This product was not acquired from another company. General comments on Cost Increase Factors: As a private company, we do not publicly disclose a majority of this information. However, Purdue Pharma LP does continue to make significant investments into the research and development of new medicines to address unmet medical needs of patients. We are focusing our research and development efforts in various therapeutic areas, including oncology, non-pain CNS disorders (insomnia and ADHD), and non-opioid pain medications. Successful development of these therapies could produce both positive impacts for patients with unmet medical needs and the public health.
Rx0000056	Purdue Pharma LP	03/31/2019	59011075204	BUTRANS 20MCG/HOUR TDS 4S	01/02/2019	67.72	780.60	None	Innovator Multiple Source Drug	None	1	None	1	None	None	None	None	None	None	None	None	None	None	None	None	General comment on acquisition information: This product was not acquired from another company. General comments on Cost Increase Factors: As a private company, we do not publicly disclose a majority of this information. However, Purdue Pharma LP does continue to make significant investments into the research and development of new medicines to address unmet medical needs of patients. We are focusing our research and development efforts in various therapeutic areas, including oncology, non-pain CNS disorders (insomnia and ADHD), and non-opioid pain medications. Successful development of these therapies could produce both positive impacts for patients with unmet medical needs and the public health.
Rx0000056	Purdue Pharma LP	03/31/2019	59011075004	BUTRANS 5 MCG/HOUR TDS 4S	01/02/2019	25.50	293.95	None	Innovator Multiple Source Drug	None	1	None	1	None	None	None	None	None	None	None	None	None	None	None	None	General comment on acquisition information: This product was not acquired from another company. General comments on Cost Increase Factors: As a private company, we do not publicly disclose a majority of this information. However, Purdue Pharma LP does continue to make significant investments into the research and development of new medicines to address unmet medical needs of patients. We are focusing our research and development efforts in various therapeutic areas, including oncology, non-pain CNS disorders (insomnia and ADHD), and non-opioid pain medications. Successful development of these therapies could produce both positive impacts for patients with unmet medical needs and the public health.
Rx0000056	Purdue Pharma LP	03/31/2019	59011075704	BUTRANS 7.5 MCG/HOUR TDS 4S	01/02/2019	35.69	411.52	None	Innovator Multiple Source Drug	None	1	None	1	None	None	None	None	None	None	None	None	None	None	None	None	General comment on acquisition information: This product was not acquired from another company. General comments on Cost Increase Factors: As a private company, we do not publicly disclose a majority of this information. However, Purdue Pharma LP does continue to make significant investments into the research and development of new medicines to address unmet medical needs of patients. We are focusing our research and development efforts in various therapeutic areas, including oncology, non-pain CNS disorders (insomnia and ADHD), and non-opioid pain medications. Successful development of these therapies could produce both positive impacts for patients with unmet medical needs and the public health.
Rx0000056	Purdue Pharma LP	03/31/2019	59011027660	HYSINGLA ER 100MG TABLETS 60S	01/02/2019	229.67	2647.30	12/21/2031	Single Source Drug	None	1	None	1	None	None	None	None	None	None	None	None	None	None	None	None	General comment on acquisition information: This product was not acquired from another company. General comments on Cost Increase Factors: As a private company, we do not publicly disclose a majority of this information. However, Purdue Pharma LP does continue to make significant investments into the research and development of new medicines to address unmet medical needs of patients. We are focusing our research and development efforts in various therapeutic areas, including oncology, non-pain CNS disorders (insomnia and ADHD), and non-opioid pain medications. Successful development of these therapies could produce both positive impacts for patients with unmet medical needs and the public health.
Rx0000056	Purdue Pharma LP	03/31/2019	59011027760	HYSINGLA ER 120MG TABLETS 60S	01/02/2019	254.52	2933.69	12/21/2031	Single Source Drug	None	1	None	1	None	None	None	None	None	None	None	None	None	None	None	None	General comment on acquisition information: This product was not acquired from another company. General comments on Cost Increase Factors: As a private company, we do not publicly disclose a majority of this information. However, Purdue Pharma LP does continue to make significant investments into the research and development of new medicines to address unmet medical needs of patients. We are focusing our research and development efforts in various therapeutic areas, including oncology, non-pain CNS disorders (insomnia and ADHD), and non-opioid pain medications. Successful development of these therapies could produce both positive impacts for patients with unmet medical needs and the public health.
Rx0000056	Purdue Pharma LP	03/31/2019	59011027160	HYSINGLA ER 20MG TABLETS 60S	01/02/2019	49.17	566.73	12/21/2031	Single Source Drug	None	1	None	1	None	None	None	None	None	None	None	None	None	None	None	None	General comment on acquisition information: This product was not acquired from another company. General comments on Cost Increase Factors: As a private company, we do not publicly disclose a majority of this information. However, Purdue Pharma LP does continue to make significant investments into the research and development of new medicines to address unmet medical needs of patients. We are focusing our research and development efforts in various therapeutic areas, including oncology, non-pain CNS disorders (insomnia and ADHD), and non-opioid pain medications. Successful development of these therapies could produce both positive impacts for patients with unmet medical needs and the public health.
Rx0000056	Purdue Pharma LP	03/31/2019	59011027260	HYSINGLA ER 30MG TABLETS 60S	01/02/2019	71.77	827.23	12/21/2031	Single Source Drug	None	1	None	1	None	None	None	None	None	None	None	None	None	None	None	None	General comment on acquisition information: This product was not acquired from another company. General comments on Cost Increase Factors: As a private company, we do not publicly disclose a majority of this information. However, Purdue Pharma LP does continue to make significant investments into the research and development of new medicines to address unmet medical needs of patients. We are focusing our research and development efforts in various therapeutic areas, including oncology, non-pain CNS disorders (insomnia and ADHD), and non-opioid pain medications. Successful development of these therapies could produce both positive impacts for patients with unmet medical needs and the public health.
Rx0000056	Purdue Pharma LP	03/31/2019	59011027360	HYSINGLA ER 40MG TABLETS 60S	01/02/2019	96.69	1114.47	12/21/2031	Single Source Drug	None	1	None	1	None	None	None	None	None	None	None	None	None	None	None	None	General comment on acquisition information: This product was not acquired from another company. General comments on Cost Increase Factors: As a private company, we do not publicly disclose a majority of this information. However, Purdue Pharma LP does continue to make significant investments into the research and development of new medicines to address unmet medical needs of patients. We are focusing our research and development efforts in various therapeutic areas, including oncology, non-pain CNS disorders (insomnia and ADHD), and non-opioid pain medications. Successful development of these therapies could produce both positive impacts for patients with unmet medical needs and the public health.
Rx0000056	Purdue Pharma LP	03/31/2019	59011027460	HYSINGLA ER 60MG TABLETS 60S	01/02/2019	133.88	1543.18	12/21/2031	Single Source Drug	None	1	None	1	None	None	None	None	None	None	None	None	None	None	None	None	General comment on acquisition information: This product was not acquired from another company. General comments on Cost Increase Factors: As a private company, we do not publicly disclose a majority of this information. However, Purdue Pharma LP does continue to make significant investments into the research and development of new medicines to address unmet medical needs of patients. We are focusing our research and development efforts in various therapeutic areas, including oncology, non-pain CNS disorders (insomnia and ADHD), and non-opioid pain medications. Successful development of these therapies could produce both positive impacts for patients with unmet medical needs and the public health.
Rx0000056	Purdue Pharma LP	03/31/2019	59011027560	HYSINGLA ER 80MG TABLETS 60S	01/02/2019	180.51	2080.58	12/21/2031	Single Source Drug	None	1	None	1	None	None	None	None	None	None	None	None	None	None	None	None	General comment on acquisition information: This product was not acquired from another company. General comments on Cost Increase Factors: As a private company, we do not publicly disclose a majority of this information. However, Purdue Pharma LP does continue to make significant investments into the research and development of new medicines to address unmet medical needs of patients. We are focusing our research and development efforts in various therapeutic areas, including oncology, non-pain CNS disorders (insomnia and ADHD), and non-opioid pain medications. Successful development of these therapies could produce both positive impacts for patients with unmet medical needs and the public health.
Rx0000056	Purdue Pharma LP	03/31/2019	59011041010	OXYCONTIN 10MG TABLETS 100S	01/02/2019	34.92	402.46	03/29/2030	Innovator Multiple Source Drug	None	1	None	1	None	None	None	None	None	None	None	None	None	None	None	None	General comment on acquisition information: This product was not acquired from another company. General comments on Cost Increase Factors: As a private company, we do not publicly disclose a majority of this information. However, Purdue Pharma LP does continue to make significant investments into the research and development of new medicines to address unmet medical needs of patients. We are focusing our research and development efforts in various therapeutic areas, including oncology, non-pain CNS disorders (insomnia and ADHD), and non-opioid pain medications. Successful development of these therapies could produce both positive impacts for patients with unmet medical needs and the public health.
Rx0000056	Purdue Pharma LP	03/31/2019	59011041020	OXYCONTIN 10MG TABLETS HUD 20S	01/02/2019	7.17	82.64	03/29/2030	Innovator Multiple Source Drug	None	1	None	1	None	None	None	None	None	None	None	None	None	None	None	None	General comment on acquisition information: This product was not acquired from another company. General comments on Cost Increase Factors: As a private company, we do not publicly disclose a majority of this information. However, Purdue Pharma LP does continue to make significant investments into the research and development of new medicines to address unmet medical needs of patients. We are focusing our research and development efforts in various therapeutic areas, including oncology, non-pain CNS disorders (insomnia and ADHD), and non-opioid pain medications. Successful development of these therapies could produce both positive impacts for patients with unmet medical needs and the public health.
Rx0000056	Purdue Pharma LP	03/31/2019	59011041510	OXYCONTIN 15MG TABLETS 100S	01/02/2019	51.40	592.49	03/29/2030	Innovator Multiple Source Drug	None	1	None	1	None	None	None	None	None	None	None	None	None	None	None	None	General comment on acquisition information: This product was not acquired from another company. General comments on Cost Increase Factors: As a private company, we do not publicly disclose a majority of this information. However, Purdue Pharma LP does continue to make significant investments into the research and development of new medicines to address unmet medical needs of patients. We are focusing our research and development efforts in various therapeutic areas, including oncology, non-pain CNS disorders (insomnia and ADHD), and non-opioid pain medications. Successful development of these therapies could produce both positive impacts for patients with unmet medical needs and the public health.
Rx0000056	Purdue Pharma LP	03/31/2019	59011041520	OXYCONTIN 15MG TABLETS HUD 20S	01/02/2019	10.55	121.56	03/29/2030	Innovator Multiple Source Drug	None	1	None	1	None	None	None	None	None	None	None	None	None	None	None	None	General comment on acquisition information: This product was not acquired from another company. General comments on Cost Increase Factors: As a private company, we do not publicly disclose a majority of this information. However, Purdue Pharma LP does continue to make significant investments into the research and development of new medicines to address unmet medical needs of patients. We are focusing our research and development efforts in various therapeutic areas, including oncology, non-pain CNS disorders (insomnia and ADHD), and non-opioid pain medications. Successful development of these therapies could produce both positive impacts for patients with unmet medical needs and the public health.
Rx0000056	Purdue Pharma LP	03/31/2019	59011042010	OXYCONTIN 20MG TABLETS 100S	01/02/2019	65.12	750.57	03/29/2030	Innovator Multiple Source Drug	None	1	None	1	None	None	None	None	None	None	None	None	None	None	None	None	General comment on acquisition information: This product was not acquired from another company. General comments on Cost Increase Factors: As a private company, we do not publicly disclose a majority of this information. However, Purdue Pharma LP does continue to make significant investments into the research and development of new medicines to address unmet medical needs of patients. We are focusing our research and development efforts in various therapeutic areas, including oncology, non-pain CNS disorders (insomnia and ADHD), and non-opioid pain medications. Successful development of these therapies could produce both positive impacts for patients with unmet medical needs and the public health.
Rx0000056	Purdue Pharma LP	03/31/2019	59011042020	OXYCONTIN 20MG TABLETS HUD 20S	01/02/2019	13.36	153.96	03/29/2030	Innovator Multiple Source Drug	None	1	None	1	None	None	None	None	None	None	None	None	None	None	None	None	General comment on acquisition information: This product was not acquired from another company. General comments on Cost Increase Factors: As a private company, we do not publicly disclose a majority of this information. However, Purdue Pharma LP does continue to make significant investments into the research and development of new medicines to address unmet medical needs of patients. We are focusing our research and development efforts in various therapeutic areas, including oncology, non-pain CNS disorders (insomnia and ADHD), and non-opioid pain medications. Successful development of these therapies could produce both positive impacts for patients with unmet medical needs and the public health.
Rx0000056	Purdue Pharma LP	03/31/2019	59011043010	OXYCONTIN 30MG TABLETS 100S	01/02/2019	90.56	1043.86	03/29/2030	Innovator Multiple Source Drug	None	1	None	1	None	None	None	None	None	None	None	None	None	None	None	None	General comment on acquisition information: This product was not acquired from another company. General comments on Cost Increase Factors: As a private company, we do not publicly disclose a majority of this information. However, Purdue Pharma LP does continue to make significant investments into the research and development of new medicines to address unmet medical needs of patients. We are focusing our research and development efforts in various therapeutic areas, including oncology, non-pain CNS disorders (insomnia and ADHD), and non-opioid pain medications. Successful development of these therapies could produce both positive impacts for patients with unmet medical needs and the public health.
Rx0000056	Purdue Pharma LP	03/31/2019	59011043020	OXYCONTIN 30MG TABLETS HUD 20S	01/02/2019	18.58	214.17	03/29/2030	Innovator Multiple Source Drug	None	1	None	1	None	None	None	None	None	None	None	None	None	None	None	None	General comment on acquisition information: This product was not acquired from another company. General comments on Cost Increase Factors: As a private company, we do not publicly disclose a majority of this information. However, Purdue Pharma LP does continue to make significant investments into the research and development of new medicines to address unmet medical needs of patients. We are focusing our research and development efforts in various therapeutic areas, including oncology, non-pain CNS disorders (insomnia and ADHD), and non-opioid pain medications. Successful development of these therapies could produce both positive impacts for patients with unmet medical needs and the public health.
Rx0000056	Purdue Pharma LP	03/31/2019	59011044010	OXYCONTIN 40MG TABLETS 100S	01/02/2019	111.52	1285.43	08/24/2027	Innovator Multiple Source Drug	None	1	None	1	None	None	None	None	None	None	None	None	None	None	None	None	General comment on acquisition information: This product was not acquired from another company. General comments on Cost Increase Factors: As a private company, we do not publicly disclose a majority of this information. However, Purdue Pharma LP does continue to make significant investments into the research and development of new medicines to address unmet medical needs of patients. We are focusing our research and development efforts in various therapeutic areas, including oncology, non-pain CNS disorders (insomnia and ADHD), and non-opioid pain medications. Successful development of these therapies could produce both positive impacts for patients with unmet medical needs and the public health.
Rx0000056	Purdue Pharma LP	03/31/2019	59011044020	OXYCONTIN 40MG TABLETS HUD 20S	01/02/2019	22.87	263.57	08/24/2027	Innovator Multiple Source Drug	None	1	None	1	None	None	None	None	None	None	None	None	None	None	None	None	General comment on acquisition information: This product was not acquired from another company. General comments on Cost Increase Factors: As a private company, we do not publicly disclose a majority of this information. However, Purdue Pharma LP does continue to make significant investments into the research and development of new medicines to address unmet medical needs of patients. We are focusing our research and development efforts in various therapeutic areas, including oncology, non-pain CNS disorders (insomnia and ADHD), and non-opioid pain medications. Successful development of these therapies could produce both positive impacts for patients with unmet medical needs and the public health.
Rx0000056	Purdue Pharma LP	03/31/2019	59011046010	OXYCONTIN 60MG TABLETS 100S	01/02/2019	157.90	1819.96	08/24/2027	Innovator Multiple Source Drug	None	1	None	1	None	None	None	None	None	None	None	None	None	None	None	None	General comment on acquisition information: This product was not acquired from another company. General comments on Cost Increase Factors: As a private company, we do not publicly disclose a majority of this information. However, Purdue Pharma LP does continue to make significant investments into the research and development of new medicines to address unmet medical needs of patients. We are focusing our research and development efforts in various therapeutic areas, including oncology, non-pain CNS disorders (insomnia and ADHD), and non-opioid pain medications. Successful development of these therapies could produce both positive impacts for patients with unmet medical needs and the public health.
Rx0000056	Purdue Pharma LP	03/31/2019	59011046020	OXYCONTIN 60MG TABLETS HUD 20S	01/02/2019	32.39	373.38	08/24/2027	Innovator Multiple Source Drug	None	1	None	1	None	None	None	None	None	None	None	None	None	None	None	None	General comment on acquisition information: This product was not acquired from another company. General comments on Cost Increase Factors: As a private company, we do not publicly disclose a majority of this information. However, Purdue Pharma LP does continue to make significant investments into the research and development of new medicines to address unmet medical needs of patients. We are focusing our research and development efforts in various therapeutic areas, including oncology, non-pain CNS disorders (insomnia and ADHD), and non-opioid pain medications. Successful development of these therapies could produce both positive impacts for patients with unmet medical needs and the public health.
Rx0000056	Purdue Pharma LP	03/31/2019	59011048010	OXYCONTIN 80MG TABLETS 100S	01/02/2019	194.60	2243.03	08/24/2027	Innovator Multiple Source Drug	None	1	None	1	None	None	None	None	None	None	None	None	None	None	None	None	General comment on acquisition information: This product was not acquired from another company. General comments on Cost Increase Factors: As a private company, we do not publicly disclose a majority of this information. However, Purdue Pharma LP does continue to make significant investments into the research and development of new medicines to address unmet medical needs of patients. We are focusing our research and development efforts in various therapeutic areas, including oncology, non-pain CNS disorders (insomnia and ADHD), and non-opioid pain medications. Successful development of these therapies could produce both positive impacts for patients with unmet medical needs and the public health.
Rx0000056	Purdue Pharma LP	03/31/2019	59011048020	OXYCONTIN 80MG TABLETS HUD 20S	01/02/2019	39.92	460.12	08/24/2027	Innovator Multiple Source Drug	None	1	None	1	None	None	None	None	None	None	None	None	None	None	None	None	General comment on acquisition information: This product was not acquired from another company. General comments on Cost Increase Factors: As a private company, we do not publicly disclose a majority of this information. However, Purdue Pharma LP does continue to make significant investments into the research and development of new medicines to address unmet medical needs of patients. We are focusing our research and development efforts in various therapeutic areas, including oncology, non-pain CNS disorders (insomnia and ADHD), and non-opioid pain medications. Successful development of these therapies could produce both positive impacts for patients with unmet medical needs and the public health.
Rx0000095	Salix Pharmaceuticals, Inc.	03/31/2019	65649041112	ANUSOl-HC® (Hydrocortisone Acetate Suppository, USP) 25mg	01/18/2019	17.29	593.57	None	Non-innovator Multiple Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	None
Rx0000095	Salix Pharmaceuticals, Inc.	03/31/2019	65649041124	ANUSOl-HC® (Hydrocortisone Acetate Suppository, USP) 25mg	01/18/2019	34.58	1187.17	None	Non-innovator Multiple Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	None
Rx0000095	Salix Pharmaceuticals, Inc.	03/31/2019	65649040130	ANUSOl-HC® (Hydrocortisone Cream, USP) 2.5%	01/18/2019	3.88	133.31	None	Non-innovator Multiple Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	None
Rx0000095	Salix Pharmaceuticals, Inc.	03/31/2019	65649010302	APRISO™ (mesalamine) extended-release capsules 0.375g	01/18/2019	28.89	510.31	05/01/2030	Single Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	On 6/18/2015 the product had a price decrease from $522 to $379.49.
Rx0000095	Salix Pharmaceuticals, Inc.	03/31/2019	65649020175	MOVIPREP® (PEG-3350, Sodium Sulfate, Sodium Chloride, Potassium Chloride, Sodium Ascorbate & Ascorbic Acid for Oral Solution)	01/18/2019	5.98	105.69	09/01/2024	Single Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	None
Rx0000095	Salix Pharmaceuticals, Inc.	03/31/2019	65649070141	OSMOPREP® (sodium phosphate monobasic monohydrate, USP, sodium phosphate dibasic anhydrous, USP) Tablets	01/18/2019	20.01	686.93	06/22/2028	Single Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	None
Rx0000095	Salix Pharmaceuticals, Inc.	03/31/2019	65649065103	UCERIS® (budesonide) Rectal Foam two 54 ml Canisters 2 mg/actuation	01/18/2019	35.52	627.53	09/07/2031	Single Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	The product was launched on 12/01/2014. The rights to the product was acquired in 2008
Rx0000095	Salix Pharmaceuticals, Inc.	03/31/2019	65649030103	XIFAXAN® (rifaximin) 200mg Tablets	01/18/2019	45.49	621.28	07/24/2029	Single Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	None
Rx0000095	Salix Pharmaceuticals, Inc.	03/31/2019	65649030302	XIFAXAN® (rifaximin) 550mg Tablets	01/18/2019	173.41	2368.48	10/02/2029	Single Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	None
Rx0000095	Salix Pharmaceuticals, Inc.	03/31/2019	65649030303	XIFAXAN® (rifaximin) 550mg Tablets HUD 6 cards of 10	01/18/2019	173.41	2368.48	10/02/2029	Single Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	None
Rx0000027	Sandoz Inc.	09/30/2019	00781194382	AMOX C XR 1000/62.5MG 28TB BT	07/08/2019	15.48	171.85	None	Non-innovator Multiple Source Drug	None	1	Market conditions and dynamics	None	N/A	None	None	None	None	None	None	None	None	None	None	None	Acquisition information is not applicable; Sandoz Inc. did not acquire the product within the previous five years. This NDC has no unexpired patents. Sandoz Inc. provides this report consistent with its understanding and interpretation of California SB 17 Chapter 603 Chapter 9 § 127679 and its provisions. In providing this report, Sandoz Inc. does not waive any rights that may have at law or in equity with respect to the applicability, interpretation, or application of California SB 17 Chapter 603 Chapter 9 § 127679 as it may relate to Sandoz Inc. or any of its affiliates now or in the future. Sandoz Inc., on behalf of itself and affiliates, expressly reserves all such rights. We believe that this submission and of all Sandoz Inc.’s related information herein is confidential and proprietary commercial or financial information not subject to disclosure, including under the California Public Records Act (Government Code Section 6250 et seq.) and applicable laws pertaining to trade secrets. We request that your company or organization maintain the confidentiality of this submission and of all Sandoz Inc.’s related information herein to the maximum extent permitted by law. When any of this information is requested, whether under the California Public Records Act (Government Code Section 6250 et seq.) or otherwise, we request that your company or organization notify us of the request and afford us the opportunity to submit objections to disclosure.
Rx0000027	Sandoz Inc.	09/30/2019	00781194339	AMOX C XR 1000/62.5MG 40TB BT	07/08/2019	22.11	245.49	None	Non-innovator Multiple Source Drug	None	1	Market conditions and dynamics	None	N/A	None	None	None	None	None	None	None	None	None	None	None	Acquisition information is not applicable; Sandoz Inc. did not acquire the product within the previous five years. This NDC has no unexpired patents. Sandoz Inc. provides this report consistent with its understanding and interpretation of California SB 17 Chapter 603 Chapter 9 § 127679 and its provisions. In providing this report, Sandoz Inc. does not waive any rights that may have at law or in equity with respect to the applicability, interpretation, or application of California SB 17 Chapter 603 Chapter 9 § 127679 as it may relate to Sandoz Inc. or any of its affiliates now or in the future. Sandoz Inc., on behalf of itself and affiliates, expressly reserves all such rights. We believe that this submission and of all Sandoz Inc.’s related information herein is confidential and proprietary commercial or financial information not subject to disclosure, including under the California Public Records Act (Government Code Section 6250 et seq.) and applicable laws pertaining to trade secrets. We request that your company or organization maintain the confidentiality of this submission and of all Sandoz Inc.’s related information herein to the maximum extent permitted by law. When any of this information is requested, whether under the California Public Records Act (Government Code Section 6250 et seq.) or otherwise, we request that your company or organization notify us of the request and afford us the opportunity to submit objections to disclosure.
Rx0000027	Sandoz Inc.	09/30/2019	00781214501	AMPICILLIN 500MG 100CP BT	07/08/2019	4.66	51.78	None	Non-innovator Multiple Source Drug	None	1	Market conditions and dynamics	None	N/A	None	None	None	None	None	None	None	None	None	None	None	Acquisition information is not applicable; Sandoz Inc. did not acquire the product within the previous five years. This NDC has no unexpired patents. Sandoz Inc. provides this report consistent with its understanding and interpretation of California SB 17 Chapter 603 Chapter 9 § 127679 and its provisions. In providing this report, Sandoz Inc. does not waive any rights that may have at law or in equity with respect to the applicability, interpretation, or application of California SB 17 Chapter 603 Chapter 9 § 127679 as it may relate to Sandoz Inc. or any of its affiliates now or in the future. Sandoz Inc., on behalf of itself and affiliates, expressly reserves all such rights. We believe that this submission and of all Sandoz Inc.’s related information herein is confidential and proprietary commercial or financial information not subject to disclosure, including under the California Public Records Act (Government Code Section 6250 et seq.) and applicable laws pertaining to trade secrets. We request that your company or organization maintain the confidentiality of this submission and of all Sandoz Inc.’s related information herein to the maximum extent permitted by law. When any of this information is requested, whether under the California Public Records Act (Government Code Section 6250 et seq.) or otherwise, we request that your company or organization notify us of the request and afford us the opportunity to submit objections to disclosure.
Rx0000027	Sandoz Inc.	09/30/2019	00781214505	AMPICILLIN 500MG 500CP BT	07/08/2019	22.74	252.40	None	Non-innovator Multiple Source Drug	None	1	Market conditions and dynamics	None	N/A	None	None	None	None	None	None	None	None	None	None	None	Acquisition information is not applicable; Sandoz Inc. did not acquire the product within the previous five years. This NDC has no unexpired patents. Sandoz Inc. provides this report consistent with its understanding and interpretation of California SB 17 Chapter 603 Chapter 9 § 127679 and its provisions. In providing this report, Sandoz Inc. does not waive any rights that may have at law or in equity with respect to the applicability, interpretation, or application of California SB 17 Chapter 603 Chapter 9 § 127679 as it may relate to Sandoz Inc. or any of its affiliates now or in the future. Sandoz Inc., on behalf of itself and affiliates, expressly reserves all such rights. We believe that this submission and of all Sandoz Inc.’s related information herein is confidential and proprietary commercial or financial information not subject to disclosure, including under the California Public Records Act (Government Code Section 6250 et seq.) and applicable laws pertaining to trade secrets. We request that your company or organization maintain the confidentiality of this submission and of all Sandoz Inc.’s related information herein to the maximum extent permitted by law. When any of this information is requested, whether under the California Public Records Act (Government Code Section 6250 et seq.) or otherwise, we request that your company or organization notify us of the request and afford us the opportunity to submit objections to disclosure.
Rx0000027	Sandoz Inc.	03/31/2019	61314014410	BRIMONIDINE TAR 0.15% 10ML	03/14/2019	24.31	280.27	08/19/2025	Non-innovator Multiple Source Drug	None	1	Market conditions and dynamics	None	N/A	None	None	None	None	None	None	None	None	None	None	https://reports.siera.oshpd.ca.gov/api/report/drug-pricing/attachment?id=53	Acquisition information is not applicable; Sandoz Inc. did not acquire the product within the previous five years
Rx0000027	Sandoz Inc.	03/31/2019	61314014415	BRIMONIDINE TAR 0.15% 15ML	03/14/2019	36.47	420.43	08/19/2025	Non-innovator Multiple Source Drug	None	1	Market conditions and dynamics	None	N/A	None	None	None	None	None	None	None	None	None	None	https://reports.siera.oshpd.ca.gov/api/report/drug-pricing/attachment?id=54	Acquisition information is not applicable; Sandoz Inc. did not acquire the product within the previous five years
Rx0000027	Sandoz Inc.	03/31/2019	61314014405	BRIMONIDINE TAR 0.15% 5ML	03/14/2019	12.16	140.17	08/19/2025	Non-innovator Multiple Source Drug	None	1	Market conditions and dynamics	None	N/A	None	None	None	None	None	None	None	None	None	None	https://reports.siera.oshpd.ca.gov/api/report/drug-pricing/attachment?id=52	Acquisition information is not applicable; Sandoz Inc. did not acquire the product within the previous five years
Rx0000027	Sandoz Inc.	09/30/2019	00781602246	CLARITHROMYCIN OS 125MG/5ML 100ML BT	07/08/2019	9.81	108.86	None	Non-innovator Multiple Source Drug	None	1	Market conditions and dynamics	None	N/A	None	None	None	None	None	None	None	None	None	None	None	Acquisition information is not applicable; Sandoz Inc. did not acquire the product within the previous five years. This NDC has no unexpired patents. Sandoz Inc. provides this report consistent with its understanding and interpretation of California SB 17 Chapter 603 Chapter 9 § 127679 and its provisions. In providing this report, Sandoz Inc. does not waive any rights that may have at law or in equity with respect to the applicability, interpretation, or application of California SB 17 Chapter 603 Chapter 9 § 127679 as it may relate to Sandoz Inc. or any of its affiliates now or in the future. Sandoz Inc., on behalf of itself and affiliates, expressly reserves all such rights. We believe that this submission and of all Sandoz Inc.’s related information herein is confidential and proprietary commercial or financial information not subject to disclosure, including under the California Public Records Act (Government Code Section 6250 et seq.) and applicable laws pertaining to trade secrets. We request that your company or organization maintain the confidentiality of this submission and of all Sandoz Inc.’s related information herein to the maximum extent permitted by law. When any of this information is requested, whether under the California Public Records Act (Government Code Section 6250 et seq.) or otherwise, we request that your company or organization notify us of the request and afford us the opportunity to submit objections to disclosure.
Rx0000027	Sandoz Inc.	09/30/2019	00781602252	CLARITHROMYCIN OS 125MG/5ML 50ML BT	07/08/2019	5.30	58.88	None	Non-innovator Multiple Source Drug	None	1	Market conditions and dynamics	None	N/A	None	None	None	None	None	None	None	None	None	None	None	Acquisition information is not applicable; Sandoz Inc. did not acquire the product within the previous five years. This NDC has no unexpired patents. Sandoz Inc. provides this report consistent with its understanding and interpretation of California SB 17 Chapter 603 Chapter 9 § 127679 and its provisions. In providing this report, Sandoz Inc. does not waive any rights that may have at law or in equity with respect to the applicability, interpretation, or application of California SB 17 Chapter 603 Chapter 9 § 127679 as it may relate to Sandoz Inc. or any of its affiliates now or in the future. Sandoz Inc., on behalf of itself and affiliates, expressly reserves all such rights. We believe that this submission and of all Sandoz Inc.’s related information herein is confidential and proprietary commercial or financial information not subject to disclosure, including under the California Public Records Act (Government Code Section 6250 et seq.) and applicable laws pertaining to trade secrets. We request that your company or organization maintain the confidentiality of this submission and of all Sandoz Inc.’s related information herein to the maximum extent permitted by law. When any of this information is requested, whether under the California Public Records Act (Government Code Section 6250 et seq.) or otherwise, we request that your company or organization notify us of the request and afford us the opportunity to submit objections to disclosure.
Rx0000027	Sandoz Inc.	09/30/2019	00781602346	CLARITHROMYCIN OS 250MG/5ML 100ML BT	07/08/2019	14.31	158.81	None	Non-innovator Multiple Source Drug	None	1	Market conditions and dynamics	None	N/A	None	None	None	None	None	None	None	None	None	None	None	Acquisition information is not applicable; Sandoz Inc. did not acquire the product within the previous five years. This NDC has no unexpired patents. Sandoz Inc. provides this report consistent with its understanding and interpretation of California SB 17 Chapter 603 Chapter 9 § 127679 and its provisions. In providing this report, Sandoz Inc. does not waive any rights that may have at law or in equity with respect to the applicability, interpretation, or application of California SB 17 Chapter 603 Chapter 9 § 127679 as it may relate to Sandoz Inc. or any of its affiliates now or in the future. Sandoz Inc., on behalf of itself and affiliates, expressly reserves all such rights. We believe that this submission and of all Sandoz Inc.’s related information herein is confidential and proprietary commercial or financial information not subject to disclosure, including under the California Public Records Act (Government Code Section 6250 et seq.) and applicable laws pertaining to trade secrets. We request that your company or organization maintain the confidentiality of this submission and of all Sandoz Inc.’s related information herein to the maximum extent permitted by law. When any of this information is requested, whether under the California Public Records Act (Government Code Section 6250 et seq.) or otherwise, we request that your company or organization notify us of the request and afford us the opportunity to submit objections to disclosure.
Rx0000027	Sandoz Inc.	09/30/2019	00781602352	CLARITHROMYCIN OS 250MG/5ML 50ML BT	07/08/2019	7.72	85.72	None	Non-innovator Multiple Source Drug	None	1	Market conditions and dynamics	None	N/A	None	None	None	None	None	None	None	None	None	None	None	Acquisition information is not applicable; Sandoz Inc. did not acquire the product within the previous five years. This NDC has no unexpired patents. Sandoz Inc. provides this report consistent with its understanding and interpretation of California SB 17 Chapter 603 Chapter 9 § 127679 and its provisions. In providing this report, Sandoz Inc. does not waive any rights that may have at law or in equity with respect to the applicability, interpretation, or application of California SB 17 Chapter 603 Chapter 9 § 127679 as it may relate to Sandoz Inc. or any of its affiliates now or in the future. Sandoz Inc., on behalf of itself and affiliates, expressly reserves all such rights. We believe that this submission and of all Sandoz Inc.’s related information herein is confidential and proprietary commercial or financial information not subject to disclosure, including under the California Public Records Act (Government Code Section 6250 et seq.) and applicable laws pertaining to trade secrets. We request that your company or organization maintain the confidentiality of this submission and of all Sandoz Inc.’s related information herein to the maximum extent permitted by law. When any of this information is requested, whether under the California Public Records Act (Government Code Section 6250 et seq.) or otherwise, we request that your company or organization notify us of the request and afford us the opportunity to submit objections to disclosure.
Rx0000027	Sandoz Inc.	03/31/2019	61314064175	NEOMYCIN/POLYMYXIN B/HYDROC OPHT 7.5ML SUSP	03/14/2019	11.82	136.20	None	Non-innovator Multiple Source Drug	None	1	Market conditions and dynamics	None	N/A	None	None	None	None	None	None	None	None	None	None	https://reports.siera.oshpd.ca.gov/api/report/drug-pricing/attachment?id=57	Acquisition information is not applicable; Sandoz Inc. did not acquire the product within the previous five years. This NDC has no unexpired patents.
Rx0000027	Sandoz Inc.	03/31/2019	61314064610	NEOMYCIN/POLYMYXIN B/HYDROC OTIC 10ML LDP SOLN	03/14/2019	8.88	83.90	None	Non-innovator Multiple Source Drug	None	1	Market conditions and dynamics	None	N/A	None	None	None	None	None	None	None	None	None	None	https://reports.siera.oshpd.ca.gov/api/report/drug-pricing/attachment?id=55	Acquisition information is not applicable; Sandoz Inc. did not acquire the product within the previous five years. This NDC has no unexpired patents.
Rx0000027	Sandoz Inc.	03/31/2019	61314064511	NEOMYCIN/POLYMYXIN B/HYDROC OTIC 10ML SUSP	03/14/2019	8.88	83.90	None	Non-innovator Multiple Source Drug	None	1	Market conditions and dynamics	None	N/A	None	None	None	None	None	None	None	None	None	None	https://reports.siera.oshpd.ca.gov/api/report/drug-pricing/attachment?id=56	Acquisition information is not applicable; Sandoz Inc. did not acquire the product within the previous five years. This NDC has no unexpired patents.
Rx0000027	Sandoz Inc.	06/30/2019	00781300407	SOMATROPIN IJ 10MG/1.5ML 1X1CARTRIDGE BOX (OMNITROPE)	05/01/2019	59.55	1250.46	None	Single Source Drug	None	1	Market conditions and dynamics	None	N/A	None	None	None	None	None	None	None	None	None	None	https://reports.siera.oshpd.ca.gov/api/report/drug-pricing/attachment?id=281	Acquisition information is not applicable; Sandoz Inc. did not acquire the product within the previous five years. This NDC has no unexpired patents.
Rx0000027	Sandoz Inc.	06/30/2019	00781300107	SOMATROPIN IJ 5MG/1.5ML 1X1CARTRIDGE BOX (OMNITROPE)	05/01/2019	29.77	625.23	None	Single Source Drug	None	1	Market conditions and dynamics	None	N/A	None	None	None	None	None	None	None	None	None	None	https://reports.siera.oshpd.ca.gov/api/report/drug-pricing/attachment?id=280	Acquisition information is not applicable; Sandoz Inc. did not acquire the product within the previous five years. This NDC has no unexpired patents.
Rx0000092	Santarus, Inc.	03/31/2019	68012025820	CYCLOSET® (bromocriptine mesytate tablets) 0.8 mg tablets	01/18/2019	47.48	838.74	04/30/2032	Single Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	The product was not acquired within the last 5 years.
Rx0000035	Saol Therapeutics Inc	03/31/2019	70504005202	HepaGam B 1 mL	01/01/2019	15.84	193.85	None	Single Source Drug	None	1	None	1	None	1	09/28/2017	Aptevo Therapeutics Inc.	None	1	non-public	164.59	None	2015	150.63	None	None
Rx0000035	Saol Therapeutics Inc	03/31/2019	70504005302	HepaGam B 1 mL (NovaPlus)	01/01/2019	15.84	193.85	None	Single Source Drug	None	1	None	1	None	1	09/28/2017	Aptevo Therapeutics Inc.	None	1	non-public	164.59	None	2015	150.63	None	None
Rx0000035	Saol Therapeutics Inc	03/31/2019	70504005102	HepaGam B 5 mL	01/01/2019	69.33	848.37	None	Single Source Drug	None	1	None	1	None	1	09/28/2017	Aptevo Therapeutics Inc.	None	1	non-public	720.33	None	2015	659.20	None	None
Rx0000035	Saol Therapeutics Inc	03/31/2019	70504005402	HepaGam B 5mL (NovaPlus)	01/01/2019	69.33	848.37	None	Single Source Drug	None	1	None	1	None	1	09/28/2017	Aptevo Therapeutics Inc.	None	1	non-public	720.33	None	2015	659.20	None	None
Rx0000035	Saol Therapeutics Inc	03/31/2019	70504012602	VARIZIG	01/01/2019	134.19	1641.62	None	Single Source Drug	None	1	None	1	None	1	09/28/2017	Aptevo Therapeutics Inc.	None	1	non-public	1306.34	None	2015	1185.00	None	None
Rx0000035	Saol Therapeutics Inc	03/31/2019	70504310002	WinRho SDF 1000 mcg	01/01/2019	141.06	1726.06	None	Single Source Drug	None	1	None	1	None	1	09/28/2017	Aptevo Therapeutics Inc.	None	1	non-public	1437.65	None	2015	1182.75	None	None
Rx0000035	Saol Therapeutics Inc	03/31/2019	70504330002	WinRho SDF 300 mcg	01/01/2019	42.06	514.61	None	Single Source Drug	None	1	None	1	None	1	09/28/2017	Aptevo Therapeutics Inc.	None	1	non-public	428.62	None	2015	352.63	None	None
Rx0000035	Saol Therapeutics Inc	03/31/2019	70504300002	WinRho SDF 3000 mcg	01/01/2019	423.19	5178.18	None	Single Source Drug	None	1	None	1	None	1	09/28/2017	Aptevo Therapeutics Inc.	None	1	non-public	4312.91	None	2015	3548.24	None	None
Rx0000035	Saol Therapeutics Inc	03/31/2019	70504350002	WinRho SDF 500 mcg	01/01/2019	70.53	863.03	None	Single Source Drug	None	1	None	1	None	1	09/28/2017	Aptevo Therapeutics Inc.	None	1	non-public	718.82	None	2015	591.37	None	None
Rx0000086	Seattle Genetics, Inc.	03/31/2019	51144005001	ADCETRIS, 50mg, single-dose vial, packaged singly	01/01/2019	287.00	7662.00	12/31/2031	Single Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	(1) Seattle Genetics does not believe information related to the unit sales volume in the U.S., cost increase factors, or change/improvement descriptions are in the public domain or otherwise publicly available. As a result, for these data elements, Seattle Genetics limits its response pursuant to Cal. Health & Safety Code § 127679(b). (2) As described in our publicly available financial disclosures, for ADCETRIS and our related ADC technology, we own ten patents in the United States and Europe that will expire between 2020 and 2031. However, the specific day and month of the patent expiration is not publicly available, though the Office of Statewide Health Planning and Development's ("OSHPD") portal does not permit Seattle Genetics to insert only a year for this data field. As a result, Seattle Genetics has entered "12/31/2031" for the "patent expiration date" field in order to submit a report to OSHPD, though this does not reflect the actual date and month which Seattle Genetics' patents expire. In addition, the reported patent expiration date does not reflect any pending patents, patent term extensions, pediatric exclusivity, or patent-related litigation, each of which is speculative and which may extend or shorten the reported expiration date. (3) Seattle Genetics did not acquire this product from another manufacturer within the previous five years. As a result, we have left columns N-U blank because they are not applicable to this product.
Rx0000086	Seattle Genetics, Inc.	09/30/2019	51144005001	Brentuximab Vedotin 50 MG Solution Reconstituted 1 EA UD	07/01/2019	299.00	7960.00	12/31/2031	Single Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	(1) Seattle Genetics does not believe information related to the unit sales volume in the U.S., cost increase factors, or change/improvement descriptions are in the public domain or otherwise publicly available. As a result, for these data elements, Seattle Genetics limits its response pursuant to Cal. Health & Safety Code § 127679(b). (2) As described in our publicly available financial disclosures, for ADCETRIS and our related ADC technology, we own ten patents in the United States and Europe that will expire between 2020 and 2031. However, the specific day and month of the patent expiration is not publicly available, though the Office of Statewide Health Planning and Development's ("OSHPD") portal does not permit Seattle Genetics to insert only a year for this data field. As a result, Seattle Genetics has entered "12/31/2031" for the "patent expiration date" field in order to submit a report to OSHPD, though this does not reflect the actual date and month which Seattle Genetics' patents expire. In addition, the reported patent expiration date does not reflect any pending patents, patent term extensions, pediatric exclusivity, or patent-related litigation, each of which is speculative and which may extend or shorten the reported expiration date. (3) Seattle Genetics did not acquire this product from another manufacturer within the previous five years. As a result, we have left columns N-U blank because they are not applicable to this product.
Rx0000121	Secura Bio, Inc.	09/30/2019	00078065006	Farydak 10 mg	08/12/2019	773.29	8913.22	06/13/2028	Single Source Drug	728	None	Farydak was acquired from Novartis on March 1, 2019 by Secura Bio, Inc., a newly established company. FDA clinical trial obligations, start-up costs and selling and general costs required to support the product exceed revenues from the product and have resulted in operating losses for the company, necessitating price increases.	None	None	None	03/01/2019	Novartis	65000000	None	Acquisition price may be higher depending on contingent milestones.	8139.93	8059.34	2015	6860.00	None	None
Rx0000121	Secura Bio, Inc.	12/31/2019	00078065006	Farydak 10 mg capsule 6x blister pack	12/02/2019	846.76	9759.98	06/13/2028	Single Source Drug	None	1	None	1	None	1	03/01/2019	Novartis AG	None	1	None	8139.93	8059.34	2015	6860.00	None	None
Rx0000121	Secura Bio, Inc.	09/30/2019	00078065106	Farydak 15 mg	08/12/2019	773.29	8913.22	06/13/2028	Single Source Drug	397	None	Farydak was acquired from Novartis on March 1, 2019 by Secura Bio, Inc., a newly established company. FDA clinical trial obligations, start-up costs and selling and general costs required to support the product exceed revenues from the product and have resulted in operating losses for the company, necessitating price increases.	None	None	None	03/01/2019	Novartis	65000000	None	Acquisition price may be higher due to contingent milestones.	8139.93	8059.34	2015	6860.00	None	None
Rx0000121	Secura Bio, Inc.	12/31/2019	00078065106	Farydak 15 mg capsule 6x blister pack	12/02/2019	846.76	9759.98	06/13/2028	Single Source Drug	None	1	None	1	None	1	03/01/2019	Novartis AG	None	1	None	8139.93	8059.34	2015	6860.00	None	None
Rx0000121	Secura Bio, Inc.	09/30/2019	00078065206	Farydak 20 mg	08/12/2019	773.29	8913.22	06/13/2028	Single Source Drug	935	None	Farydak was acquired from Novartis on March 1, 2019 by Secura Bio, Inc., a newly established company. FDA clinical trial obligations, start-up costs and selling and general costs required to support the product exceed revenues from the product and have resulted in operating losses for the company, necessitating price increases.	None	None	None	03/01/2019	Novartis	65000000	None	Acquisition price may be higher due to contingent milestones.	8139.93	8059.34	2015	6860.00	None	None
Rx0000121	Secura Bio, Inc.	12/31/2019	00078065206	Farydak 20 mg capsule 6x blister pack	12/02/2019	846.76	9759.98	06/13/2028	Single Source Drug	None	1	None	1	None	1	03/01/2019	Novartis AG	None	1	None	8139.93	8059.34	2015	6860.00	None	None
Rx0000004	Shionogi Inc.	03/31/2019	59630058090	Osphena (ospemifene) 60MG Tablets	01/01/2019	36.61	648.00	None	Single Source Drug	126054	None	The factors contributing to this WAC increase are anticipated increases over 2018 of distribution service fees charged by wholesalers and rebates payable under contracts with government and commercial third party payers.	None	None	None	None	None	None	None	None	None	None	None	None	None	Osphena was developed by Shionogi. The pricing at launch was $474.00
Rx0000061	Shire US	06/30/2019	54092070202	Firazyr 30mg/3ml	04/15/2019	324.68	11147.49	07/15/2019	Single Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	Shire is now part of Takeda. Not acquired in last 5 years; Takeda’s approach to pricing medicines in the U.S. reflects our strong commitment to bringing the right treatment options to patients who may benefit from them. Please see Takeda's US Pricing Philosophy at: https://www.takeda.com/en-us/corporate-responsibility/takeda-pricing-philosophy/
Rx0000061	Shire US	06/30/2019	54092070203	Firazyr 30mg/3ml	04/15/2019	974.05	33442.49	07/15/2019	Single Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	Shire is now part of Takeda. Not acquired in last 5 years; Takeda’s approach to pricing medicines in the U.S. reflects our strong commitment to bringing the right treatment options to patients who may benefit from them. Please see Takeda's US Pricing Philosophy at: https://www.takeda.com/en-us/corporate-responsibility/takeda-pricing-philosophy/
Rx0000061	Shire US	06/30/2019	68875010201	Gattex Subcutaneous Kit 5 MG	04/15/2019	1143.84	39271.88	05/01/2026	Single Source Drug	None	1	None	1	None	1	02/21/2015	NPS Pharma	None	1	None	31350.00	None	2013	24247.00	None	Shire is now part of Takeda. Takeda’s approach to pricing medicines in the U.S. reflects our strong commitment to bringing the right treatment options to patients who may benefit from them. Please see Takeda's US Pricing Philosophy at: https://www.takeda.com/en-us/corporate-responsibility/takeda-pricing-philosophy/
Rx0000061	Shire US	06/30/2019	68875010301	Gattex Subcutaneous Kit 5 MG	04/15/2019	43.86	1505.74	05/01/2026	Single Source Drug	None	1	None	1	None	1	02/21/2015	NPS Pharma	None	1	None	1202.00	None	2013	929.00	None	Shire is now part of Takeda. Takeda’s approach to pricing medicines in the U.S. reflects our strong commitment to bringing the right treatment options to patients who may benefit from them. Please see Takeda's US Pricing Philosophy at: https://www.takeda.com/en-us/corporate-responsibility/takeda-pricing-philosophy/
Rx0000061	Shire US	06/30/2019	47783010101	Kalbitor Subcutaneous Sol 10 mg/ml	04/15/2019	430.13	14767.63	None	Single Source Drug	None	1	None	1	None	1	01/22/2016	Dyax Corp.	None	1	None	11910.00	None	2015	11910.00	None	Shire is now part of Takeda. Please note that Patent Expiration Date is not publicly available for Kalbitor. For more information about Takeda’s approach to pricing medicines in the U.S., please refer to Takeda's US Pricing Philosophy at: https://www.takeda.com/en-us/corporate-responsibility/takeda-pricing-philosophy/
Rx0000061	Shire US	06/30/2019	68875020502	Natpara 100 mcg/dose	04/15/2019	288.85	9917.15	None	Single Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	Shire is now part of Takeda. Not acquired in last 5 years; Please note that Patent Expiration Date is not publicly available for Natpara. For more information about Takeda’s approach to pricing medicines in the U.S., please refer to Takeda's US Pricing Philosophy at: https://www.takeda.com/en-us/corporate-responsibility/takeda-pricing-philosophy/
Rx0000061	Shire US	06/30/2019	68875020202	Natpara 25 mcg/dose	04/15/2019	288.85	9917.15	None	Single Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	Shire is now part of Takeda. Not acquired in last 5 years; Please note that Patent Expiration Date is not publicly available for Natpara. For more information about Takeda’s approach to pricing medicines in the U.S., please refer to Takeda's US Pricing Philosophy at: https://www.takeda.com/en-us/corporate-responsibility/takeda-pricing-philosophy/
Rx0000061	Shire US	06/30/2019	68875020302	Natpara 50 mcg/dose	04/15/2019	288.85	9917.15	None	Single Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	Shire is now part of Takeda. Not acquired in last 5 years; Please note that Patent Expiration Date is not publicly available for Natpara. For more information about Takeda’s approach to pricing medicines in the U.S., please refer to Takeda's US Pricing Philosophy at: https://www.takeda.com/en-us/corporate-responsibility/takeda-pricing-philosophy/
Rx0000061	Shire US	06/30/2019	68875020402	Natpara 75 mcg/dose	04/15/2019	288.85	9917.15	None	Single Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	Shire is now part of Takeda. Not acquired in last 5 years; Please note that Patent Expiration Date is not publicly available for Natpara. For more information about Takeda’s approach to pricing medicines in the U.S., please refer to Takeda's US Pricing Philosophy at: https://www.takeda.com/en-us/corporate-responsibility/takeda-pricing-philosophy/
Rx0000061	Shire US	06/30/2019	54092060601	Xiidra 5% (60 count 12ml)	04/15/2019	15.21	522.21	07/25/2033	Single Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	Shire is now part of Takeda. Not acquired in last 5 years; Takeda’s approach to pricing medicines in the U.S. reflects our strong commitment to bringing the right treatment options to patients who may benefit from them. Please see Takeda's US Pricing Philosophy at: https://www.takeda.com/en-us/corporate-responsibility/takeda-pricing-philosophy/
Rx0000149	Strongbridge Biopharma plc	09/30/2019	71090000101	Keveyis (dichlorphenamide) oral tablet, 50mg, Bottle of 100	08/05/2019	1565.65	18961.81	None	Single Source Drug	None	1	None	1	None	1	12/12/2016	Taro Pharmaceuticals Industries	8500000	None	None	13650.00	13650.00	2015	13650.00	None	None
Rx0000001	SUN PHARMACEUTICALS	03/31/2019	10631011531	Absorica 10mg Capsule	02/14/2019	195.08	1063.91	09/21/2021	Single Source Drug	4680	None	(1) Enhanced discounting in the Managed Care and Medicaid markets (2) Overal inflation at a rate of approximately 3% (3) Enhanced marketing activity to support pharmacist/patient access to Absorica	None	None	1	None	None	None	None	None	None	None	None	None	None	This drug was developed by Sun Pharmaceutical Industries, Inc. (Sun) This report includes confidential, trade secret information of Sun that would cause competitive harm to Sun if publicly disclosed because: (1) Sun uses this information when it negotiates sales contracts for the product and if customers have this data, it may prejudice Sun's ability to negotiate terms of such contracts; (2) Sun competes with other companies in the sale of drugs based on pricing and other factors; thus, if competitors have access to data about Sun's production cost, other product costs, and profit margin, it will prejudice Sun's ability to competitively price its products. For these reasons, Sun requests protection of the information of this submission from public disclosure, pursuant to the Defend Trade Secret Act (DTSA), Pub.L. 114–153, 130 Stat. 376, 18 U.S.C. § 1836, et seq. The reason this information is protected from misappropriation and disclosure under the DTSA is because such constitutes information that Sun treats as secret, takes steps to keep secret, and which has independent economic value from not being generally known nor readily ascertainable.
Rx0000001	SUN PHARMACEUTICALS	03/31/2019	10631011631	Absorica 20mg Capsule	02/14/2019	195.08	1063.91	09/21/2021	Single Source Drug	23913	None	(1) Enhanced discounting in the Managed Care and Medicaid markets (2) Overal inflation at a rate of approximately 3% (3) Enhanced marketing activity to support pharmacist/patient access to Absorica	None	None	1	None	None	None	None	None	None	None	None	None	None	This drug was developed by Sun Pharmaceutical Industries, Inc. (Sun) This report includes confidential, trade secret information of Sun that would cause competitive harm to Sun if publicly disclosed because: (1) Sun uses this information when it negotiates sales contracts for the product and if customers have this data, it may prejudice Sun's ability to negotiate terms of such contracts; (2) Sun competes with other companies in the sale of drugs based on pricing and other factors; thus, if competitors have access to data about Sun's production cost, other product costs, and profit margin, it will prejudice Sun's ability to competitively price its products. For these reasons, Sun requests protection of the information of this submission from public disclosure, pursuant to the Defend Trade Secret Act (DTSA), Pub.L. 114–153, 130 Stat. 376, 18 U.S.C. § 1836, et seq. The reason this information is protected from misappropriation and disclosure under the DTSA is because such constitutes information that Sun treats as secret, takes steps to keep secret, and which has independent economic value from not being generally known nor readily ascertainable.
Rx0000001	SUN PHARMACEUTICALS	03/31/2019	10631013331	Absorica 25mg Capsule	02/01/2019	209.89	1143.91	09/21/2021	Single Source Drug	8677	None	(1) Enhanced discounting in the Managed Care and Medicaid markets (2) Overal inflation at a rate of approximately 3% (3) Enhanced marketing activity to support pharmacist/patient access to Absorica	None	None	1	None	None	None	None	None	None	None	None	None	None	This drug was developed by Sun Pharmaceutical Industries, Inc. (Sun) This report includes confidential, trade secret information of Sun that would cause competitive harm to Sun if publicly disclosed because: (1) Sun uses this information when it negotiates sales contracts for the product and if customers have this data, it may prejudice Sun's ability to negotiate terms of such contracts; (2) Sun competes with other companies in the sale of drugs based on pricing and other factors; thus, if competitors have access to data about Sun's production cost, other product costs, and profit margin, it will prejudice Sun's ability to competitively price its products. For these reasons, Sun requests protection of the information of this submission from public disclosure, pursuant to the Defend Trade Secret Act (DTSA), Pub.L. 114–153, 130 Stat. 376, 18 U.S.C. § 1836, et seq. The reason this information is protected from misappropriation and disclosure under the DTSA is because such constitutes information that Sun treats as secret, takes steps to keep secret, and which has independent economic value from not being generally known nor readily ascertainable.
Rx0000001	SUN PHARMACEUTICALS	03/31/2019	10631011731	Absorica 30mg Capsule	02/01/2019	209.89	1143.91	09/21/2021	Single Source Drug	89648	None	(1) Enhanced discounting in the Managed Care and Medicaid markets (2) Overal inflation at a rate of approximately 3% (3) Enhanced marketing activity to support pharmacist/patient access to Absorica	None	None	1	None	None	None	None	None	None	None	None	None	None	This drug was developed by Sun Pharmaceutical Industries, Inc. (Sun) This report includes confidential, trade secret information of Sun that would cause competitive harm to Sun if publicly disclosed because: (1) Sun uses this information when it negotiates sales contracts for the product and if customers have this data, it may prejudice Sun's ability to negotiate terms of such contracts; (2) Sun competes with other companies in the sale of drugs based on pricing and other factors; thus, if competitors have access to data about Sun's production cost, other product costs, and profit margin, it will prejudice Sun's ability to competitively price its products. For these reasons, Sun requests protection of the information of this submission from public disclosure, pursuant to the Defend Trade Secret Act (DTSA), Pub.L. 114–153, 130 Stat. 376, 18 U.S.C. § 1836, et seq. The reason this information is protected from misappropriation and disclosure under the DTSA is because such constitutes information that Sun treats as secret, takes steps to keep secret, and which has independent economic value from not being generally known nor readily ascertainable.
Rx0000001	SUN PHARMACEUTICALS	03/31/2019	10631013431	Absorica 35mg Capsule	02/01/2019	209.89	1143.91	09/21/2021	Single Source Drug	10980	None	(1) Enhanced discounting in the Managed Care and Medicaid markets (2) Overal inflation at a rate of approximately 3% (3) Enhanced marketing activity to support pharmacist/patient access to Absorica	None	None	1	None	None	None	None	None	None	None	None	None	None	This drug was developed by Sun Pharmaceutical Industries, Inc. (Sun) This report includes confidential, trade secret information of Sun that would cause competitive harm to Sun if publicly disclosed because: (1) Sun uses this information when it negotiates sales contracts for the product and if customers have this data, it may prejudice Sun's ability to negotiate terms of such contracts; (2) Sun competes with other companies in the sale of drugs based on pricing and other factors; thus, if competitors have access to data about Sun's production cost, other product costs, and profit margin, it will prejudice Sun's ability to competitively price its products. For these reasons, Sun requests protection of the information of this submission from public disclosure, pursuant to the Defend Trade Secret Act (DTSA), Pub.L. 114–153, 130 Stat. 376, 18 U.S.C. § 1836, et seq. The reason this information is protected from misappropriation and disclosure under the DTSA is because such constitutes information that Sun treats as secret, takes steps to keep secret, and which has independent economic value from not being generally known nor readily ascertainable.
Rx0000001	SUN PHARMACEUTICALS	03/31/2019	10631011831	Absorica 40mg Capsule	02/01/2019	209.89	1143.91	09/21/2021	Single Source Drug	126347	None	(1) Enhanced discounting in the Managed Care and Medicaid markets (2) Overal inflation at a rate of approximately 3% (3) Enhanced marketing activity to support pharmacist/patient access to Absorica	None	None	1	None	None	None	None	None	None	None	None	None	None	This drug was developed by Sun Pharmaceutical Industries, Inc. (Sun) This report includes confidential, trade secret information of Sun that would cause competitive harm to Sun if publicly disclosed because: (1) Sun uses this information when it negotiates sales contracts for the product and if customers have this data, it may prejudice Sun's ability to negotiate terms of such contracts; (2) Sun competes with other companies in the sale of drugs based on pricing and other factors; thus, if competitors have access to data about Sun's production cost, other product costs, and profit margin, it will prejudice Sun's ability to competitively price its products. For these reasons, Sun requests protection of the information of this submission from public disclosure, pursuant to the Defend Trade Secret Act (DTSA), Pub.L. 114–153, 130 Stat. 376, 18 U.S.C. § 1836, et seq. The reason this information is protected from misappropriation and disclosure under the DTSA is because such constitutes information that Sun treats as secret, takes steps to keep secret, and which has independent economic value from not being generally known nor readily ascertainable.
Rx0000001	SUN PHARMACEUTICALS	06/30/2019	62756052940	Desmopressin Acetate 40mcg/10ml Solution for Injection	04/03/2019	401.20	594.20	None	Non-innovator Multiple Source Drug	0	1	Sun's Desmopressin Acetate is being re-launched to the market after a hiatus.This product is priced to reflect a discount off of the current price of the  Reference Drug listed by the FDA and to be competitively priced in the market.	None	No change or improvement have been made for this product	None	None	None	None	None	None	None	None	None	None	None	1) Sun Pharma did not acquire the drug. 2)This product was re-launched in April 2019, and there were no reported sales for the past years prior to April 2019. Therefore, the Volume Sales Units for the year 2018 were zero 3) This report includes confidential, trade secret information of Sun Pharmaceutical Industries, Inc. (Sun) that would cause competitive harm to Sun if publicly disclosed because: (1) Sun uses this information when it negotiates sales contracts for the product and if customers have this data, it may prejudice Sun's ability to negotiate terms of such contracts; (2) Sun competes with other companies in the sale of drugs based on pricing and other factors; thus, if competitors have access to data about Sun's production cost, other product costs, and profit margin, it will prejudice Sun's ability to competitively price its products. For these reasons, Sun requests protection of the information of this submission from public disclosure, pursuant to the Defend Trade Secret Act (DTSA), Pub.L. 114–153, 130 Stat. 376, 18 U.S.C. § 1836, et seq. The reason this information is protected from misappropriation and disclosure under the DTSA is because such constitutes information that Sun treats as secret, takes steps to keep secret, and which has independent economic value from not being generally known nor readily ascertainable
Rx0000165	Supernus Pharmaceuticals, Inc.	03/31/2019	17772012101	Oxtellar XR, 150mg Capsule, 100CT	01/01/2019	49.05	662.21	04/13/2027	Single Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	None
Rx0000165	Supernus Pharmaceuticals, Inc.	03/31/2019	17772012201	Oxtellar XR, 300mg Capsule, 100CT	01/01/2019	68.15	919.99	04/13/2027	Single Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	None
Rx0000165	Supernus Pharmaceuticals, Inc.	03/31/2019	17772012301	Oxtellar XR, 600mg Capsule, 100CT	01/01/2019	124.77	1684.42	04/13/2027	Single Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	None
Rx0000165	Supernus Pharmaceuticals, Inc.	03/31/2019	17772010301	Trokendi XR, 100mg Capsule, 100CT	01/01/2019	182.75	2467.18	04/04/2028	Single Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	None
Rx0000165	Supernus Pharmaceuticals, Inc.	03/31/2019	17772010330	Trokendi XR, 100mg Capsule, 30 CT	01/01/2019	54.83	740.15	04/04/2028	Single Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	None
Rx0000165	Supernus Pharmaceuticals, Inc.	03/31/2019	17772010401	Trokendi XR, 200mg Capsule, 100CT	01/01/2019	249.99	3374.92	04/04/2028	Single Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	None
Rx0000165	Supernus Pharmaceuticals, Inc.	03/31/2019	17772010430	Trokendi XR, 200mg Capsule, 30 CT	01/01/2019	75.00	1012.48	04/04/2028	Single Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	None
Rx0000165	Supernus Pharmaceuticals, Inc.	03/31/2019	17772010101	Trokendi XR, 25mg Capsule, 100 CT	01/01/2019	70.81	955.95	04/04/2028	Single Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	None
Rx0000165	Supernus Pharmaceuticals, Inc.	03/31/2019	17772010130	Trokendi XR, 25mg Capsule, 30 CT	01/01/2019	21.24	286.79	04/04/2028	Single Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	None
Rx0000165	Supernus Pharmaceuticals, Inc.	03/31/2019	17772010201	Trokendi XR, 50mg Capsule, 100CT	01/01/2019	92.24	1245.23	04/04/2028	Single Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	None
Rx0000165	Supernus Pharmaceuticals, Inc.	03/31/2019	17772010230	Trokendi XR, 50mg Capsule, 30 CT	01/01/2019	27.67	373.56	04/04/2028	Single Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	None
Rx0000105	Takeda Pharmaceuticals America, Inc.	03/31/2019	64764017130	Dexilant 30mg 30ct	01/03/2019	8.22	282.46	03/05/2032	Single Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	Not acquired in last 5 years; Takeda’s approach to pricing medicines in the U.S. reflects our strong commitment to bringing the right treatment options to patients who may benefit from them. Please see Takeda's US Pricing Philosophy at: https://www.takeda.com/en-us/corporate-responsibility/takeda-pricing-philosophy/
Rx0000105	Takeda Pharmaceuticals America, Inc.	03/31/2019	64764017530	Dexilant 60mg 30ct	01/03/2019	8.22	282.46	03/05/2032	Single Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	Not acquired in last 5 years; Takeda’s approach to pricing medicines in the U.S. reflects our strong commitment to bringing the right treatment options to patients who may benefit from them. Please see Takeda's US Pricing Philosophy at: https://www.takeda.com/en-us/corporate-responsibility/takeda-pricing-philosophy/
Rx0000105	Takeda Pharmaceuticals America, Inc.	03/31/2019	64764017590	Dexilant 60mg 90ct	01/03/2019	24.68	847.39	03/05/2032	Single Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	Not acquired in last 5 years; Takeda’s approach to pricing medicines in the U.S. reflects our strong commitment to bringing the right treatment options to patients who may benefit from them. Please see Takeda's US Pricing Philosophy at: https://www.takeda.com/en-us/corporate-responsibility/takeda-pricing-philosophy/
Rx0000105	Takeda Pharmaceuticals America, Inc.	03/31/2019	64764030020	Entyvio 300mg 20mL Vial	01/04/2019	182.92	6280.49	None	Single Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	Not acquired in last 5 years; Please note that Patent Expiration Date is not publicly available for Entyvio. For more information about Takeda’s approach to pricing medicines in the U.S., please refer to Takeda's US Pricing Philosophy at: https://www.takeda.com/en-us/corporate-responsibility/takeda-pricing-philosophy/
Rx0000105	Takeda Pharmaceuticals America, Inc.	09/30/2019	64764030020	Entyvio 300mg 20mL Vial	07/03/2019	188.41	6468.90	None	Single Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	Product was not acquired from another company. Please note that Patent Expiration Date is not publicly available for Entyvio. For more information about Takeda’s approach to pricing medicines in the U.S., please refer to Takeda's US Pricing Philosophy at: https://www.takeda.com/en-us/corporate-responsibility/takeda-pricing-philosophy/
Rx0000105	Takeda Pharmaceuticals America, Inc.	03/31/2019	64764080510	Rozerem 8mg 100ct	01/03/2019	37.76	1296.74	11/16/2021	Single Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	Not acquired in last 5 years; Takeda’s approach to pricing medicines in the U.S. reflects our strong commitment to bringing the right treatment options to patients who may benefit from them. Please see Takeda's US Pricing Philosophy at: https://www.takeda.com/en-us/corporate-responsibility/takeda-pricing-philosophy/
Rx0000105	Takeda Pharmaceuticals America, Inc.	03/31/2019	64764080530	Rozerem 8mg 30ct	01/03/2019	11.33	389.03	11/16/2021	Single Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	Not acquired in last 5 years; Takeda’s approach to pricing medicines in the U.S. reflects our strong commitment to bringing the right treatment options to patients who may benefit from them. Please see Takeda's US Pricing Philosophy at: https://www.takeda.com/en-us/corporate-responsibility/takeda-pricing-philosophy/
Rx0000105	Takeda Pharmaceuticals America, Inc.	03/31/2019	64764073030	Trintellix 10mg 30ct	01/03/2019	5.67	383.67	03/21/2032	Single Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	Not acquired in last 5 years; Takeda’s approach to pricing medicines in the U.S. reflects our strong commitment to bringing the right treatment options to patients who may benefit from them. Please see Takeda's US Pricing Philosophy at: https://www.takeda.com/en-us/corporate-responsibility/takeda-pricing-philosophy/
Rx0000105	Takeda Pharmaceuticals America, Inc.	03/31/2019	64764075030	Trintellix 20mg 30ct	01/03/2019	5.67	383.67	03/21/2032	Single Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	Not acquired in last 5 years; Takeda’s approach to pricing medicines in the U.S. reflects our strong commitment to bringing the right treatment options to patients who may benefit from them. Please see Takeda's US Pricing Philosophy at: https://www.takeda.com/en-us/corporate-responsibility/takeda-pricing-philosophy/
Rx0000105	Takeda Pharmaceuticals America, Inc.	03/31/2019	64764072030	Trintellix 5mg 30ct	01/03/2019	5.67	383.67	03/21/2032	Single Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	Not acquired in last 5 years; Takeda’s approach to pricing medicines in the U.S. reflects our strong commitment to bringing the right treatment options to patients who may benefit from them. Please see Takeda's US Pricing Philosophy at: https://www.takeda.com/en-us/corporate-responsibility/takeda-pricing-philosophy/
Rx0000105	Takeda Pharmaceuticals America, Inc.	03/31/2019	64764091830	Uloric 40mg 30ct	01/03/2019	9.63	330.03	09/08/2031	Single Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	Not acquired in last 5 years; Takeda’s approach to pricing medicines in the U.S. reflects our strong commitment to bringing the right treatment options to patients who may benefit from them. Please see Takeda's US Pricing Philosophy at: https://www.takeda.com/en-us/corporate-responsibility/takeda-pricing-philosophy/
Rx0000105	Takeda Pharmaceuticals America, Inc.	03/31/2019	64764067730	Uloric 80mg 30ct	01/03/2019	9.63	330.03	09/08/2031	Single Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	Not acquired in last 5 years; Takeda’s approach to pricing medicines in the U.S. reflects our strong commitment to bringing the right treatment options to patients who may benefit from them. Please see Takeda's US Pricing Philosophy at: https://www.takeda.com/en-us/corporate-responsibility/takeda-pricing-philosophy/
Rx0000019	Teva Pharmaceuticals USA	03/31/2019	63459051230	ACTIQ 1200MCG	01/01/2019	422.10	4913.00	09/05/2006	Innovator Multiple Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	"The drug was not acquired within the last 5 years."
Rx0000019	Teva Pharmaceuticals USA	03/31/2019	63459051630	ACTIQ 1600MCG	01/01/2019	520.80	6060.80	09/05/2006	Innovator Multiple Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	"The drug was not acquired within the last 5 years."
Rx0000019	Teva Pharmaceuticals USA	03/31/2019	63459050230	ACTIQ 200MCG	01/01/2019	176.90	2058.60	09/05/2006	Innovator Multiple Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	"The drug was not acquired within the last 5 years."
Rx0000019	Teva Pharmaceuticals USA	03/31/2019	63459050430	ACTIQ 400MCG	01/01/2019	223.90	2605.50	09/05/2006	Innovator Multiple Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	"The drug was not acquired within the last 5 years."
Rx0000019	Teva Pharmaceuticals USA	03/31/2019	63459050630	ACTIQ 600MCG	01/01/2019	274.40	3193.20	09/05/2006	Innovator Multiple Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	"The drug was not acquired within the last 5 years."
Rx0000019	Teva Pharmaceuticals USA	03/31/2019	63459050830	ACTIQ 800MCG	01/01/2019	324.80	3779.70	09/05/2006	Innovator Multiple Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	"The drug was not acquired within the last 5 years."
Rx0000019	Teva Pharmaceuticals USA	03/31/2019	57844011001	ADDERALL 10MG 100	01/01/2019	60.50	703.60	01/06/2021	Non-innovator Multiple Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	"Teva developed and launched the drug."
Rx0000019	Teva Pharmaceuticals USA	03/31/2019	57844011201	ADDERALL 12.5MG 100	01/01/2019	60.50	703.60	01/06/2021	Non-innovator Multiple Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	"Teva developed and launched the drug."
Rx0000019	Teva Pharmaceuticals USA	03/31/2019	57844011501	ADDERALL 15MG 100	01/01/2019	60.50	703.60	01/06/2021	Non-innovator Multiple Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	"Teva developed and launched the drug."
Rx0000019	Teva Pharmaceuticals USA	03/31/2019	57844012001	ADDERALL 20MG 100	01/01/2019	60.50	703.60	01/06/2021	Non-innovator Multiple Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	"Teva developed and launched the drug."
Rx0000019	Teva Pharmaceuticals USA	03/31/2019	57844013001	ADDERALL 30MG 100	01/01/2019	60.50	703.60	01/06/2021	Non-innovator Multiple Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	"Teva developed and launched the drug."
Rx0000019	Teva Pharmaceuticals USA	03/31/2019	57844010501	ADDERALL 5MG 100	01/01/2019	60.50	703.60	01/06/2021	Non-innovator Multiple Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	"Teva developed and launched the drug."
Rx0000019	Teva Pharmaceuticals USA	03/31/2019	57844011701	ADDERALL 7.5MG 100	01/01/2019	60.50	703.60	01/06/2021	Non-innovator Multiple Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	"Teva developed and launched the drug."
Rx0000019	Teva Pharmaceuticals USA	03/31/2019	63459070060	AMRIX 15 MG	01/01/2019	204.80	2383.00	02/26/2025	Innovator Multiple Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	"The drug was not acquired within the last 5 years."
Rx0000019	Teva Pharmaceuticals USA	03/31/2019	63459070160	AMRIX 30 MG	01/01/2019	204.80	2383.00	02/26/2025	Innovator Multiple Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	"The drug was not acquired within the last 5 years."
Rx0000019	Teva Pharmaceuticals USA	03/31/2019	51285052302	ANTABUSE 250MG 100	01/01/2019	70.80	824.30	None	Non-innovator Multiple Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	"No patent expiration date listed - no patents ever listed; The drug was not acquired within the last 5 years."
Rx0000019	Teva Pharmaceuticals USA	03/31/2019	51285052402	ANTABUSE 500MG 100	01/01/2019	113.30	1318.90	None	Non-innovator Multiple Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	"No patent expiration date listed - no patents ever listed; The drug was not acquired within the last 5 years."
Rx0000019	Teva Pharmaceuticals USA	03/31/2019	51285042410	AYGESTIN 5MG 50	01/01/2019	20.50	238.20	None	Non-innovator Multiple Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	"No patent expiration date listed - no patents ever listed; The drug was not acquired within the last 5 years."
Rx0000019	Teva Pharmaceuticals USA	03/31/2019	68546014256	AZILECT 0.5MG 30	01/01/2019	67.20	782.50	08/27/2027	Innovator Multiple Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	"Teva developed and launched the drug."
Rx0000019	Teva Pharmaceuticals USA	03/31/2019	68546022956	AZILECT 1MG 30	01/01/2019	67.20	782.50	08/27/2027	Innovator Multiple Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	"Teva developed and launched the drug."
Rx0000019	Teva Pharmaceuticals USA	06/30/2019	00591280560	CLARITHROMYCIN 500MG ER TABLETS 60	04/10/2019	204.35	429.64	None	Non-innovator Multiple Source Drug	None	1	None	1	None	1	08/02/2016	Watson/Actavis	None	None	Teva acquired this particular molecule/product as part of a broader deal involving other assets, and its acquisition price was incorporated into that deal’s overall purchase price.	225.29	225.29	2014	225.29	None	Teva temporarily discontinued this product on July 23, 2018, and reintroduced it on April 10, 2019.
Rx0000019	Teva Pharmaceuticals USA	06/30/2019	00703505103	DESMOPRESSIN ACETATE INJ 4MCG/ML 10X1ML	06/06/2019	536.20	595.20	None	Non-innovator Multiple Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	This product was not acquired within the past 5 years. Also, Teva stopped selling this product in January 2012. Teva re-launched the product in June 2019. Given that the product was off the market for nearly 7.5 years, we believe that its reintroduction is more properly viewed as a new launch / re-launch at a higher WAC than before, rather than a price increase. We are nonetheless including the product in this report out of an abundance of caution.
Rx0000019	Teva Pharmaceuticals USA	06/30/2019	00703505401	DESMOPRESSIN ACETATE INJ 4MCG/ML 1X10ML	06/06/2019	536.20	595.20	None	Non-innovator Multiple Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	This product was not acquired within the past 5 years. Also, Teva stopped selling this product in January 2012. Teva re-launched the product in June 2019. Given that the product was off the market for nearly 7.5 years, we believe that its reintroduction is more properly viewed as a new launch / re-launch at a higher WAC than before, rather than a price increase. We are nonetheless including the product in this report out of an abundance of caution.
Rx0000019	Teva Pharmaceuticals USA	03/31/2019	63459054128	FENTORA 100MCG	01/01/2019	129.50	1506.90	06/15/2028	Single Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	"The drug was not acquired within the last 5 years."
Rx0000019	Teva Pharmaceuticals USA	03/31/2019	63459054228	FENTORA 200MCG	01/01/2019	163.60	1903.90	06/15/2028	Single Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	"The drug was not acquired within the last 5 years."
Rx0000019	Teva Pharmaceuticals USA	03/31/2019	63459054428	FENTORA 400MCG	01/01/2019	237.40	2762.40	06/15/2028	Single Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	"The drug was not acquired within the last 5 years."
Rx0000019	Teva Pharmaceuticals USA	03/31/2019	63459054628	FENTORA 600MCG	01/01/2019	308.20	3586.40	06/15/2028	Single Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	"The drug was not acquired within the last 5 years."
Rx0000019	Teva Pharmaceuticals USA	03/31/2019	63459054828	FENTORA 800MCG	01/01/2019	379.65	4418.30	06/15/2028	Single Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	"The drug was not acquired within the last 5 years."
Rx0000019	Teva Pharmaceuticals USA	03/31/2019	52544008001	FIORICET 50/300/40MG 100	01/01/2019	44.00	512.00	None	Non-innovator Multiple Source Drug	None	1	None	1	None	1	08/02/2016	Watson/Actavis	None	1	"Teva acquired this particular molecule/product as part of a broader deal involving other assets, and its acquisition price was incorporated into that deal’s overall purchase price."	449.93	None	2013	227.00	None	"No patent expiration date listed - no patents ever listed"
Rx0000019	Teva Pharmaceuticals USA	03/31/2019	52544008201	FIORICET/CODEINE 50/300/40/30MG 100	01/01/2019	92.10	1071.90	None	Non-innovator Multiple Source Drug	None	1	None	1	None	1	08/02/2016	Watson/Actavis	None	1	"Teva acquired this particular molecule/product as part of a broader deal involving other assets, and its acquisition price was incorporated into that deal’s overall purchase price."	942.09	None	2013	475.00	None	"No patent expiration date listed - no patents ever listed"
Rx0000019	Teva Pharmaceuticals USA	03/31/2019	63459041230	GABITRIL 12MG	01/01/2019	31.20	362.70	06/10/2017	Innovator Multiple Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	"The drug was not acquired within the last 5 years."
Rx0000019	Teva Pharmaceuticals USA	03/31/2019	63459041630	GABITRIL 16MG	01/01/2019	40.80	474.90	06/10/2017	Innovator Multiple Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	"The drug was not acquired within the last 5 years."
Rx0000019	Teva Pharmaceuticals USA	03/31/2019	63459040230	GABITRIL 2MG	01/01/2019	24.10	280.50	06/10/2017	Innovator Multiple Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	"The drug was not acquired within the last 5 years."
Rx0000019	Teva Pharmaceuticals USA	03/31/2019	63459040430	GABITRIL 4MG	01/01/2019	24.10	280.50	06/10/2017	Innovator Multiple Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	"The drug was not acquired within the last 5 years."
Rx0000019	Teva Pharmaceuticals USA	03/31/2019	57844021552	GALZIN 25MG 250	01/01/2019	35.00	407.30	None	Single Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	"No patent expiration date listed - no patents ever listed. Teva developed and launched the drug."
Rx0000019	Teva Pharmaceuticals USA	03/31/2019	57844020852	GALZIN 50MG 250	01/01/2019	58.30	678.80	None	Single Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	"No patent expiration date listed - no patents ever listed. Teva developed and launched the drug."
Rx0000019	Teva Pharmaceuticals USA	03/31/2019	51285013197	LOESTRIN 21 1.0MG/20MCG 105	01/01/2019	56.80	661.30	None	Non-innovator Multiple Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	"No patent expiration date listed - no patents ever listed. Teva developed and launched the drug."
Rx0000019	Teva Pharmaceuticals USA	03/31/2019	51285012797	LOESTRIN 21 1.5MG/30MCG 105	01/01/2019	56.80	661.30	None	Non-innovator Multiple Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	"No patent expiration date listed - no patents ever listed. Teva developed and launched the drug."
Rx0000019	Teva Pharmaceuticals USA	03/31/2019	51285012870	LOESTRIN FE 28 1.5MG/30MCG 140	01/01/2019	56.80	661.30	None	Non-innovator Multiple Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	"No patent expiration date listed - no patents ever listed. Teva developed and launched the drug."
Rx0000019	Teva Pharmaceuticals USA	03/31/2019	51285012570	LOESTRIN FE 28 1MG/20MCG 140	01/01/2019	56.80	661.30	None	Non-innovator Multiple Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	"No patent expiration date listed - no patents ever listed. Teva developed and launched the drug."
Rx0000019	Teva Pharmaceuticals USA	03/31/2019	51285009287	LOSEASONIQUE 182	01/01/2019	66.10	769.00	12/05/2028	Innovator Multiple Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	"Teva developed and launched the drug."
Rx0000019	Teva Pharmaceuticals USA	03/31/2019	51285012058	MIRCETTE 28 .15MG/.02MG .01MG	01/01/2019	71.20	828.50	10/20/2008	Non-innovator Multiple Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	"Teva developed and launched the drug."
Rx0000019	Teva Pharmaceuticals USA	03/31/2019	63459021530	NUVIGIL 150MG	01/01/2019	68.40	795.90	06/18/2024	Innovator Multiple Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	"The drug was not acquired within the last 5 years."
Rx0000019	Teva Pharmaceuticals USA	03/31/2019	63459022030	NUVIGIL 200MG	01/01/2019	68.40	795.90	06/18/2024	Innovator Multiple Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	"Teva developed and launched the drug."
Rx0000019	Teva Pharmaceuticals USA	03/31/2019	63459022530	NUVIGIL 250MG	01/01/2019	68.40	795.90	06/18/2024	Innovator Multiple Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	"The drug was not acquired within the last 5 years."
Rx0000019	Teva Pharmaceuticals USA	03/31/2019	63459020530	NUVIGIL 50MG	01/01/2019	22.70	264.50	06/18/2024	Innovator Multiple Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	"The drug was not acquired within the last 5 years."
Rx0000019	Teva Pharmaceuticals USA	03/31/2019	51285006390	PREFEST 180	01/01/2019	72.50	844.00	03/20/2020	Non-innovator Multiple Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	"The drug was not acquired within the last 5 years."
Rx0000019	Teva Pharmaceuticals USA	03/31/2019	59310057922	PROAIR INH AERO 90MCG 1INH 200	01/01/2019	5.36	64.93	05/18/2031	Innovator Multiple Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	"Launched NDC subsequent to acquiring molecule, which was in development (but not yet on market) at time of acquisition.”
Rx0000019	Teva Pharmaceuticals USA	03/31/2019	59310058020	PROAIR RESPICLICK 200 DOSE-117	01/01/2019	4.50	60.70	08/28/2035	Single Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	"Launched NDC subsequent to acquiring molecule, which was in development (but not yet on market) at time of acquisition.”
Rx0000019	Teva Pharmaceuticals USA	03/31/2019	00575620030	PROGLYCEM 50MG/ML 30ML	01/01/2019	27.80	323.70	None	Single Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	"No patent expiration date listed - no patents ever listed; CMS Market Date is defaulted to 1990."
Rx0000019	Teva Pharmaceuticals USA	03/31/2019	63459010130	PROVIGIL 100MG	01/01/2019	95.70	1113.70	05/29/2024	Innovator Multiple Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	"The drug was not acquired within the last 5 years."
Rx0000019	Teva Pharmaceuticals USA	03/31/2019	63459020130	PROVIGIL 200MG	01/01/2019	144.60	1682.80	05/29/2024	Innovator Multiple Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	"The drug was not acquired within the last 5 years."
Rx0000019	Teva Pharmaceuticals USA	03/31/2019	59310020606	QNASL AERO 4.9GM 60	01/01/2019	18.87	228.55	10/21/2031	Single Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	"The drug was not acquired within the last 5 years."
Rx0000019	Teva Pharmaceuticals USA	03/31/2019	59310021012	QNASL AERO 80MCG 8.7GM 120	01/01/2019	18.87	228.55	10/21/2031	Single Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	"The drug was not acquired within the last 5 years."
Rx0000019	Teva Pharmaceuticals USA	03/31/2019	51285043187	QUARTETTE 182	01/01/2019	79.10	920.90	03/11/2029	Innovator Multiple Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	"The drug was not acquired within the last 5 years."
Rx0000019	Teva Pharmaceuticals USA	03/31/2019	51285008787	SEASONIQUE 182	01/01/2019	66.10	769.00	12/05/2028	Innovator Multiple Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	"The drug was not acquired within the last 5 years."
Rx0000019	Teva Pharmaceuticals USA	03/31/2019	51285055402	SURMONTIL 100MG 100	01/01/2019	101.90	1185.70	None	Innovator Multiple Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	"No patent expiration date listed - no patents ever listed. The drug was not acquired within the last 5 years."
Rx0000019	Teva Pharmaceuticals USA	03/31/2019	51285053802	SURMONTIL 25MG 100	01/01/2019	44.20	514.30	None	Innovator Multiple Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	"No patent expiration date listed - no patents ever listed. The drug was not acquired within the last 5 years."
Rx0000019	Teva Pharmaceuticals USA	03/31/2019	51285053902	SURMONTIL 50MG 100	01/01/2019	72.30	841.30	None	Innovator Multiple Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	"No patent expiration date listed - no patents ever listed. The drug was not acquired within the last 5 years."
Rx0000019	Teva Pharmaceuticals USA	03/31/2019	51285036801	TREXALL 10MG	01/01/2019	78.00	908.00	None	Non-innovator Multiple Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	"No patent expiration date listed - no patents ever listed. The drug was not acquired within the last 5 years."
Rx0000019	Teva Pharmaceuticals USA	03/31/2019	51285036901	TREXALL 15MG	01/01/2019	117.00	1362.00	None	Non-innovator Multiple Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	"No patent expiration date listed - no patents ever listed. The drug was not acquired within the last 5 years."
Rx0000019	Teva Pharmaceuticals USA	03/31/2019	51285036601	TREXALL 5MG	01/01/2019	39.00	454.00	None	Non-innovator Multiple Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	"No patent expiration date listed - no patents ever listed. The drug was not acquired within the last 5 years."
Rx0000019	Teva Pharmaceuticals USA	03/31/2019	51285036701	TREXALL 7.5MG	01/01/2019	58.50	681.00	None	Non-innovator Multiple Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	"No patent expiration date listed - no patents ever listed. The drug was not acquired within the last 5 years."
Rx0000019	Teva Pharmaceuticals USA	03/31/2019	51285004001	ZIAC 10MG/6.25MG 30	01/01/2019	16.70	194.00	03/24/2000	Innovator Multiple Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	"The drug was not acquired within the last 5 years."
Rx0000019	Teva Pharmaceuticals USA	03/31/2019	51285004702	ZIAC 2.5MG/6.25MG 100	01/01/2019	55.55	646.40	03/24/2000	Innovator Multiple Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	"The drug was not acquired within the last 5 years."
Rx0000019	Teva Pharmaceuticals USA	03/31/2019	51285005002	ZIAC 5MG/6.25MG 100	01/01/2019	55.55	646.40	03/24/2000	Innovator Multiple Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	"The drug was not acquired within the last 5 years."
Rx0000134	Therakos, Inc.	03/31/2019	64067021601	UVADEX (Methoxsalen) STERILE SOLUTION, 20 mcg/ML	01/01/2019	29.00	470.00	07/30/2008	Single Source Drug	None	1	Mallinckrodt has voluntarily made a public pledge on responsible drug pricing and innovation which is our social contract to those we serve and which can be found at https://www.mallinckrodt.com/corporate-responsibility/pledge-on-drug-pricing--innovation/. Our commitment is to price our innovative products responsibly while providing broad patient access. In so doing, we continue to invest in innovation that brings value to patients, providers, and the U.S. healthcare system through research and development, quality manufacturing, as well as through patient education and disease awareness.	None	The current price increase for Uvadex is not necessitated by a change or improvement. Please see the Cost Increase Factors field for the larger principles set forth in our pledge.	None	09/28/2015	The Gores Group	None	1	None	360.00	300.00	2008	95.00	None	None
Rx0000057	Theratechnologies Inc.	06/30/2019	62064001160	Tesamorelin Acetate 1 MG Solution Reconstituted 1 EA UD	04/08/2019	425.00	5300.00	05/26/2020	Single Source Drug	None	1	None	1	Recent research has demonstrated a decrease in liver fat, which is an important health concern for patients living with HIV and lipohypertrophy On-going studies to assess the impact of Egrifta on people living with HIV and mild cognitive impairment	None	None	None	None	None	None	None	None	None	None	None	This product was developed by Theratechnologies Inc.
Rx0000090	UCB, Inc	03/31/2019	50474077066	BRIVARACETAM 100MG TAB	01/01/2019	74.90	1145.00	02/21/2021	Single Source Drug	128620000	None	None	1	None	1	None	None	None	None	None	None	None	None	None	None	None
Rx0000090	UCB, Inc	03/31/2019	50474097075	BRIVARACETAM 100MG TAB	01/01/2019	32.11	490.72	02/21/2021	Single Source Drug	128620000	None	None	1	None	1	None	None	None	None	None	None	None	None	None	None	None
Rx0000090	UCB, Inc	03/31/2019	50474077009	BRIVARACETAM 100MG TAB UD	01/01/2019	124.84	1908.34	02/21/2021	Single Source Drug	128620000	None	None	1	None	1	None	None	None	None	None	None	None	None	None	None	None
Rx0000090	UCB, Inc	03/31/2019	50474087015	BRIVARACETAM 100MG TAB UD	01/01/2019	74.90	1145.00	02/21/2021	Single Source Drug	128620000	None	None	1	None	1	None	None	None	None	None	None	None	None	None	None	None
Rx0000090	UCB, Inc	03/31/2019	50474037066	BRIVIACT 10MG TAB	01/01/2019	74.90	1145.00	02/21/2021	Single Source Drug	128620000	None	None	1	None	1	None	None	None	None	None	None	None	None	None	None	None
Rx0000090	UCB, Inc	03/31/2019	50474047066	BRIVIACT 25MG TAB	01/01/2019	74.90	1145.00	02/21/2021	Single Source Drug	128620000	None	None	1	None	1	None	None	None	None	None	None	None	None	None	None	None
Rx0000090	UCB, Inc	03/31/2019	50474047009	BRIVIACT 25MG TAB UD	01/01/2019	124.84	1908.34	02/21/2021	Single Source Drug	128620000	None	None	1	None	1	None	None	None	None	None	None	None	None	None	None	None
Rx0000090	UCB, Inc	03/31/2019	50474057066	BRIVIACT 50MG TAB	01/01/2019	74.90	1145.00	02/21/2021	Single Source Drug	128620000	None	None	1	None	1	None	None	None	None	None	None	None	None	None	None	None
Rx0000090	UCB, Inc	03/31/2019	50474057009	BRIVIACT 5OMG TAB UD	01/01/2019	124.84	1908.34	02/21/2021	Single Source Drug	128620000	None	None	1	None	1	None	None	None	None	None	None	None	None	None	None	None
Rx0000090	UCB, Inc	03/31/2019	50474067066	BRIVIACT 75MG TAB	01/01/2019	74.90	1145.00	02/21/2021	Single Source Drug	128620000	None	None	1	None	1	None	None	None	None	None	None	None	None	None	None	None
Rx0000090	UCB, Inc	03/31/2019	50474070062	CIMZIA LYOPHOLIZED POWDER FOR INJECTION	01/01/2019	283.11	4327.43	02/13/2024	Single Source Drug	1057280000	None	None	1	None	1	None	None	None	None	None	None	None	None	None	None	None
Rx0000090	UCB, Inc	03/31/2019	50474071079	CIMZIA PRE-FILLED SYRINGE	01/01/2019	283.11	4327.43	02/13/2024	Single Source Drug	1057280000	None	None	1	None	1	None	None	None	None	None	None	None	None	None	None	None
Rx0000090	UCB, Inc	03/31/2019	50474071081	CIMZIA STARTER KIT	01/01/2019	849.33	12982.29	02/13/2024	Single Source Drug	1057280000	None	None	1	None	1	None	None	None	None	None	None	None	None	None	None	None
Rx0000090	UCB, Inc	03/31/2019	50474080103	NEUPRO 1MG 30 PATCH	01/01/2019	25.86	672.48	03/30/2021	Single Source Drug	119180000	None	None	1	None	1	None	None	None	None	None	None	None	None	None	None	None
Rx0000090	UCB, Inc	03/31/2019	50474080203	NEUPRO 2MG 30 PATCH	01/01/2019	25.86	672.48	03/30/2021	Single Source Drug	119180000	None	None	1	None	1	None	None	None	None	None	None	None	None	None	None	None
Rx0000090	UCB, Inc	03/31/2019	50474080303	NEUPRO 3MG 30 PATCH	01/01/2019	25.86	672.48	03/30/2021	Single Source Drug	119180000	None	None	1	None	1	None	None	None	None	None	None	None	None	None	None	None
Rx0000090	UCB, Inc	03/31/2019	50474080403	NEUPRO 4MG 30 PATCH	01/01/2019	25.86	672.48	03/30/2021	Single Source Drug	119180000	None	None	1	None	1	None	None	None	None	None	None	None	None	None	None	None
Rx0000090	UCB, Inc	03/31/2019	50474080503	NEUPRO 6MG 30 PATCH	01/01/2019	25.86	672.48	03/30/2021	Single Source Drug	119180000	None	None	1	None	1	None	None	None	None	None	None	None	None	None	None	None
Rx0000090	UCB, Inc	03/31/2019	50474080603	NEUPRO 8MG 30 PATCH	01/01/2019	25.86	672.48	03/30/2021	Single Source Drug	119180000	None	None	1	None	1	None	None	None	None	None	None	None	None	None	None	None
Rx0000090	UCB, Inc	03/31/2019	00131247835	VIMPAT 100MG TAB	01/01/2019	56.55	864.33	03/17/2022	Single Source Drug	969960000	None	None	1	None	1	None	None	None	None	None	None	None	None	None	None	None
Rx0000090	UCB, Inc	03/31/2019	00131247860	VIMPAT 100MG TAB, UD	01/01/2019	62.21	950.83	03/17/2022	Single Source Drug	969960000	None	None	1	None	1	None	None	None	None	None	None	None	None	None	None	None
Rx0000090	UCB, Inc	03/31/2019	00131247935	VIMPAT 150MG TAB	01/01/2019	59.89	915.39	03/17/2022	Single Source Drug	969960000	None	None	1	None	1	None	None	None	None	None	None	None	None	None	None	None
Rx0000090	UCB, Inc	03/31/2019	00131247960	VIMPAT 150MG TAB, UD	01/01/2019	65.87	1006.97	03/17/2022	Single Source Drug	969960000	None	None	1	None	1	None	None	None	None	None	None	None	None	None	None	None
Rx0000090	UCB, Inc	03/31/2019	00131248035	VIMPAT 200MG TAB	01/01/2019	59.91	915.65	03/17/2022	Single Source Drug	969960000	None	None	1	None	1	None	None	None	None	None	None	None	None	None	None	None
Rx0000090	UCB, Inc	03/31/2019	00131248060	VIMPAT 200MG TAB, UD	01/01/2019	65.90	1007.30	03/17/2022	Single Source Drug	969960000	None	None	1	None	1	None	None	None	None	None	None	None	None	None	None	None
Rx0000090	UCB, Inc	03/31/2019	00131247735	VIMPAT 50MG TAB	01/01/2019	36.17	552.85	03/17/2022	Single Source Drug	969960000	None	None	1	None	1	None	None	None	None	None	None	None	None	None	None	None
Rx0000090	UCB, Inc	03/31/2019	00131247760	VIMPAT 50MG TAB, UD	01/01/2019	39.80	608.20	03/17/2022	Single Source Drug	969960000	None	None	1	None	1	None	None	None	None	None	None	None	None	None	None	None
Rx0000090	UCB, Inc	03/31/2019	00131181067	VIMPAT INJECTION 200MG/20ML	01/01/2019	49.48	756.26	03/17/2022	Single Source Drug	969960000	None	None	1	None	1	None	None	None	None	None	None	None	None	None	None	None
Rx0000090	UCB, Inc	03/31/2019	00131541070	VIMPAT ORAL SOLUTION 10MG LIQUID	01/01/2019	46.79	715.14	03/17/2022	Single Source Drug	969960000	None	None	1	None	1	None	None	None	None	None	None	None	None	None	None	None
Rx0000090	UCB, Inc	03/31/2019	00131541071	VIMPAT ORAL SOLUTION 10MG LIQUID	01/01/2019	23.40	357.58	03/17/2022	Single Source Drug	969960000	None	None	1	None	1	None	None	None	None	None	None	None	None	None	None	None
Rx0000097	Valeant Pharmaceuticals North America, LLC	03/31/2019	00187006410	ATIVAN® Tablets 1mg 1,000s	01/18/2019	1830.35	32336.16	None	Innovator Multiple Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	The NDC# for this product changed on 02/03/2014. The product was not acquired within the last 5 years
Rx0000097	Valeant Pharmaceuticals North America, LLC	03/31/2019	00187006301	ATIVAN® Tablets .5mg 100s	01/18/2019	139.90	2471.60	None	Innovator Multiple Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	The NDC# for this product changed on 02/03/2014. The product was not acquired within the last 5 years
Rx0000097	Valeant Pharmaceuticals North America, LLC	03/31/2019	00187006401	ATIVAN® Tablets 1mg 100s	01/18/2019	186.89	3301.70	None	Innovator Multiple Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	The product was not acquired within the last 5 years.
Rx0000097	Valeant Pharmaceuticals North America, LLC	03/31/2019	00187006501	ATIVAN® Tablets 2mg 100s	01/18/2019	297.84	5261.87	None	Innovator Multiple Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	The NDC# for this product changed on 12/12/2013. The product was not acquired within the last 5 years.
Rx0000097	Valeant Pharmaceuticals North America, LLC	03/31/2019	00187510001	ELIDEL® (pimecrolimus) Cream 1%	01/18/2019	16.93	299.05	None	Innovator Multiple Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	The product was not acquired within the last 5 years.
Rx0000097	Valeant Pharmaceuticals North America, LLC	03/31/2019	00187510102	ELIDEL® (pimecrolimus) Cream 1%	01/18/2019	33.86	598.11	None	Innovator Multiple Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	The product was not acquired within the last 5 years.
Rx0000097	Valeant Pharmaceuticals North America, LLC	03/31/2019	00187510203	ELIDEL® (pimecrolimus) Cream 1%	01/18/2019	56.42	996.83	None	Innovator Multiple Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	The product was not acquired within the last 5 years.
Rx0000097	Valeant Pharmaceuticals North America, LLC	03/31/2019	00187305050	ONEXTON™ (Clindamycin Phosphate and Benzoyl Peroxide) Gel, 1.2%/3.75%	01/18/2019	31.65	559.16	08/05/2029	Innovator Multiple Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	The product was not acquired within the last 5 years.
Rx0000097	Valeant Pharmaceuticals North America, LLC	03/31/2019	00187149825	TIMOPTIC® in OCUDOSE® (TIMOLOL MALEATE OPHTHALMIC SOLUTION) 0.25%, 0.3mL	01/18/2019	23.68	418.27	None	Single Source Drug	None	1	None	1	None	1	11/06/2015	Aton Pharma, Inc.	None	1	None	332.12	None	2009	87.08	None	1.The product was introduced to the market before acquisition by Valeant Pharmaceuticals North America LLC. (VPNA). The year of introduction and WAC at introduction contained in this report is the only information available to VPNA. VPNA has no knowledge of the actual date of introduction nor the WAC at introduction. 2. In regards to the 5 yr. WAN history the product was acquired on 11/06/2015. The information related to WAC history before that day is from publicly available sources and VPNA is unable to verify the accuracy of that information. 3. The NDC# for this product changed on 11/06/2015
Rx0000097	Valeant Pharmaceuticals North America, LLC	03/31/2019	00187149605	TIMOPTIC® in OCUDOSE® (TIMOLOL MALEATE OPHTHALMIC SOLUTION) 0.50%, 0.3mL	01/18/2019	27.00	476.97	None	Single Source Drug	None	1	None	1	None	1	08/09/2015	Aton Pharma, Inc.	None	1	None	378.73	None	2009	104.84	None	1.The product was introduced to the market before acquisition by Valeant Pharmaceuticals North America LLC. (VPNA). The year of introduction and WAC at introduction contained in this report is the only information available to VPNA. VPNA has no knowledge of the actual date of introduction nor the WAC at introduction. 2. In regards to the 5 yr. WAN history the product was acquired on 08/09/2015. The information related to WAC history before that day is from publicly available sources and VPNA is unable to verify the accuracy of that information.
Rx0000097	Valeant Pharmaceuticals North America, LLC	03/31/2019	00187099445	ZOVIRAX® Cream 5gm	01/18/2019	47.79	844.29	None	Innovator Multiple Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	The product was not acquired within the last 5 years.
Rx0000097	Valeant Pharmaceuticals North America, LLC	03/31/2019	00187099395	ZOVIRAX® Ointment 30gm	01/18/2019	82.81	1463.00	None	Innovator Multiple Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	The product was not acquired within the last 5 years.
Rx0000210	Validus Pharmaceuticals	03/31/2019	30698041912	Equetro® (extended release carbamazepine capsules - bottle of 120) 100mg	01/02/2019	40.21	463.46	05/19/2024	Single Source Drug	3482	None	API cost increase, Shipping cost increase, Manufacturer cost increases	None	N/A	None	None	None	None	None	None	None	None	None	None	None	None
Rx0000210	Validus Pharmaceuticals	03/31/2019	30698042312	Equetro® (extended release carbamazepine capsules - bottle of 120)300mg	01/02/2019	50.92	586.87	05/19/2024	Single Source Drug	6660	None	API cost increase, Shipping cost increase, Manufacturer cost increases	None	N/A	None	None	None	None	None	None	None	None	None	None	None	None
Rx0000210	Validus Pharmaceuticals	03/31/2019	30698042112	Equetro®(extended release carbamazepine capsules - bottle of 120) 200mg	01/02/2019	45.33	522.53	05/19/2024	Single Source Drug	13051	None	API cost increase, Shipping cost increase, Manufacturer cost increases	None	N/A	None	None	None	None	None	None	None	None	None	None	None	None
Rx0000210	Validus Pharmaceuticals	06/30/2019	30698006701	Lasix 20mg Tablet 100 count (Bottle of 100)	04/01/2019	6.79	78.29	None	Non-innovator Multiple Source Drug	13327	None	API cost increase, Shipping cost increase, Manufacturer cost increases	None	N/A	None	12/10/2015	Sanofi	25000000	None	purchased as a part of a portfolio from Sanofi, so the 25M acquisition price included a variety of products.	59.63	59.63	2016	59.63	None	None
Rx0000210	Validus Pharmaceuticals	06/30/2019	30698006605	Lasix 80mg Tablet 50 count (Bottle of 50)	04/01/2019	7.70	88.70	None	Non-innovator Multiple Source Drug	4684	None	API cost increase, Shipping cost increase, Manufacturer cost increases	None	N/A	None	12/10/2015	Sanofi	25000000	None	purchased as a part of a portfolio from Sanofi, so the 25M acquisition price included a variety of products.	67.57	67.57	2016	67.57	None	None
Rx0000210	Validus Pharmaceuticals	06/30/2019	30698006001	Lasix40mg Tablet 100 count (Bottle of 100)	04/01/2019	9.52	109.72	None	Non-innovator Multiple Source Drug	21301	None	API cost increase, Shipping cost increase, Manufacturer cost increases	None	N/A	None	12/10/2015	Sanofi	25000000	None	purchased as a part of a portfolio from Sanofi, so the 25M acquisition price included a variety of products.	83.56	83.56	2016	83.56	None	None
Rx0000210	Validus Pharmaceuticals	06/30/2019	30698045801	Lopressor 50mg tablets (Bottle of 100)	04/01/2019	21.87	252.07	None	Non-innovator Multiple Source Drug	5209	None	API cost increase, Shipping cost increase, Manufacturer cost increases	None	N/A	None	None	None	None	None	None	None	None	None	None	None	Column 14 - 22 have been left blank as this product was acquired more than 5 years ago.
Rx0000210	Validus Pharmaceuticals	06/30/2019	30698045901	Lopressor100mg tablets (Bottle of 100)	04/01/2019	32.69	376.79	None	Non-innovator Multiple Source Drug	824	None	API cost increase, Shipping cost increase, Manufacturer cost increases	None	N/A	None	None	None	None	None	None	None	None	None	None	None	Column 14 - 22 have been left blank as this product was acquired more than 5 years ago.
Rx0000210	Validus Pharmaceuticals	06/30/2019	30698045201	Lotensin HCT 10/12.5 Tablet (Bottle of 100)	04/01/2019	23.12	266.52	None	Non-innovator Multiple Source Drug	83	None	API cost increase, Shipping cost increase, Manufacturer cost increases	None	N/A	None	None	None	None	None	None	None	None	None	None	None	Column 14 - 22 have been left blank as this product was acquired more than 5 years ago.
Rx0000210	Validus Pharmaceuticals	06/30/2019	30698045301	Lotensin HCT 20/12.5 Tablet (Bottle of 100)	04/01/2019	23.12	266.52	None	Non-innovator Multiple Source Drug	335	None	API cost increase, Shipping cost increase, Manufacturer cost increases	None	N/A	None	None	None	None	None	None	None	None	None	None	None	Column 14 - 22 have been left blank as this product was acquired more than 5 years ago.
Rx0000210	Validus Pharmaceuticals	06/30/2019	30698045401	Lotensin HCT 20/25 Tablet (Bottle of 100)	04/01/2019	23.12	266.52	None	Non-innovator Multiple Source Drug	1168	None	API cost increase, Shipping cost increase, Manufacturer cost increases	None	N/A	None	None	None	None	None	None	None	None	None	None	None	Column 14 - 22 have been left blank as this product was acquired more than 5 years ago.
Rx0000098	Vanda Pharmaceuticals Inc.	03/31/2019	43068010102	Fanapt 1 mg tablets; bottles of 60	01/01/2019	87.19	1177.10	12/28/2031	Single Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	None
Rx0000098	Vanda Pharmaceuticals Inc.	03/31/2019	43068011002	Fanapt 10 mg tablets; bottles of 60	01/01/2019	171.81	2319.45	12/28/2031	Single Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	None
Rx0000098	Vanda Pharmaceuticals Inc.	03/31/2019	43068011202	Fanapt 12 mg tablets; bottles of 60	01/01/2019	171.81	2319.45	12/28/2031	Single Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	None
Rx0000098	Vanda Pharmaceuticals Inc.	03/31/2019	43068010202	Fanapt 2 mg tablets; bottles of 60	01/01/2019	87.19	1177.10	12/28/2031	Single Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	None
Rx0000098	Vanda Pharmaceuticals Inc.	03/31/2019	43068010402	Fanapt 4 mg tablets; bottles of 60	01/01/2019	87.19	1177.10	12/28/2031	Single Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	None
Rx0000098	Vanda Pharmaceuticals Inc.	03/31/2019	43068010602	Fanapt 6 mg tablets; bottles of 60	01/01/2019	107.28	1448.34	12/28/2031	Single Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	None
Rx0000098	Vanda Pharmaceuticals Inc.	03/31/2019	43068010802	Fanapt 8 mg tablets; bottles of 60	01/01/2019	107.28	1448.34	12/28/2031	Single Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	None
Rx0000098	Vanda Pharmaceuticals Inc.	03/31/2019	43068011304	Fanapt 8 tablet titration pack	01/01/2019	11.62	156.95	12/28/2031	Single Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	None
Rx0000098	Vanda Pharmaceuticals Inc.	03/31/2019	43068022001	Hetlioz; 20 mg capsules; bottles of 30	01/01/2019	1163.06	15701.35	02/12/2035	Single Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	None
Rx0000066	ViiV Healthcare	03/31/2019	49702022318	SELZENTRY TAB 150MG	01/01/2019	45.33	1556.20	11/25/2022	Single Source Drug	None	1	None	1	The price increase listed are not related to any identified or claimed change or improvement.	None	None	None	None	None	None	None	None	None	None	None	Note on Patent Expiration Date: Pursuant to Sec. 96070(d), if the drug is under patent, the patent expiration date is provided.  The date provided is the latest expiration date of all patents listed with the USFDA under 21 CFR 314.53. Note on Acquisition Fields: This drug was developed by ViiV Healthcare, therefore the following fields related to drug acquisition have been left blank: ACQUISITION_DATE, ACQUIRED_FROM_COMPANY, ACQUISITION_PRICE, ACQUISITION_PRICE_NONPUBLIC, ACQUISITION_PRICE_COMMENT, WAC_AT_ACQUISITION, YEAR_INTRODUCED, WAC_AT_INTRODUCTION.
Rx0000066	ViiV Healthcare	03/31/2019	49702022418	SELZENTRY TAB 300MG	01/01/2019	45.33	1556.20	11/25/2022	Single Source Drug	None	1	None	1	The price increase listed are not related to any identified or claimed change or improvement.	None	None	None	None	None	None	None	None	None	None	None	Note on Patent Expiration Date: Pursuant to Sec. 96070(d), if the drug is under patent, the patent expiration date is provided.  The date provided is the latest expiration date of all patents listed with the USFDA under 21 CFR 314.53. Note on Acquisition Fields: This drug was developed by ViiV Healthcare, therefore the following fields related to drug acquisition have been left blank: ACQUISITION_DATE, ACQUIRED_FROM_COMPANY, ACQUISITION_PRICE, ACQUISITION_PRICE_NONPUBLIC, ACQUISITION_PRICE_COMMENT, WAC_AT_ACQUISITION, YEAR_INTRODUCED, WAC_AT_INTRODUCTION.
Rx0000066	ViiV Healthcare	03/31/2019	49702022613	TIVICAY TAB 10MG	01/01/2019	16.58	348.10	12/08/2029	Single Source Drug	None	1	None	1	The price increase listed are not related to any identified or claimed change or improvement.	None	None	None	None	None	None	None	None	None	None	None	Note on Patent Expiration Date: Pursuant to Sec. 96070(d), if the drug is under patent, the patent expiration date is provided.  The date provided is the latest expiration date of all patents listed with the USFDA under 21 CFR 314.53. Note on Acquisition Fields: This drug was developed by ViiV Healthcare, therefore the following fields related to drug acquisition have been left blank: ACQUISITION_DATE, ACQUIRED_FROM_COMPANY, ACQUISITION_PRICE, ACQUISITION_PRICE_NONPUBLIC, ACQUISITION_PRICE_COMMENT, WAC_AT_ACQUISITION, YEAR_INTRODUCED, WAC_AT_INTRODUCTION.
Rx0000066	ViiV Healthcare	03/31/2019	49702022713	TIVICAY TAB 25MG	01/01/2019	41.44	870.25	12/08/2029	Single Source Drug	None	1	None	1	The price increase listed are not related to any identified or claimed change or improvement.	None	None	None	None	None	None	None	None	None	None	None	Note on Patent Expiration Date: Pursuant to Sec. 96070(d), if the drug is under patent, the patent expiration date is provided.  The date provided is the latest expiration date of all patents listed with the USFDA under 21 CFR 314.53. Note on Acquisition Fields: This drug was developed by ViiV Healthcare, therefore the following fields related to drug acquisition have been left blank: ACQUISITION_DATE, ACQUIRED_FROM_COMPANY, ACQUISITION_PRICE, ACQUISITION_PRICE_NONPUBLIC, ACQUISITION_PRICE_COMMENT, WAC_AT_ACQUISITION, YEAR_INTRODUCED, WAC_AT_INTRODUCTION.
Rx0000066	ViiV Healthcare	03/31/2019	49702022813	TIVICAY TAB 50MG	01/01/2019	82.88	1740.49	12/08/2029	Single Source Drug	None	1	None	1	The price increase listed are not related to any identified or claimed change or improvement.	None	None	None	None	None	None	None	None	None	None	None	Note on Patent Expiration Date: Pursuant to Sec. 96070(d), if the drug is under patent, the patent expiration date is provided.  The date provided is the latest expiration date of all patents listed with the USFDA under 21 CFR 314.53. Note on Acquisition Fields: This drug was developed by ViiV Healthcare, therefore the following fields related to drug acquisition have been left blank: ACQUISITION_DATE, ACQUIRED_FROM_COMPANY, ACQUISITION_PRICE, ACQUISITION_PRICE_NONPUBLIC, ACQUISITION_PRICE_COMMENT, WAC_AT_ACQUISITION, YEAR_INTRODUCED, WAC_AT_INTRODUCTION.
Rx0000066	ViiV Healthcare	03/31/2019	49702023113	TRIUMEQ TAB	01/01/2019	84.16	2889.36	12/08/2029	Single Source Drug	None	1	None	1	The price increase listed are not related to any identified or claimed change or improvement.	None	None	None	None	None	None	None	None	None	None	None	Note on Patent Expiration Date: Pursuant to Sec. 96070(d), if the drug is under patent, the patent expiration date is provided.  The date provided is the latest expiration date of all patents listed with the USFDA under 21 CFR 314.53. Note on Acquisition Fields: This drug was developed by ViiV Healthcare, therefore the following fields related to drug acquisition have been left blank: ACQUISITION_DATE, ACQUIRED_FROM_COMPANY, ACQUISITION_PRICE, ACQUISITION_PRICE_NONPUBLIC, ACQUISITION_PRICE_COMMENT, WAC_AT_ACQUISITION, YEAR_INTRODUCED, WAC_AT_INTRODUCTION.
Rx0000065	West Therapeutic Development, LLC	06/30/2019	13913000901	Lazanda Nasal Spray 100mcg	05/01/2019	69.24	934.70	01/26/2032	Single Source Drug	None	1	None	1	None	1	11/07/2017	Depomed	None	1	None	752.57	521.53	2014	302.48	None	Prices reflect available Medispan data received
Rx0000065	West Therapeutic Development, LLC	06/30/2019	13913001301	Lazanda Nasal Spray 300mcg	05/01/2019	96.70	1305.40	01/26/2032	Single Source Drug	None	1	None	1	None	1	11/07/2017	Depomed	None	1	None	1051.04	691.01	2016	691.02	None	Prices reflect Medispan available data received
Rx0000065	West Therapeutic Development, LLC	06/30/2019	13913001001	Lazanda Nasal Spray 400mcg	05/01/2019	110.41	1490.30	01/26/2032	Single Source Drug	None	1	None	1	None	1	11/07/2017	Depomed	None	1	None	1200.08	923.14	2014	432.48	None	Prices reflect available Medispan data received
Rx0000082	Zydus Pharmaceuticals (USA) Inc.	06/30/2019	70710147801	Fomepizole 1.5g/1.5mL Solution for Injection	04/25/2019	639.06	1500.00	None	Non-innovator Multiple Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	This is an AP rated generic drug that was not acquired in the last 5 years.